0001144204-15-006466.txt : 20150206 0001144204-15-006466.hdr.sgml : 20150206 20150206061001
ACCESSION NUMBER: 0001144204-15-006466
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT: 12
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE: 20150206
DATE AS OF CHANGE: 20150206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 22nd Century Group, Inc. CENTRAL INDEX KEY: 0001347858 STANDARD INDUSTRIAL CLASSIFICATION:	CIGARETTES [2111] IRS NUMBER: 980468420 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER:	001-36338 FILM NUMBER: 15581962 BUSINESS ADDRESS: STREET 1: 9530 MAIN STREET CITY: CLARENCE, STATE: NY ZIP: 14031 BUSINESS PHONE: (716) 270-1523 MAIL ADDRESS: STREET 1: 9530 MAIN STREET CITY: CLARENCE, STATE: NY ZIP: 14031 FORMER COMPANY: FORMER CONFORMED NAME:	Touchstone Mining LTD DATE OF NAME CHANGE:	20051222 10-K 1 v399452_10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31,
2014 or ¨ Transitional Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36338 22nd Century Group, Inc. (Exact name of registrant as specified in
its charter) Nevada 98-0468420 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 9530 Main Street, Clarence, New York
14031 (Address of principal executive offices) (716) 270-1523 Registrant’s telephone number, including
area code Securities registered under Section 12(b)
of the Act: None Securities registered under Section 12(g)
of the Act: Common Stock (Par Value - $0.00001 per
share) Indicate by check mark if the registrant is a well-known seasoned
issuer as defined in Rule 405 of the Securities Act Yes ¨ No x Indicate by check mark if the registrant is not required to
file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ¨ No x Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements
for the past 90 days. Yes x No ¨ Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files) Yes x No ¨ Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨ Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, or a non-accelerated filer. Large Accelerated Filer ¨ Accelerated Filer ¨ Non-Accelerated Filer ¨ Smaller Reporting Company x Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act).Yes ¨ No x As of June 30, 2014, the last business day of the
registrant’s most recently completed second fiscal quarter, the aggregate value of the registrant’s common stock
(excluding the 16,135,155 shares held by affiliates), based upon the $3.07 price at which such common stock was last sold on
June 30, 2014, was approximately $133.4 million. As of February 4, 2015, there were 64,335,042 shares of common
stock issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant's Proxy Statement
for its 2015 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K.
Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of December 31, 2014. 22nd Century Group, Inc. Table of Contents PART I Item 1. Business. 4 Item 1A. Risk Factors. 16 Item 1B. Unresolved Staff Comments. 29 Item 2. Properties. 29 Item 3. Legal Proceedings. 29 Item 4. Mine Safety Disclosures 29 PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 29 Item 6. Selected Financial Data. 30 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 31 Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 37 Item 8. Financial Statements and Supplementary Data. 37 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 37 Item 9A. Controls and Procedures. 38 Item 9B. Other Information. 41 PART III Item 10. Directors, Executive Officers and Corporate Governance. 41 Item 11. Executive Compensation. 42 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 42 Item 13. Certain Relationships and Related Transactions, and Director Independence. 42 Item 14. Principal Accounting Fees and Services 42 PART IV Item 15. Exhibits and Financial Statement Schedules. 42 2 Cautionary Note Regarding Forward-Looking
Statements This Annual Report on Form 10-K contains
forward-looking statements concerning our business, operations and financial performance and condition as well as our plans, objectives
and expectations for our business operations and financial performance and condition that are subject to risks and uncertainties.
All statements other than statements of historical fact included in this Annual Report on Form 10-K are forward-looking statements.
You can identify these statements by words such as “aim,” “anticipate,” “assume,” “believe,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “potential,” “positioned,” “predict,”
“should,” “target,” “will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates,
forecasts and projections about our business and the industry in which we operate and our management's beliefs and assumptions.
These statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and
other factors that are in some cases beyond our control. All forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those that we expected, including: · Our ability to manage our growth effectively; · Our ability to comply with existing and new government regulations; · Our ability to retain key personnel; · Our ability to enter into additional licensing transactions; · Our ability to achieve profitability and positive cash flows; · The potential for our clinical trials to produce negative or inconclusive
results; · Our ability to obtain significant revenue for our tobacco products
in the U.S.; · Our ability to obtain U.S. Food and Drug Administration (“FDA”)
clearance for our potentially modified risk tobacco products and FDA approval for our X-22 smoking cessation aid; · Our ability to gain market acceptance for our products; · Our
ability to raise additional capital; · Any
potential negative impact from entering the cannabis space; · Our
ability to comply with government regulations; · Our ability to compete with competitors that may have greater resources
than we have; · The potential for our competitors to develop products that are less
expensive, safer or more effective than ours; · The potential exposure to product liability claims, product recalls
and other claims; and · Our ability to adequately protect our intellectual property and to
avoid infringement on rights of third parties. For the discussion of these risks and uncertainties
and others that could cause actual results to differ materially from those contained in our forward-looking statements, please
refer to “Risk Factors” in this Annual Report on Form 10-K. The forward-looking statements included in this Annual
Report on Form 10-K are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking
statement as a result of new information, future events or otherwise, except as otherwise required by law. Unless the context otherwise requires, references
to the “Company” “we” “us” and “our” refer to 22nd Century Group, Inc., a Nevada
corporation, and its direct and indirect subsidiaries. 3 PART I Item 1. Business. Background 22nd Century Group, Inc. was incorporated
under the laws of the State of Nevada on September 12, 2005 under the name Touchstone Mining Limited. On January 25, 2011, we entered
into a reverse merger transaction with 22nd Century Limited, LLC, which we refer to herein as the merger. Upon the closing of the
merger, 22nd Century Limited, LLC became our wholly-owned subsidiary. After the merger, we succeeded to the business of 22nd Century
Limited, LLC as our sole line of business. 22nd Century Limited, LLC was originally
formed as a New York limited liability company on February 20, 1998 as 21st Century Limited, LLC and subsequently merged with a
newly-formed Delaware limited liability company, 22nd Century Limited, LLC, on November 29, 1999. Since inception, 22nd Century
Limited, LLC has used biotechnology to regulate the nicotine content in tobacco plants. Overview We are a plant biotechnology company
specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine
and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. We are focused
on tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants
through genetic engineering and plant breeding. We own or exclusively control 128 issued patents plus an additional 52
pending patent applications. The patents owned by or exclusively licensed to us include patents issued in 96 countries. We are in the process of
transitioning from researching and developing our proprietary technology and tobaccos to commercializing our technology and
products. Our long-term focus is on licensing, manufacturing and selling of our tobacco products to reduce the harm caused by
smoking. Annual worldwide tobacco product sales, including cigarettes and smokeless products, are approximately $800 billion,
most of which are cigarette sales, according to Euromonitor International. 4 We are primarily involved in the following
activities: · The international licensing of our technology, proprietary tobaccos, and trademarks; · The international sale of our branded proprietary tobaccos; · The manufacture, marketing and distribution of RED SUN and MAGIC proprietary cigarettes; · The production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (“NIDA”), a part of the National Institutes of Health (“NIH”); · The research and development of potentially less harmful or modified risk tobacco products and novel tobacco plant varieties; · The development of X-22 , a prescription-based smoking cessation aid consisting of very low nicotine (“VLN”) cigarettes; · The pursuit of necessary regulatory approvals and clearances from the FDA to market in the U.S X-22 as a prescription smoking cessation aid and BRAND A and BRAND B as reduced-risk or modified risk cigarettes; · The contract manufacturing of third-party branded tobacco products; and · The research and development in Canada of unique plant varieties of hemp/cannabis, such as (i) plants with low to no amounts of delta-9-tetrahydrocannabinol, or THC, for the legal hemp industry, (ii) plants with high levels of THC for the legal recreational cannabis markets, and (iii) plants with high levels of cannabidiol, or CBD, and other non-THC cannabinoids for the legal medical marijuana markets. Our prospects depend on our ability to generate and sustain revenues from (i) the international licensing
and/or sale of our proprietary tobacco, technology and products; (ii) the domestic and international sales of our brands,
including RED SUN and MAGIC ; (iii) the further development of our potential modified risk tobacco products and
our X-22 smoking cessation aid; and (iv) the manufacture of the filtered cigar and cigarette brands of third-parties at our manufacturing facility in
North Carolina. Our ability to generate meaningful revenue from our potential modified risk tobacco
products in the United States depends on obtaining FDA authorization to market these products as modified risk; and our
ability to generate meaningful revenue in the United States from X-22 depends on FDA approval. If these products are
authorized and approved by the FDA, we must still meet the challenges of successful marketing, distribution and consumer
acceptance. We believe our proprietary technology,
tobaccos and products can generate multiple significant revenue streams from licensing of our technology and tobacco and
from the sales of our products. We also believe that our products
address unmet needs of smokers; for those who desire to quit, an innovative smoking cessation aid, and for those who are
unable or unwilling to quit smoking, cigarettes that may reduce the level of exposure to tobacco toxins. 5 Intellectual Property Our proprietary technology enables us to
decrease or increase the level of nicotine (and other nicotinic alkaloids such as nornicotine, anatabine and anabasine) in tobacco
plants by decreasing or increasing the expression of gene(s) responsible for nicotine production in the tobacco plant using genetic
engineering. The basic techniques include, but are not limited to, those that are used in the production of genetically modified
(“GM”) varieties of other crops, which are also known as “biotech crops.” We own or exclusively control 128
issued patents plus an additional 52 pending patent applications, The patents owned by us or exclusively licensed to us
include patents issued in 96 countries. The patents and patent applications that we own include the intellectual property that
we acquired from the National Research Council of Canada (“NRC”) on December 23, 2014 that was previously
licensed to us by NRC on an exclusive basis. A “patent family” is a set of patents granted in various countries
to protect a single invention. Our patent coverage in the United States and China, two of the most valuable smoking
cessation and cigarette markets in the world, consists of 19 issued patents and 19 pending applications and 6 issued patents
and 4 pending patent applications, respectively. We have exclusive rights to all uses of the following genes responsible
for nicotine content in tobacco plants: NBB , QPT , A622 , MPO and several transcription factor
genes. We have exclusive rights to plants with altered nicotine content produced from modifying expression of these genes
and tobacco products produced from these plants. We also have the exclusive right to license and sublicense these patent
rights. In September 2014, we entered
into a Sublicense Agreement with Anandia Laboratories, Inc. (the “Anandia Sublicense”). Under the terms of the
Anandia Sublicense, we were granted an exclusive sublicense in the United States and a co-exclusive sublicense in the
remainder of the world, excluding Canada, to 1 U.S. patent and 20 patent applications relating to four genes in the
cannabis plant that are required for the production of cannabinoids, the active ingredients in the cannabis plant. The
Anandia Sublicense continues through the life of the last-to-expire patent, which is expected to be in 2035. As a plant biotechnology company,
our entry into the legal hemp/cannabis markets is a natural evolution of our activities in a plant that
has important research and commercial value and applications. We intend to engage in research and development activities
in Canada to create unique plant varieties of hemp/cannabis, such as (i) plants with low to no amounts
of THC for the legal hemp industry, (ii) plants with high levels of THC for the
legal recreational cannabis markets, and (iii) plants with high levels of CBD and other non-THC cannabinoids
for the legal medical marijuana markets. We own various registered trademarks in
the United States. We also have exclusive plant variety rights in the United States (plant variety protection certificates are
issued by the U.S. Department of Agriculture) and Canada. A PVP certificate prevents anyone other than the owner/licensee from
planting, propagating, selling, importing and exporting a plant variety for twenty (20) years in the U.S. and generally for twenty
(20) years in other member countries of the International Union for the Protection of New Varieties of Plants, known as UPOV, an
international treaty concerning plant breeders’ rights. There are currently more than 70 countries that are members of UPOV. 6 Licensing our technology and tobacco We have been in negotiations with
various parties in the tobacco and pharmaceutical industries for licensing our technology and products. On October 1, 2013,
our subsidiary, 22nd Century Limited, LLC (“22nd Century Ltd.”), entered into a Research License and Commercial
Option Agreement (the “BAT Research Agreement”) with British American Tobacco (Investments) Limited
(“BAT”), a subsidiary of British American Tobacco plc. Under the terms of the BAT Research
Agreement, BAT receives an exclusive worldwide license to certain patent rights (subject to worldwide rights retained by 22nd
Century Ltd. for use in its own brands and products) and licensed intellectual property rights (as such terms are defined in the BAT
Research Agreement) of 22nd Century Ltd. within the field of use (as defined in the BAT Research Agreement) for a period of
up to four (4) years (the “Research Term”). During the Research Term, BAT also has an option, which can be
exercised by BAT at any time during the Research Term, to obtain an exclusive worldwide license (subject to worldwide rights
retained by 22nd Century Ltd. for use in its own products and brands) to commercialize certain products derived from
utilizing the patent rights and licensed intellectual property rights under the terms of a commercial license agreement (the
“Commercial License”). Simultaneous with the signing of the BAT
Research Agreement, BAT paid 22nd Century Ltd. a non-refundable fee of $7.0 million. Further, 22nd Century Ltd. may receive payments
from BAT of up to an additional $7.0 million during the Research Term in the event certain milestones are met by BAT with respect
to its research and development of the patent rights and licensed intellectual property rights licensed by 22nd Century Ltd. to
BAT. There are four separate milestones, two of which BAT would pay 22nd Century Ltd. $2.0 million for each milestone achieved,
and two of which BAT would pay 22nd Century Ltd. $1.5 million for each milestone achieved. BAT may terminate the BAT Research Agreement
at any time, subject to the requirements for certain payments to 22nd Century Ltd. by BAT upon termination as set forth therein.
22nd Century Ltd. may also terminate the BAT Research Agreement in the event of certain uncured breaches of the BAT Research Agreement
as set forth therein. BAT also granted to 22nd Century Ltd. a
worldwide license to any and all registered research results (as such term is defined in the BAT Research Agreement) developed
and owned by BAT which results or arises from any research, development or other activities of BAT under the BAT Research Agreement,
with the terms of such license from BAT to 22nd Century Ltd. (i) to be on commercially reasonable terms to be negotiated in good
faith between the parties, but in any event on terms which are no more onerous than the terms of the Commercial License, if any,
and (ii) to be dependent on what, if any, research results the Company elects to license. If BAT exercises the option for a worldwide
Commercial License, BAT is required to pay 22nd Century Ltd. $3.0 million in aggregate annual license fees over a 2-year ramp-up
period, and thereafter, a royalty of (i) $100 per metric ton of licensed tobacco that is supplied to, or grown and ready for shipment
to, BAT and its affiliates (other than Reynolds American, Inc. and Reynolds’ affiliates) and all other third parties; and
(ii) $200 per metric ton of licensed tobacco supplied to, or grown and processed by, BAT’s affiliate Reynolds American, Inc. The minimum and maximum amount of annual
royalties under the terms of the Commercial License, which commence after the two-year ramp-up period from the exercise of the
commercial option, are $3.0 million and $15.0 million, respectively, for a period of three years. Thereafter, the minimum and maximum
annual royalties increase to $5.0 million and $25 million, respectively, until September 28, 2028. Thereafter, no further minimum
royalties are due and the maximum annual royalties due remain at $25 million until expiration of the Commercial License. Beginning three years from the start of
the Commercial License, both 22nd Century Ltd. and BAT may license/sublicense rights to any unaffiliated third party for use of
the technology outside the United States and 22nd Century Ltd. and BAT will equally share all profit from all such licensees/sublicensees.
Inside the United States, BAT may only sublicense BAT’s commercial rights to Reynolds American Inc. 22nd Century Ltd. may
sublicense any party in the United States. 7 RED SUN and MAGIC Cigarettes Our subsidiary, Goodrich Tobacco Company,
LLC (“Goodrich Tobacco”), introduced in a limited capacity two super-premium priced cigarette brands, RED SUN and MAGIC , into the U.S. market in the first quarter 2011. There have been de minimis sales
of these brands since we intentionally did not expand the marketing and distribution of these brands until after the Company became
a subsequent participating manufacturer under the MSA, which occurred on August 29, 2014, when the 46 Settling States under the
MSA approved the Company to acquire NASCO Products, LLC (“NASCO”) and become a subsequent participating manufacturer
under the MSA, as explained in greater detail below under “MSA Membership.” Both of the RED SUN and MAGIC brands are available in regular and menthol and all brand styles are king size and packaged in hinge-lid hard packs. In 2015,
we intend to focus marketing efforts for RED SUN on national and regional distributors, tobacconists, smokeshops and other
tobacco outlets in the U.S. The ban in 2009 by the FDA of all cigarettes with characterizing flavors (with the exception of menthol)
has resulted in a product void in these specialty tobacco channels for super-premium priced products. We believe that certain
U.S. cigarette wholesalers and retailers will carry our brands, among other reasons, to increase their margins. MSA Membership In September 2013, the Company
entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) to purchase all of the issued
and outstanding membership interests of NASCO, a federally licensed tobacco product manufacturer and subsequent
participating manufacturer under the MSA (the “NASCO Acquisition”). The initial purchase price for the
transaction was $1,000,000 (the “Purchase Price”), subject to potential closing date adjustments for any unpaid
liabilities of NASCO. The Purchase Price was to be paid as follows: (i) a cash payment of $200,000 and (ii) the issuance of
$800,000 in value of unregistered shares of common stock of the Company. The Purchase Agreement was subject to various
conditions, including required consents and authorizations from the National Association of Attorneys General
(“NAAG”) and the 46 Settling States under the MSA. On May 13, 2014, the Company and NASCO executed
the First Amendment to the Purchase Agreement (the “Amendment”). The Amendment increased the Purchase Price
of the NASCO Acquisition to $1,050,000 and increased the cash payment to $250,000. In addition, the amendment eliminated the Company’s
closing requirement to enter into a management agreement and sales representation agreement with an affiliate of NASCO. On August 29, 2014, the Company
entered into an Amended Adherence Agreement with the 46 Settling States under the MSA pursuant to which the Company was
approved to acquire NASCO and become a subsequent participating manufacturer under the MSA. On that same date, the Company
closed the NASCO Acquisition and became a subsequent participating manufacturer under the MSA. NASCO is now a wholly-owned
subsidiary of the Company. Manufacturing In December 2013, Goodrich Tobacco
purchased certain (i) cigarette manufacturing equipment, and (ii) equipment parts, factory items, office furniture and
fixtures, vehicles and computers from the bankruptcy estate of PTM Technologies, Inc. (“PTM”) for $3.22 million.
In January 2014, Goodrich Tobacco purchased additional miscellaneous equipment, factory items, office furniture and fixtures,
vehicles and computers from the bankruptcy estate of Renegade Tobacco Co. (“Renegade”) for $210,000. PTM and
Renegade were related companies located in North Carolina undergoing Chapter 7 liquidation proceedings in the United States
Bankruptcy Court for the Middle District of North Carolina. Goodrich Tobacco subsequently received $631,484 in net proceeds
from auctioning off certain cigarette manufacturing equipment and other items not required for operations at the
Company’s factory in Mocksville, North Carolina. The warehouse and cigarette
manufacturing facility were primarily in a pre-manufacturing stage during 2014 as we sought approval during that time for the
Company and its factory to become a subsequent participating manufacturer under the MSA. During 2014, we incurred various
expenses to prepare the facility for production. Expenses incurred during the year ended December 31, 2014 amounted to
$1,168,876 and consisted primarily of expenses for salaries and benefits for employees, sub-contract labor, rent, utilities
and other miscellaneous costs. We did manufacture a quantity of filtered cigars during 2014 resulting in revenue of $81,456.
On August 29, 2014, the Company closed its acquisition of NASCO and became a subsequent participating manufacturer under
the MSA. The Company is now manufacturing its cigarette brands in the United States through its wholly-owned subsidiary,
NASCO, at the Company’s factory in North Carolina. Now that we have become a licensed tobacco
products manufacturer and a subsequent participating manufacturer under the MSA, we believe that our ability to produce RED
SUN and MAGIC at our factory in North Carolina has increased our distribution potential for our cigarette brands in
the U.S. International Sales During 2014, Goodrich Tobacco signed a
letter of intent with Orion, a cigarette manufacturer in Poland, to contract manufacture the Company’s proprietary tobacco
products for distribution in the European Union. In December 2014, the Company and Orion set out to finalize a manufacturing agreement
to be entered into by the parties. Distribution of MAGIC brand cigarettes is expected to commence in Spain in the first
quarter of 2015. Orion is a manufacturer and distributor of smoking tobaccos, cigarettes, filter tubes, and smoking accessories
with distribution in more than 20 countries. In December 2014, the Company also finalized a new distribution agreement with a
European partner to be entered into by the parties in January 2015 for the launch of sales of the Company’s products in
The Netherlands, Belgium and Luxemburg in 2015. The Company is also evaluating the sale and distribution of its products in other
European countries and in Asia, including China. 8 The Tobacco Control Act and Our Potentially
Modified Risk Cigarettes – BRAND A and BRAND B In a 2005 analyst report, The Third
Innovation, Potentially Reduced Exposure Cigarettes , JP Morgan examined the effects of regulation by the U.S. Food and
Drug Administration (“FDA”) of tobacco, including the market for safer cigarettes. JP Morgan’s proprietary
survey of over 600 smokers found that 90% of smokers are willing to try a safer cigarette. Among JP Morgan’s other
conclusions, it stated: “FDA oversight would imbue PREPS [‘potential reduced exposure products’ which
essentially equate to potential modified risk tobacco products] with a regulatory ‘stamp of approval’ and allow
for more explicit comparative health claims with conventional cigarettes. Consumers should trust the FDA more than industry
health claims.” Prior to the Family Smoking Prevention and Tobacco Control Act (“Tobacco Control Act”)
becoming law in 2009, no regulatory agency or body had the authority to assess potential modified risk tobacco products. The Tobacco Control Act granted the
FDA authority over the regulation of all tobacco products. While the Act prohibits the FDA from banning cigarettes outright,
it allows the FDA to require the reduction of nicotine or any other compound in tobacco and cigarette smoke. The Tobacco
Control Act also banned all sales in the U.S. of cigarettes with characterizing flavors (other than menthol). As of June
2010, all cigarette companies were required to cease the use of the terms “low tar,” “light” and
“ultra light” in describing cigarettes sold in the U.S. Besides numerous other regulations, including certain
marketing restrictions, for the first time in history, a U.S. regulatory agency will scientifically evaluate cigarettes that
may pose lower health risks as compared to conventional cigarettes. The Tobacco Control Act establishes procedures
for the FDA to regulate the labeling and marketing of modified risk tobacco products, which includes cigarettes that (i) reduce
exposure to tobacco toxins and (ii) are reasonably likely to pose lower health risks, as compared to conventional cigarettes (“Modified
Risk Cigarettes”). The Tobacco Control Act requires the FDA to issue specific regulations and guidance regarding applications
submitted to the FDA for the authorization to label and market Modified Risk Cigarettes. On March 30, 2012, the FDA issued Modified
Risk Tobacco Product Applications Draft Guidance. We believe that two types of our cigarettes in development, which we refer
to as BRAND A and BRAND B , may qualify as Modified Risk Cigarettes. In addition, the Tobacco Control Act allows the FDA to mandate the
use of reduced risk technologies in conventional tobacco products and cigarettes (e.g., Marlboro ® ), which could
create opportunities for us to license our proprietary technology and/or our tobaccos to larger competitors. We intend to seek FDA authorization to
market BRAND A and BRAND B as Modified Risk Cigarettes. The Company has continued to gather additional information
since the FDA’s draft guidance on the subject, including from the FDA, to submit complete applications for our two Modified
Risk Cigarette candidates. Depending on how many exposure studies and other information the FDA will require, it is likely that
we will require additional capital to complete the entire FDA authorization process for our Modified Risk Cigarettes. The amount
of capital is currently unknown since it is uncertain how many exposure studies the FDA will require for BRAND A and BRAND
B . We believe that our BRAND A and BRAND B cigarettes will benefit smokers who are unable or unwilling to quit
smoking and who may be interested in cigarettes which reduce exposure to certain tobacco smoke toxins and/or pose a lower health
risk than conventional cigarettes. This includes approximately one-half of the 42 million adult smokers in the United States who
do not attempt to quit in a given year. Compared to commercial cigarettes, the tobacco in BRAND A has approximately 95%
less nicotine than tobacco in cigarettes previously marketed as “light” cigarettes and BRAND B ’s smoke
contains an extraordinary low amount of “tar” per milligram of nicotine. We believe that BRAND A and BRAND
B will achieve market share in the global cigarette market among smokers who will not quit but are interested in reducing
the harmful effects of smoking. We believe this new regulatory environment represents a paradigm shift for the tobacco industry.
There is no guarantee, however, that we will (i) have sufficient capital to complete the FDA authorization process for our potential
Modified Risk Cigarettes, (ii) obtain FDA authorization to market BRAND A or BRAND B as Modified
Risk Cigarettes, or (iii) achieve significant share of the market even with FDA authorization to market our products as Modified
Risk Cigarettes. BRAND A Cigarettes Compared to commercial
tobacco cigarettes, BRAND A has the lowest nicotine content. The tobacco in BRAND A contains approximately 95%
less nicotine than tobacco in leading “light” cigarette brands. Clinical studies have demonstrated that smokers
who smoke very low nicotine (“VLN”) cigarettes containing our proprietary tobacco smoke fewer cigarettes per day
resulting in significant reductions in smoke exposure, including “tar,” nicotine and carbon monoxide. Due to the
very low nicotine levels, compensatory smoking does not occur with VLN cigarettes containing our proprietary tobacco
(Hatsukami et al . 2010). In a June 16, 2010 press release, Dr. David
Kessler, the former FDA Commissioner, recommended that “[t]he FDA should quickly move to reduce nicotine levels in cigarettes
to non-addictive levels. If we reduce the level of the stimulus, we reduce the craving. It is the ultimate harm reduction strategy.”
Shortly thereafter in a Washington Post newspaper article, Dr. Kessler said that the amount of nicotine in a cigarette should
drop from about 10 milligrams to less than 1 milligram. BRAND A contains approximately 0.7 milligrams of nicotine per cigarette. A Phase II smoking cessation clinical trial
at the University of Minnesota Masonic Comprehensive Cancer Center (Hatsukami et al . 2010) also measured exposure of various
smoke compounds in smokers from smoking a VLN cigarette containing our proprietary tobacco over a six (6)-week period. Smokers
significantly reduced their smoking as compared to their usual brand of cigarettes. The number of VLN cigarettes smoked per day
on average decreased from 19 (the baseline number of cigarettes of smokers’ usual brand) to 12 by the end of the six (6)-week
period, even though participants were instructed to smoke ad libitum (as many cigarettes as desired) during treatment.
Furthermore, besides significant reductions in other biomarkers, carbon monoxide (CO) levels, an indicator of smoke exposure,
significantly decreased from 20 parts per million (baseline) to 15 parts per million. Cotinine, a metabolite and biomarker of
nicotine, significantly decreased from 4.2 micrograms/mL (baseline) to 0.2 micrograms/ml. All differences were statistically significant
(P<0.05). A recently completed study led by the
University of Pittsburgh directly compared perceptions of and smoking behaviour with SPECTRUM research cigarettes
of different nicotine content produced by us for NIDA in a total of 840 subjects (Clinicial Trials.gov Identifier:
NCT01681875). The study included groups of 120 smokers that received VLN cigarettes with the same nicotine level as used in
the initial X-22 Phase IIb study or the nicotine level used in the University of Minnesota and Queen Mary University trials
as discussed below under the heading “X-22 Smoking Cessation Aid.” Results from this study are expected to be
available shortly. Utilizing the results of these and other
independent clinical trials, we intend to submit to the Center for Tobacco Products ("CTP") of the FDA an application for BRAND
A as a Modified Risk Cigarette. We believe these and other results
and future exposure studies the FDA may require will result in a modified risk cigarette claim for BRAND A . We
further believe smokers who desire to smoke fewer cigarettes per day while also satisfying cravings and reducing exposure to
nicotine will find BRAND A beneficial. There is, however, no guarantee that BRAND A will be classified as a
Modified Risk Cigarette by the FDA. 9 BRAND B Cigarettes Using a proprietary high nicotine tobacco
blend in conjunction with specialty cigarette components, BRAND B allows the smoker to achieve a satisfactory amount of
nicotine per cigarette while inhaling less “tar” and carbon monoxide. At the same time, we do not expect exposure
to nicotine from BRAND B to be significantly higher than some commercially available full flavor cigarette brands. We believe
smokers who desire to reduce smoke exposure but are less concerned about nicotine will find BRAND B beneficial. BRAND
B has a “tar” yield between typical “light” and “ultra-light” cigarettes, but a nicotine
yield of typical full flavor cigarettes. In a 2001 report, entitled Clearing
the Smoke, Assessing the Science Base for Tobacco Harm Reduction , the Institute of Medicine notes that a low “tar”/moderate
nicotine cigarette is a viable strategy for reducing the harm caused by smoking. The report states: “Retaining nicotine
at pleasurable or addictive levels while reducing the more toxic components of tobacco is another general strategy for harm reduction.”
We believe that evaluation of BRAND B in short-term human exposure studies will confirm that exposure to smoke, including
certain tobacco smoke toxins and carbon monoxide, is significantly reduced when smoking BRAND B as compared to smoking
the leading brands of cigarettes. Our Company has engaged a major contract
research organization (“CRO”) with extensive experience in tobacco exposure studies to assist us in certain regulatory
activities at the CTP related to the Company’s research to support the development of potentially less harmful or modified
risk cigarettes. The Company and the CRO met with the CTP on November 12, 2014 to discuss the development plan and proof of concept
study for BRAND B , a cigarette that produces smoke containing an extraordinarily low amount of “tar” per milligram
of nicotine. We believe results from this and other
exposure studies will warrant a modified risk claim for BRAND B . There is, however, no guarantee that BRAND
B will be classified as a Modified Risk Cigarette by the FDA. X-22 Smoking Cessation Aid X-22 is a
tobacco-based botanical medical product for use as an aid to smoking cessation. The X-22 therapy protocol utilized in
our sponsored Phase IIb clinical trial calls for the patient to smoke our VLN cigarettes over a six-week treatment period to
facilitate the goal of the patient quitting smoking by the end of the treatment period. We believe this therapy protocol has
been successful in independent clinical trials because VLN cigarettes made from our proprietary tobacco satisfy
smokers’ cravings for cigarettes while (i) greatly reducing nicotine exposure and nicotine dependence and (ii)
extinguishing the association between the act of smoking and the rapid delivery of nicotine. X-22 involves the same
smoking behavior as conventional cigarettes and because patients are simply switching to VLN cigarettes for 6 weeks, X-22 does not expose the smoker to any new drugs or new side effects. Annual manufacturer sales of smoking cessation aids in the U.S.,
all of which must be approved by the FDA, are approximately $1 billion. Outside the United States, the smoking cessation market
is in its infancy and is approximately $3 billion. Approximately 50% of U.S. smokers attempt
to quit smoking each year, but only 2% to 5% actually quit smoking in a given year. It takes smokers an average of 8 to 11 “quit
attempts” before achieving long-term success. Approximately 95% of “self-quitters” (i.e., those who attempt to
quit smoking without any treatment) relapse and resume smoking. The Institute of Medicine, the health arm of the National Academy
of Sciences, in a 2007 report concludes: “There is an enormous opportunity to increase population prevalence of smoking cessation
by reaching and motivating the 57 percent of smokers who currently make no quit attempt per year.” We believe that our X-22 smoking cessation aid will be attractive to smokers who have been frustrated in their previous attempts to quit smoking using other
therapies. Use of existing smoking cessation aids results
in relapse rates that can be as high as 90% in the first year after a smoker initially “quits.” Smokers currently have
the following limited choices of FDA-approved products to help them quit smoking: · varenicline (Chantix ® /Champix ® outside the U.S.), manufactured by Pfizer, Inc., · bupropion (Zyban ® ), manufactured by GlaxoSmithKline plc, and · nicotine replacement therapy, or “NRT,” which is available in the U.S. in several forms: gums, patches, nasal sprays, inhalers and lozenges. Chantix ® and Zyban ® are pills and are nicotine free. Chantix ® , Zyban ® , the nicotine nasal spray and the nicotine inhaler
are available by prescription only in the U.S. Nicotine gums, nicotine patches, and nicotine lozenges are available over-the-counter
in the U.S. Chantix ® was introduced in
the U.S. market in the fourth quarter 2006. Since 2007, Chantix ® has been the best-selling smoking cessation aid
in the United States, with sales, according to Pfizer Inc., of approximately $701 million in 2007, $489 million in 2008, $386 million
in 2009, $330 million in 2010, $326 million in 2011, $313 million in 2012 and $343 million in 2013. In July 2009, the FDA required
a “Boxed Warning,” the most serious type of warning in prescription drug labeling, for both Chantix ® and Zyban ® based on the potential side effects of these drugs. Despite this Boxed Warning, worldwide sales of Chantix ® in 2009 to 2013 were approximately $700 million, $755 million, $720 million, $670 million and $648 million, respectively. Other than Chantix ® and
Zyban ® , the only FDA-approved smoking cessation therapy in the United States is nicotine replacement therapy
(“NRT”). These products consist of gums, patches, nasal sprays, inhalers and lozenges. Nicotine gums and nicotine
patches have been sold in the U.S. for approximately 30 years and 22 years, respectively, and millions of smokers have
already tried NRT products and failed to stop smoking due to the limited effectiveness of these products. According
to Perrigo Company plc, a pharmaceutical company that sells NRT products, retail sales of NRT products in the United States
were approximately $900 million in its fiscal year ended June 30, 2014. 10 Research and Development Since our inception, the majority of
our research and development (“R&D”) efforts have been outsourced to highly qualified groups in their respective fields.
Since 1998, we have had multiple R&D agreements with North Carolina State University (“NCSU”) resulting in
exclusive worldwide licenses to various patented technologies. We have utilized the same model employed by many public-sector
research organizations which entails obtaining an exclusive option or license agreement to any invention arising out of
funded research. In all cases, we fund and control all patent filings as the exclusive licensee. This model of contracting
with public-sector researchers has enabled the Company to control R&D costs while achieving our desired results,
including obtaining exclusive intellectual property rights relating to our outsourced R&D. Other R&D partners with the same arrangement
have included the National Research Council of Canada, Plant Biotechnology Institute in Saskatoon, Canada (“NRC”),
and the Nara Institute of Science and Technology in Nara, Japan (“NAIST”). The majority of this R&D has involved
the biosynthesis of nicotine in plants. Our R&D agreements with NCSU, NRC and NAIST expired in 2009. In 2010, NAIST assigned
to us all of their worldwide patents and patent applications that were previously licensed to us on an exclusive basis.
These patents and patent applications were a result of our R&D at NAIST. On December 23, 2014, we purchased from NRC all the
patents and patent applications that were previously licensed to us on an exclusive basis. In November 2011, we entered into
an R&D agreement with the University of Virginia (“UVA”) relating to nicotine biosynthesis in tobacco
plants with a total budget of $500,000 for the period from November 2011 through December 31, 2013. The term of the R&D
agreement with UVA was subsequently extended to May 31, 2016, with a total budget of $972,727. In 2014, we incurred
approximately $223,000 of expenses for the R&D agreement at UVA. We have committed to an R&D agreement
with NCSU relating to nicotine biosynthesis in tobacco plants with a total budget of approximately $163,000 for the period from
February 2014 through January 2016. Upon identifying a suitable joint venture partner or licensee to fund further X-22 clinical trials, we may also carry out additional X-22 clinical trials. During the years ended December 31, 2014, 2013 and 2012,
we incurred total research and development expenses of approximately $1,249,007, $744,000 and $729,000, respectively. Sources of Raw Materials We obtain a large portion of our tobacco
leaf requirements from farmers in multiple U.S. states that are under direct contracts with us. The contracts prohibit the transfer
of our proprietary seedlings and plant materials to other parties. We purchase the balance of our tobacco requirements through
third parties. As we expand our sales and distribution of our current commercial brands and proceed to market with our X-22 smoking cessation aid and BRAND A and BRAND B cigarettes, we plan to increase the amount of tobacco leaf we obtain
directly from farmers under contract, both in the United States and in foreign countries. 11 Products RED SUN and MAGIC Cigarettes Goodrich Tobacco introduced two super-premium
priced cigarette brands, RED SUN and MAGIC , into the U.S. market in the first quarter 2011. Both brands are available
in regular and menthol and all brand styles are king size and packaged in hinge-lid hard packs. In 2015, we intend to focus our
marketing and sales efforts for RED SUN on independent retailers, tobacconists, smokeshops and other tobacco outlets in
the U.S. The ban in 2009 by the FDA of all cigarettes with characterizing flavors (with the exception of menthol) has resulted
in a product void in these tobacco channels for super-premium priced products. We believe that certain U.S. cigarette wholesalers
and retailers will carry our brands, among other reasons, to increase their margins. To facilitate Goodrich Tobacco becoming a
subsequent participating manufacturer under the MSA, we had previously curtailed the sales and marketing of these products in
order to minimize the fines and penalties that we would be required to pay when we were approved to become a subsequent participating
manufacturer under the MSA. When we were approved on August 29, 2014 by the 46 Settling States to become a subsequent participating
manufacturer under the MSA, Goodrich Tobacco was required to pay an aggregate of $17,546 in fines for prior sales of RED SUN and MAGIC in the U.S. market when those brands were previously produced by a non-participating manufacturer. On a going-forward
basis, RED SUN and MAGIC will be produced by our NASCO subsidiary at our factory in North Carolina, which is now
a subsequent participating manufacturer under the MSA. SPECTRUM Government Research Cigarettes NIDA,
a part of NIH, provides the scientific community with controlled and uncontrolled
research chemicals and drug compounds in its Drug Supply Program. NIDA included an option to develop and produce research cigarettes
with various levels of nicotine (from very low to high), or Research Cigarette Option, in its request for proposals for a five-year
contract for Preparation and Distribution of Research and Drug Products. We agreed, as a subcontractor to RTI International (“RTI”)
in RTI’s contract with NIDA for the Research Cigarette Option, to supply modified nicotine (from very low to high) cigarettes
to NIDA. In August 2010, we met with officials from NIDA, FDA, RTI, the National Cancer Institute and the Centers for Disease
Control and Prevention to finalize certain aspects of the design of these research cigarettes. These government research cigarettes
produced by us under the mark SPECTRUM were distributed by NIDA to researchers free of charge. Goodrich Tobacco has thus
far delivered approximately 17.5 million SPECTRUM research cigarettes. On July 7, 2014, Goodrich Tobacco entered into a
Teaming Agreement with RTI to work together to respond to a new request from NIDA for the potential purchase by NIDA from RTI
of additional SPECTRUM research cigarettes to be produced and sold by Goodrich Tobacco to RTI. BRAND A and BRAND B The Tobacco Control Act establishes procedures
for the FDA to regulate the labeling and marketing of cigarettes that (i) reduce exposure to tobacco toxins and (ii) are reasonably
likely to pose lower health risks as compared to conventional cigarettes (“Modified Risk Cigarettes”). The Tobacco
Control Act requires the FDA to issue specific regulations and guidance regarding applications submitted to the FDA for the authorization
to label and market modified risk tobacco products, including Modified Risk Cigarettes. On March 30, 2012, the FDA issued Modified
Risk Tobacco Product Applications Draft Guidance. We have been continuing to gather additional information since the FDA’s
draft guidance on the subject, including from the FDA, to submit complete applications for our two Modified Risk Cigarette candidates.
Depending on how many exposure studies and other information the FDA will require, it is likely that we will require additional
capital to complete the entire FDA authorization process for our Modified Risk Cigarettes. Compared to commercial
tobacco cigarettes, BRAND A has the lowest nicotine content. The tobacco in BRAND A contains approximately 95%
less nicotine than tobacco in leading “light” cigarette brands. Clinical studies have demonstrated that smokers
who smoke VLN cigarettes containing our proprietary tobacco smoke fewer cigarettes per day
resulting in significant reductions in smoke exposure, including “tar,” nicotine and carbon monoxide. Due to the
very low nicotine levels, compensatory smoking does not occur with VLN cigarettes containing our proprietary tobacco
(Hatsukami et al . 2010). Using a proprietary high nicotine tobacco
blend in conjunction with specialty cigarette components, BRAND B allows the smoker to achieve a satisfactory amount of
nicotine per cigarette while inhaling less “tar” and carbon monoxide. At the same time, we do not expect exposure to
nicotine from BRAND B to be significantly higher than some commercially available full flavor cigarette brands. We believe
smokers who desire to reduce smoke exposure but are less concerned about nicotine will find BRAND B beneficial. BRAND B has a “tar” yield between typical “light” and “ultra-light” cigarettes, but a nicotine yield
of typical full flavor cigarettes. Utilizing the results of previously
conducted independent clinical trials (see below under “X-22 Smoking Cessation Aid”), we intend to submit to
the Center for Tobacco Products (“CTP”) of the FDA an
application for BRAND A as a Modified Risk Cigarette. Our Company has engaged a major
contract research organization (“CRO”) with extensive experience in tobacco exposure studies to assist us in
certain regulatory activities at the CTP related to the Company’s research to support the development of potentially
less harmful or modified risk cigarettes. The Company and the CRO met with the CTP on November 12, 2014 to discuss the
development plan and proof of concept study for BRAND B , a cigarette that produces smoke containing an extraordinarily
low amount of “tar” per milligram of nicotine. We believe that these two cigarette products
in development, which we refer to as BRAND A and BRAND B , will qualify as Modified Risk Cigarettes. Compared to
commercial cigarettes, the tobacco in BRAND A has approximately 95% less nicotine than tobacco in cigarettes previously
marketed as “light” cigarettes, and BRAND B ’s smoke contains an extraordinarily low amount of “tar”
per milligram of nicotine. However, there can be no assurance that BRAND A or BRAND B will be approved as Modified
Risk Cigarettes. X-22 Smoking Cessation
Aid X-22 is a tobacco-based botanical
medical product for use as an aid to smoking cessation. The X-22 therapy protocol utilized in our sponsored Phase IIb clinical
trial calls for the patient to smoke our VLN cigarettes over a six-week treatment period to facilitate the goal of the patient
quitting smoking by the end of the treatment period. We believe this therapy protocol has been successful in independent clinical
trials because VLN cigarettes made from our proprietary tobacco satisfy smokers’ cravings for cigarettes while (i) greatly
reducing nicotine exposure and nicotine dependence and (ii) extinguishing the association between the act of smoking and the rapid
delivery of nicotine. X-22 involves the same smoking behavior as conventional cigarettes and because patients are simply
switching to VLN cigarettes for 6 weeks, X-22 does not expose the smoker to any new drugs or new side effects. Our Investigational
New Drug Application for X-22 , a kit of VLN cigarettes, was cleared by the FDA in July 2011 and has been updated annually.
Our X-22 Phase IIb clinical trial was completed in the first quarter of 2012 and did not demonstrate a statistically significant
difference in quitting between X-22 and the active control, a cigarette containing conventional nicotine levels. However,
the median number of X-22 cigarettes smoked during the trial was significantly reduced compared to patients’ baseline
of usual brand of cigarettes. In evaluating the results of this trial, we believe we may have reduced the nicotine content of X-22 by too great a percentage, to a level less than half the nicotine content of VLN cigarettes used in various independent
smoking-cessation clinical trials that have demonstrated that use of VLN cigarettes increases quit rates. The recently completed
study led by the University of Pittsburgh with SPECTRUM research cigarettes of different nicotine content produced by us
for NIDA (ClinicalTrails.gov Identifier: NCT01681875) included 120 smokers that received VLN cigarettes with the same nicotine
level as used in the initial X-22 Phase IIb study and 120 smokers that received VLN cigarettes with the nicotine level
used in the University of Minnesota and Queen Mary University trials, as described below in greater detailed under “Smoking
Cessation Clinical Trials with VLN Cigarettes.” Results from this study, which are expected to be available shortly, will
provide a direct comparison of smoker perception of and behavior with cigarettes of these nicotine contents. 12 Due to
the limited effectiveness and/or serious side effects of existing FDA-approved smoking cessation products (all of which have
been on the market approximately between 8 and 30 years), we believe that if additional clinical trials demonstrate
increased smoking cessation rates, then X-22 can capture a share of this market by replacing sales and market share
from existing smoking cessation aids and expanding the smoking cessation market by encouraging more smokers to attempt to
quit smoking. In contrast to the results of our Phase IIb trial results, the following independent studies have demonstrated
that VLN cigarettes increase quit rates, whether used alone, in conjunction with Chantix ® (varenicline) or
nicotine replacement therapy (“NRT”) such as nicotine patches, gums or lozenges: · Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen
J, Allen SS, Shields PG, MurphySE, Stepanov I, Hecht SS. 2010. Reduced nicotine content cigarettes: effects on toxicant exposure,
dependence and cessation. Addiction 105:343-355. · Phase II clinical trial · Reduced nicotine content cigarettes and nicotine patch. Hatsukami
DK, Hertsgaard LA, Vogel RI, Jensen JA, Murphy SE, Hecht SS, Carmella SG, al'Absi M, Joseph AM, Allen SS. 2013. Reduced nicotine
content cigarettes and nicotine patch. Cancer Epidemiol Biomarkers Prev . 22(6):1015-24. · Phase II clinical trial · Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, Laugesen
M, Parag V, Whittaker R. 2012. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline
care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Addiction .
2012 Oct; 107(10):1857-67. · Phase III/IV clinical trial · Becker KM, Rose JE, Albino AP. 2008. A randomized trial of nicotine
replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine Tob Res 10(7):1139-48. · Phase II clinical trial · Rezaishiraz H, Hyland A, Mahoney MC, O’Connor RJ, Cummings KM.
2007. Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings? Nicotine Tob
Res . Nov; 9(11):1139-46. · Phase II clinical trial A separate and
yet unpublished clinical trial evaluated whether the use of our VLN cigarette in combination with Chantix ® or in
combination with NRT increases abstinence rates over the use of Chantix ® or the use of NRT (NCT01250301). Certain results of this unpublished study were disclosed in a presentation at the 2013 Society
for Research on Nicotine and Tobacco (“SRNT”) annual meeting given by Hayden McRobbie, Ph.D. of Queen Mary University
of London, Wolfson Institute of Preventative Medicine, who was the principal investigator of the study. Pfizer Inc. was also a
collaborator of the study. The study included one hundred smokers who were prescribed varenicline (trademarked Chantix, or Champix
outside the U.S.) and one hundred smokers who were prescribed NRT. Half the smokers of each of these groups were randomly selected
to also use our VLN cigarettes for the first 2 weeks of treatment. All smokers received 9 weekly behavioral support sessions throughout
the 12-week study period. The group that used our VLN cigarettes had a 70% quit rate one week after stopping VLN cigarette use
compared to a 53% quit rate of the group not using VLN cigarettes after week 1 (p=0.02). The group that used our VLN cigarettes
had a 64% four-week continuous abstinence rate during weeks 3 to 6 compared to a 50% four-week continuous abstinence rate during
weeks 1 to 4 (p=0.06). Quit rates at 12 weeks post treatment were not reported in the presentation. FDA approval must
be obtained, as has been the case for decades, before a product can be marketed for quitting smoking. The Tobacco Control Act
provides that products for quitting smoking or smoking cessation, such as X-22 , be considered for “Fast Track”
designation by the FDA. The “Fast Track” programs of the FDA are intended to facilitate development and expedite review
of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. We believe
that upon completion of a company-sponsored clinical trial demonstrating efficacy, X-22 will qualify for “Fast Track”
designation by the FDA. However, there is no guarantee that the FDA will grant “Fast Track” designation to X-22 . We believe that our VLN cigarettes
are an effective aid to smoking cessation. We are currently in the process of identifying potential joint venture partners or
licensees to fund the remaining X-22 clinical trials. Upon identifying a suitable joint venture partner or licensee,
we will then request a meeting with the FDA, and thereafter we may resume
our own sponsored X-22 clinical trials. There is no guarantee that we will (ii) identify a joint venture partner or
licensee to fund the remaining X-22 clinical trials, (ii) obtain the funds necessary to complete additional clinical
trials, (iii) obtain FDA approval, or (iv) capture significant share of the smoking cessation market upon FDA approval. 13 Government Regulation Smoking Cessation Aids Government authorities in the U.S. and foreign
countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution,
sampling, marketing and import and export of pharmaceutical products. FDA approval must be obtained, as has been the case for decades,
before a product can be marketed for quitting smoking or reducing withdrawal symptoms. In addition, as with all FDA-approved prescription
drugs, the FDA must approve the brand name of our X-22 smoking cessation aid. The FDA approval process for smoking cessation
aids is similar to that required by the FDA for new drug approvals, although the cost to complete clinical trials for a smoking
cessation aid such as X-22 are generally far less than clinical trials for drugs. The primary endpoint of the clinical trial
for smoking cessation aids is smoking abstinence, which is generally confirmed by inexpensive, noninvasive biomarker tests. Since
potential quitters are already smokers, X-22 will not expose participants in the clinical trials to any new compounds, unlike
a new chemical entity, such as Chantix ® . The process of obtaining governmental approvals
and complying with ongoing regulatory requirements requires the expenditure of substantial time and financial resources. In addition,
statutes, rules, regulations and policies may change and new legislation or regulations may be issued that could delay such approvals.
If we fail to comply with applicable regulatory requirements at any time during the product development process, approval process,
or after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDA’s
refusal to approve pending applications, withdrawals of approvals, clinical holds, warning letters, product recalls, product seizures,
total or partial suspension of our operations, injunctions, fines, civil penalties or criminal prosecution. Any agency enforcement
action could have a material adverse effect on us. The Affordable Care Act and other government
and private sector initiatives targeted to potentially limit the growth of healthcare costs are continuing in the U.S. and many
other countries where we intend to sell our products, including our X-22 smoking cessation aid. These changes are causing
the marketplace to put increased emphasis on the delivery of more cost-effective medical products. Government healthcare programs in the United
States, including Medicare and Medicaid, private healthcare insurance and managed-care plans have attempted to control costs by
limiting the amount of reimbursement for which they will pay for particular procedures or treatments. This may create price sensitivity
among potential customers for our X-22 smoking cessation aid, even if we obtain FDA approval for it. Some third-party payers
must also approve coverage for new or innovative devices or therapies before they will reimburse healthcare providers who use the
medical devices or therapies. Even though a new medical product may have been cleared for commercial distribution, we may find
limited demand for X-22 until reimbursement approval has been obtained from governmental and private third-party payers. Modified Risk Cigarettes The Tobacco Control Act, which became law
in June 2009, prohibits the FDA from banning cigarettes outright or mandating that nicotine levels be reduced to zero. However,
among other things, it allows the FDA to require the reduction of nicotine or any other compound in cigarettes. In 2009, the Tobacco
Control Act banned all sales in the United States of cigarettes with flavored tobacco (other than menthol). As of June 2010, all
cigarette companies were required to cease using the terms “low tar,” “light” and “ultra light”
in describing cigarettes sold in the United States. We believe this new regulatory environment represents a paradigm shift for
the tobacco industry and will create opportunities for us in marketing BRAND A and BRAND B and in licensing our proprietary
technology and/or tobaccos to larger competitors. For the first time in history, a U.S. regulatory
agency will scientifically evaluate cigarettes that may pose lower health risks as compared to conventional cigarettes. The Tobacco
Control Act establishes procedures for the FDA to regulate the labeling and marketing of modified risk tobacco products, which
includes cigarettes that (i) reduce exposure to tobacco smoke toxins and/or (ii) pose lower health risks, as compared to conventional
cigarettes (“Modified Risk Cigarettes”). The Tobacco Control Act requires the FDA to issue specific regulations and
guidance regarding applications that must be submitted to the FDA for the authorization to label and market Modified Risk Cigarettes.
We believe that BRAND A and BRAND B will qualify as Modified Risk Cigarettes. We will need significant additional
capital to complete the FDA authorization process for our Modified Risk Cigarettes. The amount of capital is currently unknown
since it is uncertain how many exposure studies the FDA will require for BRAND A and BRAND B . In addition, the Tobacco
Control Act allows the FDA to mandate the use of reduced risk technologies in conventional tobacco products and cigarettes (e.g.,
Marlboro ® ) which could create opportunities for us to license our proprietary technology and/or our tobaccos to
larger competitors. In addition to providing our SPECTRUM cigarettes to NIDA for researchers, we have been directly supplying our proprietary cigarettes to independent researchers
so that additional studies can be conducted to obtain additional information on our products. We expect this information will
assist us, along with our own funded studies, in obtaining the necessary FDA authorizations to market BRAND A and BRAND
B as Modified Risk Cigarettes and to obtain FDA approval for X-22 as a prescription smoking cessation aid. 14 Competition In the market for FDA-approved smoking cessation
aids, our principal competitors include Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, and Perrigo Company plc. The
industry consists of major domestic and international companies, most of which have existing relationships in the markets into
which we plan to sell, as well as financial, technical, marketing, sales, manufacturing, scaling capacity, distribution and other
resources, and name recognition substantially greater than ours. Cigarette companies compete primarily on
the basis of product quality, brand recognition, brand loyalty, taste, innovation, packaging, service, marketing, advertising,
retail shelf space and price. Cigarette sales can be significantly influenced by weak economic conditions, erosion of consumer
confidence, competitors’ introduction of low-price products or innovative products, higher cigarette taxes, higher absolute
prices and larger gaps between price categories, and product regulation that diminishes the ability to differentiate tobacco products.
Domestic competitors include Philip Morris USA, Reynolds American Inc., Lorillard Inc., Commonwealth Brands, Inc., Liggett Group
LLC and Vector Tobacco Inc. International competitors include Philip Morris International, Inc., Japan Tobacco Inc., Imperial Tobacco
Group plc, and regional and local tobacco companies. Biomass Products Biomass products are products such as ethanol
made from the organic material, usually plants densely grown over a given area. We have funded extensive biomass field trials conducted
by NCSU and work on feedstock digestibility and bioconversion at the National Renewable
Energy Lab. Bioconversion is the conversion of organic matter into a source of energy, such as ethanol in our own research, through
the action of microorganisms. Tobacco has a number of advantages as a starting point for development of novel bioproduct crop systems.
Because tobacco is a widely cultivated crop, grown in over 100 countries throughout the world, tobacco agronomy is highly understood.
For decades tobacco has been used as a model system for plant biology, and recently the tobacco genome has been mapped. Tobacco
plants rapidly sprout back after each harvest and produce large amounts of leaf and total biomass. Tobacco grown for cigarettes
yields about 3,000 pounds of cured leaf per acre (~20% moisture) per year from 7,500 tobacco plants. In our field trials in North
Carolina, nicotine-free tobacco grown for biomass yields about 100,000 pounds of fresh weight per acre (which equals 10,000 pounds
of dry weight) per year with multiple machine harvests from about 80,000 tobacco plants. The results of our biomass studies have
been summarized in a comprehensive feasibility study relating to our nicotine-free tobacco biomass crop ( Verfola ) to produce
a variety of bioproducts. First, protein and other plant fractions are extracted, and then biofuels and other products are produced
from the remaining cellulosic residue. In 2009, we put our biomass development
projects on hold so that our management could focus its attention and resources on our modified risk cigarette business and our X-22 smoking cessation business. We do not plan to move forward with potential biomass business activities until some period
of time after FDA approval of X-22 or FDA authorization to market Brand A or Brand B as a Modified Risk Cigarette.
We currently are not spending any capital for such potential biomass business activities nor do we have any current plans to do
so in the foreseeable future. Cannabis Research in Canada Botanical Genetics is a wholly-owned subsidiary of the Company
and was incorporated to facilitate an equity investment in Anandia Laboratories, Inc. (“Anandia”), a plant biotechnology
company based in Vancouver, Canada, that closed on April 14, 2014. On September 15, 2014, Botanical Genetics was granted a sublicense
by Anandia to 23 patent applications relating to four genes in the cannabis plant that are required for the production of cannabinoids,
the active ingredients in the cannabis plant, with such sublicense being exclusive in the United States and co-exclusive with Anandia
everywhere else in the world, except Canada where Anandia has retained exclusive rights. The Anandia sublicense continues through
the life of the last-to-expire patent, which is expected to be in 2035. We do not conduct any activities
related to cannabis in the United States. Our research facilities for cannabis are located exclusively in Canada. Through
licenses granted by the Canadian government to Anandia, we will be conducting research and development in Canada with Anandia
of unique plant varieties of hemp/cannabis, such as (i) plants with low to no amounts of delta-9-tetrahydrocannabinol, or
THC, for the legal hemp industry, (ii) plants with high levels of THC for the legal recreational cannabis market, and (iii)
plants with high levels of cannabidiol, or CBD, and other non-THC cannabinoids for the legal medical marijuana markets. In
Canada, licenses to cultivate, possess and supply cannabis for medical research are granted by agencies of the Canadian
federal government. In order to carry out research in other countries, similar licenses are required to be issued by the
relevant authority in each country. As of December 31, 2014, there are 23 states in the United States
plus the District of Columbia that have laws and/or regulations that recognize, in one form or another, legitimate medical uses
for cannabis and consumer use of cannabis in connection with medical treatment. Additionally, the states of Colorado and Washington
have legalized cannabis for adult use. Furthermore, the states of Alaska and Oregon have approved legalized cannabis for adult
use in laws that will become effective in 2015. Many other states are considering similar legislation. Conversely, under the federal
Controlled Substance Act (the “CSA”), the policies and regulations of the federal government and its agencies are that
cannabis has no medical benefit and a range of activities are prohibited, including cultivation, possession, personal use and interstate
distribution of cannabis. In the event the U.S. Department of Justice (the “DOJ”) begins strict enforcement of the
CSA in states that have laws legalizing medical marijuana and recreational marijuana in small amounts, there may be a direct and
adverse impact to any future business or prospects that we have in the cannabis business. Employees We currently employ twenty three (23) people
and we consider our employee relations to be good. 15 Item 1A. Risk Factors. You should carefully consider the risk
factors set forth below and in other reports that we file from time to time with the Securities and Exchange Commission and the
other information in this Annual Report on Form 10-K. The matters discussed in the risk factors, and additional risks and uncertainties
not currently known to us or that we currently deem immaterial, could have a material adverse effect on our business, financial
condition, results of operation and future growth prospects and could cause the trading price of our common stock to decline. Risks Related to Our Business and Operations We have had a history of losses, and we may be unable
to achieve and sustain profitability. We have experienced net losses
of approximately $15.6 million, $26.1 million and $6.7 million during the years ended December 31, 2014, 2013 and
2012, respectively. At December 31, 2014, we had current assets of $10,706,806, current liabilities of $2,673,407, and cash
on hand of $6,402,687. We believe the cash balance is adequate to sustain operations and meet all current obligations as they
come due for a period of approximately 12 months. Excluding contract growing of our proprietary tobacco with farmers,
extraordinary expenses such as potential clinical trials, capital expenditures for our factory, and initial expenses
associated with the launch of our RED SUN cigarette brand, our monthly cash expenditures are approximately $500,000. While
our current cash balance is adequate to sustain operations for approximately 12 months, generating net income in the
future will depend on our ability to successfully operate our cigarette manufacturing facility, sell and market our
proprietary tobacco products and generate additional royalty revenue from the licensing our intellectual property. There is
no guarantee that we will be able to achieve or sustain profitability in the future. An inability to successfully achieve
profitability may decrease our long-term viability. We have had a history of negative cash flow, and our ability
to sustain positive cash flow is uncertain. We have had a history of negative cash
flow from operating activities, before cash used in investing activities and cash from financing activities, including
approximately $6.6 million during the year ended December 31, 2014. As indicated above, we believe our cash on hand is adequate to sustain operations and meet all current
obligations as they come due for a period in excess of 12 months. Continued generation of positive cash flow from operations
will depend on our ability to successfully implement the net income generating activities discussed in the previous risk
factor discussion. An inability to successfully implement our net income producing initiatives may decrease our
long-term viability. Our limited operating history makes it difficult to evaluate
our current business and future prospects. We have been in existence since 1998, but
our activities have been previously limited primarily to licensing and funding research and development activities. Our limited
operating history may make it difficult to evaluate our current business and our future prospects. We have encountered and will
continue to encounter risks and difficulties frequently experienced by growing companies in rapidly changing industries, including
increasing expenses as we continue to grow our business. If we do not manage these risks successfully, our business will be harmed. We will mainly depend on third parties to market, sell
and distribute our products, and we currently have no commercial arrangements for the marketing, sale or distribution of our X-22
smoking cessation aid. We expect to depend on third parties to
a great extent to market, sell and distribute our products and we currently have no arrangements with third parties in place to
provide such services for our X-22 smoking cessation aid. We cannot be sure that we will be able to enter into such arrangements
on acceptable terms, or at all. If we are unable to enter into marketing, sales and distribution arrangements with third parties
for our X-22 smoking cessation aid, we would need to incur significant sales, marketing and distribution expenses in connection
with the commercialization of X-22 and any future potential products. We do not currently have a dedicated sales force,
and we have no experience in the sales, marketing and distribution of pharmaceutical products. Developing a sales force is expensive
and time-consuming, and we may not be able to develop this capacity. If we are unable to establish adequate sales, marketing and
distribution capabilities, independently or with others, we may not be able to generate significant revenue and may not become
profitable. We have no experience in managing growth. If we fail to
manage our growth effectively, we may be unable to execute our business plan or address competitive challenges adequately. During 2014, we grew from nine (9)
to twenty three (23) employees. Any growth in our business will place a significant strain on our managerial,
administrative, operational, financial, information technology and other resources. We intend to further expand our overall
business, customer base, employees and operations, which will require substantial management effort and significant
additional investment in our infrastructure. We will be required to continue to improve our operational, financial and
management controls and our reporting procedures and we may not be able to do so effectively. As such, we may be unable to
manage our growth effectively. Our working capital requirements involve estimates based
on demand expectations and may increase beyond those currently anticipated, which could harm our operating results and financial
condition. We have no experience in selling Modified
Risk Cigarettes or smoking cessation products on a commercial basis. As a result, we intend to base our funding and inventory decisions
on estimates of future demand. If demand for our products does not increase as quickly as we have estimated, our inventory and
expenses could rise, and our business and operating results could suffer. Alternatively, if we experience sales in excess of our
estimates, our working capital needs may be higher than those currently anticipated. Our ability to meet any demand for our products
may depend on our ability to arrange for additional financing for any ongoing working capital shortages, since it is likely that
cash flow from sales will lag behind our investment requirements. 16 We have limited experience in operating and managing a
manufacturing facility. We have limited experience operating and
managing a manufacturing facility. The manufacture of products are subject to strict quality control, testing and record keeping
requirements, and continuing obligations regarding the submission of safety reports and other post-market information. In addition,
the manufacturing of our own products will be expensive to operate without sufficient production volume. If we are unable
to successfully manufacture or sell our products, we will still be liable for the costs associated with operating a manufacturing
facility. Accordingly, the operation of such manufacturing facility could have a material adverse effect on our results
of operations. Our manufacturing facility is subject to FDA regulations. Manufacturers of tobacco and pharmaceutical
products must comply with FDA regulations which require, among other things, compliance with the FDA’s evolving regulations
on Current Good Manufacturing Practices (“cGMP(s)”), which are enforced by the FDA through its facilities inspection
program. The manufacture of products are subject to strict quality control, testing and record keeping requirements, and continuing
obligations regarding the submission of safety reports and other post-market information. We cannot guarantee that our current
manufacturing facility will pass FDA and/or similar inspections in foreign countries to produce our tobacco products or the final
version of our X-22 smoking cessation aid, or that future changes to cGMP manufacturing standards will not also negatively
affect the cost or sustainability of our manufacturing facility. We will likely require additional capital before we can
complete the FDA authorization process for our X-22 smoking cessation aid and our Modified Risk Cigarettes. We are currently seeking a suitable joint
venture partner or licensee willing to fund further clinical trials for FDA approval of our X-22 smoking cessation aid.
At that time we will resume our own sponsored X-22 clinical trials. There is no guarantee that we will identify a joint
venture partner or licensee willing to fund further X-22 clinical trials on terms that are acceptable to us. We estimate
the cost of completing two Phase III trials to be approximately $20 million. We will also likely require additional capital in
the future before we can complete the FDA authorization process for our Modified Risk Cigarettes. The cost of completing the FDA
authorization process for each of our two potential Modified Risk Cigarettes is difficult to estimate since it is currently unknown
exactly what the FDA will require, including the number and size of exposure studies. If we raise additional funds through the
issuance of equity securities to complete the FDA authorization process for our Modified Risk Cigarettes, our stockholders may
experience substantial dilution, or the equity securities may have rights, preferences or privileges senior to those of existing
stockholders. If we raise additional funds through debt financings, these financings may involve significant cash payment obligations
and covenants that restrict our ability to operate our business and make distributions to our stockholders. We could also wait for
our own revenues and profits to be sufficient for us to provide such funding, which could delay our completion of the FDA authorization
process for our Modified Risk Cigarettes. We also could elect to seek funds through arrangements with collaborators or licensees.
To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish
some rights to our technologies or our potential products or grant licenses on terms that are not favorable to us. If we choose to resume and fund our own
clinical trials for FDA approval of our X-22 smoking cessation product and we cannot raise additional capital on acceptable
terms, we may not be able to, among other things: • complete clinical trials
of our X-22 smoking cessation aid; • undertake the steps necessary
to seek FDA authorization of our Modified Risk Cigarettes; • develop or enhance our
potential products or introduce new products; • expand our development,
sales and marketing and general and administrative activities; • attract tobacco growers,
customers or manufacturing and distribution partners; • acquire complementary technologies,
products or businesses; • expand our operations in
the United States or internationally; • hire, train and retain
employees; or • respond to competitive
pressures or unanticipated working capital requirements. 17 If our X-22 smoking cessation aid does not gain market
acceptance among physicians, patients, third-party payers and the medical community, we may be unable to generate significant revenue. Our X-22 smoking cessation aid may
not achieve market acceptance among physicians, patients, third-party payers and others in the medical community. If we receive
FDA approval for the marketing of X-22 as a smoking cessation aid in the U.S., the degree of market acceptance could depend
upon a number of factors, including: • limitations on the indications for use for which X-22 may be marketed; • the establishment and demonstration in the medical community of the clinical efficacy and safety of our potential products and their potential advantages over existing products; • the prevalence and severity of any side effects; • the strength of marketing and distribution support; and • sufficient third-party coverage or reimbursement. The market may not accept our X-22 smoking cessation aid, based on any number of the above factors. Even if the FDA approves the marketing of X-22 as a smoking
cessation aid, there are other FDA-approved products available and there will also be future competitive products which directly
compete with X-22 . The market may prefer such existing or future competitive products for any number of reasons, including
familiarity with or pricing of such products. The failure of any of our potential products to gain market acceptance could impair
our ability to generate revenue, which could have a material adverse effect on our future business, financial condition, results
of operations and cash flows. 18 Our principal competitors in the smoking cessation market
have, and any future competitors may have, greater financial and marketing resources than we do, and they may therefore develop
products or other technologies similar or superior to ours or otherwise compete more successfully than we do. We have no experience in selling
smoking cessation products. Competition in the smoking cessation aid products industry is intense, and we may not be able to
successfully compete in the market. In the market for FDA-approved smoking cessation aids, our principal competitors include
Pfizer Inc., GlaxoSmithKline plc, Perrigo Company plc and Novartis International AG. The industry consists of major domestic
and international companies, most of which have existing relationships in the markets which we plan to sell, as well as
financial, technical, marketing, sales, manufacturing, scaling capacity, distribution and other resources and name
recognition substantially greater than ours. In addition, we expect new competitors will enter the markets for our products
in the future. Potential customers may choose to do business with our more established competitors, because of their
perception that our competitors are more stable, are more likely to complete various projects, can scale operations more
quickly, have greater manufacturing capacity, are more likely to continue as a going concern and lend greater credibility to
any joint venture. If we are unable to compete successfully against manufacturers of other smoking cessation products, our
business could suffer, and we could lose or be unable to obtain market share. We face intense competition in the market for our RED
SUN and MAGIC cigarettes and our BRAND A and BRAND B cigarettes, and our failure to compete effectively could have a material adverse
effect on our profitability and results of operations. Cigarette companies compete
primarily on the basis of product quality, brand recognition, brand loyalty, taste, innovation, packaging, service,
marketing, advertising, retail shelf space and price. We are subject to highly competitive conditions in all aspects of our
business and we may not be able to effectively market and sell our RED SUN and MAGIC cigarettes or other cigarettes we
may introduce to the market such as our BRAND A and BRAND B cigarettes as Modified Risk Cigarettes, upon
FDA authorization. The competitive environment and our competitive position can be significantly influenced by weak
economic conditions, erosion of consumer confidence, competitors’ introduction of low-price products or innovative
products, higher cigarette taxes, higher absolute prices and larger gaps between price categories, and product regulation
that diminishes the ability to differentiate tobacco products. Domestic competitors include Philip Morris USA Inc.,
Reynolds American Inc., Lorillard Inc., Commonwealth Brands, Inc., Liggett Group LLC, and Vector Tobacco Inc. International
competitors include Philip Morris International Inc., JT International SA, Imperial Tobacco Group plc and regional and local
tobacco companies. Our competitors may develop products that are less expensive,
safer or more effective, which may diminish or eliminate the commercial success of any potential product that we may commercialize. If our competitors market products that
are less expensive, safer or more effective than our potential products, or that reach the market before our potential products,
we may not achieve commercial success. The market may choose to continue utilizing existing products for any number of reasons,
including familiarity with or pricing of these existing products. The failure of our X -22 smoking cessation aid or our
cigarette brands to compete with products marketed by our competitors would impair our ability to generate revenue, which would
have a material adverse effect on our future business, financial condition, results of operations and cash flows. Our competitors
may: • develop
and market products that are less expensive or more effective than our products; • commercialize
competing products before we or our partners can launch our products; and • initiate
or withstand substantial price competition more successfully than we can. If we fail to stay at the forefront of technological change,
we may be unable to compete effectively. Our competitors may render our technologies
obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating
the advantages that we believe we derive from our research approach and proprietary technologies. Our competitors may: • operate larger research and development programs or have substantially greater financial resources than we do; • have greater success in recruiting skilled technical and scientific workers from the limited pool of available talent; • more effectively negotiate third-party licenses and strategic relationships; and • take advantage of acquisition or other opportunities more readily than we can. 19 Government mandated prices, production control programs,
shifts in crops driven by economic conditions and adverse weather patterns may increase the cost or reduce the quality of the tobacco
and other agricultural products used to manufacture our products. We depend upon independent tobacco farmers
to grow our specialty proprietary tobaccos with specific nicotine contents for our products. As with other agricultural commodities,
the price of tobacco leaf can be influenced by imbalances in supply and demand, and crop quality can be influenced by variations
in weather patterns, diseases and pests. We must also compete with other tobacco companies for contract production with independent
tobacco farmers. Tobacco production in certain countries is subject to a variety of controls, including government mandated prices
and production control programs. Changes in the patterns of demand for agricultural products could cause farmers to plant less
tobacco. Any significant change in tobacco leaf prices, quality and quantity could affect our profitability and our business. Our future success depends on our ability to retain key
personnel. Our success will depend to a significant
extent on the continued services of our senior management team, and in particular Henry Sicignano III, our President and Chief
Operating Officer, John Brodfuehrer, our Chief Financial Officer, Michael Moynihan, Ph.D., our Vice President of R&D, and Thomas
James, Esq., our Vice President, General Counsel and Secretary. The loss or unavailability of any of these individuals may significantly
delay or prevent the development of our potential products and other business objectives by diverting management’s attention
to transition matters. While each of these individuals is party to employment agreements with us, they could terminate their relationships
with us at any time, and we may be unable to enforce any applicable employment or non-compete agreements. We also rely on consultants and advisors
to assist us in formulating our research and development, manufacturing, distribution, marketing and sales strategies. All of our
consultants and advisors are either self-employed or employed by other organizations, and they may have conflicts of interest or
other commitments, such as consulting or advisory contracts with other organizations, that may affect their ability to contribute
to us. Product liability claims, product recalls or other claims
could cause us to incur losses or damage our reputation. The risk of product liability claims or
product recalls, and associated adverse publicity, is inherent in the development, manufacturing, marketing and sale of tobacco
and smoking cessation products. We do not currently have product liability insurance for our products or our potential products
and do not expect to be able to obtain product liability insurance at reasonable commercial rates for these products. Any product
recall or lawsuit seeking significant monetary damages may have a material adverse effect on our business and financial condition.
A successful product liability claim against us could require us to pay a substantial monetary award. We cannot assure you that
such claims will not be made in the future. Negative press from entering the cannabis space could
have a material adverse effect on our business, financial condition and results of operations. Despite growing support for the cannabis
industry and legalization of cannabis in certain U.S. states, many individuals and businesses remain opposed to the cannabis industry.
Any negative press resulting from our recent entry into the cannabis space could result in a loss of current or future business.
It could also adversely affect the public’s perception of us and lead to reluctance by new parties to do business with us
or to own our common stock. We cannot assure you that additional business partners, including but not limited to financial institutions
and customers, will not attempt to end or curtail their relationships with us. Any such negative press or cessation of business
could have a material adverse effect on our business, financial condition and results of operations. Any business related cannabinoid production is dependent
on laws pertaining to the cannabis industry . As of December 31, 2014, 23 states and
the District of Columbia allow their citizens to use medical marijuana. Additionally, the states of Colorado and Washington have
legalized cannabis for adult use. Furthermore, the states of Alaska and Oregon have approved legalized cannabis for adult use in
laws that will become effective in 2015. The state laws are in conflict with the federal Controlled Substances Act, or CSA, which
makes marijuana use, possession and interstate distribution illegal on a federal level. 20 We do not currently conduct any activities
related to cannabis in the United States. Our research facilities for cannabis are located exclusively in Canada. In Canada, licenses
to cultivate, possess and supply cannabis for medical research are granted by agencies of the federal government in Canada. In
order to carry out research in other countries, similar licenses are required to be issued by the relevant authority in each country. Local, state, federal and international
medical marijuana laws and regulations are broad in scope and subject to evolving interpretations, which could require us to incur
substantial costs associated with compliance requirements. In addition, violations of these laws, or allegations of such violations,
could disrupt our business and result in a material adverse effect on our operations. In addition, it is possible that regulations
may be enacted in the future that will be directly applicable to our proposed business regarding cannabinoid production. We cannot
predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional
governmental regulations or administrative policies and procedures, when and if promulgated, could have on our proposed business. Risks Related to Regulatory Approvals and Insurance Reimbursement If we fail to obtain FDA and foreign regulatory approvals
of X-22 as a smoking cessation aid and FDA authorization to market BRAND A and BRAND B as Modified Risk Cigarettes, we will be
unable to commercialize these potential products in and outside the U.S., other than the sale of our BRAND A and BRAND B cigarettes
as conventional cigarettes. There can be no assurance that our X-22 smoking cessation aid will be approved by the FDA, European Medicines Agency (“EMA”), or any other governmental body. In addition,
there can be no assurance that all necessary approvals will be granted for our potential products or that review or actions
will not involve delays caused by requests for additional information or testing that could adversely affect the time to
market for and sale of our potential products. Our ability to complete the FDA-approval process in a timely manner is
dependent, in part, on our ability to obtain “Fast Track” designation for X-22 by the FDA. We submitted a request for Fast
Track designation for X-22 , and on August 18, 2011, the FDA informed us that it would not grant the designation of X-22 as a Fast Track product at that time because we had not yet demonstrated that X-22 showed potential to address an
unmet medical need. Except for our Phase IIb clinical trial, all smoking cessation studies with VLN cigarettes containing our proprietary tobacco were independent studies and were not sponsored by
us under our own IND application. We plan to reapply for Fast Track
designation, but not until results of a clinical trial conducted by us demonstrates an advantage (over currently approved
smoking cessation products) in one of the following areas: efficacy, safety or improvement in some other factor such as
compliance (a patient using a product as directed) or convenience. There is no guarantee that the FDA will grant Fast Track
designation to X-22 . We may also not obtain Priority Review of our X-22 New Drug Application
(“NDA”), which would further delay FDA approval of X-22 . The length of the FDA’s review of a NDA
without a Priority Review designation is normally ten months from the date of filing of the NDA, although it is possible in
certain cases for such review time to be longer. However, the FDA’s goal for reviewing a product with Priority Review
status is normally six months from the date of the filing of a NDA. If we do not obtain Priority Review of our NDA, we would
then expect the timing of FDA approval of X-22 to be extended several additional months. Even if X-22 is
approved by the FDA, the FDA may require the product to only be prescribed to patients who have already failed to quit
smoking with another approved therapy. Further, failure to comply with applicable regulatory requirements can, among other
things, result in the suspension of regulatory approval as well as possible civil and criminal sanctions. 21 The development, testing, manufacturing
and marketing of our potential products are subject to extensive regulation by governmental authorities in the United States and
throughout the world. In particular, the process of obtaining approvals by the FDA, the EMA
and other international FDA equivalent agencies in targeted countries is costly and time consuming, and the time required for such
approval is uncertain. Our X-22 smoking cessation aid must undergo rigorous clinical testing and an extensive regulatory
approval process mandated by the FDA or EMA. Such regulatory review includes the determination of manufacturing capability and
product performance. Generally, only a small percentage of pharmaceutical products are ultimately approved for commercial sale. The scope of review, including
product testing and exposure studies, to be required by the FDA under the Tobacco Control Act in order for cigarettes such as BRAND
A and BRAND B to be marketed as Modified Risk Cigarettes has not yet been fully established, even though the FDA
issued Modified Risk Tobacco Product Applications Draft Guidance on March 30, 2012. We may be unsuccessful in
establishing that BRAND A or BRAND B are Modified Risk Cigarettes, and we may fail to demonstrate that either BRAND
A or BRAND B significantly reduces exposure to certain tobacco smoke toxins. Even upon demonstrating significant
reduced exposure to certain tobacco smoke toxins, the FDA may decide that allowing a modified risk claim is not in the best
interest of the public health, and the FDA may not allow us to market our BRAND A and/or BRAND B cigarettes as
Modified Risk Cigarettes. The FDA could force the removal of our products from the
U.S. market. The FDA could force us to remove from the
U.S. market our tobacco products such as RED SUN or MAGIC since these are not grandfathered products under the Tobacco
Control Act, and the FDA could force us to remove from the U.S. market BRAND A and/or BRAND B even after FDA authorization
to market BRAND A and BRAND B as Modified Risk Cigarettes. We intend to distribute and sell our potential
products outside of the United States, which will subject us to other regulatory risks. In addition to seeking approval from the
FDA for our X-22 smoking cessation aid in the United States, we intend to seek governmental approvals required to market X-22 and our other potential products in other countries. Marketing of our X-22 smoking cessation aid is not permitted
in certain countries until we have obtained required approvals or exemptions in the individual country. The regulatory review process
varies from country to country, and approval by foreign governmental authorities is unpredictable, uncertain and generally expensive.
Our ability to market our potential products could be substantially limited due to delays in receipt of, or failure to receive,
the necessary approvals or clearances. We anticipate commencing the applications required in some or all of these countries following
approval by the FDA; however, we may decide to file applications in advance of the FDA approval if we determine such filings to
be both time and cost effective. If we export any of our potential products or products that have not yet been cleared for commercial
distribution in the United States, such products may be subject to FDA export restrictions. Failure to obtain necessary regulatory
approvals could impair our ability to generate revenue from international sources. Market acceptance of our X-22 smoking cessation aid could
be limited if users are unable to obtain adequate reimbursement from third-party payers. Government health administration authorities,
private health insurers and other organizations generally provide reimbursement for FDA-approved smoking cessation products, and
our commercial success could depend in part on these third-party payers agreeing to reimburse patients for the costs of our X-22 smoking cessation aid. Even if we succeed in bringing our X-22 smoking cessation aid to market, there is no assurance that
third-party payers will consider X-22 cost effective or provide reimbursement in whole or in part for its use. Significant uncertainty exists as to the
reimbursement status of newly approved health care products. Our X-22 smoking cessation aid is intended to replace or alter
existing therapies or procedures. These third-party payers may conclude that our X-22 smoking cessation aid is less safe,
effective or cost-effective than these existing therapies or procedures. Therefore, third-party payers may not approve X-22 for reimbursement. If third-party payers do not approve X-22 or our potential products for reimbursement or fail to reimburse for them adequately, sales could suffer as some physicians or
their patients could opt for a competing product that is approved for reimbursement or is adequately reimbursed. Even if third-party
payers make reimbursement available, these payers’ reimbursement policies may adversely affect our ability and the ability
of our potential collaborators to sell our potential products on a profitable basis. The trend toward managed healthcare in the
United States, such as the Affordable Care Act enacted on March 23, 2010, and legislative proposals to reform healthcare and government
insurance programs could significantly influence the purchase of healthcare services and products, resulting in lower prices and
reduced demand for our potential products which could adversely affect our business, financial condition, results of operations
and cash flows. 22 In addition, legislation and regulations
affecting the pricing of our potential products may change in ways adverse to us before or after the FDA or other regulatory agencies
approve any of our potential products for marketing. While we cannot predict the likelihood of any of these legislative or regulatory
proposals, if any government or regulatory agency adopts these proposals, they could materially adversely affect our business,
financial condition, results of operations and cash flows. Our clinical trials for any of our potential products
may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical and/or
preclinical testing for these potential products or cease our trials. We do not know whether clinical trials of
our potential products will demonstrate safety and efficacy sufficiently to result in marketable products. Because our clinical
trials for our X-22 smoking cessation aid and any other potential products may produce negative or inconclusive results,
we may decide, or regulators may require us, to conduct additional clinical and/or preclinical testing for these potential products
or cease our clinical trials. If this occurs, we may not be able to obtain approval or marketing authorization for these potential
products or our anticipated time of bringing these potential products to the market may be substantially delayed and we may also
experience significant additional development costs. We may also be required to undertake additional clinical testing if we change
or expand the indications for our potential products. Risks Related to the Tobacco Industry Our business faces significant governmental action aimed
at increasing regulatory requirements with the goal of preventing the use of tobacco products. Cigarette companies face significant governmental
action, especially in the United States pursuant to the Tobacco Control Act, including efforts aimed at reducing the incidence
of tobacco use, restricting marketing and advertising, imposing regulations on packaging, warnings and disclosure of flavors or
other ingredients, prohibiting the sale of tobacco products with certain flavors or other characteristics, limiting or prohibiting
the sale of tobacco products by certain retail establishments and the sale of tobacco products in certain packaging sizes, and
seeking to hold retailers and distributors responsible for the adverse health effects associated with both smoking and exposure
to environmental tobacco smoke. Governmental actions, combined with the diminishing social acceptance of smoking and private actions
to restrict smoking, have resulted in reduced industry volume in the United States and certain other countries, and we expect that
these factors will continue to reduce consumption levels in these countries. Certain of such actions may have a favorable
impact on our X-22 smoking cessation aid, or on our BRAND A and BRAND B cigarettes if we are able to market
them as Modified Risk Cigarettes. However, there is no assurance of such favorable impact and such actions may have a negative
impact on our ability to market RED SUN and MAGIC . Significant regulatory developments
will take place over the next few years in many markets, driven principally by the World Health Organization’s
Framework Convention on Tobacco Control (“FCTC”). The FCTC is the first international public health treaty on
tobacco, and its objective is to establish a global agenda for tobacco regulation with the purpose of reducing initiation of
tobacco use and encouraging cessation. In addition, the FCTC has led to increased efforts by tobacco control advocates and
public health organizations to reduce the appeal of tobacco products. Partly because of some or a combination of these
efforts, unit sales of tobacco products in certain markets, principally Western Europe and Japan, have been in general
decline and we expect this trend to continue. Our operating results could be significantly affected by any significant
decrease in demand for cigarettes, any significant increase in the cost of complying with new regulatory requirements and
requirements that lead to a commoditization of tobacco products such as the implementation of plain packaging in
Australia. 23 If implemented in the future, the FDA requirement regarding
graphic health warnings on cigarette packaging and in cigarette advertising is likely to have a negative impact on sales of our
products. In November 2010, as required by the Tobacco
Control Act, the FDA issued a proposed rule to modify the required warnings that appear on cigarette packages and in cigarette
advertisements. These warning were finalized on June 21, 2011 and consist of nine new textual warning statements accompanied by
color graphics depicting the negative health consequences of smoking. The FDA selected nine images from the originally proposed
36 images after reviewing the relevant scientific literature, analyzing the results from an 18,000 person study and considering
more than 1,700 comments from a variety of groups. The graphic health warnings were to be located beneath the cellophane wrapping
on cigarette packages, and will comprise the top 50 percent of the front and rear panels of cigarette packages. The graphic health
warnings will occupy 20 percent of a cigarette advertisement and will be located at the top of the advertisement. Each warning
is accompanied by a smoking cessation phone number, 1-800-QUIT-NOW. Although these graphic health warnings were supposed to be
implemented in September 2012, a federal judge ruled that these warnings are unconstitutional. If and when these graphic health
warnings are implemented, all cigarettes manufactured for sale or distribution in the United States will need to include these
new graphic health warnings on their packages. Any reduction in the number of smokers will probably reduce the demand for MAGIC and RED SUN , as well as X-22 , BRAND A and BRAND B , if and when implemented by the FDA. MAGIC , RED SUN , BRAND A and BRAND B will be subject to these new packaging and advertising regulations . It
is unclear at this time whether the FDA may require X-22 and SPECTRUM to be subject to these new packaging and advertising
regulations. We may become subject to litigation related to cigarette
smoking and exposure to environmental tobacco smoke, or ETS, which could severely impair our results of operations and liquidity. Although we are not currently subject to
legal proceedings, we may become subject to litigation related to the sale of our RED SUN and MAGIC cigarettes and,
upon FDA authorization, our BRAND A and BRAND B cigarettes. Legal proceedings covering a wide range of matters related
to tobacco use are pending or threatened in various U.S. and foreign jurisdictions. Various types of claims are raised in these
proceedings, including product liability, consumer protection, antitrust, tax, contraband shipments, patent infringement, employment
matters, claims for contribution and claims of competitors and distributors. Litigation is subject to uncertainty and
it is possible that there could be adverse developments in pending cases. An unfavorable outcome or settlement of pending tobacco
related litigation could encourage the commencement of additional litigation. The variability in pleadings, together with the actual
experience of management in litigating claims, demonstrates that the monetary relief that may be specified in a lawsuit bears little
relevance to the ultimate outcome. Damages claimed in some tobacco-related
litigation are significant and, in certain cases range into the billions of dollars. We anticipate that new cases will continue
to be filed. The FCTC encourages litigation against tobacco product manufacturers. It is possible that our results of operations,
cash flows or financial position could be materially affected by an unfavorable outcome or settlement of litigation. Cigarettes are subject to substantial taxes. Significant
increases in cigarette-related taxes have been proposed or enacted and are likely to continue to be proposed or enacted in numerous
jurisdictions. These tax increases may affect our sales and profitability and make us less competitive versus certain of our competitors. Tax regimes, including excise taxes, sales
taxes and import duties, can disproportionately affect the retail price of manufactured cigarettes versus other tobacco products,
or disproportionately affect the relative retail price of our RED SUN and MAGIC cigarettes and, upon FDA authorization,
our BRAND A and BRAND B cigarettes versus lower-priced cigarette brands manufactured by our competitors. Increases
in cigarette taxes are expected to continue to have an adverse impact on sales of cigarettes resulting in (i) lower consumption
levels, (ii) a shift in sales from manufactured cigarettes to other tobacco products or to lower-price cigarette categories, (iii)
a shift from local sales to legal cross-border purchases of lower price products, and (iv) illicit products such as contraband
and counterfeit. We may become subject to governmental investigations on
a range of matters. Tobacco companies are often subject to investigations,
including allegations of contraband shipments of cigarettes, allegations of unlawful pricing activities within certain markets,
allegations of underpayment of custom duties and/or excise taxes, and allegations of false and misleading usage of descriptors
such as “lights” and “ultra-lights.” We cannot predict the outcome of any to which we may become subject,
and we may be materially affected by an unfavorable outcome of future investigations. Risks Related to Intellectual Property Our proprietary rights may not adequately protect our
intellectual property, products and potential products, and if we cannot obtain adequate protection of our intellectual property,
products and potential products, we may not be able to successfully market our products and potential products. Our commercial success will depend in part
on obtaining and maintaining intellectual property protection for our technologies, products and potential products. We will only
be able to protect our technologies, products and potential products from unauthorized use by third parties to the extent that
valid and enforceable patents cover them, or other market exclusionary rights apply. 24 The patent positions of life sciences companies,
like ours, can be highly uncertain and involve complex legal and factual questions for which important legal principles remain
unresolved. No consistent policy regarding the breadth of claims allowed in such companies’ patents has emerged to date in
the United States. The general patent environment outside the United States also involves significant uncertainty. Accordingly,
we cannot predict the breadth of claims that may be allowed or that the scope of these patent rights could provide a sufficient
degree of future protection that could permit us to gain or keep our competitive advantage with respect to these products and technology.
Additionally, life science companies like ours are often dependent on creating a pipeline of products. We may not be able to develop
additional potential products or proprietary technologies that produce commercially viable products or that are themselves patentable. Although there are currently no challenges
to any portion of our intellectual property, our issued patents may be subject to challenge and possibly invalidated by third parties.
Changes in either the patent laws or in the interpretations of patent laws in the United States or other countries may diminish
the value of our intellectual property. In addition, others may independently develop similar or alternative products and technologies
that may be outside the scope of our intellectual property. Should third parties obtain patent rights to similar products or technology,
this may have an adverse effect on our business. We also rely on trade secrets to protect
our technology, products and potential products, especially where we do not believe patent protection is appropriate or obtainable.
Trade secrets, however, are difficult to protect. While we believe that we use reasonable efforts to protect our trade secrets,
our own, our licensees’ or our strategic partners’ employees, consultants, contractors or advisors may unintentionally
or willfully disclose our information to competitors. We seek to protect this information, in part, through the use of non-disclosure
and confidentiality agreements with employees, consultants, advisors and others. These agreements may be breached, and we may not
have adequate remedies for a breach. In addition, we cannot ensure that those agreements will provide adequate protection for our
trade secrets, know-how or other proprietary information or prevent their unauthorized use or disclosure. To the extent that consultants or key employees
apply technological information independently developed by them or by others to our products and potential products, disputes may
arise as to the proprietary rights of the information, which may not be resolved in our favor. Key employees are required to assign
all intellectual property rights in their discoveries to us. However, these key employees may terminate their relationship with
us, and we cannot preclude them indefinitely from dealing with our competitors. If our trade secrets become known to competitors
with greater experience and financial resources, the competitors may copy or use our trade secrets and other proprietary information
in the advancement of their products, methods or technologies. If we were to prosecute a claim that a third party had illegally
obtained and was using our trade secrets, it could be expensive and time consuming and the outcome could be unpredictable. In addition,
courts outside the United States are sometimes less willing to protect trade secrets than courts in the United States. Moreover,
if our competitors independently develop equivalent knowledge, we would lack any contractual claim to this information, and our
business could be harmed. The ability to commercialize our potential products will
depend on our ability to sell such products without infringing the patent or proprietary rights of third parties. If we are sued
for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and an unfavorable
outcome could have a significant adverse effect on our business. The ability to commercialize our potential
products will depend on our ability to sell such products without infringing the patents or other proprietary rights of third parties.
Third-party intellectual property rights in our field are complicated, and third-party intellectual property rights in these fields
are continuously evolving. While we have conducted searches for such third-party intellectual property rights, we have not performed
specific searches for third-party intellectual property rights that may raise freedom-to-operate issues, and we have not obtained
legal opinions regarding commercialization of our potential products. As such, there may be existing patents that may affect our
ability to commercialize our potential products. In addition, because patent applications
are published up to 18 months after their filing, and because patent applications can take several years to issue, there may be
currently pending third-party patent applications and freedom-to-operate issues that are unknown to us, which may later result
in issued patents. If a third-party claims that we infringe
on its patents or other proprietary rights, we could face a number of issues that could seriously harm our competitive position,
including: • infringement claims that, with or without merit, can be costly and time consuming to litigate, can delay the regulatory approval process and can divert management’s attention from our core business strategy; • substantial damages for past infringement which we may have to pay if a court determines that our products or technologies infringe upon a competitor’s patent or other proprietary rights; 25 • a court order prohibiting us from commercializing our potential products or technologies unless the holder licenses the patent or other proprietary rights to us, which such holder is not required to do; • if a license is available from a holder, we may have to pay substantial royalties or grant cross licenses to our patents or other proprietary rights; and • redesigning our process so that it does not infringe the third-party intellectual property, which may not be possible, or which may require substantial time and expense including delays in bringing our potential products to market. Such actions could harm our competitive
position and our ability to generate revenue and could result in increased costs. Our patent applications may not result in issued patents,
which may have a material adverse effect on our ability to prevent others from commercially exploiting products similar to ours. We own or exclusively control 128
issued patents plus and additional 52 pending patent application. The patents owned by or exclusively licensed to us include
patents issued in 96 countries. We cannot assure you these patent applications will issue, in whole or in part, as patents.
Patent applications in the United States are maintained in secrecy until the patents are published or are issued. Since
publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months,
we cannot be certain that we are the first creator of inventions covered by pending patent applications or the first to file
patent applications on these inventions. We also cannot be certain that our pending patent applications will result in
issued patents or that any of our issued patents will afford protection against a competitor. In addition, patent
applications filed in foreign countries are subject to laws, rules and procedures that differ from those of the United
States, and thus we cannot be certain that foreign patent applications related to U.S. patents will be issued. Furthermore,
if these patent applications issue, some foreign countries provide significantly less effective patent enforcement than in
the United States. The status of patents involves complex legal
and factual questions and the breadth of claims allowed is uncertain. Accordingly, we cannot be certain that the patent applications
that we or our licensors file will result in patents being issued, or that our patents and any patents that may be issued to us
in the near future will afford protection against competitors with similar technology. In addition, patents issued to us may be
infringed upon or designed around by others and others may obtain patents that we need to license or design around, either of which
would increase costs and may adversely affect our operations. We license certain patent rights from third-party owners.
If such owners do not properly maintain or enforce the patents underlying such licenses, our competitive position and business
prospects could be harmed. We license rights to third-party intellectual
property that is necessary or useful for our business, and we may enter into additional licensing agreements in the future. Our
success could depend in part on the ability of some of our licensors to obtain, maintain and enforce patent protection for their
intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully
prosecute the patent applications to which we are licensed. Even if patents are issued with respect to these patent applications,
our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing
these patents, or may pursue such litigation less aggressively than we could. Without protection for the intellectual property
we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our
competitive business position and harm our business prospects. Our two worldwide exclusive licenses
relating to tobacco, one from NCSU and the other from National Research
Council of Canada, Plant Biotechnology Institute (“NRC”), each involve multiple patent families. The
exclusive rights under the NCSU agreement expires on the date on which the last patent or registered plant variety covered by
the subject license expires in the country or countries where such patents or registered plant varieties are in effect. The
NCSU license relates predominately to issued patents, and our exclusive rights in the NCSU license will expire in
2023. The exclusive rights granted to us under the NRC agreement would have expired on the date on which
the last patent covered by the subject license expires in the country or countries where such patents are in effect. The NRC
license related to issued patents and patent applications, and our exclusive rights in the NRC license was
previously scheduled to expire in 2028. On December 23, 2014, we purchased from NRC all the issued patents and patent
applications that were exclusively licensed to us by NRC. Our worldwide sublicense from Anandia, a plant biotechnology company based in Vancouver, Canada, grants us exclusive
rights in the United States and co-exclusive rights with Anandia everywhere else in the world (except not in Canada where
Anandia retains exclusive rights) to 23 patent applications relating to four genes in the cannabis plant that are required
for the production of cannabinoids, the active ingredients in the cannabis plant. The Anandia sublicense continues through the
life of the last-to-expire patent, which is expected to be in 2035. 26 Risks Related to Ownership of Our Common Stock An active trading market for our common stock may not
be sustained, and you may not be able to resell your shares at or above the price at which you purchased them. An active trading market for our
shares may not be sustained. In the absence of an active trading market for our common stock, shares of common stock may not
be able to be resold at or above the purchase price of such shares. Although there can be no assurances, we expect that our
common stock will continue to be quoted on the New York Stock Exchange MKT (NYSE MKT) on which the shares of our common stock
are currently quoted. However, even if our common stock continues to be quoted on the NYSE MKT, there is no assurance that an
active market for our common stock will continue in the foreseeable future. There also can be no assurance that we can
maintain such listing on the NYSE MKT. It may be more difficult to dispose of shares or obtain accurate quotations as to the
market value of our common stock compared to securities of companies whose shares are traded on national stock exchanges. Our stock price may be highly volatile and could decline
in value. Our common stock is currently traded on
the NYSE MKT and the market prices for our common stock have been volatile. Further, the market prices for securities in general
have been highly volatile and may continue to be highly volatile in the future. The following factors, in addition to other risk
factors described in this section, may have a significant impact on the market price of our common stock: • results from and any delays in any
clinical trials programs; • failure or delays in entering potential
products into clinical trials; • failure or discontinuation of any
of our research programs; • delays in establishing new strategic
relationships; • delays in the development
of our potential products and commercialization of our potential products; • market conditions in our
sector and issuance of new or changed securities analysts’ reports or recommendations; • general economic conditions,
including recent adverse changes in the global financial markets; • actual and anticipated fluctuations
in our quarterly financial and operating results; • developments or disputes concerning
our intellectual property or other proprietary rights; • introduction of technological
innovations or new commercial products by us or our competitors; • issues in manufacturing or distributing
our products or potential products; • market acceptance of our products
or potential products; • third-party healthcare reimbursement
policies; • FDA or other United States or foreign
regulatory actions affecting us or our industry; • litigation or public concern about
the safety of our products or potential products; • additions or departures of key personnel; • third-party sales of large blocks
of our common stock; • sales of our common stock
by our executive officers, directors or significant stockholders; and • equity sales by us of our
common stock or securities convertible into common stock to fund our operations. These and other external factors may cause
the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily
selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, in the
past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation
against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial
costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management. Future sales of our common stock will result in dilution
to our common stockholders. Sales of a substantial number of shares
of our common stock in the public market may depress the prevailing market price for our common stock and could impair our ability
to raise capital through the future sale of our equity securities. Additionally, if the holders of outstanding options or warrants
exercise or convert those shares, as applicable, our common stockholders will incur dilution in their relative percentage ownership. The
prospect of this possible dilution may also impact the price of our common stock. 27 We are controlled by our current officers and directors. As of February 3, 2015,
our directors and executive officers as a group beneficially owned approximately 24.6% of our common stock. Accordingly,
our directors and executive officers will have substantial influence over, and may have the ability to control, the election
of our board of directors and the outcome of issues submitted to a vote of our stockholders. We do not expect to declare any dividends on our common
stock in the foreseeable future. We have not paid cash dividends to date on our common stock.
We currently intend to retain our future earnings, if any, to fund the development and growth of our business, and we do not anticipate
paying any cash dividends on our common stock for the foreseeable future. Additionally, the terms of any future debt facilities
may preclude us from paying dividends on the common stock. As a result, capital appreciation, if any, of our common stock could
be the sole source of gain for the foreseeable future. Anti-takeover provisions contained in our articles of
incorporation and bylaws, as well as provisions of Nevada law, could impair a takeover attempt. Our amended and restated articles of incorporation
and bylaws currently contain provisions that, together with Nevada law, could have the effect of rendering more difficult or discouraging
an acquisition deemed undesirable by our board of directors. Our corporate governance documents presently include the following
provisions: · providing for a “staggered” board of directors in which only one-third (1/3) of the directors can be elected in any year; · authorizing blank check preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock; and · limiting the liability of, and providing indemnifications to, our directors and officers. These provisions, alone or together, could
delay hostile takeovers and changes in control of us or changes in our management. As a Nevada corporation, we also may
become subject to the provisions of Nevada Revised Statutes Sections 78.378 through 78.3793, which prohibit an acquirer,
under certain circumstances, from voting shares of a corporation’s stock after crossing specific threshold ownership
percentages, unless the acquirer obtains the approval of the stockholders of the issuer corporation. The first such threshold
is the acquisition of at least one-fifth, but less than one-third of the outstanding voting power of the issuer. We may
become subject to the above referenced Statutes if we have 200 or more stockholders of record, at least 100 of whom are
residents of the State of Nevada, and do business in the State of Nevada directly or through an affiliated corporation. As a Nevada corporation, we are subject
to the provisions of Nevada Revised Statutes Sections 78.411 through 78.444, which prohibit an “interested stockholder”
from entering into a combination with the corporation, unless certain conditions are met. An “interested stockholder”
is a person who, together with affiliates and associates, beneficially owns (or within the prior two years did own) 10 percent
or more of the corporation’s voting stock. Any provision of our amended and restated
articles of incorporation, our bylaws or Nevada law that has the effect of delaying or deterring a change in control of our Company
could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect
the price that some investors are willing to pay for our common stock. 28 Item 1B Unresolved Staff Comments. None. Item 2. Properties. Our principal administrative offices are
located in Clarence, New York. We currently lease 3,800 square feet of office space. The lease
expires August 31, 2015, after which we have two (2) additional lease renewal option periods of one (1) year each. Scheduled rent
remaining as of December 31, 2014 is $28,840 for 2015. We have a lease for our warehouse
and cigarette manufacturing facility located in North Carolina. The lease
commenced on January 14, 2014, and has an initial term of twelve (12) months (the “Initial Term”). The lease
contains four (4) additional extensions; one for an additional one (1) year and three for an additional two (2) years
in duration, exercisable at the option of NASCO. The lease calls for minimum lease
payments of $96,000 during the Initial Term, $123,000 for the one (1) year optional extension, $144,525 and $153,750 for each
year of the first two (2) year optional extensions, and $169,125 for each year of the final two (2) year
optional extensions. Item 3. Legal Proceedings. From time to time we may be involved in
claims arising in the ordinary course of business. To our knowledge, no legal proceedings, governmental actions, investigations
or claims are currently pending against us or involve us that, in the opinion of our management, could reasonably be expected to
have a material adverse effect on our business and financial condition. Item 4. Mine Safety Disclosures. Not applicable PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Our common stock is quoted on the NYSE
MKT under the symbol “XXII.” As of February 4, 2015, there were 89 holders of record of shares of our
common stock. The following table sets forth, for the quarters indicated, the high and low bid prices per share of our common
stock, as derived from quotations provided by (i) the OTC Bulletin Board Information Center for the period prior to March 11,
2014, when our common stock was quoted on the OTC Bulletin Board, and (ii) the NYSE MKT for the period beginning on March
11, 2014, when our common stock commenced being listed and quoted on the NYSE MKT. Quarter Ended High Bid Low Bid December 31, 2014 $ 2.67 $ 1.50 September 30, 2014 $ 3.35 $ 1.90 June 30, 2014 $ 3.87 $ 2.14 March 31, 2014 $ 6.36 $ 1.75 December 31, 2013 $ 2.19 $ 0.87 September 30, 2013 $ 1.74 $ 0.70 June 30, 2013 $ 0.90 $ 0.46 March 31, 2013 $ 1.07 $ 0.51 Dividend Policy We have not previously and do not plan to
declare or pay any dividends on our common stock. Our current policy is to retain all funds and any earnings for use in the operation
and expansion of our business. Payment of future dividends, if any, will be at the discretion of our board of directors after taking
into account various factors, including current financial condition, operating results and current and anticipated cash needs. Recent issuances of Unregistered Securities None. 29 Shares authorized for issuance under
equity compensation plans On October 21, 2010, the Company established
the 2010 Equity Incentive Plan, or EIP, for officers, employees, directors, consultants and advisors to the Company and its affiliates,
consisting of 4,250,000 shares of common stock. The EIP authorized the grant of incentive stock options, nonqualified stock options,
stock appreciation rights, restricted stock, restricted stock units, performance shares, restricted stock and restricted stock
units. There are no awards remaining to be issued from the EIP at December 31, 2014. On April 12, 2014, the stockholders of the Company approved the 22nd Century Group, Inc. 2014
Omnibus Incentive Plan (the “OIP”). The OIP allows for the granting of equity and cash incentive awards to eligible
individuals over the life of the OIP, including the issuance of up to 5,000,000 shares of the Company’s common stock pursuant
to awards under the OIP. The OIP has a term of ten years and is administered by the Compensation Committee of our Board of Directors
to determine the various types of incentive awards that may be granted to recipients under this plan and the number of shares
of common stock to underlie each such award under the OIP. The following table summarizes the number
of stock options and shares of restricted stock granted, net of forfeitures and sales, the weighted-average exercise price
of such stock options and the number of securities remaining to be issued under all outstanding equity compensation plans as of
December 31, 2014: Number of securities remaining available for Number of securities to Weighted-average issuance under equity be issued upon exercise exercise price of compensation plans of outstanding options, outstanding options, (excluding securities warrants and rights warrants and rights reflected in column (a)) (a) (b) (c) Equity compensation plans approved by security holders 1,804,000 (1) $ 1.38 (2) 4,852,444 Equity compensation plans not approved by security holders 0 N/A 0 Total 1,804,000 4,852,444 (1) Includes 911,000 restricted stock awards that are issued but not vested as of December 31, 2014. (2) Weighted average exercise price only applies to the 890,000 shares issuable upon exercise of outstanding stock options. Item 6. Selected Financial Data. This item is not applicable to us as a smaller
reporting company. 30 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. This discussion should be read in
conjunction with the other sections of this Form 10-K, including “Risk Factors,” and the Financial Statements. The
various sections of this discussion contain a number of forward-looking statements, all of which are based on our current
expectations and could be affected by the uncertainties and risk factors described throughout this Annual Report on Form
10-K. See “Forward-Looking Statements.” Our actual results may differ materially. For purposes of this
Management’s Discussion and Analysis of Financial Condition and Results of Operations, references to the
“Company,” “we,” us” or “our” refer to the operations of 22nd Century Group, Inc.
and its direct and indirect subsidiaries for the periods described herein. Business Overview We are a plant biotechnology company
specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine
and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. We focused on
tobacco harm reduction and smoking cessation products. We own or exclusively control 128 issued patents plus an additional 52
pending patent applications. The patents owned by or exclusively licensed to us include patents issued in 96 countries. Our long-term focus is the research, development,
licensing, manufacturing, and selling of our products to reduce the harm caused by smoking. Annual worldwide
tobacco product sales, cigarettes and smokeless products, are approximately $800 billion and most of which are cigarette sales
according to Euromonitor International. • The international licensing of our technology, proprietary tobaccos, trademarks; • The international sale of our branded proprietary tobaccos; • The manufacture, marketing and distribution of RED SUN and MAGIC proprietary cigarettes; • The production of SPECTRUM research cigarettes for NIDA,
a part of NIH ; • The research and development of potentially less harmful or modified risk tobacco products and novel tobacco plant varieties; • The development of X-22 , a prescription-based smoking cessation
aid consisting of VLN cigarettes; • The pursuit of necessary regulatory approvals and clearances from the FDA to market in the U.S. X-22 as a prescription smoking cessation aid and BRAND A and BRAND B as reduced-risk or Modified Risk Cigarettes; • The contract manufacturing of third-party branded tobacco products; and • The research and development in Canada of unique plant varieties of hemp/cannabis, such as (i) plants with low to no amounts of delta-9-tetrahydrocannabinol, or THC, for the legal hemp industry, (ii) plants with high levels of THC for the legal recreational cannabis market, and (iii) plants with high levels of cannabidiol, or CBD, and other non-THC cannabinoids for the legal medical marijuana markets. 31 We believe our proprietary technology,
tobaccos and products can generate multiple significant revenue streams from licensing of our technology and tobacco and
from the sales of our products. As previously reported, on October 25,
2014, our Board of Directors terminated the employment of Joseph Pandolfino, our former Chief Executive Officer, pursuant to
Section 4.2 (Termination Without Cause) of Mr. Pandolfino's Employment Agreement and formed an Executive Committee of the
Board, consisting of the existing independent directors, to assist our management until the Board completes its search for
and selection of a new Chief Executive Officer. Although Mr. Pandolfino will not be re-joining us as an employee or officer,
he remains a member of the Board of Directors. Since October 2014, the Executive Committee
has been primarily working with management to assist it with forming the proper strategic direction of our business and to streamline
and organize our business in light of the termination of Mr. Pandolfino. The Executive Committee expects to hire a third party
advisory firm during the first quarter of 2015 in order to assist with the search for and selection of a new Chief Executive Officer. Please refer to the “Business”
section in this Annual Report on Form 10-K for additional information regarding our business and operations. Results of Operations Year Ended December 31, 2014 Compared to Year Ended December
31, 2013 Revenue - Royalties from licensing. In the year ended December 31, 2014, we
realized no licensing revenue. During the year ended December 31, 2013 we realized royalty revenue of $7.0 million from the worldwide
Research License and Commercial Option Agreement entered into with BAT. Revenue - Sale of products. We realized revenue of $528,991 from the
sale of products during the year ended December 31, 2014, as compared to revenue of $278,383 during the year ended December 31,
2013, an increase of $250,608 or 90%. The revenue of $528,991 for the year ended December 31, 2014, consisted of $447,535 in revenue
derived from the sale of 5.5 million SPECTRUM research cigarettes during January 2014 and from the production of filtered
cigars in our North Carolina manufacturing facility in the amount of $81,456. The revenue for the year ended December 31, 2013,
was derived from the sale of our proprietary VLN tobacco to a customer in the Netherlands in the amount of $52,500 and from the
sale of our VLN tobacco to the FDA as a subcontractor under a government contract between RTI and the FDA in the amount of $225,883. Costs of goods sold - Royalties for licensing . During the year ended December
31, 2014, we revised the estimate of the royalty fee due to NRC in connection with the $7,000,000 fee
received from BAT in the fourth quarter of 2013. The new amount due to NRC of $660,000 exceeded the
estimate of $413,566, originally recorded in the year ended December 31, 2013, by $246,434. Costs of goods sold - Products . In the year ended December 31, 2014, costs
of goods sold were $252,002 or 47.6% of revenue. The cost of goods sold consists of $177,696 relating to the production of the SPECTRUM research cigarettes and $74,306 relating to the manufacture of the filtered cigars. In the year ended December 31,
2013, the cost of goods sold were $48,105 or 17.3% of revenue. Research and development expense . Research and development expense was $1,249,007
for the year ended December 31, 2014, an increase of $504,777, or 67.8%, from $744,230 for the year ended December 31, 2013. This
increase was primarily the result of increases in stock based compensation of approximately $220,000, research and development
payroll and related benefits of approximately $104,000, royalty and license fees of approximately $187,000, and $15,000 of costs
associated with an FDA modified-risk application, partially offset by a decrease in contractual research and development costs
of approximately $39,000 during the year ended December 31, 2014 as compared to the year ended December 31, 2013. 32 General and administrative expense . General and administrative expense was $8,793,151
in the year ended December 31, 2014, an increase of $4,686,457, or 114.1%, from $4,106,694 in the year ended December 31, 2013.
The increase was primarily due to increases in employee stock based compensation of approximately $1,047,000, employee related
costs of approximately $693,000, legal and professional fees of approximately $986,000, costs relating to press releases of approximately
$78,000, the write off of an uncollectible advance in the approximate amount of $43,000, NYSE MKT related costs of approximately
$176,000, costs associated with severance liability of approximately $637,000, director fee costs of approximately $157,000, the
expense associated with the Crede consulting agreement in the approximate amount of $2,091,000, and other administrative costs
of approximately $171,000, partially offset by decreases in stock based compensation and cash payments to third-party service providers
of approximately $1,318,000 and $75,000, respectively, during the year ended December 31, 2014 as compared to the year ended December
31, 2013. Pre-manufacturing facility costs. On August 29, 2014, we
completed the transaction to purchase all of the issued and outstanding membership interests of NASCO. The purchase
transaction was subject to various conditions, including the required consents of the 46 Settling States of the MSA to an
amendment of NASCO’s existing adherence agreement to the MSA, with the Company becoming a signatory to such amended
adherence agreement as part of our acquisition of NASCO. On August 29, 2014, the Company became a signatory to the amended
adherence agreement. NASCO operates our cigarette manufacturing facility in North Carolina. Prior to the closing of our
acquisition of NASCO, the factory was primarily in a pre-manufacturing stage, incurring various expenses relating to preparing
and upgrading the warehouse and manufacturing facility for production. Those expenses included salaries and benefits for
employees, sub-contract labor, rent, utilities and other miscellaneous costs and amounted to $1,176,676 during the year ended
December 31, 2014. There were no expenses relating to the cigarette manufacturing facility during the year ended December 31,
2013. We manufactured a modest quantity of filtered cigars during the year ended December 31, 2014 generating revenue in
the amount of $81,456. We also commenced manufacturing our proprietary cigarette brands and an MSA brand for a chain of
independent smokeshops during the fourth quarter of 2014. Sales of these brands commenced during the first quarter of 2015.
NASCO will also continue to manufacture non-MSA filtered cigars. Sales and marketing costs . Sales and marketing costs were $85,930
for the year ended December 31, 2014, an increase of $76,878, or 849.3%, from $9,052 for the year ended December 31, 2013.
The increase is primarily the result of costs associated with participation in tobacco industry trade shows, RED SUN packaging design costs, and materials used for marketing trips to Europe and Asia. Amortization and depreciation expense. Amortization and depreciation expense for
the year ended December 31, 2014 amounted to $462,772, an increase of $318,483 or 220.7% from $144,289 for the year ended December
31, 2013. Amortization expense relates to amortization taken on capitalized patent costs. Amortization expense for the year ended
December 31, 2014 was $232,760 an increase of $91,499 or 64.8% from $141,261 for the year ended December 31, 2013. The increase
is primarily due to an adjustment to the 2013 amortization that was recorded in the first quarter of 2014 and by amortization on
additional investments in patents during the years ended December 31, 2014 and 2013 in the amount of $641,866 and $332,826, respectively,
partially offset by a change in the estimated useful lives of one of the patent families during the year ended December 31, 2013.
Depreciation expense for the year ended December 31, 2014 was $230,012, an increase of $226,984 from $3,028 for the year ended
December 31, 2013. This increase is mainly due to approximately $2.9 million of cigarette manufacturing equipment placed in service
during the second quarter of 2014. 33 Warrant liability loss - net . The warrant liability loss of $3,676,691
for the year ended December 31, 2014 was due to an increase in the warrants liability recorded in the first quarter of 2014 in
the amount of $3,841,943 in conjunction with the Warrant Amendment program offset by a decrease in the estimated fair value of
the warrants during the year in the amount of $165,252, primarily attributable to the decrease in the Company’s underlying
stock price from $2.14 per share at December 31, 2013, as compared to $1.65 per share at December 31, 2014. In a private placement in the first
quarter of 2013, we issued warrants which were accounted for as derivatives and upon issuance a liability at the estimated fair
value was recorded. At the date of issuance of these warrants, the value exceeded that total consideration received by an aggregate
of $3,987,655 resulting in an immediate charge to expense for this amount. In connection with the exercise of 1,101,034 Series
B Warrants in July 2013, we issued a like number of Series C Warrants which were accounted for as derivatives and upon issuance
a liability at the estimated fair value was recorded. At the date of issuance of these warrants, the value was estimated to be
$1,622,069 which exceeded the sum of the net proceeds received in the exercise and the reclassification of warrant liability to
capital by $343,079 resulting in an immediate charge to expense for this amount. These two charges added to the loss on warrant
liability of $19,271,977, resulting from an increase in the fair value during the year ended December 31, 2013 for all warrants
we have issued, resulting in a total loss on warrant liability-derivative for the year of $23,602,711. The loss on warrant liability
of $19,271,977 was primarily the result of an increase in the Company’s underlying stock price from $0.75 per share at December
31, 2012, as compared to $2.14 per share at December 31, 2013. Future periods will reflect a gain or loss
based on the change in the fair value of the derivatives, which is based on a number of factors including the Company’s stock
price. Loss on equity investment. The loss on equity investment
of $101,165 for the year ended December 31, 2014, consists of (i) our 25% share of Anandia’s net loss from our
initial April 11, 2014 investment in Anandia through December 31, 2014 in the amount of $84,350, plus (ii) amortization of the intangible asset represented by the difference between our equity investment in Anandia
and our portion of the book value of the net assets of Anandia in the amount of $16,815. Interest expense and amortization of debt discount and expense . Interest expense and amortization of
debt discount and debt issuance costs decreased during the year ended December 31, 2014 to $7,094 from $748,605 during the
year ended December 31, 2013. This decrease of $741,511 or 99.1% was primarily the result of a decrease in the amortization
of debt discount and debt issuance costs relating to convertible notes issued on August 9, 2012 that were converted into
common stock in August of 2013, payment of the majority of the Company’s interest bearing debt in the fourth quarter of
2013, and the recording as interest expense the excess of the fair value of warrants issued during the year ended December
31, 2013 over the proceeds realized in the amount of approximately $509,000. The Company’s demand bank loan is the only
remaining interest bearing debt outstanding at December 31, 2014. Net loss . We had a net loss for the year ended December
31, 2014 of $15,595,358 as compared to a net loss of $26,153,158 for the year ended December 31, 2013. The decrease in the net
loss of $10,557,800 or 40.4%, was primarily the result of a decrease in the warrant liability loss - net in the amount of $19,926,020,
a decrease in interest expense and amortization of debt discount in the amount of $741,511, a decrease in the warrant amendment
inducement expense of $3,591,765 and an increase in the gain on the sale of machinery and equipment of $71,121, offset by a decrease
in gross profit of $6,786,157, an increase in operating expenses of $6,763,271, and a decrease in other income of $206,374. 34 Liquidity and Capital Resources Working Capital As of December 31, 2014, we had working
capital of approximately $8.0 million, as compared to working capital of approximately $6.8 million at December 31, 2013, an increase
of approximately $1.2 million. The $1.2 million increase in working capital was primarily the result of net working capital remaining
from the net proceeds of the $9.3 million raised in the September 2014 common stock private placement after operating and investing
activities during the year ended December 31, 2014. We must successfully execute our
business plan to increase revenue in order to achieve positive cash flows to sustain adequate liquidity without requiring
additional funds from external sources to meet minimum operating requirements. The Company’s Form S-3 universal shelf
registration statement was filed with the U.S. Securities and Exchange Commission (“SEC”) on April 18, 2014, and
became effective on June 5, 2014. The universal shelf registration statement will allow, but not compel, the Company to raise
up to $45 million of capital over a three-year period through a wide array of securities at times and in amounts to be
determined by the Company. There can be no assurance that additional capital, if required, will be available on acceptable
terms or at all. Cash demands on operations In 2014, we had an operating loss of approximately
$11.7 million and used cash in operations of approximately $6.6 million during the year ended December 31, 2014. Excluding
contract growing of our proprietary tobacco with farmers, extraordinary expenses such as potential clinical trials, capital expenses
for our factory, and initial expenses associated with the launch of our RED SUN cigarette brand, our monthly cash expenditures
are approximately $500,000. We believe that cash on hand at December 31, 2014 of $6,402,687 is adequate to sustain operations
and meet all current obligations as they come due for a period of approximately 12 months. Net Cash (used in) provided by Operating
Activities In the year ended December 31, 2014, $6,582,730
of cash was used operating activities compared to $3,855,834 of cash provided by operating activities in the year ended December
31, 2013, a decrease of $10,438,564. This decrease in cash provided by operations was mainly due to the license revenue received
from BAT under the Research License and Commercial Option Agreement in the amount of $7,000,000 in 2013 as compared to no revenue
from licensing in 2014. In addition, approximately $3,400,000 in additional cash was consumed in operating activities. Net Cash used in Investing Activities In the year ended December 31, 2014, we
used $2,707,992, as compared to $3,742,789 of cash used in investing activities during the year ended December 31, 2013, a decrease
of $984,797. The decrease in cash used in investing activities is primarily due to a decrease in the acquisition of machinery and
equipment in the amount of $3,239,966, and an increase in proceeds received on the sale of machinery and equipment in the amount
of $631,484, offset by increases in the acquisition of patents and trademarks of $436,653, license fees of $1,450,000, the cash
portion of the equity investment in Anandia of $700,000, and the cash portion of the NASCO transaction of $250,000. Net Cash from Financing Activities During the year ended December 31, 2014,
we generated $9,862,810 from our financing activities, as compared to $5,717,366 of cash generated from financing activities during
the year ended December 31, 2013, an increase of $4,145,444. The $9,862,810 generated during the year ended December 31, 2014 was
mainly the a result of net cash proceeds received from a common stock private placement in September 2014, in the amount of $9,324,088,
and net cash proceeds from the exercise of stock warrants and stock options in the amount of $535,251. The $5,717,366 of cash generated
during the year ended December 31, 2013 was primarily the result of the net proceeds from the Series A-1 Preferred stock placement
in the amount of $2,034,664, net cash proceeds received from the exercise of warrants in the amount of $2,254,999, proceeds received
from the issuance of notes payable in the amount of $150,000, proceeds received from the exercise of stock options in the amount
of $5,200, and net cash proceeds received from the Warrant Exchange Program in the amount of $3,239,385. These proceeds raised
were partially offset by payments on notes payable, convertible notes payable and net payments to related parties and officers
in the amount of $1,620,299, $339,250 and $8,993, respectively. Critical Accounting Policies and Estimates Accounting principles generally accepted
in the United States of America, or U.S. GAAP, require estimates and assumptions to be made that affect the reported amounts in
our consolidated financial statements and accompanying notes. Some of these estimates require difficult, subjective and/or complex
judgments about matters that are inherently uncertain and, as a result, actual results could differ from those estimates. Due to
the estimation processes involved, the following summarized accounting policies and their application are considered to be critical
to understanding our business operations, financial condition and results of operations. 35 Revenue Recognition We recognize revenue at the point the product
is shipped to a customer and title has transferred. Revenue from the sale of our products is recognized net of cash discounts,
sales returns and allowances. Federal cigarette excise taxes are included in net sales and accounts receivable billed to customers,
except on sales of SPECTRUM and exported cigarettes in which such taxes do not apply. We were chosen to be a subcontractor
for a government contract between RTI International (“RTI”) and NIDA to supply research cigarettes to NIDA. These
government research cigarettes are distributed under the Company’s mark SPECTRUM . Future revenue under this
arrangement is expected to be related to the delivery of SPECTRUM and will be recognized at the point the product is
shipped and title has transferred. In September 2013, we received a purchase order for an additional 5.5
million SPECTRUM research cigarettes that were manufactured and shipped in January 2014. Total revenue from this order
was approximately $447,535 and a down payment on the order was received in the fourth quarter of 2013 in the amount of
$179,014. The down payment has been recorded as deferred revenue on the Company’s balance sheet at December 31, 2013.
There were no SPECTRUM cigarettes delivered during the year ended December 31, 2013. As described above, we license our
patented technology to third parties. Revenue is recognized from licensing arrangements as contractually defined in licensing
agreements. We account for milestone elements contained in licensing agreements in accordance with ASC 605. Simultaneous with
the signing of the Research License and Commercial Option Agreement, BAT paid us a non-refundable $7,000,000. Revenue
was recognized for this amount since delivery of the patented technology took place, we had no further performance
obligations, and the fee was fixed. We will be entitled to receive additional payments from BAT, up to an additional
$7,000,000, during the Research Term in the event certain milestones are met by BAT with respect to BAT’s research
and development of our patent rights licensed by the Company to BAT. There are four separate milestones, two of which BAT
would pay us $2 million for each milestone achieved, and two of which BAT would pay us $1.5
million for each milestone achieved. In addition, the Company could earn additional future royalties if BAT elects to
exercise the Commercial Option Agreement during the Research Term. No amount related to the
research milestones was recognized during 2014 or 2013. A portion of the patented technology sublicensed to BAT was
exclusively licensed to 22nd Century Ltd. by NRC. Pursuant to the terms of the license agreement with NRC, 22nd Century
Ltd. was obligated to make a royalty payment to NRC from the monies received from BAT. During the quarter ended
September 30, 2014, 22nd Century Ltd. and NRC mutually agreed on a payment of $660,000 that was paid in December 2014. 22nd
Century Ltd. had previously estimated the payment to be $413,566. The difference in the amount of $246,434 has been recorded
as Royalty for licensing in the Cost of goods sold section of the Company’s Consolidated Statements of Operations for
the year ended December 31, 2014. Impairment of Long-Lived Assets We review the carrying value of amortizing
long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may
no longer be appropriate. We also assess recoverability of the asset by estimating the future undiscounted net cash flows expected
to result from the asset, including eventual disposition. If the estimated future undiscounted net cash flows are less than the
carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and
its fair value. Non-amortizing intangibles (e.g., patents and trademarks) are reviewed annually for impairment. We have not recognized
any impairment losses during the two year period ended December 31, 2014. Amortization Estimates of Intangible Assets We generally determine amortization based
on the estimated useful lives of the assets and record amortization expense on a straight-line method over such lives. The remaining
life of the primary patent in each patent family is generally used to determine the estimated useful life of the related patent
costs. Valuation of our Equity Securities We use a fair-value based method to determine
compensation for all arrangements under which Company employees and others receive shares, options or warrants to purchase common
shares of 22nd Century Group. Stock based compensation expense is recorded over the requisite service period based on estimates
of probability and time of achieving milestones and vesting. For accounting purposes, the shares will be considered issued and
outstanding upon vesting. 36 Income taxes The Company recognizes deferred tax assets
and liabilities for any basis differences in its assets and liabilities between tax and GAAP reporting, and for operating loss
and credit carry-forwards. In light of the Company’s history of cumulative net operating losses and the uncertainty of their
future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December
31, 2014 and 2013. Derivative Financial Instruments We do not use derivative instruments to
hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such
instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that
are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued
at each reporting date, with changes in fair value reported in the consolidated statement of operations. The methodology
for valuing our outstanding warrants classified as derivative instruments utilizes a lattice model approach which includes probability
weighted estimates of future events including volatility of our common stock. A financial asset or liability’s classification
within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The warrant
liability is measured at fair value using certain estimated factors such as volatility and probability which are classified within
Level 3 of the valuation hierarchy. Significant unobservable inputs are used in the fair value measurement of the Company’s
derivative warrant liabilities include volatility. Significant increases (decreases) in the volatility input would result
in a significantly higher (lower) fair value measurement. A 10% increase or decrease in the volatility factor used as of
December 31, 2014 would have the impact of increasing or decreasing the liability by approximately $22,000. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period.
Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
settlement of the derivative instrument could be required within twelve months of the balance sheet date. Inflation Inflation did not have a material effect on our operating
results for the years ended December 31, 2014 and 2013. Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements
as defined by Item 303(a)(4) of Regulation S-K. Item 7A. Quantitative and Qualitative Disclosures about Market Risk. As a smaller reporting
company, we are not required to present the information required by this item. Item 8. Financial Statements and Supplementary Data. The required financial statements and the
notes thereto are contained in a separate section of this Form 10-K Information section beginning with the page following Item
15 (Exhibits and Financial Statement Schedules). Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. None 37 Item 9A. Controls and Procedures. Evaluation of Disclosure Controls and Procedures The Company maintains disclosure
controls and procedures that are designed to ensure that information required to be disclosed in its Exchange Act
(defined below) reports is
recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that
such information is accumulated and communicated to the Company’s management, including the Company’s president and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. Our president and chief financial officer, after evaluating the effectiveness of the Company’s “disclosure controls and
procedures” (as defined in the Securities Exchange Act of 1934 (“Exchange Act”) Rules 13a-15(e) or 15d-15(e)) as of the
end of the period covered by this annual report, has concluded that our disclosure controls and procedures were not effective
and that material weaknesses described below exist in our internal control over financial reporting based on his evaluation
of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15. Management’s Annual Report on Internal Control over
Financial Reporting Our management is responsible for establishing
and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed
by, or under the supervision of, the president and the chief financial officer and effected by our board of directors, management
and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. Our evaluation of internal control over
financial reporting includes using the COSO framework, an integrated framework for the evaluation of internal controls issued by
the Committee of Sponsoring Organizations of the Treadway Commission in 1992, to identify the risks and control objectives related
to the evaluation of our control environment. Based on our evaluation under the frameworks
described above, our management concluded that as of December 31, 2014, that our internal controls over financial reporting were
not effective and that material weaknesses exist in our internal control over financial reporting. The material
weakness consists of controls associated with segregation of duties and controls associated with accounting for complex and non-routine
transactions relating to certain equity and derivative instruments. To address the material weakness we performed additional
analyses and other post-closing procedures to ensure that our consolidated financial statements were prepared in accordance with
accounting principles generally accepted in the United States of America (U.S. GAAP). Notwithstanding this material
weakness, management believes that the financial statements included in this Annual Report on Form 10-K fairly present, in all
material respects, our financial condition, result of operations and cash flows for the periods presented. Freed Maxick CPA’s, P.C., the Company’s independent registered public accounting firm, has
audited the consolidated financial statements as of and for the year ended December 31, 2014, and the effectiveness of the Company’s
internal control over financial reporting as of December 31, 2014, as stated in their reports, which are included herein. Changes in Internal Control over Financial Reporting There was no change in the Company’s
internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the quarter ended December 31,
2014 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
reporting. 38 REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM The Board of Directors and Shareholders 22 nd Century Group, Inc. We have audited 22 nd Century
Group, Inc. and Subsidiaries (the “Company”) internal control over financial reporting as of December 31, 2014, based
on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission in 1992. The Company’s management is responsible for maintaining effective internal control over
financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying
“Management’s Annual Report on Internal Controls Over Financial Reporting”. Our responsibility is to express
an opinion on the Company's internal control over financial reporting based on our audit. We conducted our audit in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all
material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk
that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on
the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We
believe that our audit provides a reasonable basis for our opinion. A company's internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal
control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that,
in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
with authorizations of management and directors of the company; and (c) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect
on the financial statements. Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate. 39 A material weakness is a deficiency, or
a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a
material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis.
The following material weaknesses have been identified and included in management's assessment. Material weaknesses related to financial
closing and reporting process . The Company did not maintain a sufficient complement of qualified
accounting staff resulting in ineffective controls due to a lack of segregation of duties and a lack of secondary review. Additionally,
the Company did not maintain sufficient technical resources to ensure that the financial statements and notes to the financial
statements were presented fully in accordance with GAAP and with all required disclosures. The Company’s corporate accounting
and financial reporting function is currently performed by one person on staff. That person performs nearly all aspects of the
financial reporting process, including but not limited to access to the underlying accounting records and systems, the ability
to post and record journal entries, the responsibility to perform reconciliations of account balances, as well as the responsibility
for the preparation of the financial statements. These material weaknesses were considered
in determining the nature, timing, and extent of audit tests applied in our audit of the 2014 financial statements, and this report
does not affect our report dated February 5, 2015 on those financial statements. In our opinion, because of the effect of
the material weaknesses described above on the achievement of the objectives of the control criteria, the Company has not maintained
effective internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control
— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 1992. We have also audited, in accordance with
the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets as of December
31, 2014 and 2013 and the related consolidated statements of operations, shareholders’ equity and cash flows of the Company
for the years then ended and our report dated February 5, 2015 expressed an unqualified opinion. /s/ FREED MAXICK CPAs, P.C. Buffalo, New York February 5, 2015 40 Item 9B. Other Information. None. PART III Item 10. Directors, Executive Officers and Corporate Governance. Information concerning our executive officers,
directors and corporate governance is incorporated herein by reference to our definitive proxy statement to be filed with the Securities
and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K with respect to its 2015 Annual
Meeting of Stockholders. Set forth below is information regarding
our directors, executive officers and key personnel. Name Age Position Henry Sicignano, III 47 President, Chief Operating Officer and Director John T. Brodfuehrer 57 Chief Financial Officer and Treasurer Michael R. Moynihan, Ph.D. 62 Vice President of R&D Thomas L. James, Esq. 56 Vice President, General Counsel and Secretary Joseph Alexander Dunn, Ph.D. 61 Director* James W. Cornell 58 Director** Richard M. Sanders 61 Director*** Joseph Pandolfino 46 Director**** 41 * Dr. Dunn is currently Associate Dean for Research and Professor
of Pharmaceutical Sciences at D’Youville College of Pharmacy in Buffalo, New York and has served in this capacity since April
1, 2010. ** Mr. Cornell is currently the President and Chief Executive
Officer of Praxiis, LLC, an enterprise that provides support for clients in organizational change, leadership development and transactional
advisory services. Mr. Cornell is also the current Manager of Larkin Center Management, LLC, a real estate development company,
and has served in this capacity since October 2010. *** Since August 2009, Mr. Sanders has served as a General Partner
of Phase One Ventures, LLC, a venture capital firm which focuses on nanotechnology and biotechnology start-up opportunities in
New Mexico and surrounding states. **** Since October 25, 2014, Mr. Pandolfino ceased serving as
an employee of 22nd Century Group, Inc. and its affiliates. Code of Ethics In 2006, we adopted
a Code of Ethics that applies to all of our employees. A copy of our Code of Ethics is available on our website at xxiicentury.com
and will be provided to any person requesting same without charge. To request a copy of our Code of Ethics, please make a written
request to our President c/o 22nd Century Group, Inc., 9530 Main Street, Clarence, New York 14031. Future material amendments or
waivers relating to the Code of Ethics will be disclosed on our website referenced in this paragraph within four business days
following the date of such amendment or waiver. Item 11. Executive Compensation. Information is incorporated herein by reference
to our definitive proxy statement to be filed with the Securities and Exchange Commission within 120 days after the end of the
fiscal year covered by this Form 10-K with respect to its 2015 Annual Meeting of Stockholders . Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. Information is incorporated herein by reference
to our definitive proxy statement to be filed with the Securities and Exchange Commission within 120 days after the end of the
fiscal year covered by this Form 10-K with respect to its 2015 Annual Meeting of Stockholders . Item 13. Certain Relationships and Related Transactions, and Director Independence. Information is incorporated herein by reference
to our definitive proxy statement to be filed with the Securities and Exchange Commission within 120 days after the end of the
fiscal year covered by this Form 10-K with respect to its 2015 Annual Meeting of Stockholders. Item 14. Principal Accounting Fees and Services. Information is incorporated
herein by reference to our definitive proxy statement to be filed with the Securities and Exchange Commission within 120 days after
the end of the fiscal year covered by this Form 10-K with respect to its 2015 Annual Meeting of Stockholders . PART IV Item 15. Exhibits and Financial Statement Schedules. (a) Financial Statements 42 22nd CENTURY GROUP, INC. AND SUBSIDIARIES INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Financial Statements: Consolidated Balance Sheets F-3 Consolidated Statements of Operations F-4 Consolidated Statements of Shareholders’ Equity F-5 Consolidated Statements of Cash Flows F-6 - F-7 Notes to Consolidated Financial Statements F-8 - F-23 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM The Board of Directors
and Shareholders 22 nd Century Group, Inc. We have
audited the accompanying consolidated balance sheets of 22 nd Century Group, Inc. and Subsidiaries as of December 31,
2014 and 2013, and the related consolidated statements of operations, shareholders’ equity, and cash flows for the years
then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express
an opinion on these financial statements based on our audits. We conducted
our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our
opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position
of 22 nd Century Group, Inc. and Subsidiaries as of December 31, 2014 and 2013, and the results of its operations and
cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. We have
also audited, in accordance with the standards of the Public Accounting Oversight Board (United States), 22 nd Century
Group, Inc. and Subsidiaries internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control - Integrated Framework issued by Committee of Sponsoring Organizations of the Treadway Commission in 1992. Our report dated February 5, 2015 expressed
an opinion that 22 nd Century Group, Inc. had not maintained effective internal control over financial reporting as of
December 31, 2014, based on criteria established in Internal
Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 1992. /s/
FREED MAXICK CPAs, P.C. Buffalo, New York February 5,
2015 F- 2 22nd CENTURY GROUP INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31, 2014 2013 ASSETS Current assets: Cash $ 6,402,687 $ 5,830,599 Due from related party 46,069 42,069 Due from officers - 7,471 Inventory, net 2,064,796 1,406,280 Prepaid consulting fees 1,978,785 - Prepaid expenses and other assets 214,469 - Machinery and equipment held for resale - 457,696 Total current assets 10,706,806 7,744,115 Machinery and equipment, net 2,850,615 2,997,760 Other assets: Intangible assets, net 7,077,759 1,544,869 Equity investment 1,318,335 - Total other assets 8,396,094 1,544,869 Total assets $ 21,953,515 $ 12,286,744 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Demand bank loan $ 174,925 $ 174,925 Current portion of note payable 320,513 - Accounts payable 884,412 54,665 Accrued expenses 1,081,545 575,730 Accrued severance 212,012 - Deferred revenue - 179,014 Total current liabilities 2,673,407 984,334 Long-term portion of note payable 605,217 - Long-term portion of accrued severance 412,308 - Warrant liability 3,042,846 3,779,522 Total liabilities 6,733,778 4,763,856 Commitments and contingencies (Note 17) - - Shareholders' equity Capital stock authorized: 10,000,000 preferred shares, $.00001 par value 300,000,000 common shares, $.00001 par value Capital stock issued and outstanding: 64,085,042 common shares (56,902,770 at December 31, 2013) 641 569 Capital in excess of par value 70,744,190 47,452,055 Accumulated deficit (55,525,094 ) (39,929,736 ) Total shareholders' equity 15,219,737 7,522,888 Total liabilities and shareholders' equity $ 21,953,515 $ 12,286,744 See accompany notes to consolidated financial
statements. F- 3 22nd CENTURY GROUP INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS Years Ended December 31, 2014 2013 Revenue: Royalties from licensing $ - $ 7,000,000 Sale of products 528,991 278,383 528,991 7,278,383 Cost of goods sold: Royalties for licensing 246,434 413,566 Products 252,002 48,105 498,436 461,671 Gross profit 30,555 6,816,712 Operating expenses: Research and development (including stock based compensation of $331,467 and $111,563, respectively) 1,249,007 744,230 General and administrative (including stock based compensation of $4,165,078 and $2,250,399, respectively) 8,793,151 4,106,694 Pre-manufacturing facility costs (including stock based compensation of $27,923 and $0, respectively) 1,176,676 - Sales and marketing costs 85,930 9,052 Amortization and depreciation 462,772 144,289 11,767,536 5,004,265 Operating (loss) income (11,736,981 ) 1,812,447 Other income (expense): Warrant liability loss - net (3,676,691 ) (23,602,711 ) Warrant amendment inducement expense (144,548 ) (3,736,313 ) Gain on the sale of machinery and equipment 71,121 - Loss on equity investment (101,165 ) - Income tax credit refund - 122,024 Interest expense and amortization of debt discount and expense: Related parties - (17,889 ) Other (7,094 ) (730,716 ) (3,858,377 ) (27,965,605 ) Net loss $ (15,595,358 ) $ (26,153,158 ) Loss per common share - basic and diluted $ (0.26 ) $ (0.60 ) Common shares used in basic earnings per share calculation 59,993,413 43,635,182 See accompany notes to consolidated financial statements. F- 4 22nd CENTURY GROUP INC. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Years Ended December 31, 2014 and 2013 Preferred Common Par value Par value Shares Shares of Preferred of Common Contributed Accumulated Shareholders' Outstanding Outstanding Shares Shares Capital Deficit Equity (Deficit) Balance at December 31, 2012 - 34,286,979 $ - $ 344 $ 7,645,017 $ (13,776,578 ) $ (6,131,217 ) Common stock issued upon exercise of Convertible Notes - 2,406,720 - 24 (24 ) - - Preferred stock issued in January 2013 private placement 2,500 416,666 - 4 (4 ) - - Conversion of preferred stock to common stock (2,500 ) 4,166,666 - 42 (42 ) - - Exercise of warrants - 6,820,218 - 68 14,097,526 - 14,097,594 Exercise of options - 20,000 - - 5,200 - 5,200 Stock based compensation - 2,820,000 - 28 2,361,934 - 2,361,962 Other contributed capital - - - - 1,660 - 1,660 Warrant exchange program - 5,804,368 - 58 23,340,789 - 23,340,847 Common stock issued in payment of accrued dividends - 161,153 - 1 (1 ) - - Net loss - - - - - (26,153,158 ) (26,153,158 ) Balance at December 31, 2013 - 56,902,770 $ - $ 569 $ 47,452,055 $ (39,929,736 ) $ 7,522,888 Stock based compensation - 1,282,768 - 13 2,433,240 - 2,433,253 Warrants issued as compensation for services - - - - 1,260,000 - 1,260,000 Exercise of warrants - 1,167,737 - 12 486,939 - 486,951 Exercise of options - 70,000 - 1 48,299 - 48,300 Common stock issued in September 2014 private placement - 3,871,767 - 39 9,324,049 - 9,324,088 Stock issued in connection with acquisition of NASCO Products, LLC - 640,000 - 6 1,951,994 - 1,952,000 Stock issued in connection with equity investment - 150,000 - 1 394,499 - 394,500 Other capital contribution - - - - 25,200 - 25,200 Warrant amendments - - - - 7,367,915 - 7,367,915 Net loss - - - - - (15,595,358 ) (15,595,358 ) Balance at December 31, 2014 - 64,085,042 $ - $ 641 $ 70,744,190 $ (55,525,094 ) 15,219,737 See accompany notes to consolidated financial
statements. F- 5 22nd CENTURY GROUP INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Years Ended December 31, 2014 2013 Cash flows from operating activities: Net loss $ (15,595,358 ) $ (26,153,158 ) Adjustments to reconcile net loss to cash (used in) provided by operating activities: Amortization and depreciation 462,772 144,289 Amortization of license fees 32,524 - Amortization of debt issuance costs - 4,232 Amortization of debt discount - 134,296 Loss on equity investment 101,165 - Gain on the sale of machinery and equipment (71,121 ) - Interest due to debt conversion - 526,448 Warrant liability loss 3,676,691 23,602,711 Warrant amendment inducement expense 144,548 3,736,313 Equity based employee compensation expense 2,293,083 980,162 Equity based payments for outside services 2,231,385 1,381,800 Severance expense 624,320 (Increase) decrease in current assets: Inventory (620,660 ) (175,754 ) Prepaid expenses and other assets (214,469 ) 10,044 Increase (decrease) in current liabilities: Accounts payable 625,389 (629,101 ) Accrued interest payable to related parties - (3,567 ) Accrued expenses (93,985 ) 118,105 Deferred revenue (179,014 ) 179,014 Net cash (used in) provided by operating activities (6,582,730 ) 3,855,834 Cash flows from investing activities: Acquisition of patents and trademarks (726,989 ) (290,336 ) Acquisition machinery and equipment (212,487 ) (2,994,757 ) Purchase of machinery and equipment held for resale - (457,696 ) Payment of license fees (1,450,000 ) - Acquisition of NASCO Products, LLC (250,000 ) - Proceeds from the sale of machinery and equipment 631,484 - Equity investment and advance (700,000 ) - Net cash used in investing activities (2,707,992 ) (3,742,789 ) Cash flows from financing activities: Net proceeds from exercise of warrants 486,951 2,254,999 Net proceeds from exercise of options 48,300 5,200 Net proceeds from warrant exchange program - 3,239,385 Proceeds from issuance of notes - 150,000 Payments on borrowings - notes payable - (1,620,299 ) Payments on borrowings - convertible notes - (339,250 ) Net proceeds from September 2014 common stock private placement 9,324,088 - Net proceeds from January 2013 preferred stock private placement - 2,034,664 Other capital contribution - 1,660 Net payments to related party (4,000 ) (5,100 ) Net advances from (to) officers 7,471 (3,893 ) Net cash provided by financing activities 9,862,810 5,717,366 Net increase in cash 572,088 5,830,411 Cash - beginning of period 5,830,599 188 Cash - end of period $ 6,402,687 $ 5,830,599 Cash paid during the period for interest $ 7,094 $ 135,247 Cash paid during the period for income taxes $ - $ - F- 6 22nd CENTURY GROUP INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (continued) Years Ended December 31, 2014 2013 Supplemental disclosure of investing and financing activities Reclassification of derivative liability to equity due to warrant amendments $ 7,367,915 $ 14,433,178 Patent and trademark additions included in accounts payable $ 193,454 $ 42,490 Machinery and equipment additions included in accounts payable $ 10,904 $ - License fee included in accrued expenses $ 300,000 $ - Equity investment included in accrued expenses $ 325,000 $ - Issuance of common stock for equity investment $ 394,500 $ - Issuance of common stock for acquisition of NASCO Products, LLC $ 1,952,000 $ - Issuance of warrants as a derivative liability issued under a consulting agreement and included in prepaid consulting fees $ 2,810,000 $ - Warrants issued under a consulting agreement resulting in an increase in capital and included in prepaid consulting fees $ 1,260,000 $ - Reclassification of machinery and equipment purchases to inventory $ 37,856 $ - Other capital contribution $ 25,200 $ - Patent additions acquired with note payable $ 925,730 $ - Accounts payable converted to promissory notes $ - $ 769,377 Accrued interest converted to promissory notes $ - $ 26,422 Notes payable and accrued interest converted to common shares $ - $ 1,650,305 Common stock issued in payment of preferred stock dividend payable $ - $ 93,361 Common stock issued for fees relating to January 2013 preferred stock private placement $ - $ 416,666 Refinance of convertible note to note payable $ - $ 57,500 Issuance of warrants as derivative liability instruments and reduction of capital $ - $ 5,675,634 Increase in warrant liability and reduction in capital as a result of lowering the exercise price on certain warrants $ - $ 626,328 Reclassification of derivative liability to equity due to warrant exchange program $ - $ 19,639,465 Common stock issued for fees relating to December 2013 warrant exchange program $ - $ 462,000 See accompanying notes to consolidated financial statements. F- 7 22nd CENTURY GROUP, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2014 NOTE 1. - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES Principles of
Consolidation - The accompanying consolidated financial statements include the accounts of 22nd Century Group,
Inc. (“22nd Century Group”), its three wholly-owned subsidiaries, 22nd Century Limited, LLC (“22nd Century Ltd”), NASCO Products, LLC
(“NASCO”), and Botanical Genetics, LLC (“Botanical Genetics”), and a 51% owned subsidiary, 22nd
Century Asia Ltd. (“22nd Century Asia”), and two wholly-owned subsidiaries of 22nd Century Ltd, Goodrich Tobacco
Company, LLC (“Goodrich Tobacco”) and Hercules Pharmaceuticals, LLC (“Hercules Pharma”)
(collectively, “the Company”). All intercompany accounts and transactions have been eliminated. Nature of Business - 22nd Century Ltd, is a plant biotechnology company specializing in technology that allows for the level of nicotine and other
nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased
through genetic engineering and plant breeding. The Company owns or exclusively controls 128 issued patents plus an
additional 52 pending patent applications. The patents owned by or exclusively licensed to us include patents issued in 96
countries. Goodrich Tobacco and Hercules Pharma are business units for the Company’s (i) premium cigarettes and
potential modified risk tobacco products and (ii) smoking cessation product, respectively. The Company acquired the
membership interests of NASCO on August 29, 2014. NASCO is a federally licensed tobacco products manufacturer, a
participating member of the tobacco Master Settlement Agreement (“MSA”) between the tobacco industry and the
Settling States under the MSA, and operates the Company’s cigarette manufacturing business in North Carolina. Botanical
Genetics is a wholly-owned subsidiary of 22nd Century Group, and was incorporated to facilitate an equity investment more
fully described in Note 10. 22nd Century Asia was newly-formed during the third quarter of 2014 in connection with the
Company’s efforts to sell its proprietary tobacco products in Asia, more fully described in Note 6. Preferred Stock Authorized - The Company is authorized to issue “blank check” preferred stock, which could be issued with voting, liquidation,
dividend and other rights superior to our common stock. On January 11, 2013, the Company designated the rights of and issued 2,500
shares of Series A-1 Preferred Stock. As of June 7, 2013, all 2,500 outstanding shares of Series A-1 Preferred Stock were converted
into an aggregate of 4,166,666 shares of common stock of the Company and no shares of preferred stock remain outstanding. Concentration of Credit
Risk - Financial instruments that potentially subject the Company to concentration of credit risk consist of cash
accounts in financial institutions. Although the cash accounts exceed the federally insured deposit amount, management does
not anticipate nonperformance by the financial institutions. Management reviews the financial viability of these institutions
on a periodic basis. Inventory - Inventories are valued at the lower of cost or market. Cost is determined using an average cost method for tobacco leaf
inventory and the first-in, first-out (FIFO) method on all other inventories. Inventories are evaluated to
determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or
reserved as appropriate. Inventories at December 31, 2014 and 2013 consist of the following: December 31, 2014 December 31, 2013 Inventory - tobacco leaf $ 1,537,521 $ 1,398,747 Less: inventory reserve 50,623 50,623 Inventory - tobacco leaf, net 1,486,898 1,348,124 Inventory - finished goods Cigarettes and filtered cigars 154,568 13,206 Inventory - raw materials Cigarette and filtered cigar components 423,330 44,950 $ 2,064,796 $ 1,406,280 Fixed assets – Fixed assets are recorded at their acquisition cost and depreciated on a straight line basis over their estimated useful lives
ranging from 3 to 10 years. Depreciation commences when the asset is placed in service. F- 8 Intangible Assets - Intangible assets are recorded at cost and consist primarily of (1) expenditures incurred with third parties related to the processing
of patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties, (2)
license fees paid for third-party intellectual property, (3) costs to become a signatory under the tobacco Master Settlement Agreement
(“MSA”), and (4) license fees paid to acquire a predicate cigarette brand. The amounts capitalized relate to intellectual
property that the Company owns or to which it has exclusive rights. The Company’s intellectual property capitalized costs
are amortized using the straight-line method over the remaining statutory life of the primary patent in each of the Company’s
two primary patent families, which expire in 2019 and 2028 (the assets’ estimated lives, respectively). Periodic maintenance
or renewal fees are expensed as incurred. Annual minimum license fees are charged to expense. License fees paid for
third-party intellectual property are amortized on a straight-line basis over the last to expire patents, which patent expiration
dates range from 2028 through 2035. The Company believes costs associated with becoming a signatory to the MSA and acquiring the
predicate cigarette brand have an indefinite life and as such, no amortization is taken. Total intangible assets at December 31,
2014 and December 31, 2013 consist of the following: December 31, 2014 December 31, 2013 Intangible assets, net Patent and trademark costs $ 4,405,586 $ 2,559,412 Less: accumulated amortization 1,247,303 1,014,543 Patent and trademark costs, net 3,158,283 1,544,869 License fees, net (see Note 17) 1,450,000 - Less: accumulated amortization 32,524 - License fees, net 1,417,476 - MSA signatory costs (see Note 7) 2,202,000 - License fee for predicate cigarette brand 300,000 - $ 7,077,759 $ 1,544,869 Amortization expense relating to the above
intangible assets for the years ended December 31, 2014 and 2013 amounted to $265,284 and $141,261, respectively. During the year ended December 31, 2013,
the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial
statements. The estimated annual average amortization
expense for the next five years is approximately $310,000 for patent costs and $98,000 for license fees. Impairment of Long-Lived Assets - The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances
indicate that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability
of the asset by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition.
If the estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded
equal to the difference between the asset’s carrying value and its fair value. There was no impairment loss recorded during
the years ended December 31, 2014 or 2013. Income Taxes - The
Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and
GAAP reporting, and for operating loss and credit carry-forwards. In light of the Company’s history
of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance
to fully offset its net deferred tax assets as of December 31, 2014 and 2013. F- 9 The Company’s federal and state tax
returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2014. Refundable taxes
and tax credits – The Company accounts for income tax refunds or tax refundable tax credits as discrete items
and recognized the amount in the period in which the funds are received. During the year ended December 31, 2013, the Company received
notice from the New York State Department of Taxation and Finance of a no change audit with respect to its income tax return filed
for the period ending September 30, 2011. The subject return contained a refundable credit in the amount of $122,024. The
refund was recorded as Other income in the Company’s Consolidated Statement of Operations for the year ended December 31,
2013. There were no such transactions during the year ended December 31, 2014. Stock Based Compensation - The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees
and others receive shares, options or warrants to purchase common shares of 22nd Century Group. Stock based compensation expense
is recorded over the requisite service period based on estimates of probability and time of achieving milestones and vesting. For
accounting purposes, the shares will be considered issued and outstanding upon vesting. Revenue Recognition
– The Company recognizes revenue from product sales at the point the product is shipped to a customer and title has
transferred. Revenue from the sale of the Company’s products is recognized net of cash discounts, sales returns and allowances.
Cigarette federal excise taxes are included in net sales and accounts receivable billed to customers, except on sales of SPECTRUM research cigarettes and exported cigarettes, to which such taxes do not apply. The Company was chosen to
be a subcontractor for a 5-year government contract between RTI International (“RTI”) and the National Institute
on Drug Abuse (“NIDA”) to supply NIDA with research cigarettes. These government research cigarettes are
distributed under the Company’s mark, SPECTRUM . In September 2013, the Company received a purchase order for 5.5
million SPECTRUM research cigarettes that were shipped in January 2014. Total revenue from this order was
approximately $448,000 for the year ended December 31, 2014. A down payment of $179,014 was received in the fourth quarter of
2013 and was recorded as deferred revenue on the Company’s balance sheet at December 31, 2013. There were no SPECTRUM cigarettes
delivered during the year ended December 31, 2013. The Company licenses
its patented technology to third parties. Revenue is recognized from licensing arrangements as contractually defined in
licensing agreements. The Company accounts for milestones elements contained in licensing agreements in accordance with ASC
605. On October 1, 2013, 22nd Century Ltd entered into a worldwide Research License and Commercial Option Agreement
(the “Agreement”) with British American Tobacco (Investments) Limited (“BAT”), a subsidiary of
British American Tobacco plc, that grants BAT access to 22nd Century Ltd’s patented technology which alters levels of
nicotinic alkaloids in tobacco plants. Simultaneous with the signing of the Agreement, BAT paid the Company a
non-refundable $7,000,000. The Company will be entitled to receive additional payments from BAT of up to an additional
$7,000,000 during the term of the Research License in the event certain milestones are met with respect to the ongoing
research and development of the Company’s licensed technology to BAT. No amount related to the additional research
milestones was recognized during the year ended December 31, 2014. During the term of the Research License, BAT will have the
option to enter into a Commercial License agreement which will provide for future annual payments, royalty payments and
minimum annual royalties. A portion of the patented technology sublicensed to BAT was exclusively licensed to 22nd Century
Ltd by a third party licensor proir to the acquisition by 22nd Century Ltd of such patented technology from such licensor on
December 23, 2014 (see Note 12 for the more detailed discussion). Pursuant to the terms of the license agreement with such
licensor, 22nd Century Ltd was obligated to make a royalty payment to the licensor with respect to a portion of the
non-refundable $7,000,000 paid by BAT to the Company on October 1, 2013. From October 2013 to September 2014, 22nd Century
Ltd and the third party licensor were in discussions as to the amount of royalty due to the licensor from 22nd Century Ltd.
During the quarter ended September 30, 2014, 22nd Century Ltd and the third party licensor mutually agreed on a payment of
$660,000 that was paid in December 2014. 22nd Century Ltd had previously estimated the payment to be $413,566. The
difference in the amount of $246,434 has been recorded as Royalty for licensing in the Cost of goods sold section of the
Company’s Consolidated Statements of Operations for the year ended December 31, 2014. F- 10 Derivatives – The Company does use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company
evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair
value reported in the consolidated statement of operations. The methodology for valuing outstanding warrants
classified as derivative instruments utilizes a lattice model approach which includes probability weighted estimates of
future events including volatility of our common stock. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period.
Derivative instrument liabilities are classified on the balance sheet as current or non-current based on whether or not
net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. Research and Development - Research and development costs are expensed as incurred. Loss Per Common Share - Basic loss per common share is computed using the weighted-average number of common shares outstanding. Diluted loss per
share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded
from the computation if their effect is anti-dilutive. Commitment and Contingency Accounting
- The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that
if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial statements.
If not, the Company will disclose any material commitments or contingencies that may arise. Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United
States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Fair Value of Financial Instruments - Financial instruments include cash, receivables, accounts payable, accrued expenses, demand bank loan, and
warrant liability. Other than warrant liability, fair value is assumed to approximate carrying values for these financial
instruments, since they are short term in nature, they are receivable or payable on demand, or had stated interest rates that approximate
the interest rates available to the Company as of the reporting date. The determination of the fair value of the warrant
liability includes unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 15. Equity Investments – The
Company accounts for investments in equity securities of other entities under the equity method of accounting if the Company’s
investment in the voting stock is greater than or equal to 20% and less than a majority, and the Company has the ability to have
significant influence over the operating and financial policies of the investee. Accounting Pronouncements - In
May 2014, the FASB issued ASU 2014-09, ”Revenue from Contracts with Customers”, which supersedes nearly
all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues
when promised goods or services are transferred to customers in an amount that reflects the consideration to which an
entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core
principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are
required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and
interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the
application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a
retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which
includes additional footnote disclosures). The Company is currently evaluating the impact of the pending adoption of ASU
2014-09 on its consolidated financial statements and have not yet determined the method by which it will adopt the standard
in 2017. F- 11 NOTE 2. – NYSE MKT EXCHANGE On March 11, 2014, the Company’s common
stock began trading on the NYSE MKT exchange under the ticker symbol XXII. The Company’s common stock had been previously
quoted on the OTC Bulletin Board under the ticker symbol of XXII.OB. NOTE 3. – FINANCIAL CONDITION At December 31, 2014, the Company had current
assets of $10,706,806 and current liabilities of $2,673,407 resulting in positive working capital of $8,033,399. Cash on hand at
December 31, 2014 was $6,402,687. The Company believes it will have adequate cash reserves to sustain operations and meet
all current obligations as they come due for a period of approximately 12 months. The Company’s Form S-3 universal shelf
registration statement was filed with the U.S. Securities and Exchange Commission (“SEC”) on April 18, 2014, and became
effective on June 5, 2014. The universal shelf registration statement will allow, but not compel, the Company to raise up to $45
million of capital over a three-year period through a wide array of securities at times and in amounts to be determined by the
Company. NOTE 4. – SEPTEMBER 2014 COMMON
STOCK PRIVATE PLACEMENT On September 17, 2014, the Company issued
3,871,767 shares of its common stock for $10,000,000. Net cash proceeds from the issuance were $9,324,088 after deducting expenses
associated with the common stock issuance. As a condition of the
private placement, the parties executed a Registration of Rights Agreement pursuant to which the Company agreed to provide
certain registration rights with respect to certain of the issued securities under the Securities Act of 1933. Accordingly,
on October 10, 2014, the Company filed a Form S-3 Registration Statement with the SEC. On October 23, 2014, the SEC declared
the Registration Statement effective. NOTE 5. - JANUARY 2013 PREFERRED
STOCK PRIVATE PLACEMENT On January 11,
2013, the Company sold 2,500 shares of newly created Series A-1 10 % Convertible Preferred Stock (the “Series A-1 Preferred
Stock”) and warrants for $2.5 million. Net proceeds from this issuance were $2.035 million. During 2013, all Series
A-1 Preferred Stock was converted into shares of the Company’s common stock and all related warrants to purchase shares of
the Company’s common stock were exercised. Net proceeds from the exercise of warrants to purchase shares of the Company’s
common stock were $2.090 million. NOTE 6. – CONSULTING AGREEMENT
AND JOINT VENTURE In connection with a joint venture
arrangement entered into on September 29, 2014 by the Company’s newly-formed and 51% owned subsidiary, 22nd Century
Asia, the Company entered into a six-month Consulting Agreement (the “Consulting Agreement”) with Crede CG III,
Ltd. (“Crede”). Crede will provide consulting services to 22nd Century Asia with respect to the Company’s
efforts to sell its proprietary tobacco products into the Asian market. In connection with the Company’s entry into
such a joint venture and the Consulting Agreement, the Company issued Crede 1,250,000 Tranche 1A Warrants (the “Tranche
1A Warrants”) and 1,000,000 Tranche 1B Warrants (the “Tranche 1B Warrants”). The Tranche 1A Warrants have
an exercise price of $3.36 per share and the Tranche 1B Warrants have an exercise price of $2.5951 per share. The Tranche 1A
Warrants and the Tranche 1B Warrants each have a term of two years and are exercisable at any time. In addition, the Company
issued 1,000,000 Tranche 2 Warrants (the “Tranche 2 Warrants”) and 1,000,000 Tranche 3 Warrants (the
“Tranche 3 Warrants”). The Tranche 2 Warrants and the Tranche 3 Warrants each have a term of 5 years and an
exercise price of $3.3736 per share. The Tranche 2 Warrants and Tranche 3 Warrants only become exercisable if certain revenue
milestones are met by 22nd Century Asia subsequent to a certain commencement date, such commencement date likely to occur
between January 1, 2016 and January 1, 2017, and the Company is cash flow positive from its investment in 22nd Century Asia.
The Tranche 1A Warrants, the Tranche 1B Warrants, the Tranche 2 Warrants and the Tranche 3 Warrants all contain a
traditional cashless exercise provision. F- 12 In addition to the traditional
cashless exercise provision, the Tranche 1A Warrants contain an Exchange Rights clause (the “Exchange Rights”) that
provides that the Tranche 1A Warrants may be exercised on cashless basis by exchanging such warrants for shares of the Company’s
common stock using a negotiated Black-Scholes pricing formula beginning on the day that is sixty one days after September 17, 2014,
subject to certain conditions in the Exchange Rights. The number of shares issuable pursuant to the Exchange Rights is determined
by dividing (a) the product of the number of Tranche 1A Warrants to be exchanged and the per share price resulting from the negotiated
Black-Scholes pricing formula, by (b) the Exchange Price, defined as the closing bid price of the Company’s common stock
two days prior to the date of the exchange. The maximum number shares issuable under the Exchange Rights is limited to 5,000,000
shares. The Company valued
the Tranche 1A Warrants and Tranche 1B Warrants using the Black-Scholes pricing model as of the date of issuance. The
resulting fair value of the Tranche 1A Warrants and Tranche 1B Warrants amounted to $2,810,000 and $1,260,000, respectively,
and have been recorded as Prepaid consulting fees on the Company’s Consolidated Balance Sheets and are being amortized
over the six month term of the Consulting Agreement. During the year ended December 31, 2014, $2,091,215 of the Prepaid
consulting fees were amortized and are included in General and administrative costs on the Company’s Consolidated
Statements of Operations. The Exchange Rights contained in the Tranche 1A Warrants cause the financial instrument to be
considered a liability in accordance with FASB Accounting Standards Codification Topic 480 – “Distinguishing
Liabilities from Equity” (“ASC 480”). More specifically, ASC 480 requires a financial instrument to be
classified as a liability if such financial instrument contains a conditional obligation that the issuer must or may settle
by issuing a variable number of its equity securities if, at inception, the monetary value of the obligation is based on a
known fixed monetary amount. As such, the fair value of the Tranche 1A Warrants are included in the Warrant liability on
the Company’s Consolidated Balance Sheets at December 31, 2014. The Tranche 1B Warrants do not contain such Exchange
Rights and accordingly the fair value has been recorded as an increase in capital. No value has been assigned to the Tranche
2 Warrants and the Tranche 3 Warrants as they are not exercisable until certain revenue milestones are attained, as described
above. NOTE 7. – BUSINESS COMBINATION On September 17, 2013, the Company
entered into a Membership Interest Purchase Agreement, which was subsequently amended on May 13, 2014, to purchase all of the
issued and outstanding membership interests of NASCO Products, LLC (“NASCO”), a North Carolina limited liability
company (the “Transaction”). NASCO is a federally licensed tobacco product manufacturer and a participating
member of the tobacco Master Settlement Agreement known as the MSA, an agreement among 46 U.S. states and the tobacco
industry administered by the National Association of Attorneys General (“NAAG”). The Transaction was subject to
various conditions, including the required consents of the Settling States of the MSA to an amendment of NASCO’s
existing adherence agreement to the MSA, with the Company becoming a signatory to such amended adherence agreement as part of
the Company’s acquisition of NASCO. On August 29, 2014, the Company became a signatory to the amended adherence
agreement under the MSA, and accordingly, the Transaction closed on August 29, 2014. The purchase price for the Transaction
(the “Purchase Price”) consisted of (i) a cash payment of $250,000 and (ii) the issuance of 640,000 unregistered shares
of the Company’s common stock. The common stock issued on August 29, 2014 had a market value of $1,952,000, resulting in
a total Purchase Price of $2,202,000. The Purchase Price has been recorded as an Intangible asset in the Other assets section of
the Company’s Consolidated Balance Sheets. The Company believes the intangible asset has an indefinite life and as such,
no amortization is recorded. The Company also acquired cash of approximately $105,000 and a like amount of accrued expenses. In connection with the
initial recording of the acquisition the Company recorded a deferred tax liability associated with the excess of the book
value over the tax basis of assets acquired during the third quarter of 2014. During the final accounting for the acquisition
it was determined that the book and tax basis were equal and the need for the deferred tax liability was no longer necessary.
As a result, the initial recording of the deferred tax liability and associated goodwill from August 2014 was reversed. F- 13 NOTE 8. – MANUFACTURING FACILITY On December 11, 2013, the Company closed
on a $3,220,000 purchase of certain cigarette manufacturing equipment from the bankruptcy estate of a company located in North
Carolina that was liquidating under Chapter 7 of the U.S. Bankruptcy Code. Additionally, on January 13, 2014, the Company closed
on a $210,000 purchase of various cigarette manufacturing equipment parts, office furniture and fixtures, vehicles and computer
software and equipment from a second bankruptcy estate of a company located in North Carolina that was liquidating under Chapter
7 of the U.S. Bankruptcy Code. A portion of the equipment from these two transactions was not required for the Company’s
manufacturing operations and was subsequently sold at auction during the first quarter of 2014. The Company’s
warehouse and cigarette manufacturing facility was primarily in a pre-manufacturing stage during the year ended December 31,
2014. During this time period, the Company incurred various expenses to prepare the facility for production. Expenses
incurred during the year ended December 31, 2014 amounted to $1,176,676 and consisted primarily of expenses for salaries and
benefits for employees, sub-contract labor, rent, utilities and other miscellaneous costs and are reported as
Pre-manufacturing facility costs on the Company’s Consolidated Statements of Operations. During the second quarter of
2014, the Company placed $2,997,140 of cigarette manufacturing equipment in service. Depreciation taken on the equipment
during the year ended December 31, 2014 amounted to $224,519 and is included in Amortization and depreciation on the
Company’s Consolidated Statements of Operations. The Company did manufacture a quantity of filtered cigars during the
year ended December 31, 2014 resulting in revenue of $81,456. As discussed in Note 7, on August 29, 2014, the Company closed
on the acquisition of NASCO. Accordingly, the Company and NASCO are now signatories under the MSA. NASCO commenced
manufacturing the Company’s proprietary cigarette brands and an MSA brand for an independent chain of retail smoke
shops during the fourth quarter of 2014 at its manufacturing facility. Sales of these MSA brands commenced during the first
quarter of 2015. NASCO will also continue to manufacture non-MSA filtered cigars. NOTE 9. – MACHINERY AND EQUIPMENT Machinery and equipment at December 31,
2014 and 2013 consists of the following: December 31, December 31, 2014 2013 Cigarette manufacturing equipment $ 3,031,375 $ 3,220,000 Office furniture, fixtures and equipment 55,355 17,059 Leasehold improvements - 14,500 Deposit for purchase of machine parts and other assets - 210,000 3,086,730 3,461,559 Less: cigarette manufacturing equipment held for resale - 457,696 3,086,730 3,003,863 Less: accumulated depreciation 236,115 6,103 Machinery and equipment, net $ 2,850,615 $ 2,997,760 On December 11, 2013
and January 13, 2014, the Company acquired machinery and equipment in the amount of $3,220,000 and $210,000, respectively,
as described in Note 8. A portion of the equipment from these two transactions was not required for the
Company’s manufacturing operations and was subsequently sold at auction during the first quarter of 2014. The Company
allocated $457,696 and $88,167 of the purchase price of these sold assets from the two transactions, respectively. The
Company realized net proceeds from the auction sale of $631,484, resulting in a gain on the sale of assets of $85,621. The
remaining cigarette manufacturing equipment was placed in service during the second quarter of 2014. Depreciation expense was
$230,012 and $3,027 for the years ended December 31, 2014 and 2013, respectively. F- 14 NOTE 10. – EQUITY INVESTMENT AND ADVANCE On April 11, 2014, the Company,
through a newly formed wholly-owned subsidiary, Botanical Genetics, LLC, entered into an investment agreement (the
“Agreement”) with Anandia Laboratories, Inc., a Canadian plant biotechnology company (“Anandia”). The
Agreement provided for the Company to make an initial investment of $250,000 in Anandia in return for (i) a ten percent (10%)
equity interest in Anandia, and (ii) certain rights granted to the Company for four patent families (the “Intellectual
Property”). The $250,000 investment was made on April 14, 2014. On September 15, 2014, certain milestones were achieved
triggering an additional cash investment in Anandia in the amount of $450,000 in return for (i) an additional fifteen percent
(15%) equity interest in Anandia, and (ii) a worldwide sublicense agreement to the Intellectual Property, including an
exclusive sublicense agreement within the U.S. In addition, the Company issued 150,000 unregistered shares of the
Company’s common stock to Anandia with a value on the day of issuance in the amount of $394,500, and on March 31, 2015,
the Company will issue to Anandia unregistered shares of the Company’s common stock with an aggregate market value of
$325,000 at the time of the issuance. The additional $325,000 payable in shares of common stock is included in the Equity
investment and in Accrued expenses on the Company’s Consolidated Balance Sheets at December 31, 2014. In January 2014, the Company made
a non-interest bearing advance to Anandia in the amount of $92,894. $50,000 of this amount was applied to a sublicense fee paid
to Anandia, under a certain sublicense more fully described in Note 17. The balance of $42,894 has been written off and is included
in General and administrative expense on the Company’s Consolidated Statements of Operations. The Company uses the
equity method of accounting to record its 25% ownership interest in Anandia. As of December 31, 2014, the Company’s
equity investment balance in Anandia was $1,318,335 and is classified within Other assets on the accompanying Consolidated
Balance Sheets. As of December 31, 2014, the carrying value of our investment in Anandia was approximately $1,199,000 in
excess of our share of the book value of the net assets of Anandia, with such difference attributable to intangible assets.
This intangible asset is being amortized over the expected benefit period and this amortization expense of $16,815 has been
included in the Loss on equity investment in the accompanying Consolidated Statements of Operations. In addition, the
Company has recorded an equity loss of $84,350, representing 25% of Anandia’s net loss covering the period beginning
with the Company’s initial investment through December 31, 2014, resulting in a total loss on equity investment
of $101,165. NOTE 11. - DEMAND BANK LOAN The demand loan is among the Company’s
short term liabilities and is payable to a commercial bank under a revolving credit agreement and is guaranteed by a former officer
and current director of the Company. This loan had a balance of $174,925 at December 31, 2014 and 2013. The Company is required
to pay interest monthly at an annual rate of 0.75% above the prime rate, or 4.00% at December 31, 2014 and 2013. The Company is
current in meeting this interest payment obligation. The terms of the demand loan include an annual “clean-up” provision,
which requires the Company to repay all principal amounts outstanding for a period of 30 consecutive days every year. The Company
has not complied with this requirement; however, the bank has not demanded payment. The bank has a lien on all of the Company’s
assets. NOTE 12. - NOTES PAYABLE AND PATENT ACQUISITION On December 22, 2014, the Company
entered into a Purchase Agreement (the “Agreement”) with the National Research Council of Canada
(“NRC”) to acquire certain patent rights that the Company had previously licensed from NRC under a license
agreement between the parties. The Purchase Agreement provided for the payment by the Company to NRC of the total amount of
$1,873,000, of which (i) $660,000 was required to be paid at the closing under the Purchase Agreement for the payment due in
2013 from the Company to NRC as a result of the monies received by the Company from BAT in October 2013, and (ii) the
remaining balance of $1,213,000 being for the purchase of the NRC patent rights, of which $213,000 was paid in cash at the
closing on December 23, 2014, and with the remaining $1,000,000 balance to be paid in three equal installments of
approximately $333,333 in December of 2015, 2016 and 2017, respectively, with no interest on the installment payments unless
the Company defaults in any such installment payment. As such, the Company computed the present value of the note payable
using the Company’s incremental borrowing rate. The resulting present value of the note payable amounted to $925,730;
with $320,513 and $605,217 recorded as the current and long-term portion of the note payable, respectively. The cost of
the acquired patents in the amount of $1,138,730 (cash of $213,000 plus the discounted notes payable in the amount of
$925,730) are included in Intangible assets, net on the Company’s Consolidated Balance Sheets. All previous license
agreements between NRC and the Company were terminated as a condition of the Purchase Agreement. NRC has a security interest
in these patent rights acquired by the Company from NRC until the note payable has been satisfied. F- 15 NOTE 13. – SEVERANCE LIABILITY As of December 31, 2014, the Company
has recorded an accrual for service in the amount of $624,320 in accordance with FASB ASC 712. The severance accrual relates to the October 25, 2014 termination of Joseph Pandolfino, the
Company’s former Chairman of the Board and Chief Executive Officer, pursuant to Section 4.2 (Termination by the Company
Without Cause) of Mr. Pandolfino’s Employment Agreement, dated as of January 25, 2011. The Employment Agreement
stipulates that Mr. Pandolfino shall receive severance payments in the gross amount of $18,750 per month, subject to
customary withholdings, over a term of 36 months. Amounts owed Mr. Pandolfino have been discounted using the Company’s
incremental borrowing rate, resulting in current and long-term liabilities of $212,012 and $412,308, respectively. In
addition, 320,000 unvested equity awards vested upon termination. The additional equity based compensation of approximately
$60,000 associated with the vesting of these equity awards was recorded as expense during the fourth quarter of 2014. NOTE 14. - DUE FROM RELATED PARTY The Company has conducted transactions
with a related party, Alternative Cigarettes, Inc. (“AC”). AC is entirely owned by certain shareholders of the Company,
including the Company’s former CEO and current director. During the years ended December 31, 2014 and 2013, transactions
with AC consisted mainly of advances and repayments. The net amount due from AC amounted to $46,069 and $42,069 as of December
31, 2014 and 2013, respectively. No interest has been accrued or paid on amount due from or to AC and there are no repayment terms. NOTE 15. - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR
COMMON STOCK During the fourth quarter of 2013,
the Company initiated a warrant exchange program (the “Warrant Exchange Program”) with existing warrant holders. As
a result of the Warrant Exchange Program, the Company had 10,653,469 outstanding warrants remaining at December 31, 2013, a reduction
from 19,616,308, as of September 30, 2013. Of the remaining outstanding warrants at December 31, 2013, 3,921,381 warrants contained
anti-dilution features that provide for adjustments to the exercise price and number of warrants outstanding if the Company issues
shares of common stock of 22nd Century Group at a price that is less than the respective warrant exercise prices. These provisions
require that such warrants be classified as derivatives for accounting purposes, which means they are reported as a liability and
adjusted to fair value at each balance sheet date. In March 2014, the Company entered
into warrant amendments with existing warrant holders (the “Warrant Amendments”) with the goal of further reducing
the Company’s warrant liability. To that end, the Company offered financial inducements to certain non-management warrant
holders to (i) exercise their warrants on a cash basis, (ii) exercise their warrants on a cashless basis, or (iii) agree to have
the anti-dilution feature removed from their warrants in exchange for a reduction in the exercise price contained in their respective
warrants. The warrant holders also had the option to maintain the terms and conditions of their original warrant. Management elected
to have the anti-dilution feature removed from their warrants without inducement. As a result of the Warrant Amendments, subsequent
warrant exercises during the year ended December 31, 2014, and additional warrants issued during the third quarter of 2014, there
are 13,544,600 warrants outstanding at December 31, 2014 that do not contain the anti-dilution features. A total of 129,809 warrants
containing anti-dilution features remain outstanding at December 31, 2014. The Company calculated the cost of inducement as the
difference between the fair value of the warrants immediately after the Warrant Amendments closed, less the fair value of the warrants
immediately prior to the completion of the Warrant Amendments. The Company estimated the total cost of inducement to be $144,548.
This expense has been recorded as an Other expense on the Company’s Consolidated Statements of Operations, and as an increase
to the derivative warrant liability that was subsequently reversed into capital. F- 16 As discussed in Note 6, the Company
issued warrants to Crede on September 29, 2014, in connection with a joint venture and Consulting Agreement, whereby Crede will
provide consulting services to 22nd Century Asia with respect to the Company’s efforts to sell its proprietary tobacco products
into the Asian market. The terms and conditions relating to the issued warrants are discussed in detail in Note 6. Outstanding warrants at December
31, 2014 consist of the following: Number of Exercise Warrant Description Warrants Price Expiration January 2011 PPO $3.00 warrants 2,817,952 $ 2.2029 January 25, 2016 January 2011 PPO $3.00 warrants 653,869 $ 2.0000 January 25, 2016 January 2011 PPO $3.00 warrants 3,062,665 $ 1.9600 January 25, 2016 January 2011 PPO $1.50 warrants 292,965 $ 1.2672 January 25, 2016 January 2011 PPO $1.50 warrants (1) 37,177 $ 1.2018 January 25, 2016 January 2011 PPO $1.50 warrants 62,329 $ 1.2018 January 25, 2016 January 2011 PPO $1.50 warrants 10,831 $ 1.1718 January 25, 2016 December 2011 convertible NP warrants 172,730 $ 1.1984 February 8, 2017 December 2011 convertible NP warrants 802,215 $ 1.3816 February 6, 2018 May 2012 PPO warrants 401,700 $ 0.6000 May 15, 2017 November 2012 PPO warrants 925,100 $ 0.6000 November 9, 2017 August 2012 convertible NP warrants (1) 92,632 $ 0.9520 August 8, 2018 August 2012 convertible NP warrants 92,244 $ 0.9060 August 8, 2018 Crede Tranche 1A Warrants (2) 1,250,000 $ 3.3600 September 29, 2016 Crede Tranche 1B Warrants 1,000,000 $ 2.5951 September 29, 2016 Crede Tranche 2 Warrants (3) 1,000,000 $ 3.3736 September 29, 2019 Crede Tranche 3 Warrants (3) 1,000,000 $ 3.3736 September 29, 2019 Total warrants outstanding (4) 13,674,409 (1) Includes anti-dilution features. (2) Include Exchange Rights (see Note 6 for detailed discussion). (3) Exercisable upon attainment of certain revenue milestones (see Note 6 for detailed discussion). (4) Includes 3,725,962 warrants (27.3%) held by officers and directors that have had the anti-dilution
feature removed. The Company
estimates the value of warrant liability upon issuance of the warrants and at each balance sheet date using the binomial lattice
model to allocate total enterprise value to the warrants and other securities in the Company’s capital structure. Volatility
was estimated based on historical observed equity volatilities and implied (forward) or expected volatilities for a sample group
of guideline companies and consideration of recent market trends. As a result of the Exchange Rights
contained in the Tranche 1A Warrants, the financial instrument is considered a liability in accordance with FASB Accounting Standards
Codification Topic 480 – “Distinguishing Liabilities from Equity” (“ASC 480”). More specifically,
ASC 480 requires a financial instrument to be classified as a liability if such financial instrument contains a conditional obligation
that the issuer must or may settle by issuing a variable number of its equity securities if, at inception, the monetary value of
the obligation is based on a known fixed monetary amount. F- 17 The following table is a roll-forward summary of
the warrant liability: Fair value at December 31, 2012 $ 4,173,140 Fair value of warrant liability upon conversion of remaining December 14, 2011 Notes – Q1 2013 1,445,091 Fair value of warrant liability upon issuance - Q1 2013 6,022,319 Fair value of warrant liability upon issuance - Q2 2013 711,675 Fair value of warrant liability upon issuance - Q3 2013 1,622,069 Fair value of warrant liability upon conversion of August 9, 2012 Notes - Q3 2013 731,662 Fair value of warrant liability upon reduction of exercise price of Series A and Series C warrants – Q3 2013 626,328 Reclassification of warrant liability to equity upon exercise of warrants - Q2 2013 (204,513 ) Reclassification of warrant liability to equity upon exercise of warrants - Q3 2013 (6,542,904 ) Reclassification of warrant liability to equity upon exercise of warrants - Q4 2013 (7,712,170 ) Cost of inducement from Warrant Exchange Program - Q4 2013 3,274,313 Reclassification of warrant liability to equity resulting from Warrant Exchange Program - Q4 2013 (19,639,465 ) Loss as a result of change in fair value 19,271,977 Fair value at December 31, 2013 $ 3,779,522 Reclassification of warrant liability to equity resulting from Warrant Amendments - Q1 2014 (7,367,915 ) Cost of inducement from Warrant Amendments - Q1 2014 144,548 Fair value of warrant liability resulting from issuance of Crede Tranche 1A Warrants – Q3 2014 2,810,000 Loss as a result of change in fair value 3,676,691 Fair value at December 31, 2014 $ 3,042,846 The aggregate net loss as a result of the
Company’s warrant liability for the years ended December 31, 2014 and 2013 amounted to $3,676,691 and $19,271,977, respectively,
which is included in Other income (expense) as part of Warrant liability loss – net in the accompanying Consolidated Statements
of Operations. The loss for the year ended December 31, 2013, also includes a charge to Other income (expense) in the amount of
$4,330,734 as a result of (i) warrant liabilities issued in connection with the Series A-1 Preferred Stock in excess of net proceeds
raised in the amount of $3,987,655 in January 2013, and (ii) warrant liabilities issued in connection with the July 2013 issuance
of 1,101,034 Series C Warrants in excess of the sum of the net process received upon exercise and the reclassification of the warrant
liability to capital, in the amount of $343,079. Warrant liabilities issued during the year ended December 31, 2013, in connection
with the December 14, 2011 convertible notes and the August 9, 2012 convertible notes converted to common stock in excess of the
conversion amount by $17,386 and $509,062, respectively, were recorded as additional interest expense. FASB ASC 820 - “Fair
Value Measurements and Disclosures” establishes a valuation hierarchy for disclosure of the inputs to valuation used to
measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: · Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; · Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the
asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial
instrument; and · Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities
at fair value. A financial asset’s or
a financial liability’s classification within the hierarchy is determined based on the lowest level input that is
significant to the fair value measurement. The warrant liability is measured at fair value using certain estimated factors
such as volatility and probability which are classified within Level 3 of the valuation hierarchy. Significant unobservable
inputs that are used in the fair value measurement of the Company’s derivative warrant liabilities include volatility.
Significant increases (decreases) in the volatility input would result in a significantly higher (lower) fair value
measurement. F- 18 The following table summarizes the Company’s
warrant activity since December 31, 2012: Number of Warrants Warrants outstanding at December 31, 2012 12,972,664 Warrants issued 11,570,274 Warrants issued as part of Warrant Exchange Program 138,666 Additional warrants due to anti-dilution provisions 1,665,400 Warrants exercised during 2013 (9,831,414 ) Warrants exercised as part of Warrant Exchange Program (5,862,121 ) Warrants outstanding at December 31, 2013 10,653,469 Warrants issued in conjunction with consulting agreement (see Note 6) 4,250,000 Warrants exercised during 2014 (1,247,443 ) Additional warrants due to anti-dilution provisions 18,383 Warrants outstanding at December 31, 2014 13,674,409 Composition of outstanding warrants: Warrants containing anti-dilution feature 129,809 Warrants without anti-dilution feature 13,544,600 (1) 13,674,409 (1) Include 1,250,000 warrants containing Exchange Rights (see Note 6 for detailed discussion). NOTE 16. - RETIREMENT PLAN The Company sponsors a defined contribution
plan under IRC Section 401(k). The plan covers all employees who meet the minimum eligibility requirements. Under the
401(k) plan eligible employees are allowed to make voluntary deferred salary contribution to the plan, subject to statutory limits. The Company has elected to make Safe Harbor Non-elective Contributions to the plan for eligible employees in the amount of three
percent (3%) of the employee’s compensation. Total employer contributions to the plan for the years ended December
31, 2014 and 2013 amounted to $27,485 and $34,873, respectively. The contribution for the year ended December 31, 2013 includes
a contribution made for 2012 in the first quarter of 2013. NOTE 17. – COMMITMENTS AND CONTINGENCIES License Agreements - Under its exclusive worldwide license agreement with North Carolina State University (“NCSU”), the Company is required
to pay minimum annual royalty payments, which are credited against running royalties on sales of licensed products. The minimum
annual royalty for each of 2014 and 2015 is $75,000, and in 2016 the minimum annual royalty increases to $225,000. The license
agreement continues through the life of the last-to-expire patent, which is expected to be 2022. The license agreement also requires
a milestone payment of $150,000 upon FDA approval or clearance of a product that uses the NCSU licensed technology. The Company
is also responsible for reimbursing NCSU for actual third-party patent costs incurred. These costs vary from year to year and the
Company has certain rights to direct the activities that result in these costs. During the years ended December 31, 2014 and 2013,
the costs incurred related to capitalized patent costs and patent maintenance expense amounted to $123,968 and $101,902 respectively. In addition, on February 10, 2014,
the Company entered into a sponsored research and development agreement (the “Agreement”) with NCSU. Under the terms
of the Agreement, the Company is required to pay NCSU $162,408 over the two-year term of the Agreement, which grants certain licensing
rights to the Company. A payment of $81,204 was made in February 2014 and a final payment of $81,204 is due and payable on February
1, 2015. The Company has two other exclusive
license agreements which require aggregate annual license fees of approximately $75,000, which are credited against running royalties
on sales of licensed products. Each license agreement continues through the life of the last-to-expire patents. On December 22,
2014, the Company entered into a Purchase Agreement (see Note 12 for details) with one of these licensors to acquire certain patent
rights the Company had previously licensed from such licensor. The Company has no future commitment to that licensor. F- 19 All payments made under the above
referenced license agreements and the sponsored research and development agreement are initially recorded as a Prepaid expense
on the Company’s Consolidated Balance Sheets and subsequently expensed on a straight-line basis over the applicable period
and included in Research and development costs on the Company’s Consolidated Statements of Operations. On August 22, 2014, the Company entered
into a Commercial License Agreement with Precision PlantSciences, Inc. (the “Precision License”). The Precision License
grants the Company a non-exclusive, but fully paid up right and license to use technology and materials owned by Precision PlantSciences
for a license fee of $1,250,000. An initial cash payment of $725,000 was made upon execution of the Precision License with an unconditional
obligation to pay the remaining $525,000 in $25,000 increments as materials are provided to the Company. The remaining $525,000
was paid during December 2014. The Precision License continues through the life of the last-to-expire patent, which is expected
to be in 2028. On August 27, 2014, the Company entered
into an additional exclusive License Agreement (the “License Agreement”) with NCSU. Under the License Agreement, the
Company paid NCSU a non-refundable, non-creditable lump sum license fee of $125,000. Additionally, the License Agreement calls
for the Company to pay NCSU three non-refundable, non-creditable license maintenance fees in the amount of $15,000 per annum in
each of December 2015, 2016 and 2017. Beginning in calendar year 2018, the Company is obligated to pay to NCSU an annual minimum
royalty fee of $20,000 in 2018, $30,000 in 2019, and $50,000 per year thereafter for the remaining term of the License Agreement.
The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. There were no costs reimbursed
under the License Agreement through December 31, 2014. The License Agreement continues through the life of the last-to-expire patent,
which is expected to be in 2034. On September 15, 2014, the Company
entered into a Sublicense Agreement with Anandia Laboratories, Inc. (the “Anandia Sublicense”). Under the terms of
the Anandia Sublicense, the Company was granted an exclusive sublicense in the United States and a co-exclusive sublicense in the
remainder of the world, excluding Canada, to the licensed Intellectual Property (more fully discussed in Note 10). The Anandia
Sublicense calls for an up-front fee of $75,000, an annual license fee of $10,000, and a running royalties on future net sales.
The Anandia Sublicense continues through the life of the last-to-expire patent, which is expected to be in 2035. The Precision License, the License
Agreement with NCSU and the Anandia Sublicense are included in Intangible assets, net in the Company’s Consolidated Balance
Sheets and the applicable license fees will be amortized over the term of the agreements based on their last-to-expire patent date.
Amortization during the year ended December 31, 2014 and 2013 amounted to $32,524 and $0, respectively, and was included in Research
and development costs on the Company’s Consolidated Statements of Operations. Lease Agreements - On
October 9, 2013, the Company executed a guaranty that guarantees performance by NASCO of its obligations to a landlord under a
certain triple net lease of the same date between NASCO and a landlord for a manufacturing facility and warehouse located in North
Carolina. Upon the NASCO transaction closing on August 29, 2014, the lease became a direct obligation of the Company. The lease
commenced on January 14, 2014, and has an initial term of twelve (12) months. The lease contains four (4) additional extensions;
one for an additional one (1) year and three for an additional two (2) years in duration, exercisable at the option of NASCO. The
lease expense for the year ended December 31, 2014 amounted to $97,593. The future minimum lease payments under the lease are $123,000,
$298,275, $338,250 and $338,250 during the one (1) year optional extension, and each of the three (3), two (2) year optional extensions,
respectively. The Company has extended the lease for its office space
in Clarence, New York for a one-year renewal option expiring August 31, 2015, with the
Company having the option to extend this lease for either or both of two (2) additional renewal periods, each consisting of
one (1) year. Future minimum lease payments for the years ended December 31, 2015, 2016 and 2017 are approximately $44,000,
$45,000 and $31,000, respectively, if the Company exercises each of the optional renewal periods. On January 25, 2013, the Company entered
into a two and one-half year lease for manufacturing space in Depew, New York, which commenced February 1, 2013. This lease was
cancelled during the third quarter of 2014. There are no remaining rent commitments under this lease. F- 20 NOTE 18. - EARNINGS PER COMMON SHARE The following table sets forth the computation
of basic and diluted earnings per common share for the year ended December 31, 2014 and 2013: December 31, December 31, 2014 2013 Net loss attributed to common shareholders $ (15,595,358 ) $ (26,153,158 ) Denominator for basic earnings per share-weighted average shares outstanding 59,993,413 43,635,182 Effect of dilutive securities: Warrants, restricted stock and options outstanding - - Denominator for diluted earnings per common share-weighted average shares adjusted for dilutive securities 59,993,413 43,635,182 Loss per common share - basic and diluted $ (0.26 ) $ (0.60 ) Securities outstanding
that were excluded from the computation of earnings per share for the year ended December 31, 2014 and 2013 because they would
have been anti-dilutive are as follows: December 31, December 31, 2014 2013 Warrants 13,674,409 10,653,469 Restricted stock 250,000 500,000 Options 890,000 660,000 14,814,409 11,813,469 NOTE 19. - STOCK BASED COMPENSATION On October 21, 2010, the Company
established the 2010 Equity Incentive Plan (“EIP”) for officers, employees, directors, consultants and advisors to
the Company and its affiliates, consisting of 4,250,000 shares of common stock. The EIP had a term of ten years and is administered
by our Board of Directors (the “Board”) or a committee to be established by our Board (the “Administrator”),
to determine the various types of incentive awards that may be granted to recipients under this plan and the number of shares of
common stock to underlie each such award under the EIP. On March 30, 2011, the Company filed a Form S-8 registration statement
with the SEC to register all of the shares of common stock of 22nd Century Group that it may issue under the EIP. During the first quarter of 2014,
the Company issued restricted stock awards from the EIP for 850,000 restricted shares to employees and directors that will vest
on January 27, 2015. All awards were valued at the closing price on the measurement date of the award. Subsequent to this issuance
of restricted stock, there are no shares remaining to be issued from the EIP. F- 21 On April 12, 2014, the stockholders
of the Company approved the 22nd Century Group, Inc. 2014 Omnibus Incentive Plan (the “OIP”). The OIP allows for the
granting of equity and cash incentive awards to eligible individuals over the life of the OIP, including the issuance of up to
5,000,000 shares of the Company’s common stock pursuant to awards under the OIP. The OIP has a term of ten years and is administered
by the Compensation Committee of our Board of Directors to determine the various types of incentive awards that may be granted
to recipients under this plan and the number of shares of common stock to underlie each such award under the OIP. On April 18,
2014, the Company filed a Form S-8 registration statement with the SEC to register the 5,000,000 shares of common stock of 22nd
Century Group that may be issued under the OIP. During the year ended December
31, 2014, the Company issued restricted stock awards from the OIP for 147,556 restricted shares to eligible individuals having
vesting periods ranging from zero to three years from the award date. All awards were valued at the closing price on the measurement
date of the award. For the years ended December
31, 2014 and 2013, the Company recorded compensation expense related to restricted stock and stock option awards granted
under the EIP and OIP of $2,293,082 and $998,214, respectively. The Company also recorded equity based compensation for the years ended
December 31, 2014 and 2013 as payment to third parties for services rendered in the amount $140,170 and $1,363,748,
respectively. As of December 31, 2014, unrecognized
compensation expense related to non-vested restricted shares and stock options amounted to approximately $672,000, which is expected
to be recognized approximately as follows: $473,000, $160,000, and $39,000 during 2015, 2016 and 2017, respectively. The fair value of each option
grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the
years ended December 31, 2014 and 2013: 2014 2013 Risk-free interest rate 1.80 % 1.89 % Expected dividend yield 0 % 0 % Expected stock price volatility 90 % 90 % Expected life of options 10 years 10 years The Company estimated the expected volatility
based on data used by a peer group of public companies. The expected term was estimated using the contract life of the option.
The risk-free interest rate assumption was determined using yield of the equivalent U.S. Treasury bonds over the expected term.
The Company has never paid any cash dividends and does not anticipate paying any cash dividends in the foreseeable future. Therefore,
the Company assumed an expected dividend yield of zero. A summary of all stock option activity since
December 31, 2012 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2012 465,000 $ 0.69 Granted in 2013 215,000 $ 0.80 Exercised in 2013 (20,000 ) $ 0.26 Outstanding at December 31, 2013 660,000 $ 0.74 Granted in 2014 300,000 $ 2.61 Exercised in 2014 (70,000 ) $ 0.69 Outstanding at December 31, 2014 890,000 $ 1.38 8.0 years $ 532,900 Exercisable at December 31, 2014 640,000 $ 0.89 7.7 years $ 532,900 F- 22 There were 300,000 options granted from
the OIP during the year ended December 31, 2014 (215,000 options granted during the year ended December 31, 2013). The weighted
average grant date fair value of options issued during the year ended December 31, 2014 was $2.07 ($0.68 for the year ended December
31, 2013). The total fair value of options that vested during the year ended December 31, 2014 amounted to $103,250 ($242,160 for
the year ended December 31, 2013). During the year ended December 31, 2014, 70,000 options were exercised for cash proceeds of
$48,300. During the year ended December 31, 2013, 20,000 options were exercised for cash proceeds of $5,200. NOTE 20. - INCOME TAXES The following is a summary of the components
giving rise to the income tax provision (benefit) for the years ended December 31, 2014 and 2013. The provision (benefit) for income taxes
consists of the following: 2014 2013 Current: Federal $ - $ - State - - Total current - - Deferred: Federal (3,494,787 ) 829,306 State 160,319 186,414 Total deferred (3,334,468 ) 1,015,720 Change in valuation allowance 3,334,468 (1,015,720 ) $ - $ - The provision (benefit) for income tax varies
from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss as follows: 2014 2013 Statutory federal rate (34.0 )% (34.0 )% Permanent items 0.6 1.8 Derivative liability 8.4 35.5 Stock based compensation 2.5 - State tax provision, net of federal benefit 1.1 0.5 Valuation allowance 21.4 (3.9 ) Effective tax rate (benefit) provision 0.0 % 0.0 % Individual components of deferred taxes
consist of the following: 2014 2013 Deferred tax assets: Net operating loss carry-forward $ 4,775,536 $ 2,616,624 Derivative liability - 21,725 Inventory reserve 17,713 19,584 Stock-based compensation 809,319 131,450 Start-up expenditures 388,130 - Loss on equity investment 35,398 - Severance liability 218,450 - Other 6,561 1,292 6,251,107 2,790,675 Deferred tax liabilities: Inventory - (52,445 ) Fixed assets (80,251 ) (2,956 ) Patents and trademarks (624,010 ) (523,157 ) Other intangible assets (21,986 ) - (726,247 ) (578,558 ) Valuation allowance (5,524,860 ) (2,212,117 ) Net deferred taxes $ - $ - The Company has incurred a net operating
loss of approximately $13,700,000 through December 31, 2014 and this amount is being carried forward to future years and expires in 2031
and 2032. Due to the uncertainty of the Company’s ability to generate sufficient taxable income in the future before they
expire, the company has recorded a valuation allowance to reduce the net deferred tax asset to zero. This NOL is included in the
net deferred tax asset that has been fully offset by the valuation allowance. ASC 740 provides guidance on the financial
statement recognition and measurement for uncertain income tax positions that are taken or expected to be taken in a company’s
income tax return. The Company has no uncertain tax positions as of December 31, 2014. The Company’s federal and state tax
returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations.
There are no pending audits as of December 31, 2014. NOTE 21. - SUBSEQUENT EVENTS On January 14, 2015,
the Company’s Board of Directors approved the Company’s Compensation Committee recommendation to award
officers, employees and directors of the Company stock awards in the form of stock options from the Company’s OIP in an
aggregate amount of approximately $1,059,000. The stock options will be granted on February 16, 2015, with an exercise price
based on the average closing price of the Company’s common stock for the three trading days immediately preceding the
date of the grant. On January 19, 2015, the
Company became obligated to issue 70,423 shares of its common stock, par value $0.00001 per share, to Smoker Friendly
International, LLC (“Smoker Friendly”) under the terms of an agreement between the Company and Smoker Friendly. F- 23 Item 15 (b) Exhibits In reviewing the agreements included
as exhibits to this report, please remember they are included to provide you with information regarding their terms and are not
intended to provide any other factual or disclosure information about the Company, its subsidiaries or other parties to the agreements.
The agreements contain representations and warranties by each of the parties to the applicable agreement. These representations
and warranties have been made solely for the benefit of the other parties to the applicable agreement and: · should
not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties
if those statements prove to be inaccurate; · have
been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement,
which disclosures are not necessarily reflected in the agreement; · may
apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and · Were
made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are
subject to more recent develpoments. Accordingly, these representations and warranties
may not describe the actual state of affairs as of the date they were made or at any other time. We acknowledge that, notwithstanding
the inclusion of the foregoing cautionary statements, we are responsible for considering whether additional specific disclosures
of material information regarding material contractual provisions are required to make the statements in this report not misleading. Additional information about the Company may be found elsewhere in this report and the Company’s other public files,
which are available without charge through the SEC’s website at http://www.sec.gov. Exhibit No. Description 2.1 Membership Interest Purchase Agreement between 22nd Century Group, Inc. and Ralph Angiuoli dated September 17, 2013 (incorporated by reference to Form 8-K filed with the Commission on September 17, 2013). 2.2 First Amendment to Membership Interest Purchase Agreement, dated May 13, 2014, between 22nd Century Group, Inc. and Ralph Angiuoli (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the Commission on May 19, 2014) 2.3 Stock Purchase Agreement, dated September 17, 2014, by and between 22nd Century Group, Inc. and Crede CG III, Ltd. (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the Commission on September 18, 2014) 2.4 Investment Agreement, dated April 11, 2014, by and between 22nd Century Group, Inc. and Anandia Laboratories Inc. (incorporated by reference to Exhibit 2.2 to the Company’s Form 8-K filed with the Commission on September 18, 2014) 2.5 Purchase Agreement, dated December 22, 2014, by and between 22nd Century Limited, LLC and the National Research Council of Canada (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the Commission on December 29, 2014) 3.1 Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.2 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2010 filed with the Commission on December 3, 2010). 3.1.1 Amendment to Certificate of Incorporation of the Company (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement filed with the Commission on March 4, 2014) 3.2 Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Commission on January 30, 2014) . 4.1 Form of Warrant dated as of January 25, 2011 issued to LLC members of 22nd Century Limited, LLC prior to the consummation of the Private Placement Offering upon consummation of the merger of 22nd Century Limited, LLC with the Company (incorporated herein by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K filed with the Commission on February 1, 2011). 4.2 Form of Warrant dated as of January 25, 2011 issued to investors in the Private Placement Offering upon consummation of the merger of 22nd Century Limited, LLC with the Company (Incorporated herein by reference to Exhibit 10.5 of the Company’s Current Report on Form 8-K filed with the Commission on February 1, 2011). 4.3 Form of Warrant dated as of January 25, 2011 issued to the Placement Agent and Sub-Agent upon consummation of the merger of 22nd Century Limited, LLC with the Company (incorporated herein by reference to Exhibit 10.6 of the Company’s Current Report on Form 8-K filed with the Commission on February 1, 2011). 44 4.4 Form of Common Stock Purchase Warrant (incorporated herein by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the Commission on December 14, 2011). 4.5 Form of Common Stock Purchase Warrant (incorporated herein by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Commission on May 18, 2012). 4.6 Form of Common Stock Purchase Warrant (incorporated herein by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Commission on November 13, 2012). 4.7 Form of Tranche 1A Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the Commission on September 30, 2014) 4.8 Form of Tranche 1B Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed with the Commission on September 30, 2014) 4.9 Form of Tranche 2 Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Form 8-K filed with the Commission on September 30, 2014) 4.10 Form of Tranche 3 Warrant (incorporated by reference to Exhibit 4.4 to the Company’s Form 8-K filed with the Commission on September 30, 2014) 10.1† 2010 Equity Incentive Plan (incorporated herein by reference to Exhibit 4.3 to the Company’s Form S-8 filed with the Commission on March 30, 2011). 10.2† Employment Agreement dated as of January 25, 2011 by and between the Company and Joseph Pandolfino (incorporated herein by reference to Exhibit 10.15 of the Company’s Current Report on Form 8-K filed with the Commission on February 1, 2011). 10.3† Employment Agreement dated as of January 25, 2011 by and between the Company and Henry Sicignano III (incorporated herein by reference to Exhibit 10.16 of the Company’s Current Report on Form 8-K filed with the Commission on February 1, 2011). 10.4† Employment Agreement dated as of March 15, 2011 by and between the Company and Michael R. Moynihan (incorporated by reference to Exhibit 10.18 to the Company’s Form S-1 registration statement filed with the Commission on June 6, 2011). 10.5†† License Agreement dated March 6, 2009 between North Carolina State University and 22nd Century Limited, LLC (incorporated by reference to Exhibit 10.21 to the Company’s Form S-1 registration statement filed with the Commission on August 26, 2011). 10.5.1 Amendment dated August 9, 2012 to License Agreement dated March 6, 2009 between North Carolina State University and 22nd Century Limited, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on August 20, 2012). 10.6†† License Agreement dated May 1, 2009 between The National Research Council of Canada and 22nd Century Limited, LLC (incorporated by reference to Exhibit 10.22 to the Company’s Form S-1 registration statement filed with the Commission on August 26, 2011). 10.7 Letter Agreement between the Company and North Carolina State University dated November 22, 2011 (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on November 23, 2011). 10.8† Employment Agreement between John Brodfuehrer and the Company dated March 19, 2013 (incorporated by reference to Form 8-K filed on March 25, 2013). 10.9† Form of Restricted Stock Award Agreement (incorporated by reference to Form 10-Q filed on May 10, 2013). 10.10† Form of Stock Option Award Agreement (incorporated by reference to Form 10-Q filed on May 10, 2013). 10.11†† Research License and Commercial Option Agreement with British American Tobacco (Investments) Limited dated October 1, 2013 (incorporated by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Commission on January 30, 2014). 10.12 † 22nd Century Group, Inc. 2014 Omnibus Incentive Plan (incorporated by reference to Appendix B to the Company’s Definitive Proxy Statement filed with the Commission on March 4, 2014) 10.13 † Form of Restricted Stock Award Agreement under 22nd Century Group, Inc. 2014 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the Commission on April 14, 2014) 10.14 † Form of Stock Option Award Agreement under 22nd Century Group, Inc. 2014 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Form 8-K filed with the Commission on April 14, 2014) 10.15 † Employment Agreement dated May 12, 2014 by and between the Company and Thomas James (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on May 14, 2014) 10.16 Registration Rights Agreement, dated September 17, 2014, by and between 22nd Century Group, Inc. and Crede CG III, Ltd. (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on September 18, 2014) 10.17 Consulting Agreement, dated September 29, 2014, by and between 22nd Century Group, Inc., Crede CG III, Ltd. and Terren Peizer (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on September 30, 2014) 45 21.1* Subsidiaries 23.1* Consent of Freed Maxick CPAs, P.C. 31.1* Section 302 Certification 31.2* Section 302 Certification 32.1* Written Statement of Principal Executive Officer and Chief Financial Officer pursuant to 18.U.S.C §1350 101* Interactive data files formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Cash Flows, and (iv) the Notes to the Consolidated Financial Statements. 101.INS XBRL Instance Document* 101.SCH XBRL Taxonomy Extension Schema Document* 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document* 101.DEF XBRL Taxonomy Extension Definition Linkbase Document* 101.LAB XBRL Taxonomy Extension Label Linkbase Document* 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document* *Filed herewith. † Management
contract or compensatory plan, contract or arrangement. †† Certain
portions of the exhibit have been omitted pursuant to a confidential treatment order. An unredacted copy of the exhibit has been
filed separately with the United States Securities and Exchange Commission pursuant to the request for confidential treatment. 46 SIGNATURES Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. 22nd CENTURY GROUP, INC. Date: February 5, 2015 By: /s/ Henry Sicignano, III Henry Sicignano, III President, Chief Operating Officer and Director (Principal Executive Officer) Date: February 5, 2015 By: /s/ John T. Brodfuehrer John T. Brodfuehrer Chief Financial Officer (Principal Accounting and Financial Officer) Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. Date: February 5, 2015 By: /s/ Henry Sicignano III Henry Sicignano III President, Chief Operating Officer and Director Date: February 5, 2015 By: /s/ Joseph Alexander Dunn, Ph.D. Joseph Alexander Dunn, Ph.D. Director Date: February 5, 2015 By: /s/ James W. Cornell James W. Cornell Director Date: February 5, 2015 By: /s/ Richard M. Sanders Richard M. Sanders Director Date: By: Joseph Pandolfino Director 47 EX-21.1 2 v399452_ex21-1.htm EXHIBIT 21.1 EXHIBIT 21.1 SUBSIDIARIES OF 22nd CENTURY GROUP, INC. NAME STATE OF FORMATION PERCENTAGE OWNERSHIP 22nd Century Limited, LLC Delaware 100% Goodrich Tobacco Company, LLC Delaware 100% Hercules Pharmaceuticals, LLC Delaware 100% NASCO Products, LLC North Carolina 100% Botanical Genetics, LLC Delaware 100% 22nd Century Asia Ltd. Bermuda 51% EX-23.1 3 v399452_ex23-1.htm EXHIBIT 23.1 EXHIBIT 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM We consent to the incorporation
by reference in Registration Statement Numbers 333-173166 and 333-195380 on Form S-8 and in Registration Statement Numbers
333-195386 and 333-199273 on Form S-3 of 22nd Century Group, Inc. of our report, dated February 5, 2015 , on
the consolidated financial statements as of and for the years ended December 31, 2014 and 2013, appearing in this Annual
Report on Form 10-K of 22nd Century Group, Inc. /s/ Freed Maxick CPAs, P.C. Buffalo, NY February 5, 2015 EX-31.1 4 v399452_ex31-1.htm EXHIBIT 31.1 EXHIBIT 31.1 CERTIFICATIONS I, Henry Sicignano, III, President and Chief Operating Officer
of 22nd CENTURY GROUP, INC., certify that: 1. I have reviewed this annual report on Form 10-K of 22nd
CENTURY GROUP, INC.; 2. Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have: a. Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared; b. Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant’s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant’s
internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant’s internal control over financial reporting. 5. The registrant’s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of registrant’s board of directors (or persons performing equivalent functions): a. All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: February 5, 2015 /s/ Henry Sicignano, III Henry Sicignano, III President and Chief Operating Officer (Principal Executive Officer) EX-31.2 5 v399452_ex31-2.htm EXHIBIT 31.2 EXHIBIT 31.2 CERTIFICATIONS I, John T. Brodfuehrer, Chief Financial Officer of 22nd CENTURY
GROUP, INC., certify that: 1. I have reviewed this annual report on Form 10-K of 22nd
CENTURY GROUP, INC.; 2. Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have: a. Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared; b. Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant’s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant’s
internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant’s internal control over financial reporting. 5. The registrant’s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of registrant’s board of directors (or persons performing equivalent functions): a. All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: February 5, 2015 /s/ John T. Brodfuehrer John T. Brodfuehrer Chief Financial Officer (Principal Financial Officer) EX-32.1 6 v399452_ex32-1.htm EXHIBIT 32.1 EXHIBIT 32.1 Written Statement of the Chief Executive
Officer and Chief Financial Officer Pursuant to 18 U.S.C. §1350 Solely for the purposes of complying with 18 U.S.C. §1350,
I, the undersigned President and Chief Operating Officer of 22nd CENTURY GROUP, INC. (the “Company”), and I, the undersigned
Chief Financial Officer of the Company, hereby certify, to the best of my knowledge, that the annual report on Form 10-K of the
Company for the year ended December 31, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or
Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company. This certification is being furnished solely to accompany this
Report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934
and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless
of any general incorporation language in such filing. Date: February 5, 2015 /s/ Henry Sicignano, III Henry Sicignano, III President and Chief Operating Officer Date: February 5, 2015 /s/ John T. Brodfuehrer John T. Brodfuehrer Chief Financial Officer EX-101.INS 7 xxii-20141231.xml XBRL INSTANCE DOCUMENT 0001347858 2013-01-01 2013-01-31 0001347858 2013-01-01 2013-06-30 0001347858 2013-01-01 2013-09-30 0001347858 2013-01-01 2013-12-31 0001347858 2014-01-01 2014-03-31 0001347858 2014-01-01 2014-09-30 0001347858 2014-01-01 2014-12-31 0001347858 2014-01-13 0001347858 2015-02-04 0001347858 2013-03-31 0001347858 2014-04-14 0001347858 2014-06-05 0001347858 2013-06-30 0001347858 2014-06-30 0001347858 2012-08-01 2012-08-09 0001347858 2013-09-30 0001347858 2013-10-01 2013-10-07 0001347858 2011-12-01 2011-12-14 0001347858 2014-12-01 2014-12-22 0001347858 2013-12-11 0001347858 2014-12-22 0001347858 2012-12-31 0001347858 2013-12-31 0001347858 2014-12-31 0001347858 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2014-01-01 2014-12-31 0001347858 us-gaap:PrivatePlacementMember us-gaap:PreferredStockMember 2014-01-01 2014-12-31 0001347858 xxii:WarrantExchangeProgramMember us-gaap:WarrantMember 2014-01-01 2014-12-31 0001347858 xxii:SeriesOnePreferredStockMember 2013-01-11 0001347858 xxii:SeriesOnePreferredStockMember 2013-06-07 0001347858 us-gaap:CommonStockMember 2013-06-07 0001347858 xxii:SpectrumOrderMember 2013-01-01 2013-12-31 0001347858 xxii:SpectrumOrderMember 2014-01-01 2014-12-31 0001347858 us-gaap:MaximumMember 2014-01-01 2014-12-31 0001347858 us-gaap:MinimumMember 2014-01-01 2014-12-31 0001347858 us-gaap:IntellectualPropertyMember 2014-12-31 0001347858 us-gaap:LicensingAgreementsMember 2014-12-31 0001347858 us-gaap:LicensingAgreementsMember 2014-01-01 2014-12-31 0001347858 us-gaap:LicensingAgreementsMember 2014-07-01 2014-09-30 0001347858 us-gaap:SubsidiariesMember 2014-12-31 0001347858 us-gaap:IntellectualPropertyMember 2013-12-31 0001347858 us-gaap:LicensingAgreementsMember 2013-12-31 0001347858 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2013-12-31 0001347858 xxii:LicenseFeeMember 2013-12-31 0001347858 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2014-12-31 0001347858 xxii:LicenseFeeMember 2014-12-31 0001347858 xxii:SeriesOnePreferredStockMember 2013-01-01 2013-01-31 0001347858 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0001347858 xxii:ConsultingAgreementMember 2014-01-01 2014-09-30 0001347858 xxii:ConsultingAgreementMember xxii:Tranche1aWarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:ConsultingAgreementMember xxii:Tranche1bWarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:Tranche2WarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:Tranche3WarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:Tranche1aWarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:ConsultingAgreementMember 2014-01-01 2014-12-31 0001347858 xxii:CigareteManufacturingEquipmentMember 2014-01-01 2014-06-30 0001347858 xxii:FilteredCigarsMember 2014-01-01 2014-12-31 0001347858 xxii:CigareteManufacturingEquipmentMember 2013-01-01 2013-12-31 0001347858 xxii:CigareteManufacturingEquipmentMember 2014-01-01 2014-12-31 0001347858 us-gaap:MachineryAndEquipmentMember 2014-01-01 2014-12-31 0001347858 xxii:AnandiaLaboratoriesIncMember 2014-09-30 0001347858 xxii:AnandiaLaboratoriesIncMember 2014-12-31 0001347858 xxii:AnandiaLaboratoriesIncMember us-gaap:CommonStockMember 2014-09-30 0001347858 us-gaap:SubsequentEventMember xxii:AnandiaLaboratoriesIncMember 2015-03-01 2015-03-31 0001347858 xxii:AnandiaLaboratoriesIncMember 2014-01-01 2014-01-31 0001347858 xxii:AnandiaLaboratoriesIncMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-01-31 0001347858 xxii:AnandiaLaboratoriesIncMember 2014-01-01 2014-12-31 0001347858 xxii:AlternativeCigarettesIncMember 2013-12-31 0001347858 xxii:AlternativeCigarettesIncMember 2014-12-31 0001347858 xxii:WarrantExchangeProgramMember us-gaap:WarrantMember 2013-09-30 0001347858 xxii:OfficersAndDirectorsMember 2014-12-31 0001347858 xxii:SeriesCWarrantMember 2013-01-01 2013-12-31 0001347858 xxii:OfficersAndDirectorsMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsOneMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsTwoMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsThreeMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsFourMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsFiveMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsSixMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsSevenMember 2014-01-01 2014-12-31 0001347858 xxii:December2011ConvertibleNotesPayableWarrantsOneMember 2014-01-01 2014-12-31 0001347858 xxii:December2011ConvertibleNotesPayableWarrantsTwoMember 2014-01-01 2014-12-31 0001347858 xxii:May2012PrivatePlacementOfferingWarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:November2012PrivatePlacementOfferingWarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:August2012ConvertibleNotesPayableWarrantsOneMember 2014-01-01 2014-12-31 0001347858 xxii:August2012ConvertibleNotesPayableWarrantsTwoMember 2014-01-01 2014-12-31 0001347858 xxii:CredeTranche1AWarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:CredeTranche1BWarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:CredeTranche2WarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:CredeTranche3WarrantsMember 2014-01-01 2014-12-31 0001347858 xxii:NotesPayable2011MemberMember 2013-03-31 0001347858 xxii:NotesPayable2012MemberMember 2013-09-30 0001347858 xxii:SeriesAndSeriesCWarrantsMemberMember 2013-09-30 0001347858 xxii:CredeTranche1AWarrantsMember 2014-09-30 0001347858 us-gaap:ScenarioForecastMember 2014-12-31 0001347858 us-gaap:ScenarioForecastMember 2015-12-31 0001347858 us-gaap:ScenarioForecastMember 2016-12-31 0001347858 us-gaap:PatentsMember 2013-01-01 2013-12-31 0001347858 us-gaap:PatentsMember 2014-01-01 2014-12-31 0001347858 us-gaap:LicensingAgreementsMember us-gaap:ScenarioForecastMember 2015-02-01 0001347858 xxii:PrecisionLicenseMember 2014-08-01 2014-08-22 0001347858 us-gaap:LicensingAgreementsMember 2014-08-01 2014-08-27 0001347858 xxii:AnandiaSublicenseMember 2014-09-01 2014-09-15 0001347858 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-12-31 0001347858 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-12-31 0001347858 us-gaap:ManufacturingFacilityMember 2013-01-01 2013-12-31 0001347858 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-12-31 0001347858 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-12-31 0001347858 us-gaap:ManufacturingFacilityMember 2014-01-01 2014-12-31 0001347858 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001347858 us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001347858 us-gaap:OptionMember 2013-01-01 2013-12-31 0001347858 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001347858 us-gaap:RestrictedStockMember 2014-01-01 2014-12-31 0001347858 us-gaap:OptionMember 2014-01-01 2014-12-31 0001347858 xxii:EquityincentiveplantwentytenmemberMember 2010-10-21 0001347858 xxii:OmnibusIncentivePlanMember xxii:EquityincentiveplantwentytenmemberMember 2013-01-01 2013-12-31 0001347858 xxii:ThirdPartyMember 2013-01-01 2013-12-31 0001347858 xxii:OmnibusIncentivePlanMember xxii:EquityincentiveplantwentytenmemberMember 2014-01-01 2014-12-31 0001347858 xxii:ThirdPartyMember 2014-01-01 2014-12-31 0001347858 us-gaap:ScenarioForecastMember 2017-12-31 0001347858 xxii:OmnibusIncentivePlanMember 2014-01-01 2014-12-31 0001347858 xxii:OmnibusIncentivePlanMember 2013-01-01 2013-12-31 0001347858 xxii:OmnibusIncentivePlanMember us-gaap:CommonStockMember 2014-04-01 2014-04-30 0001347858 xxii:EquityincentiveplantwentytenmemberMember 2014-10-01 2014-10-21 0001347858 xxii:EquityincentiveplantwentytenmemberMember 2014-01-01 2014-03-31 0001347858 us-gaap:EmployeeStockOptionMember 2012-12-31 0001347858 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0001347858 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001347858 us-gaap:EmployeeStockOptionMember 2013-12-31 0001347858 us-gaap:EmployeeStockOptionMember 2014-12-31 0001347858 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001347858 us-gaap:RetainedEarningsMember 2012-12-31 0001347858 us-gaap:PreferredStockMember 2012-12-31 0001347858 us-gaap:CommonStockMember 2012-12-31 0001347858 us-gaap:PreferredStockMember 2013-01-01 2013-12-31 0001347858 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001347858 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0001347858 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0001347858 us-gaap:PreferredStockMember 2014-01-01 2014-12-31 0001347858 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0001347858 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0001347858 us-gaap:PreferredStockMember 2013-12-31 0001347858 us-gaap:CommonStockMember 2013-12-31 0001347858 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001347858 us-gaap:RetainedEarningsMember 2013-12-31 0001347858 us-gaap:PreferredStockMember 2014-12-31 0001347858 us-gaap:CommonStockMember 2014-12-31 0001347858 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001347858 us-gaap:RetainedEarningsMember 2014-12-31 0001347858 xxii:CommonStock2014Member 2013-01-01 2013-12-31 0001347858 xxii:PreferredStock2013Member 2013-01-01 2013-12-31 0001347858 xxii:CommonStock2014Member 2014-01-01 2014-12-31 0001347858 xxii:PreferredStock2013Member 2014-01-01 2014-12-31 0001347858 us-gaap:PatentsMember 2014-12-22 0001347858 us-gaap:PatentsMember 2014-12-01 2014-12-22 0001347858 us-gaap:PatentsMember 2014-12-23 0001347858 xxii:EmployementAgreementMember 2014-12-31 0001347858 xxii:EmployementAgreementMember 2014-01-01 2014-12-31 0001347858 xxii:EmployementAgreementMember 2014-10-01 2014-12-31 0001347858 xxii:OmnibusIncentivePlanMember us-gaap:MinimumMember 2014-01-01 2014-12-31 0001347858 xxii:OmnibusIncentivePlanMember us-gaap:MaximumMember 2014-01-01 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsOneMember 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsTwoMember 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsThreeMember 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsFourMember 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsFiveMember 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsSixMember 2014-12-31 0001347858 xxii:January2011PrivatePlacementOfferingWarrantsSevenMember 2014-12-31 0001347858 xxii:December2011ConvertibleNotesPayableWarrantsOneMember 2014-12-31 0001347858 xxii:December2011ConvertibleNotesPayableWarrantsTwoMember 2014-12-31 0001347858 xxii:May2012PrivatePlacementOfferingWarrantsMember 2014-12-31 0001347858 xxii:November2012PrivatePlacementOfferingWarrantsMember 2014-12-31 0001347858 xxii:August2012ConvertibleNotesPayableWarrantsOneMember 2014-12-31 0001347858 xxii:August2012ConvertibleNotesPayableWarrantsTwoMember 2014-12-31 0001347858 xxii:CredeTranche1AWarrantsMember 2014-12-31 0001347858 xxii:CredeTranche1BWarrantsMember 2014-12-31 0001347858 xxii:CredeTranche2WarrantsMember 2014-12-31 0001347858 xxii:CredeTranche3WarrantsMember 2014-12-31 0001347858 us-gaap:EmployeeSeveranceMember 2014-01-01 2014-12-31 0001347858 xxii:AnandiaLaboratoriesIncMember 2014-01-31 0001347858 us-gaap:SubsequentEventMember xxii:SmokerFriendlyInternationalMember 2015-01-19 0001347858 us-gaap:SubsequentEventMember xxii:OmnibusIncentivePlanMember 2015-01-01 2015-01-14 0001347858 xxii:SmokerFriendlyInternationalMember us-gaap:SubsequentEventMember 2015-01-01 2015-01-19 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 3. &#150; FINANCIAL CONDITION</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">At December 31, 2014, the Company had current assets of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,706,806</font> and current liabilities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,673,407</font> resulting in positive working capital of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,033,399</font>. Cash on hand at December 31, 2014 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,402,687</font>.&#160; <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company believes it will have adequate cash reserves to sustain operations and meet all current obligations as they come due for a period of approximately 12 months.&#160;</font></font></font> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s Form S-3 universal shelf registration statement was filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on April 18, 2014, and became effective on June 5, 2014. The universal shelf registration statement will allow, but not compel, the Company to raise up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45</font> million of capital over a three-year period through a wide array of securities at times and in amounts to be determined by the Company.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><font style="FONT-SIZE: 10pt">NOTE 4. &#150; SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On September 17, 2014, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,871,767</font> shares of its common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font>. Net cash proceeds from the issuance were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,324,088</font> after deducting expenses associated with the common stock issuance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As a condition of the private placement, the parties executed a Registration of Rights Agreement pursuant to which the Company agreed to provide certain registration rights with respect to certain of the issued securities under the Securities Act of 1933. Accordingly, on October 10, 2014, the Company filed a Form S-3 Registration Statement with the SEC. On October 23, 2014, the SEC declared the Registration Statement effective.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><font style="FONT-SIZE: 10pt">NOTE 5. - JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">On January 11, 2013, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500</font>&#160;shares of newly created Series A-1 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> % Convertible Preferred Stock (the &#8220;Series A-1 Preferred Stock&#8221;) and warrants for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font>&#160;million. Net proceeds from this issuance were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.035</font> million. During 2013, all Series A-1 Preferred Stock was converted into shares of the Company&#8217;s common stock and all related warrants to purchase shares of the Company&#8217;s common stock were exercised. Net proceeds from the exercise of warrants to purchase shares of the Company&#8217;s common stock were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.090</font> million.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><font style="FONT-SIZE: 10pt">NOTE 6. &#150; CONSULTING AGREEMENT AND JOINT VENTURE</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In connection with a joint venture arrangement entered into on September 29, 2014 by the Company&#8217;s newly-formed and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 51</font>% owned subsidiary, 22nd Century Asia, the Company entered into a six-month Consulting Agreement (the &#8220;Consulting Agreement&#8221;) with Crede CG III, Ltd. (&#8220;Crede&#8221;). Crede will provide consulting services to 22nd Century Asia with respect to the Company&#8217;s efforts to sell its proprietary tobacco products into the Asian market. In connection with the Company&#8217;s entry into such&#160;a joint venture and the Consulting Agreement, the Company issued Crede <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,250,000</font> Tranche 1A Warrants (the &#8220;Tranche 1A Warrants&#8221;) and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> Tranche 1B Warrants (the &#8220;Tranche 1B Warrants&#8221;). The Tranche 1A Warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.36</font> per share and the Tranche 1B Warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5951</font> per share. The Tranche 1A Warrants and the Tranche 1B Warrants each have a term of two years and are exercisable at any time. In addition, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> Tranche 2 Warrants (the &#8220;Tranche 2 Warrants&#8221;) and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> Tranche 3 Warrants (the &#8220;Tranche 3 Warrants&#8221;). The Tranche 2 Warrants and the Tranche 3 Warrants each have a term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years and an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.3736</font> per share. The Tranche 2 Warrants and Tranche 3 Warrants only become exercisable if certain revenue milestones are met by 22nd Century Asia subsequent to a certain commencement date, such commencement date likely to occur between January 1, 2016 and January 1, 2017, and the Company is cash flow positive from its investment in 22nd Century Asia. The Tranche 1A Warrants, the Tranche 1B Warrants, the Tranche 2 Warrants and the Tranche 3 Warrants all contain a traditional cashless exercise provision.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">In addition to the traditional cashless exercise provision, the Tranche 1A Warrants contain an Exchange Rights clause (the &#8220;Exchange Rights&#8221;) that provides that the Tranche 1A Warrants may be exercised on cashless basis by exchanging such warrants for shares of the Company&#8217;s common stock using a negotiated Black-Scholes pricing formula beginning on the day that is sixty one days after September 17, 2014, subject to certain conditions in the Exchange Rights. The number of shares issuable pursuant to the Exchange Rights is determined by dividing (a) the product of the number of Tranche 1A Warrants to be exchanged and the per share price resulting from the negotiated Black-Scholes pricing formula, by (b) the Exchange Price, defined as the closing bid price of the Company&#8217;s common stock two days prior to the date of the exchange. The maximum number shares issuable under the Exchange Rights is limited to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company valued the Tranche 1A Warrants and Tranche 1B Warrants using the Black-Scholes pricing model as of the date of issuance. The resulting fair value of the Tranche 1A Warrants and Tranche 1B Warrants amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,810,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,260,000</font>, respectively, and have been recorded as Prepaid consulting fees on the Company&#8217;s Consolidated Balance Sheets and are being&#160;amortized over the six month term of the Consulting Agreement. During the year ended December 31, 2014, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,091,215</font> of the Prepaid consulting fees were amortized and are included in General and administrative costs on the Company&#8217;s Consolidated Statements of Operations. The Exchange Rights contained in the Tranche 1A Warrants cause the financial instrument to be considered a liability in accordance with FASB Accounting Standards Codification Topic 480 &#150; &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). More specifically, ASC 480 requires a financial instrument to be classified as a liability if such financial instrument contains a conditional obligation that the issuer must or may settle by issuing a variable number of its equity securities if, at inception, the monetary value of the obligation is based on a known fixed monetary amount. As such, the fair value of the Tranche 1A Warrants are included in the Warrant liability on the Company&#8217;s Consolidated Balance Sheets at December 31, 2014. The Tranche 1B Warrants do not contain such Exchange Rights and accordingly the fair value has been recorded as an increase in capital. No value has been assigned to the Tranche 2 Warrants and the Tranche 3 Warrants as they are not exercisable until certain revenue milestones are attained, as described above.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 7. &#150; BUSINESS COMBINATION</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On September 17, 2013, the Company entered into a Membership Interest Purchase Agreement, which was subsequently amended on May 13, 2014, to purchase all of the issued and outstanding membership interests of NASCO Products, LLC (&#8220;NASCO&#8221;), a North Carolina limited liability company (the &#8220;Transaction&#8221;). NASCO is a federally licensed tobacco product manufacturer and a participating member of the tobacco Master Settlement Agreement known as the MSA, an agreement among 46 U.S. states and the tobacco industry administered by the National Association of Attorneys General (&#8220;NAAG&#8221;). The Transaction was subject to various conditions, including the required consents of the Settling States of the MSA to an amendment of NASCO&#8217;s existing adherence agreement to the MSA, with the Company becoming a signatory to such amended adherence agreement as part of the Company&#8217;s acquisition of NASCO. On August 29, 2014, the Company became a signatory to the amended adherence agreement under the MSA, and accordingly, the Transaction closed on August 29, 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The purchase price for the Transaction (the &#8220;Purchase Price&#8221;) consisted of (i) a cash payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> and (ii) the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 640,000</font> unregistered shares of the Company&#8217;s common stock. The common stock issued on August 29, 2014 had a market value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,952,000</font>, resulting in a total Purchase Price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,202,000</font>. The Purchase Price has been recorded as an Intangible asset in the Other assets section of the Company&#8217;s Consolidated Balance Sheets. The Company believes the intangible asset has an indefinite life and as such, no amortization is recorded. The Company also acquired cash of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">105,000</font> and a like amount of accrued expenses.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in"> In connection with the initial recording of the acquisition the Company recorded a deferred tax liability associated with the excess of the book value over the tax basis of assets acquired during the third quarter of 2014. During the final accounting for the acquisition it was determined that the book and tax basis were equal and the need for the deferred tax liability was no longer necessary. As a result, the initial recording of the deferred tax liability and associated goodwill from August 2014 was reversed.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 8. &#150; MANUFACTURING FACILITY</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On December 11, 2013, the Company closed on a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,220,000</font> purchase of certain cigarette manufacturing equipment from the bankruptcy estate of a company located in North Carolina that was liquidating under Chapter 7 of the U.S. Bankruptcy Code. Additionally, on January 13, 2014, the Company closed on a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">210,000</font> purchase of various cigarette manufacturing equipment parts, office furniture and fixtures, vehicles and computer software and equipment from a second bankruptcy estate of a company located in North Carolina that was liquidating under Chapter 7 of the U.S. Bankruptcy Code. A portion of the equipment from these two transactions was not required for the Company&#8217;s manufacturing operations and was subsequently sold at auction during the first quarter of 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s warehouse and cigarette manufacturing facility was primarily in a pre-manufacturing stage during the year ended December 31, 2014. During this time period, the Company incurred various expenses to prepare the facility for production. Expenses incurred during the year ended December 31, 2014 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,176,676</font> and consisted primarily of expenses for salaries and benefits for employees, sub-contract labor, rent, utilities and other miscellaneous costs and are reported as Pre-manufacturing facility costs on the Company&#8217;s Consolidated Statements of Operations. During the second quarter of 2014, the Company placed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,997,140</font> of cigarette manufacturing equipment in service. Depreciation taken on the equipment during the year ended December 31, 2014 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">224,519</font> and is included in Amortization and depreciation on the Company&#8217;s Consolidated Statements of Operations. The Company did manufacture a quantity of filtered cigars during the year ended December 31, 2014 resulting in revenue of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">81,456</font>. As discussed in Note 7, on August 29, 2014, the Company closed on the acquisition of NASCO. Accordingly, the Company and NASCO are now signatories under the MSA. NASCO commenced manufacturing the Company&#8217;s proprietary cigarette brands and an MSA brand for an independent chain of retail smoke shops during the fourth quarter of 2014 at its manufacturing facility. Sales of these MSA brands commenced during the first quarter of 2015. NASCO will also continue to manufacture non-MSA filtered cigars.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 9. &#150; MACHINERY AND EQUIPMENT</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Machinery and equipment at December 31, 2014 and 2013 consists of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Right; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="right"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Cigarette manufacturing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,031,375</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,220,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Office furniture, fixtures and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>55,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,059</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deposit for purchase of machine parts and other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>210,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,086,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,461,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Less: cigarette manufacturing equipment held for resale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>457,696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,086,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,003,863</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Less: accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>236,115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Machinery and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,850,615</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,997,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <br/> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 11, 2013 and January 13, 2014, the Company acquired machinery and equipment in the amount of</font> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,220,000</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> and</font> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">210,000</font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">, respectively, as described in Note 8. A portion of the equipment from these two transactions was not required for the Company&#8217;s manufacturing operations and was subsequently sold at auction during the first quarter of 2014. The Company allocated</font> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">457,696</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,167</font> of the purchase price of these sold assets from the two transactions, respectively. The Company realized net proceeds from the auction sale of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">631,484</font>, resulting in a gain on the sale of assets of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">85,621</font>. The remaining cigarette manufacturing equipment was placed in service during the second quarter of 2014. Depreciation expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">230,012</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,027</font> for the years ended December 31, 2014 and 2013, respectively.&#160;&#160;</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE</font></b> <font style="FONT-SIZE: 10pt"><b>10. &#150; EQUITY INVESTMENT AND ADVANCE</b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On April 11, 2014, the Company, through a newly formed wholly-owned subsidiary, Botanical Genetics, LLC, entered into an investment agreement (the &#8220;Agreement&#8221;) with Anandia Laboratories, Inc., a Canadian plant biotechnology company (&#8220;Anandia&#8221;). The Agreement provided for the Company to make an initial investment of $250,000 in Anandia in return for (i) a ten percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%) equity interest in Anandia, and (ii) certain rights granted to the Company for four patent families (the &#8220;Intellectual Property&#8221;). The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> investment was made on April 14, 2014. On September 15, 2014, certain milestones were achieved triggering an additional cash investment in Anandia in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">450,000</font> in return for (i) an additional fifteen percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font>%) equity interest in Anandia, and (ii) a worldwide sublicense agreement to the Intellectual Property, including an exclusive sublicense agreement within the U.S. In addition, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000</font> unregistered shares of the Company&#8217;s common stock to Anandia with a value on the day of issuance in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">394,500</font>, and on March 31, 2015, the Company will&#160;issue to Anandia unregistered shares of the Company&#8217;s common stock with an aggregate market value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">325,000</font> at the time of the issuance. The additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">325,000</font> payable in shares of common stock is included in the Equity investment and in Accrued expenses on the Company&#8217;s Consolidated Balance Sheets at December 31, 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">In January 2014, the Company made a non-interest bearing advance to Anandia in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">92,894</font>. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> of this amount was applied to a sublicense fee paid to Anandia, under a certain sublicense more fully described in Note 17. The balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,894</font> has been written off and is included in General and administrative expense on the Company&#8217;s Consolidated Statements of Operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company uses the equity method of accounting to record its <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% ownership interest in Anandia. As of December 31, 2014, the Company&#8217;s equity investment balance in Anandia was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,318,335</font> and is classified within Other assets on the accompanying Consolidated Balance Sheets. As of December 31, 2014, the carrying value of our investment in Anandia was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,199,000</font> in excess of our share of the book value of the net assets of Anandia, with such difference attributable to intangible assets. This intangible asset is being amortized over the expected benefit period and this amortization expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,815</font> has been included in the Loss on equity investment in the accompanying Consolidated Statements of Operations. In addition, the Company has recorded an equity loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">84,350</font>, representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of Anandia&#8217;s net loss covering the period beginning with the Company&#8217;s initial investment through December 31, 2014, resulting in a total loss on equity investment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">101,165</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE</font></b> <font style="FONT-SIZE: 10pt"><b>11. - DEMAND BANK LOAN</b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The demand loan is among the Company&#8217;s short term liabilities and is payable to a commercial bank under a revolving credit agreement and is guaranteed by a former officer and current director of the Company. This loan had a balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">174,925</font> at December 31, 2014 and 2013. The Company is required to pay interest monthly at an annual rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.75</font>% above the prime rate, or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.00</font>% at December 31, 2014 and 2013. The Company is current in meeting this interest payment obligation. The terms of the demand loan include an annual &#8220;clean-up&#8221; provision, which requires the Company to repay all principal amounts outstanding for a period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30</font> consecutive days every year. The Company has not complied with this requirement; however, the bank has not demanded payment. The bank has a lien on all of the Company&#8217;s assets.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 14. - DUE FROM RELATED PARTY</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company has conducted transactions with a related party, Alternative Cigarettes, Inc. (&#8220;AC&#8221;). AC is entirely owned by certain shareholders of the Company, including the Company&#8217;s former CEO and current director. During the years ended December 31, 2014 and 2013, transactions with AC consisted mainly of advances and repayments. The net amount due from AC amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">46,069</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,069</font> as of December 31, 2014 and 2013, respectively. No interest has been accrued or paid on amount due from or to AC and there are no repayment terms.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 5830599 6402687 42069 46069 7471 0 1406280 2064796 0 1978785 0 214469 457696 0 7744115 10706806 2997760 2850615 1544869 7077759 0 1318335 1544869 8396094 12286744 21953515 174925 174925 54665 884412 575730 1081545 179014 0 984334 2673407 3779522 3042846 4763856 6733778 569 641 47452055 70744190 -39929736 -55525094 7522888 15219737 12286744 21953515 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <strong>NOTE 15.&#160;- WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK</strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">During the fourth quarter of 2013, the Company initiated a warrant exchange program (the &#8220;Warrant Exchange Program&#8221;) with existing warrant holders. As a result of the Warrant Exchange Program, the Company had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,653,469</font> outstanding warrants remaining at December 31, 2013, a reduction from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19,616,308</font>, as of September 30, 2013. Of the remaining outstanding warrants at December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,921,381</font> warrants contained anti-dilution features that provide for adjustments to the exercise price and number of warrants outstanding if the Company issues shares of common stock of 22nd Century Group at a price that is less than the respective warrant exercise prices. These provisions require that such warrants be classified as derivatives for accounting purposes, which means they are reported as a liability and adjusted to fair value at each balance sheet date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">In March 2014, the Company entered into warrant amendments with existing warrant holders (the &#8220;Warrant Amendments&#8221;) with the goal of further reducing the Company&#8217;s warrant liability. To that end, the Company offered financial inducements to certain non-management warrant holders to (i) exercise their warrants on a cash basis, (ii) exercise their warrants on a cashless basis, or (iii) agree to have the anti-dilution feature removed from their warrants in exchange for a reduction in the exercise price contained in their respective warrants. The warrant holders also had the option to maintain the terms and conditions of their original warrant. Management elected to have the anti-dilution feature removed from their warrants without inducement. As a result of the Warrant Amendments, subsequent warrant exercises during the year ended December 31, 2014, and additional warrants issued during the third quarter of 2014, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13,544,600</font> warrants outstanding at December 31, 2014 that do not contain the anti-dilution features. A total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 129,809</font> warrants containing anti-dilution features remain outstanding at December 31, 2014. The Company calculated the cost of inducement as the difference between the fair value of the warrants immediately after the Warrant Amendments closed, less the fair value of the warrants immediately prior to the completion of the Warrant Amendments. The Company estimated the total cost of inducement to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">144,548</font>. This expense has been recorded as an Other expense on the Company&#8217;s Consolidated Statements of Operations, and as an increase to the derivative warrant liability that was subsequently reversed into capital.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">As discussed in Note 6, the Company issued warrants to Crede on September 29, 2014, in connection with a joint venture and Consulting Agreement, whereby Crede will provide consulting services to 22nd Century Asia with respect to the Company&#8217;s efforts to sell its proprietary tobacco products into the Asian market. The terms and conditions relating to the issued warrants are discussed in detail in Note 6.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Outstanding warrants at December 31, 2014 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div>Warrant&#160;Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"> <div>Expiration</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $3.00 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,817,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.2029</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $3.00 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>653,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.0000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $3.00 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,062,665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.9600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>292,965</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.2672</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants <sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,177</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>62,329</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,831</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.1718</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>December 2011 convertible NP warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>172,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.1984</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>February 8, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>December 2011 convertible NP warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>802,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.3816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>February 6, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>May 2012 PPO warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>401,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.6000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>May 15, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>November 2012 PPO warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>925,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.6000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>November 9, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>August 2012 convertible NP warrants<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,632</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.9520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>August 8, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>August 2012 convertible NP warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.9060</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>August 8, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 1A Warrants <sup style="font-style:normal"> (2)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.3600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 1B Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.5951</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 2 Warrants <sup style="font-style:normal"> (3)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.3736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 3 Warrants <sup style="font-style:normal"> (3)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.3736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Total warrants outstanding <sup style="font-style:normal"> (4)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Includes anti-dilution features.</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(2)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Include Exchange Rights (see Note 6 for detailed discussion).</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(3)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Exercisable upon attainment of certain revenue milestones (see Note 6 for detailed discussion).</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(4)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Includes <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,725,962</font> warrants (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27.3</font>%) held by officers and directors that have had the anti-dilution feature removed.</font></div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.35pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt" align="justify"><font style="FONT-SIZE: 10pt">The Company estimates the value of warrant liability upon issuance of the warrants and at each balance sheet date using the binomial lattice model to allocate total enterprise value to the warrants and other securities in the Company&#8217;s capital structure. Volatility was estimated based on historical observed equity volatilities and implied (forward) or expected volatilities for a sample group of guideline companies and consideration of recent market trends.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 17.1pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">As a result of the Exchange Rights contained in the Tranche 1A Warrants, the financial instrument is considered a liability in accordance with FASB Accounting Standards Codification Topic 480 &#150; &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). More specifically, ASC 480 requires a financial instrument to be classified as a liability if such financial instrument contains a conditional obligation that the issuer must or may settle by issuing a variable number of its equity securities if, at inception, the monetary value of the obligation is based on a known fixed monetary amount.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 23.1pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table is a roll-forward summary of the warrant liability:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 23.1pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,173,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon conversion of remaining December 14, 2011 Notes &#150; Q1 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,445,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon issuance - Q1 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,022,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon issuance - Q2 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>711,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon issuance - Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,622,069</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon conversion of August 9, 2012 Notes - Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>731,662</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon reduction of exercise price of Series A and Series C warrants &#150; Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>626,328</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity upon exercise of warrants - Q2 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(204,513)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity upon exercise of warrants - Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6,542,904)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity upon exercise of warrants - Q4 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,712,170)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Cost of inducement from Warrant Exchange Program - Q4 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,274,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity resulting from Warrant Exchange Program - Q4 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(19,639,465)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Loss as a result of change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,271,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,779,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity resulting from Warrant Amendments - Q1 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,367,915)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Cost of inducement from Warrant Amendments - Q1 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>144,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability resulting from issuance of Crede Tranche 1A Warrants &#150; Q3 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,810,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Loss as a result of change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,676,691</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,042,846</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The aggregate net loss as a result of the Company&#8217;s warrant liability for the years ended December 31, 2014 and 2013 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,676,691</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,271,977</font>, respectively, which is included in Other income (expense) as part of Warrant liability loss &#150; net in the accompanying Consolidated Statements of Operations. The loss for the year ended December 31, 2013, also includes a charge to Other income (expense) in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,330,734</font> as a result of (i) warrant liabilities issued in connection with the Series A-1 Preferred Stock in excess of net proceeds raised in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,987,655</font> in January 2013, and (ii) warrant liabilities issued in connection with the July 2013 issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,101,034</font> Series C Warrants in excess of the sum of the net process received upon exercise and the reclassification of the warrant liability to capital, in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">343,079</font>. Warrant liabilities issued during the year ended December 31, 2013, in connection with the December 14, 2011 convertible notes and the August 9, 2012 convertible notes converted to common stock in excess of the conversion amount by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,386</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">509,062</font>, respectively, were recorded as additional interest expense.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">FASB ASC 820 - &#8220;Fair Value Measurements and Disclosures&#8221; establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div> </td> </tr> </table> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</font></div> </td> </tr> </table> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Level 3 inputs are unobservable inputs based on the Company&#8217;s own assumptions used to measure assets and liabilities at fair value.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">A financial asset&#8217;s or a financial liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The warrant liability is measured at fair value using certain estimated factors such as volatility and probability which are classified within Level 3 of the valuation hierarchy. Significant unobservable inputs that are used in the fair value measurement of the Company&#8217;s derivative warrant liabilities include volatility. Significant increases (decreases) in the volatility input would result in a significantly higher (lower) fair value measurement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes the Company&#8217;s warrant activity since December 31, 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 86%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of&#160;Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Warrants outstanding at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,972,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,570,274</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants issued as part of Warrant Exchange Program</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>138,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Additional warrants due to anti-dilution provisions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,665,400</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants exercised during 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(9,831,414)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants exercised as part of Warrant Exchange Program</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,862,121)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Warrants outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>10,653,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants issued in conjunction with consulting agreement (see Note 6)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants exercised during 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,247,443)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Additional warrants due to anti-dilution provisions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Warrants outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Composition of outstanding warrants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants containing anti-dilution feature</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>129,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants without anti-dilution feature</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,544,600</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div><sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 38.55pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="51"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Include <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,250,000</font> warrants containing Exchange Rights (see Note 6 for detailed discussion).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 17. &#150; COMMITMENTS AND CONTINGENCIES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <b><i><font style="FONT-SIZE: 10pt">License Agreements -</font></i></b> <font style="FONT-SIZE: 10pt">Under its exclusive worldwide license agreement with North Carolina State University (&#8220;NCSU&#8221;), the Company is required to pay minimum annual royalty payments, which are credited against running royalties on sales of licensed products. The minimum annual royalty for each of 2014 and 2015 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font></font>, and in 2016 the minimum annual royalty increases to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">225,000</font>. The license agreement continues through the life of the last-to-expire patent, which is expected to be 2022. The license agreement also requires a milestone payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> upon FDA approval or clearance of a product that uses the NCSU licensed technology. The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. These costs vary from year to year and the Company has certain rights to direct the activities that result in these costs. During the years ended December 31, 2014 and 2013, the costs incurred related to capitalized patent costs and patent maintenance expense amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">123,968</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">101,902</font> respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">In addition, on February 10, 2014, the Company entered into a sponsored research and development agreement (the &#8220;Agreement&#8221;) with NCSU. Under the terms of the Agreement, the Company is required to pay NCSU $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">162,408</font> over the two-year term of the Agreement, which grants certain licensing rights to the Company. A payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">81,204</font> was made in February 2014 and a final payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">81,204</font> is due and payable on February 1, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company has two other exclusive license agreements which require aggregate annual license fees of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font>, which are credited against running royalties on sales of licensed products. Each license agreement continues through the life of the last-to-expire patents. On December 22, 2014, the Company entered into a Purchase Agreement (see Note 12 for details) with one of these licensors to acquire certain patent rights the Company had previously licensed from such licensor. The Company has no future commitment to that licensor.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">All payments made under the above referenced license agreements and the sponsored research and development agreement are initially recorded as a Prepaid expense on the Company&#8217;s Consolidated Balance Sheets and subsequently expensed on a straight-line basis over the applicable period and included in Research and development costs on the Company&#8217;s Consolidated Statements of Operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On August 22, 2014, the Company entered into a Commercial License Agreement with Precision PlantSciences, Inc. (the &#8220;Precision License&#8221;). The Precision License grants the Company a non-exclusive, but fully paid up right and license to use technology and materials owned by Precision PlantSciences for a license fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,250,000</font>. An initial cash payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">725,000</font> was made upon execution of the Precision License with an unconditional obligation to pay the remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">525,000</font> in $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> increments as materials are provided to the Company. The remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">525,000</font> was paid during December 2014. The Precision License continues through the life of the last-to-expire patent, which is expected to be in 2028.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On August 27, 2014, the Company entered into an additional exclusive License Agreement (the &#8220;License Agreement&#8221;) with NCSU. Under the License Agreement, the Company paid NCSU a non-refundable, non-creditable lump sum license fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,000</font>. Additionally, the License Agreement calls for the Company to pay NCSU three non-refundable, non-creditable license maintenance fees in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000</font></font></font> per annum in each of December 2015, 2016 and 2017. Beginning in calendar year 2018, the Company is obligated to pay to NCSU an annual minimum royalty fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> in 2018, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font> in 2019, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> per year thereafter for the remaining term of the License Agreement. The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. There were no costs reimbursed under the License Agreement through December 31, 2014. The License Agreement continues through the life of the last-to-expire patent, which is expected to be in 2034.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On September 15, 2014, the Company entered into a Sublicense Agreement with Anandia Laboratories, Inc. (the &#8220;Anandia Sublicense&#8221;). Under the terms of the Anandia Sublicense, the Company was granted an exclusive sublicense in the United States and a co-exclusive sublicense in the remainder of the world, excluding Canada, to the licensed Intellectual Property (more fully discussed in Note 10). The Anandia Sublicense calls for an up-front fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font>, an annual license fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>, and a running royalties on future net sales. The Anandia Sublicense continues through the life of the last-to-expire patent, which is expected to be in 2035.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Precision License, the License Agreement with NCSU and the Anandia Sublicense are included in Intangible assets, net in the Company&#8217;s Consolidated Balance Sheets and the applicable license fees will be amortized over the term of the agreements based on their last-to-expire patent date. Amortization during the year ended December 31, 2014 and 2013 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32,524</font> and $0, respectively, and was included in Research and development costs on the Company&#8217;s Consolidated Statements of Operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <b><i><font style="FONT-SIZE: 10pt">Lease Agreements</font></i></b> <b><font style="FONT-SIZE: 10pt">-</font></b> <font style="FONT-SIZE: 10pt">On October 9, 2013, the Company executed a guaranty that guarantees performance by NASCO of its obligations to a landlord under a certain triple net lease of the same date between NASCO and a landlord for a manufacturing facility and warehouse located in North Carolina. Upon the NASCO transaction closing on August 29, 2014, the lease became a direct obligation of the Company. The lease commenced on January 14, 2014, and has an initial term of twelve (12) months. The lease contains four (4) additional extensions; one for an additional one (1) year and three for an additional two (2) years in duration, exercisable at the option of NASCO. The lease expense for the year ended December 31, 2014 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">97,593</font>. The future minimum lease payments under the lease are $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">123,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">298,275</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">338,250</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">338,250</font> during the one (1) year optional extension, and each of the three (3), two (2) year optional extensions, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company has extended the lease for its office space in Clarence, New York for a one-year renewal option expiring August 31, 2015, with the Company having the option to extend this lease for either or both of two (2) additional renewal periods, each consisting of one (1) year. Future minimum lease payments for the years ended December 31, 2015, 2016 and 2017 are approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">44,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,000</font>, respectively, if the Company exercises each of the optional renewal periods.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On January 25, 2013, the Company entered into a two and one-half year lease for manufacturing space in Depew, New York, which commenced February 1, 2013. This lease was cancelled during the third quarter of 2014. There are no remaining rent commitments under this lease.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 18. - EARNINGS PER COMMON SHARE</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table sets forth the computation of basic and diluted earnings per common share for the year ended December 31, 2014 and 2013:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Net loss attributed to common shareholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(15,595,358)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(26,153,158)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Denominator for basic earnings per share-weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,993,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>43,635,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Effect of dilutive securities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants, restricted stock and options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Denominator for diluted earnings per common share-weighted average shares adjusted for dilutive securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,993,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>43,635,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Loss per common share - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.26)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.60)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Securities outstanding that were excluded from the computation of earnings per share for the year ended December 31, 2014 and 2013 because they would have been anti-dilutive are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,653,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>890,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>660,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>14,814,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,813,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 19. - STOCK BASED COMPENSATION</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On October 21, 2010, the Company established the 2010 Equity Incentive Plan (&#8220;EIP&#8221;) for officers, employees, directors, consultants and advisors to the Company and its affiliates, consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,250,000</font> shares of common stock. The EIP had a term of ten years and is administered by our Board of Directors (the &#8220;Board&#8221;) or a committee to be established by our Board (the &#8220;Administrator&#8221;), to determine the various types of incentive awards that may be granted to recipients under this plan and the number of shares of common stock to underlie each such award under the EIP. On March 30, 2011, the Company filed a Form S-8 registration statement with the SEC to register all of the shares of common stock of 22nd Century Group that it may issue under the EIP.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">During the first quarter of 2014, the Company issued restricted stock awards from the EIP for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 850,000</font> restricted shares to employees and directors that will vest on January 27, 2015. All awards were valued at the closing price on the measurement date of the award. Subsequent to this issuance of restricted stock, there are no shares remaining to be issued from the EIP.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">On April 12, 2014, the stockholders of the Company approved the 22nd Century Group, Inc. 2014 Omnibus Incentive Plan (the &#8220;OIP&#8221;). The OIP allows for the granting of equity and cash incentive awards to eligible individuals over the life of the OIP, including the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares of the Company&#8217;s common stock pursuant to awards under the OIP. The OIP has a term of ten years and is administered by the Compensation Committee of our Board of Directors to determine the various types of incentive awards that may be granted to recipients under this plan and the number of shares of common stock to underlie each such award under the OIP. On April 18, 2014, the Company filed a Form S-8 registration statement with the SEC to register the 5,000,000 shares of common stock of 22nd Century Group that may be issued under the OIP.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">During the year ended December 31, 2014, the Company issued restricted stock awards from the OIP for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 147,556</font> restricted shares to eligible individuals having vesting periods ranging from zero to three years from the award date. All awards were valued at the closing price on the measurement date of the award.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">For the years ended December 31, 2014 and 2013, the Company recorded compensation expense related to restricted stock and stock option awards granted under the EIP and OIP of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,293,082</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">998,214</font>, respectively. The Company also recorded equity based compensation for the years ended December 31, 2014 and 2013 as payment to third parties for services rendered in the amount $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">140,170</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,363,748</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">As of December 31, 2014, unrecognized compensation expense related to non-vested restricted shares and stock options amounted to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">672,000</font>, which is expected to be recognized approximately as follows: $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">473,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,000</font>, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39,000</font> during 2015, 2016 and 2017, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2014 and 2013:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Expected stock price volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Expected life of options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company estimated the expected volatility based on data used by a peer group of public companies. The expected term was estimated using the contract life of the option. The risk-free interest rate assumption was determined using yield of the equivalent U.S. Treasury bonds over the expected term. The Company has never paid any cash dividends and does not anticipate paying any cash dividends in the foreseeable future. Therefore, the Company assumed an expected dividend yield of zero.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of all stock option activity since December 31, 2012 is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 99%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">465,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Granted in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">215,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Exercised in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(20,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">660,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Granted in 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Exercised in 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(70,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">890,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.0 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">532,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Exercisable at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">640,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7.7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">532,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">There were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 300,000</font> options granted from the OIP during the year ended December 31, 2014 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">215,000</font> options granted during the year ended December 31, 2013). The weighted average grant date fair value of options issued during the year ended December 31, 2014 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.07</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.68</font> for the year ended December 31, 2013). The total fair value of options that vested during the year ended December 31, 2014 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">103,250</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">242,160</font> for the year ended December 31, 2013). During the year ended December 31, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70,000</font> options were exercised for cash proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">48,300</font>. During the year ended December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000</font> options were exercised for cash proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,200</font>.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 21. - SUBSEQUENT EVENTS<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></b></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On January 14, 2015, the Company&#8217;s Board of Directors approved the Company&#8217;s Compensation Committee recommendation to award officers, employees and directors of the Company stock awards in the form of stock options from the Company&#8217;s OIP in an aggregate amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,059,000</font>. The stock options will be granted on February 16, 2015, with an exercise price based on the average closing price of the Company&#8217;s common stock for the three trading days immediately preceding the date of the grant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On January 19, 2015, the Company became obligated to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70,423</font> shares of its common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.00001</font> per share, to Smoker Friendly International, LLC (&#8220;Smoker Friendly&#8221;) under the terms of an agreement between the Company and Smoker Friendly.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Nature of Business</font></i></strong> <font style="FONT-SIZE: 10pt"><i> -</i> 22nd Century Ltd, is a plant biotechnology company specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The Company owns or exclusively controls 128 issued patents plus an additional&#160;52 pending patent applications. The patents owned by or exclusively licensed to us include patents issued in 96 countries. Goodrich Tobacco and Hercules Pharma are business units for the Company&#8217;s (i) premium cigarettes and potential modified risk tobacco products and (ii) smoking cessation product, respectively. The Company acquired the membership interests of NASCO on August 29, 2014. NASCO is a federally licensed tobacco products manufacturer, a participating member of the tobacco Master Settlement Agreement (&#8220;MSA&#8221;) between the tobacco industry and the Settling States under the MSA, and operates the Company&#8217;s cigarette manufacturing business in North Carolina. Botanical Genetics is a wholly-owned subsidiary of 22nd Century Group, and was incorporated to facilitate an equity investment more fully described in Note 10. 22nd Century Asia was newly-formed during the third quarter of 2014 in connection with the Company&#8217;s efforts to sell its proprietary tobacco products in Asia, more fully described in Note 6.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Principles of Consolidation</font></i></strong> <font style="FONT-SIZE: 10pt"><i> -</i> The accompanying consolidated financial statements include the accounts of 22nd Century Group, Inc. (&#8220;22nd Century Group&#8221;), its three wholly-owned subsidiaries, 22nd Century Limited, LLC (&#8220;22nd Century Ltd&#8221;), NASCO Products, LLC (&#8220;NASCO&#8221;), and Botanical Genetics, LLC (&#8220;Botanical Genetics&#8221;), and a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 51</font>% owned subsidiary, 22nd Century Asia Ltd. (&#8220;22nd Century Asia&#8221;), and two wholly-owned subsidiaries of 22nd Century Ltd, Goodrich Tobacco Company, LLC (&#8220;Goodrich Tobacco&#8221;) and Hercules Pharmaceuticals, LLC (&#8220;Hercules Pharma&#8221;) (collectively, &#8220;the Company&#8221;). All intercompany accounts and transactions have been eliminated.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Preferred Stock Authorized</font></i></strong> <font style="FONT-SIZE: 10pt"><i> -</i> The Company is authorized to issue &#8220;blank check&#8221; preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock. On January 11, 2013, the Company designated the rights of and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500</font> shares of Series A-1 Preferred Stock. As of June 7, 2013, all <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500</font> outstanding shares of Series A-1 Preferred Stock were converted into an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,166,666</font> shares of common stock of the Company and no shares of preferred stock remain outstanding.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Inventory</font></i> <font style="FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> <i>-</i> Inventories are valued at the lower of cost or market. Cost is determined using an average cost method for tobacco leaf inventory and the first-in, first-out (FIFO)&#160;method on all other inventories. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. Inventories at December 31, 2014 and 2013 consist of the following:</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - tobacco leaf</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,537,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,398,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Less:&#160;&#160;inventory reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - tobacco leaf, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,486,898</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,348,124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Cigarettes and filtered cigars</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>154,568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,206</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Cigarette and filtered cigar components</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>423,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,064,796</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,406,280</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Fixed assets</font></i></strong> <font style="FONT-SIZE: 10pt"><i> &#150;</i> Fixed assets are recorded at their acquisition cost and depreciated on a straight line basis over their estimated useful lives ranging from 3 to 10 years. Depreciation commences when the asset is placed in service.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Intangible Assets</font></i></strong> <font style="FONT-SIZE: 10pt"><strong>-</strong> Intangible assets are recorded at cost and consist primarily of (1) expenditures incurred with third parties related to the processing of patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties, (2) license fees paid for third-party intellectual property, (3) costs to become a signatory under the tobacco Master Settlement Agreement (&#8220;MSA&#8221;), and (4) license fees paid to acquire a predicate cigarette brand. The amounts capitalized relate to intellectual property that the Company owns or to which it has exclusive rights. The Company&#8217;s intellectual property capitalized costs are amortized using the straight-line method over the remaining statutory life of the primary patent in each of the Company&#8217;s two primary patent families, which expire in 2019 and 2028 (the assets&#8217; estimated lives, respectively). Periodic maintenance or renewal fees are expensed as incurred.&#160;&#160;Annual minimum license fees are charged to expense. License fees paid for third-party intellectual property are amortized on a straight-line basis over the last to expire patents, which patent expiration dates range from 2028 through 2035. The Company believes costs associated with becoming a signatory to the MSA and acquiring the predicate cigarette brand have an indefinite life and as such, no amortization is taken. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Total intangible assets at December 31, 2014 and December 31, 2013 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patent and trademark costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,405,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,559,412</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less:&#160;&#160;accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,247,303</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,014,543</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patent and trademark costs, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,158,283</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,544,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fees, net (see Note 17)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,450,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less:&#160;&#160;accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fees, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,417,476</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>MSA signatory costs (see Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,202,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fee for predicate cigarette brand</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,077,759</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,544,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Amortization expense relating to the above intangible assets for the years ended December 31, 2014 and 2013 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">265,284</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">141,261</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the year ended December 31, 2013, the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial statements.&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The estimated annual average amortization expense for the next five years is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">310,000</font> for patent costs and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">98,000</font> for license fees.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment of Long-Lived Assets</font></i></strong><font style="FONT-SIZE: 10pt">&#160;&#160;<strong>-</strong> The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability of the asset by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition. If the estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset&#8217;s carrying value and its fair value. There was no impairment loss recorded during the years ended December 31, 2014 or 2013.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</font></i></strong> <font style="FONT-SIZE: 10pt"><strong>-</strong> The Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and GAAP reporting, and for operating loss and credit carry-forwards. &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In light of the Company&#8217;s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2014 and 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s federal and state tax returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations.&#160;&#160;There are no pending audits as of December 31, 2014.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Stock Based Compensation</font></i></strong> <font style="FONT-SIZE: 10pt"><i>-</i> The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees and others receive shares, options or warrants to purchase common shares of 22nd Century Group. Stock based compensation expense is recorded over the requisite service period based on estimates of probability and time of achieving milestones and vesting. For accounting purposes, the shares will be considered issued and outstanding upon vesting.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition &#150;</font></i></strong> <font style="FONT-SIZE: 10pt">The Company recognizes revenue from product sales at the point the product is shipped to a customer and title has transferred. Revenue from the sale of the Company&#8217;s products is recognized net of cash discounts, sales returns and allowances. Cigarette federal excise taxes are included in net sales and accounts receivable billed to customers, except on sales of <i> SPECTRUM</i> research cigarettes and exported cigarettes, to which such taxes do not apply.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company was chosen to be a subcontractor for a 5-year government contract between RTI International (&#8220;RTI&#8221;) and the National Institute on Drug Abuse (&#8220;NIDA&#8221;) to supply NIDA with research cigarettes. These government research cigarettes are distributed under the Company&#8217;s mark, <i>SPECTRUM</i>. In September 2013, the Company received a purchase order for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.5</font> million <i>SPECTRUM</i> research cigarettes that were shipped in January 2014. Total revenue from this order was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">448,000</font> for the year ended December 31, 2014. A down payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">179,014</font> was received in the fourth quarter of 2013 and was recorded as deferred revenue on the Company&#8217;s balance sheet at December 31, 2013. There were no <i>SPECTRUM</i> cigarettes delivered during the year ended December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company licenses its patented technology to third parties. Revenue is recognized from licensing arrangements as contractually defined in licensing agreements. The Company accounts for milestones elements contained in licensing agreements in accordance with ASC 605. On October 1, 2013, 22nd Century Ltd entered into a worldwide Research License and Commercial Option Agreement (the &#8220;Agreement&#8221;) with British American Tobacco (Investments) Limited (&#8220;BAT&#8221;), a subsidiary of British American Tobacco plc, that grants BAT access to 22nd Century Ltd&#8217;s patented technology which alters levels of nicotinic alkaloids in tobacco plants. Simultaneous with the signing of the Agreement, BAT paid the Company a non-refundable $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,000,000</font>. The Company will be entitled to receive additional payments from BAT of up to an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,000,000</font> during the term of the Research License in the event certain milestones are met with respect to the ongoing research and development of the Company&#8217;s licensed technology to BAT. No amount related to the additional research milestones was recognized during the year ended December 31, 2014. During the term of the Research License, BAT will have the option to enter into a Commercial License agreement which will provide for future annual payments, royalty payments and minimum annual royalties. A portion of the patented technology sublicensed to BAT was exclusively licensed to 22nd Century Ltd by a third party licensor proir to the acquisition by 22nd Century Ltd of such patented technology from such licensor on December 23, 2014 (see Note 12 for the more detailed discussion). Pursuant to the terms of the license agreement with such licensor, 22nd Century Ltd was obligated to make a royalty payment to the licensor with respect to a portion of the non-refundable $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,000,000</font> paid by BAT to the Company on October 1, 2013. From October 2013 to September 2014, 22nd Century Ltd and the third party licensor were in discussions as to the amount of royalty due to the licensor from 22nd Century Ltd. During the quarter ended September 30, 2014, 22nd Century Ltd and the third party licensor mutually agreed on a&#160;payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">660,000</font> that was paid in December 2014. 22nd Century Ltd had previously estimated the payment to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">413,566</font>. The difference in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">246,434</font> has been recorded as Royalty for licensing in the Cost of goods sold section of the Company&#8217;s Consolidated Statements of Operations for the year ended December 31, 2014.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> Derivatives</font></i></strong> <font style="FONT-SIZE: 10pt"> <strong>&#150;</strong> The Company does use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations. &#160; The methodology for valuing outstanding warrants classified as derivative instruments utilizes a lattice model approach which includes probability weighted estimates of future events including volatility of our common stock. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Research and Development -</font></i></strong> <font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Loss Per Common Share -</font></i></strong> <font style="FONT-SIZE: 10pt">Basic loss per common share is computed using the weighted-average number of common shares outstanding. &#160; Diluted loss per share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded from the computation if their effect is anti-dilutive. &#160;</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Commitment and Contingency Accounting -</font></i></strong> <font style="FONT-SIZE: 10pt">The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial statements. If not, the Company will disclose any material commitments or contingencies that may arise.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates -</font></i></strong> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Fair Value of Financial Instruments</font></i></strong> <font style="FONT-SIZE: 10pt"><i>- <strong>&#160;</strong></i> Financial instruments include cash, receivables, accounts payable, accrued expenses, demand bank loan, and warrant liability.&#160;&#160;Other than warrant liability, fair value is assumed to approximate carrying values for these financial instruments, since they are short term in nature, they are receivable or payable on demand, or had stated interest rates that approximate the interest rates available to the Company as of the reporting date.&#160; The determination of the fair value of the warrant liability includes unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 15.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Equity Investments &#150;</font></i></strong> <font style="FONT-SIZE: 10pt">The Company accounts for investments in equity securities of other entities under the equity method of accounting if the Company&#8217;s investment in the voting stock is greater than or equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>% and less than a majority, and the Company has the ability to have significant influence over the operating and financial policies of the investee.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY:times new roman,times,serif">Accounting Pronouncements</font> -</font></i></strong> <font style="FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09, &#8221;Revenue from Contracts with Customers&#8221;, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the&#160;pending adoption of ASU 2014-09 on its consolidated financial statements and have not yet determined the method by which it will adopt the standard in 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Total intangible assets at December 31, 2014 and December 31, 2013 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patent and trademark costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,405,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,559,412</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less:&#160;&#160;accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,247,303</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,014,543</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patent and trademark costs, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,158,283</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,544,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fees, net (see Note 17)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,450,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less:&#160;&#160;accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fees, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,417,476</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>MSA signatory costs (see Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,202,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fee for predicate cigarette brand</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,077,759</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,544,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Machinery and equipment at December 31, 2014 and 2013 consists of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Right; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="right"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Cigarette manufacturing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,031,375</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,220,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Office furniture, fixtures and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>55,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,059</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deposit for purchase of machine parts and other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>210,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,086,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,461,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Less: cigarette manufacturing equipment held for resale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>457,696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,086,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,003,863</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Less: accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>236,115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Machinery and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,850,615</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,997,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">Outstanding warrants at December 31, 2014 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 6pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div>Warrant&#160;Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"> <div>Expiration</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $3.00 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,817,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.2029</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $3.00 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>653,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.0000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $3.00 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,062,665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.9600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>292,965</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.2672</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants <sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,177</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>62,329</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>January 2011 PPO $1.50 warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,831</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.1718</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>January 25, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>December 2011 convertible NP warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>172,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.1984</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>February 8, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>December 2011 convertible NP warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>802,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.3816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>February 6, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>May 2012 PPO warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>401,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.6000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>May 15, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>November 2012 PPO warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>925,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.6000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>November 9, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>August 2012 convertible NP warrants<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,632</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.9520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>August 8, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>August 2012 convertible NP warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.9060</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>August 8, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 1A Warrants <sup style="font-style:normal"> (2)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.3600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 1B Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.5951</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 2 Warrants <sup style="font-style:normal"> (3)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.3736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Crede Tranche 3 Warrants <sup style="font-style:normal"> (3)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.3736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>September 29, 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Total warrants outstanding <sup style="font-style:normal"> (4)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Includes anti-dilution features.</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(2)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Include Exchange Rights (see Note 6 for detailed discussion).</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(3)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Exercisable upon attainment of certain revenue milestones (see Note 6 for detailed discussion).</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.05pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="31"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="20"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(4)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Includes <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,725,962</font> warrants (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27.3</font>%) held by officers and directors that have had the anti-dilution feature removed.</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 23.1pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table is a roll-forward summary of the warrant liability:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 23.1pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,173,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon conversion of remaining December 14, 2011 Notes &#150; Q1 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,445,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon issuance - Q1 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,022,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon issuance - Q2 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>711,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon issuance - Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,622,069</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon conversion of August 9, 2012 Notes - Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>731,662</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability upon reduction of exercise price of Series A and Series C warrants &#150; Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>626,328</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity upon exercise of warrants - Q2 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(204,513)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity upon exercise of warrants - Q3 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6,542,904)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity upon exercise of warrants - Q4 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,712,170)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Cost of inducement from Warrant Exchange Program - Q4 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,274,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity resulting from Warrant Exchange Program - Q4 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(19,639,465)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Loss as a result of change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,271,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,779,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Reclassification of warrant liability to equity resulting from Warrant Amendments - Q1 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,367,915)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Cost of inducement from Warrant Amendments - Q1 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>144,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value of warrant liability resulting from issuance of Crede Tranche 1A Warrants &#150; Q3 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,810,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Loss as a result of change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,676,691</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Fair value at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,042,846</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the Company&#8217;s warrant activity since December 31, 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 86%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of&#160;Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Warrants outstanding at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,972,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,570,274</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants issued as part of Warrant Exchange Program</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>138,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Additional warrants due to anti-dilution provisions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,665,400</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants exercised during 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(9,831,414)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants exercised as part of Warrant Exchange Program</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,862,121)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Warrants outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>10,653,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants issued in conjunction with consulting agreement (see Note 6)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants exercised during 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,247,443)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Additional warrants due to anti-dilution provisions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Warrants outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div>Composition of outstanding warrants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants containing anti-dilution feature</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>129,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>Warrants without anti-dilution feature</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,544,600</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div><sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 38.55pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="51"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Include <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,250,000</font> warrants containing Exchange Rights (see Note 6 for detailed discussion).</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 10000000 10000000 0.00001 0.00001 300000000 300000000 0.00001 0.00001 56902770 64085042 56902770 64085042 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth the computation of basic and diluted earnings per common share for the year ended December 31, 2014 and 2013:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Net loss attributed to common shareholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(15,595,358)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(26,153,158)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Denominator for basic earnings per share-weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,993,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>43,635,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Effect of dilutive securities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants, restricted stock and options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Denominator for diluted earnings per common share-weighted average shares adjusted for dilutive securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,993,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>43,635,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Loss per common share - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.26)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.60)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Securities outstanding that were excluded from the computation of earnings per share for the year ended December 31, 2014 and 2013 because they would have been anti-dilutive are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>13,674,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,653,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>890,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>660,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>14,814,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,813,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2014 and 2013:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Expected stock price volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Expected life of options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A summary of all stock option activity since December 31, 2012 is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 99%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">465,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Granted in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">215,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Exercised in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(20,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">660,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Granted in 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Exercised in 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(70,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">890,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.0 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">532,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Exercisable at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">640,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7.7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">532,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 2500 2500 4166666 5500000 448000 10 Years 3 Years 310000 98000 7000000 246434 0 413566 660000 7000000 0.51 0.2 141261 265284 2559412 0 4405586 1450000 1014543 0 1247303 32524 1544869 0 3158283 1417476 0 0 2202000 300000 8033399 6402687 The Company believes it will have adequate cash reserves to sustain operations and meet all current obligations as they come due for a period of approximately 12 months. 45000000 The universal shelf registration statement will allow, but not compel, the Company to raise up to $45 million of capital over a three-year period through a wide array of securities at times and in amounts to be determined by the Company. 9324088 10000000 3871767 2500 0.1 2500000 2035000 2090000 0.51 1250000 1000000 1000000 1000000 3.36 2.5951 3.3736 P5Y P5Y P2Y P2Y 5000000 2810000 1260000 0 250000 640000 1952000 105000 2997140 1176676 81456 3220000 210000 278383 528991 413566 48105 252002 6816712 30555 744230 1249007 4106694 8793151 0 9052 85930 144289 462772 5004265 11767536 1812447 -11736981 -23602711 -3676691 3736313 144548 0 71121 0 -101165 17889 0 730716 7094 -27965605 -3858377 -26153158 -15595358 -0.60 -0.26 43635182 59993413 3220000 210000 631484 85621 3220000 3031375 17059 55355 14500 0 210000 0 3461559 3086730 3003863 3086730 6103 236115 250000 450000 1199000 0.1 0.15 0.25 150000 325000 325000 394500 50000 42894 84350 0.25 0.0075 0.0075 0.04 0.0400 30 days 42069 46069 19616308 10653469 3987655 3725962 13544600 19271977 3676691 3921381 129809 343079 0 1101034 0.273 2016-01-25 2016-01-25 2016-01-25 2016-01-25 2016-01-25 2016-01-25 2016-01-25 2017-02-08 2018-02-06 2017-05-15 2017-11-09 2018-08-08 2018-08-08 2016-09-29 2016-09-29 2019-09-29 2019-09-29 6022319 1445091 711675 1622069 731662 626328 2810000 4173140 204513 6542904 7712170 19639465 -7367915 3274313 144548 12972664 11570274 138666 1665400 18383 9831414 1247443 5862121 4250000 13674409 13674409 75000 75000 225000 150000 101902 123968 123000 298275 338250 338250 162408 81204 81204 two-year term&#160; 75000 1250000 125000 10000 725000 525000 32524 111563 2250399 0 331467 4165078 27923 0 0 43635182 59993413 11813469 10653469 500000 660000 14814409 13674409 250000 890000 4250000 998214 1363748 2293082 140170 672000 473000 160000 39000 0.68 2.07 242160 103250 5200 48300 0 215000 300000 5000000 P10Y P10Y 850000 147556 0.0189 0.0180 0 0 0.9 0.9 P10Y P10Y 465000 215000 300000 20000 70000 660000 890000 640000 0.69 0.80 2.61 0.26 0.69 0.74 1.38 0.89 P8Y P7Y8M12D 532900 532900 -6131217 7645017 -13776578 0 344 34286979 0 2361962 0 28 2361934 0 2433253 0 13 2433240 0 0 2820000 0 1282768 1260000 0 0 1260000 0 14097594 0 68 14097526 0 486951 0 12 486939 0 0 6820218 0 1167737 5200 0 0 5200 0 48300 0 1 48299 0 0 20000 0 70000 9324088 0 39 9324049 0 0 3871767 0 6 1951994 0 0 394500 0 1 394499 0 0 150000 1660 0 0 1660 0 25200 0 0 25200 0 7367915 0 0 7367915 0 -26153158 0 0 0 -26153158 -15595358 0 0 0 -15595358 0 569 47452055 -39929736 0 641 70744190 -55525094 0 56902770 0 64085042 144289 462772 0 4232 0 134296 0 0 71121 526448 0 980162 2293083 1381800 2231385 175754 620660 -10044 214469 -629101 625389 -3567 0 118105 -93985 179014 -179014 3855834 -6582730 290336 726989 2994757 212487 0 1450000 0 0 0 700000 -3742789 -2707992 2254999 486951 150000 0 1620299 0 339250 0 0 2034664 9324088 0 1660 0 5100 4000 -3893 7471 5717366 9862810 5830411 572088 188 135247 7094 0 0 14433178 7367915 42490 193454 0 300000 0 325000 0 394500 0 0 2810000 0 1260000 0 37856 0 25200 769377 0 26422 0 1650305 0 93361 0 416666 0 57500 0 5675634 0 626328 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"></font></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>NOTE 1. - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></strong></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principles of Consolidation</font></i></strong> <font style="FONT-SIZE: 10pt"> <i>-</i> The accompanying consolidated financial statements include the accounts of 22nd Century Group, Inc. (&#8220;22nd Century Group&#8221;), its three wholly-owned subsidiaries, 22nd Century Limited, LLC (&#8220;22nd Century Ltd&#8221;), NASCO Products, LLC (&#8220;NASCO&#8221;), and Botanical Genetics, LLC (&#8220;Botanical Genetics&#8221;), and a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 51</font>% owned subsidiary, 22nd Century Asia Ltd. (&#8220;22nd Century Asia&#8221;), and two wholly-owned subsidiaries of 22nd Century Ltd, Goodrich Tobacco Company, LLC (&#8220;Goodrich Tobacco&#8221;) and Hercules Pharmaceuticals, LLC (&#8220;Hercules Pharma&#8221;) (collectively, &#8220;the Company&#8221;). All intercompany accounts and transactions have been eliminated.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Nature of Business</font></i></strong> <font style="FONT-SIZE: 10pt"><i> -</i> 22nd Century Ltd, is a plant biotechnology company specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The Company owns or exclusively controls 128 issued patents plus an additional&#160;52 pending patent applications. The patents owned by or exclusively licensed to us include patents issued in 96 countries. Goodrich Tobacco and Hercules Pharma are business units for the Company&#8217;s (i) premium cigarettes and potential modified risk tobacco products and (ii) smoking cessation product, respectively. The Company acquired the membership interests of NASCO on August 29, 2014. NASCO is a federally licensed tobacco products manufacturer, a participating member of the tobacco Master Settlement Agreement (&#8220;MSA&#8221;) between the tobacco industry and the Settling States under the MSA, and operates the Company&#8217;s cigarette manufacturing business in North Carolina. Botanical Genetics is a wholly-owned subsidiary of 22nd Century Group, and was incorporated to facilitate an equity investment more fully described in Note 10. 22nd Century Asia was newly-formed during the third quarter of 2014 in connection with the Company&#8217;s efforts to sell its proprietary tobacco products in Asia, more fully described in Note 6.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Preferred Stock Authorized</font></i></strong> <font style="FONT-SIZE: 10pt"> <i>-</i> The Company is authorized to issue &#8220;blank check&#8221; preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock. On January 11, 2013, the Company designated the rights of and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500</font> shares of Series A-1 Preferred Stock. As of June 7, 2013, all <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500</font> outstanding shares of Series A-1 Preferred Stock were converted into an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,166,666</font> shares of common stock of the Company and no shares of preferred stock remain outstanding.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i>Concentration of Credit Risk</i> -</strong> Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in financial institutions. Although the cash accounts exceed the federally insured deposit amount, management does not anticipate nonperformance by the financial institutions. Management reviews the financial viability of these institutions on a periodic basis.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> </font></i></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Inventory</font></i> <font style="FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> <i>-</i> Inventories are valued at the lower of cost or market. Cost is determined using an average cost method for tobacco leaf inventory and the first-in, first-out (FIFO)&#160;method on all other inventories. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. Inventories at December 31, 2014 and 2013 consist of the following:</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - tobacco leaf</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,537,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,398,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Less:&#160;&#160;inventory reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - tobacco leaf, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,486,898</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,348,124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Cigarettes and filtered cigars</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>154,568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,206</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Cigarette and filtered cigar components</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>423,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,064,796</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,406,280</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fixed assets</font></i></strong> <font style="FONT-SIZE: 10pt"><i>&#150;</i> Fixed assets are recorded at their acquisition cost and depreciated on a straight line basis over their estimated useful lives ranging from 3 to 10 years. Depreciation commences when the asset is placed in service.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Intangible Assets</font></i></strong> <font style="FONT-SIZE: 10pt"> <strong>-</strong> Intangible assets are recorded at cost and consist primarily of (1) expenditures incurred with third parties related to the processing of patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties, (2) license fees paid for third-party intellectual property, (3) costs to become a signatory under the tobacco Master Settlement Agreement (&#8220;MSA&#8221;), and (4) license fees paid to acquire a predicate cigarette brand. The amounts capitalized relate to intellectual property that the Company owns or to which it has exclusive rights. The Company&#8217;s intellectual property capitalized costs are amortized using the straight-line method over the remaining statutory life of the primary patent in each of the Company&#8217;s two primary patent families, which expire in 2019 and 2028 (the assets&#8217; estimated lives, respectively). Periodic maintenance or renewal fees are expensed as incurred.&#160;&#160;Annual minimum license fees are charged to expense. License fees paid for third-party intellectual property are amortized on a straight-line basis over the last to expire patents, which patent expiration dates range from 2028 through 2035. The Company believes costs associated with becoming a signatory to the MSA and acquiring the predicate cigarette brand have an indefinite life and as such, no amortization is taken. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Total intangible assets at December 31, 2014 and December 31, 2013 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patent and trademark costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,405,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,559,412</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less:&#160;&#160;accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,247,303</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,014,543</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patent and trademark costs, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,158,283</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,544,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fees, net (see Note 17)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,450,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less:&#160;&#160;accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fees, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,417,476</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>MSA signatory costs (see Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,202,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>License fee for predicate cigarette brand</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,077,759</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,544,869</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Amortization expense relating to the above intangible assets for the years ended December 31, 2014 and 2013 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">265,284</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">141,261</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the year ended December 31, 2013, the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial statements.&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The estimated annual average amortization expense for the next five years is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">310,000</font> for patent costs and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">98,000</font> for license fees.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Impairment of Long-Lived Assets</font></i></strong><font style="FONT-SIZE: 10pt">&#160;&#160;<strong>-</strong> The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability of the asset by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition. If the estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset&#8217;s carrying value and its fair value. There was no impairment loss recorded during the years ended December 31, 2014 or 2013.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Income Taxes</font></i></strong> <font style="FONT-SIZE: 10pt"> <strong>-</strong> The Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and GAAP reporting, and for operating loss and credit carry-forwards. &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In light of the Company&#8217;s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2014 and 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s federal and state tax returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations.&#160;&#160;There are no pending audits as of December 31, 2014.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Refundable taxes and tax credits</font></i></strong> <font style="FONT-SIZE: 10pt"><strong>&#150;</strong> The Company accounts for income tax refunds or tax refundable tax credits as discrete items and recognized the amount in the period in which the funds are received. During the year ended December 31, 2013, the Company received notice from the New York State Department of Taxation and Finance of a no change audit with respect to its income tax return filed for the period ending September 30, 2011. The subject return contained a refundable credit in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">122,024</font>.&#160; The refund was recorded as Other income in the Company&#8217;s Consolidated Statement of Operations for the year ended December 31, 2013. There were no such transactions during the year ended December 31, 2014.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock Based Compensation</font></i></strong> <font style="FONT-SIZE: 10pt"><i>-</i> The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees and others receive shares, options or warrants to purchase common shares of 22nd Century Group. Stock based compensation expense is recorded over the requisite service period based on estimates of probability and time of achieving milestones and vesting. For accounting purposes, the shares will be considered issued and outstanding upon vesting.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition &#150;</font></i></strong> <font style="FONT-SIZE: 10pt">The Company recognizes revenue from product sales at the point the product is shipped to a customer and title has transferred. Revenue from the sale of the Company&#8217;s products is recognized net of cash discounts, sales returns and allowances. Cigarette federal excise taxes are included in net sales and accounts receivable billed to customers, except on sales of <i> SPECTRUM</i> research cigarettes and exported cigarettes, to which such taxes do not apply.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company was chosen to be a subcontractor for a 5-year government contract between RTI International (&#8220;RTI&#8221;) and the National Institute on Drug Abuse (&#8220;NIDA&#8221;) to supply NIDA with research cigarettes. These government research cigarettes are distributed under the Company&#8217;s mark, <i>SPECTRUM</i>. In September 2013, the Company received a purchase order for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.5</font> million <i>SPECTRUM</i> research cigarettes that were shipped in January 2014. Total revenue from this order was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">448,000</font> for the year ended December 31, 2014. A down payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">179,014</font> was received in the fourth quarter of 2013 and was recorded as deferred revenue on the Company&#8217;s balance sheet at December 31, 2013. There were no <i>SPECTRUM</i> cigarettes delivered during the year ended December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.45pt; MARGIN: 0in 0in 0pt 2pt"> <font style="FONT-SIZE: 10pt">The Company licenses its patented technology to third parties. Revenue is recognized from licensing arrangements as contractually defined in licensing agreements. The Company accounts for milestones elements contained in licensing agreements in accordance with ASC 605. On October 1, 2013, 22nd Century Ltd entered into a worldwide Research License and Commercial Option Agreement (the &#8220;Agreement&#8221;) with British American Tobacco (Investments) Limited (&#8220;BAT&#8221;), a subsidiary of British American Tobacco plc, that grants BAT access to 22nd Century Ltd&#8217;s patented technology which alters levels of nicotinic alkaloids in tobacco plants. Simultaneous with the signing of the Agreement, BAT paid the Company a non-refundable $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,000,000</font>. The Company will be entitled to receive additional payments from BAT of up to an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,000,000</font> during the term of the Research License in the event certain milestones are met with respect to the ongoing research and development of the Company&#8217;s licensed technology to BAT. No amount related to the additional research milestones was recognized during the year ended December 31, 2014. During the term of the Research License, BAT will have the option to enter into a Commercial License agreement which will provide for future annual payments, royalty payments and minimum annual royalties. A portion of the patented technology sublicensed to BAT was exclusively licensed to 22nd Century Ltd by a third party licensor proir to the acquisition by 22nd Century Ltd of such patented technology from such licensor on December 23, 2014 (see Note 12 for the more detailed discussion). Pursuant to the terms of the license agreement with such licensor, 22nd Century Ltd was obligated to make a royalty payment to the licensor with respect to a portion of the non-refundable $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,000,000</font> paid by BAT to the Company on October 1, 2013. From October 2013 to September 2014, 22nd Century Ltd and the third party licensor were in discussions as to the amount of royalty due to the licensor from 22nd Century Ltd. During the quarter ended September 30, 2014, 22nd Century Ltd and the third party licensor mutually agreed on a&#160;payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">660,000</font> that was paid in December 2014. 22nd Century Ltd had previously estimated the payment to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">413,566</font>. The difference in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">246,434</font> has been recorded as Royalty for licensing in the Cost of goods sold section of the Company&#8217;s Consolidated Statements of Operations for the year ended December 31, 2014.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Derivatives</font></i></strong> <font style="FONT-SIZE: 10pt"><strong>&#150;</strong> The Company does use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations. &#160; The methodology for valuing outstanding warrants classified as derivative instruments utilizes a lattice model approach which includes probability weighted estimates of future events including volatility of our common stock. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development -</font></i></strong> <font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Loss Per Common Share -</font></i></strong> <font style="FONT-SIZE: 10pt">Basic loss per common share is computed using the weighted-average number of common shares outstanding. &#160; Diluted loss per share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded from the computation if their effect is anti-dilutive. &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Commitment and Contingency Accounting -</font></i></strong> <font style="FONT-SIZE: 10pt">The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial statements. If not, the Company will disclose any material commitments or contingencies that may arise.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 32.45pt; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates -</font></i></strong> <font style="FONT-SIZE: 10pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</font></i></strong> <font style="FONT-SIZE: 10pt"><i>- <strong>&#160;</strong></i> Financial instruments include cash, receivables, accounts payable, accrued expenses, demand bank loan, and warrant liability.&#160;&#160;Other than warrant liability, fair value is assumed to approximate carrying values for these financial instruments, since they are short term in nature, they are receivable or payable on demand, or had stated interest rates that approximate the interest rates available to the Company as of the reporting date.&#160; The determination of the fair value of the warrant liability includes unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 15.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Equity Investments &#150;</font></i></strong> <font style="FONT-SIZE: 10pt">The Company accounts for investments in equity securities of other entities under the equity method of accounting if the Company&#8217;s investment in the voting stock is greater than or equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>% and less than a majority, and the Company has the ability to have significant influence over the operating and financial policies of the investee.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY:times new roman,times,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accounting Pronouncements</font> -</font></i></strong> <font style="FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09, &#8221;Revenue from Contracts with Customers&#8221;, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the&#160;pending adoption of ASU 2014-09 on its consolidated financial statements and have not yet determined the method by which it will adopt the standard in 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 2. &#150; NYSE MKT EXCHANGE</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On March 11, 2014, the Company&#8217;s common stock began trading on the NYSE MKT exchange under the ticker symbol XXII. The Company&#8217;s common stock had been previously quoted on the OTC Bulletin Board under the ticker symbol of XXII.OB.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 7278383 528991 461671 498436 0 -122024 0 10-K false 2014-12-31 2014 FY 22nd Century Group, Inc. 0001347858 --12-31 No No Yes Smaller Reporting Company 133400000 XXII 64335042 624320 0 0 24 -24 0 0 2406720 0 0 42 -42 0 -2500 4166666 23340847 0 58 23340789 0 0 5804368 0 0 1 -1 0 0 161153 19639465 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"></font></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>NOTE 20. - INCOME TAXES</font></strong></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following is a summary of the components giving rise to the income tax provision (benefit) for the years ended December 31, 2014 and 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The provision (benefit) for income taxes consists of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Current:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,494,787)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>829,306</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>186,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total deferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(3,334,468)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,015,720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,334,468</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,015,720)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The provision (benefit) for income tax varies from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Statutory federal rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(34.0)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34.0)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Permanent items</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>8.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Stock based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div>2.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>State tax provision, net of federal benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>21.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.9)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Effective tax rate (benefit) provision</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Individual components of deferred taxes consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred tax assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net operating loss carry-forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>4,775,536</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,616,624</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,725</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Inventory reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>17,713</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,584</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>809,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Start-up expenditures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>388,130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Loss on equity investment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>35,398</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Severance liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>218,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>6,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,292</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,251,107</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,790,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred tax liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(52,445)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(80,251)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,956)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Patents and trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(624,010)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(523,157)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(21,986)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(726,247)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(578,558)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(5,524,860)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,212,117)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net deferred taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company has incurred a net operating loss of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,700,000</font> through December 31, 2014 and this amount is being carried forward to future years and expires in 2031 and 2032. Due to the uncertainty of the Company&#8217;s ability to generate sufficient taxable income in the future before they expire, the company has recorded a valuation allowance to reduce the net deferred tax asset to zero. This NOL is included in the net deferred tax asset that has been fully offset by the valuation allowance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">ASC 740 provides guidance on the financial statement recognition and measurement for uncertain income tax positions that are taken or expected to be taken in a company&#8217;s income tax return. &#160; The Company has no uncertain tax positions as of December 31, 2014. &#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s federal and state tax returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2014.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The provision (benefit) for income taxes consists of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Current:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,494,787)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>829,306</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 21px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>186,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total deferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(3,334,468)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,015,720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,334,468</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,015,720)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The provision (benefit) for income tax varies from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Statutory federal rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(34.0)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34.0)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Permanent items</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>8.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Stock based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div>2.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>State tax provision, net of federal benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>21.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.9)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Effective tax rate (benefit) provision</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Individual components of deferred taxes consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred tax assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net operating loss carry-forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>4,775,536</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,616,624</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,725</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Inventory reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>17,713</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,584</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>809,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Start-up expenditures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>388,130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Loss on equity investment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>35,398</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="65%"> <div>Severance liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>218,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>6,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,292</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,251,107</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,790,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred tax liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(52,445)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(80,251)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,956)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Patents and trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(624,010)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(523,157)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(21,986)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(726,247)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(578,558)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(5,524,860)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,212,117)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net deferred taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 0 0 0 0 0 829306 -3494787 186414 160319 1015720 -3334468 -1015720 3334468 0 0 0.340 0.340 0.018 0.006 0.355 0.084 0.005 0.011 0.039 -0.214 0.0 0.0 2616624 4775536 21725 0 19584 17713 131450 809319 1292 6561 0 2790675 6251107 52445 0 2956 80251 523157 624010 578558 726247 2212117 5524860 0 0 0 320513 13700000 0 605217 0 412308 457696 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 16. - RETIREMENT PLAN</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company sponsors a defined contribution plan under IRC Section 401(k).&#160; The plan covers all employees who meet the minimum eligibility requirements.&#160; Under the 401(k) plan eligible employees are allowed to make voluntary deferred salary contribution to the plan, subject to statutory limits.&#160; The Company has elected to make Safe Harbor Non-elective Contributions to the plan for eligible employees in the amount of three percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>%) of the employee&#8217;s compensation.&#160; Total employer contributions to the plan for the years ended December 31, 2014 and 2013 amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,485</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,873</font>, respectively. The contribution for the year ended December 31, 2013 includes a contribution made for 2012 in the first quarter of 2013.&#160;</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 3239385 0 0 10904 0.03 34873 27485 0 212012 0 925730 462000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. Inventories at December 31, 2014 and 2013 consist of the following:</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - tobacco leaf</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,537,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,398,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Less:&#160;&#160;inventory reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - tobacco leaf, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,486,898</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,348,124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Cigarettes and filtered cigars</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>154,568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,206</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Inventory - raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Cigarette and filtered cigar components</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>423,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,064,796</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,406,280</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1398747 1537521 50623 50623 1348124 1486898 13206 154568 44950 423330 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> Refundable taxes and tax credits</font></i></strong> <font style="FONT-SIZE: 10pt"><strong>&#150;</strong> The Company accounts for income tax refunds or tax refundable tax credits as discrete items and recognized the amount in the period in which the funds are received. During the year ended December 31, 2013, the Company received notice from the New York State Department of Taxation and Finance of a no change audit with respect to its income tax return filed for the period ending September 30, 2011. The subject return contained a refundable credit in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">122,024</font>.&#160; The refund was recorded as Other income in the Company&#8217;s Consolidated Statement of Operations for the year ended December 31, 2013. There were no such transactions during the year ended December 31, 2014.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 25000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 12. - NOTES PAYABLE AND PATENT ACQUISITION</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On December 22, 2014, the Company entered into a Purchase Agreement (the &#8220;Agreement&#8221;) with the National Research Council of Canada (&#8220;NRC&#8221;) to acquire certain patent rights that the Company had previously licensed from NRC under a license agreement between the parties. The Purchase Agreement provided for the payment by the Company to NRC of the total amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,873,000</font>, of which (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">660,000</font> was required to be paid at the closing under the Purchase Agreement for the payment due in 2013 from the Company to NRC as a result of the monies received by the Company from BAT in October 2013, and (ii) the remaining balance of $1,213,000 being for the purchase of the NRC patent rights, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">213,000</font> was paid in cash at the closing on December 23, 2014, and with the remaining $1,000,000 balance to be paid in three equal installments of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> approximately</font> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">333,333</font></font></font> in December of 2015, 2016 and 2017, respectively, with no interest on the installment payments unless the Company defaults in any such installment payment. As such, the Company computed the present value of the note payable using the Company&#8217;s incremental borrowing rate. The resulting present value of the note payable amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">925,730</font>; with $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">320,513</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">605,217</font> recorded as the current and long-term portion of the note payable, respectively. The cost of the acquired patents in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,138,730</font> (cash of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">213,000</font> plus the discounted notes payable in the amount of $925,730) are included in Intangible assets, net on the Company&#8217;s Consolidated Balance Sheets. All previous license agreements between NRC and the Company were terminated as a condition of the Purchase Agreement. NRC has a security interest in these patent rights acquired by the Company from NRC until the note payable has been satisfied.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 15000 15000 15000 20000 30000 50000 1873000 660000 333333 333333 333333 75000 925730 320513 605217 1138730 97593 44000 45000 31000 213000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 13. &#150; SEVERANCE LIABILITY</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of December 31, 2014, the Company has recorded an accrual for service in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">624,320</font> in accordance with FASB ASC 712. The severance accrual relates to the October 25, 2014 termination of Joseph Pandolfino, the Company&#8217;s former Chairman of the Board and Chief Executive Officer, pursuant to Section 4.2 (Termination by the Company Without Cause) of Mr. Pandolfino&#8217;s Employment Agreement, dated as of January 25, 2011. The Employment Agreement stipulates that Mr. Pandolfino shall receive severance payments in the gross amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,750</font> per month, subject to customary withholdings, over a term of 36 months. Amounts owed Mr. Pandolfino have been discounted using the Company&#8217;s incremental borrowing rate, resulting in current and long-term liabilities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">212,012</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">412,308</font>, respectively. In addition, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 320,000</font> unvested equity awards vested upon termination. The additional equity based compensation of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> associated with the vesting of these equity awards was recorded as expense during the fourth quarter of 2014.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 212012 0 320000 60000 0 0 4 -4 0 2500 416666 P6M P0Y P3Y 2817952 653869 3062665 292965 37177 62329 10831 172730 802215 401700 925100 92632 92244 1250000 1000000 1000000 1000000 2.2029 2.0000 1.9600 1.2672 1.2018 1.2018 1.1718 1.1984 1.3816 0.6000 0.6000 0.9520 0.9060 3.3600 2.5951 3.3736 3.3736 18750 P36M 509062 17386 88167 1250000 3.00 3.00 3.00 1.50 1.50 1.50 1.50 92894 7000000 16815 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i>Concentration of Credit Risk</i> -</strong> Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in financial institutions. Although the cash accounts exceed the federally insured deposit amount, management does not anticipate nonperformance by the financial institutions. Management reviews the financial viability of these institutions on a periodic basis.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.00001 0 388130 0 35398 0 218450 0 21986 1059000 70423 3027 230012 0 0.025 224519 Includes anti-dilution features. Include Exchange Rights (see Note 6 for detailed discussion). Exercisable upon attainment of certain revenue milestones (see Note 6 for detailed discussion). Include 1,250,000 warrants containing Exchange Rights (see Note 6 for detailed discussion). Includes 3,725,962 warrants (27.3%) held by officers and directors that have had the anti-dilution feature removed. EX-101.SCH 8 xxii-20141231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - NYSE MKT EXCHANGE link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - FINANCIAL CONDITION link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - CONSULTING AGREEMENT AND JOINT VENTURE link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - BUSINESS COMBINATION link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - MANUFACTURING FACILITY link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - MACHINERY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - EQUITY INVESTMENT AND ADVANCE link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - DEMAND BANK LOAN link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - NOTES PAYABLE AND PATENT ACQUISITION link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - SEVERANCE LIABILITY link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - DUE FROM RELATED PARTY link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - RETIREMENT PLAN link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - MACHINERY AND EQUIPMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Tables) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - FINANCIAL CONDITION (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT(Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - CONSULTING AGREEMENT AND JOINT VENTURE (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - BUSINESS COMBINATION (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - MANUFACTURING FACILITY (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - MACHINARY AND EQUPMENT (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - MACHINERY AND EQUIPMENT (Details) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - EQUITY INVESTMENT AND ADVANCE (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - DEMAND BANK LOAN (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 149 - Disclosure - NOTES PAYABLE AND PATENT ACQUISITION (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 150 - Disclosure - SEVERANCE LIABILITY (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 151 - Disclosure - DUE FROM RELATED PARTY (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 152 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 153 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Details) link:presentationLink link:definitionLink link:calculationLink 154 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Roll-Forward of Warrant Liability from Initial Valuation) (Details) link:presentationLink link:definitionLink link:calculationLink 155 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Warrant Activity) (Details) link:presentationLink link:definitionLink link:calculationLink 156 - Disclosure - RETIREMENT PLAN (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 157 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 158 - Disclosure - EARNINGS PER COMMON SHARE (Computation of Basic and Diluted Earnings Per Common Share) (Details) link:presentationLink link:definitionLink link:calculationLink 159 - Disclosure - EARNINGS PER COMMON SHARE (Anti-Dilutive Securities Outstanding Excluded from Computation) (Details) link:presentationLink link:definitionLink link:calculationLink 160 - Disclosure - STOCK BASED COMPENSATION (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 161 - Disclosure - STOCK BASED COMPENSATION (Schedule of Fair Value Assumptions) (Details) link:presentationLink link:definitionLink link:calculationLink 162 - Disclosure - STOCK BASED COMPENSATION (Summary of All Stock Option Activity) (Details) link:presentationLink link:definitionLink link:calculationLink 163 - Disclosure - INCOME TAXES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 164 - Disclosure - INCOME TAXES (Schedule of Provision (Benefit) for Income Taxes) (Details) link:presentationLink link:definitionLink link:calculationLink 165 - Disclosure - INCOME TAXES (Schedule of statutory federal rate to pre-tax accounting loss) (Details) link:presentationLink link:definitionLink link:calculationLink 166 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) link:presentationLink link:definitionLink link:calculationLink 167 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 xxii-20141231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 xxii-20141231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 xxii-20141231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Quarterly Financial Information Disclosure [Abstract] Additional Financial Information Disclosure [Text Block] FINANCIAL CONDITION Equity [Abstract] Schedule of Stock by Class [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Private Placement [Member] Class of Stock [Line Items] Stockholders Equity Note Disclosure [Text Block] SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT WARRANTS FOR COMMON STOCK Preferred Stock [Table] Preferred Stock [Member] Preferred Stock [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangement Disclosure [Text Block] CONSULTING AGREEMENT AND JOINT VENTURE Business Combinations [Abstract] Business Combination Disclosure [Text Block] BUSINESS COMBINATION Other Income and Expenses [Abstract] Other Operating Income And Expense [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Manufacturing Facility [Member] Pre-Manufacturing Facility [Member] Other Operating Income And Expense [Line Items] Other Operating Income and Expense [Text Block] MANUFACTURING FACILITY Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] MACHINERY AND EQUIPMENT Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures Disclosure [Text Block] EQUITY INVESTMENT AND ADVANCE Debt Disclosure [Abstract] Short-term Debt [Text Block] DEMAND BANK LOAN Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] DUE FROM OR TO RELATED PARTY Consolidated Balance Sheets [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Convertible Preferred Stock [Member] Statement [Line Items] Assets ASSETS Current Assets Current assets: Cash Cash Cash - beginning of period Cash - end of period Due From Related Parties, Current Due from related party Due From Officers Or Stockholders, Current Due from officers Inventory, Net, Total Inventory, net Inventory, Net Other Prepaid Expense, Current Prepaid consulting fees Prepaid Expense, Current, Total Prepaid expenses and other assets Disposal Group, Including Discontinued Operation, Assets, Current Machinery and equipment held for resale Less: cigarette manufacturing equipment held for resale Assets, Current, Total Total current assets Property, Plant and Equipment, Net Machinery and equipment, net Machinery and equipment, net Other Assets Other assets: Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Advances to Affiliate Equity investment Assests Noncurrent Excluding Property Plant And Equipment Net Total other assets Sum of the carrying amounts as of the balance sheet date of all assets excluding property plant and equipment that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Assets, Total Total assets Liabilities and Shareholders' Deficit LIABILITIES AND SHAREHOLDERS' DEFICIT Current Liabilities Current liabilities: Short-Term Bank Loans and Notes Payable Demand bank loan Notes Payable, Current Current portion of note payable Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Notes Payable, Noncurrent Long-term portion of note payable Accounts Payable and Accrued Liabilities, Noncurrent Long-term portion of accrued severance Derivative Liability, Noncurrent Warrant liability Fair value of warrant liability upon Issuance / conversion Liabilities, Total Total liabilities Common Stock, Value, Issued Common shares value Additional Paid in Capital, Total Capital in excess of par value Retained Earnings (Accumulated Deficit), Total Accumulated deficit Stockholders Equity, Including Portion Attributable to Noncontrolling Interest, Total Total shareholders' equity Beginning balance Ending balance Commitments and Contingencies Commitments and contingencies (Note 17) Warrants For Common Stock [Abstract] Type of Agreements [Axis] Type of Agreements [Domain] Warrant Exchange Program [Member] Warrant [Member] Commitments and Contingencies Disclosure [Abstract] Commitments Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Earnings Per Common Share [Abstract] Earnings Per Share [Text Block] EARNINGS PER COMMON SHARE Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK BASED COMPENSATION Subsequent Events [Abstract] Subsequent Events [Text Block] SUBSEQUENT EVENTS Consolidation, Policy [Policy Text Block] Principles of Consolidation Nature Of Operations [Policy Text Block] Nature of Business Disclosure of accounting policy for nature of business. Preferred Stock Authorized Preferred stock authorized Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Risk Credit Risk Inventory, Policy [Policy Text Block] Inventory Property, Plant and Equipment, Policy [Policy Text Block] Fixed assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Income Tax, Policy [Policy Text Block] Income Taxes Refundable Taxes And Tax Credits Policy [Policy Text Block] Refundable taxes and tax credits Disclosure of accounting policy for refundable taxes and tax credits for the reporting period. Share-Based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock Based Compensation Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Derivatives, Policy [Policy Text Block] Derivatives Research and Development Research and Development Earnings Per Share, Policy [Policy Text Block] Loss Per Common Share Commitments and Contingencies, Policy [Policy Text Block] Commitment and Contingency Accounting Use Of Estimates, Policy [Policy Text Block] Use of Estimates Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair value of financial instruments Schedule of Inventory, Current [Table Text Block] Schedule of Inventory, Current Property, Plant and Equipment [Table Text Block] MACHINERY AND EQUIPMENT Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule Of Warrants Outstanding Schedule Of Derivative Liabilities At Fair Value [Table Text Block] Roll-Forward of Warrant Liability from Intitial Valuation Derivative Liabilities Warrant Activity [Table Text Block] Warrant Activity Tabular disclosure of warrant activity. Scenario [Axis] Scenario, Unspecified [Domain] Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of Basic and Diluted Earnings Per Common Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table Text Block] Schedule Outstanding Excluded from Computation Because they would have bee Anti-dilutive Schedule Of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Fair Value Assumptions Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding [Table Text Block] Summary of All Stock Option Activity Condensed Financial Statements [Table] Nature of Expense [Axis] Interim Period, Costs Not Allocable [Domain] Cash [Member] Non Cash Convertible Debt Related Expense [Member] Non-Cash Convertible Debt Related Expense [Member] Series Preferred Stock [Member] Series A [Member] Series One Preferred Stock [Member] Series A One Preferred Stock [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Convertible Debt [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Products and Services [Axis] Products and Services [Domain] SPECTRUM Order [Member] Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Legal Entity [Axis] Entity [Domain] Third Party Licensor [Member] Subsidiaries [Member] 22nd Century Asia Ltd [Member] Cigarete Manufacturing Equipment [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Intellectual Property [Member] Patent and Trademarks [Member] Licensing Agreements [Member] Condensed Financial Statements, Captions [Line Items] Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Convertible Preferred Stock, Shares Issued Upon Conversion Revenue Other Manufactured Products Property, Plant and Equipment, Estimated Useful Lives Finite-Lived Intangible Assets, Amortization Expense, after Year Five Licenses Revenue Royalties from licensing License Costs Royalties for licensing Deferred Revenue Property, Plant and Equipment, Additions Deferred Revenue, Revenue Recognized Equity Method Investment, Ownership Percentage Amortization of Intangible Assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Unclassified Indefinite-lived Intangible Assets [Member] MSA Signatory Costs [Member] Finite-Lived Intangible Assets, Net [Abstract] Intangible assets, net Finite-Lived Intangible Assets, Gross Patent and trademark costs Finite-Lived Intangible Assets, Accumulated Amortization Less: accumulated amortization Finite-Lived Intangible Assets, Net Patent and trademark costs, net Other Indefinite-lived Intangible Assets License fee for predicate cigarette brand Items Included in Consolidated Statement of Financial Condition [Abstract] Financial Condition [Table] Liabilities, Current, Total Total current liabilities Working Capital Carrying amount of working capital as of balance sheet date. Cash and Cash Equivalents, at Carrying Value, Total Liquidity Disclosure, Sufficient Cash and Waivers Note Capital Required to be Well Capitalized Description of Regulatory Requirements, Capital Adequacy Purposes Stock Issued During Period, Value, New Issues Common stock issued in September 2014 private placement Proceeds from Issuance or Sale of Equity Stock Issued During Period, Shares, New Issues Common stock issued in September 2014 private placement, shares January 2013 Preferred Stock Private Placement [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Series A Warrant [Member] Series A Warrant [Member] Series B Warrant [Member] Series C Warrant [Member] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Related Party [Axis] Related Party [Domain] Chardan Capital Markets, LLC [Member] Subsidiary, Sale of Stock [Line Items] Preferred Stock, Dividend Rate, Percentage Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Proceeds From Issuance Of Convertible Preferred Stock Proceeds from sale of preferred shares and convertible notes Proceeds from Warrant Exercises Net proceeds from exercise of warrants Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Consulting Agreement [Member] Tranche 1A Warrants [Member] Tranche 1B Warrants [Member] Tranche 2 Warrants [Member] Tranche 3 Warrants [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Sale of Stock, Percentage of Ownership before Transaction Warrants Issued Expected Term Represents the expected terms of warrants issued during period. Weighted Average Number of Shares, Contingently Issuable Issuance of Stock and Warrants for Services or Claims Equity based payments for outside services Finite-Lived Intangible Assets, Remaining Amortization Period Business Combination, Separately Recognized Transactions [Table] Business Combination, Separately Recognized Transactions [Line Items] Payments to Acquire Businesses, Gross Acquisition of NASCO Products, LLC Stock Issued During Period, Shares, Acquisitions Stock issued in connection with acquisition of NASCO Products, LLC, shares Stock Issued During Period, Value, Acquisitions Issuance of common stock for acquisition of NASCO Products, LLC Stock issued in connection with acquisition of NASCO Products, LLC Cash Acquired from Acquisition Manufacturing Facilty [Abstract] Manufacturing Facilty Manufacturing Facilty [Table] Entity by Location [Axis] Location [Domain] Other Cost and Expense, Operating Pre-manufacturing facility costs (including stock based compensation of $27,923 and $0, respectively) Sales Revenue, Goods, Gross Sale of products Other Depreciation and Amortization Consolidated Statements Of Operations [Abstract] Revenue, Net [Abstract] Revenue: Cost of Goods Sold [Abstract] Cost of goods sold: Cost of Goods Sold, Total Products Gross Profit Gross profit Costs and Expenses [Abstract] Operating expenses: Research and Development Expense, Total Research and development (including stock based compensation of $331,467 and $111,563, respectively) General and Administrative Expense, Total General and administrative (including stock based compensation of $4,165,078 and $2,250,399, respectively) Selling and Marketing Expense Sales and marketing costs Depreciation, Depletion and Amortization, Nonproduction, Total Amortization and depreciation Costs and Expenses, Total Total operating expenses Operating Income (Loss), Total Operating (loss) income Other Income (Expense) Other income (expense): Gain Loss From Warrant Liability Warrant liability loss - net Warrant liability loss Represents the value of gain or loss from warrant liability. Warrant Exchange Inducement Expense Warrant amendment inducement expense Warrant amendment inducement expense Amount of inducement expenses on warrant exchange. Gain (Loss) on Disposition of Assets, Total Gain on the sale of machinery and equipment Equity Method Investment, Realized Gain (Loss) on Disposal Loss on equity investment Loss on equity investment Income Tax Refund Income tax credit refund Income Tax Refund Income Tax Refund. Interest Expense, Related Party Related parties Interest Expense, Other Other Interest and Debt Expense [Abstract] Interest expense and amortization of debt discount and expense: Net Income (Loss) Attributable to Parent Net loss Net loss attributed to common shareholders Earnings Per Share, Basic and Diluted, Total Loss per common share - basic and diluted (in dollars per share) Loss per common share - basic and diluted Weighted Average Number of Shares Outstanding, Basic, Total Common shares used in basic earnings per share calculation (in shares) Denominator for basic earnings per share-weighted average shares outstanding Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Machinery and Equipment, Gross Cigarette manufacturing equipment Property, Plant and Equipment, Other, Gross Deposit for purchase of machine parts and other assets Proceeds from Sale of Machinery and Equipment Proceeds from Sale of Machinery and Equipment Proceeds from the sale of machinery and equipment Furniture and Fixtures, Gross Office furniture, fixtures and equipment Leasehold Improvements, Gross Leasehold improvements Property Plant And Equipment Including Assets Held For Sale Property Plant And Equipment Including Assets Held For Sale It represents the amount of property, plant and equipment including assets held for sale as of balance sheet date. Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Schedule of Equity Method Investments [Table] Equity Method Investee [Member] Anandia Laboratories, Inc [Member] Patents [Member] Sub License [Member] Income Statement Location [Axis] Income Statement Location [Domain] General and Administrative Expense [Member] Schedule of Equity Method Investments [Line Items] Equity Method Investments Sale of Stock, Number of Shares Issued in Transaction Equity Method Investment Summarized Financial Information, Equity Sale of Stock, Consideration Received on Transaction Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend Percentage of Net Loss Percentage of net loss during the reporting period. Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt Instrument, Basis Spread on Variable Rate Annual interest rate above prime rate Debt Instrument, Interest Rate, Effective Percentage Interest rate Debt Instrument, Frequency of Periodic Payment Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Table] Warrant One [Member] Warrant Two [Member] Warrant Three [Member] Warrant Four [Member] Warrant 5 [Member] Warrant Five [Member] Warrant 6 [Member] Warrant Six [Member] Series A-1 Preferred Stock [Member] Private Placement Debt Due May Twenty Twelve [Member] Private Placement Debt Due May 2012 Notes Due Twenty Thirteen [Member] Notes Due 2013 [Member] Period Four [Member] Period Four [Member] Private Placement And Merger [Member] January 2011 Private Placement Offering One [Member] January 2011 Private Placement Offering Two [Member] New Note [Member] New Note [Member] New Note [Member] August 2012 [Member] November 2012 [Member] Financing and Arrangement [Axis] Financing and arrangement [Domain] Upon Issuance of August 9, 2012 Notes [Member] Plan Name [Axis] Plan Name [Domain] Title of Individual [Axis] Relationship to Entity [Domain] Officers And Directors [Member] Derivative, by Nature [Axis] Class of Warrant or Right, Outstanding Warrants outstanding upon conversion of convertible notes Number of warrants Warrant outstanding beginning balance Warrant outstanding ending balance Proceeds from Issuance of Preferred Stock and Preference Stock Warrants and Rights Outstanding Warrants Without Provision Of Anti Dilution Warrants without anti-dilution feature Number of warrants issued without the provision of anti-dilution. Derivative, Gain (Loss) on Derivative, Net, Total Loss as a result of change in fair value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Warrants With Provision Of Anti Dilution Warrants containing anti-dilution feature Number of warrants issued with the provision of anti-dilution. Proceeds from Issuance of Warrants Stock Issued During Period Shares Warrant Exercised Value of stock issued as a result of the exercise of warrants. Percentage of Warrants Outstanding Represents the percentage of warrants outstanding as of balance sheet date. Derivative, Name [Domain] January 2011 Private Placement Offering Warrants One [Member] January 2011 Private Placement Offering Warrants Two [Member] January 2011 Private Placement Offering Warrants Three [Member] January 2011 Private Placement Offering Warrants Four [Member] January 2011 Private Placement Offering Warrants Five [Member] January 2011 Private Placement Offering Warrants Six [Member] January 2011 Private Placement Offering Warrants Seven [Member] December 2011 Convertible Notes Payable Warrants One [Member] December 2011 Convertible Notes Payable Warrants Two [Member] May 2012 Private Placement Offering Warrants [Member] November 2012 Private Placement Offering Warrants [Member] August 2012 Convertible Notes Payable Warrants One [Member] August 2012 Convertible Notes Payable Warrants Two [Member] Crede Tranche 1A Warrants [Member] Crede Tranche 1B Warrants [Member] Crede Tranche 2 Warrants [Member] Crede Tranche 3 Warrants [Member] Class of Warrant or Right [Line Items] Notes Payable 2012 Member [Member] Series A and Series C Warrants Member [Member] Notes Payable 2011 Member [Member] Reclassification Of Warrant Liability To Equity Upon Exercise Of Warrants Reclassification of Warrant liability to equity upon exercise of Warrants The amount of reclassification of warrant liability under exercise of warrants. Reclassification Of Warrant Liability To Equity Resulting From Warrant Exchange Program Reclassification of warrant liability to equity resulting from Warrant Exchange The amount reclassification of warrant liability under Warrant Exchange Program. Reclassification of derivative liability to equity due to warrant amendments Reclassification of warrant liability to equity resulting from Warrant Amendments Reclassification of derivative liability to equity due to warrant amendments Reclassification of derivative liability to equity due to warrant amendments Inducement Costs From Warrant Amendments Cost of inducement from Warrant Amendments- Q1 2014 Represents the amount of cost of inducement from warrant amendments. Class Of Warrant Or Right Issued Warrants issued The shares of warrants issued. Warrants issued in conjunction with consulting agreement Number of warrants issued upon consulting agreement during the reporting period. Class Of Warrants Or Rights Issued Under Warrant Exchange Program warrants issued as part of Warrant Exchange Program It represents the number of class of warrants or rights issued as a part of warrant exchange program. Common Stock Warrants Issued Additional Number Additional warrants due to anti-dilution provisions Additional warrants due to anti-dilution provisions. Number Of Warrants Exercised Warrants exercised Warrants exercised. Number Of Warrants Exercised Under Warrant Exchange Program Warrants exercised as part of Warrant Exchange Program It represents the number of warrants are exercised as a part of warrant exchange program. Composition of outstanding warrants [Abstract] Composition of outstanding warrants: Warrants Outstanding Warrant outstanding and exercisable ending balance Number of warrants outstanding as of reporting date. Other Commitments [Table] Period Type [Axis] Period Type [Axis]. Period Type [Domain] Period Type [Domain]. Fiscal Year Twenty Twelve [Member] Fiscal Year 2012 [Member] Fiscal Year Twenty Thirteen [Member] Fiscal Year 2013 [Member] Fiscal Year Twenty Fourteen [Member] Fiscal Year 2014 [Member] Fiscal Year Twenty Fifteen [Member] Fiscal Year 2015 [Member] Fiscal Year Twenty Sixteen [Member] Fiscal Year 2016 [Member] Precision License [Member] Scenario, Forecast [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Purchase Provision Terms [Member] Membership Purchase Agreement [Member] Other Commitments [Line Items] Royalty Guarantees, Commitments, Amount Annual minimum royalty payments Milestone Payment Milestone payment upon approval of a product Milestone payment upon approval of a product. Facility Membership and Operations Costs Capital Leases, Future Minimum Payments Due, Next Twelve Months Capital Leases, Future Minimum Payments Due in Two Years Capital Leases, Future Minimum Payments Due in Three Years Capital Leases, Future Minimum Payments Due in Four Years Acquisition Of Patents and Trademarks Acquisition of patents and trademarks Other Accrued Liabilities, Noncurrent Research And Development Arrangement Contract Terms Represents the research and development arrangement contract terms. Finite-lived Intangible Assets Acquired Obligation To Pay Remaining License Cost Amount of remaining license cost the company is obligated to pay. Amortization of Other Deferred Charges Amortization of license fees Research and Development Expense [Member] Allocated Share-based Compensation Expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Earnings Per Share, Diluted, Other Disclosures [Abstract] Effect of dilutive securities: Weighted Average Number Diluted Shares Outstanding Adjustment, Total Warrants, restricted stock and options outstanding Weighted Average Number Of Shares Outstanding, Basic and Diluted Denominator for diluted earnings per common share-weighted average shares adjusted for dilutive securities Restricted Stock [Member] Options Held [Member] Options [ Member] Convertible Debt Issued December 14 2011 [Member] Convertible Debt Securities Two [Member] Convertible Debt Issued August 9, 2012 [Member] Convertible Debt Securities [Member] Convertible Note [Member] Securities Outstanding But Excluded From Computation Of Earnings Per Share Securities outstanding but excluded from computation of earnings per share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Equity Award [Domain] EquityIncentivePlanTwentyTen [Member] Equity Incentive Plan 2010 [Member] Third Party [Member] Grant Date [Axis] Grant Date [Domain] Grant Date On April 1 2013 [Member] Omnibus Incentive Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized Share-based Compensation, Total Equity based employee compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total Unrecognized compensation expense related to non-vested restricted shares and stock option Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Proceeds from Stock Options Exercised Net proceeds from exercise of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Exercise of options, shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Stock Issued During Period, Shares, Restricted Stock Award, Gross Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility Fair Value Assumptions, Expected Term Expected life of options Option Indexed to Issuer's Equity [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Options Outstanding, Beginning of Period Options Outstanding, End of Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Exercisable, End of Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Outstanding, Beginning of Period Options Outstanding, End of Period Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable, End of Period Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options Outstanding, End of Period Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable, End of Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options Outstanding, End of Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Exercisable at December 31, 2014 Subsequent Event [Table] Consolidated Statement Of Shareholders' Deficit [Abstract] Additional Paid-in Capital [Member] Contributed Capital [Member] Retained Earnings [Member] Accumulated Deficit [Member] Noncontrolling Interest [Member] Shares, Outstanding, Beginning Balance Beginning balance, shares Ending balance, shares Stock Issued During Period, Value, Conversion of Convertible Securities Common stock issued upon exercise of Convertible Notes Stock Issued During Period, Shares, Conversion of Convertible Securities Common stock issued upon exercise of Convertible Notes, shares Stock Issues During Period Value Private Placement Preferred stock issued in January 2013 private placement Number of preferred stock issues during the period value of private placement. Stock Issues During Period Shares Private Placement Preferred stock issued in January 2013 private placement (in shares) Shares of preferred stock issues during the period for private placement. Conversion of Stock, Amount Issued Conversion of preferred stock to common stock Conversion of Stock, Shares Issued Conversion of preferred stock to common stock, shares Stock issued During Period Value Warrant Exchange Program Warrant exchange program Value of stock issued under warrant exchange program. Stock issued During Period Shares Warrant Exchange Program Warrant exchange program, shares Number of shares issued under warrant exchange program. Dividends, Common Stock, Stock Common stock issued in payment of accrued dividends Common Stock Dividends, Shares Common stock issued in payment of accrued dividends, shares Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures, Total Stock based compensation Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures, Total Stock based compensation, shares Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Warrants issued as compensation for services Stock Issued During Period Warrants Excercised Value Exercise of warrants Value of stock issued as a result of exercise of warrants. Stock Issued During Period Warrants Excercised Exercise of warrants, shares Number of warrants exercised during the current period. Stock Issued During Period, Value, Stock Options Exercised Exercise of options Consolidated Statements Of Cash Flows [Abstract] Period [Axis] Period [Axis]. Period [Domain] Period [Domain]. Period One [Member] January 2013 [Member] Period Two [Member] May 2012 [Member] Common Stock 2014 [Member] Preferred Stock 2013 [Member] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to cash (used in) provided by operating activities: Depreciation, Depletion and Amortization Amortization and depreciation Amortization Of Financing Costs Amortization of debt issuance costs Amortization Of Debt Discount Amortization of debt discount Gain (Loss) on Disposition of Property Plant Equipment Gain on the sale of machinery and equipment Non Cash Interest On Convertible Debt Interest due to debt conversion It may represents non cash interest on convertible debt during the period. Severance Costs Severance expense Increase (Decrease) in Inventories, Total Inventory Increase (Decrease) In Prepaid Expense Prepaid expenses and other assets Increase (Decrease) In Operating Assets [Abstract] (Increase) decrease in current assets: Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Due to Related Parties, Total Accrued interest payable to related parties Increase (Decrease) in Accrued Liabilities, Total Accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Machinery and Equipment Acquisition machinery and equipment Payments to Acquire Property, Plant, and Equipment Purchase of machinery and equipment held for resale Payments for Fees Payment of license fees Payments to Acquire Investments, Total Equity investment and advance Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Net proceeds from warrant exchange program The cash inflow associated with the amount received due from warrant exchange program. Proceeds From Notes Payable Proceeds from issuance of notes Payments On Borrowings Payments on borrowings - notes payable Repayments Of Convertible Debt Payments on borrowings - convertible notes Proceeds from Issuance of Private Placement Net proceeds from private placement Proceeds from Contributed Capital Other capital contribution Net Payments To Related Party Net payments to related party Net Advances From (Payments To) Officers Net advances from (to) officers Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase in cash Interest Paid, Net Cash paid during the period for interest Income Taxes Paid Cash paid during the period for income taxes Patent and Trademark Additions Included In Accounts Payable Patent and trademark additions included in accounts payable Patent and trademark additions included in accounts payable during the reporting period. Noncash or Part Noncash Acquisition, Payables Assumed Machinery and equipment additions included in accounts payable License Fee Included In Accrued Expenses License fee included in accrued expenses Amount of license fee included in accrued expenses. Equity Investment Included In Accrued Expenses Equity investment included in accrued expenses Total amount of equity investment included in accrued expenses. Stock Repurchased During Period, Value Issuance of common stock for equity investment Issuance Of Derivative Liability Warrants Issued Under Consulting Agreement Issuance of warrants as a derivative liability issued under a consulting agreement and included in prepaid consulting fees Represents Issuance Of Derivative Liability Warrants Issued Under Consulting Agreement during this period. Warrants Issued Under Consulting Agreement Resulting In Capital Warrants issued under a consulting agreement resulting in an increase in capital and included in prepaid consulting fees Represents Warrants issued under a consulting agreement resulting in an increase in capital and included in prepaid consulting fees. Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of investing and financing activities Reduction Of Accounts Payable Not Rrelated To Operating Activities [Abstract] Reduction of accounts payable not related to operating activities: Reduction Of Accounts Payable Not Rrelated To Operating Activities Abstract. Reclassification Of Machinery And Equipment Purchases To Inventory Reclassification of machinery and equipment purchases to inventory Reclassification of machinery and equipment purchases to inventory during the reporting period. Other Contributed Capital Other capital contribution The value represents other contributed capital. Finite Lived Intangible Assets Acquired With Notes Payable Patent additions acquired with note payable Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from acquisition of notes payable. Conversion Of Accounts Payable To Note Payable Accounts payable converted to promissory notes Conversion of accounts payable to note payable. Conversion Of Accrued Interest To Note Payable Accrued interest converted to promissory notes It represents that the accrued interest is converted to note payable during the reporting period. Conversion Of Notes Payable and Accrued Interest To Common Stock Notes payable and accrued interest converted to common shares It represent that the notes payable and accrued interests are converted to common shares. Dividend Payable On Preferred Stock Common stock issued in payment of preferred stock dividend payable It represent the dividend payable on preferred stock. Issuance Of Common Stock Value In Payment Of Financing Cost Common stock issued for fees relating to January 2013 preferred stock private placement Common stock issued for fees relating to preferred stock private placement. Nature Of Business and Summary Of Significant Accounting Policies NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Stock Exchange [Abstract] New York Stock Exchange Market Dislcosure [Text Block] NYSE MKT EXCHANGE The entire disclosure for NYSE MKT exchange. Cost of Revenue Cost of Revenue Revenues Revenues Nonoperating Income (Expense), Total Total other income (expense) Document And Entity Information [Abstract] Document Information [Table] Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Public Float Increase (Decrease) In Operating Liabilities [Abstract] Increase (decrease) in current liabilities: Stock Issued During Period, Value, Other Stock issued in connection with equity investment Stock Issued During Period, Shares, Other Stock issued in connection with equity investment, shares Adjustments to Additional Paid in Capital, Other Other capital contribution Adjustments to Additional Paid in Capital, Warrant Issued Warrant amendments Refinance Of Note Payable To Accounts Payable Refinance of convertible note to note payable It represent the refinance of convertible note to note payable during the period. Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] INCOME TAXES Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current: Current Federal Tax Expense (Benefit) Federal Current State and Local Tax Expense (Benefit) State Current Income Tax Expense (Benefit) Total current Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred: Deferred Federal Income Tax Expense (Benefit) Federal Deferred State and Local Income Tax Expense (Benefit) State Deferred Income Tax Expense (Benefit) Total deferred Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in valuation allowance Income Tax Expense (Benefit) Total income tax provision (benefit) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Statutory federal rate Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Permanent items Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Derivative liability Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Stock based compensation Components of Deferred Tax Assets [Abstract] Deferred tax assets: Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carry-forward Deferred Tax Assets, Derivative Instruments Derivative liability Deferred Tax Assets, Inventory Inventory reserve Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Stock-based compensation Deferred Tax Liabilities Start up expenditures Start-up expenditures Amount of deferred tax liability attributable to taxable temporary differences from Start up expenditures. Stock Issued During Period Shares Stock Options Exercised1 Number of share options (or share units) exercised during the current period. Deferred Tax Assets, Equity Method Investments Loss on equity investment Components of Deferred Tax Liabilities [Abstract] Deferred tax liabilities: Deferred Tax Liabilities, Inventory Inventory Deferred Tax Liabilities, Property, Plant and Equipment Fixed assets Deferred Tax Liabilities, Intangible Assets Patents and trademarks Deferred Tax Liabilities Other Intangible Assets Other intangible assets Amount of deferred tax liability attributable to taxable temporary differences from Other Intangible Assets. Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Assets, Net Net deferred taxes Accrued Severance Liabilities Current Accrued severance Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Deferred Revenue, Current Deferred revenue Operating Loss Carryforwards Net operating loss carry forwards Stockholders' Equity, Including Portion Attributable To Noncontrolling Interest [Abstract] Shareholders' equity Liabilities and Equity, Total Total liabilities and shareholders' equity Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Compensation and Retirement Disclosure [Abstract] Pension and Other Postretirement Benefits Disclosure [Text Block] RETIREMENT PLAN Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans [Axis] Defined Benefit Plan and Other Postretirement Benefit Plan [Domain] Issuance Of Warrants As Derivative Liability Instrument Issuance of warrants as derivative liability instruments and reduction of capital Issuance of warrants as derivative liability instrument. Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Funded Percentage Defined Benefit Plan, Contributions by Employer Increase Warrant Liability Adjustments Increase in warrant liability and reduction in capital as a result of lowering the exercise price on certain warrants Amount of Increase in warrant liability and reduction in capital as a result of lowering the exercise price on certain warrants. Reclassification Of Derivative Liability To Equity Due To Warrant Exchange Program Reclassification of derivative liability to equity due to warrant exchange program Reclassification of derivative liability to equity due to warrant exchange program. Issuance Of Common Stock Value For Fees Common stock issued for fees relating to December 2013 warrant exchange program Common stock issued for fees relating to warrant exchange program. Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Intangible Assets and Goodwill License Fee [Member] Inventory, Net [Abstract] Inventory, Current [Table] Inventory [Line Items] Inventory Tobacco Leaf Gross Inventory - tobacco leaf Amount before valuation and LIFO reserves of inventory tobacco leaf gross expected to be sold, or consumed within one year or operating cycle, if longer. Inventory Valuation Reserves Less: inventory reserve InventoryTobacco Leaf Net Inventory - tobacco leaf, net Amount after valuation and LIFO reserves of inventory tobacco leaf net expected to be sold, or consumed within one year or operating cycle, if longer. Inventory, Finished Goods and Work in Process, Gross [Abstract] Inventory - finished goods Inventory, Finished Goods and Work in Process, Gross Cigarettes and filtered cigars Inventory, Raw Materials and Supplies, Gross [Abstract] Inventory - raw materials Inventory, Raw Materials and Supplies, Gross Cigarette and filtered cigar components Equity Method Investments, Policy [Policy Text Block] Equity Investments Obligation To Pay Remaining License Cost In Increments Amount of remaining license cost the company is obligated to pay in increments. Notes Payable And Patent Acquisition [Abstract] Notes Payable And Patent Acquisition [Text Block] NOTES PAYABLE AND PATENT ACQUISITION The entire disclosure for Notes Payable And Patent Acquisition. Anandia Sublicense [Member] License Maintenance Fees Due Current Amount of license maintenance fees due in the next fiscal year following the latest fiscal year. Notes Payable And Patent Acquisition [Table] These table contains detailed information for Notes Payable And Patent Acquisition. License Maintenance Fees Due In Two Years Amount of license maintenance fees due in the second fiscal year following the latest fiscal year. License Maintenance Fees Due In Three Years Amount of license maintenance fees due in the third fiscal year following the latest fiscal year. Minimum Royalty Fee Payments Due In Year Four Amount of minimum royalty fee payments due in the fourth fiscal year following the latest fiscal year. Minimum Royalty Fee Payments Due In Year Five Amount of minimum royalty fee payments due in the fifth fiscal year following the latest fiscal year. Minimum Royalty Fee Payments Due Thereafter Amount of minimum royalty fee payments due after the fifth fiscal year following the latest fiscal year. Notes Payable And Patent Acquisition [Line Items] Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Other Commitment Other Commitment, Due in Next Twelve Months Other Commitment, Due in Second Year Other Commitment, Due in Third Year Other Commitment, Due in Fourth Year Upfront Fee Represents the amount of upfront fees during the period. Other Commitment, Due in Fifth Year Capital Leases, Future Minimum Payments Due Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Severance Liability [Abstract] Severance Liability [Text Block] SEVERANCE LIABILITY The entire disclosure for Severance Liability. Severance Liability [Table] A table that contains information regarding severance liability. Restructuring Type [Axis] Type of Restructuring [Domain] Employee Severance [Member] Severance Liability [Line Items] Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Monthly Severance Cost Amount of monthly expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation Severance Term Represents the term of employment agreement Document Information [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Option Indexed to Issuer's Equity, Type [Domain] Employee Stock Option [Member] Employement Agreement [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price Warrants Expiration Date Expiration Expiration date of warrants outstanding. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Exercise Price Of Warrants Represents the exercise price of warrants during period. Manufacturing Facility [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Filtered Cigars [Member] Machinery and Equipment [Member] Related Party Transaction [Line Items] Alternative Cigarettes, Inc. [Member] Warrants Price Warrants price of descriptions. Non-Interest Bearing Advance Represents the value of non-interest bearing advances made as of reporting date. Payments for Royalties Director [Member] Officer [Member] Employees [Member] New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Severance Payments Severance liability Deferred Tax Assets, Other Other Deferred Tax Assets, Gross Total deferred tax assets Deferred Tax Liabilities, Gross Total deferred tax liabilities Stock Issued During Period, Shares, Share-based Compensation, Gross Subsequent Event [Line Items] Smoker Friendly International [Member] Depreciation Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State tax provision, net of federal benefit Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Valuation allowance Effective Income Tax Rate Reconciliation, Percent Effective tax rate (benefit) provision EX-101.PRE 12 xxii-20141231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R39.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 FINANCIAL CONDITION (Narrative) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Jun. 05, 2014 Dec. 31, 2013 Condensed Financial Statements, Captions [Line Items] Assets, Current, Total $ 10,706,806 us-gaap_AssetsCurrent $ 7,744,115 us-gaap_AssetsCurrent Liabilities, Current, Total 2,673,407 us-gaap_LiabilitiesCurrent 984,334 us-gaap_LiabilitiesCurrent Working Capital 8,033,399 xxii_WorkingCapital Cash and Cash Equivalents, at Carrying Value, Total 6,402,687 us-gaap_CashAndCashEquivalentsAtCarryingValue Liquidity Disclosure, Sufficient Cash and Waivers Note The Company believes it will have adequate cash reserves to sustain operations and meet all current obligations as they come due for a period of approximately 12 months. Capital Required to be Well Capitalized $ 45,000,000 us-gaap_CapitalRequiredToBeWellCapitalized Description of Regulatory Requirements, Capital Adequacy Purposes The universal shelf registration statement will allow, but not compel, the Company to raise up to $45 million of capital over a three-year period through a wide array of securities at times and in amounts to be determined by the Company. X - Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The amount of Total Capital required to be categorized as well as capitalized under the regulatory framework for prompt corrective action. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 505 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35709795&loc=SL5958568-112826 + Details Name: us-gaap_CapitalRequiredToBeWellCapitalized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_CondensedFinancialStatementsCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Description of the regulatory requirements for capital adequacy purposes. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 505 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35709795&loc=SL5958568-112826 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 505 -Section 50 -Paragraph 1H -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35709795&loc=d3e65071-112826 + Details Name: us-gaap_DescriptionOfRegulatoryRequirementsCapitalAdequacyPurposes Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. + References No definition available. + Details Name: us-gaap_LiquidityDisclosureSufficientCashAndWaiversNote Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Carrying amount of working capital as of balance sheet date. + References No definition available. + Details Name: xxii_WorkingCapital Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 14 R54.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Roll-Forward of Warrant Liability from Initial Valuation) (Details) (USD $) 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Mar. 31, 2014 Jun. 30, 2013 Sep. 30, 2013 Dec. 31, 2014 Dec. 31, 2013 Mar. 31, 2013 Dec. 31, 2012 Sep. 30, 2014 Class of Warrant or Right [Line Items] Fair value of warrant liability upon Issuance / conversion $ 711,675 us-gaap_DerivativeLiabilitiesNoncurrent $ 1,622,069 us-gaap_DerivativeLiabilitiesNoncurrent $ 3,042,846 us-gaap_DerivativeLiabilitiesNoncurrent $ 3,779,522 us-gaap_DerivativeLiabilitiesNoncurrent $ 6,022,319 us-gaap_DerivativeLiabilitiesNoncurrent $ 4,173,140 us-gaap_DerivativeLiabilitiesNoncurrent Reclassification of Warrant liability to equity upon exercise of Warrants (204,513) xxii_ReclassificationOfWarrantLiabilityToEquityUponExerciseOfWarrants (6,542,904) xxii_ReclassificationOfWarrantLiabilityToEquityUponExerciseOfWarrants (7,712,170) xxii_ReclassificationOfWarrantLiabilityToEquityUponExerciseOfWarrants Reclassification of warrant liability to equity resulting from Warrant Exchange (19,639,465) xxii_ReclassificationOfWarrantLiabilityToEquityResultingFromWarrantExchangeProgram Reclassification of warrant liability to equity resulting from Warrant Amendments (7,367,915) xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantAmendments 7,367,915 xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantAmendments 14,433,178 xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantAmendments Cost of inducement from Warrant Amendments- Q1 2014 144,548 xxii_InducementCostsFromWarrantAmendments 3,274,313 xxii_InducementCostsFromWarrantAmendments Loss as a result of change in fair value 3,676,691 us-gaap_DerivativeGainLossOnDerivativeNet 19,271,977 us-gaap_DerivativeGainLossOnDerivativeNet Crede Tranche 1A Warrants [Member] Class of Warrant or Right [Line Items] Fair value of warrant liability upon Issuance / conversion 2,810,000 us-gaap_DerivativeLiabilitiesNoncurrent / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche1AWarrantsMember Notes Payable 2012 Member [Member] Class of Warrant or Right [Line Items] Fair value of warrant liability upon Issuance / conversion 731,662 us-gaap_DerivativeLiabilitiesNoncurrent / us-gaap_DebtInstrumentAxis = xxii_NotesPayable2012MemberMember Series A and Series C Warrants Member [Member] Class of Warrant or Right [Line Items] Fair value of warrant liability upon Issuance / conversion 626,328 us-gaap_DerivativeLiabilitiesNoncurrent / us-gaap_DebtInstrumentAxis = xxii_SeriesAndSeriesCWarrantsMemberMember Notes Payable 2011 Member [Member] Class of Warrant or Right [Line Items] Fair value of warrant liability upon Issuance / conversion $ 1,445,091 us-gaap_DerivativeLiabilitiesNoncurrent / us-gaap_DebtInstrumentAxis = xxii_NotesPayable2011MemberMember X - Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a),(c),(d),(e) -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959 + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Represents the amount of cost of inducement from warrant amendments. + References No definition available. + Details Name: xxii_InducementCostsFromWarrantAmendments Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Reclassification of derivative liability to equity due to warrant amendments + References No definition available. + Details Name: xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantAmendments Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The amount reclassification of warrant liability under Warrant Exchange Program. + References No definition available. + Details Name: xxii_ReclassificationOfWarrantLiabilityToEquityResultingFromWarrantExchangeProgram Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The amount of reclassification of warrant liability under exercise of warrants. + References No definition available. + Details Name: xxii_ReclassificationOfWarrantLiabilityToEquityUponExerciseOfWarrants Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=xxii_NotesPayable2011MemberMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=xxii_NotesPayable2012MemberMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=xxii_SeriesAndSeriesCWarrantsMemberMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_CredeTranche1AWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R48.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 DEMAND BANK LOAN (Narrative) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Debt Instrument [Line Items] Demand bank loan $ 174,925 us-gaap_ShortTermBankLoansAndNotesPayable $ 174,925 us-gaap_ShortTermBankLoansAndNotesPayable Annual interest rate above prime rate 0.75% us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 0.75% us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Interest rate 4.00% us-gaap_DebtInstrumentInterestRateEffectivePercentage 4.00% us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Frequency of Periodic Payment 30 days X - Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. + References No definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Description of the frequency of periodic payments (monthly, quarterly, annual). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Carrying amount at the balance sheet date of borrowings from a bank, not elsewhere enumerated in the taxonomy, with a maturity within one year (or within one operating cycle if longer) from the date of borrowing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details Name: us-gaap_ShortTermBankLoansAndNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#8O%`R5`(``%HH```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VL&.VC`4!=!]I?Y#Y&U%
M3.PXG5:$64S;93M2IQ_@)@\2D=B1[9G"W]QH_W21QUGB5W^PO'7273P]"UE0XQ*7\R]:LML^#?Q1B,']TPGOG[@N?[OL5'X]J:DGOMPE?=QQA\V_%?UFU^6KM)3P\Y
MDM*N5FU%M:T>^_@$4C\XTK5OB$+?I=,Q[75K7G*?V#]=[/ETR*X<9/Q^T^`+
M +3Z[__PVWCT;
MXB!RH:5#W>U8;>RP,?;H+E_XJK=&8U.OIOK(;CXU`Y>_`0``__\#`%!+`P04
M``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D
M[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6
M#Z!B(F=I%, ;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P
M4 P>J/OH\^;*W-$UO>"_F?6*73HQ`
MGA,[RW;E0V8+J &PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;',@H@0!**```0``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````"\FLUN
MVD`4A?>5^@[6[(NY\T=2Q631JE*V;?H`EAFP%;"19_K#VW=$6X=(S2D+ZVR0
M/(CQU=QSSGAU,NE+\?+/=3ZQ9[%PZ92X\-&>U4\GH[YUO_??-ANNR9\
M')IOA]"G?]RC_#&,3[$-(>5-ZW$74J6FI5B>W]%^D6M6Y2OE"+L<0>5832['
M:EC.BEW."I7C#;D_5VC'+E&SK&.7XU`YCLU*!UGI9F7E
M% ?G]?
M(X"SM8*EPB:F@\1DVQJZ6MB`$@@H80-*(*`TFP@:$L'0I0.U8]@N-]#FEDT$
M"XG@9HW@:QZIXLV%M+3L>GI(#UEU@2\8K802$_#SD`#0]"RZ6DA/1V;G@[2T[.UXZ%V/!L2
M'D*"+ATT6K`S$$:@L/$I$)_"QJ=@?+)[96"S#%O'!D&PO
M=V]R:V)O;VLN>&ULE)A= [!RZ_OZU7K9 \6"<39E;+,
M\\U%NYW-EN$ZR+XEFS"F*XLD70 ES.]ND83#/EF&8KU=MK=.QVNL@BI5*
MX2+]C$:R6$2SZQU=:5_O@YRDK7FX"+:KW*?P
M=NJ4+\W0-*OX9Y&*ARA\S3X6%6;K[3&*Y\EK\5=*[?O>TLF!U_+28S3/EW2]
MT^GL?[L+H^=EOON1Y-N@7V:0[E-^MN(RO%U&!(OG@L=YE+\+.ZZR'R6TA476
M;8I,55KI141?4GNN%HZC2G_L>..A/6`^'X@>&S*GSX5WQ[GO@80&$MH7),0D
M`!4=5,I 8WC-0.:O[XC!_ZO+BWKVI9SO/B]&]+_C/_AUS;C&EUCFL/*^OO+$=HL)F0T&P#&S?'CMPUS-B?']7
MM5-?[/$)[62/NT+KJ`8IC$9C1WC^N'\O)IC)LP-,)4Y_,&=*X18J.BWD-]QU
MB=B_0N@/LJH>A74Z]&WG5K!;EY>0E?G\,;8='W605E7"=;\7%%&/$E3/"E*J
M2IB.*)H;UJ>-+1RA;_;0]G$OSQ!/5>)SQ/IWA`+EHT"!_S^U)T6UH/M(IBJA
M62SQGX3M/'#/+Y:60FSP4-0_RB":JL3F@%,D1=]P[L5PS`ZX0!I5&<>QSSTQ
M84^L-^3ES2=4\H4??7(-/4`V50E.CS]PMVQ:0YOUZFGL(IS4C6O-;S#EXL8=
MCX3+AV4#G##W8!NZ"*4F0?G(7+KW1TD1F.-;EXW*>!XAB"Y"J4E0NMRWW0K%
M"75@7(@4:A*%13G9Y?Y538$*M$";4[ER;#!=Q%&3 KUT07D:Q&*'9+VZ%U7/CLYZ'K2*`F$>A->Q[!
M7)!#)-#`P.0A@IJ,8&-CQ5G1108UB-+0A3!AQ#"JTOP-GM$T7P(( `82#(9M10UC^L#(439D%`NSJ>GY_6!$*)L2"@?&]@?.8(4&8@R
M&;7(CH_NG1+J(,J&A')5Z\61YN\(+R?X,1VDVI"H/M4S!F$>1/0$M$?(0*C)
MJ,75>")`A`QDFHR:3OU(L(N(."27T!]$VI"0=AH/"`EC82:$.$FU*1#&G!:F$@T&36'FH6PGYF(-!E?$L)^9B+39'Q)
M"/N9B5"341.J'8AV2:X8"C#7"+4I0=UX/D*H382:C)H_I^=@/UEOT!^$VI2@
M/JW#Z`$>=9!I4V:Z?'Z23UM5HD#'0J;)J,5U 7IJ,XHX$HNR/M2JO57IX);MMHC+&`3&;^?JNI-GTA< EIEOMOCYI_O7MOO:'X08/+!PZC?^81C.=T'05P?1E/VZ/8L3W-FU75,.56US!A//];$>?HQ&?:^I[K[L3VU7/A_AW-])7%87V^/%S'Q3
M5UW;M[MA#>8")#H_,P]X`)8>[K O$;N-_)G=%1/W@X7YTT#^U>.V-
M_[W^T+[^TM7;W^J3`&]#G&0$GMOVJX1^V #B8/?TT1N"/SMN*7?ER'/YL
M7W\5]?XP0+@3.)$\V-WVQZ/H*_`HF%G31%JJVB,0@-]>4\O4`(^4W\>_K_5V
M.&S\*%TG+(P(P+UGT0]/M33I>]5+/[3-OP@BRA0:H =[
M+(?RX;YK7SU(&MBR/Y 2SM++QN>_!(7H(S[S"(WA,03V"\>?Z6F+%&3N[=Z08(=4.IE%;R`D&4DE-.. !,H<90HP$,A8LE\A&9)3Y]1J2
M8, @2&J=QY*1V80)B$B6ICK9%##3C=F(2;!/+G.S-$:*()=`F794Q
M`7%&0ET:%B\"/>)V8B/:8>9D;ZXP2"WF61QIEV#EV8B4I$S;L,E)J;PYG`2%
MU12$S/%*KC!(+@J31+M%<4,C"$@SR4W;L,E)/;V='*JO*9-&6:,P$,08:6ZN
MV)M+!34VE_TL!MVXGO`$==?RD)/0N1@Z.E%8$!;'--+9:;-T]%RR
M3"'A/F`Y%_;,"5-.$(,L,\8CDN@<4I$T(3$)TY3KL]HTI>`N=R;*M.5,)]-S
M^>X$E:R<25B:,@=2*$CL]"B;X"*E)W.ISYP0Y@JC_)=P(X+*>Z;6\S!YKP@6
M*3U!V;9 3LP#*L*->6>0#Q9
M,E A&]*&\4?F4W4.Y?L'#."J,8DKB.(F=.BEL2`21CH@V8_-\HUG M+`P!53P1@SS!3U1[:@04%`%7U8TZ7>)Z=QC1COMT?2E:IO2O2$B(48**&$*N
M$W/ZP@?$YOV`.V*?RZ]@B+V[JZ)D-0M*0_I.OZ)..Y!M]89XHJ)#0*;O):[K
M7CD.,69Y&BMV4BU2?CI7?NYD=*XP[SC'%/T589FAS3:O1:)/YZ+/=3=13C$%
M?<5"MPH*9415*XM"1G3@;7*+%)_.%9^$KN0KT$74LB2+F!/6PL90QM,D?>^#
M0":2*6K7DWY$V]4(Y>9\1"D0?H:O2)+P)$J \`46)<3X%D*F.`7$*5DCNKTHQ/'8>U7[(B=\%#PPK4[3Q\_C
M\-%9SV$J.8[P@ND`7/Y5[\7G;[^M1[1[$#D^&:@<1U.%;$BZ$]C[.YYW:`
M<>#X[P'&OP(F6N$:P+NV'2X7 &ULG%=1
MCZHX%'[?9/\#X?T"14$QZLT(S.Y-[B:;S=[=9\2J9(`2BN/,O]]S6L"VSE5G
M?5`Y?/WXOM-#3[O\^E:5UBMM>LORS-K7_B1TLX"AIJO[&/7-0O7Y?F15AEW6$-KN+-G;95U
M7-ZT--N)057I^IX7NE56U+9D6+2/M.DK2TS#K0SX]%
MPP>V*G^$KLK:EU/S)6=5`Q3;HBRZ=T%J6U6^^':H69MM2_#]1J99/G"+BROZ
MJLA;QMF^ KDKP`&FW6KI?F4_D45*`MM=+T6"_BGHF2O_
M+7YDY]_:8O>]J"ED&^8)9V#+V`M"O^TP!(/=J]'/8@;^;*T=W6>GLON+G7^G
MQ>'8P70'X`B-+7;O">4Y9!1H'%_(R%D)`N#;J@HL# @$
M,V]"`&YM*>^>"Z2TK?S$.U;]*T$$18TD?D\"OST)"9RI'\SFGV&9]"SPW('%
M=_QY0(+POA97^A)I2K(N6R];=K:@]D`Y;S*L9+(`9LS/!+(LW8P9^UG"P"22
M/"'+RHYL"X9SF.77=1@%2_<59B;O,1N)@>\1$P0S'1-?\_@Z(AD0F%]\=#K0
M8A6`I]$8)%LU]O&$#_H1C/H'UHT,J&+#*-2EQ->8B8Y(/D!X.B2]AH31)2N:
M(R@`U=$P5;>=X2"84B7K8337-6PD9CJZC\U`8@92):!IG/X?C3AH94,FQLH(
MH\C0*#%S45L1O#H3(Y'Q/4"B`HS!J;PG,J#9@3="3?GM5"-8MS'SC`=M)"80
M-B:^%Q"C9.)[@$0"IH+!8$^'>^:[$'[&!H)-&\28#8F1-D(O\,FE9,5;&=\#
M)!+PL8WAGFEC]AD;"#9M&(O)1F*4PCRRDQ
MBD8SD)B!5`EH&F%]5C7>UH9@,W]&L6XD1I8!FJ@$773%_;!+)+F*I'U$^O6)-DVZ &2-`MQ4KW$\M=TH]1%2L873'VFL<5
MR\ZD*S;[-Y&@6XJ5!M $3'#M
M,,M":6:]9#.")P>D423+@X# 0)Q]W/D8\
M)@O8:V('&F_`N:#)#O2/K#T4-;=*N@=*SYF!B%:>+.1%QQJQK]ZR#DX$XN\1
M3H`4=JN>`^`]8]UP@0\8SY3K_P```/__`P!02P,$%``&``@````A`)T)3EH)
M!```)0X``!D```!X;"]W;W)K &ULE%==;Z,Z$'U?
MZ?X'Q/L")@'2*,FJ8/7N2KO2U=7]>";@)*B`(TR:]M_O#.;#=G8;VH<0IL>'
M,V?&@[/Y\EJ5U@MK1,'KK4T +:I*U_>\T*W2HK8EP[J9P\$/AR)CE&>7BM6M)&E8F;:@7YR*LQC8JFP.
M794VSY?SYXQ79Z#8%V71OG6DME5EZV_'FC?IOH2\7\DRS0;N[N:&OBJRA@M^
M:!V@ M_4C6E(2VN]MT!OU7L*M0OEOBQ*]_
M-D7^O:@9N`UUP@KL.7]&Z+<<0[#8O5G]U%7@K\;*V2&]E.W?_/J5%<=3"^4.
M("-,;)V_428RBWR]K2U%Z$31-Z"`-S:
M,]$^%4AI6]E%M+SZ7X)(3R5)_)X$KCT)"9VE'T2KC[`L>A:X#BS!QUF6/0M<
M!Q;?\57!9>C+Z_CO;P6\D
M>426K?U@6^"H@%YYV47$V[@O4-^LQ\02`Y\CQM<1R2TB"%8ZA@X8;!U(8 LN&>0B&.5BUZ#^6`94;0O]N =!9G4C`I)4J
M`4T:[-+YTA!L2C-*&$L,/$Z1O]2=3`;,T!E4"6CJPH^H0["I+M"?'$M,T!E'
MO!4)E@8BN8N@*B*(@F@QF:^)CW3QN.D7,*#?WS2XR$PB-)*0&)G$DO@+S]B^
MR3T`E8!E9\-OU.,;7AE9[ZM&L*DZ,E1+S-22B1F@2D`S$B;>?"D(OK>3)4:1
M8@:H$M"D$"C@?"T=VO3%*%;7$7!5!"YEWO`))>J$5T>#N[952-RS.NC
MYL$H6P^:GI[<1*@:T?7@N)ZO1P[W]Z F67&
MO(B)!,GR^<3WS&&=W$70'M'EI.O%L:WHG3=#B!SVNFYSB/0@ \+O"0
M8?0C'5>:IP,\.)IJP[L3KUME;!+S?1;W(.DRO.[@3^_3I$=,?4'5B.XJ3O"/
MNRKGONHJ\6Y [Q&@%%^>UN4!LF+-D26L+(65\0N>
MQ`E,[3$Z_DIX]/% P`2STG@A(U\I@O;UI^[HZG
M>]["\;S[>H*?8PS.:YX#X`/G[7"##QA_X.U^`@``__\#`%!+`P04``8`"```
M`"$`B(M3]7$"``!I!@``&0```'AL+W=O =>P-/[HZS1GFLC5)/C)(HQX@U3A6@V.?[U MXV=N\/WL\Z?I0>FMJ3BW"!@:D^/*VG9"B&$5E]1$JN4-K)1*2VIAJ#?$M)K3
MP@?)FJ1QG!%)18,#PT1?PZ'*4C"^5&PG>6,#B>8UM:#?5*(U+VR274,GJ=[N
MVANF9`L4:U$+^^Q),9)L\KAIE*;K&GP?DR%E+]Q^"T$O/
M=^2.`--L6@APX,J.-"]S_)!,%ADFLZFOSV_!#Z;SC4RE#E^T*+Z)AD.QH4VN
M`6NEM@[Z6+@I""87T2O?@.\:%;RDN]K^4(>O7&PJ"]T>@2'G:U(\+[EA4%"@
MB=*18V*J!@'P1%*XG0$%H4?_/HC"5CD>9-%H'`\2@*,U-W8E'"5&;&>LDG\"
M*#E1!9+T1#(`]:?U-$IO1\DH>Y^%!$7>X)):.IMJ=4"P:2"G::G;@LD$F)VS
M`=3G;6=@R<4\N"`?"F@#W=C/QFDR)7LH(3MAYI>801^Q>`,1GR$$])U%@O6N
MR/^+ >=M=[LH8?D>7`?5GC]+6N@.D4I#/1RPS[]?J"./![K0B83N;.
M1"]S]I',#MSW?-&*`/EW*WKK;[0BW!;A,+5TPY^HWHC&H)J7T/\X&H,1'>Z*
M,+"J]8=FK2R<S+P-U&YY_$["\```#__P,`4$L#!!0`
M!@`(````(0!;?NLIDPL``'(_```9````>&PO=V]R:W-H965T 5IN]LL#_;/W?-D_[YKEX]=T.9UDDZG
ML\EFN7X;^Q'N=]>,L7UZ6J_:9KOZOFG?#GZ07?NZ/-CWOW]9O^^/HVU6UPRW
M6>Z^?7__;;7=O-LAOJY?UX>_ND''H\WJWCR_;7?+KZ\V[S^3?+DZCMW]`'\9?DWA2+\>3SIZY`
M_UVW/_?D_Z/]R_:GVJT?_UB_M;;:=I[BQ
M?5I^?SW\:_M3M^OGEX.=[L)FY!*[?_RK:? /AY6& Z* '[>9_7I2$H?P@
M:1C$_@Z#)/E=GA;EO!OE3&06(NWO/C*=%TDQ^9`9=`O3GI;C7,Y3?R<=%/VZOOWI>O"Y-Z.YN8VLRO$'_LTV[^:;#O+;I`O;I2'L8VWX7N[0G]\
M+M/\T^2'756KH*E04Q2S6%,?-6X1N8$;#^S/T\!%4<9!XAC4:])8(8^*X["*
M`^V!7W+NP(:`B2W5J5YV_?%ZN5ZXL5YN%%>OXQNJ/+`'/>59ID6<13VD805L
M4#-+V#CB>/#^6%E\)'E4'-^>PF&S:1RC45*F;*;,D&9^&B>JLUW_M,[#>\UQ
M^3FQ7;=1]1:G!` "@X4!XX,MAMY#9;,$V
M!\E#%`U)%FF9+$IVPM`\QA`0EA&(MTB2;LV)I'F((B!)/K%GCF3L#=S[S+HJGSCJY"B*2.Y`&B`@D-$:Z
MF,.Y!&(4$`W$4!)7P%DUT@87,O?&+CZ'LI-4E7@1S9R3!C3B1)S_Y7O!Z<63
MIP*B@1A*XJ2=E;H^:6^\HJ1S]@ZKQ(O\Q!73Q73&SI-UI$C*;,[VC28(^KJ)
M**2?KL_4NZW(T*:P$1!+%C+EI'$?_^QII%\(`H@$HH!H
M((:2.%-GD$BF5RYK;ZNBN<5E3;Q7R)B3)N%$!'+ZN$^*U0`DX:T`@@$H@"HH$82N*,G? 6YUOZ2"BF?NPGC2@$8&4_K;-S@=5,(0&8BB)T_Z0:\L&
M7!N_]5L%49]L#:0!(H!((`J(!F(HB3-V]N?Z1O=FZ4*C I+E\V"J$^S!M(`$8'\JJ SKW=NM\3P<1S11/X@]TWDS"$`J*!&$KB0GS(H^4#'JW@-[F"B!:$
MN[8&-`*(!**`:""&DBCCXB93UJDO73T+(I(ID`:(`"*!*"`:B*$DSO1#/JP8
M\&%PK@XBFC'X,-`((!*(`J*!F$#".7\Q2V;9M/^Z8%P#9YJ(7SF_QQ7>8L6-
MSN_T!!'-W8?UI`&-`"*!*"`:B*$DSI0YLPN9>FMU_KQ5>%&?5PVD`2*`2"`*
MB`9B*(DSO Y[V+(C;$+N%40T0J`&P.-`"*!J$!"MR;39,J_PJ U9XYV6W
MR.,772M$-:(&D4`D$2E$&I&)4)P?,V5NBMTW[VY\I*L8_0XO"\[O*^.?Y38/V>Z:7?/;=V^ONY'J^UW]YBPVYE/U#_"7!5S
M^PSSW.T9\,KB^'0S>\4^]OPE'8I([NON04ZF%\F]?>X3CR#2>_O`(_(OQ M>3;PBFUC^TKI7IF'Y?/K?_6.Z>UV_[T6O[9%.=WKD'?W?^F6G_QV'[
MWCUU^W5[L,\Z=_]]L&PO=V]R:W-H965T :_X!X/X#O.$IRU*ZJGCG2&6DTFLLS39P$=R6%6L7?;VAPWX_O>?V[?)]W9_V'2[AVDR6TPG[6[=
M/6UV+P_3__S[\V_+Z>1P7.V>5F_=KGV8_FH/T]\?__J7^Q_=_NOAM6V/$SO#
M[O`P?3T>W^_F\\/ZM=VN#K/NO=W91YZ[_79UM'_N7^:']WV[>NH';=_FZ6)1
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ML"NR^MG__V/S='Q]F&;EK*@666+MDR_MX?AYXZ:<3M;?#L=N^S]O2F`J/TD*
MD]C_ATFRBP/LH_VSVO]AP'*6IT6U[)_UPC/E,-!F&YXI"7'EP+DOMU\]O3JN
M'N_WW8^)W25M08?WE=O!DSL[F5NVS"Z^G^&TD!^MHUU`-\DG-\O#M)Y.[/"#
MW?C?'ZNBO)]_MQML#9Y&>E+J4(/#;1TWK?:"7V,G&"3,;0&G*NR"\RK PNB+/U#5>YYOJ@YX:8;MS#U"["
M:86J(I3O8WI/T>])2596>;Y@E2AO25(;+TR4);1>329:E$66EVPB0RQI7:5E
MF9]F(17;TGC%KE XSWH&Q<
MT%PP2"#9JC'9G)FMF]A-O,?O)NDRJ>J"'U*\(Z377#!((&'="P-T8+R\D,[,
MPRY/.Y'?I[VGZO?I=)8NTGH1?M@>H;P9Y>:"00+);0_"\;F=F>;.\H+E]IZR
MSYVG61V:PQ]!_.,H*AK`$[TW)!Y3Y,@DCL1@P@G]L*!HX3%8H0D=5>(3>@9=/@@GWN3;RQXZE_S0
MJ)-'S<6&'!@/R0H!GMH8`)8A(_:)KH1BLT+R.
M$?%Y/5%PWC/]Y4T7^@MQ"0)SQ21((8'3F]C5C^+L8AN^`5/8\$HH6B@&*S3I
M*':E,>P"$TXHV"4\!BLTH=V0\1L_=6ZVAJ*_P`0O#>NT%NT%CE"#%HK!"DT\
MBEWN'$4DYNT%IJ&]TK*R5Y!./_SU(;AQ>O\D03'80]./@ED:`S,P?=QL8`CQ
MM%`,5FC@FV#F3D7YLN?LJ-6`*>120M%",5BA24?!+(V!&9AP0@$SX3%8H0D9
MS*+/V],8KH$)N%8E%3NS5V#@Y^WL&*C!%HHV6*$%,=3%%Q1#O912+UTDK'$5
M.*Y6Q/%H8&!?(ZW(00?!,+XB3ZO+7$R]Z4*K>L/5@KP-;R*DD(+<51)>T/4K
M)_TH=J#/V>HW8`HIE%"T4`Q6:-)1L,QB8`DFG%#`4G@,5FC"4;#,8F`))CC1
M2S-^KJK`$$K00C%8H8%'L3*+82683JR430D.G%CP$7MHXE%\S&+X"*:/FPX,
M.+"?-R@&>VC@F_B8G>,CNSK:@"FD4$+10C%8H4E'\3&+X2.8`;
M]M#$CA.(;U<2>ZI 0R_P(03"GX)C\$*33B*7WD,O\`$_67?3.-ON2EPA!JT4`Q6
M:.)1`,MC``:F`6!)O 0S,P# P"$TXH
MV"4\!BLT(6-7]"7G,@9C8!H:K &\/C5>@0D8>"9W?Q62%8QD`33 :5OS\&1K7I3>5/8/910M%`,5N@N-`J.50P I:53:KGR<4H6%04`Q6:.11>*QB\`@FWXSIK+"O8/GAA?-/
MPQBE6
M(BYCB`BF$Q&K#+](Y3@!]]7J!!]A8%\OK>Y6/BYC^`BFX25L)=ZX`,/5@@0?
M8>"9@D;Q<7F.C^SMH`9,86=10M%",5BA2SZ*C\L8/H())Q1\%!Z#%9J0\3'Z
MRL(R!I5@NMC%?IZKNP4GJH&YS^P6C)_Q)<6@=.E-L5WLW5>K\[:P40T\S9GJ
M&&OCJXO![M*;+G2Q-UPMR-MP04@A>V`]BL6]^V%JWS< /T9^P[SV?+6\^_@[RPV8W/N,)U=6 -S9/J;QABE]C>,21S72T>R8=[B;!'[$U&
M/J7G1B1WJK^+!/,WZ9TZY_]4+^PS]$<4/J)V]S$Y.U>=VD?ZV>:G0?8.(^^K
ME_8?J_W+9G>8O+7/MMC%S)T^[_T]2OP?Q^Z]OQ7'E^YH[RW2__IJ[R73VGM>
M+&;6_-QUQ^$/MZ2GN],\_A\``/__`P!02P,$%``&``@````A`$^S(IL4!@``
MPAD``!D```!X;"]W;W)K &ULE)E=;^HX$(;O5]K_
M$.6^)':^`)4>%?(I[4JKU7Y \^]W'`>P9]@"O6C+P^O!\WKL
M3-WG;S_JO?&];+NJ.2Q,-K%-HSP4S;HZ;!?FWW_%3U/3Z/K\L,[WS:% >AFD+?=Y#_/O=M6Q
M.T6KBWO"U7G[_G%\*IKZ""'>JGW5_QR"FD9=S+/MH6GSMSWD_8.Y>7&*/;P@
MX>NJ:)NNV?03"&?)B=*<9];,@D@OS^L*,A"V&VVY69BO;)YQ9EHOSX-!_U3E
M9Z?\;G2[YC-IJ_5OU:$$MV&=Q`J\- TPD!MO9=?'E0AI&L5'US?UOU(T9'0.PL151%B:,A^$=%-SWER"P
MGZWO4"3%J%E*#7P_:SQOJFM65.-[*$YX1I\N*Z(3PI1?2*%Y!3V
M!%(,,@58X-[90J@TU/64H`L\
M"BL,0@PB#&(,$@Q2##(%:/G!&:56D-B$#IRZ7U>2&+0PP46E4HP
ME5N4,3_P]!&A*F`^Y[:/O(M4A6.[?.KZ>HQ84P3!S..H6!-5X=N CYLI!F$SD35+J5',E,`;S'SBMNLQM`]"3>%[+I_9
M:(DB'#76QL!9P!D^2A,\)L4@4X!F#CS'L#GBN/^ZTL0@;`Y:\Z74*.9@$&(0
M81!+,/K)9KXS E&*0*4!+'1Z^CZ +KC2'$N@$.7I.E
MU%SR6V$08A!)(#V# 6Y.#0KL:I@,QZP68"J,L%14PPR!6@6,'CTW._!
MH-9-"/"N78XBQ05"0D(B0F)"$D)20C*5Z)F*EDXI^Z]7F\D&$![BER J>ASE$SO
M+&O9'>EKB_JRI;BP@,-=+6M,PE$CBP]Z5-]'C6Y$HL2$)(2DA&0JT1T0[MDWPPHOF=))C6N.24@T$2$Q(0DA*2&92O2,10^C9'QC'\N.YT9U
M*VW1F"DF(&ULE%5=;YLP%'V?M/]@^;U\A4"(0JHF
M7;=*G31-^WAVC`&K@)'M-.V_WS4.+)"N2_-`L#D^]YQ[+Y?5]7-=H2 LJ6K*:*$>TK($GN9`UT;"4A:M:R4C6':HK-_"\R*T);[!E6,I+.$2>
M$]MS=XHR^YE0*)7+M`)UKA9Y[3MS$!:;U*N/@P*0=29:G^,9?
M;F/LKE==?GYQ=E`G]TB5XO!9\NR!-PR2#64R!=@)\6B@]YG9@L/NV>F[K@#?
M),I83O:5_BX.7Q@O2@W5GH,AXVN9O=PR12&A0.,$
MN_\#SW29XEGDS&-OY@,5I'BV3E/D%.Z1&S.<GQ(#'PJ+$'P?>6(P?!)VVV`F3
MT2_^=#6MWWM.C+1'[]%NP%/MDP[>6$ROW7.\*S.OY0S&UMNM
M;PY-%4YRM;$8*.[0&E$R%=ECAO?0#D8[-VHF"[9E5:40%7LS]$RAAMUA'M\$
MIJDG^QN8T]U4 M=D+#A.QN
M2_@@,GC%/0?`N1"Z7QCAPR=V_0&ULG)G;CN(X$(;O
M5]IW0+D?P(&$@YH>=0[VCK0KK59[N$Y#:*(!@I+T],S;;SEV2+F*`;KG8F@^
M?E?\IQQ7)7GX_/VP'WS+J[HHCRM/#,?>(#^NRTUQ?%EY__PM/\V]0=UDQTVV
M+X_YRON1U][GQU]_>7@KJZ_U+L^;`40XUBMOUS2GY6A4KW?Y(:N'Y2D_PB_;
MLCID#7RM7D;UJ 3'Q@2I
M\GW6P/SK77&JNVB']3WA#EGU]?7T:5T>3A#BN=@7S8\VJ# SV"PM_*-9569?;9@CA1F:BW/-BM!A!I,>'30$.]&D?5/EVY3V)
MI9J,O='C0WN"_BWRMQK]/:AWY9NJBLWOQ3&'LPUYTAEX+LNO6OIEHQ$,'K'1
MLLW`G]5@DV^SUWWS5_GV6UZ\[!I(=P".M+'EYD>2UVLXHQ!FZ` =W(0H?T!NO7NBD/_QF1L*%,
M$-\&F_^T)\'(@C?$65JH\!G%T4,YT$P#>>S^^`#_+/R1>!WG245;>PAM`:FM8M-\>PYG_,/H&"VUM-1'7$$7.Y!JX4ER-NJ019XUS9N"ZPV=&+PK8 X!(Z,1
MOM_.";9U]_?8_-Z[3BA(*9`T9+_,VF6@T`#'(VR/U.,4M- Y'L,9V20B
MHPE:AY/VM!.3MP2)$?1G(:5`4J`0LLF)%+(3(:X\P/`W].MO88"\14^"&)
MD!@!6ID42`H4`HX[`9O\_?9:M>LOG-/=Q8KZZ<6,)(RDC$A&%":N"UWPT?*[
M;ZL4IDV`8H(J`%EED15A-V983Q*F21F1C"A,7#>Z;B,WUR\F8:K\]3IF1?9R
M$HL%JT*QE6!;)G)/4J:1C"CG4%.WWKDV=15'-N],FJG]V"XO6,)(R(AE1F+CN=%5_OSO3"V!WX9Q ER_GYSI@EPS,UH1=-WGK"%FHG/IY.`;"^Q%>#,F2$]29E&,J(P< 4KM7(E-X7;_?$PE1X;"ZDG45D1?V\8D821E)&
M)",*$\>-3QJ,^W;Y=M2M6TLK0FX821A)&9&,*$QN)A9$,J(P< 7\)(RHAD1&'BNB$-PYT;-V\<>'ONTS8A9B1A
M)&5$,J(LZ1LM5+Y==[IFOS]7IM*[&SE]\N33=B!F)&$D940RHC!QW5QH&>Y8
M>:9EN+'RC*A?9[%/2?/W@G/!(+.'%">>)6,*[$>"C\P!X3W?*7O(_LNJE.-:#?;Z%0XV'^F58
M9=[TF2]->6I?##V7#;RA:__ ,-XN0Q0E84#;DE>L
M/2[#[_\^?)J&@9"DK4C-6[H,7ZD(/Z]^_VUQYOVC.%$J`U!HQ3(\2=G-XUB4
M)]H0$?&.MO#FP/N&2+CMC['H>DHJ36KJ>)(D.&X(:T.C,._OT>"'`ROIEI=/
M#6VE$>EI323X%R?6B8M:4]XCUY#^\:G[5/*F`XD]JYE\U:)AT)3SK\>6]V1?
M0^X7E)'RHJUO1O(-*WLN^$%&(!]/2P#+^@^0ZA
M,%XM=(%^,'H6UN]`G/CYCYY5WUA+H=K0)]6!/>>/"OJU4H^`'(_8#[H#?_=!
M10_DJ9;_\/.?E!U/$MJ=0R(5;%Z];JDHH:(@$TURI53R&@S`WZ!A:C2@(N1%
M7\^LDJ=EF.(H+Y(4`3S84R$?F)(,@_))2-[\9T`ZT55D,HC`=1!!DV@RS5&.
M/Z"2#BIPO:B@:)KG&9X6]WO)!A5@7%3N]Q*;ZNAB;XDDJT7/SP%,,.07'5'?
M`YJ#LJIR"KUZO\I07L7YHDB:"F@!H_&\PGBVB)^AG>6`68\QJ8O8C!$X]U2V
M8TR:N#*[,03C-TP,.:]AH8T?#ZM(4)0PL,(BU\/:8#(]AJI"&__!UG^PLQXX
M'N$?V1YO-T*!ER%(7;VER<3S9C!3W:84QC\M Q,8@W]UN',H&%+WDKJ)Z`
MW2V$$P>FUHYSWWPIDA_+FYZUP>0Z5IZGN1_*O+="V014)/ZH[2R"DP"^"CO!
M[88HL.\\6!BHBP?-F^W/`+N+NMH9["^W^)4XBN3&P857\+7!&,MI,L6%O[YL
M#,(:)(>2892/1LFB."G4V>3#BZTBN2G2!'LC93#O-^7R[CI2YH&)G.4%GGEJ
M.XOAV)_]BGU% 96$PS":H)+2=(I]A:(G45Q4B#8WNPNW/Z@-=KU
MGR:%5_X!-`Q^BA'ROIK-@+`".!R,$M^^S7#]JPW/FJ*?^#?;H[U%9/XW`, .]"_2'UDK@IH>
M8`=+(G4 5&K1G74_[J?P``
M`/__`P!02P,$%``&``@````A`)LTX9$B!```_`X``!@```!X;"]W;W)K U,X;[FE%VJ.+O,!UA+&N+K"8M/KH?F+I?3C__=+B3_H7>,&8..+3TZ-X8Z_:^
M3_,;;C+JD0ZW\$M)^B9C\+6_^K3K<5:(14WMAT&P\9NL:EWIL.^7>)"RK'*<
MDORUP2V3)CVN,P;\]%9U5+DU^1*[)NM?7KM53IH.+"Y57;$/8>HZ3;[_=FU)
MGUUJV/8LO,_NFRGM"2 *:0X9!ALO
M7'.GG-0`!*].4_&C`AG*WN4?5P6['=UHXZVW081`[EPP9\(@W@?/%#HA;LU6C_B$@\N\#ZZ_-\V?)D2
MD>$T8]GIT).[`\<8-DV[C#:Z(3$4R5\2F(ITK
MUJ/"V`,47-_#Y]GE8J@"=(W*[F9T%:DZ2T4LSB?/76('4BU@@$")EX-P\=&%
M38X@6PM$*N!U5.Q,1:(48YFU@$$&G;B 4J)7%MD=K"0CFQ8PV/AU69LQGY]^+K;8K,8\2XG!9G5FHB0CFQ8PV)Y,
MMF7SCR^R&*?&ERTJ)5J+RL!:',A-'$7K(+82FFIK#$8$`WEY`H7:HK,'R*`Q
M4FCU=C)JQASJ$1.0S^[%%49RTNMS!5G->1XT$O#RHTM,,DHF/FDLDF[R\4&]
MG$^.=8//ZLLSDIJ-((OA_M`^@(-@.@"I'C'I^+!>3B='NTX7VA,&J?$_S>70
M:O!DU$SI4ZL@8@)"&1X`Y&KS_(7623\CJ9'C.0S0+'OJ]PE.BYAP?&POSYX<
M\D;V[/'";RUA`_"'XU4MG`$JS02H14Q`/K*7`\H!;P#:LP6IB\!G@$HS`6H1
M$Y#/[>6` <9
M6?0)1T:VHL51%'G3&9!T\GE%WDUWV15_S_IKU5*GQB4 (.G3`QW9?[]5
M%&(U[*HS%XZ4;[\\7=5=-(LO;T5NO I
M;>DZ*;=)KDJYM-^EMK^L_OBT.*OJ11^DK"UP*/72/M3U<>ZZ.CW((M&..LH2
M?MFIJDAJN*SVKCY6,MDV@XK/>*C=+DMEK-)3( W(GW$KDBJE]/Q S<7`OLC22FFUJQVP 9.W/!:;789C`#3+M5R=W2?A+S6$QL=[5H
M$O1?)L^:?;?T09W_K++M]ZR4D&VH$U9@H]0+2K]M,02#WFO_G
M;%L?EO8H=(*)-Q(@MS92U\\96MI6>M*U*OXGD6BMR,1O3>!_:R("9^P'D^E'
M7$:MR_CJXCO^-!!!>)_%I7DU:8J3.EDM*G6V8.T!N3XFN)+%')PQ/R/(,LVF
MR]CO$@:90I,G=%G:,]N"X1JJ_+H*Q7CAOD)ETE:S)@U\=IH@F)B::.CCFXKX
MHL"BPQ2Z>4!N^3Q^7=\++HH1%^N-_&L*CMRC5I&&L_$+.`@8(/6M9_;J_MO'4KXJ`T[!J)NS2(Q#QB\F`_9CP/YHFZN)&GP7(3K-4W)8[:R*T%QP>9H-B4/PY*
MK9R#!M/>(E\+UN];T'XDYAJ3"QLQX[I34&K;=PK*>GO+TX_$>'B$#=\4W>3!
M[LMX'BPH]6R>IV'_$$9CAV>2V?>C]O?K0HQYQ*3$/OQQ2NK>!J7?>_JLX1B/
MF1&^WSP]/: @@3R?40E9[& C-@"YJ=6S.Q1M5PXF^^7J`
M-S@)!T7/`?%.J?IR@3?HW@E7/P$``/__`P!02P,$%``&``@````A`*,K]O.*
M!@``81T``!D```!X;"]W;W)K &ULG%EM;^)(#/Y^
MTOV'*-\7R(10BDI7"YF]6^E..IWNY7,:`D1+"$K2[>Z_/SN>)!X/QTO[@98'
MVWG&X_'C,D\?OQR^EKOLZSQ(,*Q7OK[ICDMQN,ZW6=%4H_*4W:$3[9E
M520-O*UVX_I49 M2&\)5R35U]?3A[0L3A#B)3_DS8\VJ.\5Z>++[EA6R PW1&L"!>VV/R(LSJ%C$*8D8HP4EH>@`"\>D6.
MI0$92;ZWO]_R3;-?^N%L%#U,P@#,O9>L;C[G&-+WTM>Z*8M_R2@PH2B(,D'@
MMPD21*.IBA[F]T0)393I$$6-U#P*HMD=7(!UNR#X?3^7,66G37:5#!L/[ZE.!Y"!80N KZ2NB6A
M,2ZI>]"*`,Y_%D3]@UHR:]=FH-):Q& LPITDJN8V8E=D0U;!0&TBE!%LI[BS@%;@]@E
MW7V&:L"/ZX/-_G+NT5BRE@5#-HRU!&():`98W'#*$&WS^L%#IVL'CVP81PG$
M$M`,L#A".Y8 Q=-$,L$@'Q^03D&3'#J:/"4K8\29DMN`Q(Z-YHC-%)7D
M?J:D/Y=[;T!&`Z^U0:@(@K8;RR)PG#1';.JH)HSZE3(@[;$HA^+IJX`)%*EU
MC[`]"0>E)1B[4HGS8
MU%$T&/4KM4L28U%V:Y?ID*'ZW5M9#!&[.0Y2.P@FB,VTS/Z=GUN4"14=D[%)+LR1IRIHV^.C39(
MH%1;-Y-1-/1HFSD\G5?!C3E&+S%#.#T#GHU&G#DAIF?0_Q_VX!$[3IHC-G6A
M=TC]AJ2?TSTYJRM']WJ$]PXQ+,>]4=\[.&*3%[IW(_DS^J<D\(:,DX+!W@]C7"CG8_Q21Q2+1&+'1G/$9HK2PYK;C65-
M@@6;/S!U!DXE56WM(+:([83%%=[F=*FF3EU#V`3+BH'2M"+AY`Z:2-4WN.
M;>IWZ9\ZIW]RX#1&O&=TBLCV)!3_KL2.F^:(35K(WHT'[XS\.=]3*"EV:X-0
MOM6\'?%EPY-.FH>QJ.-1XZ5R>4AJK46/#N6\88Q8O@W2SQNBN\2.A^:(S?==
MJAB>4<6IK!-CQ'D[JNC8:([83%&8[CZ$( 1QQ";]+LD+STB>TRZ,$'0^VEY2O>
M5N$,VZ/]3=HGA=^T"WP=+."Z`^>6_@.XX#HEN^SWI-KEQ]H[9%L(.1D]0*XK
MNB*C-TUY:J]V7LH&KK;:/_=PE9G!A0F,S[ZW+ X,/Z"]'G_\#``#__P,`
M4$L#!!0`!@`(````(0"=8^GT80,``+8*```9````>&PO=V]R:W-H965T D&)\_K- C(BG-*T+6HJ:9>2-*7(W^_QINA/R66T8TQXXU"HC&ZV;B>^K?,,JJ@:B
M837<60E940V7 ^>VHC=%\F+;[QFD&VH$U9@*<0S2I\*7(+-_LGN1U.!'](KV(IN2_U3
M[+XROMYH*'XMF=*/'"V)EV^5%M5?*PKW5M8DVIL,@7Y_/QI$HR1,TO==?$MD
M`GR@FLZF4NP\Z!IXIFHH]F`X`>=#9):CC?5_H4*,:'*/+AD9$P^B4%"?EUD:
MAU/_!7*:[S7S4TWD*A8'!98"\%I&B+S+>#[K!Q04(PI6`=GF=@&\6[9A[[EG
M%$$K<4@@0UT2S-80NNDR$6X"70 ,^A2UVZRRE#<9\JZ5%9S9XJP)RY@H45F&HZ)+?7D*#8)0G#?MM8
M3:=M.@O.D_%-U/N9O]^XN.F]QK6:#D%GP2&`X7`]`6YR M#?[ +@`+R>PHY-=^*-^KFPHOW(BX(S4P4.
M$]AX5G+\==L\V6."?8M63*[9@I6E\G*QQ2-`!*.H76V/)_<1CO;>^AR/+;CN
MMS?@U-#0-?M.Y9K7RBO9"BR#P2V,.6G/'?9"B\:\NY="PWG!?-W`^9#!"R\8
M@'@EA#Y &ULE)=1CYLX$,??*]UW0+P7
M8@(!HB35)FCO*K525=VUSP2/B>L(F;=E7K.6KMU7*MQ/F[\^
MK"Z,/XD3I=(!AU:LW9.4W=+W17&B32X\UM$6?CDPWN02+OG1%QVG>=D/:FH_
MF,T6?I-7K8L.2S[%@QT.54$S5IP;VDHTX;3.)?"+4]6)JUM33+%K ;^0,"^NWOW%G7U3%9P)=I`>V/D(>C_G
MU$]]K/D$_*GH1VG='G-CE;UZ57ZJ60K:A
M3JH">\:>E/1SJ4(PV+\;_=A7X!MW2GK(S[7\SB[_T.IXDE#N"&:D)K8L7S,J
M"L@HV'A!I)P*5@,`O#M-I98&9"1_Z3\O52E/:W>^\*)X-B5J)9,E.%_S@[.Y9>Q7"8-,*9,'Y;)V4]>!7`BH\O-F$:8K
M_QDJ4PR:+6K@?=1$,U.SN_BG^+
M`9TM,N^[NU?,347VAF* +>&'29[KB%QF#O38=4XEM3*M86]1H
MF!B(>LPH2-+4RG&F"X(XF2>CI9'1Q9^@*K&-&IKIV:)&0\4`H@9!&!%KIV7:
M"`,M-M'47I]#1WU_KZA!-J*U.;:HT1`Q,""2($QB IJ,H\>^V+6HT%#N0:0$#A4#9IK/T:CLO
MX_+%%CB(-)HA@E5,2!A9J ZM):U::M-(*]W>POX[(8,%&D8]J1;##J
M-2:7ZM$:U_NKB6!'?[_U#B*=!X>-D4S7F#RJ+4_GP29NYL?NOP1%P]9+TYB$
M8T_%A\,@T0%QT!L)4[U9`YQ82.SH)JC=,^#4IW;(2+$;(OBH",@,7E;7,!3S
M`,[2F@0SBR=!/.(TE!_ICM:U\`/K[+7H[@3X$ZB1@Q7?J9*KB_NT'
M.!AV^9%^S?FQ:H53TP-8SKP8'@T &Q/ME_?
MJM)XI2TO6!V:9&&;!JUS=BCJ4VC^_=?SE\`T>)?5AZQD-0W-=\K-K[N??]I>
M6?O"SY1V!C#4/#3/7==L+(OG9UIE?,$:6L/(D;55UL%C>[)XT]+LT$^J2LNQ
M;=^JLJ(VD6'3/L+!CL ;;J69MMB_!]QM99OG(W3_,Z*LB;QEGQVX!=!8*G7M>
M6VL+F';;0P$.1-J-EAY#\XEL4N*:UF[;)^B?@EZY]-O@9W;]I2T.OQ4UA6S#
M.HD5V#/V(J#?#B($DZW9[.=^!?YHC0,]9I>R^Y-=?Z7%Z=S! LXPYF?+^?VF'?`N2)\$2
MFFO3@(QRJ)77G>\%6^L5UC,-$ $2(Q12T"09P240@E0(6&)A I8U?JQ-@$,3,C`EV?>U`H@0
M$_0%Y,).=5>>JCY6$`X \'_$CIBDVUFJ:Q`A!B7[+ED&&B!&P%V_
MR3@V;KY4"BCR5S\B7TS2Y6LE%"$&Y:\("BCJ11>B':O?
MW[YBDJ[>UY*/F+OJ8AQ#9TMOY:^UR 9(O!13YV0*LRUYILA$S
ME+EKVT3;^K$,GT3
M$@1A003036E6X@%PLY+,(JD<486+&^OSPO&>4X5K6RB"EE<4`]Y104!\K5+C
M`2`+QRFWB.B;IXI"X=@&8V=6T?9$8UJ6W,C91;2X#EP/4W1JOY\<<8EK\8AL
MH(^"N#4-0%?<9"?Z>]:>BIH;)3T"I;T0K6>+?34^=*SI^\$]ZZ`?[G^>X?\/
MA&PO=V]R:W-H965T Z6[TFJU'\^4.`EJB".@3?OO=\P8L$UNFGO[4,)DYG#.
MS."QL_SR7AVM-U8W)3^M;#)S;8N="KXM3_N5_ 0NW]=YI
MSC7+MUU0=70\UZ5.E9 *Y/);M1P=J6U6Q^+H_\3I_/H+N=Q+D18_=W4S@J[*H
M>U3*2!MJWAM6E[]ATY$0B&()T'@>@7D1J`O`^$J`STZ\^*0A%0\
M_D9D("/A*B,5VC?B`+73"]>>*IG%81C0.+KZ1`<3UN4_S=M\O:SYQ8*FAI0T
MYUR\(F0!D2+Q/I0/GSV4XGN5@!((D$>!LK+GM@7A#;3/VSJ*O:7S!B4OI,\&
M?>#_X$,]7_=)IC@&2MI[B!X0C\X4@P.:!F%015.8Z*@?%"90A+#^<1LTJ"I"
M2@P5?="HU-"9]AX];#:%]=T!5=,%3:;JNOZ&]'41SE!0)>>1-Q]PNP1NT"<8
M)":F(34-F6+0N$$;W\]-.*]L$#[T0Q0;>=J@3]AU%'%IZ`?4H)]\[I*BRZ@P
MTV*\>>11&@Q9T11!Q]RO2#CKBOSYB(O91I^12V(:4M.0H4$F@Y"V>=>Q2;W-$'J3X0+XB"P'B?$W09Y:6F
M(=-`YK%/`C(VH\:?P)A2!=S7[5V4KL2?QT.5L0K2:>293"SIQ)))BTQ`&%./
M>.-HT+F+J64T$(G$WN8[6YY^02 NT4`;Z:1*P[#1DDY\,M6B
M,Q233&%X9P_A_%.+$+ACE\H>0J>15T+0(C/GS>-I" C[%.%,X]=W]@WM@@E-12["Y+&RD4P@+S;!X^-38O2>C5[_S3:>F3#/I
MBL1T,Q3]Q*X>CK*3<>8;;;J13IJBP#6&7C)ZC8KD",;3)1Y25!,JPK,PGL4J
M5N]9PH['QBKXJSCG4MCR#M;A#/[HB5VZ84_$V?R:W5O`.6/J_T@H!-`KWT`1
MX9OHZC=Q_P.`,SP>#N#G?,_^R.M]>6JL(]L!<7 G#_!3"X/3FSL#YQWG;7\#=)WAQYOU_P```/__`P!02P,$%``&``@````A
M`")5'8>A`@``708``!D```!X;"]W;W)K &ULG)5;
M;]HP&(;O)^T_6+YOG`1H`!&J`F*KM$G3M,.U<9S$(HXCVT#[[_?9+BF';NMV
M`[']^LWS'>S,[AYE@_9JBP%XRO%=I*W-IAHWE`+_*86G3FZ2?86.TGU=M?=
M,"4[L-B(1M@G;XJ19-.'JE6:;AJ(^S$94G;T]H,K>RF85D:5-@([$D"O8YZ0
M"0&G^:P0$(%+.]*\S/%],EV.,)G/?'Y^"'XP)\_(U.KP08OBDV@Y)!O*Y`JP
M46KKI`^%FX+-Y&KWVA?@BT8%+^FNL5_5X2,756VAVB,(R,4U+9Y6W#!(*-A$
MJ<=@J@$`^$52N,Z`A-!'_W\0A:US/+B-1ED\2$".-MS8M7"6&+&=L4K^#*+$
M0?4FZ;/)`.B?U],H'8^2T>W?74@@\@&NJ*7SF58'!$T#[S0==2V83,'Y&%G@
MZ&/]7:B`YTSNG4N.)QA!%`;*LY]GX\F,["&G[%FSN-:DYXKE4>%*`7@](T1^
MROAZUH\H3NQ07.H .<1U@?#1]`MPNCM:\!]#7;A9MD=-5>5%VI56JYG=9QJ7;=1`64"W
MN__]9A()%1FG%L.\V.VO3P;$R4N=XO+P^\_-NO>CWNU7S?:QG]P-^[UZNVR>
M5]O7Q_Z??ZC?IOW>_K#8/B_6S;9^[/^J]_W?G_[^MX>/9O=M_U;7AYZKL-T_
M]M\.A_?[P6"_?*LWB_U=\UYOW?^\-+O-XN#^W+T.]N^[>O%\'+19#]+AO%P3W__=OJ?7^JMEE>4VZSV'W[
M_O[;LMF\NQ)?5^O5X=>Q:+^W6=[;UVVS6WQ=N[Y_)OEB>:I]_`/*;U;+7;-O
M7@YWKMR`GBCV/!O,!J[2T\/SRG7@;>_MZI?'_I?DWN:3_N#IX6C0?U;UQY[]
MN[=_:S[T;O7\C]6V=FZ[>?(S\+5IOGFI??;(#1[`:'6L_UR^+[^O#O
MYL/4J]>W@YOND>O(-W;__*NL]TOGJ"MSEXY\I66S=D_`_>QM5GYI.$<6/X^_
M/U;/A[?'?C:^&TV&6>+DO:_U_J!6OF2_M_R^/S2;_Y(H":6H2!J*N-^A2)+?
MI=-1,AK?4"4+5=SO4Y7T]BIYJ.*>?5LE3T>3Z2T=C4,5]_M4971W *P>'K8-1\]MYO<7.S?%WYO)O>N\FG&:7[.:^#_+0$W][[(
M%U_EL>_&N]G=NW7[XVDRRQX&/]Q:6P;-'#5IK"A."K^P?-GR!-JRH]$D'E2=
M-*=!BH#[>7XNH]$X'J1/FM,@(X%E8."L.OOE5B7WJWMGG&SQ8F_+Z6'F!/AS
M$RX5'8IA_.1+E(S&0E.A9C++XSJJ2S.*-;I+(\PT71HQ2[9+,ST_5N2PV['7
M.^S%[I1ADSV9S G]]QF3NI
M+Z\D/^BQ[UP\+^KI4,SYG#33X_9+TFPH!04)6B-*"2H)E`1:`B.!92#JVYVA
MM_?M!\F^$S&_I!D=^TYGTW0B%G%!`M:W!)4$2@(M@9'`,A#U[4[]V_OV@V3?
MXKB *N4)&B=J210$F@)C`26@X$91.VK9]4"N
MAK/H%#]*(!40!40#,4`L)[$)/DBQ[7!Y%204N_AU;C06? AV+RA2<2^FPS9%4MI+2$1>
MS"8C>1]2!$';;@FD`J*`:"`&B.4D-L"GI-L-H&P5&R`.P7E"(C(@SS$&!@$W
M@(:TI`*-`J*!&""6D]@`'Y=N-X!"5F1`(M;SW+]BX:XEP8!1AP$LJH4;34FJ
M4*2U1`'10`P0RTEL@,]-MQM`:2LV0`;BA$3A.$@Z#&"9+1@@216*ZT'$.Z5A+2E!4P%10#00`\1R
M$G?JUBU?Z]?EN=2/BN=VFHBX-@\B6O.)7XGB&E`"K>D`HT"HH$8():3
MV`$?M=ANO](!"FC1KA^"`R0*#HS37.:\(B5%VV\)I`*B@&@@!HCE)'9`Q+A/
M]G57?),WN2F/;^YM!FE-$02\<8AOH%%`-!`#Q'(2-^X#$YOZ3QJG>,6G'&_K
M_)L[Y]C6BZXV@",6-F":P`DC$
M=G_\*DZ1RB!6`JF`*"`:B`%B.8D;%_'MRLW?%>/@TD:B"P;(G%>FDE1`%!`-
MQ`"QG,0&B%1WI0$4T^(5(%_A2$ETP0`(>V%(NSDJ(`J(!F*`6$YB`WR$8DO_
M2@,H>,4&R)OXE$1D@/L0`%[_9'PKPQ!N@-0HT&@@!HCE)#+`OZQ[NP''43(!
MR)OX("(#_%LY,@`$0=MN":0"HH!H(`:(Y20V0(2]ZU9`1NDM6@&IZ&\>1&1`
M5P(*`FZ`3(45:!00#<0`L9S$!K@F_L(*\*/$"DCE37Q&HK:_`D@)I`*B@&@@
M!HCE).Y89+[+%_Z,0IK[>>%>-HAXIY#M0%,!44`T$`/$ E.VRSJR72I?
MGP@BWJF,;B5H*B`*B`9B@-A`:$O%R3)N_*9LEV&VFPRA<1+QQB4I0Z%64P%1
M0#00`\1R$G=Z4WC+*'9]LIAE-BO"L+:O$D@%1`'10`P0RTG Q8IC,Y/HH@Z+UJ`*B@&@@!HCE)'9$Q+=/#K*.
MV";?99EG,I450$H@%1`%1`,Q0"PG R3UC&"388R@^8R3Q5`2B!5(-3ZI..>7,$8#<0`L9S$G?^E#)9W93!Y)QY$
M?/)E*BM!4P5"#HPZ'9!5-%0Q0"PGL0,^+K$-?ET,SREDN:=RSF93>& 8GPK*8AXIY#-0%,!44`T$`/$ E,VRREV\<7<<99#
M-@O#VMY+(!40%4@XW?'F7,,0`\1R$C O=9%O5[O>\OFN_^N0>8^
MM'*FY^]!?$G]YWD%GR?WQ?'+!(*7R;W[G+C3#\[_X;ZV\+YXK?^YV+VNMOO>
MNGYQ#S6\F[BEOZ,O/M`?A^;]^"'YK\W!?6'A^,\W]P65VGT\?7CGQ"]- &PO=V]R:W-H965T E6:9.F:1_/)C%@-8DCVY3VW^\ZAM1V6*%]H.3D^.2 4\8\8)
M;5(W]`+7P4U!2])L4_?WKX>;Q'6X0$V)*MK@U'W%W+U=?OZT.%#VQ'<8"P<4
M&IZZ.R':N>_S8H=KQ#W:X@;N;"BKD8!+MO5YRS`JNT5UY4=!,/%K1!I7* AZR\778'^$'S@VG>'[^CA"R/E-])@J#;LD]R!-:5/DOI82@@6
M^X/5#]T._&!.B3=H7XF?]/`5D^U.P';'D$@&FY>O&>8%5!1DO"B62@6MP`!\
M.C61K0$502_=_P,IQ2YU1Q,OG@:C$.C.&G/Q0*2DZQ1[+FC]5Y&Z1+U(=!09
M@?OC_=@;1_$T^8C*^*@"SSVI1%Z4Q&$\N>S%5[FZ,F5(H.6"T8,#O0?.>8MD
M)X=S4#[51Z7I*_:_@D&EI,B=5$G=F>M`+3CL\O,R2>*%_PP[4QPY]XH#GSTG
MCJ K3S6WY*(,DRP4GU7@&ZW22QK*S.
M B=)TNMVI;M7G'&?>F4#F0WD&F!X
M@_;4O R))9I9'Q=$\VD"F@&G7=W"6FW]A?F-U8GX]
MWT@(/X^/)Y2+K(2SM]U5NZ`X6D(;R&P@UP##X\3T^'[U)?E2ARB.YLT&,AO(
M-;G*YR(PP"2.K
MR14G[EIX&HPCZXQ8J?N:91O(-#17**DL_J9)1U-12IMWV-V1:O`-+`V\*YP]3TY2Z$+3M9HDU%3`%=5]W,/5B>#\'
M'I`WE(K3A9S7^CEZ^0\``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL`
M`!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5
M_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU
M>[6 6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0
MVJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG
M9()]B.(NCD:"8LT`;Q) __/QY.1`R:"'1BR^?_/;LR8NO/OW]N\ *1R5D1SBB!4-
M?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC
M>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG
M%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>]
M;=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM
M&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O -29#`P<7""P
M68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/
MC^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9
MF]B (K5"MQ:FNP;\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/9
M9/G"FZU,,3V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2C
MLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!
MGS&5 LY;6TSY1;G-.F*EV(&9\ F_W4`BA;JI)6@8,[F3\N>]I
M!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O] 2!=(.SB"QLD.VF#2I*QIT]9)6RW;
MK"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<
M8[Z4%3]F\=%]0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+
M`P04``8`"````"$`!F2NO9H.``#,EP``#0```'AL+W-T>6QE '"W@WV:K_
M>\\,KS/&P`"#QZG:J'MM;,Y\YS'?.7/`S.VW+YZK_&B'D1/X2W5\.5(5V[>"
MC>,_+=4_/QH7 W#)]L@],P8WH9/6K0+;7,3D9,\5YN,1E>:9SJ^FDBX
M\2P>(9X9?MGO+JS`VYFQLW9!OWH$=_T[.0;*]-UUJ%#OK8U/<=]30Y/R`$:&.GW/`?<
M1`YJR0BG'6=-T&0ZS0D,1J ;8( B_0Y6!%;H[&(2($-K
MR#DZ2B)BYRJ-]P@F@N.Z>7$_G9'R%X[ 10A.[=5L6;5Z>#!HIZE 7HF_\;!#OZ[#N(8KF_=W6X
M:MD9V;\U9\(50+C8MU3C9\?Z`H,Q#:;$-LD00XV0LYY.5A/ZM3ZZUF>3JV3!
M)FAHS]XX>Z^L73[VT;@$,Q+;-BN.;.CG@Z3A4#0Y->*%U'V<9U!74T]SG@`Q
MD84$YQDB="P:_KPZHC/X=$0G CY")(#>S-?[P8#!DI.S/` .2-"I>GI0I4/I;MNI])
M+?+7;5[^0$?Q[O9EBVZ7@7N8R/TDY&X7EWQ;-H351,QWX5!;%LQO?&*7CNJ
MPC.MP#-.!?'@Z3.^7C$^V(G;'GW&AY[;42>"7:2.#\'%/;[(>(!N568/%-#8!>0U91K"R*06Z'
MF5:8`-[4F,"`K"LFY8VK.%^:01#I`H;"(D`#=181%Y6( X%UB$H
M*`@5R88`=DV=E+ATG3>/CCT=79ZLGQ*EH[@#+J80FMI\BM$D]R:3IJGRG,0.C_#*I/\
M&M&"`W:HDE^OQHZ%C_P4FKM'^P76HLDUMY=M=;,78&4-CGJ$E9B*\:&5K2IM
M!A=NGQY8^ANB47/26&ELS.=Q=6Q=W1@@C1AH9T$V"*!_Z88@4U.V'4C,I1B$
M3P7Q5#&&C,G'%08H1 6A)E#
M3X.N2(M9T=#H;Y2K6N!E+\5F=F2CH(.-Z7TL/8Q\N/@\KQ`X";H.(8#8EPD!
M!B_IA/.;LQ,#$3\YB"OEQ6I+&X5X1K6X-P40'`Y1<
M(#COZ&B`^T:B@XWQAC3,$G"G:.: $QWF_%QY6+>ER!E9TM
MAAN&]WL9>0\J&Q[NF<=!7W@LU;:*TR%)"F!EB_":1%:"^T8R`VMT>/>6TG$)
M[MLP.L3*FBYU28.XJ4#N%-KI,JX-F[&@&LBL#ZCF#G#5C*O/8^U]SY7=A+):
MB25Z+WW+*2Q/OLFO0K@+\WKKGBO0\U]!,'8MPVT?MITFG]`P;N(L`2N(OG@;
MK%X7SE+LR^)MQ1-G@+>4B(7;M\QS1Y,;5^H8E^">[R0D=XMES6`F13>$"%=N
MXRP3*C$T\4"GR.0$!?KSV:72$HT];C)$VTN`E:,5#=;VE\'_?V$-"F4AT=_H
M\RH"@>/KHF8OE ">\9&)V%T[&KT((Q)"KFD(-\-H8[.U,8^2XR@*QJV':%DO$,6FEQC`*$^3EVT_:4TJG
MBK;G6A:,6)0>72V**8]S+84<7)D\_F?A%!'(G2"PO1#3PN$AW-<3(**RT]QC
MA"OOO$79?/\QCKS3`VW#QBRZ,MG4I:Q.M,(YC3$W5GJ]#/>,N;%2BP8V8MN2
M7%DYL?%0 (J.5D_=`G-$S
MRM&LA+`NBN)!FF)"R_8F"Y]JX@E?:- Y6`EG(Z$9Z]70[,^
M(U C/4@Y:S4Y9`S[) "$L
M$#.>O7E/#;>O>=GH+ F`HY>UKPEN.=;70G_\2K.K'57
MPR`+9 [Q,
M%`[I]%9A67V)!_"R-55=`%06>'C:I`[OM_)A0I:AR#,%C"W,QD#ISA?6PIT6
M0IV;K#"; >R>6CC.VOOX1*@LXAI!(`RP/SDG"#;7MAJ /"CICD=Z;D89+6
M/H+-V.Z3@^G3_^ID06616)9T)K`L8**VLO)9,2$/&$6XH$/>5A8,G^":@K9(
M%NQUTUI6WF&%'>T96?``N+:XX)04%VO[&:?M]6-^I`]*1O8"E7EP85F%'TD*
M0;)`Y;:R"C^"X[`L4+FMK,*/@!#)TF&0MK(*/X(7L"P(M[:R L8EF%']E8)2JWQ57X$:0B>^GP05M9A1]9
MGM`Y>0+K6/B1M?V,T_:'C,I&_(0SXA,IA>_@%;(1:6'RV"B14GB-C?(I9Y0G
M4@I_L?&MFYN,==F`(7F&!\;*=*V]
M:Y*-QC)!I`9%"I%*B4O2LVU]45:P"5LNB)T/)(WR"'IXV;FF;\9!^*J0!_7F
MXEBGSSC%_3X( KF$?'1\;_8&S9R6):`
MAU!S2?ID[^/0S../G5(33L-\(EOWY3)8BJ`[\1W6C)]@I[[,B.0&1C1W2`'/
M8X(_[6-D1G(6$C+AY*5')X;-95-OLG.8P.+!\1C`P[-S$0>,PBGC+V;HD]G"
M3-V#&*W0J'@6.53_FY=B&T=J]]B$S7/I!H_Y>@`,M;&WYMZ-'_,/EVKQ^H]T
MVV8(IO1;WSD_!C$5L52+UQ_)?M@PBZ$=`73S,8(]EN%?91\Z2_7?#_?7B_
MQN1B/KJ?7^A3>W:QF-V_OYCIJ_OW[XW%:#):_0=,YKE^=/,RUI?J .96O1+@12B9YM._9;SFZ?@``V+$!`!0```!X;"]S:&%R9613=')I;F=S
M+GAM;.R=VVX PWR'1D#$24&3S)$HRVAJ4*+*;MD1R2,IVPYB+9%62
M+*M85:Z#)!K[PN^PKP;8`_2S]*/X2?;WKQ61&9E91;*[1]T#>P`?Q,HXKECG
M0\17__KI9IA]**:SP7CTFR\VUS>^R(I1;]P?C*Y^\\6[\X.UYU]DLWD^ZN?#
M\:CXS1>WQ>R+?WWYO__75[/9/*/O:/:;+Z[G\\FOO_QRUKLN;O+9^GA2C/AR
M.9[>Y'/^G%Y].9M,B[P_NRZ*^ ?C5_^7K<6]P4HWG6'?6S_=%\,+_-#DO.'K\[
M>YT]>O+5E_.77WVI+M[M=YAO6,QF
MV7A^74P_#F9%-IL4O#68]VWQ;Y5*7N?SUMQAS(/!L)AF>S2X&D];`Y[=Y$-]/RTF
MX^D<3,SVQC>3?-1J>#[-A:C9V>W-Q7C87-G,W'O?<=
MQXE9=KR8&Z8S8K-;>1+GMY/6GC8WUG[7[-`%7?N&L@?#?/5P)\5T,!9*+X=6
M.6T`;6A^`#G,FC,>?-O\I=G;#F9IWP"5/Q3#X=K[T?@CD"GR&?3>SPYGLT4Q
M;0Y]-&[^$H;X_7BX&,US$,N.N+7*"/^`,M4)G\WS>7M3WQ:K1CA97`P'O>Q@
M.,[GS;7L'1^=';\Y?-T]WW^=O>J^Z1[M[6=GW^SOGY^M8A4I!6^WQ@NKS6>S
M8C[[=>MS/KMN_O9Z4627T_%--BV&8'D_F^33>0M_RU;CR\M!#R;] QXC4P$BA?YZ'T&LHZ:*XAC&*N#)XTOL]%X7H`PMSF[:S;O]DQDSN[X
M/EV`;_&PE_2W[[,"H9^/>JT)7A>7!?R\SR>XO6]_HI)SMOSO1F/+I:FQ?3
MF^R!6UO:(>_U[E[O'_*I2;JXDA:1^8+C9XZHN5"$R\W`L,-)`W(2+:$&T3A[
M?*33V'SVI-GM^^^^_Z[YFVD7U^-A'UK^%Z.$C/.[GN"9M%
M?RKF`U2$)ZNX,)PJ(-_,)7,`4KZ87X^G@[^V-:]6CY50BF!_X,#UYC]LU(%D
M9K^)&_41P\[&JW6.&CS/SA%F;_>/D'!]GQR?YI]_P0,;3J^
MS9$4()Y))T0H(F&)PG,&?S>DFX[[B]Z\13-A_-;O>V/,`I#U:CSNS[(9E'#7
M$A`E*U=PLF+F.$-801/*Z+.0RV0ZOFQ3P?$$EF=B,G+']N**&>IK[]JPO@\0
MAV.7?8\'H]YP8=JFX28,?0:3[*&8`D%&==;]:!LS8&?WF?5_M+FYV7FZN]V1
MP,2TF`\8[[;%2+XND+50N\1$WK\9C$QY5^/LH;/N=#9WGW8VGCWW>; ?%UK9/CC%SYW:%
M6LYH;_+I>S@"T]ILS:/LWDC[_ZO#5L#I%Y,I!IK]T&SL?`O3LW'"S785#CP>
M@BE/X+&<84O*N>[AW[+'`5V>M-"E)7P0\:#?VC)M+;;%(@NFP6`$;16F6H49
MFJO]&B,Y`[/@G)E4+I'6S7+MK-GUC19"5ZEO=ZI`AP:`;)Y_RGK(_X@"8BW5(. EO<7!33EB>A.QR.>V:XG&EC:\[MV&O%[?;=G&C"]S3EH*\3#AK:
M9ZNF3-E@M\X&[^NZ7%1*4IY]TSW=_^;XS>O]T[-_R?;_[=WA^;>K9*9A5W,[
ML,B@DIBS8.7J`QK *O`D6IUZ.32ZE9._@J'STB8!MX-I=1G
M^3Q+3=JMYK9:/3I1(;VO9\1WZ5&9:SK98B)&\ZF8]N1%@PWLC;&X8-XRSX[0
MGY?H"4Y\/VR4N,CF;JI# Q`:W#/$JM4XY;6ULN8N5[5;->Y^
M@M8?W=9L;6-9FX>,-YY(#MPY7&BR:C3?387OV*XC*9I@V\?!'#6VA_B?X9EP
M]#OJGNT=9U&U[F1OWNPUX>.:3R]8H+*%C6,Q0+,E7LL[6,[VW [9-]G!
MF^,_K#2B]W#L9I?#\<=@+5?6!?82+&VIOZ_;__/"?8VS#.Z.P3+&D80 M,5$.S2LZB#99\!8[QE41AR6&E>RB'XA^
MS84WZ!AD[.,EG[YO,8ENTNF!=N_)`O\Y6,\'#DKVEQL`JK>GN7BMTHW:G,+P\Y7>JMW7@EPR0
MDQLMLU`"$I@/Y6(\G8X_`@1S[:CUJO#+RE[.$-TB6CJ?; D
MQKF?>D"FQ_/Q$U!^>1A1S8WF4T&S[&27S8.CQ9B>\:8EH4[C!OA/2AL4B.(N
M(:[='"VTQ!`P4VAU&XMJ]MTC*2KQX8R)1XZW=.P[^Z$U(I_R3VTU\6PQF0S-
M#X<75F(.)]Z"+!$VDI`,JWX(R$Z+WI!H(6DD^$^"VDTX2):G/+J1J]^*50=U
M*@C.B,BK=:838YIUG@D>X+-C(C1D F+_W!2"Y)JB'&S_#*$GU]-"W+4HH!I%2GKPCQB!.PU)7&`K0NR"%E*KU($`C79-+Q!.$9W('YJ+
M6$8Q2W>X4G; /WSU_=[JO$,"K=V>'1_MG9UGWZ'5V]N[MV^[IMQ8:./SZZ/#@K&X&URIE
M_H$KSF@42FTSAC[+_M2]4&)F;]X*N!P=G^]GF^L$HH[^:UC;!\?Z;+R8"U?1#\<7+K#7[
M@"Z?9P4OUUJ3?9Z)E!:]9*OGL`1I99;)*AX!#PPXA!`*JB7H0@YJ1)3#Q;7.`5
M&>13?`6D(:>YP6\&Y$45?7,3MX=^,^_[P$L,7VMMOWL3$/=W\5=98+`F1M:5V9X,\8T7K[77J4S7:_.-X]?[%PFO#
M,F(G^YI,Z2*=C#.5.(&W3LB!5HOUC/@LJMJ O_)F68X/()CL,Y\O]G?6(]=\?+96\Q@?^0_E9"AX4-X/%3=8;
M7-%K+N>401",(8\5=GM#-8^*6K+I8/:^.J607V>-'P\8:'8S?F]R";)W-0:S
M2)IS/:&K?ABE!::EW9C*.+L>3(`&S(EL(5,X7$*@*'475P1'LBT2TZ0=K@>G
MJ6'Z98&J"\H2$'!O@@#K##>L8T;N4TQ6*Z8@(Q8-208H-FZB^/3"OCWK&M>]*.8?Q273OLK00F'S1'A]L%$$)%/J9L%^
MUQ>&$7F`YWBKX+$2MB7._OUO'%9Y0,DV-%1YSJ#*$2EOUQ3&@,MPZO4E0A/L
M9N/+13@HVA!@H;Q'Z_J(K0*.CJ>D8TL&`*"8[L>?(I"6RP34`0\O%SJ4?C'K
M$0FFGRV3'IL;ZW5I:4)8TXR*C^@7(.P-S1,_WOQZ,.UG?R$C0R>BM 0)"`N.M4HPN$(_O,PH/>^\A8O'"U/71@4ZDN,%]
MJ5Q!&@6>;-ZB#Y*!5QVX#2D2;LAU\/YZIHI3,FA(L AMM"X=7H$H-[C\41
M\BM8Y978`\M1DO%N9W=W-QD25:1RN](F(5S;V0B"] B\T-A0Z^U!)>WIC '\,&8S&
M2B@.XIYTBO$(@I2,,9\BZIGF6[6HM]5@U#4-"E(ZZLT_A!(N$Z%\FL$LDFW)
M>X>Z`4&B3/4LO7>V"ED/Z^[K1%;\[)C9HHU_7/=*A+HXIK1G*ZSJ9YA!.FAS
MS!H:6X'*%.Q2[X
M4]/#:K9[U/SA#:;/KU78%\_D-NZ_V7+5%$O+4-/&Q>W8B[
M'`Q!2QJ;[=!*CTG'G>:1K-2R'M4.ICPH*W)"_C7AM=.- S;4GDW-[);REF0[Z^3*BSA#F%'4F_%D=QV-EP12[4T>S,70W[N:H%9
MUG)WK<3^EX5]:_;/)[9_Z9C$8;.*OH5K)69%)H[-C>Q4C`>E\/'F$]QPYDF3
MX]@H!U;^+3X7\+8?(?6TT7%-#72`P9PJTYP7^-,E``KF$(!YO/ZGFO(!"R3#*,S?TE$O@
MF1?:;)1"#W1&N2?I\ K^43I(OQ$Y/:
MP5)5[6F<2*Q'4(O,:\V85]2=`O=B(S(?U58ALX6NR>`H+\U6=003IMY&),!D
M*2B=%-KJ:]B=K5-!( %V"L,%RDZC9V@"D,3:PM;']M(93>'"&`X(8
MD=`!^UCEP)'=&`4*'U(:9#DZ(MRS=FA..A'!5I*/1\VP`?``*V^%.*CCEC@3
MN#];]*X5&HEHZ_M!Z,WS]P57.GFE*D= R8!&$RL1HCE1-ZW`"(0&
M%0^!DIB7(UU^@ >
M^]='FSN;G:U='([(WO*"@:!F55![O2ASDJ3#K9APN^ZP]&1J^`BXMT1+=#:+
MV1#Y::#NR#>=^F2H&`Y34A?UY;
M4.[L,)KJ*:Y&_E=&SD;%ISDV.4=BJJQT5+-H/YD*C$;S:'MSH[.!#U8'%#84
M)!1D_^C%\_+C,.&H#7B;V73(S@:$/R`[Y(W=;/.&B?OX;76'E.\IL64^CW'Q
M4@*C-= RNZ-*>03D0!I(`K^IV[#:^0:#H@E^5FSJ@>
M*.-_E$8-0C@R2\=%V2*OXP8T-=,'&>$Z6*DZ7>,TYO5;>)?O1QQ:W+]X@UZHJ3O&`
M::7GD!PC5RS@$*-IPTF_AB5(&E=D91=M0,&E84STDD4%SDO$^Q+'"<^(L,3`D/E\P1J78IB..,F:4P(ELM3(D+>5U>!*WPS
M_F#LQ3B]2?&T7XF.&AJL^[K;/0&)" RJ#M0P73^'R(P1B:+KI!'W
M9^M9PN(3/^KA"(55CI\E]HZS)[/@@YHGH2BF4)^5;6I>T>`"4K+D9:QA'Q%"
MB30^AQ'Y/3UU'Z[6E1JR>/XR$0E&]R'N9/LR-V*_I'B3:,Y^Y_ZW H'F[?PEOT%4#`KR@YTR)86,9SF1NJ$@!45([-%*_>7V
MMW[SJ81B="VD\.#0_3'F0>PNO5[5#65%J[+!OQU/WWN&%'0B#UI4A)%N@?IA
M*P=5.4@NC`_&@E.,I6@$JT9T)!JH`4T$BS(_1)N)5!LVC`"6[M.F6U>G8AS<
M:5YFMFHRI/FEL`^\-H`R`!;&]VAS:ZNSL;6#86(>-C\NTQ)*E0!:]5LTPH+#
M(*G':2_-_3Z#"7B@FPF.V87SA')?=QEMI9HBU@$0Y9BHY_\V%)05UM_.*KW$
M:RU>Y;K82CN(M]VUM(3/8\(\E(M\QF#0+YS>D?(0@C00/FE[@^F:VS*H'QQ,
M=&90T#.+-ZUX/S%`M2F8XM7A%2>#L+-
MA):,HEC*)!J-17S05'6UFLFM6G*SY22NPQ]T@Y2OO[;6Z$U)E?L8LH)$_4*;
M\AJ'R.9\(%P)T02QB?'57_C=O"&'DXH5Z2^Z0X\\$-@$Y2KTP)'A.]9%P?R\
MGAVPN9#NHF;L#6-'\0:QT9GG-'WD=GF9;.:JZT.!&!%>URFU*4W"LANRXM@E
MZ93J6I#;=N%N=NI,72`FQ>T7#D2FV"@WRX
M!5'_#CAK>EU8`T+"3``&$3"K?H?R8@#*A9PL
M92YHE`9BV?NW*T38 ED.#T_)#&&+`Q2/:%?'!)*,>=72S&/QA1E-O[Q,*28P9-&V>OIXBKK
MD@W.O:]T.N(">^O%MDD^G6!4Z";K^5/)$+X[\\\$.T=RF
M9?.(6G)Q9/TPS*2.G!(0#Y75!`IY`[*'!%:19L-)O[-3^>$E!NY0CQF^"XO@
M08ND/O[1YK,7'14>:.SR0(.2?DEN-Q48]1J%;3.A0_.0AI-XB>+:.?6F6(KW
M<=K3-Q*-+;]!4X%O\>-_>!E0L7BT5SGAI4"NM3252N>H:Q)FX'K81_I@39&6^`C"`A\TC-IBQLP#4B5=8MD1*D8J
M? C3/OF4#/;F9L>L]T-`NC'H^P8(<8MOUE9
MF5#3QRERQ2A$9MF"@0?E1>/IL/]1EZ6=1J*.D5+),"0%>ANA]R'FJNFI24F5
M2`#Q5?YB,LR6](K,4AR!&8_C*#8R*@MJN5A-NK&\!-S(' Z[^Y,-(
M(GNALCD@5XXU&?;$LB$U[CA5Y.95]US`L3C#N%ZP9"7,_[$E)NHE38)E1`B+D0=73GR6(.K9(
M2\S0[T$0LV>2W-<2A]"C9PI`ZK]U#(IV"/"3&FWZ=6!L2=5CY('AQBC!A84L
M)J:-@T#A5A4.M9HGI4,@<1.7WD(+P8"E6W"HO. MQH(0,:\K!]I=,/)3MK.R0+AMW 8C=$*7../F;BQ9)/^!\[(K`0$"-- V?I29M6"-NHH`MJ6O:F(%EY7",0PBUI%9@Y43OD)CAK!!D5.9S"@+9:<7QS
M[X>N^H9HNHEX.V*##.[[]+M T"K43HK&7R=DY>*
M+CE`9J!#R!'EJ=G: 5"\6TO1:^4(>\M]6@;9?PPEW;T
M1,?\)?.-O49C\!OT_B=\A>/W9[J=YQS$BUS!:O#DF^B71P&BX$=8F-HF)D)5
M"]52 K_E&2B>CY57&'6B -3;4&C:4XECW!$]0H91G
M[%098HV9*Z_W((B$M(%TCVK5H*2J=RWJ0]JLW7AB*2AS67TD$".;$&4\B]$7
MRT@ZNE.X^J%1;5A"PN[>8,Z@V#.(^8]0(ZMWXMRMD(Q5+5@N3&6 :5&V @?#[2;1;#6FJ;E7<6\4*X@V9S`6HEP*!
MZ(1E%"A CNV&,^O*$SRL\OB]+\T2TD3Y"\PO'\FKK2BV 7W@(T= X$'%3(SQO`XO-96365RN-@O96PN,
M';MM#AA&2F3V2%::.:D>^2?/R
M9T@D?H)I \\">OA.5(RIDRC*+D"W5IR(%Z$<13/46DSG;
MBZLWD]H9LCY6;:-$K/2/4AR")J2^,ED]3F!#R;(!-9D=T,3:W`0HI2;B$%%6
MH6U-*4JEKP?PN*+[KM992*7FG4AP,.:7,\5CL9WZV= -
MTNL\*^#X7'.0[6_$&Q%/IQR$N"18E&U+X:6Q5RT'6!EBTR2(##0I6!=D4W71
M7U$IZ'KU(HHYGDGQ88E>-QTCXQ*NED!:)5L/I(#^7L_6:NT'Y36GAY4Q\,MB
M8VOVSQ=!61Y:7FL'_U1S\?F609U':],_*P.HL"#5 YAHT5-.BZ-1AS&*/U[/I*:)K`+/S2`BR+U)NX+&\QXD(1KO2U
MV0 @AFX$,$0_?(J4SYRI]QEMF79V\PQ(906?^1U8C^'055]HG+0R9D@22_GOE3I4(+^-X4(6[A"MNZ,FY%E1/'9>E
MWBDJ8,IHDJ816L=J:'ME3_6!XO5!*0H';XE1U5R:2J+!+SY#N?(7'(F3X00!
MW$8]K(X)\J&H8VOC5RZZRAH=U>[]F2-4\7L43A'+E.ROX6.Z'0-8F,."7GH-
M`SMR,+I$;HALRH2^X$M@\1JP(K4)-R#:`^P!^WP?Q4J=J%LIQ"?3\0B(^!N/
MO[AR=#C*WJ+0N8M.%+OK]S],TWTWZOA*00@1Q
M;^'Y 9.EYX?8/N!.O*$"N[C$&E9Z_>[,DOQ0'*",7F4XN.
M[3J5FYP9W`1-T@X%!^ZH$V[**G#9N+4N["[KU/V\'>><6 H'3N$EU+6\48M7VPHT.H"M[JV2;:[QN7V@,3U<6SI%2@0T8
M*IDX8XC+BC2%0?T!F(-JPE!V':[*`9:NT%RH&C>IG0JV/>12>6[SOB9F'RFN
ME;2#`8*VP"C1"O#F*`2/&W[-)&I].1[/1Q*$E<4Q(R9YSC"1#0M'W6NG&)+[
M#2,P8[VU>22(6N%%U*=RY@:ULQ9ES8C^_*T#2+MBT*:HN.]?6&Z\GK61CC6'
MHD`GW"[2LEA;D%6$&\/6YAP.*&`36XOT3.&4SY:(^?G+HV_/]K.WOSO/]O^X
M]TWWZ.M]5WICH&C^\LQ$VGY\".R>UQ:VUJ4B9/>.>BP&KAS5#D\I1V;LQ$TG)]C8`+$-6ZG`5GD3]3YC2L;^#@>PAH=GMS,1YF?_SCX6'M
M2+U>-9U!D4*+Y4U@P"%%%Z ]HOCX\/SP^:H+\WQ9VF2^X=I!8@O`:_!T*1+]V
M'PCJW7V/7VS[<3Q@SFX[C:Y^)J9(!RJ(-CC;?$1U_[.-W.%=A;O?T18=H.9GC^+:GBDX/*6$PH'C4S\VH2^]#)(WQSL+$PO:)C,
MFZ$7D!X6:S>A5MO=30$A2AN(VPP9!IP*#8R+VU7R,!,E\DLZ!`XO1IM81ISM
MYE9PQ6NMT=BL\.2\00X''']VMK8-SBF=C_QVK*-B>`D\KY1Z[*A1,A"#AY=R
ME;S51-I9I1$+EB5A`RD]UR3\D@?H;'_/?#_\V446#+/-YR:^0`IUNRAZ/*F6
M2$+:V<6Y+N0(Q6O]#UVJ\2U=8-CAXFY"'G`\J']2#&M 7!]D5[\`A%4_Y/ _KY[OI^=
MO.GN[;_=/SK/'@OV`-!9;7R\OL,%Q?ZV^DE\6[U\F>=)DV4L'2'[/W1&!;NU9)JP3%JWN>XY`M5.I*AT9=
MZ+O6QP&I+R1)Z@;_'U'#*66"X)`SE&>R>A80RK/3E#W0^]2OWB[S))5S7R9?
MN2J1@C"DY*#G`0;+BXN:7HWOA-O@C-4`X9@\%=N&50EF7/+VO;/Y.$V&Z+DB?"Y
M6CIOS&%S>/(5O8N@KL*H`LN*X4J+H'5\O^T>O=/C6);?=7*Z?[!_>KK/FUFK
M6,%JFA X"?;2U_I1[B[VJA=Q:.$V3R6!R1);@%\G3A[O;8BE,
MF8\GO$(DHY*L7H3I`K`0[8,=6CYLM?V$VMM:L9:NP6/2;[D-,818K//`L2PY
M,3[@UU^^;<7JE06/D(@BZO&5+(D$L>RC
MD8+QW3TV@^[T=79X>,B#7_&%,?M9K5#WK84IZJ78J>:;H:9S/X*I9;5$U2[/
MD[B+(I%!3;C`JPDJN):O.TZMB.7N=T]`=HVBX4 N4.1;OU`9F_1R"Z'3`H\?2-KO9'ZQ\AHW%0UCRK61'
MFU'/R 3E*-86[/8#TDE%@G"^>;E;CN)U1#I(L11B_:@)+I/"U>G!)^@GWE?H5-G1^IT`J">[\!P-
MEW7JZCB_YZQ4*]R%:]"L_X;]$3$NZJ+R&LIMH51=$J-TJYM Z,/RSD9%%
M/(+HD%LF^(5+J"6,(@00XC;-W5=NGJQ,CA%L"RY&&76&.Z5J(KOQ@0I0>`2#
MJ-(5%_R8MOD*^^W]VAF%\L!:5EU/,S`FI6XYZ,>-\5[=YA[//AX+VPR+0A3K
MWC"L='[%2+1H0Z4:5!8Q9.&/U!`?*BDBV)-"0SNO!A`=^ZJ YT]L0@['+K@0ZV6`:JIE9P1278A-],S-BTH:F'LE
M3US0(/;#R^MEVN!#@8WKZ39[?.&+*[>#)=6#7<3:TQ".50::]G)!O4\IX;2+
M0/IM/5K2Q8Z)YB!,()(8IE#7N#F'_$U.3@)740>P-,%?F ?5HOV*QH;03.A$,"_/IN(Z(6"E+2Q'YI!@7N9+Q$U'\\8W
MG)Q ]C)D
M#S6[.[A22.QHRFE+);LT_;2`N^KT._*Z;[Q@UYM/I8*I_:K]F&U6+4L`T7I#
M,HKY0O7",/F#!JR\KV)']SHCTSS3^CZ8E-X70X6J@,D1H(G(@?^;V6-+7X8%
M/1,$VE@50ZORB40!L`V=G6+=#$790_DFE21>H[[;L@B2I`=6[+FR$#99?80U
M+?YR/IZ0C;WS?,-,0.Q_`C)R]RTHQ!9;>%.5I+BXW[=$&@23N=9514YG5]?>
M*C=`N&C#4YS2(;1IW\%1"VG+_W?7[N2W];=(X4ZU#8:RG:6=`WC5@W^64K^*
M9P#S(#3-]*`^AI"(`KF2EUZ+((ZIC]JSKJ'DF1S)AHJ52\W1)I!3B,.-A_*2![>H9+*H$9^Y#\2;9+PFJ.;:7R)PPTKY?NQ-.QM6,)E48858>
M42.,)*M,^4(M'H8E!:QQ;Z$S@?0A3F(EW0[KLI 4HA42
M]T:$1LUUXWM+ 4+0JG"MME],=-G[MEYR/C'J2\F*%QXXX0[T0AH^$_>VGM>
MNK _)!7YQO/Z9;:1L58>Z%P(>KGPJ+P H:QW?M`,?RF>I_8A0^9GCAD?\(3Q ,0ZRT`0,'%&-RLNHNB'N`^+I3+IS;KX:%;>S+$I3NY6JV_W:
M(7-.WP1 Q6%U^47+L65H9IXG+;"::46_#=@PIFJQ\2H30J7/^MM
M!Z0D+,)0RRQD>M@)F19;YD/E?1*29$4G@**G)C4(EA&5B/EFV[MH$%?)[2T9
M>ICY%!%YV:B ,1[#H-AF"UO)?).K3RNY91Z=@!
M0Z"CBO-6AFM`;8H928LSZ[&QF!;K.F?FTGGN]H.L2"TH/?Q(/R5_,&-$B.(J
M#3EU3,>#4;PSCA27JR%6M//KH^@B%.):\I7&CTJW^NWNN`]Q,?)0GB%PL#3X
MK.8I["%KZ,)37%V(I;_8R$NW;XDC2G*U4N52NJ.-OWB*?LK=*V!M5*ZEE(&0
M K7:@!:6'K:#%+XO/$0 T8[#T5!$2))U8Y?
ME$&>3_I`>LV(DH*,70-Q2TUA1Y$:TRTI<8@33+P:I8)LJS/Y4"[)8UV6]!T%
MQTC/],:15T!",W#AL)[.P%/.\^W`@.>V3*-5[J3(Q#E/2(EL'\.*D;6*!,[*
MWK7PBOE)(L.J+G!3AA'W6#=#7V^)9A]T]XB*'1Y]3=+UWN&;P_-OFZV >$(CI;
M6\[Z2BX,"D7EM!=OS4PT#R&%#)F)" ] `427=?JA;W[EZR>48JQB7V,'8W
M5X;S3C76DS`,>TS_YO.'@E?BY=/4SP((Z2@X2L>7 0&[ \SL;M"!4
M$Z2VGJ4TL3R9%FOU38#S7$Z2+.TN=U3" 8Y=1^%`/7&&0CE`L4Z&?;#[;)6MU-Z"P
MO1S'MPHJ,(UR<5H$.9F`*^#\!>ZR2SE`]*6\`5R1IXLUT!S\( :T2*9D]@M3ATKMPHP%?!01/SF=%'-5)ZVQ*\/Q4Y]QK"JC@
M3@)Y(-"&+*V?GV6DX6S=ZKQX\:RSN;,A/G8_3P7#9A[6!T_2UW#M\;_H;ZW(
M\4<=Z19I>D\W7]B!@H.@FDKMC$%WW27K#C[!OY\N`@),5!JCIYI6:$:59(-I
M+$W79M0/]61;14`0HHC8RVV`4?T%:32-"NYWD15HD"C/,63*>(^>;W9VGI*G
MTF4LOVW-MWJD8@?BE6PJ"OX7=\N,_\_>F>[6D5QY_E42!@VP`))-\E+;>%S`
M%7E919N;24J:@C$?N%RIV,6MN92L1C_*?*BWF._U9//[GQ,1&1F1>4G)LJ>,
MF8;MIFYFQG+B[%MH[[DNQ.AF(3)V:1'%O0J$;N-+!-*QK?!$X?+<
MDY0`A* D`W
M-D$Q"N6=S=WE-:HQM:8W':CWMJU=,] ;0VJ`S.$"#V::%R&J/
M^\N.MH^9DPKG$/&"#JGZXACG:@X/9VIG%F"O%C5%@3P]BMOZ][C+2$14>M/D
M+V^V]I5Z7&IN^^D:7G*.@91.<9+TGD=J/TC35TK4SOA)4^VH!(R(`DXM)FD)
M&YF7=+F4W*]7+(,2.!"0=3(35J;*J'#O?9L_OSX@X=),Y=[W"H6&$N>@S717
M6'ZW+< #>3P<>YWQNT%3SW5'
MP5>+]"TJ=#54"@-!1SW5_`/**"9]PJ)ULL*B J+IOIJ&,OAM^L\M:I
M-L-_&PP'*AQ>+#Q_Y1K(W,N7"RODL#MK*1U(B>&XXNCF/P86)QTBO.L5N18M1VHH=5U!(A5=:R]QSJ'3M)74A'4%TW'PP)NMG'%\.
M9KH^>_ELX?GJBD_=WCK].&J;8JJL=Q/;06?(A66_DE)H%4%O,[U[;I7&E BA5;*D`9WM#:$O_8KE'/S1;NV\GAT=6
M]2%&/-YX2S%8E6$JEDO,;&=*J>T9YG-JY.QD9XFB;Y%D,K4&PQG6[4BVM-.S
MFMB$&S#^J6TLJMG_@5>EKN`8E`AZ`K"!1>K[=?\M+&Z,3D&5D[?S!IMU^D'K
MT#]NKQ\^_(C&YLGBZ/3J=O$1MG_Q:9%()/^0^79^=HZ[AJ;$>##I:GU\87Y^
M8A58Q-O;ZUQ0DJ?RFEH2SS9SJT?';XH'F >0=!U(\;Y3`JXA"&:8,.:2I1O,H\*AO6
M-0^Y$!5.=!]@EL(FDHX>9WAR7"=_HF39M6*80>ZIYN)L67ZG4L7F5Y9__TV,
M$<=8E,S-,`"[0A*8^SKZ9T*IB74B9YDH1-E1&>%*<4.@V@7=\>[DE"VFL!LU
MG-ZX)^H[+2"R3:23$ +Q1ZRG*M0_;:0G$E9ZJ*G6*#T
M4-_/LMD&/CZ);0`:L^=`&//E9H!M82&P&`=N!>9:2`/N`7-GT/?G9(=UP/[L
MJ6#/&]>#XG4WYG``O7#-PU-L$Z?N!4EP9(STCB0,#WLTI]=6NX -L/P:33MBP5B)=J!T"I?4H!^]PI94\$(("F)X.7,0#>!!CI32
MXW_]Q8*Q^<1?LFY?+(#Y0(N1#W(Y5H&5T6IP^]_;(LS3PEZTH+@?%[L9ULW%
MCV(3'3; MA,PR,=PU6QL!MI#U\9$N,N*N^&8-+0L?1XPYZW"*#*ZH#W'*&>+6YS/HZ"@/
MY:@5GV0(HJ9H6"GDZ#6];7:`D8>4+#EZ]=GO&XG5;I)")AB6Y-8`!I52UJ$\
MVT"8- 461G^8K*WR56!.76"A@%:BAR9;!52=?Q"
M771^9,UV![&&2#%2R;%LV<5RRVC?PLHK[N!97A:4VO"9QC!*%K1T"'DLS7^1
MHM]JYDGR&JNQ:'W6#)T W2"JHVXE@=W!-EM&C->R^#@KB0&&JW-822/8"(A^@^:._J/3-E0G-<01
MT3!6!V(?V:WU>DD'A\Y$AQF@&)/"[8#T)&>G/;I9U%Y[:*6PV3SR[NM-R\\P
M4$QG91G/^//8-*RU
M;/H!V#54CCCMT,/OXAH, `7,1:>XBF_I6/!
M\C*//VLA<>^P&C4.<3IF@6E!*5W'[RFQZ)5.F/6V]Y]TCMLC%MGR,>8(LQY?
M+3[<8,2X]:8:G9A"F)*(,SXA?42!-"!!JB`&C1J3`0I7:6!5M!J$>Y]IP8I>
MY3U,1LOR1>-C\=;.5M.`08-S3ZZ2[EF(*U^%7AZF(`6&U9Z10B9_:'Z\_J@A
MG) ^@5X"4CY]>4;:SU!T.L\UYS*G`I5KE#9=7Y+#9'_\P?KT],8_X
M/ATYJ/@=K^.F.>QMRK.++4V \9"OT!YIL?F2
MV? &$>_P=)NDR]XX1(*%GO)C(FT6E[$$-1E/@WR+#)LX3U2@C].5/[$0SRA3
MV9_J)2Y223E@[3XK#T8D,WA4006:-#`D%WU.`OH-9?`E'8LL/XU_>FEX
MI/+&!0.B>`SLU7H`20N#N:DL!"Z1@K2%]CQ2IZG12!!*"V#Y0,E].NZ#YY\$
M3A$F63C"%D;25N+J[$'0S":,[$N!3ZNIS`^'A*UCZQ[-U/+/F?Q3O
ME_!S*F/84%?W^`Q.0FX.SR&]%UZ,EO_@QX>789D`_(A]$M[A)D502PW!VLN3
MM-XH-O62,N$6)0[+Q)Q\4]T3\14KZR%21XI$.7I*`!NT.L2^,GJIE3;S,9DR
MX>P-/BM[7U%TI0BR-TW?JE'U>&'?WUBB1FZ4;)7VTH+%60+.Y& V-
MZA""^%*5V!/9I4PM+UPV?@$< [3!4,RNBTI"X1+.E
M:I&>@"V?L-YAP"HZ/""*"%,0\T5D/%^5(16>)HON#J/O[CWNE4J*'T[>3@X4
M/FFVM\:O>S,1#Z57F(\GUF1]>E1&CSR&\(31QV;5)781PT*S;4*.()B[M,LXN+=K`6O=.9YX?O!/
MFX(9ZF%$)'\B M+:TFHS?Q104#\4`NL=GF"T4-0.
M?$??:(D[Z);M^FQ)D\N;BVL7FTGX4ZH;<5K[HG2$>`PFMFE,(=K8]QV^S?,;
M2JY%U::W=.>3!P6*"_(U`WA0+1)+^4#[5>BC]=#C3WKQ;%FVNYL?E@"6RK$I
MJ;O&?^OW-BB'`+9[A]P$:R$RXWML@S8+9KJ@\HQM9/#N(X1;K+&M8,T8E=><
MEZ #_+U\^+ 9@LHW!L8$)
M R+VYAL%E%R'"L]_[;-/3>07.T-WL"&2"-@E?X')ZTHB,H/8@F
MX_\2%@_FL.NFP4*UIIKZ^LG45$_SL:[[1=*(*:2D')!\BZ"E!R/-G@"WUV6]
MH[[@*L!*]Z@JC"%YRM6\3T2"5SB*]K"J/,Y4XGKD7),]4SLB1D>'!(D!W40[
M+>$,\%=\W3YWM;G>-HN774QN$I]>'I^KNXF0T$,,L`18I-G I[N9!J __=O]M
MG@XPN,3R1:>D9W1P76R^;-/EB!DR]N8?CCJBF8-5)%XX1YS6&T#)]^_=D#&$
M#7K1\(_;+L';IA>D:K\X5B`WLSU*HW-HN.X*9?13;_#\V6AA#43.?4MA$MFM
MHABQX!X'&SO6S-92$RPUQ7'EUKD2P7IG.9@L4["&1X6[QK0B&@=:)HXI#L'[X(ZSLW]'PKO)&52Q
MV&9&;K=3"`K2:NOE$T#RA7;OGX!% 3$+UN&$;7S&I-Z\`WQ(@$=)HJI
M$Z_"$.2.#;X\`[A9%3S;M0Y?T2E`GV0"*E(,*TZU%0/W\/5NTD\W52?L#!Z)
M`#-;M_B&!2NLF[0)3C]&%+;8+\A^MCAA_=XO'&LH>/CP6,&52O'NSL`5A2I2A]&FX^7>L4YHI#E37F\
M$BHP!_=4A;)%A%XG37Y6<8([.-/>&.L3&J+%K=J[=.T_`Z
M*!ZX$)^MK2T\QVY(P^2,LH>1KW$X_'S6[:RAD^G%+DYZ#`ZJ^AA&ND)WS9?+
MK]K)`K:8G.J7`"YJ.D*N;U6N_D6-FC3!4S,]'96BYZH],K$^K3D+PT?_CG[.
M.!^KUB\)/.=$]D@().,-9FH-PO3X7<63S%FMQAO)._G$02$C5Q,U+I*(^VWR
M,NIZIN[697BU][$[Y'OV#UM`HLRMBBPGHT6"O4(L0S^62()]-1>:$8E-@U'(+J
M L!*ARDC;WJCAAN'9YO&6RM,A0;Q,I`
MD@)#2;&=CPFOOFZD`DHP_S.G"G<2WTXQQ7R&WW9?UB-.II?OFE/,1*L?7V!!
M"8+2-CI@I]9;Y4%`;E 5]K"7!4K;8?IBQ(!>MJ'8B@YQN&QEUZ[I_?67
MZ_ ?*WFW- 'XB!__-V=
MW>=%,Z&;^]]Q961?]OOMAY,__FYS$Y<4_Z>7;C?1#/SS(_(`[NC1_;$YP%=W
MI:>65/S)'Z_HAW^[W;>TE?F58(]VLS:2*P$M @#%E-PB-OVNIBM9\&G;D(WM9_M*??'"R?O(F8F:2M]R.6 NWM/=1S]Z?>IY9E]M_W2T=F3(:
MJ;^C6/Z6-K76 >!R&24J2&LD
MU3>5;`[BTO)4+9#@W>5DNTL*1PLX%DQGA1I?-%W:ZVCA!>&F5\]7$V-OYE=?
M+(VHM["J3+2HD!_GAF'T0X>XD]EZT:KLA5LT@:L=2_&)-D54K-UP2.D``9$R
M-=5`$\L"HGJ2\,VE"R9X(2@X:4`68XM[_J*4DK W
M6`VXDGQ509?N3.DEL$HR(\:LQ)9@O>?:>[SNB2:DA"+PORTU;Z^9O6U?$6%`
M[)D*75S=7!^H;5KD(18-F&4;4@[$1`=1T06P'4['THL**8&4H
MY+BG&\39776ZV`2E`S;Y<0_\3A\&[G@SVG:];>-^8H`W<
M3$&Z!/YN@BXM
MH'W9-MA_$%]UBG_"+M9Z\6`]9,)E_D2+H;T+7L`D1?9#N)`#[Q_IP866"[X0VT0DM2[*&?3 M?:5^M\UPT8YQFK9SJLCTD[P[:9>4.XYYA?=
M33,?/,B$J)3PZ7UI(^VD8)R7:ZGW@#8 9KFVISY6OOV!C)01
MSFDU!PIK%YU`';>T9(/M#6PB+JW-4"/1D)#YB]&:1U@=>Z26*O17'HLIXXI`
MRX,M=;'C4-9Q18Z^B(>PN*^0+XC/A;:>@A/!9.\N %P)+?U>;H'T_10=,-=]"98UTNE?T'`I
M+#`9=-GY9*&U&2$Z`#EPD+4>Y *^RH4A_K%\`MGK(WE&0L=I-`V
M_573ZP(B8#+/K;P@& Z;4=*[*TJ:3ZYVR)]%#'G_(JVF!:ZD2WLWY#P:D`B#4)S9E).
MS`%.U0YJP3A)2]].+F])D!]0=#I@I6I%Z%N6;ZK]/-?_W HCY2YA4QK;7
M8 VU-67!'47O,"V5R!]F,0E:
M=(GQN`_7QUMP*F)`GR'^![&V?MC`L!QEM(N'JVP?X??DZ1`^Y/)5MV6PQX=+
MBP]1B%*@V0`X`5BK9E5$H[YS,$!K!,%79.*6AZ$$_GDSTL^)_BD""/5MOB
M-4B>M5GN;`GL%14;1CLL^)9%\LD=`1^[1`57"DQ&0[9+IP`SD;`+V9KE,D9X
M"^Z1[SOXN4[#[14L(`2MZ?J'.TDA7I0(R"LYA8BV@Y>(MY.8KN2Y33JV"`'(
M/.S>:6T4 OP[[]
M9N@42PHYTH$;?[,8KU&W.RH2@\QW',_?^);=4,,FIE76[VK%*]L([:^_!/%;
MQ57C[QV'/3B59&JH%:D\'^E##TZ7>RP>"^=*E;0TY\HAQJU0_!AS!Y3R"\ET
MW _8-EISD #!;:?"<8LY8%QU"EFOYU5;@#.V5M'%E`G-<0$+*X*G.8.NJD65:
MP!%G170.)D=;!WY'\_YVW5]"P$KU'V*_!Z0BN=*6Z6N/EG_1,'>Q>60JL9K`
M2[B[2VE$"(%CA!92CTUHX]8D!4W`6K$AJF&PS1;E A)52M;*\1IOR\/C]M/G^^!;5"8?CU:(]MUJ1#(JF
M(VM/!BCI5CT;"GI$:SVZ#IQ:S2D$!Q5IF`@%5TDRQ+$56\PUO'+;V7F]#HWV
M)1Z*U1 18;KG"-,B,[.
MTB1:R^E12J3AE5^Q_N3)E1KP[3;FB:IA4_H:'EY?8Y;/T93O_X.TOH
M^;+\G_XTDT"2=AE>:H#W\?KV@ALX.)2J>M=KI8L;(\QCQ$A0QBW-)KR-X^[Z
MX1NEDY>9@6`2/2F4`0ZE4J+81,81>YY `*^N-]7+TINRK1((7V")(8F-`HEX['^A)$7#/\YP_<
M.[3?>N'7E=J/8"B_/^^PO6+UK=+)+N=6O>N=3U_#5)2D!MJRE+V7IRCWXASF
M$W@"CIG[Q?OK1?Q]@`[8J+M'A`S+2Z%?9CN9LKK54'Y;3V9>N=1YA;N/SH'6
MO:[J#1#7G'.I?2$2I-GGYY\@`V46U@(^E'U&%5)ULR]J)T2V&)
M]3E17J[Y2>U.!9L"*O-?N3T$'X?JUXPY`2'[_R)_@3FN1/P_6E&Q20CWX@+N
M4VPV7@S*N)#,=MK:"#R-LWU9Q1ZC=W?`_B_8F=%(2":PKF2=[9H9Y_NWQ/ZI
MS%V5$4C5B)Y*'V-NA885KYZ_=)XN5^*KY=4N3T]L*&L]NX7]$U3R!5'6YO2$
M^G#`2=&4T4B7N,%)'%ERE0)D#"?7/O@!4($QLD,!^IF\-] [2P&O2CYC:$13MM6%M>67;7\WVD\O.F(P;*2W
M;%0WCJVC:XL@3E9"SA95,F12JGY.3=QVL+J\AO4:>K7"0!(H$ZMQOP0]CXZ]
M;EQDYD-S*#_,"]5T;G-.PPZJYG1P5ZJ].VIZ_@+P[-3BL&P8TQ%G^G5'8$*UQN*HSKVA15^[-'%1QB.=B7*>)-GEG33P/00(A`(CS&^]*GY4*TA@?8)2\KI>Y>2#D]OYC%C?QJS#">KP^
MJG5`Z]W/HGV)=B\6E2^RXR57G,9J@"-7`^\S0C,=&26NK95X'5JT99=;=XH<
MPCB6<06+HEA:^4F+E@IE=5\M9P"QV:'Y:D)[0Q%@4&(M('0PQ-> 5';%6B]
M$DO28^Y9F`^)0'=OF]I4QT!-DA=QXZ(2\WLI@F2$G!B%GTG/L)(X!NH0
M#*L4U:O=A1@(37]PE(8'PA;%&>B0A%\`KS)VB7&*BX?+&PO`7I0(&&V`ULFI
MP*#PH9J=XJL+4%U")6-V$85L(>X_T.2S%A/6D*N')K8Y$0W %RF!\CC5EQ[&EYG7J^ JWD6T"3"33A2`SM:5L.
M6T[8^UY&"\W-.K3W0,2A,XOADT:>T^484*O_\,KC[K$9MK;BBIT*Q+S",$*T
M)14IDY&JJW/H2M5_G*T"95N`&)GMDB.:/P"IE;_5\H"LFXOI@&*;)U]X_0;\X>DMLT&5N`@T! 1R]@3-".GJ2Z
M&I-NU="(>\;#K=+UQ)AXV;,\9VK)7*+QWK'BKV@Q#$N)?Z]3R5M1J)>7!O6T
MCZ=EZR2'V:C(=UM=>+;J#^?\/NVL0:4(1M3VS]>JW1^K^]$R;VQR@L@=JQ+#
M?ZHOMIK]9*`DE//[.[W!W_Y?=CLC'V+C/\0V>L*HRX&)7:)QB_U2JF*-O)6D
M0I0ZM?5&L9W>(L\I>SWEXH!/X5I"6*J 7589&YP\D-,PMBP*+)KOZZB5YP&C7
M -+1UXG6"M\6K&+]A^O;
MGX*QSI;4*./`)8,3>-*W/,#8`RBZ,]JE6#T2,Y#AJA+S:9[VP:./T>M
MH2Y^I6UE^8"%>Y4V(XXP:VZPB4CG@(O]B)\]DZU% ^_4$V+T]G2H/2]$U5["EV6F7"$NTBG'UL$B4Z%EE4EQ[G?
MAF>TEXY7JL2I!`): )
M*NA,Q@>[1)UIW#\Y2(T#OQ\?U- ,&I/BZB@>KD/?SU([L[/S"9"]LU= ?D8O:+NBE&-/:$Q&J`](V/Z5YM%6
M^59[B*E,QC'1(:SPECCJZ4^.]2&5=<9\Y5X>A?K@IF*NLX&D9_'E3JUTJ3K3
MQ1H#R@])$$+#L:KG;&,@$R+6'!ANP@)VB[?V(%E]5)^'2RACI^J[+`2F,[$E
M:[:]A;.L,$Y/1`4_2>[$]V
M#\='6WN[Y7M9,@DH!:6W"6"QB>ZZHM8+3OZ+;ISM>_!O5C?=7>N02WW%8O/4
MM>RUVC:-(T64J!PZ'2U+??T!!1Q"10)NY.J->'/>%NR4_`0`*C^[=<6=;.V;
M+U4D&!L&("&MYS5101I=FQ9*O(O;)CU_T8(#D@=TG3VWG+3@W(A+T#,I#< :V&L#:U5AD.R@KF&Q55$FX,ISB2D
MJ0Y0L!K+05JJ-POGI#;BTI-SR1[9?MFNO#L*IW&QD'C6"?'V#':=P6)KTW&8
M#MWT^E;C`'LR"Z9:GRKP=1`D*9Q?/V"K?+KQJ"H&<8#Z,4F+9PJL0&27N$N9
M,OJF&$:!B!NB-T`N:I@(J1N=E':KL=L>GOUPTVKL6UH*N&[@.>.:-PW*18I;
M^Q8XW;%(?NAD"C;E>,31B> 'B2Y;W`4"'=@(`ZMX*5=ROIP\/)^N:
MWE]#RN#WC@;+P&(YHIXNH@8=KH$2@"R9MEAX19UNJ6D)?8EFA:LRI.>B7G4X
M1A..)C$[X9YHXF7`T_P#[XG*7A.9!%G+"5JBOG-1;N.T%N.R]Y*^Y=&19X2N
M>!HF-7ZK='P!_-Y.(=[J8E4P&D#;RXH+W)P%@/K=AEF2"S1V4F1MIBEKM['N
M+-^!:,R.6WR5_Z(RA3/*W.E&$@%>.5PJC0F>%.ZK[80T383&-I9AJ8E%6`Y2
M9%&KH/ <5-@'=X3",9.?/2SHEL[CD# ABH\TPN)E-56_3T
M:CTYO`F)<3F\&0,3,T+:U;GZ/0\3GVJ@9]$]GC7'6
ME+S,$@+WXW`&&"D\P)NY
MU8755U3?OERU7^=>R:DD+&:*Y!AP7A!82 U%!WT]N?":0I2T\A.GAZB(Z$D#3]5)<75EX$+QC-SI_3
MNVJMO+BC/*XQ3#K73O[ZCD/!=7#+1_YT3A>"]KYV:!-
M6KFZI!(.#TFHOUD%'IE,#(=BING,5.1E%+EL5=U/,[N%JY1?
MV`5E^`97_*80]_'-C?Q*W>`;!`-+!U)Q\"6X)!.R,CQ`YYXA1SK#-N4^0]NA
MIC"H%.85YVU_H[W%Y?7%\>E/BX>GB&\IL3;,HI014;8UW7+ =6G*328
M=AB/GX5KE6E^)J.#6'7GB*)[E[G]?_C")9V,B'+QL/IU/+ZIJ
MU_2:HX$K6Q2GX$BY(/E]/),+&H7#M?>\A*(;@EU$&&U?L4
M+/$]^3#T3^L#/RPA5OC:V$E#P,:P-&\#=E3^Q8A0;E'OFC=+APRL$DYI>B=D
M5V6J56?-/G\$EB5!JJ6Q9T#)S#7]+9XNE,L1GUV#JE="#SUX8
MV_-%8%(@*)E_4W.JN=??IB83AP==*6"[!J>QQ]):XPH N7WQV!?N5OA-0)!."@_/67M[)YRN=[
MK5]/UE`%C?+][Y2MR+%PH)+ .XPL$7'IFO&K`[7U5,6 M'+E_K+B:CQ*T$)_\)6-.8^"A=B!@Z8W!A)MY,:DT6Z
MQ`^;(:5K?C6DK)6C/6V`4 =+Y_&>8N"&K*4]>2JRK *!)548S!"B9:68H?]8DW.W)
M'"6F;NWBSYTT1^/_41 MRBHA-/GW/L#O$4O6G]24:BDXMJQ[EF6IP=:99OZ$*.K[\WNZ$WR6(E4!1*L;
M&K:=&?D9PJ*F?6O12L/S>@6-:K*R,F]OIHHY;P>K(`UA-.&Q;T`
M60]6;HR8)&%9*5TD-5Y6*NK&-#7B2(U3RB'LQ&C.F2%DN$7V/8F%=L@8/H:?
MY:<2[(]`WF-TBD5H!FGU38OM"57+@;>24RXG)[A-Q`:-UJ)QU$&'L3@BF:W"
MFLO4X24%.:]Q;[`CB-;"G:?T1?@4&Y76B_P9P*L^7;KE[J0=;[JR@S;M=@)I!IR@MQK
M(B!P*`28+%MI=7GD/0#Y@W+=C0>+*(GT*2+Q[#34>Q:IG\*NS/4;^_8P/J7K
M0C&XQ8.2;10($E*:>A=8=+19/#WEQ&P4#4G4S];B]HHP2@:/H)8\5WF_L,0-
MQ8%PV'!EERU,846ID:$V-?2M0EU:R,F4T)T7
M#!%F)'TAWL7;PZ0KZ677$*]QO:UZQ9P! B)IFDZF(WI#'Y00I%-LY)Z.%50+94VY`0@\WW_G2"R.*(C;B;;2
M%-!"L%=+3>B^D6,S`9=V?F.Q:6*`!:)4VKR&J5LF'!7X%/FR-FR@,+[F"W%W
MG0[+<=C5\3:W/\8!=>#E]",+$P5!C3\,\@/R>,G( 1:RB0"V;EKH>DTG2W(N--B,U_HN$?
M.60/HUU8?F;>2_?9=(>/F>UFB@$(-*,VZXNKIMS3&2ONIL&;`*'C3&@]8`)?
MS/XI(J,U2Q4(F
M7K&+O2U""]Y=-X>7US]!0TNJ
M]VB(1GAVS/A85:C(PN\_BE5G&&NH5HQ5061W?/3F8-+L;3:OWQQN[4X.O87+
MX9N=G?'!#_K] 7]][8\U=FOV][2WU=VGF][DE3 R/Z_H\?N+KP
M5M&$\DTF4L19:A_XQ)#R1EMO8UB>_BX_R(I%QKTJU!:"F7OM!6>&V[Z^^K"X
MC09\U@R\GBS56NL[2'6+XO!`QM0R-&DO8*RV;2IG\]K*1F`XB?N4>SA`FZ1_
M27/@019MO7REM1VJ60[0=U-WB`V&"MTARB$L;0T3Q7@?P#U41*9\B66C^V
M.;DGH=#IU>FG9IS,I?*C-W=V^I,0Z*A6N-E>$M#X!175)Q, @-@Z4S;55%5?'V%01?N0BT7^16(Y4AZ84TJ1&S0Y\A>8'-:L)DA
M"TVPU E$I7E/WU*WSM,$XE1YB6FHS?
M.ZQMHD3FXT!QNCZ!8,F1DG,!@2]J$K9JQH_D(&)6L%Q2$-0KQNPEF2"NSR,(
M8,9+:2^VTMHIO&8#ROT;'1@"@'C8L.77!56R5YP4;;SOKJ_IG711>=_T!$
MJEL:UN>M]H75VA20>-I%?3OC]>]AI[#0\>Y&@_:SM;\C!6A^``'>?>&=Z$/#
MQ=Z-FYR."%+$:I'MOXY/E`UV>O\_2ZQ*@-U[W[R+WV=>[_+]`[QFBXP?5)WX
M#;74T3HROPO=63
MF%?]-K@9*%-R96)@JYV0;SR5X/Y\;2]"!="][C6CCJSVD=W&):&`1CS%'@
MI9`NA?@J;G?8AK*4Q.;HL.>1YB'0YY[3)RU%P`C.4F-EI]%G.PD]D>9?!]=H
M> (Z`E+*I?P%?C[K@@'
M-)Y^T\QO6-M*NM',OSG ;3T MLS@J!Z:29ZFAP:"4^"K8A%FYU`2+LGI(MN`2"4?]7_[I`9-Y:$[,,+X,]2+E
M@M`0SK"JH*?-Y`_`A>;^`'*0UX\-2;$*MY6LNR7':,6]MKTH_`X,,4VHG"0\
MAQF2\5T^3+@R\''Y?"'.8OCH22WEF$']V$$&7Y]E6LA"L_<1C]'=C^ F$>%RRF*4=,"9R@V7T$,/,;ZHP;_:39/
MPP[^;WAT@CT0U>QRBVDP%>W=ET^_WFX:*H('1%D/[;.49MXU)=%R5,HK*;AS
M.+;V]2K-X`IQ:R,Y1&>1B6].*=8;0(]M`QJ!N8?+APN$"$9)QDM+Z&QN[8[I
M4SO>II)H=V-+943-_.CZGN7NU[*+1VU3E9<4U2UP._PF%%U@N9IU6($HOZ#6"/&I=8[TV``NQ.K47VHU3(`/5A"3CEWU/3@
MO2RC3+0+Q")"]:K\80&PR%#`(&\3"R)H\(YRU@CT/I_31GNYNF8[F'X0[@FA
MPT#F?^!T_=R02]H]'I']AUMZN-?"0`!\\':^BHYP-^Q[@#10R :G!JR1%M>;EVJ,`P2SCQOF[=WC^+6EVR!.$4LFA0PD"2!;-/
M21W45>[V0B6(9WULGC#(;/AKI*G?9N56 DH$$1-8-VQH@LB9@%6
M9X\O^V=Q*VJ8W#F8Y$_S7X6#94`N%1M=@+\J*,I:9=BBOP[:`DBFPS?;:JG>
MC+\[F/@=!W(K_6EO"Y>20FKRX7\6(;R::3^NX]HY]MN*2/080^HX9;,(+CP9STV ]V:'?QNFRB^Z'IHM8CPJN
M^-U>Z_\K]\!&XU4HR3A+E%"^W&$:.8(+=*T1?.+Y$%IO0)MRH,?,S)0:W34X
MG;&7@ST/HK_\?>;6(/((SZ>@S&K_D3QYBM>/HT@*UY$Q^1HE]O,UUQAI$_LZ
MP?$B@H73T^P7#]841):O+13L9( )5$].F6@=VYLE6(.N
M:F-QLX&82G5RTB##9,$GF[U>OCUKLDC/V>?5;&_(H#FVFX71#LEKTZTN 'Z! 9.'?4[8HE:#?M:47LXD@%_V4QI/0"_`9*>.0\N
M4`R3V^%/,T4Y"I&!Z XZ';!\^Y"FV(97_:4S
M+B>G `.)CKJ6XY.`0'>?(#GN*9>\A(O(]Y77J%6$:?KGF
M.-2`NFLH=/UN6OHL#
M!3K)VL0@S%FGTFV&/8V1-9E&@>G_8S3R7W9:+G%C^,*O0MK5
M[_ZYV=X;?Z9G=6-ZGAA'W,>7
MA0T_7H=?'GZ!^]F$_6KHWU).YP\'U(1=NZ*;]5L.D,2$5PJX)NVJ]DR8.P.P
M6%:?WIL4\G>ZBZ4S6[G.SD-PK;^NJ'@+3A`\P>5POH]AU2TJJS%-K?R^?(ZK
M!H\R9+Q+-\OFR!NO>NC^R9_2MXTHMT7JGOP->?OT;%!,\,F?;-(/!FA_WC?G
M[P/#
MD`\+O7U3&R_/(0QH>:M/\-8HBAJ*F^283WGNF?M/Q1]F(W=[Y37CCS0J0ZOW
M/`U E`J;LOJ`G
M5U_F>3VC\DL\JW>6HQW=X"AI=A7O3!`F1^UUEAIGE_7`ZA09E*:`K/1_>;K`
M59\K_J\K56()ED=F`^:.XL*-;GJ;_X9LIIN=_,CE_N*VB$9[D2E>%XJGC#""
MDC?PR5TCZ<4&E0SA]UW+/:I4/FQ+>K2RQ_+3OZY6V]E(99O8O(6%FCU"Z1TP
MI]H!,HW(0J^4_-QQ^3OJ#8'NN^;[Z9EU<6KU)I`Z 61#%)O
M=*J;E_OOGNJ([LI#4WWVNH^LS]97&TYJP-=;G)*T!D?[ZZC"]L_>_?^A[=IV
MHXAAZ*_,!Q1Q%?"$5*!"E5@0I3PA'DI;1!&TE79+X>\YOB69.,[,;)>G2MV)
M)\GD8A\?VQ\O_H3REPO#[7D9BL.2@8L#N!XIO#G1:#3S:6'1? %6MVF]0:U+XJ2J?\7-R!1% ]&=D[^)F"<1?.T6%CO
M+%B!)H%./9IU?D4]>@=:!J,+=Y9D%2RH1W> I/T"H@[ Y$Y+E#F5Q8=DA_\7=0%,79)N!=
MK`[9M24ATV!I$47K`&QBBHI>;/-'("Y;[E:_L?[.#`BHS?^T]Z/SC2&M8_'BICNDLY'&N"&
M4XD2,NKNR\WME5"`@97]\DE,%DQPO303+V38T:*9+3"!^>&ZV4)4O'0^(KX+
M3LHK[`HD)@77/;OEZCE1'Q85QJ!P'ZN\>ZWU2.K'5RCTL-X@UI*2I3*4Q7J0
MY"XYX1H.(,!+"$_=UN(H5L"B$._%4#MB*M;LZ`CN`-Z?F/@&_4,338&05]+&M=-9;SLES8=(/NB
M8-\O6!)R#C<=$;$?(1&V1-'B0$,Z*G1=T[76=),`1:TJJD=*W?M<4_WXBCX(
M',)6N,N^=LLA,;<=?58P!U#3@F)7ZODUSSC\W3\EZ#/473]=0S^&)QSKII;2
M"2HG[\=VT>.%SAE%2A%TG`I$%=6 9[XR-@]`%
MN0:H5[R_P*AP&P5]*<97SV H++E@_J
M'TNGW%;.N^YZ^O3? RZ!<4+27=SE.OU`6L]2Y.S!]W%FT#W,?CO"FP(DA0U68BCO?
MP2QP!]EA3QJ+K,KZ*S]NAS/,Z/]$Z'J0(7U:,,XXSYJKN[V#V8%[\D(Y;^VI
M$8Z.&AE#GE/%V,@8ZE&!
MO2B+$[6KHXQI,SJ(Q3CQ5=SL'T<9;4I:;C[^RM0U'3VC:+#B@A2B)-+6(SH8
M+6)2=J$>0YV5?TAHIT#)Q^>GWR\O0.3K0QJQ)C`GBT[1_4@-S/XN/=+KZ;/#
MUYWPF2;$9Z\T#Q>271B%>K8;2FI[@^@X
M"#_ *X18@-<9)1R
MLFZ>JFK`2-&:&&T^Q3A[TA)$D.C/5] 5.PQJA!)74NHE
M#JW$ X4Y)OEN+C+?,M,W;A>D$$
M12NS>M'#^G/$;TE1H'$*J$)NM%5EY(CS.N?TDS1VT*7.O6':>-#<58UD4RY[
M[3(K`[P(1/D(3\SAM_*C\,3 1'R*/-D04K-GDZ-?/
MU=T(>4KCIL"U:&B.7JE"][./'Z8[(9]41:GV(*%1.:JT;B=!H$A%.5:^:&D#
M5THA.=9P*C>!:B7%13>(UT$ .8_FT;>^(X"U$K%G-]&L7BCQ.)H^;1DB\KJ'NEVB(R2&[.[F(
MYXQ(H42I?8@+K.AES>-@'$#2;%HPJ,"TW9.TS-%#-%ED*)A-N_[\9G2G3HX]
M58G=9\F*KZRAT&R8)C,!:R&>#/I8F+]@M5-P'?I%;3$VUK_$+LOE&TJ
M#;.=0$&FKDGQNJ2*0$,AQH\3DT1$#0*P]3@S3P8T!+]T^QTK=)6C0>HG63B(
M`/?65.D5,Y'((UNE!?]CH6@?94/B?)5&2_C\EL$9=@4NL\6PJ
MQ H8-DC\PO
MD8%++-XAPB,2@-[1$2H_=;SN9N` !3:GXLLKB*.'#2M
MOYR!S^1&[IWG%LFLG+^W.^RB3W>)RR_Z\X[V\!9M`Y]ICUV-N45L3P]O8DV2FW2/^N]N<=[?06;0.?:4=NQ^86L5U-A^$H"8>Q
MBRQ.D20=AW%V4KPCE]TB9^`SN;,[SRUR5>X4^8><773MFM3B#?V&Y88URJMI
M"6]PZ& ]9"PU+9'5;P9:2P,(4^P*40^G!B%O7CMW;V%P``
M__\#`%!+`P04``8`"````"$`(2017-$%```8&```&````'AL+W=O =B@'T]\?ZTK]&:\HEX9JB^_Q\>5>VS05"
M/-:G>OAF@X9!4][]]G1NN^+Q!//^RF11OL:V'V;AF[KLVKX]#!L(MT6A\SFG
MVW0+D1[N]S7,P*0]Z*K#+OS`[G*APNW#O4W0OW7UTD_^#OIC^_)+5^]_K\\5
M9!OJ9"KPV+:?#?K;WGP%+V]G;W^R%?BS"_;5H7@^#7^U+[]6]=-Q@'(KF)&9
MV-W^V\>J+R&C$&;#K8RR/8$`^!DTM6D-R$CQU?Y^J??#<1>*>*-T)!C@P6/5
M#Y]J$S(,RN=^:)O_$&)&U#4(=T$$J'?/^88GBJGXQU&VJ,A.\&,Q%`_W7?L2
M0-?`F/VE,#W([B"RF9F`_'Q_9J#&O//!O&1?!;J' $
M3^3?(:(KL@5Y5XTP\ZG&V]H,#',(@ZLVP:YAK?P,$6FS:^:33[[P!H8HRP >\^ES3Q:T\_*,&9C(DGX^,D2DE35V!TK"9RA92SU6V5,4KU%D8*)(
M$46(X*B0!ZG3V"?R*CZ2IUO$8Q9=GO'=QOS%T:G#)J\G*<=T[> <>@L$2D<902)/>0VWE;Y?EL
M;OJ2)"5SC&MYEBH!QR[?3'*/89PG,2S+*^/G;Y7S,W1MK^F)'V2.F3;]J]>;
M@^WT-,56.;RE? 8>+ZG'LZF1"QXI
M1A9%[HB;'%R./YIG#*+ DB13B
M+76KG-_\7TJ<7XV!7:\A@^KB2'$V$X2))$CN(UJGBH\]ZZ=OU9[`T :1H
MF6-<6;406L_R-MT4I(Y%HL89^/+(KK"PNO/=01$-&46`!BU:9@:9)#:KN.08D,7!.X6B.#=V:@\GLG;Q?E^*I
M^J/HGNIS'YRJ`ZS\:*-AG`YO=O'#T%[L%>=C.\"-K/WS"#?P%=P71AN`#VT[
MO'XP1^SKG?[#_P```/__`P!02P,$%``&``@````A`#CZ(8,:!```8PX``!D`
M``!X;"]W;W)K &ULE%==CZ,V%'VOU/^`>$_`!O,1
M)5EM&$V[4BM557?[3(B3H`DXPLQDYM_WFNL!;':FX64FQ,?'YYY[ 97+I;CR&E:.HJGR%BZ;DR>O#"P+_B"*YXK7+9(T_)*WH%^>RZM\9ZN*>^BJO'EZOBX*
M45V!8E]>RO:M(W6=JEA].]6BR?<7J/N5A'GQSMU=3.BKLFB$%,=V"70>"IW6
MG'JI!TS;]:&$"I3M3L./&_ W
MH4^J`WLAGA3TVT%]!9N]R>['K@-_- D<20IL2F*^/>V(04V4).,&
MXS0IK`D
ML7YI.PW2RB@CQ+?"+3,@-$[]*!XFP=2G`O?N"2,8SY",?;(R?Z@<9TR#1J$^
M_L8\767L_:=C(H]SG3!K@G
M)#XTSHRR3--H=31EPQW)=&U6N*OGH\EO4I,G@C6XM(NR^F\)F93R9AGPRNJUI8>.47\04
MK!M 0O8QCJ!E\2
M\*(5U^YI>2]:>+CO/I[A98[#@Z>_!/!1B/;]0KV&]*^'V_\```#__P,`4$L#
M!!0`!@`(````(0`Y7RQG+@,``%D)```9````>&PO=V]R:W-H965T 2%*7*S^OAA>1#R416,:0< HU=1>7COAFEHFK`8LM+KE]:4^)4Z>++KA:2;DN(^SF8T+3S;F\N
M["N>2J%$KEVP\PSH9 :5'],:+@:&5,PJ/)&.B/[T,WG$=!-/V_BV>(V@#OJ*:K
MI10'!Q8-S*D:BDLP6(`S1C:&_!B./M9_A0HQHLDMNB0D)@X,5U">I]5\'BR]
M)\AI>M2L+S6AK=AT"BP%X/6,$/DYX^M9[U!0C"A8!61;FP?@W;.-!_.^HO![
MB44"&;J>!,4)`?-^XLD\[GT-G-$$8=@F;>2[XXFMV+REL-@F[V%#\8`M/L5L
MV(RF8YNZOOT)[D?#1-HC`G<6VY_[T:GD%COL@NOSBN(A^W"Q&4W'/G )4
M18MS9G-V^_SMO82#;-Y)/)A];30=+_1`*VMQ?,EKCXC>7%=6#-A-S\ZJM]E1
M/&0?K->UT73L2.;5A9*B<5>VQ3>-KT3_L.>AOBH3EXOH;.VO8AKW\!G:VA._:-
MRAVOE5.R'"Q]=P8[2)K>:&ZT:-K^LA4:>EI[6)3`P``6@H``!D```!X;"]W
M;W)K &ULE)9=;YLP%(;O)^T_(-^7;PB)0JHF5;=)
MFS1-^[AVP`2K@)'M-.V_WS$F!%S6I3=ML%]>/^<<^W.KO&KL;\\=C>9*QNP6)/*RI?.E-DU=GJRZ%A
M'.\KB/O9"W%V]NX>7MG7-.-,L$+:8.=HT- M:N?YR-FLNP3]IN0D1K\M4;+3)T[SK[0AD&VHDZK`GK%')?V2JR%XV7GU]D-7
M@>_ R+D`U66R,J.0K+ZCQ9YO94V\7N3`.C[>=_V
MD\B+XO^[.)JH"_`>2[Q9 >S?D918H6B
MJJ#8MGH`O`>VP%AW1N$.D@D)9.AZ$B6&;(X6#A-O\-5P6A,.M+O1P&3E\#TK
M*W&*(*PAY#`QDKW5FJ0KUB7:CFHW/S?A@7U[?2:4V.0QBK#5FG"69WYNPA._
MAT>)39[0J(S6S//,STUX%N_A46)SIT0&C]:,=LIH8+*R.G1&7_3;7XL2FYDP
M=XK61%UE;H)P&2Z2Q11N-Y8D_C)PXT$P88,.<3V;$IMLYJ[1&LWFQ=!0C:ZS
MFPB2./0N=9Z0>=#TKD?KU";;)6;];?>B9U"+YIL4
M'/AJ?YB3.FGZ*- Q(50DK8T=U3/NPEX?1X0IQU]T@C/&MNEJH]NP,
M$W"RM_A`OF%^H(VP*E*`I6LOH$MQ?3?0#Y*UW?FZ9Q+.].YG"7 2:X.X
M8$R>']0"PZUP\Q&ULE%9=;]HP%'V?M/]@^;V$?`%!
MA*I0=:NT2M.TCV>3.,1J$D>V*>V_W[TQA"0PVKVTQ#[WY-QS+C:+V]>R("]<
M:2&KF+JC,26\2F0JJFU,?_U\N)E1H@VK4E;(BL?TC6MZN_S\:;&7ZEGGG!L"
M#)6.:6Y,/7< 2\9'HD:U[!3B95R0P\JJVC:\59VA25A>.-QQ.G9**BEF&N
M/L(ALTPD_%XFNY)7QI(H7C`#^G4N:GUD*Y./T)5,/>_JFT26-5!L1"',6T-*
M29G,'[>55&Q30-^O;L"2(W?S=ST3G ^"W"RX=H\"*2D)-EI(\L_%N0>J"R)=R#Q0?UA
MW_LHB6,%-?W=,\.6"R7W!&8&7JEKAA/HSH$8&PM`DI71MOJO3J%%)+E#EIA&
ME$"YAG1>EC,O6C@O8&ERP*S.,5X?L3XB,`F0UVJ$QKL:+YM^E()@E((AH+:5
M70#N5IL_>.\%Q+B%])2`0UTE1[>N*\(B"+PC8.:?^*U(BPE:U>O.0D]!SQ&+AOZ (
M/6!+KK9\S8M"DT3N\'+P@+9=;>^M.P^_]8/U%=QGS>GOM!MPG]1LRY^8VHI*
MDX)G0#D>36':E;V1[(.1=7.L;Z2!FZ3YF,,/!PYGX7@$X$Q* ?/\WV7-S+DE+E`$,CYVZI5#OU
M?9F7M";2XRUMX,Z&BYHHN!1;7[:"DJ);5%=^%`297Q/6N)IA*B[AX)L-R^DM
MSW 6?/]%L.([:RBX#3EA`FO.[Q'ZKI7WS_E;)MJ2#N%#K"QJ;%TRV5.3@*-%Z4(E/.*Q``GT[-\-$`1\AC
M]W_/"E7.W3CSTE$0AP!WUE2J.X:4KI/OI.+U/PT*#U2:)#J0Q*#^Y@?,\A03V8C5$8%1@+Q>(W1N:CSO^E$*@E$*IH#:
MEKH`W+VV>+#O&4300RPEX)"I!-U*7GP.CHIP$;AJ"!C'S_Q:I,8DO>J54;`4
M)!]1@(OF+K396S".!^8O-2;MP@N3<9@DP:0WH1.YLB#A.(R3[!EBJ01/3)]>
M3PS!0W6#B)8:8_AC%*R=,WOGRQ+"16\EI#&&`J-@*1A]1`$N&GHP3$AC#@G%
MV>A,0A8DR-*7$\)7D_&[?STA!`_5)?;#L=08PQ^C8/D#4\+^_E`6189%;LW7$H&KM?%E.H1^GKL^X`,E7H95W%5H%C\/TJ]/"TO3A)2H-T
M4N/)N:1,1)99"*U2'QCT^[2F8DM7M*JDD_,='@8BF*5]M3^HW$0XY`?U)1Y@
ML.[W-^#\T)(M_4'$EC72J>@&*`-O!(-/Z!.(OE"\[=[B:Z[@Y-!]+>&D2.'5
M%W@`WG"NCA>X07_V7/P'``#__P,`4$L#!!0`!@`(````(0"RYYR+4PD``-\Q
M```9````>&PO=V]R:W-H965T ]'LF1;>@\3:/JBTWDX$NCH
ME71LW/>__]AM!]^KPW%3[Q^&T6@R'%3[=?V\V;\^#/_\@_TV'PZ.I]7^>;6M
M]]7#\&=U'/[^^,]_W'_4AZ_'MZHZ#70/^^/#\.UT>K\;CX_KMVJW.H[J]VJO
M7WFI#[O52?]Z>!T?WP_5ZKEIM-N.X\ED.MZM-ONA[>'N':KLZZ=NMKNMNM#E^_O?^VKG?ONHNGS79S^MET.ASL
MUG?R=5\?5D];/>X?4;I:MWTWOT#WN\WZ4!_KE]-(=S>V'Q3'O!@OQKJGQ_OG
MC1Z!L7UPJ%X>AE^B.Y7&P_'C?6/0_S;5Q]'[]^#X5G_PP^;Y7YM]I=W6\V1F
MX*FNOQJI?#9(-QY#:];,P'\.@^?J9?5M>_IO_2&JS>O;24]WID=D!G;W_+.H
MCFOMJ.YF%&>FIW6]U1]`_SW8;4QI:$=6/YJ?'YOGT]O#,)F.LMDDB;1\\%0=
M3VQCNAP.UM^.IWKW?RN*7%>VD]AUDNA/[UZ/1_$\B[+I+_22NE[TS[Z7*)W\
M2A_Z,S?#T3^[/JX>QM0UUC_;QMDHC;/9_%?,F+E>%GTO-Y@1Z4JP$V-*HC7U
MTE#&=G:;8BE6I]7C_:'^&.@5J.?O^+XRZSFZ,UVW96(GM2N A'IDNB:,N]N^/\V1Z/_ZN"W3M-$O4Q*$B;Q6F&DVW10OZ;K-L%C8J6TW;
MB%F@_^X^2Y;-PT:\U;2-!`62`N6!L3:O .#@^076&F74QJCVC9<6Z,Z[
M3YN$GS4_HYB$D@(E\X3Z=$Y#;&&HF S`->HL)IL$4 2`8N=X68>2)7LJ?%Z)I]3#4!G=U%V5I.(U+JYDWZSF.%\ED3FO35RSF
MDVA*EG1A!;UY)06,`DZ!H$!2H#P06*/G'ZRY7!2F56C-/"7C6EI-UE@SG>EL
MTY=ELW7E5M`/O*"@I(!1P"D0%$@*E`4U!]20&C@%,@*)`4*`\$/NA#&'R87EPLIA7U@2X6J[$5$4V2
M.*,5X0OB-(ZF1%!80>]D20&C@%,@*)`4*`\$SIC@[R>!SRO#J*DC&=D^K,8Z
MDLX36"+^ZYE>0F'SPK[LV4$!HX!3("B0%"@/!';H+!/8<=UY8EI16\C!M[2:
MU*Z/THTALB*[8 $$O8TE$`:$`Q%`
M)!#ED]`BD\9\BSX_22(;WD)K2&A8.E$_L!Q(`:0$PH!P(`*(!*)\$@[>!#!_
M\% E`%("84`X$`%$`E$^"4TPZ8N:.I'=173H@ETB#Q1QE(&BMA((`\*!""`2B/)):)*)9M2D
M*\*'372!232++R,K PZD
M`%("84`X$`%$`E$^"4V@6?2ZDR;&3#K/:"9U(GTR]YDM(SMQWHG:1%X`*8$P
M(!R(`"*!*)^$ON@BOV&%Q*89N6:!&V).Y!>';=:3`C0E$`:$`Q%`)!#ED]"$
MVV)J;!/HYS'$B?HAYT`*("40!H0#$4`D$.63T`0:1*]MJ%\AE)2@84`X$`%$`E$^"7TYEU$O'ZSF&SM8(>387#J17QR044%3`F%`
M.!`!1`)1/@E-.)=1KSA#;'R\L$)HQLQC2@H@)1`&A`,10"00Y9/0A-MR:'Q-
M#G4BOQ)LLYX43F-CF,FA$$5+Z(8!X4`$$`E$^21TY5SPO*(TS@5/>M M@QQ(T9'^]$WIZ5MVHG9O84`X$`%$`E$^"7VAV?/S"_OX3.:$NU].Y/L!F1,T
M)1`&A`,10"00Y9-@\&9_A%AQN2B:9I PQXA`H+^7`84,%.G,7%:'=^Z5
M_[:A9S2/?KYJDG,YE-S66#I1[TP.I`!2`F%`.!`!1`)1/@D'?UL.3:[)H4[D
MFV";]:0`30F$`>%`!!`)1/DD-,&$OE^_9D]L5M3UT%V$X5?T3M3>R)A$,U*8
M>:A(ILDL)>54.$GO6PF$`>%`!!`)1/DD=(FFT@OKY%P:I??"$IH] !*>FYE'K9E*89N?DUI;>'G]%M-1N:+T8-]0-_^ SG^J3?K"^
M^>>;_H\4E7XB>C+2XI>Z/K6_F#?H_FO&XU\```#__P,`4$L#!!0`!@`(````
M(0"X2CL2U@(``*4'```9````>&PO=V]R:W-H965T ;ZX?18D>F-)<5C$.O0`C5E&9\BJ/\>]?=U=+C+0A54I*6;$8
M/S&-K[/VR.4MWK@CP*'2,2Z,J=>^KVG!!-&>K%D%.YE4@AAX5+FO:\5(
MVAP2I1\%P=P7A%?8.:S56SQDEG'*;B4]"%899Z)820SPZX+7NG43]"UV@JC[
M0WU%I:C!8L]+;IX:4XP$77_-*ZG(OH2Z'\,IH:UW\W!F+SA54LO,>G.]#S
MFE?^R@>G[2;E4(&-'2F6Q?@F7"M!&
MBK].%)ZLG$ET,ID`_6D_\J+E+)S-_^_B.Z*FP%MBR':CY!'!I8'/U#6Q5S!<
M@[.M;`+Y.(ZNUDNE0HW6Y,:ZQ'B%$1S7T)Z'[7(>;?P'R)2>-+MSS4B1M`K;
M"L#K&*'R/N/+J; G%>]`2
MV4.0:@]@.1\A[)QFVE$GO84!P71(\'H65AQC**\K?3I==I6Y>)PFC**F;:&W
M6`W_/EV-VS0^L5SU-0-:R*:?U^NT5CRBG3WWP=$Z34L[VDTN[0Z8YN]ALN(Q
M4SA*T&DZ)F\UW$\N[P^X%N_ALN(QUZA/.Z>!;CUW?S:Z=S`TK-S8]%-
M#;`CS]Z;;K6;QC>1O %O!SR.`+'G@@SJ0T[8,=']T/[/8?````
M__\#`%!+`P04``8`"````"$` LRJRB>/9%JU2
MEN75,;+_^?OU*;0MWB15EA2LHI']2;G];?OK+YLKJ]_XB=+&`H:*1_:I: "R/KK\7-,DDP^5A>M[7N"625[9R+"NQW"PPR%/
MZ0M++R6M&B2I:9$TH)^?\C/OV,IT#%V9U&^7\U/*RC-0[/,B;SXEJ6V5Z?K[
ML6)ULB\@[@\R3]*.6UX,Z,L\K1EGA\8!.A>%#F->N2L7F+:;+(CW3`S!P^[@
MZ5=9@3]K*Z.'Y%(T?['K[S0_GAHH]P(B$H&ML\\7RE/(*-`X_D(PI:P``?#?
M*G.Q-"`CR8?\O.99 `LEMZ,`-S:4]Z\YH+2MM(+;UCY'X)(2X4D?DL"
MGRT)A#SV84!*!?#9/DQ\QP\79!%\+V18\SJ&X[]LPF&_<=RA(VF)V0XRO(^(.
M(>H(\GJ-D"Y5X_V2=5($6$@1)13:=C@`W+VVF3'O'8370S0ED*'Q2@08LJE,
M'`:+GA?%(6;>JXV5`6WF^929!3BR(:P^Y#`(C)D1,Y?%ND4K5<7=/;,0L-+'
MAR_`IHBE(0(Q2OC*@!9^,&5F`?XJ\8A19E8&M)F7^LQ=@SQ>A.(A,_;0B!TQ
M"UF`(/#@3P?$*F`>+%2`IE!L44H+/U8FP*:RE3[Q#C&H;":$F -ER;1AK:ED91="T)QX4J;&]M*
M0Q@EU]4))QQ=4H*^J;7[DA@U;4'M 2>.=^8
M<5MH0:C,=P*CFK%VWW-N@>G")OFU>!OZL@%;4) 2[KY_:V!=V20_
M)^C-6C&'[8GUN?8(&T(*4^J@C6GU\X:6*03Y>
ML1)MIL/ L.-!,4#.TZ?E@LY"4D?U(#=(H:O`<
MB">=DM9'&M.BX%;*+N*,YT-@_6A__GSVQ6NX,;Z# K/6O@0"B_GN`'``J'$L\!\(&QIKL02ZK_
M26'[/P```/__`P!02P,$%``&``@````A`%<1BJ\0`@``)00``!D```!X;"]W
M;W)K &ULC)/;CILP$(;O*_4=+-\O!M(AFY;P?A:L[WD
MRD6(X0-U4+_MQ6@O-,G>@Y/4[/;C`]-R!,16#,*=`A0CR8K73FE#MP/X/F:?
M*+NPP^$.+P4SVNK6)8`CL=![SX_DD0"I+AL!#GS;D>%MA9^SXB7'I"Y#?WX)
M/MF;9V1[/7TVHODJ%(=FPYC\`+9:[[STM?&O()C<16_"`-X,:GA+]X/[KJ RJ()#\6@%DO:W@WYF]N,)PO I_5TE,'2<=&S'2
MCG^CIA/*HH&W`$Z3)8S%Q#G'@]-C,+S5#N83'GOX'#ET(TU`W&KM+@>_2=
MO/X#``#__P,`4$L#!!0`!@`(````(0`7T2IH:`,``"`*```9````>&PO=V]R
M:W-H965T 69B9W'_6E?."^&"LF;I^A/D
M.J3)64&;W=+]^>/Q+G4=(7%3X(HU9.F^$>'>KSY^6!P9?Q9[0J0##HU8NGLI
MV[GGB7Q/:BPFK"4-_%(R7F,)EWSGB9837'1)=>4%""5>C6GC:H C=ZOP6NQKSYT-[E[.Z!8LMK:A\ZTQ=I\[G3[N&
M1*DL1\G[R-X>CE==3(L\6K!V=&!D0-@T6(UP/X M`"00T]V45SV8+[P4:DI\T:ZV!]T$3C!6;7J&JKVPS
M(^`![P`-13.A_][#GDV)%5OONM8!$R2T0"X5"4)C37:I"98TH];`
MS!E3;(]HK^FWBLP(C"AAIS,IK],IL4UGU6>M->?Z;'1`WU!1C+K7,'%Z=S1R
M1G!PC([HNCT=O5O$+LWF3,?_N3Z)QF6T=OK-(!KJ:$8TJSZH]5%4$[XC&U)5
MPLG901W"/MR:0W1X0'@(U%;G#3_`^=SB'?F*^8XVPJE(":EHHN:%ZQ->7TC6
M=@?=EDDXF;NO>W@2(W#$H`F(2\9D?Z'^8'BV6_T!``#__P,`4$L#!!0`!@`(
M````(0#MBW_8$0,``(&PO=V]R:W-H965T []H64
M`*,P'@))SCWWW&/[7F:W+W7E/7.EA6Q20OV0>+S)9"Z:54I^_7RX&1-/&];D
MK)(-3\DKU^1V_O'#;"/5DRXY-QXP-#HEI3'M-`AT5O*::5^VO($WA50U,W"K
M5H%N%6>Y"ZJK(`K#45`ST1!DF*I+.&11B(S?RVQ=\\8@B>(5,Z!?EZ+5.[8Z
MNX2N9NIIW=YDLFZ!8BDJ85X=*?'J;/JX:J1BRPKJ?J$#ENVXW MM9'U'P31+1621%L2^-Z2T)$_B(;)^`*6`!6Y`N^98?.9DAL/=@WD
MU"VS>Y!.@=E6%H,_J*.K]5^E0HV69&%94C(A'H1K6)_G^8B&L^`9/,VVF#O$
MP+7#1!TB`#6=))"Q+^FTR;O,%FPS6].ME#M\L)\F/ITFOB:-!8,S^^(3VO%B
M9L0,W$[:KV?03[2S^'Q=-B@E4$SGUH@>)D3,V/D]B:-!.!YWDGJ.PB:[W%$+
M[F>F]&VEL%3$') G+;3MO43
M9^;\@MJ@P^2'MB)FB,G'"4U&R6D%=G-X
M$;G^U[V`,=BR%?_&U$HTVJMX`:&AGT`'43A(\&PO=V]R:W-H965T MODT@2E(UJ;I5VJ1IVL>S`R98!8QLIVG__:YQ/C!IN^0EP>;XW'//M:^9W;XT
MM?-,A62\G:/`]9%#VYP7K-W,T>]?#S J42W2X^?YKMN'B2
M%:7*`896SE&E5#?U/)E7M"'2Y1UMX4W)14,4#,7&DYV@I.@7-;47^G[B-82U
MR#!,Q24 2\Z8!BS6JF
M7GM2Y#3Y]''3 3]$L0D/W#W@S/ZAN6"2UXJ%^@\(_0\Y\S+/&!:S`H&
M&6C;'4'+.;H+IJO`1]YBUAOTA]&='#P[LN*[+X(5WUA+P6VHDZ[`FO,G#7TL
M]!0L]LY6/_05^"&5LDVEH-P8,M*)38O7>RISJ!:4KDY%NI>//7@((]E2$)
M]R01J-^_#]TPQ0%._L_B&45]@O=$D<5,\)T#NP9BRH[H/1A,@5EG%K^;&:2D
MU]SI1?U20$LHQ_,"9_[,>P8+\SUF>8Z);,3J#<2)Q`-]1Y&0^E#DV[8?Q&DP
M&(RT&DQ8D8'F\L@:/$=`=8P DM;?(TV#;:UX2P\\O9E71H,-@7UDW! 7!-9
M@\>N)*/(!K-W!< @`'Q\N#1Y; 9AL9S,"2P805
M.;,CZ]X306_^6(%>-+9FE/G28(PU<1A%T:FO]!)7%B#.\.F])1#NE"N\Z=&V
M-)R-SM!R#S(-`&H23[)378PX"Q+$4&2C>]0U[S17&PO=V]R:W-H965T _.&P]'R]J4JR3-76L@ZH:$74,+K5&:BWB;TS^^'
MFSDEVK`Z8Z6L>4)?N::WJ\^?EGNIGG3!N2'`4.N$%L8TL>_KM.`5TYYL>`U?
M =LU-*JL&*#:B%.;5DE)2I?'CMI:*;4KP_1*.67KDMB]G
M])5(E=0R-Q[0^2[1*YPE=A_%=&%)_M;0%^BOX7G>>
MB2[D_JL2V7=1 [`S\5R7C.=J7Y)???N-@6
M!K9[`H[06)R]WG.=0D6!QHLFR)3*$A*`*ZD$M@94A+W8^UYDIDCH*/2B^22<
M3`%/-ER;!X& V;8:JGD
MGD#7@*1N&/9@&`/QL".P@M@U@A.ZH`1RU;`-SZMH/EOZSU"Z]("Y [%T[N+"OX2(G
M=L)A.W!>NK*7[2"X+^4B`W:P,;K$;BJ-KO!C5_95#J$31]&P(T1UE2];LN@3
M-21(:.<0N=GK1E/%U99_X66I22IW.% &PO
M=V]R:W-H965T W
MFA^4Z)PG,:)E#OJWC>SM"YOBE]`I9AX._177J@>*O6RE>QY(*5$\OZ\[;=B^
M!=]/< 4"H`M]HZ>>LS`+@6F[*24XP-B)$55!=W%^D]%P
MNQGR^2/%T4[>B6WT\8N1Y3?9"0@;E@D78*_U`T+O2RS!Y/!D]MVP`#\,*47%
M#JW[J8]?A:P;!ZN]!$/H*R^?;X7E$"C0!,D2F;ANH0%X$B5Q9T`@[*F@"0C+
MTC4%7:R"Y3I:Q``G>V'=G41*2OC!.JW^>E`\-.6YAM9NF6/;C=%'`LL-:-LS
MW#QQ#L3O]P)-(':'X()FE(",A?P>MTFVV(2/8)K_Q]QX##Q?,2,B!-%1&=0N
M5T8P*F,JV,J-+TQE7AN9R2SF,ACZ`I;NO%&"
MYX407-#EU,=II!X40]>OF6;+L9V97=@)EZ>*X$%]C-570`HW\M35:LZ+,28I
M1'#>'LZ:"_A*/#>\>M_+>JYY7@K! QY]))&60"MG9?`>7,)
M7WGC9OV^&S@V4]7S4@B>2_G*9+OY>\8?9B5,+3Z+MK6$ZP/>(0D &PO=V]R:W-H965T ??N.L4UL3RZ;O?;- J
MJ[7^O>KUSYM??UF]M=US?ZRJ00.%T2CW>_KLHK:\J6IS@,5Z:I3,V*IQ/X_ M3L.?[5M6U8?C`,OM@4?$L6#W/:KZ$B(*,C/;(TIE>X()P+]:4Y/4@(@4W]:Z
M#3>N=\-QK3O^S)N;C@7FVE/5#TE-)'6M?.F'MOF'&HT>32(.$X$K$['MV-
M4X7KQZ:Z9`/A^MA4#;JV8ZI$Q5!L5EW[IL'^@]7K+P79S58`:CQ':'RGK/E1
MTD"V$)$O1&6MPWC(AQXR_75C+Q B]EM[;4QAMKU+B]Y,8KW4/4N9.8C,C"/!DY)BF'(UP,II6&9$8D021%)$,D5PDDN]0
M$A_WG1B/OO,9;QEQIN0.$8D0B1%)$$D1R1#)12)Y!?7Z P5(Y`PPO)9
MRO)-1CP8$2(Q(@DB*2(9(KE()$?A>'G<46(L.\J(?5T^1")$8D021%)$,D1R
MD4A>D793.('N;TAB+'M%B24D)2(1)2Y Z?-ZV,%\H/C=BXL`I2\]>HB&'A!(Q)(A$E+A+
M>EB;EBLG?#S]G3N1((UTLAD/?--2#K9L^CO7R$4-*1`6'#EB)&YX#$TG=WFT
MEGUFB/2WTQH[IBU[%7(K?]H#$4,V3&T::-O*P)C?D -`#^S,/5D\P>+I
M0^*9(F[# BA*=@'752;%.)NM8 4/C+!2BE#@E*F*+F^Y>$-),Y)C@!IM80(_$2N$`6E0%.D
MY(JR$4*RYV"@L+X10\+ZQ@R]ERM(*\5:&4 7,A$Y*CA3IU81(
MO9,KK+,3 ^&94$GD-4BP>,J0=U4]))W`OJUO?RH
M=Q8[2=J12A%EZ'HVA9!?8SF[H@BC&*,$HQ2C#*-<0I+?D(_(;]\9GQD^^-)N
M5)*+-$=P.$Y9X9C*F[SP:L6+5H11C%&"48I1AE$N(3DK.:,'V3O_4">#T!`BKW`WB:O\'G`3P/
MW^#6,B!+?^,OM@D?"\;\4^X1+0)X=,4CTD4`3Z*81\L`'NXP3Y`KQ.7XE#]
M7G2'^MQKIVH/"V*.N=_1[QOTQ\#V_E,[P'>)L0P +ZN:G)D]!&JC:G
M<1!1(EJN"MEN B8:90'6BA5]*I1MFX5-O0M-IP0J7U-1A$D6SL&&RI9XAT^=PJ+*4
M7-PJOFU$:SV)%C6S4+^I9&?>V!I^#EW#]..VN^"JZ8!B+6MI7QPI)0W/[C>M
MTFQ=@^_G>,+X&[?[.*!O)-?*J-(&0!?Z0@\]S\-Y"$S+12'!`;:=:%'F=!5G
M-W%,P^7"->B/%#LS>">F4KNO6A;?92N@VS`GG,!:J4>$WA<8@N3P(/O.3>"'
M)H4HV;:V/]7NFY";RL*XI^`(C67%RZTP'#H*-$$R12:N:B@`GJ21>#2@(^PY
MIPD(R\)6.4UGP?0R2F.`D[4P]DXB)25\:ZQJ_GJ0 M@#8=P],39T!\O!8H`K$K!.=T3@G(&&C@TS*-YHOP"4SS5\R-Q\"SQR0](@31
M7AG4SE=&,"IC5["4&Q\8RJ3'9=*Q##8]A=&=-HI)@!N82..HY_<5>,S$C7SH
M:W(HF,QPHA]H8EY.IR-+!]WUH!@,].U-X[BO;-1@4#R_P0AVZGV'?<1?B!'O
M;,R+'9U$\P#"IYN*>6,)'P&)H9MWCLOE6/6T%(+'4CYRQ`UNU\$%0WM.9H<
M/VZ(&BJ?MN30>VI(`&?I_XWRJ]3OJT;HC?@BZMH0KK:X)A/80'VT7^&K!//W
MXY-L]=JL_A=8K1W;B`>F-[(UI!8E?6Y%I96*KNM8(_40%;
M*`J@JZ52]NT#E,/^;WGY#P``__\#`%!+`P04``8`"````"$`:OGP18X"``!I
M!@``&0```'AL+W=O XR,I6U!&]7R'+]P@Q\7GS_-CTKO
M3,VY1O6A3?1 Z-;\`/C0I>TGUC?ZKC-RZJVD*W4RC(U945+VMN&!@*-%&2.B:F&D@`GD@*
M-QE@"#WY]U$4MLYQ,HDF23J[CP&/MMS8C7",(%PCITQJX"!9X])>@0!T5X9U&Y7=F"G[+QUJ:Q"X%)F_+;,^",R
M#IQC>/;)C^-ISQN4`V;B!^:RGLE'A!PXQ^D@_RLK`RB&&ULE%==;Z,X%'U?:?\#XGT"!AQ"E&0T2=7=
MD7:DU6H_G@DX"2I@A-VF_?=[[4N"#1F2OK3!.3[WXUR.G=77]ZITWE@K"EZO
M73+S78?5& >)[,2J5,QXPVKXYL#;*I7PV!X]T;0LS?6FJO0"WY][55K4+C(L
MVT 0O3D4C+FQ5]@A=E;8OK\V7C%EP)[S%P7]
MGJLEV.R-=C]K!?YLG9P=TM=2_L7/O[/B>)(@-X6*5&'+_..)B0PZ"C2S@"JF
MC)>0`/QUJD*-!G0D?=?_ST4N3VLWG,]H[("?EU5!.V/!"@PL9F#5G1"F9SH!M6GM`N4U`9K0
M00:(6>C>Q7X 8]PLHQLG. F(ROP'5D08@0V%JS` =%D6C[ZC28 W@B"-J@Z5Q!./3.#H221)%/Z6)@(#L+$E`X
M&TC/8C=G8+!WFG/+61>#EX4@"/,C012'_NC@L2`^B6C40^S\/F6N9.RN03@:
M'01U(TWH(ECTP=%C.IZNA"GO5Y>03^B+?FKJ2^.!>%M-:8_VSVR8#'SXCGIH
MG=#[Z[DX.I@UHQW\8KCJ?F;>" 1!V"Y=NY8-XCR$1B:/A/*E[
M>0\9GIAXX\8+:9,>V8^T/1:U&ULC%7;;MLP#'T?
ML'\0]%[? _6GS^M
M]E(]ZY)S0P"AT0DMC6ECW]=IR6NF/=GR!K[D4M7,P%$5OFX59YD-JBL_"H*Y
M7S/14(<0JVLP9)Z+E#_(=%?SQC@0Q2MF(']=BE9W:'5Z#5S-U/.NO4EEW0+$
M5E3"O%E02NHT?BH:J=BV`MVOX92E';8]','7(E52R]QX`.>[1(\U+_VE#TCK
M529``9:=*)XG=!/&]V%(_?7*%NBOX'L]>">ZE/NO2F3?1 LUUE?LG]-RZ*TD"[9Z`(A<79VP/7*5048+QHADBI
MK"`!>)):X&A`1=AK0B,@%IDI$SJ9>[/;8!*".]ER;1X%0E*2[K21]3_G9!7Y
M#LNF]L`,6Z^4W!/H-WCKEN'TA#$`=SDYA#[+ ?>^V<8TDQ.TTS&
M-*A\>K8;'1T&0=V'(L)#H IT'E,Y2SNWH_4X-H]N!G1(KRB7Q@XYG"6`SFSTW+@$@UI+\M!YS&5
MLYR0@Z,Q!+ZZ.S9P3/)N.A`T/RT(O8;$EQ59[P,V!(#+^3%O;L6Z/59S5?`O
MO*HT2>4.UV."<2VFZ`]Z4_G>]_@\``/__`P!02P,$
M%``&``@````A`%_>(=NP`@``MP8``!D```!X;"]W;W)K &ULC%5=;YLP%'V?M/]@^;TAD"8D**1*5W6KM$G3M(]GQQBPBC&RG:;]
M][O77B@T;=87A,WQ.?>>>WU97SVJACP(8Z5N U PZ'+4G)QH_E>B=8%$B,:YB!^6\O.
M'MD4?P^=8N9^WUUPK3J@V,E&NB=/2HGBV5W5:L-V#>3]&%\R?N3VBQ-Z);G1
M5I=N`G11"/0TYU6TBH!ILRXD9("V$R/*G&[C['I)H\W:^_-;BH,=O!-;Z\-G
M(XNOLA5@-I0)"[#3^AZA=P5NP>'HY/2M+\!W0PI1LGWC?NC#%R&KVD&UYY`0
MYI453S?" !(EL3/`$/:8TP2$9>'JG,X6DWDZG<4`)SMA
MW:U$2DKXWCJM_@10[(,*7#ZT&^;89FWT@4"Y`6T[ALT39T",, M^>H
MC&!41KLPE.NP,929O2XS&\L/T00,)?>]F%>EV/!\T((
MAE(,W4J7+X0"YE0(NF%H(&:6++"GWFBUHY=X+J?SH7=)NGHA&D`Q],BS! .AD.N;U%VD!=^%_">*YL438`8EA-O'KV>`8
M'ER5\]D@>"P5=@;5"H,BW$8E3"4^B::QA.L]#H$$KE&_V\^G;8)M]7)_GFW]
MW(KZ#S`W.E:);\Q4LK6D$2503B 4)&)M`"``"(!P``
M&0```'AL+W=O MA;%2-QF-)B$EHN$ZETV9T=^_[JX^46(=:W)6ZT9D]%E8>KW^^&&UU^;!5D(X
M`@R-S6CE7)L&@>654,Q.="L:^*701C$'CZ8,;&L$R[M#J@[B,%P$BLF&>H;4
MO(=#%X7DXE;SG1*-\R1&U,R!?UO)UA[9%'\/G6+F8==> U^ZOU7( E#4F?) P+P!;5N&MR=*@1@]S8#-,_0NWS()[I!D@RP975("QRUT]G$=+Y:KX!&Z
MP0^8&X^!SQ=,CPC`36\);`PMO=Z>HS*"41G;A59N?&$H,WU=9CJ6P>13F.EE
M.3S43>`E1!+V_-Z!Q\RZM@]SS "^0T;B,GB!=ZI
M_X3# S*88_)&BQ=C(Y<3([A3[T?I*_Z5'-V09,R+`9/D
M'0'QW%C"5Z)QY%D?>:2*>WCPJEQ.@^"QE*^`%.Z(X;V`UV;(BVFB&3BZ+("G
MQ@*^ C]+[`'6U:*[\R4LK&D%@5PAI,$;J/QF]0_.-UV.VVK'6S`
M[FL%_W@"-D,X`7"AM3L^X!SZ_]#U/P```/__`P!02P,$%``&``@````A`'#`
MIA/H`@``"0@``!@```!X;"]W;W)K ;
MCQ_6!R$?5,681L#0J@Q76G T8@U1GNA8"V\*(1NB82E+7W62D;P/:FH_
M"H+4;PAOL658R4LX1%%PRNX$W3>LU99$LIIHT*\JWJD36T,OH6N(?-AW5U0T
M'5#L>,WU ^G0@;$=259D^"9?Z5MPS,AC*9`NR$
M>##0+[G9@F#_+/J^+\!WB7)6D'VM?XC#9\;+2D.U$TC(Y+7*G^^8HF`HT'A1
M8IBHJ$$`_**&F\X`0\A3_W_@N:XR'*=>,@_B$.!HQY2^YX82([I76C1_+"@\
M4EF2Z$@2@_KC^\B+%DF8I&^S^%91G^`=T62SEN*`H&G@3-41TX+A"IA/F5D=
M0ZZOI0HY&I(;PY+A)4:0A8+R/&["8+;V'\%3>L3 NW*9
M-A/D:IL[VBQFY,YH8^).^AX%)LA5X+IC,4GO3AR'L]21N!T#PA"^Q7_^313.
MWZ/0!+D*%XY'%C/R:+0Q46#N(N=+?[N#3)"KP/7(8FP'S:.1AC-AN78
M8U$2Q,OED(75:$>OG4P-DR7;LKI6B(J]&:L1^#_L#A/_)C*?C;-_"S=!/S?]
MX05,XHZ4[!N1)6\5JED!E($WAV:2=I;;A19=/P]W0L,,[A\KN'(9#)'``W`A
MA#XMS(@:+O'-7P```/__`P!02P,$%``&``@````A``6X@?OK"```62H``!@`
M``!X;"]W;W)K S8RN)L;9E6-[-[K_O4$-)G!%ER[T/UQO.X8AG#CD\3\
MV\_C8?:CO-3[ZO0R%TMO/BM/VVJW/WV\S/_]KV*QGL_JZ^:TVQRJ4_DR_U76
M\]]>__RGYZ_J\JW^+,OK##* =S4R^I /E8U>=+N=DUDXZ'E?2\G_?;\NLVGX_EJ ;*OC&5*\[0_[ZZ\FZ7QVW#[]\7&J+INW`_#^
M*?S-MLW=_#!(?]QO+U5=O5^7D&Z%"QURCE?Q"C*]/N_VP$"7?78IWU_FOXNG
MPI?SU>MS4Z#_[,NOVOKWK/ZLOOYRV>_^MC^54&W022OP5E7?-/2/G1Z"R:O!
M[*)1X!^7V:Y\WWP_7/]9??VUW']\7D'N`!AI8D^[7UE9;Z&BD&8I`YUI6QU@
M`?#_V7&OMP949/.S^?S:[ZZ?+W,5+H/(4P+@L[>ROA9[G7(^VWZOK]7QOP@2
M)A4FD28)?)HD0CR<1)DD\&F22'\9"2]6T?25^"8)?/9)A.^%#["!IS4E@OSY?J:P8'",I?GS?Z.(HG2*A%
M5K!5W"*#NGK.[WI2,Q70->S,'Z]0S.?5#]A-6X-)'!CA44SJP@B*R5P823&Y
M"Z,HIG!A_`ZS@G)T-8'-9M?D=BTT^&4._^]K(8(N;U.O!#'KIE*+4,`)$!&%
MI#:$E2FS8\KO%]TDS^UH%/J!QW,7-F(A5!2%L..ZYQ/JE)
MG!%3+$&,WRR2$4AOQ#([)KF8=G#!HX4=[1])Z$)K>9RNGL3I]AL$!42,)6`[
MX!(08RB@A!X9R7ZYN&O;V9U^U@`A!$WI<4)Z$B?$=E""&+=^-V*9'>/RV;$%
M"Q9VL"\'(1O]/V3U)$:6ESM!C*4>#AB%`J]?3R-/9H=]$Q.FRE26(
ML13$`51P(8<2VG&4D&O(4Q;6`"$EP!'8K&[?B`V:TV'7<6)`9@,JY7MKGW78
MU&"3`?=M;P9X$T^:E"]S2\EN
MQ-5*31`+%:P]7X4#LOC8/F/19=0&W[8V0GL!B\^T"[Z9Q17E)L>`G&JEMX(9
M";)CGI/@@D4+$AW34%N#QSFCH:!:LA.4",MU-(TS[4:<6B( RE#$(6M#J8$X5 %["7Y_YMW\7D?K&51'
M[0NF\T$70?FPSI8(!)E]YGMQ%,2LU*G!C`AI>Y5AOQFFE^QD%"/I*7/M&:8S
M1X=!F*M^CZ!+%98-,0>R'7$JB4$L5`A*2L'V1C[(6-@CE(_V!]/YH)N@?%A_
M2P2":NN1W,A MH30>LBS285EX6TX,R/23,.2[T,2=]+);P?Q.YF)D,B4,.VKZ+I0:S?3R^+$S
M("2\D"% CWSH:0%;0D$P"Q7',HY4?\'0"CSD@J3#!5F9\0XQ
M(,L-=".N%F2"6#`@[,DH8@ 3&2G-)_R`M)AQ>2K'4D!H0K\^%+X8"U[=0@1EC;;D@PWY$/DBOV
M^&(D.66MO84E^IU^C$Z$BLW.3B(MNX*&J!MQ;F*$&_E$&$5\^^3=_'X36\\@
M?/2?@J;S:=#L:E5,H\2`6A75P-(:@%M$$F2I E/4*):4=B[ UVM9U!>S`%-Y.5R0NQJ3Q2"P/7!'.>7,3\.XJ"S.^?3.DSOZ3I^S!VN_4JAV_BMB4Q(%M6VPGU"S)L,8C5
M"GW7:6VG]ZI:(Y06LT,35778(I^UR439/D?%\!=CQB0UB!%1<3H&6>Z WC^8DM2+E\$2#W\P-"- V$$$0!VKPE80!N=6^% U5=VQ_@
MN:ONI=#7_P$``/__`P!02P,$%``&``@````A`,+(AU>@"@``NS,``!@```!X
M;"]W;W)K C=`K?`X7"W^^PZ2F(TM@+;;=I_?T/-6)P9R;;L/NRVXF?RT\SP^TA*NO_M
MY_IM\J/>[E;-YF%J;I/II-XLFZ?5YN5A^K__?KDIII/=?K%Y6KPUF_IA^JO>
M37][_/O?[C^:[;?=:UWO)]##9O [V!EN=FNU[L
MX9_;E]GN?5LOGMH?K=]F-DG\;+U8;:;8P]UV3!_-\_-J67]NEM_7]6:/G6SK
MM\4>^.]>5^^[0V_KY9CNUHOMM^_O-\MF_0Y=?%V]K?:_VDZGD_7R[O>73;-=
M?'V#^_YITL7RT'?[CU[WZ]5RV^R:Y_TM=#=#HOU[+F?E#'IZO']:P1V$L$^V
M]?/#]).YFQ?)=/9XWP;HSU7]L6-_G^Q>FX]_;%=/_UIM:H@VY"EDX&O3?`O0
MWY_")?CQK/?K+VT&_KV=/-7/B^]O^_\T'_^L5R^O>TAW!G<4;NSNZ=?G>K>$
MB$(WMS8+/2V;-R``_YVL5Z$T("*+G^W_/U9/^]>'J?.W69XX`_#)UWJW_[(*
M74XGR^^[?;/^"T&&NL).+'7B@#VUV[&=S)!0>W^?%_O%X_VV^9A`TDJ"6`9H4(/
MC)"L#5#J;9[K P7BP8QR,S9S*;=N&W['-O3
MEOF10@[&Q*;]Z6`%L.*4Q7Z1$V+TF,@'VRB2UL4XBC"!>HRG%,":DJYPQ`Q3
MPC:D9%QJRZA6@I0!JQC/JD5+6F4FDU,1AH9.C/$*,2>$)BYY!:UD"0SSS0'7
MTXDTJ+!J," ]X(A(";/\BP6IN!G+[*$%BTMP>G@$`8K_L;"6L(KRY\+
MB$F2]!BYJWS!HB^`2,4%8Z8H5`1B*>179(B"5#-U.*W^%H6=JT)OR4,8#)&W
MF6.++:QF@8` LK?V]Q9KFNWY2N[$F50!A3F"2*F22GA/\,N;[@]WP][(!A+4=A,7F9F%C<
ME%L.40C)[BJ]MP-Z[Z,]HX80B&CZK+"YTR(B,.`'6>'BK4BB%PF^1:46\Y-9
M'A%D "/V[1X5#!H73CPDR?0U4$PCBEA2\SQ7,N
M$-9F:5G&U9VD>9$SN`%GR+4S$.A`S_7+B_M"!D\V.DV1U)0IC(S@@#GD:NI5
M#D&ZP*G$N"TXZTJ^T1,,4^4*IRNL12MAR^.J"X6-0,/,J!$C:Z3H26+*#,:%
M+L5=@2P^;0H$.D(0>Z`9#+OTQ!XKO#3(,S.%D111U"5%;0YMUW` 9P)KL#IL`6@Y1=!!UAAHV47;YCE;F]R!+2`4O(M5<1B&*2
M]@U!`C+8CQX)V46F$)X7:*?/HTY1R+C@YZF6Y#EU PFZJBP]5'8=DN8&CMCBQ)$_E&V>J;L`O"N4&58H@Y)?E
M-M&//N824;@D/79:F5[D%RU:25ZA++TB$-P3.F&10^=`RJY1[@4\3ZWN["`&!#:"@+_AE%]E%B]:QTT9&((Q=GNC#_;EH-PX>
M'46QE-RN +#2M#49*2@A(ZZ041JTS(JH22IG&(DR0''8,M_(LD=PR1ETN.(`%V0DM]5
M=I$-V`6+`/'C7@"KX[[=4C>G"2J?&!G``;_0#Z^JC/L%/&\>((B(TP254XPD
MB$HOYHO>!%89@K#(7!D.)G09 ;AT3QD&6KS(!"585[H1W)S`ISFIVSE3&X'[*2WR_#<3N!U
MD5[M$>`TKZM @54$.L*/
MVPN P9.[D6S*\RD)\WT)L[VTX`AUAR/VEA*<6<4 "<
MI(L`.@B!CO#C]I(:#W^ZGPN"^8"!A$1:`C_+BWP'/9S#,1E0P'[..\P>5]^["LR#'%!#K"
M$'O`"'KKG8TB)0DJ_PAKA!$A[/L(O"31%1$11-`1@MQD3.EA&<9>;),4!ZQD
M!,6^E=@D2BU11-`1BMB(,80W.OD21Q)45G)F>O0M!(Y4=.P0Q#:6.;LB1U(?MS6ZD.Q*D<0'YU=D:,K%S@S^I#Z:W?*N"Z+Q)9DK]
MSS`;4'U]#%?E".)Q85?DZ$K;SXR.BGPF*PCBH[,K8G3XMD$O45KP=99
M(1"^`*YW(Z(1Q#[U[($Z,L-O)?!;@G6]?:GG]=O;;K)LOH?O("P %^\U'\LMB^KS6[R5C]#E\EMF#);_/@"_[%O
MWMLO&+XV>_AHHOWK*WPD4\-K_\DM@)^;9G_X1WC)K?OLYO'_````__\#`%!+
M`P04``8`"````"$`&+.,+DT2``!19```&````'AL+W=O JJ(MG_IB[Y\+??7YZO?EN];]>;UX_7
MU ;M]4KC7S=O+\L=_2?[]]N
MMV_OJ^73X/3R?%M/)K/;E^7Z]3I$N'\_)__;Y^VW*TE\=3PKTLWW_]\?;+X^;EC4)\63^O=W\,0:^O7A[OW;?7S?OR
MRS/E_7O5+!\Y]O`?$/YE_?B^V6Z^[FXHW&VX4,SY[O;NEB)]^O"TI@Q\V:_>
M5U\_7G^N[MW=Y/KVTX>A0/]>KWYNL_]]M?V^^6G>UT]_7[^NJ-K4)]^!+YO-
MK][4/7E$SK?@K8 SF[:^61:D?G5E]5V
MI]:''6ET2)?^\@M.;N;5Y&YZQ'$6'>DO.YYTI?/H1W_/NU):
MH,.5TE]^P=.N]"XZTE]V/'2EMV%"#/.K7^Z6GSZ\;WY>T:*EEF_?EGX+J.XI
M%D^LT)7]5/NSF493S`?Y[*-\O"9_FD1;6AZ_?:JKZL/M;S2E'Z/-PXB-M.C8
MPL]?'[8O@2J!+H$I@2V!R\`M%6%?"9K6?T$E?!1?"D!Z*`
M:"`&B`7B 2&4="! B`*B`9B@%@@+B 6B4;2I"4+I`>B@&@@!H@%XG(BLJJHB7E:?LU.
MR?I '#R(2'R(1D:V=%:Y/5OK>(%"*-R""RB)Q`LA9>D&23_'"+JR!?Z);$
M5_[`*%N\B'I$"I%&9!!91$X@F9]7'EE^OM?US#^GG-WNH&%$[A')=L_+=N^M
MN&A]!4@ATH@,(HO("23+X95)5HXC[8XZ)F]W1'F[`?45((5((S*(+"(GD,R/
M6I'G=^G2]F&*I1V1[/6B[/7>*O4:D*H`:40&D47D!)*U\)KE]%Y'A9/W.APJ0'U$4QJAE^''SCLY'U2RXE@:8YEDE<6J)S*6358<
MRXE8LCA>U63%.;+0HP;*JQ"0J`*@O@IH.M_72B'2$66Q#%I91$XXROR\9CD]
MOZAP\OP"\M,K]:\NC@VZ*EK-]OGUC*1C\?RIV&H^G$=4+9W]E,$UVZ3@AM'!
MX):M8O#IW6+>%'<=QS9#D:$6KDSO=LV-:WHI16-Y5V[0SF/WA"K)`AKU2(,LH!IK6
MD^*"7+0(<62AO)K+"G5D;D3MEU $%5-P8BAM6YQ_)R#%K5,\H;0HJHFDJGV:K5!C#*#E:
M='1L-3C*E+W>RU*^;.X'T9@_,-8!^467;?W%E.VBE=CZ@^.TWD\1%:VF7LO^
M]JFII]-IH1@U!C+LE0)91C%0OJ
M_1Y)2V)*FT$V74JIR5;M,!%HYVKF=\7NI:---J4,NQT,;MDJ!!_>-EW`],BO
M7);OB-3\Y^;MSQ[1J-?\C$9;'FPI$24!T[%50CTBA4@C,H@L(B>0R)MV9)@V
MEYTZ#9'D=LI(-JYX\NR2%:^/'I%"I!$91!:1$TB6XRQU2'M[V6Y&J;<=HAZ1
M0J01&406D1-(YE>HPV&7F-27O`M$.SPD'Y'H=[G7=^R8#MM[1`J11F00641.
M(%F/0CH>OBO0'0Q2CBCO-Z">'9.50J01&406D1-(YD>MR.\*1_+SUL42#B@[
M$.G\)N_E3TJFCZBA[35M_]/BB$(E*U[H&F.99'4@EDU6',N)6+(*A2Z\Z-XX
M1;D845:)#E$?47,7[WI5\;"JD@'GHC&,25;#YT8F57'.8),!AW$BC"Q)H1N/
M3`P4B/XXT*PE%%J^DBJ.1FTK:+4AQQ
MI%0\PTA<55T$MS)XW;9W3578.(Z$#QET3:)TEZT?'Z387`+R[VAF%2WF=3>\
M.LVT?!)%Q_1LH*(5;85^>=")T'PZ*2)IC&38+46RC&*D2=6T31')B4ARFAT1
MDB>=]?N*E+4*J"&]EM6JV$JZZ"AF7W1,SZ$J6C7U4*MIU2[J19&AQDB&W5(D
MRRA$HF,-.M 9WUEJLD$U&5&QY91G<=$J;SJC]+"J(J*9.RR0IIW0_\DW;C2[9?L+HQ3)
M B;9?M)T,08K9$.2GGV_9=143NXN.^782$ <2L,8YAIQ3'1M20)LRN"6H5KCQ [KO*D*UJ)F14=4RS%L>(FT%3T'D^1H<9(AMU2),N(%&9V544L)V+)
M:GEIFE7K\#V^"4(VO\=')#:4*'?S#24@L:$$)#84T'0
M(MF(_)]#LR&/):MUEL9M4.-&)&9#E+WY;`@H:ZJ*CEE3-<=*CB:BS-&BHQ..
M,K]"T5ZV-Z#0;4:%;G%;[Z)5UL.>'5,/%:,P&Z;^G@.3`12S8:\4R$9T;#+D
ML62Q"@U[9&M`L>H?;FG9B,D04>II'ZVRGJJ(Q&0`1X..%AU=1&,W"B_SLJWO
MLLD0M*+8$0/*W^ZD)]FA$DDE]!'YN9J6:OD4HM@J?!I@/IG/YVTQK30&-^QV
M,+AE*_X TFB54(]6"I%&9!!91$X@F9]7:-E.1U]LFZ8"WG*
M@!1::40&D47D!)(I>ZEU>LI!F(F4(TK)=/ZCT5XF)=0C4H@T(H/((G("R?R\
MQCD]OZ"(1'X1R986)T!=N[?BN=XC4H@T(H/((G("R92]JCH]Y:#!1,H1I?YU
M+:`>D4*D$1E$%I$32.;GE4J6G[]?7_9UG#9H'I%[1#2%LTVY?!)FQ^R-&$0*
MD49D$%E$3B!9#J^(LG( ^S
MMJC1&,EVEV>#R2JM[A@KS0"%5AJ10601.8%$.6:%W#KTOY[YU9T9*BY& 5W>[2B@,K$YBTAVNS@2
MZY)5ZO;>D9%"*XW((+*(G$"R&EXX9=4XLK:CS,I3CBCO-J!^!D@ATH@,(HO(
M"23S\RHIR^_R._ S.79[+LF/:MWM$"I%&9!!91$X@68ZSA-H,
MA1JCO-THU-!*(=*(#"*+R`DD\QL1:OXMAG,W QSTBA4@C
M,H@L(B>0K(673]G4/[*TH]C*IS?HKVX&J$>D$&E$!I%%Y`22^8VHM$MZC1)M
MME=:^;HN#K^Z9)5ZO7=DI-!*(S*(+"(GD*C%_"R)-EA+B<8H6]>(>D0*D49D
M$%E$3B"9WXA$HP>*"V7[EK]E5[/P# .V7U.+R/SZ/2RE,&\=6Q54JF1Z00:40&
MD47D!)+YC4BT^?R2[]+[GT D$&E$!I%%Y`22^142[ EJRX?STB
MA4@C,H@L(B>03/DL)39')<8H+= =E\U1C#&2
M*[@\+TM6J=THQM!*(S*(+"(GD"C'XBPQ-EA+,<8H:S>B'I%"I!$91!:1$TCF
M-R+&+FOW`O48(]GN\L`L6>W;C4@ATH@,(HO("23+<98>6Z`>8Y2W&_486BE$
M&I%!9!$Y@61^(WKL@N>L!6HQ1K+7Y7%9LDJ]CK'2D8I"*XW((+*(G$"R%G2I
MIVNQA; :\!]>R8K!0BC(P46FE$!I%%Y`22Y3A+IRU0IS%*Z[9#U"-2
MB#0B@\@BD$&E$!I%%Y`02M?!Y
MG[Z3#]9R)X]H6-DA ,S&ED^"D.&%G0R/`)?QBYHY'A@WXP,J&1X0.:,$*_\DW:9NP*
M:AH9'B+!9THCPQR'D89&AI+`2$LCP_?ERY$Y^=#IP,@5S,F''I3'1JAN](@Y
M-D)UHR>QL1&J&SW#C(U0W4C.CXS,R(=.H,=&R(?.8T=&YE1K:O;8"-6:SO7&
M1JC6="(V-D*UIK.AD9$9^=#;G&,CY$-O^8V-4*WIS;*Q$:HUO6\T-D*UIG=<
MQD:HUO3^P\A(2S[T<9JQ$?*A3Y:,C5"MZ3,98R-4:_IXPLC(C&I-;^R/C5"M
MZ4WND9&6?.@SEF,CY!,^IE+.T99J31_B&_.A6H>/G8$/U9H^)3;F0[6F#U.-
MC%04+7Q#M8Q6433Z4;XQ'XH6/NAX.^,(/U,/1%OKY,&;O
M5]X(IU\)O/>_`8BO0+_Y=^]_T0]'Z#?UR&>L@?2C>>0S-D)?%:?BCETQ??&;
MBCLV\C"E:H4O9\'4\O4:"G:['Z)_T.%M^6WU/\OW;^O7[=7SZBO=*NE?"R#%
M_Q[^28CP'[OXDQY?-COZIQSH#0'Z67_ZISM6](OZ$_])G:^;S8[_@Y*_W?]C
M()_^3P````#__P,`4$L#!!0`!@`(````(0"\UD\WB`(``%\&```8````>&PO
M=V]R:W-H965T &ULE%5=;YLP%'V?M/]@^;T8R->*0JIT5;=*
MJS1-^WAVC`&K&"/;:=I_OWMQ0LG2K=D+Q)?CM(->936*=/F-(EB
M2F0K3*':*J ?*#$>=X6O#&MS.FS=/1J]?[= =%OT@U+XWC.-% ;V8=M="*,[H-BH1OGGGI02+;*[JC66;QJH
M^RF9 @H4`3I3-D$J:!!.!)M$)G0$/X4__>J-_A4^)GN*L#G=;X;W?O-D'LT6\20!K3=(6$BDK^N&
M>[Y:6K,CX!60=!U'YR49$+]>"%2`V#6" 3JH/F/JW0>+]DC=$SL,=LRD_^107!.X?F2_#P9>(-RP$Q[
MGXSK@4&>7P^" 1'V32.
M"+/%PYJ"E8?H &PO=V]R:W-H965T '6/`*L;(=IKVW^]>
MO%!HHBXO"%^.S[GW7/NROGG6-7F2UBG39#2.)I3(1IA2=$7LM&Q](K*RYA_Q=I5IW9-/B
M$CK-[>.^O1)&MT"Q4[7R+QTI)5JD#V5C+-_54/=S/./BR-TM3NBU$M8X4_@(
MZ%A(]+3F:W;-@&FSSA54@+83*XN,;N/T=D799MWY\UO)@QN\$U>9PV>K\J^J
MD6`VM`D;L#/F$:$/.89@,SO9?=\UX+LEN2SXOO8_S.&+5&7EH=MS*`CK2O.7
M.^D$&`HT43)')F%J2`">1"L\&6`(?\YH`L(J]U5&IXMHOIQ,8X"3G73^7B$E
M)6+OO-%_`BCND@I<76IWW//-VIH#@78#VK4#?+Q#WC25"!"2&U2S/5[,\
MHYJL\'K\1Q8WCF5#Y(WLZKPL#MR++P6"QU(A,C@9822$>Z>E+>4G6=>."+/'
MZY[`3>JC_23:)GBRWL9GZ;:;4*S_`!.BY:7\QFVI&D=J60#E)%J"13;,F+#P
MINUN^\YXF`W=:P6_`@F7:8)M+(SQQP4(L_[GLOD+``#__P,`4$L#!!0`!@`(
M````(0`/GO(LCP(``&D&```9````>&PO=V]R:W-H965T "\>)$=L9
MJ^3O@(H/7($E.;#`^\"2SJ)L/DGCMTE(R,@7>$ ]LS.N +V.;0)>'J+#C;).
MW(S_C4_SM;]IR/`!3GI/:_Y(=2TZ@UI>`>4DFD.+=+@KPL*JWI^WC;)PQ/W/
M!JYT#G:>1`"NE++'!0B3X4]B]0&ULC%7;CMHP%'RO
MU'^P_+YQ+EQ*1%A!$>U*K515O3P;QTDLXCBR#>S^?8_C$B5EE_*"DI/QS)PY
MMED^/LL:G;@V0C49CH(0(]XPE8NFS/#/'[N'#Q@92YN [FBEX)I951A`Z`CWNAUSPNR(,"T6N8"
M.G"Q(\V+#*^C=#/'9+7L\ODE^-D,GI&IU/F3%OD7T7`(&\;D!K!7ZN"@3[DK
MP6)RM7K7#>";1CDOZ+&VW]7Y,Q=E96':4VC(]97F+UMN&`0*-$$\=4Q,U6``
M?I$4;F=`(/0YPS$(B]Q6&4YFP70>)A'`T9X;NQ..$B-V-%;)WQX4=:8\5V=M
M2RU=+;4Z(Q@WH$U+W>:)4B"^>/(,O 8`3Z!H(]K9)HL20G
M2(/]Q6P\!GY[3-PC"+CI+8&-H:77X[DH.[!3=G$Y*QM?&,HDK\LD8QG7>0(S
MO2WG%@%NT$02ASV_=^`QDR[V85^3:\%XYD;]'TVW+L/344M7Z7I0!`WT\29Q
MU#L;!0R*]P?LP)UZG["O1'Y?#1N `&48S"%2[2\$_V)5VQW-O;)PD+O'"NYM#AL\#`!<
M*&4O+R!,^G^"U1\```#__P,`4$L#!!0`!@`(````(0!$_&U,3Q8``$MP```9
M````>&PO=V]R:W-H965T 8=S!\'UL\
MB)2,)!LQ3R(U`PP&>V:N'4=)C&5;@>VLP]OO:G85NZM^+ATRZV)[YU-5L;OZ
M[V8U#]+[?_SY]'CQ^^[E]6'__.$RN5I<7NR>[_=?'IZ_?;C\GW^V[U:7%Z]O
M=\]?[A[WS[L/EW_M7B__\?'?_^W]'_N7WUZ_[W9O%Q3A^?7#Y?>WMQ\WU]>O
M]]]W3W>O5_L?NV?ZY.O^Y>GNC?[Y\NWZ])TN%L7UT]W#\Z6/
M-R2HS]UZ\/][MZ?__S:??\YH.\[![OWJC]K]\??KQ*M*?[4\(]W;W\]O/'
MN_O]TP\*\?GA\>'MKS'HY<73_4W_[7G_ )E]_7#Y:?D9ILLDLOKC^_'#/WO
MP^Z/U^C_7[Q^W__1O3Q\^8^'YQVEFP;*#_ZMWK/:64PERE2Q?I?O](#:#_
MO7AZ$RI0,_?'G[_N$R*ZZ6Y2)+R/SB\^[UK7UP(2\O[G^^ONV?
M_L\;C3V:@F0 "8LR/]_?6CTR'&+M!?#I)2;PX ;BU)?O17_$[>!R:9&/#Z"_;)UG([8$&KMDQH;1+EQ97>;HL
M5^.PH.NU']91)?7=V]W']R_[/RYH[E&$UQ]W;B8G-RZ @L&"[81N*8\3 B`#D&U,5%)HU5)).9P,9TVK:S2%TC(QR?`V<3*`U$`:("V0#L@&
M2`]D`+*-B4H&39,SDN&L/UPN:2)&TLA--MB(-!D9+;51-1E-4P=(`Z0%T@'9
M`.F!#$"V,5$)HK/-&0ERUF."I%NW3-)I6:F`U$`:("V0#L@&2`]D`+*-B>HZ
MG3!5U]U)R(W]F>NJ"Z-SPB2>5%E6&(5,1I+*&D@#I`72`=D`Z8$,0+8Q46ER
M17E\KCZ\GCAKG0TF65`(D!I(`Z0%T@'9`.F!#$"V,5%=I\I"==TI9+5V)>NY
M(G&1=%J8:)&41B23T202(`V0%D@'9`.D!S(`V<9$92JALZY*U6&5C.8Z'X(B
MG2"J$36(6D0=H@VB'M&`B+9.?C3'INHTN!HNGBQ.,>GRZGS!N*K8*$:0ELS*
M2"9839I!U"!J$76(-HAZ1`.BK4(Z::Z\BY-V1#N^&J256CIXFS"*M0.H1JL&
M48NH0[1!U",:$&T5TFF@<3TG#0$14-47;@
MFH*W4FGUJ'`-F"Y7Y&;CV223E:2B913%ZH)5',OL5#;!2F+U&&M@M*1S>]0N
MLZ'9*D>=:5 A/_,[.XE:#C.P*A8C,W+TVQM
MM+M53CK1K@@](]% (5,L_1D9Q=K=HE@%1=2"5M-JT3!BQ:;K=(V9]2T@.8G.NQ`HS!E4K,3V
M`DRNTJ*D6V_3?W9ED*#A.`.C`Q)63CK/=B,QGO/IQM'L69YV\7*:=W=F3"W-
MR(C9;K;$*@BE%A2+V8>GM>(5`G:`CLN78(MMDO PD:&CPP$CUG268FZE8YZ3R?M^FB
M5H*>>8<5JRE;&AE6[*CT/#F&/'O$>LX72;DP@5H,U`F*6S!34G!LK^?%%=1J
MW)Q8P!Y-`EZ5IC5;.?3HI!-+K3E'P,[:0$OS=I9I6P5]%`+BM=@MO("
M7J?+!!,+@;H0Z*"`O2.EPE4E,XF%P`,'GA2[R$VQL95#C]W2B74[CWAE.+DX
M\UL6M4;P+H9:	P=G];I?%>QS_9(2A>B[T5:W>=%O8)DE:-C+ M3S-$ZD*D@VGFX)."RRQ>-HPT>PD:Z]E'$#UG)11PRDFGW&U5(.7E^&S!Z? "&D'NALCO'_]&YO&>:QS)3H+'39A9
MM;TCRYQ6D"/YA^,,?!R1_%S^8R>=?VJ R$E0]Y7
M44:F,W>V-.5BE;%52$7-B,96.MD( ;YPFRP6@S5"0JYWS`BT4GT
M7JQ"&P9&1;C[M%56.H5NMP$IC.XT_G/_X^_N-)(LY!HDW=13T7-$)P1D5Q2B(=^;L6(>/
M8^T%P>CVN?K9#I]_9.=(2WWAK43O4=Q23Z2EYJ129]/'44N+4*2IEN:VGG=G
MZ6PUGC(.-W7TU$EE%#65B335%,UU^#AN:DB];NI<27Q:4[$FSCV*F^J)--64
MQS4[T,=Q4T/N=5-=512/_Y%4^B(J'O7 N7WIR+?=5D 1$G[8AV?#6B,L,HG.VJ'%"-J$'4(NH0;1#UB`9$6X5T&ES9$Z D0#
MHJU".@VN1I)Y0O(^H@]?4:EIXI&^BEG8*Q+Y9"6YJ@,*PH)];"-6_EI0GI19
M8A^6;,5FW(FHWM%;5:IWX]))33G N,FOU5NNDMQ\4Q77B6;W"BG'ID1DKTY8J6$D7:D0-(QZK,DF*TBQ]K?+2
MG7*%632W3A\JKNC"I8C;I4=ZJ.R=MRI8A4Y-CH(:L>+KJT6:+N"Q.K&9F5-Q
M6<9#Y79:1^845F=+C_0XV= X3%U-(C,TBF(56P"CV:'`4U8L7SR=TY,Q.S%9.9,:)>_)KRG*-9^CPRPV2W
M%\O)2GI0(VH8\3"]2Q?Y,C&16N6FQRDN9NAXI\\G+&N6'IFALG5OL`J]FAP%
M-6+EA^I=L G1 ^8;G3I6C
M[M1,37'VVQQTH\8N'8S,L)EEK`I6H8\^5GRWA*WHGL]XF7I-+]*OX4E/%4IW
MT108A\]6='D?^C)7592VJF!'&M70%^_HGNJ:-E!8Y[)CP:HLW1L%YL31JN"Z
M=S.5Q@FJQ#*#+LKC1%N925\%J]#+R5%0(U:\+-(-J'(-3XB)$2Z+[@VI7UH_
M1D J1,S_J*'=7@38ZA6Q[Q9$NH?+?/Z;0JD!XH=Z*71=&]M'G:
MCL2]UF1.RXSTW%H9R53!2MI?(VH$^9&B]UEF;KB+S 4A
MPW9^%[$,H?D^,]_,Z:@*5M*?FI$KEJ; 519YNLK-6;-5P76OX\)D
MKM>GW7LKL$P1%%U;0U0C:A"UB#I$&T0]H@'15B&=GKC`D?04V?@2Y)D79@LL
M>031NCH-28,OB.+5L62D!6)+_6`U
M"011@ZA%U"':(.H1#8BV"NG,Q)7:"0+!4JUD%`L$4(U6#:(648=H@ZA'-"#:
M*J33X`JJ6"!CI7#*_>C2EV)**QY%-WG92-_%79ES0SUO%38INL5QP2;K87G"
M"V*EKZA4@SV*&^S)L0;/6H6203=XMA@[*<58C[E7WZE8B5OLR;$6SUJ%?85N
ML2ML8E$<635\':02RRB>&X#J$E"#J$74(=H@ZA$-B+8*Z33,E6/\`,299]X2
M:S)!:F%=VSU0L`H+*\+!L*QF%#E:(
M:D0-HA91AVB#J$ D0#HJU"*C.K\TJST5R79H(B@2"J$36(6D0=H@VB'M&`:*N03D- L_=Z*RS8&-&&0D:_$A0>;JH9K>C`H>Y?FWU]$ZPD5LN(2DY!G0JO^Q@7
M672HPW-@A346(]49;Q6AFJU6H 2WVDFZ+NE+% ]$#6,Y*I70E\735?.]06T5OR"G#M!HP+T
M0+K")^K>R7=S5KYB4CWUR+UY'_74[H7840VD=XQ0(U8\D/25(_9IAE9,XF&,
M`^E^NEKJE_K)15B8%K T3BZ[G)]8D'2.8+OMB1`UH9M\OKMA1#2@[AI*L82N^
M#Y&LLA7TUSM%7PK0J=!:MW/5T'G]Q;)H[9&:JOG"E*"56$5355!X_Z<1Y+_!
MZV_>+A*C>(BY#6-TW653%MGR_+2;$FLLEQC1_DCJO`I1S8BV#V+5"`HGZE90
MN!S4J5BZ1ZYVB$1[9$[Z2B,N?]8>N:MU4_F3VQ>S*[92 (VH828V3KE?P9IMX
MA5'O!,VLGC2UIL[))[#W0^U+WEUZDAZ?%VU(.,[I2!Z(>^DK_YD8KR`R\PBE^L8>_GH^L^NCKA4!]/7&-\N:$ZR2@,5[4&
M5"-J$+6(.D0;1#VB`=%6(94>>CQ@)C\GO8#F7;7VA44Y$437SN?D25]4[EHP
MOJ,8SY>P$3+MC8N>X[>4W(\WV0DJ;-2=C^Y_G\G_\L[3[N7;KMH]/KY>W.]_
MNM]>HO>:/KZ?L/]EJ-MR?>.NOY%T[2>KQ8V[)#7SR9I\:"QF/BG)QU_NL=%*
M^@DJ?SD%/DGIDS'3\$E!GXS3`SXIZ9/QG`Z?K.B3<9FTG^3+&_=VSDRK :/;T#,^248_T#46%M8GR>F3
M<8CM)QFUC5[#G8F64T;IS;^Y3^@X)(.Y3^@X],;7S" ..?N$
MM$'?I#]SA,3]/-E8JM@^)M03^@9U]*&+DC?NDN//NZ^TVBS&ITY>_&_!^7^\\8OQG_=O]!MN=,&$+EG0C_;MZ`N,%^Y+
M.[_N]V_R#^K(]?0S@!__)0````#__P,`4$L#!!0`!@`(````(0#^NJ]RC0(`
M`&@&```9````>&PO=V]R:W-H965T V4"B>4LMY&\:T9LCFV27T$FJM[O^BBG9`\5&M,*^
M>%*,),L?ZDYINFFA[N=D0MF1VR_.Z*5@6AE5V0CH2$CTO.8%61!@6BU+`16X
MMB/-JP*OD_QVCLEJZ?OS1_"].?F-3*/V7[4HOXN.0[-A3&X`&Z6V#OI0NA!L
M)F>[[_T`?FA4\HKN6OM3[;]Q43<6ICV%@EQ=>?ERQPV#A@)-E$X=$U,M)`!/
M)(5S!C2$/OOW7I2V*7`VB=+K:3*=`1YMN+'WPG%BQ';&*ODWH)(#5V!)#RSP
M/K+,HND\SI+W24C(R!=X1RU=+;7:(S`-2)J>.@LF.1"_71&4XK!K!R[P`B/(
MU`R8=$`1$!V50NUS9@9VRZZU+Y38$3F6RMV6R
MC\@X,`SG)/DLO1YX@W+`3+QA3NN9?$3(@0L\'>6?+EXI!5`"=AUZF67Q`!IU
M$VQT>3<=V*L/[0R1Q!MNQ#L;\WKGS\!V[UG%[1M+A`A(G%:3O%W-?*SZ?U -L:Q-3.G=H4K#Q$APMEG;H1OXY/\K6_:,CP`0YZ
M3VO^2'4M.H-:7@%E',VA13I^/VT99..'^9P,W.@ &PO
M=V]R:W-H965T &^Z
MM$!1G+;/BJW$0FS+D)23 &X?GU^]>-[>C/S>'
MT=_N_OJ7CS]V^V^'I\WF>`467@^WHZ?C\6UV -J\K`_7N[?-*WSR9;=_
M61_AS_W7F\/;?K-^[)1>GF_B\3B_>5EO7T?>PFQ_CHW=ER_;ATVU>_C^LGD]
M>B/[S?/Z".,_/&W?#F3MY>$< =B]O8.+S]GE[_+,S.KIZ>9@M
MOK[N]NO/S^#W'U&Z?B#;W1_&_,OV8;\[[+X GW8]VOWW\^_9U`]&&/+D,
M?-[MOCG1Q:.#0/G&:#==!OZYOWK%E_?S[^:_=COME^?3I"NC/PR#DV>_RS
MVAP>(*)@YCK.G*6'W3,,`/Z]>MDZ:D!$UG_ I)E:3XISG .`&NVS"/YP=$F`=#ZY/8%^QA\@CK/R
MR9FY'4U'5Z!^`-+_?I>EXX\WOP-1'U#FWLK$4J(D"<=*9[;20*V!1@.M!N8:
M6&A@J8$5`VX@3GVPH"9,L%QM71@L9\8%B]R\)R!$+U&1(0E2J310:Z#10*N!
MN086&EAJ8,4`$1DH=!&9X=F&V.*D@6:"+9'T^-[+9-UDUY&A-$AED-H@C4%:
M@\P-LC#(TB`KCHA@P(1U03"*$FF,F1E+]2SQ""U
M01J#M`:9&V1AD*5!5AP1`8*2N2!`3KH+$+EUCTC25U!ID,H@M4$:@[0&F1MD
M89"E058R$RM#"&E@99<40$"!9($2#?OUR[U?KXM'WX=K\#IZ!8!F:8!!8>OQPY(S)N
MB,#*R6*BJJST0BRXE4=R=W%:V))43 B`PMC*&E
M1S*^U"9I)@VMN)J(KNOR^7(_$$5H:BB,3EJ&T2-1&BH/D4#(RB-)T (7>"ZDY:N>\0M]XP*N0Q\B4)Y[WO5JU%.:T2*
MKDV*)U$QS101&V.F[ Q4IM[H1@M7\?C>#H./ZIP%^8B2X_DXVYD:9Q,
M%4%77$4$-X*6\8+H=N(RO`A%D+\3\26IT#Q5!'5[JJ[\:X222>=(GB637*V5
M#6D%0RU!?`0VQF0[\NF3^5^0C6!VB5#N%8:B*I1D6%TG>GZ]N@9>L1:A=VA+
M4HRW!/D]HNO&:X(\OQ+8_^2YFGD:D@F66H)XY0S$U8\=R1M=3U5I+ MM(6/C:3RUD<7+
M!4-M,!1J9B"R:-L3,+J.\P+NR?0_>EH@H^$Z2X1.49@/3L;9M S5!2.8B*E3F&I((=EJ"WJ&R'T!/
MY7@ !+=I(JMI40TRZTG+6]8F"MAY"U41$7B;J#U5A#
M+4%\!`.Q1=M$VV@Z2:;L1\Y@"S(:!KQ$J*=P4>C>3"C).+OMP`5QQBT&7^IP
M0\$9-!!GE`K4JZ)>,<09(4_AR3B.(]-$&$-M,'22PUZQYW`RB3(69D6,!1D-
M`UXB1'Q.HD05ZDHHR3@#"2Z)LQ-74X6'Y"R^8D>F=;DE2@7$40XRY"
MR-UIG"=JJ]N04K#3$L0'8"-,IHFZTRSB,X39=I#5D-5PH25"/;,'XNPO`DL?5*>,L]N0\"GC;&;[G0R?/&+ 23/4#)2KZ-/LG@P1Q,J,M
MZHU=9$UH42:PK`V60CT-A-8KXL0<7V *_?*'4L3@+LHFS,922\;Y$`;"[!63
MGL%%PJ5\]A:(STEA&CBA)$,.-+0A+]Q!B0L>/CAIU= [D=2L;&66H)XI0W$WX\=:0XSR#OQ]^*L,)=X
M':+\4/RYDHR_VR9QRK\SG_A=E2"ZAZ`)(;Z6,4*!(Q5",%22J@D*L6^L8DM0
M,#]'"!A+MA8D%:ZX1"@/>5P)*1D&MXOA8>@J_V(:^KV0B`[NJS@'DDRUBR4D
M7W?!""7A.4M-D'M:!#1,\B)-QVJ#U5A3+4$A]G.$X%\Z!)5PH]*GK(P]DN<=(3ZHU;$*'X=E-LD"8<3X
MW`DD,3Y7`7'V_DWC3E$F#*%0>24B-%*UJ%3A8S;2/$RQ 9-/G0& \D"JL@NL75I%MND=6I.L\MOSR+;'E(
MWK'3)R7*I) X3D7DO?;"Z#
M5.^5A6J"\)9"'L=C'9^&9&Q=I8.]`83S=%UU:LHGWP;(3!6J&DI4Y'5EH1HA
MRE02Y7E8A3W_A);,U&`/\;Y+MH%(/:32I$92!JF0IEZ1H)JDL*;?>D@E2[5X99`BQ >)4Y-9B8I0CL%)K\AO
M%*)4@C[C.ZN6;Q.$,QY2&5/-3IGV4L$9#[E;B7VW
M;)M>5,R1F(4[1ZO6CT88%^[!-TND>^ `0)V ^`^/,D,9&JHZ[AX!LEL!X*0
M*CH]@P2IX**W!8^N":I1"I[#NGN\P,4\-ULP84FF;:@#N=Q%VXUD0]W(1*U)
M99`B?RJ$,EBM3LPK)(7SRCB-)ZE:.AMA7'H]U)]PK\^[\YS99@4A>TO+^7/!
M3-V)=Z4>HI#I!__W)`6LZ&.5Z.R702H$V?%H-JDL)4PK>D QCW[5SGGLRCWLVB%$M:9:&:()_'
M#W"V/$HC0UELFG@F$1HHR:$FQCUM/_\KN.X[LVHR14BE5+>F*,7R5Y%BF/1K
M@GQK^B&;Y#')4J)
MK'I%!M4HA84*;XP9V%.1)9Y4;DEZJMN<=PK5]C.PSIM"A0>4H5JYEXOQ?)7D2(O
M5+3E"S6:)'JCUJ"2J%)N6C@,C9]L%BYWN#,A&PB$1+FF8]6.EB3%RI6@=WYBXQ:C%!J(`UNF^$4GVJO$0I5H25A6J$V`&TAJ1X@G[:
M^+A!7.*-[RO@AA =A=N1>Y;(O%%K>(E2O.(L5"-$W4X\G9AS>:05\MX2
M9/O7PK4)/%>NY*)+CR-V5A3[?/_AG@LSIW4OBXHBA:@8J%:C%-WLAN/Y*1P<
MEK-T@T(3?T=Q->>O2QZ'^A_MXWHVKPC9#!(5TE1:J+%1;J+%0:Z&YA1866EIH
M)2`9'M=CZ"HXZZ!?X;L34>X>X@'Q"+1Q[E:KIF:%-ER7QTHEK,ARJ*Y=X$,]
MW?3`VP@-+3W$;C7Z]PWZ5\>];/9?-^7F^?EP];#[[MXE"-]SN/O8P_BBPR2=
M?8)[EC#'J4_@N-S,'3H;^B2#3X9T/F7Y[)-_;Z*V!I^X^WT#UK("/NF69JU3
M@`[DVNK`G:F9N^\T],D4/NEF3&4-7NGXJ4NEPN_A58_='*_Q>`8O4K-7N$_`
M^0'\$P02)K8!!8CC8!@ABD-!O(\G O
ML_1_'/$$]^?=$5Y#V1WF?H+7CF[@325C=U#XRVYWI#_&PO=V]R:W-H965T
M J^]&3CD?';9`_G^JF>#Q`W-\MM]@B=_^#T!^K;5.W]5,W`;HI'RB-
MV9_Z4V!:W^\JB("E?=243ZOQ@Q7D]G(\7=_W"?J[*M]:Y=^C=E^_I4VU^ZTZ
ME9!MF" "?]#/S1C';E4_%RZ/ZLW[*R>MYW,-T>1,0"
M"W8_HK+=0D:!9F)[C&E;'V``\/?H6+'2@(P4WU=C&QYR!!4G<00)7`6)M9@LK)GO+(#DBJ,K'.&*3Y^X
MMK=8]D^_X@BT_;#ABD^$BK[B,! RKXRHZ(KU?5._C>!U@\EJSP5[>:T`R+`D>':&(GFO1J`X&,D#
M8UF-P1^FOX7"?EU[KG %(!QNV4@"'T1&S
MX3YRY"J'E@B8&C41%P(&;8(1,V,]8HZH$1,DXHBS&,H_)DA"O%)BDQ$D5[VT
MJ&`E5:/ZJ>EE''JP'&&*;ZAFU_;U^0N%T7R(-N*(`]UE[SF>T0P3PIW>PIT)(S:/K^L[>VYYCF5RYRJWEDL+=/*U9'ZMS^^]*TKI
M]"QZ.@5D]8J=KW0(R?4_$I`O^TR,D#OD.*&.*5I)QPPAZ9AKCGK<3.@8TLZ>
M,V5_J2VHH7*%!*L?OGX;BT-ZZ3@SHW302JD=A/CG!!-U,4*+?CH]W_<=U^P`
M"1I)JA0A294AQ*E<9^YXUM*HS!R->BH]0TP3*1FZWCPLKJ"TM'!(JP`!J15`
MK&+!Y@/K!3A*Q66,G(.8T$9,O*C@7DR,0DU#&ECAEUS#5'/3XFGXQB #X:("86C5@_ [T;B@?*#*;H)ZDRA*YW0Y5*SQ;3
M6$:V+$]FZ\9UDBLUK4L*\:96B8#DZ".+0[ZTBA&25HF`(%2LN!2MI&.&D+3*
M-4>S?0=;=J2)
MB`&H57,+=4:H#>93";#KB3SQB+B8DXK(@[URD=[(C17\D3;FT`;^N0>
M5D_4]S>9=L]=Z!IG@U;:5[]C['6%T@K+-*)03*&$0BF%,@KE&J0GR-"!U[N\
M3<4?0E*(AA2**!13**%02J&,0KD&Z?$Q>:64W`?Q<3&FEI8M])D:'X$B8?7!
M7H"TPHE/*'TJK62ID7V%3%HA5ZYQZ5DPM-Y/?3+:5`(*"!07#B*D4"2@]WZ#7C)\^3JNN MQR#*T:LGTE/"1)&2DI][>;BRTC(EQ!:D0LF4L:2$MK!2"XA#CCV\=;&P MZZ5_*%"%*T4L290AQHOF&::LKJ;E-^L#YKRDD
M!:1('W["R\_QCF7S7(;EX=".MO4+.[T%*;"^'V!^M+SQ`MA(AZ9IX`_V+'C@
M9\[&'5`Z`4Q;J$,T#
M.`:@>#H/8%>?XM$BB/N-$(,_702P^7W!?AG`IC/%TV4`V\J`3P WY6'=P5-_O@.[AOV:4L$4W8^KYJ:X[
M_,$>,/QGC_6_````__\#`%!+`P04``8`"````"$`[IU]K.L*```F,0``&0``
M`'AL+W=O E7(]KM[-;3]&5?'U:/
M6VCW3R]8K5&[^0>3WVW6A_I8/Y]Z(->7%>5MONY?]T'I[N9I`RT08>\ ^->A\U0]K]ZWIW_7'TFU>7D]07>/H$6B8=.G7V%U7$-$0:;GCX32
MNMY"!>"_G=U`V(R.IG\_NQ>3J]WG:'X]YH,AAZ8-YYK(ZG^49(=COK]^.I
MWOU/&GE*2HKX2@1^'2)G'(?*,6@=/?CSC`/4J:DN_*J2/*_G!8.QJ.T9O['R
M@U^L8>]J-`K&5Y/SCA/E"+_*T>]-O,'U\!,_R*^FHO![446OE1_\7E91#X:.
M[$DQAE0OG0^FUW8^_($NWI>:YV&7BS_0]9/2L+,]^$.Y?"V68DS(IL$?6!BT
M\DQ_BQ20+GJDG"VL+_.B2;-P=5K=W1SJCP[,71":X]M*S(3>5*AB@LG"VY3[
M?QD'J294[H7,;1=Z%9+I"-/$C[M1D"@>V!(HHL6
MZ!)2$%$PIR"F(*$@I2"C8$'!DH*@[09- M6'#]40_">^%L(81NNR-($6.ZH`%71E";UB@()G:OS%JC=E`S$C$R9R1F)&$D
M921C9,'(DI& 3VQXSF];M;?'VJY(W2$=@A+FUSP
MA(@=64E@]<=8SQ@))0FNFQ72'WB!/9RC]CEJS)E&W-J(518TR#2?M,]1(S4U
MK$C`KL^*A*/%L/'$)@MKN\F2B&V#D:)DV9\IHW$;EU`2>6QHHAE),APT%Z
M1&+N+(?,%S%33:@J\4@_D;5")0Z4YC[I?*B$M1TJ23SXT:$:#>SNGRDCO:J'
MK1MV9B3)T&M"103FK;E12D":';=&J)F F%278`%X0)6%M1TD2>T"-
M/!(E960,J-8-6Q1)XD^:*%W3,+7V[B8U8S)NC5`T.2N:MO9N42M.XC1S0:`:
M 67.'6..DB]II9:C'1FQ;_YZ
MHHDS'AE#"@5BOK&EQ:;Q`FFYQ[1W*31E'\0!453`VJ:,1F3(:BL,>LA1Q-&<
MHYBCA*.4HXRC!4=+CG*."HY*"]F!%SO*"P*O-J#R$D:,WXRCD
M*.)HSE',4Z)'&R.3*O%B`S7Q,%29-HU0P2NYHPTMK-J89AA&Y;(M%J.R*A(X6`E
MLL;5CK;82UX0;;7U-*,MD15MAD*Q\+%H ;M2%WF!4.5B)S1%OL5R^(MMS>PCR-U7KPS!VO/*QS%"(R0A8YV!R9
M#EF,B(2,#-#$,,.ZI $^8.R;6.&7=<".)5HUCG:W7':D\_F1
M3B&Q93"ZA1ZRT,H8_(CDJV%QE(@0R:L!WW-UBZR!D44Q>IDU837*N6/!'4NT:DJT>X6>AG]K]?#;0S+6]4$ADD-D
M:S1#*SW.0H5@(*%6A$B.\V_P\07/(5D#F!70*T;M3W)(.N)-6L\G54Q11BMG
MB'0J+!0"&2Q_B5;:,4>D'0ON6*)5XVCWUF5':)\?H14B.416ZQE:Z1$:*F0N
M("@O[H9_W(W'KFZ1-;!R2*%/ >U
M4*R%].3JF-JDH\H6OT=W9BG*:.4,D:[B`JMH9@NK4LX="^Y8HI4C6\2QU.R6
MWYO;A`K9'TA$DH@LOC/QL8XXQIM))-'0;V>)2%D-Q3NE'W??)J[>8D(Q:L.3
M=BET])9T;).([P^8 _[W>XM!8$)28H96>N"&"@5ZE$:(_*:WKJY=O:6*TT(Q:ILU26=%2YY?6&
M)/U3E-'*&2(SMUH9/32""3E!+=%1:^6(SM:R4%9J=AD-?8B!?2%7HE"C;:]?
MEUTIP(ACJ:?N#_0HFRDK*\^DE;58262>=KACC$C+)PK!#R9$BE9Z]&>(M.."
M.R[12COFB+1CP1U+M'*D#737WS#)"14RR4ED+TD3P-?%]VX/RC`J1],[^%UH:-*P10^P7'PT12^*^$ -$`YKB?P'@'*<3V!=P)0CNL)W,%#. :T&]7$_@K174R_4$WD!!
MO9HG_;:9\)7ZV^JERE>'E\W^V-E6SY!2@^8KI(/\SEW^XZ32^;$^P??I36:_
MPO^/4,%=QD!\>O= ?N]?!]\WAN-V_W0W#FV`XV+RM]X_;M^>[X;__*$>S
MX>!X6KT]KE[W;YN[X9^;X_"W^[__[?;'_O#U^++9G`;`\':\&[Z<3N^+\?BX
M?MGL5L>;_?OF#;YYVA]VJQ/\>7@>']\/F]5CZ[1['4=!,!GO5MNWH658'/IP
M[)^>MNM-OE]_VVW>3I;DL'E=G6#\QY?M^Y'8=NL^=+O5X>NW]]%ZOWL'BB_;
MU^WISY9T.-BM%\WSV_ZP^O(*U`= WCUN(P*1]-P\K;Z]GOZU_U%OML\O)YCN
M%"(R@2T>_\PWQS5D%&ANHM0PK?>O,`#X_V"W-:4!&5G];#]_;!]/+W?#>'*3
M3H,X!//!E\WQ5&X-Y7"P_G8\[7?_M48A4EF2"$G@\PS)!<<8'>$3'8_?H%
MQP0=X1,=O5%?\(.8VG#ADWXPZO6#$W2$3W+L-](I.L+G52.%!=J.%#[I!_N-
M=(Z.\$F.%T 5Z0'A`LBHLFQVNUK[5:E!
MC1F2!\-R-P1_J*(CK(_O]VD:WHZ_0TVOT6:I;2)ND9&%*6!#FTN@D$`I@4H"
MM00:#QA#$KI,0%W_!9DP+"83%,.2`)>:6(1-%N222Z"00"F!2@*U!!H/8&'#
MJO3#/M]2:)Z-,30/;YZ3Z92'L[0V:=O1VFG,%)(KI%!(J9!*(;5"&A]A<4(3
MZ1^G,;X;IE`J7D&+ [NEG:GH&%J4;5R&@P=KD=`+5B&Y19)YV^FB($SXI!?=]Y3"4G%4G8WIEL`A
MND+=?4\ L47\B!626R2>=B50**147I6RJ172
M^%XL*B->O9WI <61C>,*K
MO53<51_NN@]WXW.SI(40KY^U3ZW^EH1G$Z$8?KC+2S(3BS-#J]`K''*,W!)!
M*/%W")T^S55IKKH75\.X>+Z,[.F]G$(KDF`#I&6P1"CT"R:9B 4J"Q'RRT-9%6CE=Q;M6!'DZ&OMV)!5^XL\/J.(^L>'^LF?>`N)B4]Y$\A@
M^S"-R9NLG*!9EY@"(6@HE*N2K%S%5`0YQUH[-F35.O*0C1#J'S+*)C>F96@A
MT01$ZQ]H@#D^XI8(%F(5BXS.4*L?JP5UL\O M0%C!!WO%:0[F&"@V5&JHT5&NH81"/SZBT"R77ZYI"9*6>7W$(@62A
M. $B%W,4)46>4,Z+=K1L,38&2 C-%+_8.QZHH%@X*+;^1"DF016GD=
M&"&0]G;7%L>D@EP8<2*(2V=%6:H^(*Z=BVL\B4?,\P,_?T5^C#7?CLS=([/W
MP!;1=?AD+C1%1E;>WHT0G`-,?H(;H8T* 7F)K/S*L%Q8&;,;51GV>V^'+XG%;?H50L@2PQ;%%6'-?'CH1K3T
M7Q16XK!%T:D>-^EA)`4;#*TM#7_2$0HF[:S#C2X^Z$+[E!JJ"`J`KJLZI5MJ
M,FL'P#-@%$W_#%C]PS*`DHBMWKD\'D9HY4^^A6!HINS#FS!@_XGR*8C!37RI
MH0HA)`UD5FOFPA/Q@Q+&5GY%8+"#/>_4*^.CIDZ8HDT
MH%D(JA!*Z,QT(QIK33_=MA>6DE@HP,O[7VO-6R)"WOK-"/(*`2'XH$$79.5-
M-D(P6K*JM&/-''DP0JU]ZLAF+OZ*MH^0:/NBDV5DY4:?(S2W]2_VB8(<8)%T
MZ]K?N]H+]"5:)2Z;U47:^B-:GK(/!&"_,T>L%2!"^LP1&Y'3NQNUUNI@(5*_
M)"N@=IF 3^SF@)0%[#A'K+6&CEC*Q<0\P) 0 WAX
M!:[*B(269.0VKHJ@B^PU6L%'NSXFX602B976$%-+SG-GM$W_W%DEQ')G(7.X
M]\I%B,K,W-00UPL) $&1N*'9D2F279.:JJB+(D=4$V6T_"J>1V(H:LM`5
M9>XK],]*:\T%&4)&!7>!)'-Q5,S0RJ\H@ER3*`C"\@FG4_G81DDF7O$0Y(AJ
MA+!2PGDJ;Z0VY*3K)!&J[K)$;:U%1JRB$W4B-'*&COYU98+ S,!9,)=DXIDI#-4%P9';#4LNP(;,SQ7*5NC1/*@BMCU`(
MNZP;@9*29.6F.-=001`62YS& ?,S:SD*KG9
M6HLU9!6HK!?9;-&3M17T=!-?D!762Q3.5.V79./:I
M"3(/`\+%F$A>P&D8#IN3
M*`W#0*BFDHP<5:6I:H*BEBF:SH/)5&[7C(EGYBK-FVC-BQ#3O&D@KZV1E9OA
M'"'O8DE!5G`SES)5$N8\*^U9(P275LBQ88X\9J-&>PNWQ%B+Q6$A)E'"5$D4
M:\5Z"4).611(#[-_J3669.;7@B*KT0IERBB-DD25@C\JGI:K]"R<355:SNC9
M-)"7$=&1Z124N$Y=%&2%6\]H%L`2X9>?2[+Q2T,QU61E= DJR\>I',]4(&0ES0;HP+IZMJZ1NJJ4N0G#UEGI;1I";Y1PAN(5&5@59
M@:?99$;3"$I&3'-)1HZJTE0U0A-<1.ETELI^US`FG@*CZ[R&^[F"L>(0$DT!
M+E/4B_QZBVPX9.6F.4>(%0QR4)W=1J0Y87E(M^Q?@*TCXYCXZL8M#*ZT0EFGE0I3UK@EQB&N;(`_PK
M1&MJQ2>+&_6H7P^I?.0R0T?60*RCN1SLUKAZN)X ,VSDQ=CB(SEXH*H S1#[ZJM],W&W.3QOLLWKZW&P
MWG\SK[5"!/>W'8SOW,;QX@&(8/6*;^#VQ\+ X?$HP6\:Z=YEF909_"'9/%@%X,D@K&>&^HRA9>-SQ%%
MP>+!MB#)!-^8A[KTH/+)HC@7=`79.(?GTP6\^*-YJND"7NW1.#R=M#`/(.EO
MX)[$PMQVT-_`;0:8BG/?+"/(.=0"^(R[$.$]Y_?5\^8?J\/S]NTX>-T\0]7VO^`N'\!&PPD2O)JP/TE[4JK
MU7YCP:C?RP[K?+,]O#_W__TO^<>\WRO*U6&SVN6'[+G_*ROZ?[[\]2]/7_GI
M>_&1967/9C@4S_V/LCP^#H?%^B/;KXI!?LP.]IVW_+1?E?;?T_NP.)ZRU:8:
MM-\-X]%H.MROMH>^S_!XZI(C?WO;KK,T7W_NLT/IDYRRW:JTQU]\;(]%DVV_
M[I)NOSI]_SS^L?OUHW@_Y:?6ZL[I_1I/5NLE=_0/I
M]]OU*2_RMW)@TPW]@:+FA^'#T&9Z>=ILK0)7]MXI>WON?XL>S7C>'[X\507Z
MSS;[*LC?O>(C_U*G[>9OVT-FJVWGR QKHR@>1)/1
M/4=BEUAU)/;UG*-S21_JP?:U&1P-YDDRF YZIET5:Y>GD[Y5\\N
M1#N-Q7'EEG7T:#.[9AG;EO-3>VZ?_]K[0;9)N9%G;*>]+'3,ZS
ML>0@Y4!P(#E0'&@.#`&!3KO/49W7];G@Y[ZMXJ5QIFP]+7P,T>?!O%JB;/)3
M^MYL5/V R!G_+6ED[Y$,&!Y$!Q
MH#DP!`3"G<5N.=E>7^=N$!,^8[.U\#%$N`=1'/N5/F`;=,H'"`XD!XJG9.]!O=*G23SG*YT&1),HGK*4@J>4'"@.
M-`>&@$!_9/U5]P)4T;P";#H7=1`IP9FT+.ZT?M,7R#;)*&8%$N?AY_4/1`'1
M0`PE81& [&3,4BSKHRFI?UB&7.J5`!!`)1`'10`PEH73G
M?+I+]SXIE,ZF:Q'YH(NN)9`4B``B@2@@&HBA)%3JC`Y1VFVGC[P]LK^)L^'.
MK0ZBBHFK\N=SB!%`)!`%1`,QE(2*G;VY7[$W1>$Q3O5< ^*[^V'>TMQ\B(@XD4`4$`W$4!(6P'D:4H`;S>T=4"!\RB]3
M(F*3:N&>U.>QI$4X'R+J)'Z(O93FV)V&ZI8(P&8B@)*A+?Y>JJ:.[J^!5<
M'43V/2`I$`%$`E%`-!!#2:B46;=N W^WVX@NO75C/+>J@B[YE32[7;@F[.$EAC``B@2@@&HBA)*R`,U=D
MO5_?^&)OQFNC>X]UY!@\_Y17G,#=H22`I$`)%`%!`-Q%`2*G4FB2CM
M.-W>6MUH TL5
MSBV_'JN#+KJ6-?'?'4TF+1=D043B+D*XQ1:05@)10#000TE8"BN+3OZ-4KCH
MT(9'$=_'QSZ(EH*3%&($$`E$`=%`#"6A4N>6R(+NV.;>8UW?Q\\:O,>US=OQ\S4D*,0*(!**`Z)JTJ*SN8KEG
M_L['XG7[1_C\XUC[[/2>+;/=KNBM\T_W>)[[ZO9,SX\.?HO=PRJ,+Z-'^V"4
MY ZD.[:?8WP^!J/!S4^W7SL-D_W0S_\ZWX
M?38 %[^US7QP$P[-N;X?/Q^+(8C=KU
M3T6ZUV0\-P^)P"4?S
M^+A9UUFS?MW5^Z,A.=3;U1'&WSYO7EIBVZTOH=NM#M]?7WY?-[L7H+C?;#?'
MGQWI'H-]MUH>F;1Z/5T`W,@.5,WUUV"_KNIWUOGWX/VN7E7A\W#GYM]#=F&
M>=(S_QW\U[6FZ?G(TQW`A'IP!8/
M/[.Z74-&@>8J3#33NMG"`.#_@]U&EP9D9/6C>[YO'H[/-\-H 'YKW`2Q>F/KV9:5;0;``-EU@$92I27%? QILU\(/>!P@>4
M#Y0^4#G`")+09P+*V\^$7FJ?S(1FT9F@&)8$V-1$7MAD02Z9#^0^4/B`\H'2
M!RH'8&'#XO3#CB'LTQV&YEL[0:$X\QT&WFPNC4W2-;AN.E.!9`+)!5((1`FD
M%$CE(BQ>:"E^O&%R]?F)UCPWPP2JR:GYA$_M$HU@,([1A!NEO5%?``+)!5((
M1`FD%$CE(BPMD``W+>>G7QMWL=.(EXA$?=VG`LD$D@ND$(@22"F0RD585-#,
MW:C,]GDU!?OC\V;]?=G`M,`,GH@V@BYF>IOFX,$:)'""%4AFD`@>_ SM;8*RVH+EY[@9%?L&]2JUHB!%5#4$J04R,(07,BJYP@FZ=".BJRLHXE
M0=:Q8HX\/JV+I7JI0$[B3-1&4&V
M*>0(19:^("N;&$60=2RE8T56G2,/62LG)^2OU;Z17ZP+&,AK_5[)IC#K72;L
M8LX0BL)^IG."M$A]NXW#*(H\15A((D5>EJ@D"(GB>>+Q5(R')TJ+,2=1']2^
MD6XL(ZCF[$RE`4)V/C.$6-\W5J%-4B$=E70L";*.%7/D\6GMY,3WM4(P`HR%
M;2"H0%JYJ5X>NO[MN#*$(ECYCE+PM259:<7^=@N=*Y[.O>Y52')%;F?)2[(R
MY$$,*FPFRL,=.4^?%E=GTO>M>?F[=R_G!01:@MA$#!3K]+%OA-V!?>/Y@NRL
M.W5F$PSBG`NH)5G!3M)/0Q+YJ]9:T91F$LHE5$A(2:B44,4@GH5/R;%0RC&"
MK$!,)91)*)=0(2$EH5)"%8-X?)^28[K=>N\H",&F3I.52BA#*(;Z[B&5O$<
MVT[@O2WDUH!B*22SLE:F>P7>2UYI#8BF8C0\)5HD.2GY8/D;2<5B-Y"6!OV4
MQU['34,T <1&9+&(#<3U>"1"-E:N
M.H,.W6U8;'6$GF..5O`#62=3XG&2S/S=B9CLCJ\(.DM> :Q?P1=$9-4
M>:`=6.J^M+EW)/P%'Z$(]JB^AD">\5TE12MWOR='*\YR@HPX@U?R:33VF`K)
MI,C-,I4$(=,XB)/88ZH8$R\S+;>M@
M]# PW]\J16221%DF4IB`C7DC,KK514Y
MRG8"R6/3_J4ETI'P:D#H@W:"5FX[(4?;!'*"3!.(PL0_XRLDCR(GRU,B%+N2
M.(S\7#$N5D+P_OX+ 7W& $&+5(!4M6K%J,%:L&H2CDHXE0HYC
M18/HZH_'IW6E$]_7^J@1IZ[4B`SD58.WK:=HQ:H!'>T XXH!N/E
M$"GRLD0E0A\5@\O%D^5IV/-[L?XIVB\&/&QT3J+0BFTEQHH5@X& GI"@CY^G3ZN_,6KKL``[$E ]=U$D&RWUSUL+D["$+N#6D^191G!I\P1^%R_N3`7X1/$"+LZ'$'
MB9.?9),%7/J0N)HLX`Z'Q+/I`NY.2%Q-%W`[0N)P;`5I/14T'$)!6D]]`F><
MD*>N+_EQAY!9.(F#[QGU'\'UTI?54_W/U>%ILV\'V_H1IGC -T>X6-H=]3[#1>(:[O6-]76KQZ8YTA_Z"_JKR;=_`0``__\#`%!+`P04
M``8`"````"$`P;/[^/@%```Z%@``&0```'AL+W=O F5^JWOS\_K77Y;ON'OICW4]&,!P[E?F<1@ND67UU;%N
MRWZ&+_49?MGCKBT'>.T.5G_IZG(W#FI/EF/;@=66S=FD#%'W"`?>[YNJ3G#U
MVM;G@9)T]:D<8/W]L;GTG*VM'J%KR^[E]?*IPNT%*)Z;4S-\&TE-HZVBXG#&
M7?E\`K\_D%=6G'M\T>C;INIPC_?##.@LNE#=YX6UL(!IO=PUX`&1W>CJ_ !_FKJ]U[XW^B/^#WKFMV7YER#VA`G$H%GC%^(:;$C$`RVM-'I
M&('?.V-7[\O7T_`'?L_KYG`$0 #(2H+MC#\SCI/!D]O/9W/>]8!X"=&=@R`;"\Z&)(,O'B>#YT$0656<4.RF'
M 2[`<4+4R#JTR7.NG^/=E!;T+R1%A6)HP'17O(E;>U[RZ6
MUAO$MV(V&]W&D2UB;D&"26@3%=BJ0*H"F0KD*E`(@`4B3$I`9/\')0@+48+[
ML.'`51I7<9M;\"&)"FQ5(%6!3`5R%2@$0'+;U=UV8;/>WF8\WF00;"@AWLY"
MC3>U\<==/H8SUI!$0[8:DFI(IB&YAA0B(OD+6UD,\WT_B?'*]"%EIL1V%G,Y
M?AMF!#-.1JZ-9*-X,IJBK"%;#4DU)-.07$,*$9%\AQKTN._$>/2=KWC#$&=*
M[EA#$@W9:DBJ(9F&Y!I2B(CD5?!OO"+&LE<40>[5*PU)*.)!M9U"[+A*B+>3
M$1 8.43X9 A3-/B
M33AD22@B2J(A"46\Q5CM'1MY 3\PHF#(EH8@C'GR.HPS;LMG(]&]K
M%QH0-_1EL5*-.7N$.9>9'>A0;5MF+D1F23!8\^."$6-9,(H@H!2;^S99`#63ZIZKB!'-*4#[QR91RZ =KJ:`W#%)21HEVS*V$G&&05 0'RM?TC, _]9)]HT2L6&]9$P\72^>$K1B"%NXZX24XI1P6,:I_ 08I#IYQH?=)2.1RXI&^D0L*%5=-O*_X
M\KT^66@;X;I+RSP*>:0NTQGIA1:]8VGK[E#']>G4&Q5^)9=5%CF=!!)\(.IZ$$73=.IZ%$732.@XW>$_CMYPR[X;.-5[
M$,L>/V0Z>O='7P86J&^ZW\```#_
M_P,`4$L#!!0`!@`(````(0`F.I0?JP(``#('```9````>&PO=V]R:W-H965T
M ZU9F]%%:>KGY^&%]T.;.5E(Z`@RMS6CE7) _/'R4/
M=O!,;*4/7XS*OZE60K-AFW`#=EK?(?0VQQ`L9B>K;_P&_#`DEP7?U^ZG/GR5
MJJPYT\"I[*/]J-QFZ!;G\=G
MZ=8?*-9_@)'5\5)^YZ94K26U+(`RFBQAMTT8>N'%Z &PO=V]R:W-H965T $$E%AP-#
MKJ_A4%4E&']0["!Y9P.)YBVUD+]I1&]>V22[ADY2_7SH;YB2/5#L12OLBR?%
M2++\L>Z4IOL6ZCXG&66OW/[C@EX*II51E8V`CH1$+VM>D14!ILVZ%%"!LQUI
M7A5XF^3W2TPV:^_/+\%/9O2.3*-.G[4HOXJ.@]G0)M>`O5+/#OI8NA`G
M=[X!WS0J>44/K?VN3E^XJ!L+W9Y#0:ZNO'QYX(:!H4`3I7/'Q%0+"$F
M`PRAYP*G("Q*VQ1XMHCFRWB6`!SMN;$[X2@Q8@=CE?P=0(E/*G#YU!ZHI9NU
M5B>*2^4^!,8RL[=E9E,99_H,6O=^H>X0X$9%9/'MP!\R
M")C,NSNN*YL*OB_DP`6>C^NXM#2`$LAZ\#2+5T,Z$U=A$JYWU8&]^F!KB"1A
M9L95+::\SL9TY@?U/U:Z@U.-$`&-43E)_'8YRZGL^V8Z\%0J1$8]"LL9-D!R
M7?-/O&T-8NK@%B^%F1ZBPYVP35V/_XUG^=;?%63X`;O:TYH_45V+SJ"65T`9
M1TOP5(=M#Q]6]7[O]LK"EOK7!BYE#F,=1P"NE+*O'R!,AFM^\P&ULG%=1;^(X$'X_Z?Y#Y/ 2K?2:G6W^QP2`U:3
M.+)-:?_]S=AIFA`#X5X0F8SG\S V.J91CJ=,^+
M1(]DQ4MXLY6J2`P\JEVH*\63S"XJ\I"-Q[.P2$1)7(2E&A)#;K H.WKA+L'KJ$P/Z]P";0]QZ=8[(@`7`^\-OXL,8C
M!-`&&="&(Z,S(F-69*"X"OQ:)B'[0/:C$X@&Y=3BJNZ`,Y"H9(M+I&_BO,NYF4H=.Y".0OM VG-C=@.-D5Y[`U*+1K=+\#"D\WZW6N$+*
MJ0& ^Y@'NK`T_3@R]3]" 8$
MH7UJ:U/W5F(?=W^7U$T:P?H:49M\I#P:0:>3(:3Z(L%\(L'.C`TXJ=Q0J;Y(
MV`!>-6<>D5AF[&=X-TP=6.?^%Y
MKH-4'G!^9S`:-];FV^*>X=UP:H^6]^Z;(VS>P,Q?)3O^/5$[4>H@YUN(.;:5
M5^ZKP3T86=GY?2,-3/OV[QZ^[CB,QV.\2[92FO&ULK)Q=;R.YL8;O`YS_8/@^MKK5+ 7%[O]ZN5A];1]67^^_'V]N_S;E__Y
MRZ>?V[=?=H_K]?Z"(KSL/E\^[O>OM]?7N_O']?-J=[5]7;_0E6_;M^?5GO[Y
M]OUZ]_JV7CV,3L]/U^5D,KM^7FU>+GV$V[>/Q-A^^[:Y7[?;^Q_/ZY>]#_*V
M?EKMJ?V[Q\WKCJ,]WW\DW//J[9 _P'A'_>W+]M=]MO^RL*=^T;BGV^N;ZYIDA?/CULJ` O/]<4_#75./7,=N'WYO
MU[M[RBB%N2IK%^E^^T0-H/^_>-ZXTJ",K'X;__[6TE_^P(^U]"8XTE]V/-;2:U\08WVUJ_WJRZ>W[B`&B`4RI$3DA<8\S ^W)R^OK@HD.NY3.,R&%$/DURK5:@Y&''+6R`=D!Z(`6*!#"D1N:9M
M(DW*\5P[8YEK3S#73NWIM9S6Y!-7,!J^)N#T2'70#H@/1`#
MQ`(94B)R30E(DW(\U\Y8YMH3S'5!19S&=85=SISZ.C7?8R1(^(U*.%O)C*LI
MT$2K0\H1=8AZ1`:1130()!)?N(TV* H#RN3>[65)Y%&TG%[HA=\2
MQ0I>U+K2V4HF7EDUT2HF/H0?VS]N@!U:]8@,(HMH$$@FWNU]27K>27S8*;W6
M=[)K600T/:B8!E&+J$/4(S*(+*)!(-D_&HJT?V[XBWK /F_M?EEL'LA)F
M2MHT*%871-6;1_3!/(9-`:@-:$J+>[+-J.G:12N.U6,L$ZV26.5$3GT;K3C6
M(&+)Y)RTCSN!J[/@D'7'6(^H"26`:M+*)!.,K^N4WUX\4=MN"T
MN#URGQ#'KRQDSILB6,T._6L924>E>CNVFH]W045-=YPZ>,\V,;AA=#2X9:L0
M?'JSF%=J"QC89@PN4Z=DQWGS!N5(X5%!6W"247V7PU;QUJ@-J(RW"!VCPM]$
MTA&!BM-C',-.,8YE](=Q!A%'YLEIB:3$SLM3$"1IY7E4TKZ0Y$G?#+@TTI2D
M8>39W@94QH6I8U3Y,JL6L\6-VI-ZC&38+4:RC$*D:;4H2M6F0422N3I)7A6H
MKP*B3^#N-HS22O&.I*[8J@M69 U*6KA^%XZ6LM-
M)2"UW.B[$K:*;6H9Q99W`95QT>W9*CH:1M'1HN/`5J.C[++2;6>5?^F"J$QX
M5%)])^6O[QF"(XT(CW0;$+684(3^^BKNJ9KGX,9-@K!K*,0J!I.5$-&D0<
MF2@E0]^IC8/:Y%XLW4K@IGH '0VCN)I8=!S8:LRH[/*?
M(2U+E)8!N5PGF5`EVP2K=.D/:%H>1KICY+3LKU^J UBC.(.#)13A(F>^0[M>^LU6K@4;KNNWMG-QUBH;L^HSA#>G0T;!6G
MEF44'0?A*/NG9.9YBR"J3]JN8,JCU`Q64RJDI%RTU&2K>BP$6KFJ^8U:O7K^
MO-AIPVY'@UNV\L''AS4+*(^TY3)][TC-?VU?_^@6C 8>[=`R.=^V)2GG.H/H;2R==WQ$NV$LG7JV`3K0[)1]0AZA$91!;1
M()!(/NU;(D7'U\O16JZ7C*)R;Q"UB#I$/2*#R"(:!)+].TD+T7:FBRN@Y*B@
M0=0&5`E%,54W[UVTXH'O,9:)5G&>ESJ6C58 *7QG
MK0K?(W$#5:FML'$[I9,.<9MK`TIE .3I-$4I5%`
M;B6/N_\4NHQJ*3@JO:T J%E`T>*4LPP$JTJ57`K@Y=U?5/I
M!\,#1T+Y[0Y5TV(Y;_YX54+'^CS*RS$N/:^F#2S)J*KK)EB)(O*Q:,9SK(YC
M>=5,9R7SJ18'/48R[!8C648ATJ2HZDJU:1"19)F]([$^=`I.Y[ M%B&/TCMUFC^PY'@DEAR/Q)(#CB;$2AQM0(GC(#Y1]N\D:>>F
M@>Z?1VK)T:=4P5$,NG=,;N.Z8$6M=?L'%?6$_B>/UWN,9!@EM^X 3*J=+3WU0-`:1U1"0^^"D7:JPFV"5+B?L&!>!CI%?!*9EK0]?>XQC
MV"G&L0%5)`N2-NE ?J@>]AC)L%N,9!F1;$A:I6(-(I;,UDERMT*Y&U"ZH#!*-$Q`R;K0
M!92L"STZ&G2TZ#@(1]F_/T/(NEI4ZTQ`:IW1YV#!2E2#CY6>`7,L?W1;EA/Z
M3K)>9S"28; J6I0VWH3'$4U!, "]DD"&O6(@&Y#[ "NQE7@DBL&C
M9$Q[CA77%!-0XF@#2AP'X2C[]V?HS@IU9T")DF@8Q;N0-B#7O#@Z^BZD8RO_
MG'P^F ;26VHE1[$R#J$74(>H1&406T2"0[)^2C,>'
MU'W-3I4L(SFDZC2OB58L!%M$':(>D4%D$0T"R2Z?I/MJU'V,TB$-5A&U:-4A
MZA$91!;1()#LG],X'YZEM5=$E"X>F24C.:3JE*B)5NS8(NH0]8@,(HMH$$AV
MV>FECW?9JRO198_PL4CM-$(2V2WUY_W48(PTK@UQ[8.OE2W9BMJ3K)#ZMC1:
MQ=Q[,5,GWU1%JQZ10601#0+)W#O%DF3HG17$ZQN1>X\RN!]8'J1*S
M6FO%L60KF7M]:A:M8NY#^#3W@'IT-(@LHD$@F7LE1-[)/0J.&@4'HA91AZA'
M9!!91(-`LG]NVT]JR\V^LKZB4C_Q]Q!UT`_I*G>0%+$FRDH?E[%CNK`?'+D`
M.K3J$1E$%M$@D,C&["0M,EI++X8R
MA9' &A;1!VB'I%!9!$-`LELG"139BA3`L)U=:8$POE[VA@)]C2U
M6RW92JZK^O@P6L7R5A-HUEK/#[A^'IZS4Z443K6+B#XZ,.K3J$1E$%M$@D$S\
M24IBADJ"4;JW@+AHT:I#U",RB"RB02#9/[=I)S/:KWFGS[NP]R 41+S^3D_H!TC@9)0^FS)5F)#J_7)1+2*N4 G=<4"9W"LE\4[DK&!0&FSIWJ#@E(S,K])S3;2*^3TX,NK0JD=D
M$%E$@T`ROR[EVPE$Z^6_29:
M<99;1!VB'I%!9!$-`LG$G[29+G`S#2B3^,QF>MY1\R+L=N+N4'\K>LE6,O=J
M2VBB5 VKJQS?3A;-61>]1)O=J,QV/GLYZ$\@BM]'J
M+_XNV4KF7FT)3;2*N<>-%JUZ1`:1130()'-_TD:[P(TVH$SN,QOM&:\76N1V
MV:G2+DNVDHE7^T$3K6+B0_BQ_?Y-(&C5(S*(+*)!()GXDW99>H$A%+U'2>+]
M*PK]*^2>UV_?U\WZZ6EWV
M;*[IBCM?RD5;T)5L?V8TIG1.D?&93ZBG^3J@,:5[W8Q/33VE9\1XY:ZFGM;9
MGM(5]VPSYT,]I2-TO$+/" DI/LW(^U%-ZLI.Y,J.>TC.1W!7J*3T?
MP"MWY>+VSG_Y2]4H_:3QUOU\,.,SG5`.LA5"5]ROWM!G.:46T._%,E O$17 (O+)M8I>/$0^N2OTHT+*;:[G]!-!RNUXY?I07/1:W=?5
M]_4_5F_?-R^[BZ?U-]KWZ)VM)*[>_(MY_3_VX2?.7[=[>J'N^&OG1WJ!\II>
ML#5Q3Z&_;;=[_@=U\?KP2N8O_Q4```#__P,`4$L#!!0`!@`(````(0#XRHY6
MF`\``(Y*```9````>&PO=V]R:W-H965T 1^["(O=
M.3&V3T^;U;K>KKZ_K=\/+LAN_;H\P/GO7S8?>XKVMCHGW-MR]^W[Q]5J^_8!
M(;YN7C>'/[J@X]';:M$^OV]WRZ^OD/?O:;%<4>SN#Q'^;;/:;??;I\,UA+MQ
M)RISGM_,;R#2_>WC!C*P91_MUD]WXR_IHIU,QC?WMUV!_K-9_]P'_Q[M7[8_
M]6[S^/?-^QJJ#>-D1^#K=OO-FK:/%H'SC?!6W0C\ _K7]:=:;
MYY-;0VHR/+W[O7GYO'P
M S%.Q'7]?[@]K8F./1ZOO^L'W[K[-*,9:+DF$4>*4HD^MRFN1=
MD"...3K"*SIFX=L?\2S0$U[1,X7B'7&`;+I,X94 >VQ0]X97>
MZOBYP6SLS@U>R>'XNSSNW&S?N71O5R\/R_G:W_3F"N0D#N_]8VIF>
M+B`:]8\K9-]1OVHHZ"0;Y(N- %1(V?+,D&K[>J!\^01I!E"!:$"-(&Q*6*&R+YR=J
MC7FB2(+A$Z06I!%$":(%,8*T(6%96;D5IN64P_44INOA9;/Z]K"%:04+Z,"X
MYJ`04#?8(#S=+BYX!OE*5",JYIW8R)*TX"/?>`,:>B7#:&]E-0N$B?9FXPTH
M3,O"\))8:7%V2Z=.B,`F0Z$?$+' H/@U=Y;RH:M2M.HNFU`(]HY4JP:M,E\%)1TU(7?M8T6ED8XM
M677OR%.V>N+\E%%]A$/J4`&-'J0LE*^S2KUNK&'$[=1(85GI';,L 2M
M4F>5AHV$CEDP=QPJH-Y]K$R64,32[WL0RBX[%:=EZ\7E;L!/4:6#SALKQ?
M/5$:A85QB'5-,8L6Q\I.0-M;OA]J1'B3P$Z4AA#HDF.%$;$T.8:3SEEE1V.U
M[+QX8:PX.K\P**7"PC@$[T`K2`5]T54A;`]AU:`56V>$HZ98/KR1CBU9#:PS
M5B:=GQ^*JC`_AZ*!+^.E%:W"@>\=J3!-ZA`L*H04HJ!C-*%9;V6D8TM6`VN#
M%4SGIXSRRI_3@\T5NCA:!*(5LD(K*#TE4Q/R@]40FG9ZXBHOYL5T%EW9*C+R
MH30A'\H0 K=`*W^:++)H4F02!-7CZ0(82!9I,BEG$M"\16!#@C5JGC2V5G
MS84F(KOF],M;,8N&JB(K/^8UHLQ/HH;"V[7YQ_U5GN=%,8EN!2@92LM0AH=*
MD[2<9M%E3 (RJ/Q#3DFH&_\:<3RIR4SN6)E5J<>*>)OVX]?70:P@#/(^L?XX^ B
M^5-+U$BD)-(2&8E:AGC*5L2=G[*3?"QE1'[\*N@!N[\$HUQ+U$BD)-(2&8E:
MAGA^5MY132AQF\C`/0VR\$X*D;\/$FWI
MVAO0>QL6AA?`"K^@`"=ZVLE$EBF*27^&%0AGD2FBHJ]'(ZT4(6^E)3*$NG?D
MR5RD+S.I+Q%%`B&2.A59^96W1@2GYM1`=/G5D`NT?K_D%D446'DK&CE](K#Q
M+L.!>7VLLCM_L)T.9(.-:I%I@GFD52J02=WX^YV\1@37%[8^R76DN1IR\5<6
M2B+-HZ37T 7D>7>8;Y\-0C?7A\AMO;2G9Q#BXD$%E=WO=NFL5"T%M1[]:$DDDWZEE\
MT@T9^$91$FE"":PA_0F(VS6&S+I@O`*1Z#M1`:GNX'Y/U]!L]L[CRTZR"@??
M.>+@I]=IPOZ+VJ>A"&$O]&]-9=5HA4&3N*J&1>&%."' :A[G*KZ.%U=!;=\L++\E%FBZ7
MF@Y1J/P)A8W@'&&64AX-686#[:Q@&2,KC5:!HV&./!FKK(+U_5-J)D=Y%HZO
M0]'X1BM9A8YL?)WCW&V+T3[1D`/;3<2FB%:%KZ9&-!S6G`K+2W9"`)YW+9-+
M!4@HT$42U1(U$BF)M$1&HI8AGK<59$&KG%@3G7QCNP(BF*#]HES,HVVI@D^L
MNNW$5Z&6J)%(2:0E,A*U#/&4+U*'N52'A'PRE42U1(U$2B(MD9&H98CG9V57
M,*2?F_U.N[&11CD7IBU0;>_)@G#PER71\M!X`UK@,*T
MB-R5%2N)O?D9EN1XEW?67/L@"B[:*HEJ0OZZI2&4!(H669@N(FA:RL9(U%*P
M;@1X@A>)NT**.T21KHWD>456?@VN"?GMJR'DK91$FI!W-(A`T5`56K+J8O&4
MK2(*VOS$F#K]%/9S@:*,;3OS6,^B5;B;$0H=Y>T[LDK!
M6QV^$6I"?M0;0O;IBCZ8T/6*S'PP340@@U;8*>F\C#\3
M;ED [@91GT2RO$(KUB?.,9#3#5G!4RJVYV?)7'[Z1#9A
MDXA(AJQ AXI,?"`MD2%DG]SH1VN@+"X=U\)\#L%J%0
M&O6+6&S1S(]R70C4$,)^R=*9Z'U%-CZ2EL@0.M4OX3GPPEBE&&S@G]*IH#-%
MO1QB:\Y^II:=!%-S9:9DCS]EJUF#.'-]\2J=P(1R=TP,B)E'2,I8H:!5*
M%$*!1"%T_(:L(K.P%]R)! K9,
MXCN7Z!A,]IJ0EZ`-(=QZKF8)3!'^-)8BF[`UW"D$BL>0%7Z:E,W+Z(*L)8LN
M#B^)58+G=XK3C:Q3'&*=4B;1-495.BO6*8C"3D&$N\X57*LD:2Q39"A-R( WC)I%T013,\XJ07PUJ1/#I
M/"U3#5F!I]UDKJ89M$PTS(J,?"@M0QE$$YQ$\/W6,E[O6A:)ER`2M9]K&*EU
M2]2+,&C]T!3BHQ*R\L-6GH:0KXP
M+7/D"5I%&"3XN7YPLI+EC4HS[( 2O!E%CO;Q06\F
M;D>1F8^OSXIOR-$^EO?K^"V9=?%972 +YP;B&^=G)_;G1MH&B=0T1'^WX-L>DMZ*AK25J)%(2
M:8F,1"U#O!H7J4GXZ121LD/=IVLNLOMQ%/>K%F_KW?.Z6K^^[D>K[7?[PR?P
M)-#];8_=K[(\3!+X69;N\0MQQ/Y@2W>I+(YD'1Y3'CH"[PY/\PX=@7=WNBE^EWRR
ML`\*2!]=)`O[ V.\&RR/P[5SP&4H;OGX+/D-'
MX"G>A7U0=R!:/E_8S\KE$?AL?&$&CSSDD([[##FN5PZ]!=?,$.VF/P2_!O2Q
M?%[_8[E[WKSO1Z_K)Y@T2?/2TW1[H#_L&_2])W?\/``#__P,`4$L#!!0`!@`(````(0`G,S$=IP@`
M``(E```9````>&PO=V]R:W-H965T IG]^2>[6TTG3%N=] ]E,?]G\_-/]>WW]VAS*LIV`PKEYF![:]A+,Y\WN4)Z*9E9?RC.<>:ZO
MIZ*%/Z\O\^9R+8M]YW0ZSNW%8CD_%=5YRA6"ZQB-^OFYVI51O7L]E>>6BUS+
M8]'"_3>'ZM*@VFDW1NY47+^^7NYV]>D"$D_5L6J_=Z+3R6D7Y"_G^EH\'2'N
M;Y9;[%"[^X/(GZK=M6[JYW8& JWVOU;G$K(-X\1&X*FNOS+3?,\0.,^)=]*-
MP._7R;Y\+EZ/[1_U>U96+X<6AMN#B%A@P?Y[5#8[R"C(S&R/*>WJ(]P`_']R
MJEAI0$:*;]WQO=JWAX>IX\U6UL)W5J#R5#9M4C')Z63WVK3UZ6]N9`DI+F(+
M$3BBR'+FK1:.!=<\^LRUO=6ZN_H-1[BW+G8X
MXA7AL;CAL!0.X$HYP_-PMPOUTMPA'O.+M6_2%`QS1X>8MSGD]=.45
M%6VQN;_6[Q-X9F'$FTO!9@`K`#&L*YZ=OM)^5&A084SDD:D\3,$?:JB!I^-M
M`R-S/W^#BMX)FRVUL76+$"U8^3+9R`2Q"1(3I";(3)`K8`Y)Z#,!5?T_9(*I
ML$Q@#%L$,C6.$39:H$MD@M@$B0E2$V0FR!6@A0W/H1KV\(2"X\R,8>K0QGFI
MA[/E-EXWGW7#&!(2$1(3DA"2$I(1DJM$BQ.FC?%Q,N.'J0>E Z-^=`F)"4D(20G)",E5HL4.,]_XV)EQ%SO>\580NR_JD)"(D)B0A)"4
MD(R07"5:5#`]CX^*&>M1"0(%HPS?VAB^W@B3$1$2$Y(0DA*2$9*K1`L4EI/Q
M@3)C/5!!'#E\A$2$Q(0DA*2$9(3D*M&B@@5N?%3,6(^*$TN)BI"($Q 6:V2C/X]!)$0C[6W80@\:QH*6]>=1
M(U 8YGRN2:O9Y4U,S>R^J6^_.CY
M4:N)MT1:6CFRUGW"0DL@V=)%`OER[HD1N;UC0AU3M)*.&2+IF&N.>MRLNS'B
MMI?LC6]HJE!#%6V16D$ >9HU$GI&6(]D)*A#^83T3&I:>%(JP"!
MU`H@5K'%D2.U$H$LZ9@BD@664<< C`:FY"5"WLL9-B10*Y,3HSH]FQ(I%+TDU(9HMNS
MH2JE9XOU74:V+-CW8Y7*^LR1ZR3OWK1TB89.K1*!Y-U'D">6+E]:Q8BD52(0
MU#2N)RE:2<F8+
M*XVP.B**8HH2BE**,HIR#>F9&&@[;6\&3],GMTMMVGDB4I/A.L8>:BBM9#:$
MENPI8VJ54)12E%&4:TC/!FOZE,GE]E)C\Q91G400R3L/*8HHBBE**$HIRBC*
M-:3'QQJZ\?'Q]D^+3S2):GP$139''VQ22"L)%`JEMET`>?Y6VG.7*=1?&))I0
MJ91*98;48NDY[M*0RC4I/2V?:CU9!V^6A&@]]=756*A"X0B+/PY5A$B^5,4"
M.>ONC=3V%O"?_FJ;H)<42A%)H4P7ZG0,H1R].B$]):PS^\\/#V_OM)F%(_;.
MU!>0ZY@_/=C"2BT@CARYE1\+*X=M++YMUOY0IHA0BEY2*$/$A99+*I1K=Z1G
MBK6*_SE3O-_4,B6Z4CFB(3P]9A,OD"^M8D1\H]1RU];0 )7Y%_?L!_'SZ5UY NO85`AN)X=(-'_D)M!+AU`_BU;R"(=0"_9U">K@/X>8+RR`_B;MHR]%,_
M@%W\`7MK$;"= RM^*ZTMU;B;'\AG*:-&]?U[Y
M-RS\CU;LUS[5+7Q[TFW='N!;HQ(V!!>LO7ZNZQ;_8!?HOU[:_`,``/__`P!0
M2P,$%``&``@````A`& H#@``E$P``!D```!X;"]W;W)K &ULK)S; 'S:[M[NA=S$>
M#M9OJ]WCYNWY;OB?WZ-/5\/!X;A\>UR^[M[6=\,_UX?A;_?__,?MC]W^Z^%E
MO3X.*,+;X6[X KL\7.S>UV_4\K3;;Y='^G7_/#J\[]?+Q\9I
M^SKRQ^/Y:+O OR2/T_O&S>#QQM
MN_I(N.UR__7;^Z?5;OM.(;YL7C?'/YN@P\%V=9,^O^WVRR^O=-]_>-/EBF,W
MOT#X[6:UWQUV3\-@_7]P>-G]B/>;QV+SMB:U:9S4"'S9[;XJT_11(7(>@7?4C,"_
M]H/']=/RV^OQW[L?R7KS_'*DX9[1':D;NWG\,U@?5J0HA;GP9RK2:O=*':!_
M!]N-2@U29/E'\_/'YO'X ("<O!+UJ>DN_=17\J\N+KWQ]>22T(DKS;4C_=2.
M'FE]PN%2.]!/[7!YX5_-O-E5X7K[4C_?Q8%]4=M(.GTH9'
M[V3GO&Z\Z3_L0JGQD1OS>)C5?]B7]#RAA<7^[W_T8T-)%,AW>EVHA]&Y46)Y?
M[4UW,^ZO)AS--!7ELPIS-Z21I;ETH%7B^_UT Z5M'M#&=RT6;*&F
ML0H;2!!*$$D02Y!(D$J029!+4$A02E!)4%M@1%IW@E-N_1V"JS!*KR2_9E/-A7(55<3FB96SGHB9SLC'I0`2`@D`A(#28"D
M0#(@.9`"2`FD`E+;Q!&WB$)$$:(848(H190ARA$5B$I$%:+:
M0>X`J&KBXTN#JH)%%C.RTAA1@"A$%"&*$26(4D09HAQ1@:A$5"&J'>1*JDJ(
M,R1M*P[:SG+^/:AC`J6RF[A3L1$P5NP8(`H118AB1`FB%%&&*$=4("H158AJ
M![DJDSCGJ*S,Q?*@D9VX@`)U_M*.!:LQ,)FYGQ9(&ZLQ*J@PH0JL848(H190ARA$5B$I$
M%:+:0:[*JK(X0V5=B-@JV[5)>V*@#MA T@5U)5.YPAJ2XU;$F[ZL-.W+E,W,[*)"Z@T`,4(8H1)8A21!FB'%&!J$14
M(:H=Y*JLRHLS5-;5B*VR7:#HQ`44>(!"1!&B&%&"*$64( [4*^7CB^;U=>''6T`J%CH.6F8T%N<1L//311W4Z81;5(X4Q>(`HVFU\T+
M(7_LB;UQ:`PX3(1A8F.EWBM1&%$;)L:`PZ1.&%>3\THI'TLIC=2#SMH^B;==
M"[::=Q(%&OGFK4VHT63<2.1=B"@11W&O)=Y-Q!@X@T\XHE'XLE
MC=3T-Z+-Y$D_6QF%`D97G8ZA1A.O$4W$B(R#=:6IN/W86''.)"?#IL:A/ZRK
MERI'/KZ6^;IZL=8RC=PDF\E39K:RDZR-18Y\8Z&V\B\;O:Y!L,ZC_\Z:52#F
M2YFXR>FXJ?'HC^LJINJ(,Q3398>M6(M$ALGC3U];V1G6.1K%6D099G5])M:=
MB&.9U(P1)1J=CI4ZCJXRJF@X0QEE+E9KC>S5&E"@/O;A%B N/!;R.RM>+0-$
M(:((48PH090BRA#EB`I$):(*4>T@5V55/)RALJXU;)6A_%C0AA`2%U"(5A&B
M&%&"*$64( L(=%S,S*
M'#.R7),>EC(SKADC JIRM$?O]&Y^H@M-,ZD?-+(.+1:,K*,-C6@KP9T*-:+G':,('6-T
M3-`Q1<)E#,7C0+3PU+ZTCUICIT'\N#Z92CF,`9(W-"F&M$4 UEJD9A#8FNTH&FA]LCT&H9O,M"(WD(P"AFU
M>?Z)_HP0YQ`$BCDVM9P:K-:1]J'M8/FBBRF',5W,&)FID&M$8;C7!5L9QY*1
M ]3*"8T>G9PK';
MV>)?R)U9RF%,Y(R1Z6)NPG3#PE;&L61D'"MTK-FJ<736MJFLUW]I;6NBB-'2
M]:Z=PE/Y\%UH1_JX"=]DH!'57(Q"1NJ=\??[3Y=]HZ4O9P+%'-ON`>X/M%4W
MB6074PYC(F>,K$EDPG"O"[8RCB4CXUBA8\U6C:,[6K+>_[71PF.`:8O KRVSBDP;N9W%J#M3$=L?XO".%
M*1XI:&1MY1:,3"X&&MD/*XWL:@<=8T8FB1..9?9A*5N9*V:,C&..C@5;&<>2
MD7&LT+%FJYYI\[>4_U,L_S42TT:4(`NV,GD4:#0U-QDR:G?$\VG?M-%'"R90
MS+%/)F2BK;H-W)4L@CB,B9PQLJ=->WTQ;41Q7["CB54R.MG+2EOIAW+_M.D4
ML">NV?>X,XE6?F _'JQ[Z2A50N453]2!O0[=?FM)^G+]:OKX?!:O=-?2$*_:GZ_6V'VV]K>9C.Z.M:FF4:6N;4TBQWLL4CG_99
M!2WDTVX-H>626IJG#;1<44NS9D'+-;4TBY)L\:D'-.'IQF4+N?1Z>&.*U53?
MTL.C+ZRAOPKJB>7YU-+L:L%G0BU-WD++E%J:(1$M]+TXG_MCD4/?U>GBO?9T
MZ;XK?Y[>?&Z_=T=A!]*P5T(:P]YAIQ'L'4`:O[[AHU'=/!.U^EKH4-TNDY?"QV(
MTW7Z6N@-)EVG;ZCH!25=IZ^%WC_2=?I:Z%TB7:>OA=[=T77ZAIY>S=%U^EKH
M-1M=IZ^%7IG1=?I:Z-.X-^H#MZ@H?4]_Z6AY\2D+ZM!#VX,&G-&P/,&2>^Y2(]$&-/A]:%=IM\ZASHN^$
M>E\^K\OE_GGS=AB\KI]HB1PW+YCV[;=*M;\Z-N_UO1M
M-&/U[0%/N]V1?Z%+C[KO$[O_/P```/__`P!02P,$%``&``@````A`!R$&OZ5
M````J0```!````!X;"]C86QC0VAA:6XN>&UL/(Y!"@(Q$`3O@G\( G[GI%Y4)18VL!]&4,2^+)&?!NZW
MZ^X(2IKCQ:7"9.!#`K/=;K1WR5^"BZRZ@<5`:&T](8H/E)T,927NS:/4[%K'
M^D19*[E%`E'+"0_C.&'N`K#:JVK@/(&*_0.H]$NT&O\C]@L``/__`P!02P,$
M%``&``@````A``L'X+(^!```L@\``!``"`%D;V-0 &UL(*($
M`2B@``$`````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````G%== -BN6$J0T>4#S)_?5W!75L)PNWSAN@
M/;MGSZX6R?GVO%IV-KHHTSR[[IZ>]+L=G27Y/,T>KKM3,?K\M=LIC Z,*DN.^`B*Z^[C\:LKWJ],GG4*U6>P'(&*XN\6"D#
MK\5#+U\LTD1[>?*TTIGIG?7[ESW];'0VU_//ZU>'W=KCU<9\U.D\3RR_ MUD!XX)#U>IDFRD"6@R!-BKS,%Z9#GQ.]='K[BPZPXSIY*E+S,N@[O?U7AR=J
MJ5UP/%BH9:F=WNZ#,];*BA:IM"@'SL9#CQ/2*H)X=D0IA+)1]3*OBQ]C)2_P_A`B(%E`DNPY$,(_H!R.D1&!N%
MCTE\!*1BYA(\?T;$-*;6ZW#*?48YEX1YDD^#@,3W:!1VSZD,;H6D/]PQ83=X
MRB.?@?8^F4@HB>0B=&]EA*?YG;`ID+.`
M
M!2JVZ]FMG(0$UYN%@G(9D7LRG-#*900=;+V[$!#UR^F,QM5&FOADV)R=-Z5R
M%(>!C.FDVG\1B1N$N",Q>-RU$)0QO(E)4!&Z0UG$5/AQ7;@(MC5J8[O'K\2J
MVQC*;FM.H1$IWO^4Q`PL0!'HP&WSP?["%:Y;;$@XM!L81Y3QYK[P&9A0* A-*=1/&.$HI+V*.+5&P:M`:)@F
MU6MJ*&1?^[8,VH4Z1WVW8RX^@/D;Q2`35#)5%'#"V&B)0MJ'*5Z0]FF*8]K'
M*8[!YNDN'S0=?+)N00T0.V'MW^'WA*T&[!]`W@UEZ6FC4CBZO9XM[%&J/IBT
MSF:\-&^'\Y82E!("H5':1S6N,C*K]R*A8?"QO46AD/:-C\^7=@R^U=HQ^%9K
MQ^!;[ #;)ZF^$_F`-(1>9IJ66^D'#SVN#I-T+@AFF>T%P:(9Y>Z`*%
MO/MU'[3,/N3@ \=?G3XHRKT'&Y"V_7=!VSN=U5?PP>G%2?^\#Q?/O6].;W?9'OP'``#__P,`4$L#
M!!0`!@`(````(0#A?H$1,0$``$`"```1``@!9&]C4')O&>PMLNBRD98F:G5QBXHS&&\*WCE@H`;3;OY=U79W1DT?ROCP\WT>Y
MV)DF^P0?=&LK1`N",K"R5=K6%7I:+_,YRD(45HFFM5"A/02TX)<7I71,MAX>
M?.O`1PTA2R0;F'05VL;H&,9!;L&(4*2&3>&F]4;$=/0U=D*^BQKPA)`9-A"%
M$E'@`S!W(Q$-2"5'I/OP30]0$D,#!FP,F!84?W !/^O-`G9TVCX]ZEF0;=
MBUW7%=VTUTC^%+^L[A_[47-M#[N2@/AA/XT(<956N=&@;O9\
M]^:;+(1MB7]GI9*]'9,>1`25I??8T>Z4/$]O[]9+Q">$7N=DDI/9FE)&KQB9
MOY;XU!KN\Q%H!H%_$T\`WGO__'/^!0``__\#`%!+`0(M`!0`!@`(````(0#8
MO%`R5`(``%HH```3``````````````````````!;0V]N=&5N=%]4>7!E &UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`````````````````
MC00``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`.&R,3ZS`@``$2@``!H`
M````````````````LP&PO=V]R
M:W-H965T &UL
M4$L!`BT`%``&``@````A`(B+4_5Q`@``:08``!D`````````````````\Q\`
M`'AL+W=O &PO=V]R:W-H965T &UL4$L!`BT`%``&``@`
M```A`$^S(IL4!@``PAD``!D````````````````` &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A``J]
M7!8C!```6`X``!D`````````````````\%(``'AL+W=O &PO=V]R:W-H965T ``!X;"]W;W)K &UL4$L!`BT`%``&``@````A`)GMMOS3`P``F0P``!D`
M````````````````HV$``'AL+W=O &PO
M=V]R:W-H965T &UL4$L!`BT`%``&``@````A`")5'8>A`@``708``!D`````````````````
M.&\``'AL+W=O &PO=V]R:W-H965T &UL4$L!`BT`%``&
M``@````A`/MBI6V4!@``IQL``!,`````````````````LG\``'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`!F2NO9H.``#,EP``#0``````
M``````````!WA@``>&PO &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`#CZ(8,:!```8PX``!D`````````````
M`````AT!`'AL+W=O &PO=V]R:W-H965T
M &UL4$L!`BT`
M%``&``@````A`'VW,L(6`P``SP@``!D`````````````````0B@!`'AL+W=O
M &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`+A*
M.Q+6`@``I0&PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`!?1*FAH`P``(`H``!D`
M````````````````F$(!`'AL+W=O &PO
M=V]R:W-H965T &UL4$L!`BT`%``&``@````A`)P,7)O2`@``#`@``!D`````````````````
MP4P!`'AL+W=O &PO=V]R:W-H965T &UL4$L!`BT`%``&
M``@````A``'!*,+/`@``VP&PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`"&8"3_5
M`@``\P&PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`'#`IA/H`@``"0@``!@`````
M````````````@FP!`'AL+W=O `$`>&PO=V]R:W-H965T &UL4$L!
M`BT`%``&``@````A`!BSC"Y-$@``460``!@`````````````````EX,!`'AL
M+W=O &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`#=3;'J1`@``3@8``!D`````````
M````````:YX!`'AL+W=O &PO=V]R:W-H
M965T &UL4$L!
M`BT`%``&``@````A`.C#+#T($@``#54``!D`````````````````?;H!`'AL
M+W=O &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A
M``?M&57!#0``:#\``!D`````````````````6^`!`'AL+W=O &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`,&S^_CX!0``.A8`
M`!D`````````````````0P$"`'AL+W=O &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A`%K-F@O4`P``=`X``!D`````````````
M````#@T"`'AL+W=O &PO=V]R:W-H965T
M &UL4$L!`BT`
M%``&``@````A`" &PO=V]R:W-H965T &UL4$L!`BT`%``&``@````A``L'X+(^!```L@\`
M`!``````````````````ODH"`&1O8U!R;W!S+V%P8V]R92YX;6Q02P4&`````$T`30`$%0``FE("````
`
end XML 17 R55.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Warrant Activity) (Details) 9 Months Ended 12 Months Ended Sep. 30, 2014 Dec. 31, 2014 Dec. 31, 2013 Class of Warrant or Right [Line Items] Warrant outstanding beginning balance 10,653,469 us-gaap_ClassOfWarrantOrRightOutstanding 10,653,469 us-gaap_ClassOfWarrantOrRightOutstanding 12,972,664 us-gaap_ClassOfWarrantOrRightOutstanding Warrants issued 11,570,274 xxii_ClassOfWarrantOrRightIssued Warrants issued in conjunction with consulting agreement 4,250,000 xxii_WarrantsIssuedInConjunctionWithConsultingAgreement warrants issued as part of Warrant Exchange Program 138,666 xxii_ClassOfWarrantsOrRightsIssuedUnderWarrantExchangeProgram Additional warrants due to anti-dilution provisions 18,383 xxii_CommonStockWarrantsIssuedAdditionalNumber 1,665,400 xxii_CommonStockWarrantsIssuedAdditionalNumber Warrants exercised (1,247,443) xxii_NumberOfWarrantsExercised (9,831,414) xxii_NumberOfWarrantsExercised Warrants exercised as part of Warrant Exchange Program (5,862,121) xxii_NumberOfWarrantsExercisedUnderWarrantExchangeProgram Warrant outstanding ending balance 13,674,409 us-gaap_ClassOfWarrantOrRightOutstanding [1] 10,653,469 us-gaap_ClassOfWarrantOrRightOutstanding Composition of outstanding warrants: Warrants containing anti-dilution feature 129,809 xxii_WarrantsWithProvisionOfAntiDilution Warrants without anti-dilution feature 13,544,600 xxii_WarrantsWithoutProvisionOfAntiDilution [2] Warrant outstanding and exercisable ending balance 13,674,409 xxii_WarrantsOutstanding [1] Includes 3,725,962 warrants (27.3%) held by officers and directors that have had the anti-dilution feature removed. [2] Include 1,250,000 warrants containing Exchange Rights (see Note 6 for detailed discussion). X - Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Number of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition The shares of warrants issued. + References No definition available. + Details Name: xxii_ClassOfWarrantOrRightIssued Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition It represents the number of class of warrants or rights issued as a part of warrant exchange program. + References No definition available. + Details Name: xxii_ClassOfWarrantsOrRightsIssuedUnderWarrantExchangeProgram Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Additional warrants due to anti-dilution provisions. + References No definition available. + Details Name: xxii_CommonStockWarrantsIssuedAdditionalNumber Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: xxii_CompositionOfOutstandingWarrantsAbstract Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Warrants exercised. + References No definition available. + Details Name: xxii_NumberOfWarrantsExercised Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition It represents the number of warrants are exercised as a part of warrant exchange program. + References No definition available. + Details Name: xxii_NumberOfWarrantsExercisedUnderWarrantExchangeProgram Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of warrants issued upon consulting agreement during the reporting period. + References No definition available. + Details Name: xxii_WarrantsIssuedInConjunctionWithConsultingAgreement Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of warrants outstanding as of reporting date. + References No definition available. + Details Name: xxii_WarrantsOutstanding Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Number of warrants issued without the provision of anti-dilution. + References No definition available. + Details Name: xxii_WarrantsWithoutProvisionOfAntiDilution Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of warrants issued with the provision of anti-dilution. + References No definition available. + Details Name: xxii_WarrantsWithProvisionOfAntiDilution Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 18 R46.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 MACHINERY AND EQUIPMENT (Details) (USD $) Dec. 31, 2014 Jan. 13, 2014 Dec. 31, 2013 Dec. 11, 2013 Property, Plant and Equipment [Line Items] Cigarette manufacturing equipment $ 3,031,375 us-gaap_MachineryAndEquipmentGross $ 3,220,000 us-gaap_MachineryAndEquipmentGross $ 3,220,000 us-gaap_MachineryAndEquipmentGross Office furniture, fixtures and equipment 55,355 us-gaap_FurnitureAndFixturesGross 17,059 us-gaap_FurnitureAndFixturesGross Leasehold improvements 0 us-gaap_LeaseholdImprovementsGross 14,500 us-gaap_LeaseholdImprovementsGross Deposit for purchase of machine parts and other assets 0 us-gaap_PropertyPlantAndEquipmentOther 210,000 us-gaap_PropertyPlantAndEquipmentOther 210,000 us-gaap_PropertyPlantAndEquipmentOther Property Plant And Equipment Including Assets Held For Sale 3,086,730 xxii_PropertyPlantAndEquipmentIncludingAssetsHeldForSale 3,461,559 xxii_PropertyPlantAndEquipmentIncludingAssetsHeldForSale Less: cigarette manufacturing equipment held for resale 0 us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent 457,696 us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Property, Plant and Equipment, Gross, Total 3,086,730 us-gaap_PropertyPlantAndEquipmentGross 3,003,863 us-gaap_PropertyPlantAndEquipmentGross Less: accumulated depreciation 236,115 us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment 6,103 us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Machinery and equipment, net $ 2,850,615 us-gaap_PropertyPlantAndEquipmentNet $ 2,997,760 us-gaap_PropertyPlantAndEquipmentNet X - Definition Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 14 -Article 5 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 + Details Name: us-gaap_FurnitureAndFixturesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765 + Details Name: us-gaap_LeaseholdImprovementsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765 + Details Name: us-gaap_MachineryAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 + Details Name: us-gaap_PropertyPlantAndEquipmentOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition It represents the amount of property, plant and equipment including assets held for sale as of balance sheet date. + References No definition available. + Details Name: xxii_PropertyPlantAndEquipmentIncludingAssetsHeldForSale Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 19 R33.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 EARNINGS PER COMMON SHARE (Tables) 12 Months Ended Dec. 31, 2014 Earnings Per Common Share [Abstract] Computation of Basic and Diluted Earnings Per Common Share The following table sets forth the computation of basic and diluted earnings per common share for the year ended December 31, 2014 and 2013: December 31, December 31, 2014 2013 Net loss attributed to common shareholders $ (15,595,358) $ (26,153,158) Denominator for basic earnings per share-weighted average shares outstanding 59,993,413 43,635,182 Effect of dilutive securities: Warrants, restricted stock and options outstanding - - Denominator for diluted earnings per common share-weighted average shares adjusted for dilutive securities 59,993,413 43,635,182 Loss per common share - basic and diluted $ (0.26) $ (0.60) Schedule Outstanding Excluded from Computation Because they would have bee Anti-dilutive Securities outstanding that were excluded from the computation of earnings per share for the year ended December 31, 2014 and 2013 because they would have been anti-dilutive are as follows: December 31, December 31, 2014 2013 Warrants 13,674,409 10,653,469 Restricted stock 250,000 500,000 Options 890,000 660,000 14,814,409 11,813,469 X - Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 20 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */
/* v2.2.0.24 */ /* DefRef Styles */
..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute;
} ..report table.authRefData a { display: block; font-weight: bold;
} ..report table.authRefData p { margin-top: 0px;
} ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right;
} ..report table.authRefData .hide a:hover { background-color: #2F4497;
} ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px;
} ..report table.authRefData table{ font-size: 1em;
} /* Report Styles */
..pl a, .pl a:visited { color: black; text-decoration: none;
} /* table */
..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em;
} ..report hr { border: 1px solid #acf;
} /* Top labels */
..report th { background-color: #acf; color: black; font-weight: bold; text-align: center;
} ..report th.void	{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left;
} ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word;
} ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden;
} ..report td.pl div.a { width: 200px;
} ..report td.pl a:hover { background-color: #ffc;
} /* Header rows... */
..report tr.rh { background-color: #acf; color: black; font-weight: bold;
} /* Calendars... */
..report .rc { background-color: #f0f0f0;
} /* Even rows... */
..report .re, .report .reu { background-color: #def;
} ..report .reu td { border-bottom: 1px solid black;
} /* Odd rows... */
..report .ro, .report .rou { background-color: white;
} ..report .rou td { border-bottom: 1px solid black;
} ..report .rou table td, .report .reu table td { border-bottom: 0px solid black;
} /* styles for footnote marker */
..report .fn { white-space: nowrap;
} /* styles for numeric types */
..report .num, .report .nump { text-align: right; white-space: nowrap;
} ..report .nump { padding-left: 2em;
} ..report .nump { padding: 0px 0.4em 0px 2em;
} /* styles for text types */
..report .text { text-align: left; white-space: normal;
} ..report .text .big { margin-bottom: 1em; width: 17em;
} ..report .text .more { display: none;
} ..report .text .note { font-style: italic; font-weight: bold;
} ..report .text .small { width: 10em;
} ..report sup { font-style: italic;
} ..report .outerFootnotes { font-size: 1em;
} XML 21 R57.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 COMMITMENTS AND CONTINGENCIES (Narrative) (Details) (USD $) 12 Months Ended 1 Months Ended 0 Months Ended Dec. 31, 2014 Dec. 31, 2013 Aug. 27, 2014 Aug. 22, 2014 Sep. 15, 2014 Dec. 31, 2016 Dec. 31, 2015 Feb. 01, 2015 Other Commitments [Line Items] Capital Leases, Future Minimum Payments Due, Next Twelve Months $ 123,000 us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent Capital Leases, Future Minimum Payments Due in Two Years 298,275 us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears Capital Leases, Future Minimum Payments Due in Three Years 338,250 us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears Capital Leases, Future Minimum Payments Due in Four Years 338,250 us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears Research and Development Expense, Total 1,249,007 us-gaap_ResearchAndDevelopmentExpense 744,230 us-gaap_ResearchAndDevelopmentExpense Acquisition Of Patents and Trademarks 726,989 us-gaap_PaymentsToAcquireIntangibleAssets 290,336 us-gaap_PaymentsToAcquireIntangibleAssets Research And Development Arrangement Contract Terms two-year term License Costs 246,434 us-gaap_LicenseCosts 413,566 us-gaap_LicenseCosts Amortization of Other Deferred Charges 32,524 us-gaap_OtherAmortizationOfDeferredCharges 0 us-gaap_OtherAmortizationOfDeferredCharges Capital Leases, Future Minimum Payments Due 97,593 us-gaap_CapitalLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due, Next Twelve Months 44,000 us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments, Due in Two Years 45,000 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Three Years 31,000 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears Scenario, Forecast [Member] Other Commitments [Line Items] Annual minimum royalty payments 75,000 us-gaap_RoyaltyGuaranteesCommitmentsAmount / us-gaap_StatementScenarioAxis = us-gaap_ScenarioForecastMember 225,000 us-gaap_RoyaltyGuaranteesCommitmentsAmount / us-gaap_StatementScenarioAxis = us-gaap_ScenarioForecastMember 75,000 us-gaap_RoyaltyGuaranteesCommitmentsAmount / us-gaap_StatementScenarioAxis = us-gaap_ScenarioForecastMember Licensing Agreements [Member] Other Commitments [Line Items] Milestone payment upon approval of a product 150,000 xxii_MilestonePayment / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Research and Development Expense, Total 162,408 us-gaap_ResearchAndDevelopmentExpense / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Acquisition Of Patents and Trademarks 81,204 us-gaap_PaymentsToAcquireIntangibleAssets / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember License Costs 75,000 us-gaap_LicenseCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember 125,000 us-gaap_LicenseCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember License Maintenance Fees Due Current 15,000 xxii_LicenseMaintenanceFeesDueCurrent / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember License Maintenance Fees Due In Two Years 15,000 xxii_LicenseMaintenanceFeesDueInTwoYears / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember License Maintenance Fees Due In Three Years 15,000 xxii_LicenseMaintenanceFeesDueInThreeYears / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Minimum Royalty Fee Payments Due In Year Four 20,000 xxii_MinimumRoyaltyFeePaymentsDueInYearFour / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Minimum Royalty Fee Payments Due In Year Five 30,000 xxii_MinimumRoyaltyFeePaymentsDueInYearFive / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Minimum Royalty Fee Payments Due Thereafter 50,000 xxii_MinimumRoyaltyFeePaymentsDueThereafter / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Licensing Agreements [Member] | Scenario, Forecast [Member] Other Commitments [Line Items] Other Accrued Liabilities, Noncurrent 81,204 us-gaap_OtherAccruedLiabilitiesNoncurrent / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember / us-gaap_StatementScenarioAxis = us-gaap_ScenarioForecastMember Patents [Member] Other Commitments [Line Items] Facility Membership and Operations Costs 123,968 us-gaap_FacilityMembershipAndOperationsCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember 101,902 us-gaap_FacilityMembershipAndOperationsCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember Precision License [Member] Other Commitments [Line Items] License Costs 1,250,000 us-gaap_LicenseCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = xxii_PrecisionLicenseMember Finite-lived Intangible Assets Acquired 725,000 us-gaap_FinitelivedIntangibleAssetsAcquired1 / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = xxii_PrecisionLicenseMember Obligation To Pay Remaining License Cost 525,000 xxii_ObligationToPayRemainingLicenseCost / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = xxii_PrecisionLicenseMember Obligation To Pay Remaining License Cost In Increments 25,000 xxii_ObligationToPayRemainingLicenseCostInIncrements / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = xxii_PrecisionLicenseMember Anandia Sublicense [Member] Other Commitments [Line Items] License Costs 10,000 us-gaap_LicenseCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = xxii_AnandiaSublicenseMember Upfront Fee $ 75,000 xxii_UpfrontFee / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = xxii_AnandiaSublicenseMember X - Definition Amount of minimum lease payments for capital leases. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737 + Details Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737 + Details Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737 + Details Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737 + Details Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737 + Details Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Costs incurred during the reporting period related to facility or amenity membership and its operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_FacilityMembershipAndOperationsCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from a business combination. + References No definition available. + Details Name: us-gaap_FinitelivedIntangibleAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_LicenseCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 24 -Article 5 + Details Name: us-gaap_OtherAccruedLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of amortization of other deferred costs recognized in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_OtherAmortizationOfDeferredCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_OtherCommitmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The amount the entity has committed to make for future royalty guarantees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 440 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013 + Details Name: us-gaap_RoyaltyGuaranteesCommitmentsAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of license maintenance fees due in the next fiscal year following the latest fiscal year. + References No definition available. + Details Name: xxii_LicenseMaintenanceFeesDueCurrent Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of license maintenance fees due in the third fiscal year following the latest fiscal year. + References No definition available. + Details Name: xxii_LicenseMaintenanceFeesDueInThreeYears Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of license maintenance fees due in the second fiscal year following the latest fiscal year. + References No definition available. + Details Name: xxii_LicenseMaintenanceFeesDueInTwoYears Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Milestone payment upon approval of a product. + References No definition available. + Details Name: xxii_MilestonePayment Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of minimum royalty fee payments due in the fifth fiscal year following the latest fiscal year. + References No definition available. + Details Name: xxii_MinimumRoyaltyFeePaymentsDueInYearFive Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of minimum royalty fee payments due in the fourth fiscal year following the latest fiscal year. + References No definition available. + Details Name: xxii_MinimumRoyaltyFeePaymentsDueInYearFour Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of minimum royalty fee payments due after the fifth fiscal year following the latest fiscal year. + References No definition available. + Details Name: xxii_MinimumRoyaltyFeePaymentsDueThereafter Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of remaining license cost the company is obligated to pay. + References No definition available. + Details Name: xxii_ObligationToPayRemainingLicenseCost Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of remaining license cost the company is obligated to pay in increments. + References No definition available. + Details Name: xxii_ObligationToPayRemainingLicenseCostInIncrements Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Represents the research and development arrangement contract terms. + References No definition available. + Details Name: xxii_ResearchAndDevelopmentArrangementContractTerms Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Represents the amount of upfront fees during the period. + References No definition available. + Details Name: xxii_UpfrontFee Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=xxii_AnandiaSublicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=xxii_PrecisionLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 22 R25.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 EARNINGS PER COMMON SHARE 12 Months Ended Dec. 31, 2014 Earnings Per Common Share [Abstract] EARNINGS PER COMMON SHARE NOTE 18. - EARNINGS PER COMMON SHARE The following table sets forth the computation of basic and diluted earnings per common share for the year ended December 31, 2014 and 2013: December 31, December 31, 2014 2013 Net loss attributed to common shareholders $ (15,595,358) $ (26,153,158) Denominator for basic earnings per share-weighted average shares outstanding 59,993,413 43,635,182 Effect of dilutive securities: Warrants, restricted stock and options outstanding - - Denominator for diluted earnings per common share-weighted average shares adjusted for dilutive securities 59,993,413 43,635,182 Loss per common share - basic and diluted $ (0.26) $ (0.60) Securities outstanding that were excluded from the computation of earnings per share for the year ended December 31, 2014 and 2013 because they would have been anti-dilutive are as follows: December 31, December 31, 2014 2013 Warrants 13,674,409 10,653,469 Restricted stock 250,000 500,000 Options 890,000 660,000 14,814,409 11,813,469 X - Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 23 R50.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 SEVERANCE LIABILITY (Narrative) (Details) (USD $) 12 Months Ended 3 Months Ended Dec. 31, 2014 Dec. 31, 2014 Dec. 31, 2013 Severance Liability [Line Items] Severance Costs $ 624,320 us-gaap_SeveranceCosts1 Severance Term 36 months Accrued Liabilities, Current 1,081,545 us-gaap_AccruedLiabilitiesCurrent 1,081,545 us-gaap_AccruedLiabilitiesCurrent 575,730 us-gaap_AccruedLiabilitiesCurrent Accounts Payable and Accrued Liabilities, Noncurrent 412,308 us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent 412,308 us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent 0 us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent Employee Severance [Member] Severance Liability [Line Items] Monthly Severance Cost 18,750 xxii_MonthlySeveranceCost / us-gaap_RestructuringCostAndReserveAxis = us-gaap_EmployeeSeveranceMember Employement Agreement [Member] Severance Liability [Line Items] Accrued Liabilities, Current 212,012 us-gaap_AccruedLiabilitiesCurrent / us-gaap_RestructuringCostAndReserveAxis = xxii_EmployementAgreementMember 212,012 us-gaap_AccruedLiabilitiesCurrent / us-gaap_RestructuringCostAndReserveAxis = xxii_EmployementAgreementMember Accounts Payable and Accrued Liabilities, Noncurrent 0 us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent / us-gaap_RestructuringCostAndReserveAxis = xxii_EmployementAgreementMember 0 us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent / us-gaap_RestructuringCostAndReserveAxis = xxii_EmployementAgreementMember Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 320,000 us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares / us-gaap_RestructuringCostAndReserveAxis = xxii_EmployementAgreementMember Allocated Share-based Compensation Expense $ 60,000 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_RestructuringCostAndReserveAxis = xxii_EmployementAgreementMember X - Definition Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 24 -Article 5 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a)(10) -URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Number of options vested. + References No definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Amount of monthly expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation + References No definition available. + Details Name: xxii_MonthlySeveranceCost Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: xxii_SeveranceLiabilityLineItems Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Represents the term of employment agreement + References No definition available. + Details Name: xxii_SeveranceTerm Namespace Prefix: xxii_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=xxii_EmployementAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 24 R42.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSULTING AGREEMENT AND JOINT VENTURE (Narrative) (Details) (USD $) 1 Months Ended 12 Months Ended 9 Months Ended Jan. 31, 2013 Dec. 31, 2014 Dec. 31, 2013 Sep. 30, 2014 Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 2,500,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Issuance of Stock and Warrants for Services or Claims 2,231,385 us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims 1,381,800 us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Amortization of Other Deferred Charges 32,524 us-gaap_OtherAmortizationOfDeferredCharges 0 us-gaap_OtherAmortizationOfDeferredCharges Tranche 1A Warrants [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Weighted Average Number of Shares, Contingently Issuable 5,000,000 us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable / us-gaap_StatementEquityComponentsAxis = xxii_Tranche1aWarrantsMember Tranche 2 Warrants [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 1,000,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants / us-gaap_StatementEquityComponentsAxis = xxii_Tranche2WarrantsMember Warrants Issued Expected Term 5 years Tranche 3 Warrants [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 1,000,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants / us-gaap_StatementEquityComponentsAxis = xxii_Tranche3WarrantsMember Warrants Issued Expected Term 5 years Exercise Price Of Warrants $ 3.3736 xxii_ExercisePriceOfWarrants / us-gaap_StatementEquityComponentsAxis = xxii_Tranche3WarrantsMember Consulting Agreement [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Sale of Stock, Percentage of Ownership before Transaction 51.00% us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 1,250,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Finite-Lived Intangible Assets, Remaining Amortization Period 6 months Amortization of Other Deferred Charges 0 us-gaap_OtherAmortizationOfDeferredCharges / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Consulting Agreement [Member] | Tranche 1A Warrants [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 1,250,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants / us-gaap_StatementEquityComponentsAxis = xxii_Tranche1aWarrantsMember / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Warrants Issued Expected Term 2 years Issuance of Stock and Warrants for Services or Claims 2,810,000 us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims / us-gaap_StatementEquityComponentsAxis = xxii_Tranche1aWarrantsMember / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Exercise Price Of Warrants $ 3.36 xxii_ExercisePriceOfWarrants / us-gaap_StatementEquityComponentsAxis = xxii_Tranche1aWarrantsMember / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Consulting Agreement [Member] | Tranche 1B Warrants [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 1,000,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants / us-gaap_StatementEquityComponentsAxis = xxii_Tranche1bWarrantsMember / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Warrants Issued Expected Term 2 years Issuance of Stock and Warrants for Services or Claims $ 1,260,000 us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims / us-gaap_StatementEquityComponentsAxis = xxii_Tranche1bWarrantsMember / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember Exercise Price Of Warrants $ 2.5951 xxii_ExercisePriceOfWarrants / us-gaap_StatementEquityComponentsAxis = xxii_Tranche1bWarrantsMember / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember X - Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of amortization of other deferred costs recognized in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_OtherAmortizationOfDeferredCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction. + References No definition available. + Details Name: us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Value of preferred stock and warrants for common stock issued. + References No definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e2646-109256 + Details Name: us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Represents the exercise price of warrants during period. + References No definition available. + Details Name: xxii_ExercisePriceOfWarrants Namespace Prefix: xxii_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Represents the expected terms of warrants issued during period. + References No definition available. + Details Name: xxii_WarrantsIssuedExpectedTerm Namespace Prefix: xxii_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=xxii_Tranche1aWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=xxii_Tranche2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=xxii_Tranche3WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: xxii_TypeOfAgreementsAxis=xxii_ConsultingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 25 R37.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) Dec. 31, 2014 Dec. 31, 2013 Inventory [Line Items] Inventory - tobacco leaf $ 1,537,521 xxii_InventoryTobaccoLeafGross $ 1,398,747 xxii_InventoryTobaccoLeafGross Less: inventory reserve 50,623 us-gaap_InventoryValuationReserves 50,623 us-gaap_InventoryValuationReserves Inventory - tobacco leaf, net 1,486,898 xxii_InventorytobaccoLeafNet 1,348,124 xxii_InventorytobaccoLeafNet Inventory - finished goods Cigarettes and filtered cigars 154,568 us-gaap_InventoryFinishedGoodsAndWorkInProcess 13,206 us-gaap_InventoryFinishedGoodsAndWorkInProcess Inventory - raw materials Cigarette and filtered cigar components 423,330 us-gaap_InventoryRawMaterialsAndSupplies 44,950 us-gaap_InventoryRawMaterialsAndSupplies Inventory, Net $ 2,064,796 us-gaap_InventoryNet $ 1,406,280 us-gaap_InventoryNet X - Definition Amount before valuation reserves of merchandise or goods held by the entity that are readily available for sale and items held by the entity which are partially complete or in the process of being readied for sale. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)(1),(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_InventoryFinishedGoodsAndWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_InventoryFinishedGoodsAndWorkInProcessAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_InventoryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)(4),(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_InventoryRawMaterialsAndSuppliesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of valuation reserve for inventory. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.BB) -URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 09 -Article 12 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount before valuation and LIFO reserves of inventory tobacco leaf gross expected to be sold, or consumed within one year or operating cycle, if longer. + References No definition available. + Details Name: xxii_InventoryTobaccoLeafGross Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after valuation and LIFO reserves of inventory tobacco leaf net expected to be sold, or consumed within one year or operating cycle, if longer. + References No definition available. + Details Name: xxii_InventorytobaccoLeafNet Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 26 R52.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Narrative) (Details) (USD $) 0 Months Ended 1 Months Ended 12 Months Ended Aug. 09, 2012 Dec. 14, 2011 Jan. 31, 2013 Dec. 31, 2014 Dec. 31, 2013 Dec. 31, 2012 Sep. 30, 2013 Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 13,674,409 us-gaap_ClassOfWarrantOrRightOutstanding [1] 10,653,469 us-gaap_ClassOfWarrantOrRightOutstanding 12,972,664 us-gaap_ClassOfWarrantOrRightOutstanding Proceeds from Issuance of Preferred Stock and Preference Stock $ 3,987,655 us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Warrant Exchange Inducement Expense 144,548 xxii_WarrantExchangeInducementExpense 3,736,313 xxii_WarrantExchangeInducementExpense Warrants Without Provision Of Anti Dilution 13,544,600 xxii_WarrantsWithoutProvisionOfAntiDilution [2] Derivative, Gain (Loss) on Derivative, Net, Total 3,676,691 us-gaap_DerivativeGainLossOnDerivativeNet 19,271,977 us-gaap_DerivativeGainLossOnDerivativeNet Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value 3,921,381 us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue Warrants With Provision Of Anti Dilution 129,809 xxii_WarrantsWithProvisionOfAntiDilution Proceeds from Issuance of Warrants 0 us-gaap_ProceedsFromIssuanceOfWarrants Interest Expense, Other 509,062 us-gaap_InterestExpenseOther 17,386 us-gaap_InterestExpenseOther 7,094 us-gaap_InterestExpenseOther 730,716 us-gaap_InterestExpenseOther Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 2,500,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Consulting Agreement [Member] Class of Warrant or Right [Line Items] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 1,250,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants / xxii_TypeOfAgreementsAxis = xxii_ConsultingAgreementMember January 2011 Private Placement Offering Warrants One [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 2,817,952 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsOneMember Warrants Price $ 3.00 xxii_WarrantsPrice / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsOneMember January 2011 Private Placement Offering Warrants Two [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 653,869 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsTwoMember Warrants Price $ 3.00 xxii_WarrantsPrice / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsTwoMember January 2011 Private Placement Offering Warrants Three [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 3,062,665 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsThreeMember Warrants Price $ 3.00 xxii_WarrantsPrice / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsThreeMember January 2011 Private Placement Offering Warrants Four [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 292,965 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFourMember Warrants Price $ 1.50 xxii_WarrantsPrice / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFourMember January 2011 Private Placement Offering Warrants Five [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 37,177 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFiveMember [3] Warrants Price $ 1.50 xxii_WarrantsPrice / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFiveMember January 2011 Private Placement Offering Warrants Six [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 62,329 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSixMember Warrants Price $ 1.50 xxii_WarrantsPrice / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSixMember January 2011 Private Placement Offering Warrants Seven [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 10,831 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSevenMember Warrants Price $ 1.50 xxii_WarrantsPrice / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSevenMember Officers And Directors [Member] Class of Warrant or Right [Line Items] Warrants and Rights Outstanding 3,725,962 us-gaap_WarrantsAndRightsOutstanding / us-gaap_TitleOfIndividualAxis = xxii_OfficersAndDirectorsMember Percentage of Warrants Outstanding 27.30% xxii_PercentageOfWarrantsOutstanding / us-gaap_TitleOfIndividualAxis = xxii_OfficersAndDirectorsMember Warrant [Member] | Warrant Exchange Program [Member] Class of Warrant or Right [Line Items] Warrants outstanding upon conversion of convertible notes 19,616,308 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_WarrantMember / us-gaap_PlanNameAxis = xxii_WarrantExchangeProgramMember Series C Warrant [Member] Class of Warrant or Right [Line Items] Proceeds from Issuance of Warrants $ 343,079 us-gaap_ProceedsFromIssuanceOfWarrants / us-gaap_ClassOfWarrantOrRightAxis = xxii_SeriesCWarrantMember Stock Issued During Period Shares Warrant Exercised 1,101,034 xxii_StockIssuedDuringPeriodSharesWarrantExercised / us-gaap_ClassOfWarrantOrRightAxis = xxii_SeriesCWarrantMember [1] Includes 3,725,962 warrants (27.3%) held by officers and directors that have had the anti-dilution feature removed. [2] Include 1,250,000 warrants containing Exchange Rights (see Note 6 for detailed discussion). [3] Includes anti-dilution features. X - Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Number of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a),(c),(d),(e) -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959 + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959 + Details Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Interest expense on all other items not previously classified. For example, includes dividends associated with redeemable preferred stock of a subsidiary that is treated as a liability in the parent's consolidated balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4D -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph -4 -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 + Details Name: us-gaap_InterestExpenseOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Value of preferred stock and warrants for common stock issued. + References No definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Represents the percentage of warrants outstanding as of balance sheet date. + References No definition available. + Details Name: xxii_PercentageOfWarrantsOutstanding Namespace Prefix: xxii_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Value of stock issued as a result of the exercise of warrants. + References No definition available. + Details Name: xxii_StockIssuedDuringPeriodSharesWarrantExercised Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Amount of inducement expenses on warrant exchange. + References No definition available. + Details Name: xxii_WarrantExchangeInducementExpense Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Warrants price of descriptions. + References No definition available. + Details Name: xxii_WarrantsPrice Namespace Prefix: xxii_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Number of warrants issued without the provision of anti-dilution. + References No definition available. + Details Name: xxii_WarrantsWithoutProvisionOfAntiDilution Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of warrants issued with the provision of anti-dilution. + References No definition available. + Details Name: xxii_WarrantsWithProvisionOfAntiDilution Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xxii_SeriesCWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TitleOfIndividualAxis=xxii_OfficersAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: xxii_TypeOfAgreementsAxis=xxii_ConsultingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 27 R67.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 SUBSEQUENT EVENTS (Narrative) (Details) (USD $) 1 Months Ended 0 Months Ended Jan. 19, 2015 Jan. 14, 2015 Dec. 31, 2014 Dec. 31, 2013 Subsequent Event [Line Items] Common Stock, Par or Stated Value Per Share $ 0.00001 us-gaap_CommonStockParOrStatedValuePerShare $ 0.00001 us-gaap_CommonStockParOrStatedValuePerShare Subsequent Event [Member] | Smoker Friendly International [Member] Subsequent Event [Line Items] Common Stock, Par or Stated Value Per Share $ 0.00001 us-gaap_CommonStockParOrStatedValuePerShare / dei_LegalEntityAxis = xxii_SmokerFriendlyInternationalMember / us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember Stock Issued During Period, Shares, New Issues 70,423 us-gaap_StockIssuedDuringPeriodSharesNewIssues / dei_LegalEntityAxis = xxii_SmokerFriendlyInternationalMember / us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember Subsequent Event [Member] | Omnibus Incentive Plan [Member] Subsequent Event [Line Items] Stock Issued During Period, Shares, Share-based Compensation, Gross 1,059,000 us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember / us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember X - Definition Face amount or stated value per share of common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. + References No definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 28 R61.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 STOCK BASED COMPENSATION (Schedule of Fair Value Assumptions) (Details) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Risk-free interest rate 1.80% us-gaap_FairValueAssumptionsRiskFreeInterestRate 1.89% us-gaap_FairValueAssumptionsRiskFreeInterestRate Expected dividend yield 0.00% us-gaap_FairValueAssumptionsExpectedDividendRate 0.00% us-gaap_FairValueAssumptionsExpectedDividendRate Expected stock price volatility 90.00% us-gaap_FairValueAssumptionsExpectedVolatilityRate 90.00% us-gaap_FairValueAssumptionsExpectedVolatilityRate Expected life of options 10 years 10 years X - Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details Name: us-gaap_FairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details Name: us-gaap_FairValueAssumptionsExpectedTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Risk-free interest rate assumption used in valuing an instrument. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration XML 29 R47.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 EQUITY INVESTMENT AND ADVANCE (Narrative) (Details) (USD $) 12 Months Ended 1 Months Ended Dec. 31, 2014 Dec. 31, 2013 Jan. 31, 2014 Mar. 31, 2015 Apr. 14, 2014 Sep. 30, 2014 Schedule of Equity Method Investments [Line Items] Equity Method Investments $ 250,000 us-gaap_EquityMethodInvestments Equity Method Investment, Ownership Percentage 20.00% us-gaap_EquityMethodInvestmentOwnershipPercentage 10.00% us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment Summarized Financial Information, Equity 325,000 us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity 325,000 us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity Equity Method Investment, Realized Gain (Loss) on Disposal (101,165) us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal 0 us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Advances to Affiliate 1,318,335 us-gaap_AdvancesToAffiliate 0 us-gaap_AdvancesToAffiliate Amortization of Intangible Assets 265,284 us-gaap_AmortizationOfIntangibleAssets 141,261 us-gaap_AmortizationOfIntangibleAssets Anandia Laboratories, Inc [Member] Schedule of Equity Method Investments [Line Items] Equity Method Investments 1,199,000 us-gaap_EquityMethodInvestments / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember 450,000 us-gaap_EquityMethodInvestments / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Equity Method Investment, Ownership Percentage 25.00% us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend 50,000 us-gaap_FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Equity Method Investment, Realized Gain (Loss) on Disposal 84,350 us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Percentage of Net Loss 25.00% xxii_PercentageOfNetLoss / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Non-Interest Bearing Advance 92,894 xxii_NoninterestBearingAdvance / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Amortization of Intangible Assets 16,815 us-gaap_AmortizationOfIntangibleAssets / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Anandia Laboratories, Inc [Member] | General and Administrative Expense [Member] Schedule of Equity Method Investments [Line Items] Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend 42,894 us-gaap_FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember Common Stock [Member] Schedule of Equity Method Investments [Line Items] Sale of Stock, Number of Shares Issued in Transaction 150,000 us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Common Stock [Member] | Anandia Laboratories, Inc [Member] Schedule of Equity Method Investments [Line Items] Equity Method Investment, Ownership Percentage 15.00% us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Subsequent Event [Member] | Anandia Laboratories, Inc [Member] Schedule of Equity Method Investments [Line Items] Sale of Stock, Consideration Received on Transaction $ 394,500 us-gaap_SaleOfStockConsiderationReceivedOnTransaction / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AnandiaLaboratoriesIncMember / us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember X - Definition Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04.2) -URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 2 -Article 6 + Details Name: us-gaap_AdvancesToAffiliate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: instant X - Definition Amount of gain (loss) on sale or disposal of an equity method investment. + References No definition available. + Details Name: us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.g) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition The amount of capitalized costs incurred in the period to renew or extend the term of a recognized finite-lived (amortizing and amortizable) intangible asset. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Represents the value of non-interest bearing advances made as of reporting date. + References No definition available. + Details Name: xxii_NoninterestBearingAdvance Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Percentage of net loss during the reporting period. + References No definition available. + Details Name: xxii_PercentageOfNetLoss Namespace Prefix: xxii_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xxii_AnandiaLaboratoriesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 30 R9.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NYSE MKT EXCHANGE 12 Months Ended Dec. 31, 2014 Stock Exchange [Abstract] NYSE MKT EXCHANGE NOTE 2.  NYSE MKT EXCHANGE On March 11, 2014, the Company’s common stock began trading on the NYSE MKT exchange under the ticker symbol XXII. The Company’s common stock had been previously quoted on the OTC Bulletin Board under the ticker symbol of XXII.OB. X - Definition The entire disclosure for NYSE MKT exchange. + References No definition available. + Details Name: xxii_NewYorkStockExchangeMarketDislcosureTextBlock Namespace Prefix: xxii_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: xxii_StockExchangeAbstract Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R62.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 STOCK BASED COMPENSATION (Summary of All Stock Option Activity) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Number of Options Exercised 0 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Employee Stock Option [Member] Number of Options Options Outstanding, Beginning of Period 660,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember 465,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Granted 300,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember 215,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Exercised (70,000) us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember (20,000) us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Options Outstanding, End of Period 890,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember 660,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Exercisable, End of Period 640,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Weighted Average Exercise Price Options Outstanding, Beginning of Period $ 0.74 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember $ 0.69 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Granted $ 2.61 us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember $ 0.80 us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Exercised $ 0.69 us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember $ 0.26 us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Options Outstanding, End of Period $ 1.38 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember $ 0.74 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Exercisable, End of Period $ 0.89 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Weighted Average Remaining Contractual Term Options Outstanding, End of Period 8 years Exercisable, End of Period 7 years 8 months 12 days Aggregate Intrinsic Value Options Outstanding, End of Period $ 532,900 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember Exercisable at December 31, 2014 $ 532,900 us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 / us-gaap_OptionIndexedToIssuersEquityEquityAxis = us-gaap_EmployeeStockOptionMember X - Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Net number of share options (or share units) granted during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Number of options outstanding, including both vested and non-vested options. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 32 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '!L;W)E &UL;G,Z=CTS1")U &UL;G,Z;STS1")U &UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T 5]);F9O #I%>&-E;%=O #I%>&-E;%=O #I%>&-E;%=O #I%>&-E;%=O #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/D-/3E-/3$E$
M051%1%]35$%414U%3E1?3T9?4TA!4CPO>#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7T-!
M4SPO>#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/DY!5%52
M15]/1E]"55-)3D534U]!3D1?4U5-34%263PO>#I.86UE/@T*("`@(#QX.E=O
M #I%>&-E;%=O #I.86UE/DY94T5?34M47T580TA!3D=%/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U #I%>&-E;%=O #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/E-%
M4%1%34)%4E\R,#$T7T-/34U/3E]35$]#2U]04CPO>#I.86UE/@T*("`@(#QX
M.E=O #I%>&-E;%=O
M #I.86UE/DI!3E5!4EE?,C`Q,U]04D5&15)2141?
M4U1/0TM?4#PO>#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE
M/D-/3E-53%1)3D=?04=2145-14Y47T%.1%]*3TE.5#PO>#I.86UE/@T*("`@
M(#QX.E=O #I%>&-E
M;%=O #I.86UE/D)54TE.15-37T-/34))3D%424].
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U #I%>&-E;%=O #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/DU!0TA)3D5265]!3D1?15%525!-14Y4/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U #I%>&-E;%=O #I7;W)K #I%>&-E;%=O #I%>&-E;%=O #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/D1515]&4D]-7U)%3$%4141?4$%25%D\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K #I7;W)K #I7;W)K #I.
M86UE/@T*("`@(#QX.E=O #I7;W)K #I7;W)K #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/DY!
M5%5215]/1E]"55-)3D534U]!3D1?4U5-34%263$\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K #I%>&-E
M;%=O #I%>&-E;%=O #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/D5!4DY)3D=37U!%4E]#3TU-3TY?4TA!4D5?5&%B;#PO>#I.86UE
M/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/E-43T-+7T)!4T5$7T-/
M35!%3E-!5$E/3E]486)L93PO>#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/DE.0T]-15]405A%4U]486)L97,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K #I%>&-E
M;%=O #I.86UE/@T*
M("`@(#QX.E=O #I%
M>&-E;%=O #I.86UE/DY!5%5215]/1E]"55-)3D53
M4U]!3D1?4U5-34%2634\+W@Z3F%M93X-"B`@("`\>#I7;W)K #I7;W)K #I%>&-E;%=O #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/D-/3E-53%1)
M3D=?04=2145-14Y47T%.1%]*3TE.5#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M #I7;W)K #I7
M;W)K #I7;W)K #I7;W)K #I7;W)K #I7;W)K #I%
M>&-E;%=O #I%>&-E;%=O #I%>&-E;%=O #I.
M86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/@T*("`@(#QX.E=O
M #I%>&-E;%=O #I.86UE/E)%5$E214U%3E1?4$Q!3E].87)R871I=F5?
M1&5T83PO>#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/D-/
M34U)5$U%3E137T%.1%]#3TY424Y'14Y#24537SPO>#I.86UE/@T*("`@(#QX
M.E=O #I%>&-E;%=O
M #I.86UE/D5!4DY)3D=37U!%4E]#3TU-3TY?4TA!
M4D5?0V]M#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE
M/D5!4DY)3D=37U!%4E]#3TU-3TY?4TA!4D5?06YT:3PO>#I.86UE/@T*("`@
M(#QX.E=O #I%>&-E
M;%=O #I.86UE/E-43T-+7T)!4T5$7T-/35!%3E-!
M5$E/3E].87)R83PO>#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.
M86UE/E-43T-+7T)!4T5$7T-/35!%3E-!5$E/3E]38VAE9#PO>#I.86UE/@T*
M("`@(#QX.E=O #I%
M>&-E;%=O #I.86UE/E-43T-+7T)!4T5$7T-/35!%
M3E-!5$E/3E]3=6UM83PO>#I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/DE.0T]-15]405A%4U].87)R871I=F5?1&5T86EL #I.86UE
M/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/DE.0T]-15]405A%4U]3
M8VAE9'5L95]O9E]0 #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/DE.0T]-15]405A%4U]38VAE9'5L95]O9E]S=&%T=3PO>#I.
M86UE/@T*("`@(#QX.E=O #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O #I.86UE/E-50E-%455%3E1?159%3E137TYA #I.86UE/@T*("`@(#QX.E=O #I%>&-E;%=O 6QE #I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T #I0 #I0 #I0 &UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@
M(#QP/E1H:7,@'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA
M '0^,C)N9"!#96YT=7)Y($=R;W5P+"!);F,N/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA 2!&
M:6QE 3PO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^
M4VUA;&QE 3QS6UB;VP\+W1D
M/@T*("`@("`@("`\=&0@8VQA 2!#;VUM
M;VX@4W1O8VLL(%-H87)E '0^/'-P86X^/"]S'0^,3`M2SQS'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^1ED\ '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^3F\\ 2!#=7)R96YT(%)E'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S '!E;G-E '0^/'-P86X^/"]S'0^/'-P86X^/"]S2!I;G9E '!E;G-E '0^)FYB '0^)FYB &-E '1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 6%L
M=&EE '0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]SF%T:6]N(&%N
M9"!D97!R96-I871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA '!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-#0L-30X
M*3QS"!C '!E;G-E(&%N9"!A;6]R=&EZ871I
M;VX@;V8@9&5B="!D:7-C;W5N="!A;F0@97AP96YS93H\+W-T '!E;G-E*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S 7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J
M879A '!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M'!E;G-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V
M7S '0O:F%V87-C
M 3X-"B`@("`\=&%B;&4@
M8VQA '0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S&-H86YG92!P '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M6UE;G0@;V8@86-C '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!O9B!W87)R86YT
M &5R8VES92!O9B!W87)R86YT '0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S&5R
M8VES92!O9B!O&5R8VES92!O9B!O'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!O9B!W87)R86YT &5R8VES92!O9B!W87)R86YT
M '0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!O9B!O'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S
M7S0V8S5?.# '0O
M:'1M;#L@8VAA 7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M2!B87-E9"!P87EM96YT '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!O9B!W87)R86YT 6UE;G1S(&]N(&)O &5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M'!E
M;G-E 2!I;G9E 2!I;G9E 2!A;F0@97%U:7!M96YT('!U 2!N;W1E 6%B;&4@86YD(&%C8W)U960@:6YT97)E
M 2!I;G-T &-H86YG92!P '0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S
M7S0V8S5?.# '0O
M:'1M;#L@8VAA 7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R 6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$PF4Z(#@N-6EN(#$Q+C!I;B6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)T9/3E0M4TE:13H@,3!P="2!' 2!' 2!,=&0F(S@R,C$[*2P@
M3D%30T\@4')O9'5C=',L($Q,0R`H)B,X,C(P.TY!4T-/)B,X,C(Q.RDL(&%N
M9"!";W1A;FEC86P@1V5N971I8W,L($Q,0R`H)B,X,C(P.T)O=&%N:6-A;"!'
M96YE=&EC 28C.#(R
M,3LI+B!!;&P@:6YT97)C;VUP86YY(&%C8V]U;G1S(&%N9"!T 6QE/3-$)T9/3E0M4TE:13H@,3!P="2!,=&0L(&ES(&$@2!C
M;VUP86YY('-P96-I86QI>FEN9R!I;B!T96-H;F]L;V=Y('1H870@86QL;W=S
M(&9O 2!O=VYS(&]R(&5X8VQU 28C.#(Q-SMS("AI*2!P 2!L:6-E;G-E9"!T;V)A8V-O('!R;V1U
M8W1S(&UA;G5F86-T=7)E 28C.#(Q-SMS(&-I9V%R971T92!M86YU9F%C='5R
M:6YG(&)U 2!O9B`R,FYD($-E
M;G1U 2!D97-C 2!D97-C 6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)T9/3E0M
M4TE:13H@,3!P="F5D/"]F;VYT/CPO:3X\+W-T 2!D97-I9VYA=&5D
M('1H92!R:6=H=',@;V8@86YD(&ES 2!A;F0@;F\@ 2!S
M=6)J96-T('1H92!#;VUP86YY('1O(&-O;F-E;G1R871I;VX@;V8@8W)E9&ET
M(')I 2!T
M:&4@9FEN86YC:6%L(&EN 6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P3PO9F]N=#X\+VD^(#QF;VYT('-T>6QE
M/3-$)T9/3E0M4U193$4Z(&YO 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C
M92`P"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 2`M('1O8F%C8V\@;&5A9CPO9&EV/B`\+W1D/B`\=&0@
M 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 2!R97-E "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,""!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO "!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"2`M(&9I;FES:&5D(&=O;V1S/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T
M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE "!S;VQI9#L@5$585"U!3$E'3CH@
M 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG &5D(&%S 6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$
M)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG 2!O9B`H,2D@97AP96YD:71U 2!L:69E(&]F('1H92!P '!I '!E;G-E+B!,:6-E;G-E(&9E97,@'!I 2!T;R!T:&4@35-!(&%N9"!A8W%U:7)I;F6QE/3-$)T9/3E0M4TE:
M13H@,3!P="6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA6QE/3-$)W=H:71E
M+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$
M)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO F%T:6]N/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`T6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO "!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`T6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"2!C;W-T 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@
M5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M "!S;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO "!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P'!E;G-E(')E;&%T:6YG('1O
M('1H92!A8F]V92!I;G1A;F=I8FQE(&%S 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG 6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P65A 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$PF%T:6]N(&5X65A 2`D/&9O
M;G0@ 6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M 6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG 2!R979I
M97=S('1H92!C87)R>6EN9R!V86QU92!O9B!I=',@86UO FEN9R!L;VYG
M+6QI=F5D(&%S 2!A 2!O9B!T:&4@87-S970@8GD@97-T:6UA=&EN9R!T:&4@9G5T=7)E('5N
M9&ES8V]U;G1E9"!N970@8V%S:"!F;&]W '!E8W1E9"!T;R!R97-U;'0@
M9G)O;2!T:&4@87-S970L(&EN8VQU9&EN9R!E=F5N='5A;"!D:7-P;W-I=&EO
M;BX@268@=&AE(&5S=&EM871E9"!F=71U 65A
M 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG 6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!O9B!T
M:&5I 2!O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P3X\ 6QE/3-$)T9/3E0M4TE:13H@,3!P="&5S(&%N9"!T87@@8W)E
M9&ET 6QE/3-$)T9/3E0M
M4TE:13H@,3!P="2!R96-E:79E9"!N;W1I8V4@
M9G)O;2!T:&4@3F5W(%EO 65A 6QE/3-$)T9/3E0M4TE:13H@,3!P="2!E;7!L;WEE97,@86YD(&]T:&5R
M 2!' 2!A;F0@=&EM92!O9B!A8VAI979I;F6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P3X\ 6QE/3-$)T9/
M3E0M4TE:13H@,3!P="F5D(&YE
M="!O9B!C87-H(&1I &5S(&%R92!I;F-L
M=61E9"!I;B!N970@ 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!W87,@8VAO 2!R96-E:79E9"!A
M('!U &EM
M871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 65A 6UE;G0@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P6QE
M/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P2!L:6-E;G-E 2!T;R!T:&ER9"!P87)T:65S+B!2979E;G5E(&ES(')E8V]G
M;FEZ960@9G)O;2!L:6-E;G-I;F2!,
M=&0@96YT97)E9"!I;G1O(&$@=V]R;&1W:61E(%)E 2!A(&YO;BUR969U;F1A8FQE("0\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B 2!W:6QL(&)E(&5N=&ET;&5D('1O(')E8V5I=F4@861D:71I;VYA
M;"!P87EM96YT 28C.#(Q-SMS(&QI8V5N F5D(&1U 65A 6UE;G1S
M+"!R;WEA;'1Y('!A>6UE;G1S(&%N9"!M:6YI;75M(&%N;G5A;"!R;WEA;'1I
M97,N($$@2!S=6)L
M:6-E;G-E9"!T;R!"050@=V%S(&5X8VQU 2!,=&0@8GD@82!T:&ER9"!P87)T>2!L:6-E;G-O 6%L
M='D@6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!"050@=&\@
M=&AE($-O;7!A;GD@;VX@3V-T;V)E 2!,=&0@:&%D('!R979I;W5S;'D@97-T:6UA=&5D
M('1H92!P87EM96YT('1O(&)E("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B 2!F;W(@;&EC96YS:6YG
M(&EN('1H92!#;W-T(&]F(&=O;V1S('-O;&0@ 28C.#(Q-SMS($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A
M=&EO;G,@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+CPO
M9F]N=#X\+V1I=CX@/&9O;G0@ 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/3E0M4TE:13H@
M,3!P="'!O 2!R
M:7-K 2!A 2P@:7,@979A;'5A
M=&5D(&%T('1H92!E;F0@;V8@96%C:"!R97!O 6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P&-L=61E9"!F 3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!E=F%L=6%T
M97,@96%C:"!C;VUM:71M96YT(&%N9"]O 2!I;B!A8V-O
M 2!I;B!T:&4@9FEN86YC:6%L
M('-T871E;65N=',N($EF(&YO="P@=&AE($-O;7!A;GD@=VEL;"!D:7-C;&]S
M92!A;GD@;6%T97)I86P@8V]M;6ET;65N=',@;W(@8V]N=&EN9V5N8VEE 2!A 6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/
M3E0M4TE:13H@,3!P="6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 2P@9F%I &EM871E(&-A &EM
M871E('1H92!I;G1E F5D(&%S(&$@3&5V96P@,R!M96%S=7)E;65N="P@
M87,@9G5R=&AE 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG 2!);G9E 2!H87,@=&AE(&%B:6QI='D@=&\@:&%V92!S:6=N:69I8V%N="!I;F9L
M=65N8V4@;W9E 6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG &ES=&EN9R!R979E;G5E(')E8V]G;FET:6]N(&=U:61A;F-E('5N9&5R
M(%4N4RX@1T%!4"X@5&AE(&-O 2!I 65T(&1E=&5R;6EN960@
M=&AE(&UE=&AO9"!B>2!W:&EC:"!I="!W:6QL(&%D;W!T('1H92!S=&%N9&%R
M9"!I;B`R,#$W+CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)W=I9'1H
M.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS'1087)T7S=E,S%E.&9C
M7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^/&1I=B!S='EL93TS1"=-05)'24XZ
M(#!P="`PF4Z(#@N-6EN
M(#$Q+C!I;B6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6UB;VP@6%A)22X@5&AE($-O;7!A;GDF(S@R,32!Q=6]T960@;VX@=&AE($]40R!"
M=6QL971I;B!";V%R9"!U;F1E 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG
M(&-E;&QS'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!H860@
M8W5R 6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="&EM871E;'D@,3(@;6]N=&AS
M+B8C,38P.SPO9F]N=#X\+V9O;G0^/"]F;VYT/B`\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="&-H86YG92!#;VUM:7-S:6]N("@F(S@R,C`[
M4T5#)B,X,C(Q.RD@;VX@07!R:6P@,3@L(#(P,30L(&%N9"!B96-A;64@969F
M96-T:79E(&]N($IU;F4@-2P@,C`Q-"X@5&AE('5N:79E 2!T;R!R86ES92!U65A 6QE/3-$)W=I9'1H.C$P,"4[
M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS'1087)T7S=E,S%E.&9C7SEA9C-?
M-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@
M("`\=&%B;&4@8VQA 6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 2!A9W)E960@=&\@
M2P@;VX@
M3V-T;V)E &5D.R7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X
M="]J879A 6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P2!C 28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A;F0@86QL(')E;&%T960@=V%R
M 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG
M(&-E;&QS'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA F%T
M:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0 '0^/'-P86X^/"]S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`PF4Z(#@N-6EN(#$Q+C!I;B6QE/3-$)T9/3E0M4TE:13H@
M,3!P="6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P2!T:&4@0V]M28C
M.#(Q-SMS(&YE=VQY+69O 2P@,C)N9"!#96YT
M=7)Y($%S:6$L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A('-I>"UM;VYT
M:"!#;VYS=6QT:6YG($%G 2!T;V)A8V-O('!R;V1U8W1S(&EN=&\@=&AE($%S:6%N
M(&UA 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG &5R
M8VES92!P 2!T:6UE
M+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@:7-S=65D(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 65A 2`Q+"`R,#$V(&%N9"!*
M86YU87)Y(#$L(#(P,3 2!I 6QE/3-$
M)T9/3E0M4TE:13H@,3!P="&-H86YG92!2:6=H=',@8VQA=7-E
M("AT:&4@)B,X,C(P.T5X8VAA;F=E(%)I9VAT 2!T:&%T(&ES('-I
M>'1Y(&]N92!D87ES(&%F=&5R(%-E2`H8BD@=&AE($5X8VAA;F=E(%!R:6-E
M+"!D969I;F5D(&%S('1H92!C;&]S:6YG(&)I9"!P 28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!T=V\@9&%Y 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 65A 6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG F5D(&%N9"!A 2!I;B!A8V-O 2P@05-#(#0X,"!R97%U:7)E 2!I 2!A;6]U;G0N($%S('-U8V@L('1H92!F
M86ER('9A;'5E(&]F('1H92!4 2!T
M:&4@9F%I &5R8VES86)L92!U;G1I;"!C97)T86EN
M(')E=F5N=64@;6EL97-T;VYE 3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M 6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$
M)T9/3E0M4TE:13H@,3!P="2!E;G1E 2!A;65N
M9&5D(&]N($UA>2`Q,RP@,C`Q-"P@=&\@2!A9&UI;FES=&5R960@8GD@=&AE($YA=&EO;F%L($%S &ES=&EN9R!A9&AE 28C.#(Q-SMS(&%C<75I 2!T;R!T:&4@86UE;F1E9"!A9&AE 2P@=&AE(%1R86YS
M86-T:6]N(&-L;W-E9"!O;B!!=6=U 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG &EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P2!A 3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R '0^/&1I=B!S='EL93TS1"=-05)'24XZ
M(#!P="`PF4Z(#@N-6EN
M(#$Q+C!I;B2!C;&]S960@;VX@82`D/&9O;G0@
M 2!#;V1E+B!!
M9&1I=&EO;F%L;'DL(&]N($IA;G5A 2!E 2!W87,@
M'!E;G-E 2!F;W(@65E 2!C;W-T 28C.#(Q-SMS($-O;G-O;&ED871E9"!3=&%T96UE;G1S
M(&]F($]P97)A=&EO;G,N($1U 6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 28C
M.#(Q-SMS($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,N
M(%1H92!#;VUP86YY(&1I9"!M86YU9F%C='5R92!A('%U86YT:71Y(&]F(&9I
M;'1E 6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE
M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS'1087)T
M7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`PF4Z(#@N-6EN(#$Q+C!I;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M2!A;F0@97%U:7!M96YT
M(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S(&-O;G-I 6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P6QE/3-$)TU!4D=)3CH@,&EN.R!72414
M2#H@.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q'1U 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@
M "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!
M3$E'3CH@ "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,""!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@ 2!A;F0@97%U:7!M96YT+"!N970\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,""!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)T9/3E0M4TE:13H@,3!P="2!A;F0@97%U:7!M96YT(&EN('1H92!A;6]U;G0@;V8\+V9O;G0^("0\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!A;&QO8V%T960\+V9O
M;G0^("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 2X@5&AE
M($-O;7!A;GD@ 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG 65A 2XF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^(#PO
M9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ
M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL 3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y
M868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R 2!-971H;V0@26YV97-T;65N=',@86YD($IO:6YT(%9E
M;G1U 6QE/3-$)T9/3E0M4TE:13H@,3!P
M="2UO=VYE9"!S=6)S:61I87)Y+"!";W1A;FEC
M86P@1V5N971I8W,L($Q,0RP@96YT97)E9"!I;G1O(&%N(&EN=F5S=&UE;G0@
M86=R965M96YT("AT:&4@)B,X,C(P.T%G 2!C;VUP86YY("@F(S@R,C`[06YA;F1I828C.#(R,3LI
M+B!4:&4@06=R965M96YT('!R;W9I9&5D(&9O 2!T;R!M
M86ME(&%N(&EN:71I86P@:6YV97-T;65N="!O9B`D,C4P+#`P,"!I;B!!;F%N
M9&EA(&EN(')E='5R;B!F;W(@*&DI(&$@=&5N('!E 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!I;G1E &-L=7-I=F4@ 2!I 2!O9B!I 2!W:6QL)B,Q-C`[:7-S=64@=&\@06YA;F1I82!U;G)E9VES=&5R960@
M '!E;G-E 28C.#(Q-SMS($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T 2!D97-C 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="28C.#(Q-SMS(&5Q
M=6ET>2!I;G9E 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6EN9R!V86QU92!O9B!O=7(@:6YV
M97-T;65N="!I;B!!;F%N9&EA('=A F5D(&]V97(@=&AE(&5X'!E;G-E(&]F
M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B 2!I;G9E 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG &5D.R7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X
M="]J879A 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/3E0M4TE:13H@,3!P="3X\8CX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2X@5&AI 6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!I 2!A="!A;B!A;FYU86P@ 2!I 7,@979E 65A &5D.R7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J879A 6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$
M)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P2!H860@2!L:6-E;G-E9"!F 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M 6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6UE;G1S('5N;&5S 2!D969A=6QT 2!C;VUP=71E9"!T:&4@6%B;&4@:6X@=&AE(&%M;W5N="!O9B`D.3(U
M+# 2!T:&4@0V]M2!F 3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S
M7S0V8S5?.# '0O
M:'1M;#L@8VAA 7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R 2!;06)S=')A8W1=/"]S=')O;F6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@
M,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M2!T
M:&4@0V]M2!7:71H;W5T($-A=7-E*2!O9B!- 6UE;G0@06=R965M96YT+"!D871E9"!A 6UE;G1S(&EN('1H92!G 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!W:71H:&]L9&EN9W,L(&]V97(@82!T97)M
M(&]F(#,V(&UO;G1H 6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2X@26X@861D:71I;VXL(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG &EM871E;'D@)#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!A=V%R9',@=V%S(')E8V]R9&5D
M(&%S(&5X6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E
M;&QS'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/
M3E0M4TE:13H@,3!P="6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P2!H87,@8V]N9'5C=&5D('1R86YS86-T:6]N 2P@06QT97)N871I=F4@0VEG87)E='1E 6UE;G1S+B!4:&4@
M;F5T(&%M;W5N="!D=64@9G)O;2!!0R!A;6]U;G1E9"!T;R`D/&9O;G0@ 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2X@3F\@:6YT97)E
M 3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R &-H86YG92!0 &-H86YG92!0 '0^/'-P
M86X^/"]S'0^/'-P86X^/"]S6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M &-H86YG92!P 2!H860@/&9O;G0@ 2!I 2!A;F0@861J=7-T960@=&\@9F%I &ES=&EN
M9R!W87)R86YT(&AO;&1E 2!O9F9E &5R8VES92!P &5R8VES97,@
M9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"!A;F0@
M861D:71I;VYA;"!W87)R86YT 2!P 2!E '!E;G-E(&]N('1H92!#;VUP86YY)B,X
M,C$W.W,@0V]N 2!R979E 6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)T9/3E0M
M4TE:13H@,3!P="6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P2!I 2!# 6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C
M92`P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E 6QE/3-$)W=H:71E
M+7-P86-E.FYO=W)A6QE
M/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 2`R,#$Q(%!0
M3R`D,RXP,"!W87)R86YT 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"2`R
M-2P@,C`Q-CPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"2`R-2P@,C`Q-CPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"2`R-2P@,C`Q
M-CPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 2`X+"`R,#$W/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 2`V+"`R,#$X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 2`Q-2P@,C`Q-SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE.FYO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE.FYO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE
M/3-$9F]N="US='EL93IN;W)M86P^("@S*3PO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$9F]N="US='EL93IN;W)M86P^("@S*3PO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE
M/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)R!A
M;&EG;CTS1&IU 6QE
M/3-$)T1)4U!,05DZ(&YO;F4[($9/3E0M4TE:13H@,3!P="6QE/3-$)U!!
M1$1)3D 6QE/3-$)U!!1$1)3D 6QE/3-$)T9/3E0M4TE:13H@,3!P="&-H86YG
M92!2:6=H=',@*'-E92!.;W1E(#8@9F]R(&1E=&%I;&5D(&1I 6QE/3-$)T1)4U!,05DZ(&YO;F4[($9/3E0M4TE:13H@,3!P
M="6QE/3-$)U!!1$1)3D 6QE/3-$)U!!1$1)3D 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q,34E.R!724142#H@,3`P)3L@1D].5"U&04U)3%DZ($-A;&EB 6QE/3-$)U!!1$1)3D 6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q
M,G!T)SX@/&9O;G0@ 3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!E 28C.#(Q-SMS(&-A
M'!E8W1E9"!V;VQA=&EL:71I
M97,@9F]R(&$@ 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!S971T;&4@8GD@:7-S=6EN9R!A('9A
M 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 2!U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 2!T;R!E<75I='D@=7!O;B!E>&5R8VES92!O9B!W87)R
M86YT 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 2!T;R!E<75I='D@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2!R97-U;'1I
M;F6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S
M;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M 6QE/3-$)T9/3E0M4TE:13H@
M,3!P="28C.#(Q-SMS('=A 65A 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG &-E 2!T;R!C87!I=&%L+"!I
M;B!T:&4@86UO=6YT(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B &-E 2P@=V5R92!R96-O
M 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$PF5S('1H92!I;G!U=',@:6YT;R!T:')E92!B 6QE/3-$)U!!1$1)3D 6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN
M(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I9CL@1D].
M5"U325I%.B`Q,G!T)SX@/&9O;G0@ 6QE/3-$)U!!
M1$1)3D 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!724142#H@,3`P)3L@
M1D].5"U&04U)3%DZ($-A;&EB F4Z(#$P6QE/3-$)T-,14%2.F)O=&@[34%21TE.
M.B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS
M97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/&9O;G0@ 2!T:')O=6=H(&UA 2!T:&4@9G5L;"!T97)M(&]F('1H92!F:6YA;F-I86P@:6YS=')U
M;65N=#L@86YD/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M=&%B;&4@ 6QE/3-$)U!!1$1)3D 6QE/3-$
M)V9O;G0M 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P28C.#(Q-SMS(&-L
M87-S:69I8V%T:6]N('=I=&AI;B!T:&4@:&EE 2!A;F0@28C.#(Q
M-SMS(&1E 2!I;G!U="!W;W5L9"!R97-U;'0@:6X@82!S:6=N
M:69I8V%N=&QY(&AI9VAE 6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@
M,3!P="6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(# 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO &5R8VES960@9'5R:6YG(#(P,3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO &5R8VES
M960@87,@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(# #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)U!!1$1)3D 6QE/3-$)U!!1$1)3D 6QE/3-$)T9/3E0M4TE:13H@,3!P="&5D.R7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X
M="]J879A '0^/'-P86X^/"]S6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)T9/
M3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P65E 2!D969E 2!L:6UI=',N)B,Q
M-C`[(%1H92!#;VUP86YY(&AA 65E 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 65E)B,X,C$W.W,@8V]M65A 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA '0^/'-P86X^
M/"]S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`PF4Z(#@N-6EN(#$Q+C!I;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P&-L=7-I=F4@=V]R;&1W:61E(&QI8V5N 2`H)B,X,C(P.TY#
M4U4F(S@R,C$[*2P@=&AE($-O;7!A;GD@:7,@ 6%L='D@2!F
M;W(@96%C:"!O9B`R,#$T(&%N9"`R,#$U(&ES("0\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B 6%L='D@:6YC 6UE;G0@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG 2!P871E;G0@8V]S=',@
M:6YC=7)R960N(%1H97-E(&-O 65A F5D
M('!A=&5N="!C;W-T 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@
M,3!P="6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P2!.0U-5("0\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B 65A
M 2`R,#$T(&%N9"!A(&9I;F%L('!A>6UE;G0@
M;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P&EM871E;'D@)#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!E>'!E;G-E9"!O;B!A('-T 28C.#(Q-SMS($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P
M97)A=&EO;G,N/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M2!A;F0@;6%T97)I86QS(&]W;F5D(&)Y(%!R96-I 2!T:&4@ 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="2!E;G1E &-L=7-I
M=F4@3&EC96YS92!!9W)E96UE;G0@*'1H92`F(S@R,C`[3&EC96YS92!!9W)E
M96UE;G0F(S@R,C$[*2!W:71H($Y#4U4N(%5N9&5R('1H92!,:6-E;G-E($%G
M 2!.0U-5('1H 6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="2!E;G1E 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG '!I '!E8W1E9"!T;R!B92!I;B`R,#,U
M+CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P28C.#(Q-SMS($-O;G-O;&ED871E9"!3=&%T
M96UE;G1S(&]F($]P97)A=&EO;G,N/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/3E0M4TE:13H@,3!P="2!E>&5C=71E9"!A(&=U87)A;G1Y
M('1H870@9W5A 2!.05-#3R!O9B!I=',@
M;V)L:6=A=&EO;G,@=&\@82!L86YD;&]R9"!U;F1E 2!A
M;F0@=V%R96AO=7-E(&QO8V%T960@:6X@3F]R=&@@0V%R;VQI;F$N(%5P;VX@
M=&AE($Y!4T-/('1R86YS86-T:6]N(&-L;W-I;F2`Q
M-"P@,C`Q-"P@86YD(&AA '1E;G-I;VYS.R!O;F4@9F]R(&%N(&%D9&ET:6]N86P@;VYE("@Q
M*2!Y96%R(&%N9"!T:')E92!F;W(@86X@861D:71I;VYA;"!T=V\@*#(I('EE
M87)S(&EN(&1U &5R8VES86)L92!A="!T:&4@;W!T:6]N(&]F
M($Y!4T-/+B!4:&4@;&5A 6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 65A '1E;G-I;VXL(&%N9"!E86-H(&]F
M('1H92!T:')E92`H,RDL('1W;R`H,BD@>65A '1E;G-I
M;VYS+"!R97-P96-T:79E;'DN/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P'1E;F1E9"!T:&4@;&5A 2!H879I;F'1E;F0@=&AI 65A 2`D/&9O;G0@ 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P65A 2`Q+"`R,#$S+B!4:&ES(&QE87-E('=A 3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)TU!
M4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@3U9%4D9,3U 6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E 6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`T6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO "!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@ 6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P6QE/3-$)T9/
M3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M
M4TE:13H@,3!P="6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U 6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)W=H:71E+7-P
M86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@
M5$585"U!3$E'3CH@ "!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,""!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG &5D.R7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J879A '0^/'-P
M86X^/"]S6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/
M3E0M4TE:13H@,3!P="6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P2!E 65E 6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 65A 2!O=7(@0F]A 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P2!I
M 2`R-RP@,C`Q-2X@06QL(&%W87)D
M 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!A2!B92!G 2!F:6QE9"!A($9O
M 6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P65A
M 65A
M 6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P6QE/3-$
M)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P2!R96-O 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG 2!A;'-O(')E8V]R9&5D
M(&5Q=6ET>2!B87-E9"!C;VUP96YS871I;VX@9F]R('1H92!Y96%R 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
MF5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E(')E;&%T960@=&\@;F]N+79E 6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG 2X\+V9O;G0^/"]D:78^(#QD:78@ 6QE/3-$)T9/3E0M4TE:13H@,3!P="65A 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$
M)TU!4D=)3CH@,&EN.R!724142#H@-S`E.R!"3U)$15(M0T],3$%04T4Z(&-O
M;&QA6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P,30\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ "!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/C$N.#D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6EE;&0\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B4\+V1I=CX@/"]T9#X@
M/"]T '!E8W1E9"!S=&]C:R!P 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CDP/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B4\+V1I=CX@
M/"]T9#X@/"]T '!E8W1E9"!L:69E(&]F(&]P=&EO;G,\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"65A 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"65A 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG 6QE/3-$)T9/3E0M
M4TE:13H@,3!P="'!E8W1E
M9"!V;VQA=&EL:71Y(&)A 2!A('!E97(@9W)O
M=7`@;V8@2!C87-H(&1I=FED96YD '!E8W1E9"!D:79I9&5N9"!Y:65L9"!O
M9B!Z97)O+CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/E=E:6=H=&5D/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO 6QE/3-$
M)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%V97)A9V4\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO 6QE
M/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%V97)A9V4\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%G9W)E9V%T93PO
M9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE &5R8VES928C,38P.U!R
M:6-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO 6QE/3-$)W=H:71E+7-P86-E.FYO
M=W)A6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/E1E 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/D=R86YT960@:6X@,C`Q,SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/D5X97)C:7-E9"!I;B`R,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B@R,"PP,#`I/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/D]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO &5R8VES
M960@:6X@,C`Q-#PO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H
M)SXH-S`L,#`P*3PO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D5X97)C
M:7-A8FQE(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE "!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ 65A 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C4S
M,BPY,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 65A 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG &5R8VES960@9F]R(&-A 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG 3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R '0^/'-P86X^/"]S6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:
M13H@,3!P="&5S(&-O;G-I
M 6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S
M;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO "!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,""!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!F961E "!A8V-O=6YT:6YG(&QO 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 2!F961E 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXH,RXY*3PO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E "!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E 6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2UF;W)W87)D/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"3PO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@
M5$585"U!3$E'3CH@ "!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,""!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO "!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH-2PU,C0L.#8P*3PO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,BPR,3(L,3$W*3PO9&EV/B`\+W1D
M/B`\=&0@ "!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)T9/3E0M4TE:13H@,3!P="&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG 65A 2!O9B!T:&4@0V]M28C.#(Q-SMS(&%B:6QI='D@
M=&\@9V5N97)A=&4@ F5R;RX@5&AI 2!O9F9S970@8GD@=&AE('9A;'5A=&EO;B!A;&QO=V%N8V4N
M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P"!P;W-I=&EO;G,@=&AA="!A "!R971U 2!H87,@
M;F\@=6YC97)T86EN('1A>"!P;W-I=&EO;G,@87,@;V8@1&5C96UB97(@,S$L
M(#(P,30N("8C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P28C.#(Q-SMS
M(&9E9&5R86P@86YD('-T871E('1A>"!R971U 65A &5D.R7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$PF4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T 28C.#(Q-SMS($])4"!I;B!A;B!A9V=R96=A=&4@86UO=6YT(&]F(&%P
M&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG 2`Q-BP@,C`Q-2P@=VET:"!A;B!E>&5R8VES92!P #L@1D].5#H@,3!P="!4
M:6UE F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M 6QE/3-$)W=I9'1H.C$P,"4[('1A
M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS'1087)T7S=E,S%E.&9C7SEA9C-?-#9C
M-5\X-S(V7S '0O
M:F%V87-C 3X-"B`@("`\
M=&%B;&4@8VQA 6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE 6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@
M:6YC;'5D92!T:&4@86-C;W5N=',@;V8@,C)N9"!#96YT=7)Y($=R;W5P+"!)
M;F,N("@F(S@R,C`[,C)N9"!#96YT=7)Y($=R;W5P)B,X,C(Q.RDL(&ET 6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2UO=VYE9"!S=6)S:61I87)I97,@;V8@,C)N
M9"!#96YT=7)Y($QT9"P@1V]O9')I8V@@5&]B86-C;R!#;VUP86YY+"!,3$,@
M*"8C.#(R,#M';V]D 2P@)B,X,C(P.W1H92!#;VUP86YY)B,X
M,C(Q.RDN($%L;"!I;G1E 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE
M+6QA>6]U=#IF:7AE9#LG(&-E;&QS'0^/&1I=B!S='EL
M93TS1"=-05)'24XZ(#!P="`P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!S2!T:&%T(&%L
M;&]W &-L
M=7-I=F5L>2!C;VYT 2!O &-L=7-I=F5L>2!L:6-E;G-E
M9"!T;R!U 2X@5&AE($-O;7!A;GD@86-Q=6ER960@=&AE
M(&UE;6)E 2!A;F0@=&AE(%-E='1L:6YG(%-T871E 2!I;G9E 2!! 2UF
M;W)M960@9'5R:6YG('1H92!T:&ER9"!Q=6%R=&5R(&]F(#(P,30@:6X@8V]N
M;F5C=&EO;B!W:71H('1H92!#;VUP86YY)B,X,C$W.W,@969F;W)T 2!T;V)A8V-O('!R;V1U8W1S(&EN($%S:6$L
M(&UO 6QE/3-$)W=I9'1H.C$P,"4[
M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QSF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE 6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="2!I F5D('1O(&ES 6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA
M>6]U=#IF:7AE9#LG(&-E;&QS'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE
M9#LG(&-E;&QS3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S '0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P3PO9F]N=#X\+VD^(#QF;VYT('-T>6QE/3-$)T9/3E0M
M4U193$4Z(&YO 6QE/3-$)T9/
M3E0M4TE:13H@,3!P="6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y
M96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P"!S;VQI
M9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E 6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 2`M('1O8F%C8V\@;&5A9CPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 2!R97-E
M "!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,""!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`T6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO "!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"2`M(&9I;FES:&5D(&=O;V1S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE #L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE "!S;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)W=I9'1H.C$P,"4[('1A
M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS&5D(&%S '0^/&1I=B!S='EL93TS
M1"=-05)'24XZ(#!P="`P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P&5D(&%S 6QE/3-$)T9/3E0M4TE:13H@,3!P="&5D.R'!E;F1I='5R97,@:6YC=7)R960@=VET:"!T:&ER9"!P
M87)T:65S(')E;&%T960@=&\@=&AE('!R;V-E 2!I;G1E;&QE8W1U86P@F5D
M(')E;&%T92!T;R!I;G1E;&QE8W1U86P@2!O=VYS(&]R('1O('=H:6-H(&ET(&AA &-L=7-I=F4@ 28C.#(Q-SMS(&EN=&5L;&5C='5A;"!P 2!C
M87!I=&%L:7IE9"!C;W-T F5D('5S:6YG('1H92!S=')A
M:6=H="UL:6YE(&UE=&AO9"!O=F5R('1H92!R96UA:6YI;F2!P871E;G0@9F%M:6QI97,L('=H
M:6-H(&5X2DN(%!E 2!I;G1E;&QE8W1U86P@'!I F%T:6]N(&ES('1A:V5N+B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M "!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'
M3CH@ 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI
M9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO F%T:6]N/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,""!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M "!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`T6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@ #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO "!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO "!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,""!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T9/3E0M4TE:
M13H@,3!P="F%T:6]N(&5X65A 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2X\+V9O;G0^/"]D:78^(#QD:78@ 6QE/3-$)T9/
M3E0M4TE:13H@,3!P="2!C:&%N9V5D('1H92!E '0@9FEV92!Y96%R &5D.R'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6EN9R!V86QU92!O9B!T:&4@87-S970L(&%N(&EM6QE/3-$)T9/
M3E0M4TE:13H@,3!P="2!B87-I "!A;F0@1T%!4"!R97!O 2UF;W)W
M87)D 6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P2!O9B!C=6UU;&%T:79E(&YE="!OF%T:6]N+"!T:&4@0V]M2!H87,@97-T86)L:7-H960@82!V86QU871I
M;VX@86QL;W=A;F-E('1O(&9U;&QY(&]F9G-E="!I=',@;F5T(&1E9F5R "!A 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M28C
M.#(Q-SMS(&9E9&5R86P@86YD('-T871E('1A>"!R971U 65A &5D.R65A
M 28C.#(Q-SMS($-O;G-O
M;&ED871E9"!3=&%T96UE;G0@;V8@3W!E &5D.R6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P3X\ 6QE/3-$)T9/3E0M4TE:13H@,3!P="2!U 65E 6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE 6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P3X\ 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/3E0M4TE:13H@,3!P
M="28C.#(Q-SMS('!R;V1U
M8W1S(&ES(')E8V]G;FEZ960@;F5T(&]F(&-A &-I &-E'!O &5S(&1O(&YO="!A2X\+V9O;G0^/"]D:78^(#QD:78@ 65A 2!.241!('=I=&@@ 28C.#(Q-SMS
M(&UA 6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2`R,#$T+B!4;W1A;"!R979E;G5E(&9R;VT@=&AI
M 2`D/&9O;G0@ 28C.#(Q-SMS
M(&)A;&%N8V4@ 65A 2!D969I;F5D(&EN(&QI8V5N 2!A8V-O=6YT 2!W:&EC:"!A;'1E 6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG 6UE;G1S(&9R;VT@0D%4(&]F('5P
M('1O(&%N(&%D9&ET:6]N86P@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!T;R!"050N($YO(&%M;W5N="!R96QA=&5D('1O('1H
M92!A9&1I=&EO;F%L(')E 6%L='D@6%L=&EE 2!A('1H:7)D
M('!A 2`R
M,FYD($-E;G1U 2!F
M 2!,=&0@=V%S(&]B;&EG
M871E9"!T;R!M86ME(&$@ 2!P87EM96YT('1O('1H92!L:6-E;G-O
M 2!O;B!/8W1O8F5R(#$L
M(#(P,3,N($9R;VT@3V-T;V)E 6%L
M='D@9'5E('1O('1H92!L:6-E;G-O 2!,=&0N
M($1U 2!,=&0@86YD('1H92!T:&ER9"!P87)T>2!L:6-E;G-O
M 2!A9W)E960@;VX@828C,38P.W!A>6UE;G0@;V8@)#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 2!E 6UE;G0@=&\@8F4@)#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG '0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P
M="`P6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M
M4TE:13H@,3!P="'!O 2!R:7-K 2!A 2P@:7,@979A;'5A=&5D(&%T('1H92!E;F0@;V8@
M96%C:"!R97!O 6QE/3-$)W=I9'1H.C$P,"4[
M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="&-L=61E9"!F 2!!8V-O=6YT:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P2!!8V-O=6YT:6YG("T\+V9O;G0^/"]I/CPO 2P@=&AE;B!T:&4@0V]M2!W
M:6QL(')E8V]R9"!T:&4@;&EA8FEL:71Y(&EN('1H92!F:6YA;F-I86P@ 2!W:6QL(&1I 2!M871E &5D.R'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P
M6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:
M13H@,3!P="2!A8V-E'!E;G-E 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E
M;&QS6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="2P@9F%I
M &EM871E(&-A 2!A &EM871E('1H92!I;G1E F5D(&%S
M(&$@3&5V96P@,R!M96%S=7)E;65N="P@87,@9G5R=&AE 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG
M(&-E;&QS2!);G9E '0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P
M="`P6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P2!);G9E 2!H87,@=&AE(&%B:6QI='D@=&\@:&%V92!S:6=N:69I8V%N="!I;F9L
M=65N8V4@;W9E &5D.R6QE/3-$)T9/3E0M4TE:13H@,3!P
M="2`R,#$T+"!T:&4@1D%30B!I 2!B92!R
M97%U:7)E9"!W:71H:6X@=&AE(')E=F5N=64@ &ES=&EN9R!5+E,N($=!05`N
M(%1H92!S=&%N9&%R9"!I '!E
M9&EE;G1S+"!O 2!E=F%L=6%T:6YG('1H
M92!I;7!A8W0@;V8@=&AE)B,Q-C`[&5D.R7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X
M="]J879A 2P@0W5R '0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P2!A;6]U;G1S(&%R92!N;W0@ "!S;VQI9#L@0D]21$52+4Q%
M1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!724142#H@.34E.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E "!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`T6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`T#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M"!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T
M6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE "!S;VQI9#L@
M5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO "!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"2`M(')A=R!M871E 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE "!S;VQI9#L@5$585"U!3$E'3CH@
M "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@ 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE "!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M F%T:6]N/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,""!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,""!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T
M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI
M9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,""!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO "!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO "!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO "!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,""!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R 2!A;F0@
M97%U:7!M96YT(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S(&-O;G-I
M 6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)TU!4D=)3CH@
M,&EN.R!724142#H@.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q'1U 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,""!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI
M9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,""!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!
M3$E'3CH@ 2!A;F0@97%U:7!M96YT+"!N970\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,""!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ "!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 6QE/3-$)T9/3E0M4TE:13H@
M,3!P="6QE/3-$)T9/3E0M
M4TE:13H@,3!P="6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V
M8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)W=H:71E+7-P86-E.FYO=W)A
M6QE/3-$)W=H:71E+7-P
M86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E "!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 2`R,#$Q(%!03R`D,RXP,"!W87)R
M86YT 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"2`R-2P@,C`Q-CPO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"2`R-2P@,C`Q-CPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"2`R-2P@,C`Q-CPO9&EV/B`\+W1D
M/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 2`X+"`R,#$W/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 2`V+"`R,#$X
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2`Q-2P@,C`Q
M-SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE.FYO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE.FYO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$9F]N="US='EL
M93IN;W)M86P^("@S*3PO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$
M9F]N="US='EL93IN;W)M86P^("@S*3PO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O
M=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)R!A;&EG;CTS1&IU 6QE/3-$)T1)4U!,05DZ
M(&YO;F4[($9/3E0M4TE:13H@,3!P="6QE/3-$)U!!1$1)3D 6QE
M/3-$)U!!1$1)3D 6QE/3-$
M)T9/3E0M4TE:13H@,3!P="&-H86YG92!2:6=H=',@*'-E
M92!.;W1E(#8@9F]R(&1E=&%I;&5D(&1I 6QE
M/3-$)T1)4U!,05DZ(&YO;F4[($9/3E0M4TE:13H@,3!P="6QE/3-$)U!!
M1$1)3D 6QE/3-$)U!!1$1)3D 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!72414
M2#H@,3`P)3L@1D].5"U&04U)3%DZ($-A;&EB 6QE/3-$
M)U!!1$1)3D 6QE/3-$)T-,
M14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/&9O;G0@
M 3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG
M(&-E;&QS2!F '0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P2!O9B!T
M:&4@=V%R 6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2!U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 2!U6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2!U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 2!U6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2!T
M;R!E<75I='D@=7!O;B!E>&5R8VES92!O9B!W87)R86YT 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2!T;R!E<75I='D@
M=7!O;B!E>&5R8VES92!O9B!W87)R86YT 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO &-H86YG92!0 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 2!R97-U;'1I;F6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 2!T;R!E<75I='D@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,""!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P&5D.R3PO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/&1I=B!S='EL93TS
M1"=-05)'24XZ(#!P="`P6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(# 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO &5R8VES960@9'5R:6YG(#(P,3,\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO &5R8VES960@87,@6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M "!S;VQI9#L@1D].5"U714E'
M2%0Z(# #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,""!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO "!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T9/3E0M4TE:13H@,3!P
M="6QE/3-$)U!!1$1)3D 6QE/3-$)U!!
M1$1)3D 6QE/3-$)T9/3E0M4TE:13H@,3!P="3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T9/
M3E0M4TE:13H@,3!P="6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)W=H:71E
M+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE "!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ &-L=61E9"!F 2!W;W5L9"!H879E(&)E92!!;G1I+61I;'5T:79E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE 6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P&-L=61E9"!F 2!W;W5L9"!H879E(&)E96X@86YT:2UD:6QU=&EV92!A 3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE "!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ "!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q
M93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R 6QE/3-$)T9/3E0M4TE:
M13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P,3,\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/E)I 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/D5X6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 3PO9&EV/B`\+W1D
M/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B4\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C$P('EE87)S/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/C$P('EE87)S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E=E:6=H=&5D
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO 6QE/3-$)W=H:71E+7-P86-E.FYO=W)A
M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/D%V97)A9V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO 6QE/3-$)W=H:71E+7-P86-E.FYO
M=W)A6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/D%V97)A9V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/D%G9W)E9V%T93PO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M &5R8VES928C,38P.U!R:6-E/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M 6QE/3-$)W=H:71E+7-P86-E.FYO=W)A6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ "!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E 6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D=R86YT960@
M:6X@,C`Q,SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D5X97)C:7-E9"!I
M;B`R,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B@R
M,"PP,#`I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D]U='-T86YD
M:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO &5R8VES960@:6X@,C`Q-#PO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXH-S`L,#`P*3PO9&EV/B`\
M+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D5X97)C:7-A8FQE(&%T($1E8V5M8F5R
M(#,Q+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M "!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C4S,BPY,#`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U
M=#IF:7AE9#LG(&-E;&QS'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA
M "!%>'!E;G-E("A"96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M '0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M&5S(&-O;G-I 6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E 6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E "!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!
M3$E'3CH@ 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@ #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,""!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M "!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,""!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE
M9#LG(&-E;&QS6QE/3-$)T9/3E0M4TE:13H@,3!P="'!E8W1E9"!B87-E9"!O;B!A6EN9R!T
M:&4@ 6QE/3-$)T9/3E0M4TE:13H@,3!P="6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XU:6X[(%=)1%1(.B`Y,"4[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P 6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@ "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO "!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,""!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,""!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P&5D.R6QE/3-$)T9/3E0M4TE:13H@,3!P="&5S(&-O;G-I 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 3PO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO '!E;F1I='5R97,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 2!I;G9E 6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@
M5$585"U!3$E'3CH@ 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE #L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q"!L:6%B:6QI=&EE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO 3PO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE 6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@
M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO 6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE "!S;VQI9#L@5$585"U!3$E'3CH@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ "!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO "!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO &5S/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE "!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO "!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D #L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M "!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M "!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D #L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P&5D.R7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J879A '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S6UE;G1S(&9O '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]SF%T:6]N($5X'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2P@4&QA;G0@
M86YD($5Q=6EP;65N="P@061D:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\ '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X
M-S(V7S '0O:F%V
M87-C 3X-"B`@("`\=&%B
M;&4@8VQA '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M2!R
M97-E 2`M(&9I;FES:&5D(&=O;V1S/"]S=')O;F2P@3F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA '0^/'-P86X^/"]S'0^/'-P86X^/"]S&-L=61I;F'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E
M/3-$=&5X="]J879A '0^/'-P86X^/"]S'0^/'-P86X^/"]S6EN9R!686QU92P@5&]T86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA 2!B96QI979E 2!C;VUE(&1U92!F;W(@82!P97)I;V0@;V8@87!P 2`Q,B!M;VYT:',N/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!297%U:7)E;65N
M=',L($-A65A 7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T'0O
M:'1M;#L@8VAA 7!E/3-$=&5X="]J879A
M '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S '1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X
M-S(V7S '0O:F%V
M87-C 3X-"B`@("`\=&%B
M;&4@8VQA '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S2P@4V%L92!O9B!3=&]C:R!;3&EN
M92!)=&5M '0^/'-P86X^
M/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'1087)T7S=E,S%E.&9C7SEA
M9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-
M"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S'0^-2!Y96%R '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^-2!Y
M96%R '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^,B!Y
M96%R '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^,B!Y96%R
M '0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!0 '0^/'-P86X^/"]S'1087)T7S=E,S%E.&9C7SEA9C-?-#9C
M-5\X-S(V7S '0O
M:F%V87-C 3X-"B`@("`\
M=&%B;&4@8VQA '0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X
M="]J879A 2!;3&EN92!)=&5M 6UE;G1S
M('1O($%C<75I '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M2!A;F0@17%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ 7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J879A 2!A;F0@
M17%U:7!M96YT+"!' 2P@4&QA;G0@86YD($5Q=6EP;65N="P@3W1H97(L($=R;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M6UE;G1S('1O($%C
M<75I 2!A;F0@17%U:7!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\ 2P@4&QA;G0L(&%N9"!%<75I'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M 2P@4&QA;G0@86YD($5Q=6EP;65N="!;
M3&EN92!)=&5M '1U 2!0;&%N="!!;F0@17%U:7!M96YT($EN8VQU9&EN9R!! '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!A;F0@97%U:7!M96YT
M+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA '0^/'-P86X^/"]S'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!-971H;V0@26YV97-T;65N="P@3W=N97)S:&EP
M(%!E '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]SF5D($=A:6X@*$QO F%T:6]N(&]F($EN=&%N9VEB
M;&4@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!-971H;V0@26YV97-T;65N=',@6TQI;F4@271E
M;7-=/"]S=')O;F2!-971H;V0@26YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA 2!-971H;V0@
M26YV97-T;65N="P@3W=N97)S:&EP(%!E '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]SF5D($=A:6X@*$QO '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S2!-971H;V0@26YV97-T;65N=',@6TQI
M;F4@271E;7-=/"]S=')O;F'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!-971H;V0@26YV97-T;65N=',@6TQI;F4@271E;7-=/"]S=')O
M;F7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E
M/3-$=&5X="]J879A '0^,S`@9&%Y 7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J
M879A 6%B;&4@06YD(%!A=&5N="!!8W%U:7-I=&EO;B!;
M3&EN92!)=&5M '0^/'-P86X^/"]S6%B;&4L($YO;F-U '0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S6%B;&4@06YD(%!A=&5N="!!8W%U:7-I=&EO
M;B!;3&EN92!)=&5M '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W
M93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S65M96YT($%G '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S6UE;G0@07=A '!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ 7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J879A '0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2`R,#$Q(%!R:79A=&4@4&QA
M8V5M96YT($]F9F5R:6YG(%=A "!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&-H86YG92!2:6=H=',@*'-E92!.;W1E
M(#8@9F]R(&1E=&%I;&5D(&1I '1087)T7S=E,S%E.&9C7SEA
M9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-
M"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'!I '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2`R,#$Q(%!R:79A=&4@4&QA8V5M96YT($]F9F5R:6YG
M(%=A 2`R,#$Q(%!R:79A=&4@4&QA
M8V5M96YT($]F9F5R:6YG(%=A '0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^2F%N(#(U+`T*"0DR
M,#$V/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'!I 2`R,#$Q(%!R:79A=&4@4&QA8V5M96YT($]F9F5R:6YG(%=A "!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!0 2`R,#$Q(%!R:79A=&4@4&QA8V5M96YT($]F
M9F5R:6YG(%=A '0^2F%N(#(U+`T*"0DR,#$V/'-P86X^
M/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S6%B;&4@5V%R '0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S&5R8VES92!0 '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M6%B;&4@5V%R '0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!0 '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'!I '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^3F]V(#DL#0H)"3(P,36%B;&4@5V%R '0^075G(#@L#0H)"3(P,3@\ '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'!I
M '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S&5R8VES92!0 '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES92!0 '0^4V5P(#(Y
M+`T*"0DR,#$Y/'-P86X^/"]S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J879A 2!U'0^/'-P86X^/"]S2!T;R!E
M<75I='D@=7!O;B!E>&5R8VES92!O9B!787)R86YT '0^/'-P86X^/"]S'0^/'-P86X^/"]S
M2!T;R!E
M<75I='D@ &-H86YG93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!U'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S&-H86YG92!0 '0^/'-P86X^/"]S&-H86YG92!0 '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S&-H86YG92!2:6=H=',@*'-E
M92!.;W1E(#8@9F]R(&1E=&%I;&5D(&1I 3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R '1087)T7S=E,S%E
M.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA 6UE
M;G1S($1U92P@3F5X="!4=V5L=F4@36]N=&AS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'!E;G-E+"!4;W1A;#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S '0^='=O+7EE87(@
M=&5R;28C,38P.SQS'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S6UE;G1S($1U92P@3F5X="!4=V5L=F4@36]N=&AS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M6UE;G1S+"!$=64@:6X@5'=O(%EE87)S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M6UE;G1S+"!$=64@:6X@5&AR964@
M665A 6%L='D@'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!&964@4&%Y;65N=',@1'5E($EN(%EE
M87(@1FEV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S6%L='D@1F5E(%!A>6UE;G1S($1U92!4:&5R96%F=&5R
M/"]T9#X-"B`@("`@("`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
M9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-
M"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^/'-P86X^/"]S'1087)T7S=E
M,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&-L=61E9"!F &-L=61E9"!F '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&-L=61E9"!F '1087)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA 65E(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5MF5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@;F]N+79E '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S6UE;G0@07=A '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M6UE;G0@
M07=A '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M6UE;G0@07=A 2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&EM=6T@6TUE;6)E 6UE;G0@07=A '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO
M '0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S65A 6UE;G0@07=A
M 2!3:&%R92UB87-E9"!087EM
M96YT($%W87)D+"!%>'!I '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^,3`@>65A '0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S'0^/'-P86X^
M/"]S2!3
M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO '0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S2!);F-E;G1I=F4@4&QA;B`R,#$P(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ 6UE;G0@07=A 2!3:&%R92U"87-E9"!087EM96YT($%W87)D+"!.
M=6UB97(@3V8@4VAA 6UE;G0@07=A 2!);F-E;G1I
M=F4@4&QA;B`R,#$P(%M-96UB97)=('P@3VUN:6)U '0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO '0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P86X^/"]S
M'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF
M8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R '0^/'-P86X^/"]S'0^/'-P86X^/"]S6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA 3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S&5R8VES86)L92P@16YD(&]F(%!E '0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^
M/'-P86X^/"]S&5R8VES86)L92P@16YD(&]F(%!E '0^-R!Y96%R '0^/'-P86X^
M/"]S'0^/'-P86X^/"]S&5R8VES86)L92!A="!$96-E;6)E '0^/'-P
M86X^/"]S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF
M8U\Y868S7S0V8S5?.# '0O:'1M;#L@8VAA 7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R 7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T'0O:'1M;#L@8VAA 7!E/3-$=&5X="]J879A &5S*2`H1&5T86EL 3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W93,Q93AF8U\Y868S7S0V
M8S5?.# '0O:'1M
M;#L@8VAA 7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R "!P "!R871E("AB96YE9FET
M*2!P '10
M87)T7S=E,S%E.&9C7SEA9C-?-#9C-5\X-S(V7S '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA "!! '!E;F1I='5R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA 2!I;G9E '0^/'-P86X^/"]S'0^/'-P86X^/"]S"!L:6%B:6QI=&EE 7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M'0O:'1M;#L@
M8VAA 7!E/3-$=&5X="]J879A '0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^/'-P
M86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S'0^
M/'-P86X^/"]S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC XML 33 R43.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 BUSINESS COMBINATION (Narrative) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Business Combination, Separately Recognized Transactions [Line Items] Payments to Acquire Businesses, Gross $ 250,000 us-gaap_PaymentsToAcquireBusinessesGross $ 0 us-gaap_PaymentsToAcquireBusinessesGross Stock Issued During Period, Value, Acquisitions 1,952,000 us-gaap_StockIssuedDuringPeriodValueAcquisitions 0 us-gaap_StockIssuedDuringPeriodValueAcquisitions Cash Acquired from Acquisition 105,000 us-gaap_CashAcquiredFromAcquisition Common Stock [Member] Business Combination, Separately Recognized Transactions [Line Items] Stock Issued During Period, Shares, Acquisitions 640,000 us-gaap_StockIssuedDuringPeriodSharesAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Stock Issued During Period, Value, Acquisitions 6 us-gaap_StockIssuedDuringPeriodValueAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Unclassified Indefinite-lived Intangible Assets [Member] Business Combination, Separately Recognized Transactions [Line Items] Other Indefinite-lived Intangible Assets $ 2,202,000 us-gaap_OtherIndefiniteLivedIntangibleAssets / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember $ 0 us-gaap_OtherIndefiniteLivedIntangibleAssets / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember X - Details Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 + Details Name: us-gaap_CashAcquiredFromAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights not otherwise specified in the taxonomy having a projected indefinite period of benefit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_OtherIndefiniteLivedIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Number of shares of stock issued during the period pursuant to acquisitions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Value of stock issued pursuant to acquisitions during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R29.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 12 Months Ended Dec. 31, 2014 Organization, Consolidation and Presentation of Financial Statements [Abstract] Principles of Consolidation Principles of Consolidation - The accompanying consolidated financial statements include the accounts of 22nd Century Group, Inc. (“22nd Century Group”), its three wholly-owned subsidiaries, 22nd Century Limited, LLC (“22nd Century Ltd”), NASCO Products, LLC (“NASCO”), and Botanical Genetics, LLC (“Botanical Genetics”), and a 51 % owned subsidiary, 22nd Century Asia Ltd. (“22nd Century Asia”), and two wholly-owned subsidiaries of 22nd Century Ltd, Goodrich Tobacco Company, LLC (“Goodrich Tobacco”) and Hercules Pharmaceuticals, LLC (“Hercules Pharma”) (collectively, “the Company”). All intercompany accounts and transactions have been eliminated. Nature of Business Nature of Business - 22nd Century Ltd, is a plant biotechnology company specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The Company owns or exclusively controls 128 issued patents plus an additional 52 pending patent applications. The patents owned by or exclusively licensed to us include patents issued in 96 countries. Goodrich Tobacco and Hercules Pharma are business units for the Company’s (i) premium cigarettes and potential modified risk tobacco products and (ii) smoking cessation product, respectively. The Company acquired the membership interests of NASCO on August 29, 2014. NASCO is a federally licensed tobacco products manufacturer, a participating member of the tobacco Master Settlement Agreement (“MSA”) between the tobacco industry and the Settling States under the MSA, and operates the Company’s cigarette manufacturing business in North Carolina. Botanical Genetics is a wholly-owned subsidiary of 22nd Century Group, and was incorporated to facilitate an equity investment more fully described in Note 10. 22nd Century Asia was newly-formed during the third quarter of 2014 in connection with the Company’s efforts to sell its proprietary tobacco products in Asia, more fully described in Note 6. Preferred stock authorized Preferred Stock Authorized - The Company is authorized to issue “blank check” preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock. On January 11, 2013, the Company designated the rights of and issued 2,500 shares of Series A-1 Preferred Stock. As of June 7, 2013, all 2,500 outstanding shares of Series A-1 Preferred Stock were converted into an aggregate of 4,166,666 shares of common stock of the Company and no shares of preferred stock remain outstanding. Concentration of Risk Credit Risk Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in financial institutions. Although the cash accounts exceed the federally insured deposit amount, management does not anticipate nonperformance by the financial institutions. Management reviews the financial viability of these institutions on a periodic basis. Inventory Inventory - Inventories are valued at the lower of cost or market. Cost is determined using an average cost method for tobacco leaf inventory and the first-in, first-out (FIFO) method on all other inventories. Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. Inventories at December 31, 2014 and 2013 consist of the following: December 31, 2014 December 31, 2013 Inventory - tobacco leaf $ 1,537,521 $ 1,398,747 Less: inventory reserve 50,623 50,623 Inventory - tobacco leaf, net 1,486,898 1,348,124 Inventory - finished goods Cigarettes and filtered cigars 154,568 13,206 Inventory - raw materials Cigarette and filtered cigar components 423,330 44,950 $ 2,064,796 $ 1,406,280 Fixed assets Fixed assets  Fixed assets are recorded at their acquisition cost and depreciated on a straight line basis over their estimated useful lives ranging from 3 to 10 years. Depreciation commences when the asset is placed in service. Intangible Assets Intangible Assets - Intangible assets are recorded at cost and consist primarily of (1) expenditures incurred with third parties related to the processing of patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties, (2) license fees paid for third-party intellectual property, (3) costs to become a signatory under the tobacco Master Settlement Agreement (“MSA”), and (4) license fees paid to acquire a predicate cigarette brand. The amounts capitalized relate to intellectual property that the Company owns or to which it has exclusive rights. The Company’s intellectual property capitalized costs are amortized using the straight-line method over the remaining statutory life of the primary patent in each of the Company’s two primary patent families, which expire in 2019 and 2028 (the assets’ estimated lives, respectively). Periodic maintenance or renewal fees are expensed as incurred. Annual minimum license fees are charged to expense. License fees paid for third-party intellectual property are amortized on a straight-line basis over the last to expire patents, which patent expiration dates range from 2028 through 2035. The Company believes costs associated with becoming a signatory to the MSA and acquiring the predicate cigarette brand have an indefinite life and as such, no amortization is taken. Total intangible assets at December 31, 2014 and December 31, 2013 consist of the following: December 31, December 31, 2014 2013 Intangible assets, net Patent and trademark costs $ 4,405,586 $ 2,559,412 Less: accumulated amortization 1,247,303 1,014,543 Patent and trademark costs, net 3,158,283 1,544,869 License fees, net (see Note 17) 1,450,000 - Less: accumulated amortization 32,524 - License fees, net 1,417,476 - MSA signatory costs (see Note 7) 2,202,000 - License fee for predicate cigarette brand 300,000 - $ 7,077,759 $ 1,544,869 Amortization expense relating to the above intangible assets for the years ended December 31, 2014 and 2013 amounted to $ 265,284 and $ 141,261 , respectively. During the year ended December 31, 2013, the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial statements. The estimated annual average amortization expense for the next five years is approximately $ 310,000 for patent costs and $ 98,000 for license fees. Impairment of Long-Lived Assets Impairment of Long-Lived Assets - The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability of the asset by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition. If the estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and its fair value. There was no impairment loss recorded during the years ended December 31, 2014 or 2013. Income Taxes Income Taxes - The Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and GAAP reporting, and for operating loss and credit carry-forwards. In light of the Company’s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2014 and 2013. The Company’s federal and state tax returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2014. Refundable taxes and tax credits Refundable taxes and tax credits  The Company accounts for income tax refunds or tax refundable tax credits as discrete items and recognized the amount in the period in which the funds are received. During the year ended December 31, 2013, the Company received notice from the New York State Department of Taxation and Finance of a no change audit with respect to its income tax return filed for the period ending September 30, 2011. The subject return contained a refundable credit in the amount of $ 122,024 . The refund was recorded as Other income in the Company’s Consolidated Statement of Operations for the year ended December 31, 2013. There were no such transactions during the year ended December 31, 2014. Stock Based Compensation Stock Based Compensation - The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees and others receive shares, options or warrants to purchase common shares of 22nd Century Group. Stock based compensation expense is recorded over the requisite service period based on estimates of probability and time of achieving milestones and vesting. For accounting purposes, the shares will be considered issued and outstanding upon vesting. Revenue Recognition Revenue Recognition  The Company recognizes revenue from product sales at the point the product is shipped to a customer and title has transferred. Revenue from the sale of the Company’s products is recognized net of cash discounts, sales returns and allowances. Cigarette federal excise taxes are included in net sales and accounts receivable billed to customers, except on sales of SPECTRUM research cigarettes and exported cigarettes, to which such taxes do not apply. The Company was chosen to be a subcontractor for a 5-year government contract between RTI International (“RTI”) and the National Institute on Drug Abuse (“NIDA”) to supply NIDA with research cigarettes. These government research cigarettes are distributed under the Company’s mark, SPECTRUM . In September 2013, the Company received a purchase order for 5.5 million SPECTRUM research cigarettes that were shipped in January 2014. Total revenue from this order was approximately $ 448,000 for the year ended December 31, 2014. A down payment of $ 179,014 was received in the fourth quarter of 2013 and was recorded as deferred revenue on the Company’s balance sheet at December 31, 2013. There were no SPECTRUM cigarettes delivered during the year ended December 31, 2013. The Company licenses its patented technology to third parties. Revenue is recognized from licensing arrangements as contractually defined in licensing agreements. The Company accounts for milestones elements contained in licensing agreements in accordance with ASC 605. On October 1, 2013, 22nd Century Ltd entered into a worldwide Research License and Commercial Option Agreement (the “Agreement”) with British American Tobacco (Investments) Limited (“BAT”), a subsidiary of British American Tobacco plc, that grants BAT access to 22nd Century Ltd’s patented technology which alters levels of nicotinic alkaloids in tobacco plants. Simultaneous with the signing of the Agreement, BAT paid the Company a non-refundable $ 7,000,000 . The Company will be entitled to receive additional payments from BAT of up to an additional $ 7,000,000 during the term of the Research License in the event certain milestones are met with respect to the ongoing research and development of the Company’s licensed technology to BAT. No amount related to the additional research milestones was recognized during the year ended December 31, 2014. During the term of the Research License, BAT will have the option to enter into a Commercial License agreement which will provide for future annual payments, royalty payments and minimum annual royalties. A portion of the patented technology sublicensed to BAT was exclusively licensed to 22nd Century Ltd by a third party licensor proir to the acquisition by 22nd Century Ltd of such patented technology from such licensor on December 23, 2014 (see Note 12 for the more detailed discussion). Pursuant to the terms of the license agreement with such licensor, 22nd Century Ltd was obligated to make a royalty payment to the licensor with respect to a portion of the non-refundable $ 7,000,000 paid by BAT to the Company on October 1, 2013. From October 2013 to September 2014, 22nd Century Ltd and the third party licensor were in discussions as to the amount of royalty due to the licensor from 22nd Century Ltd. During the quarter ended September 30, 2014, 22nd Century Ltd and the third party licensor mutually agreed on a payment of $ 660,000 that was paid in December 2014. 22nd Century Ltd had previously estimated the payment to be $ 413,566 . The difference in the amount of $ 246,434 has been recorded as Royalty for licensing in the Cost of goods sold section of the Company’s Consolidated Statements of Operations for the year ended December 31, 2014. Derivatives Derivatives  The Company does use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations. The methodology for valuing outstanding warrants classified as derivative instruments utilizes a lattice model approach which includes probability weighted estimates of future events including volatility of our common stock. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. Research and Development Research and Development - Research and development costs are expensed as incurred. Loss Per Common Share Loss Per Common Share - Basic loss per common share is computed using the weighted-average number of common shares outstanding. Diluted loss per share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded from the computation if their effect is anti-dilutive. Commitment and Contingency Accounting Commitment and Contingency Accounting - The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial statements. If not, the Company will disclose any material commitments or contingencies that may arise. Use of Estimates Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Fair value of financial instruments Fair Value of Financial Instruments - Financial instruments include cash, receivables, accounts payable, accrued expenses, demand bank loan, and warrant liability. Other than warrant liability, fair value is assumed to approximate carrying values for these financial instruments, since they are short term in nature, they are receivable or payable on demand, or had stated interest rates that approximate the interest rates available to the Company as of the reporting date. The determination of the fair value of the warrant liability includes unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 15. Equity Investments Equity Investments  The Company accounts for investments in equity securities of other entities under the equity method of accounting if the Company’s investment in the voting stock is greater than or equal to 20 % and less than a majority, and the Company has the ability to have significant influence over the operating and financial policies of the investee. Recent Accounting Pronouncements Accounting Pronouncements - In May 2014, the FASB issued ASU 2014-09, ”Revenue from Contracts with Customers”, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements and have not yet determined the method by which it will adopt the standard in 2017. X - Definition Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 450 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 450 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249 + Details Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for credit risk. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 825 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 55 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.3A-02) -URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph k -Article 1 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02, 03 -Article 3A + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for its derivative instruments and hedging activities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(n)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph n -Article 4 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41675-113959 + Details Name: us-gaap_DerivativesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. The accounting policy may include information such as: (1) initially recording an investment in the stock of an investee at cost; (2) adjusting the carrying amount of the investment to recognize the investor's share of the earnings or losses of the investee after the date of acquisition; and (3) adjustments to reflect the investor's share of changes in the investee's capital (dividends). This disclosure may also include a detailed description of the policy for determining the amount of equity method losses recognized after an investment has been reduced to zero as a result of previous losses, reasons for not using the equity method when the investor company owns 20 percent or more of the voting stock of the investee's company (including identification of the significant investee), reasons for using the equity method when the ownership percentage is less than 20 percent, and discussion of recognition of equity method losses when an investor's total investment in an investee includes, in addition to an investment in common stock, other investments such as preferred stock and loans to the investee. An entity also may describe how such investments are assessed for impairment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 12 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details Name: us-gaap_EquityMethodInvestmentsPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for determining the fair value of financial instruments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 60 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section CC -Subsection 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 05 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6390181&loc=d3e202-110218 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 05 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 740 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_IntangibleAssetsFiniteLivedPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(b)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 206 -Paragraph b -Subparagraph i, ii -Chapter 2 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + References No definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.27(b),(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 05 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6403650&loc=d3e20905-112640 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 28 -Subparagraph b -Article 5 + Details Name: us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for nature of business. + References No definition available. + Details Name: xxii_NatureOfOperationsPolicyTextBlock Namespace Prefix: xxii_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for refundable taxes and tax credits for the reporting period. + References No definition available. + Details Name: xxii_RefundableTaxesAndTaxCreditsPolicyPolicyTextBlock Namespace Prefix: xxii_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 SUBSEQUENT EVENTS 12 Months Ended Dec. 31, 2014 Subsequent Events [Abstract] SUBSEQUENT EVENTS NOTE 21. - SUBSEQUENT EVENTS On January 14, 2015, the Company’s Board of Directors approved the Company’s Compensation Committee recommendation to award officers, employees and directors of the Company stock awards in the form of stock options from the Company’s OIP in an aggregate amount of approximately $ 1,059,000 . The stock options will be granted on February 16, 2015, with an exercise price based on the average closing price of the Company’s common stock for the three trading days immediately preceding the date of the grant. On January 19, 2015, the Company became obligated to issue 70,423 shares of its common stock, par value $ 0.00001 per share, to Smoker Friendly International, LLC (“Smoker Friendly”) under the terms of an agreement between the Company and Smoker Friendly. X - Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References No definition available. + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 36 R56.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 RETIREMENT PLAN (Narrative) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Funded Percentage 3.00% us-gaap_DefinedBenefitPlanFundedPercentage Defined Benefit Plan, Contributions by Employer $ 27,485 us-gaap_DefinedBenefitPlanContributionsByEmployer $ 34,873 us-gaap_DefinedBenefitPlanContributionsByEmployer X - Definition The increase in the fair value of plan assets from contributions made by the employer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920 + Details Name: us-gaap_DefinedBenefitPlanContributionsByEmployer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DefinedBenefitPlanDisclosureLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Plan assets of a defined benefit plan, as a percentage of projected benefit obligation. + References No definition available. + Details Name: us-gaap_DefinedBenefitPlanFundedPercentage Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: instant XML 37 R44.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 MANUFACTURING FACILITY (Narrative) (Details) (USD $) 6 Months Ended 12 Months Ended Jun. 30, 2014 Dec. 31, 2014 Dec. 31, 2013 Manufacturing Facility [Line Items] Other Cost and Expense, Operating $ 1,176,676 us-gaap_OtherCostAndExpenseOperating $ 0 us-gaap_OtherCostAndExpenseOperating Sales Revenue, Goods, Gross 528,991 us-gaap_SalesRevenueGoodsGross 278,383 us-gaap_SalesRevenueGoodsGross Other Depreciation and Amortization 224,519 us-gaap_OtherDepreciationAndAmortization Payments to Acquire Machinery and Equipment 212,487 us-gaap_PaymentsToAcquireMachineryAndEquipment 2,994,757 us-gaap_PaymentsToAcquireMachineryAndEquipment Filtered Cigars [Member] Manufacturing Facility [Line Items] Sales Revenue, Goods, Gross 81,456 us-gaap_SalesRevenueGoodsGross / us-gaap_ProductOrServiceAxis = xxii_FilteredCigarsMember Cigarete Manufacturing Equipment [Member] Manufacturing Facility [Line Items] Other Cost and Expense, Operating 2,997,140 us-gaap_OtherCostAndExpenseOperating / us-gaap_PropertyPlantAndEquipmentByTypeAxis = xxii_CigareteManufacturingEquipmentMember Payments to Acquire Machinery and Equipment $ 210,000 us-gaap_PaymentsToAcquireMachineryAndEquipment / us-gaap_PropertyPlantAndEquipmentByTypeAxis = xxii_CigareteManufacturingEquipmentMember $ 3,220,000 us-gaap_PaymentsToAcquireMachineryAndEquipment / us-gaap_PropertyPlantAndEquipmentByTypeAxis = xxii_CigareteManufacturingEquipmentMember X - Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 3 -Article 5 + Details Name: us-gaap_OtherCostAndExpenseOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The other noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to allocate the cost of tangible and intangible assets over their remaining economic lives. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_OtherDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash outflow for acquisition of machinery and equipment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireMachineryAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_SalesRevenueGoodsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: xxii_ManufacturingFacilityLineItems Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ProductOrServiceAxis=xxii_FilteredCigarsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xxii_CigareteManufacturingEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R30.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) 12 Months Ended Dec. 31, 2014 Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Inventory, Current Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. Inventories at December 31, 2014 and 2013 consist of the following: December 31, 2014 December 31, 2013 Inventory - tobacco leaf $ 1,537,521 $ 1,398,747 Less: inventory reserve 50,623 50,623 Inventory - tobacco leaf, net 1,486,898 1,348,124 Inventory - finished goods Cigarettes and filtered cigars 154,568 13,206 Inventory - raw materials Cigarette and filtered cigar components 423,330 44,950 $ 2,064,796 $ 1,406,280 Schedule of Intangible Assets and Goodwill Total intangible assets at December 31, 2014 and December 31, 2013 consist of the following: December 31, December 31, 2014 2013 Intangible assets, net Patent and trademark costs $ 4,405,586 $ 2,559,412 Less: accumulated amortization 1,247,303 1,014,543 Patent and trademark costs, net 3,158,283 1,544,869 License fees, net (see Note 17) 1,450,000 - Less: accumulated amortization 32,524 - License fees, net 1,417,476 - MSA signatory costs (see Note 7) 2,202,000 - License fee for predicate cigarette brand 300,000 - $ 7,077,759 $ 1,544,869 X - Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 2 -Paragraph 6 -Subparagraph a,b,c -Article 5 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 39 R31.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 MACHINERY AND EQUIPMENT (Tables) 12 Months Ended Dec. 31, 2014 Property, Plant and Equipment [Abstract] MACHINERY AND EQUIPMENT Machinery and equipment at December 31, 2014 and 2013 consists of the following: December 31, December 31, 2014 2013 Cigarette manufacturing equipment $ 3,031,375 $ 3,220,000 Office furniture, fixtures and equipment 55,355 17,059 Leasehold improvements - 14,500 Deposit for purchase of machine parts and other assets - 210,000 3,086,730 3,461,559 Less: cigarette manufacturing equipment held for resale - 457,696 3,086,730 3,003,863 Less: accumulated depreciation 236,115 6,103 Machinery and equipment, net $ 2,850,615 $ 2,997,760 X - Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph b -Article 5 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 40 R8.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 12 Months Ended Dec. 31, 2014 Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 1. - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation - The accompanying consolidated financial statements include the accounts of 22nd Century Group, Inc. (“22nd Century Group”), its three wholly-owned subsidiaries, 22nd Century Limited, LLC (“22nd Century Ltd”), NASCO Products, LLC (“NASCO”), and Botanical Genetics, LLC (“Botanical Genetics”), and a 51 % owned subsidiary, 22nd Century Asia Ltd. (“22nd Century Asia”), and two wholly-owned subsidiaries of 22nd Century Ltd, Goodrich Tobacco Company, LLC (“Goodrich Tobacco”) and Hercules Pharmaceuticals, LLC (“Hercules Pharma”) (collectively, “the Company”). All intercompany accounts and transactions have been eliminated. Nature of Business - 22nd Century Ltd, is a plant biotechnology company specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The Company owns or exclusively controls 128 issued patents plus an additional 52 pending patent applications. The patents owned by or exclusively licensed to us include patents issued in 96 countries. Goodrich Tobacco and Hercules Pharma are business units for the Company’s (i) premium cigarettes and potential modified risk tobacco products and (ii) smoking cessation product, respectively. The Company acquired the membership interests of NASCO on August 29, 2014. NASCO is a federally licensed tobacco products manufacturer, a participating member of the tobacco Master Settlement Agreement (“MSA”) between the tobacco industry and the Settling States under the MSA, and operates the Company’s cigarette manufacturing business in North Carolina. Botanical Genetics is a wholly-owned subsidiary of 22nd Century Group, and was incorporated to facilitate an equity investment more fully described in Note 10. 22nd Century Asia was newly-formed during the third quarter of 2014 in connection with the Company’s efforts to sell its proprietary tobacco products in Asia, more fully described in Note 6. Preferred Stock Authorized - The Company is authorized to issue “blank check” preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock. On January 11, 2013, the Company designated the rights of and issued 2,500 shares of Series A-1 Preferred Stock. As of June 7, 2013, all 2,500 outstanding shares of Series A-1 Preferred Stock were converted into an aggregate of 4,166,666 shares of common stock of the Company and no shares of preferred stock remain outstanding. Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in financial institutions. Although the cash accounts exceed the federally insured deposit amount, management does not anticipate nonperformance by the financial institutions. Management reviews the financial viability of these institutions on a periodic basis. Inventory - Inventories are valued at the lower of cost or market. Cost is determined using an average cost method for tobacco leaf inventory and the first-in, first-out (FIFO) method on all other inventories. Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. Inventories at December 31, 2014 and 2013 consist of the following: December 31, 2014 December 31, 2013 Inventory - tobacco leaf $ 1,537,521 $ 1,398,747 Less: inventory reserve 50,623 50,623 Inventory - tobacco leaf, net 1,486,898 1,348,124 Inventory - finished goods Cigarettes and filtered cigars 154,568 13,206 Inventory - raw materials Cigarette and filtered cigar components 423,330 44,950 $ 2,064,796 $ 1,406,280 Fixed assets  Fixed assets are recorded at their acquisition cost and depreciated on a straight line basis over their estimated useful lives ranging from 3 to 10 years. Depreciation commences when the asset is placed in service. Intangible Assets - Intangible assets are recorded at cost and consist primarily of (1) expenditures incurred with third parties related to the processing of patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties, (2) license fees paid for third-party intellectual property, (3) costs to become a signatory under the tobacco Master Settlement Agreement (“MSA”), and (4) license fees paid to acquire a predicate cigarette brand. The amounts capitalized relate to intellectual property that the Company owns or to which it has exclusive rights. The Company’s intellectual property capitalized costs are amortized using the straight-line method over the remaining statutory life of the primary patent in each of the Company’s two primary patent families, which expire in 2019 and 2028 (the assets’ estimated lives, respectively). Periodic maintenance or renewal fees are expensed as incurred. Annual minimum license fees are charged to expense. License fees paid for third-party intellectual property are amortized on a straight-line basis over the last to expire patents, which patent expiration dates range from 2028 through 2035. The Company believes costs associated with becoming a signatory to the MSA and acquiring the predicate cigarette brand have an indefinite life and as such, no amortization is taken. Total intangible assets at December 31, 2014 and December 31, 2013 consist of the following: December 31, December 31, 2014 2013 Intangible assets, net Patent and trademark costs $ 4,405,586 $ 2,559,412 Less: accumulated amortization 1,247,303 1,014,543 Patent and trademark costs, net 3,158,283 1,544,869 License fees, net (see Note 17) 1,450,000 - Less: accumulated amortization 32,524 - License fees, net 1,417,476 - MSA signatory costs (see Note 7) 2,202,000 - License fee for predicate cigarette brand 300,000 - $ 7,077,759 $ 1,544,869 Amortization expense relating to the above intangible assets for the years ended December 31, 2014 and 2013 amounted to $ 265,284 and $ 141,261 , respectively. During the year ended December 31, 2013, the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial statements. The estimated annual average amortization expense for the next five years is approximately $ 310,000 for patent costs and $ 98,000 for license fees. Impairment of Long-Lived Assets - The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability of the asset by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition. If the estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and its fair value. There was no impairment loss recorded during the years ended December 31, 2014 or 2013. Income Taxes - The Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and GAAP reporting, and for operating loss and credit carry-forwards. In light of the Company’s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2014 and 2013. The Company’s federal and state tax returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2014. Refundable taxes and tax credits  The Company accounts for income tax refunds or tax refundable tax credits as discrete items and recognized the amount in the period in which the funds are received. During the year ended December 31, 2013, the Company received notice from the New York State Department of Taxation and Finance of a no change audit with respect to its income tax return filed for the period ending September 30, 2011. The subject return contained a refundable credit in the amount of $ 122,024 . The refund was recorded as Other income in the Company’s Consolidated Statement of Operations for the year ended December 31, 2013. There were no such transactions during the year ended December 31, 2014. Stock Based Compensation - The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees and others receive shares, options or warrants to purchase common shares of 22nd Century Group. Stock based compensation expense is recorded over the requisite service period based on estimates of probability and time of achieving milestones and vesting. For accounting purposes, the shares will be considered issued and outstanding upon vesting. Revenue Recognition  The Company recognizes revenue from product sales at the point the product is shipped to a customer and title has transferred. Revenue from the sale of the Company’s products is recognized net of cash discounts, sales returns and allowances. Cigarette federal excise taxes are included in net sales and accounts receivable billed to customers, except on sales of SPECTRUM research cigarettes and exported cigarettes, to which such taxes do not apply. The Company was chosen to be a subcontractor for a 5-year government contract between RTI International (“RTI”) and the National Institute on Drug Abuse (“NIDA”) to supply NIDA with research cigarettes. These government research cigarettes are distributed under the Company’s mark, SPECTRUM . In September 2013, the Company received a purchase order for 5.5 million SPECTRUM research cigarettes that were shipped in January 2014. Total revenue from this order was approximately $ 448,000 for the year ended December 31, 2014. A down payment of $ 179,014 was received in the fourth quarter of 2013 and was recorded as deferred revenue on the Company’s balance sheet at December 31, 2013. There were no SPECTRUM cigarettes delivered during the year ended December 31, 2013. The Company licenses its patented technology to third parties. Revenue is recognized from licensing arrangements as contractually defined in licensing agreements. The Company accounts for milestones elements contained in licensing agreements in accordance with ASC 605. On October 1, 2013, 22nd Century Ltd entered into a worldwide Research License and Commercial Option Agreement (the “Agreement”) with British American Tobacco (Investments) Limited (“BAT”), a subsidiary of British American Tobacco plc, that grants BAT access to 22nd Century Ltd’s patented technology which alters levels of nicotinic alkaloids in tobacco plants. Simultaneous with the signing of the Agreement, BAT paid the Company a non-refundable $ 7,000,000 . The Company will be entitled to receive additional payments from BAT of up to an additional $ 7,000,000 during the term of the Research License in the event certain milestones are met with respect to the ongoing research and development of the Company’s licensed technology to BAT. No amount related to the additional research milestones was recognized during the year ended December 31, 2014. During the term of the Research License, BAT will have the option to enter into a Commercial License agreement which will provide for future annual payments, royalty payments and minimum annual royalties. A portion of the patented technology sublicensed to BAT was exclusively licensed to 22nd Century Ltd by a third party licensor proir to the acquisition by 22nd Century Ltd of such patented technology from such licensor on December 23, 2014 (see Note 12 for the more detailed discussion). Pursuant to the terms of the license agreement with such licensor, 22nd Century Ltd was obligated to make a royalty payment to the licensor with respect to a portion of the non-refundable $ 7,000,000 paid by BAT to the Company on October 1, 2013. From October 2013 to September 2014, 22nd Century Ltd and the third party licensor were in discussions as to the amount of royalty due to the licensor from 22nd Century Ltd. During the quarter ended September 30, 2014, 22nd Century Ltd and the third party licensor mutually agreed on a payment of $ 660,000 that was paid in December 2014. 22nd Century Ltd had previously estimated the payment to be $ 413,566 . The difference in the amount of $ 246,434 has been recorded as Royalty for licensing in the Cost of goods sold section of the Company’s Consolidated Statements of Operations for the year ended December 31, 2014. Derivatives  The Company does use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations. The methodology for valuing outstanding warrants classified as derivative instruments utilizes a lattice model approach which includes probability weighted estimates of future events including volatility of our common stock. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. Research and Development - Research and development costs are expensed as incurred. Loss Per Common Share - Basic loss per common share is computed using the weighted-average number of common shares outstanding. Diluted loss per share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded from the computation if their effect is anti-dilutive. Commitment and Contingency Accounting - The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial statements. If not, the Company will disclose any material commitments or contingencies that may arise. Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Fair Value of Financial Instruments - Financial instruments include cash, receivables, accounts payable, accrued expenses, demand bank loan, and warrant liability. Other than warrant liability, fair value is assumed to approximate carrying values for these financial instruments, since they are short term in nature, they are receivable or payable on demand, or had stated interest rates that approximate the interest rates available to the Company as of the reporting date. The determination of the fair value of the warrant liability includes unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 15. Equity Investments  The Company accounts for investments in equity securities of other entities under the equity method of accounting if the Company’s investment in the voting stock is greater than or equal to 20 % and less than a majority, and the Company has the ability to have significant influence over the operating and financial policies of the investee. Accounting Pronouncements - In May 2014, the FASB issued ASU 2014-09, ”Revenue from Contracts with Customers”, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements and have not yet determined the method by which it will adopt the standard in 2017. X - Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592 + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 41 R32.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Tables) 12 Months Ended Dec. 31, 2014 Warrants For Common Stock [Abstract] Schedule Of Warrants Outstanding Outstanding warrants at December 31, 2014 consist of the following: Number of Exercise Warrant Description Warrants Price Expiration January 2011 PPO $3.00 warrants 2,817,952 $ 2.2029 January 25, 2016 January 2011 PPO $3.00 warrants 653,869 $ 2.0000 January 25, 2016 January 2011 PPO $3.00 warrants 3,062,665 $ 1.9600 January 25, 2016 January 2011 PPO $1.50 warrants 292,965 $ 1.2672 January 25, 2016 January 2011 PPO $1.50 warrants (1) 37,177 $ 1.2018 January 25, 2016 January 2011 PPO $1.50 warrants 62,329 $ 1.2018 January 25, 2016 January 2011 PPO $1.50 warrants 10,831 $ 1.1718 January 25, 2016 December 2011 convertible NP warrants 172,730 $ 1.1984 February 8, 2017 December 2011 convertible NP warrants 802,215 $ 1.3816 February 6, 2018 May 2012 PPO warrants 401,700 $ 0.6000 May 15, 2017 November 2012 PPO warrants 925,100 $ 0.6000 November 9, 2017 August 2012 convertible NP warrants (1) 92,632 $ 0.9520 August 8, 2018 August 2012 convertible NP warrants 92,244 $ 0.9060 August 8, 2018 Crede Tranche 1A Warrants (2) 1,250,000 $ 3.3600 September 29, 2016 Crede Tranche 1B Warrants 1,000,000 $ 2.5951 September 29, 2016 Crede Tranche 2 Warrants (3) 1,000,000 $ 3.3736 September 29, 2019 Crede Tranche 3 Warrants (3) 1,000,000 $ 3.3736 September 29, 2019 Total warrants outstanding (4) 13,674,409 (1) Includes anti-dilution features. (2) Include Exchange Rights (see Note 6 for detailed discussion). (3) Exercisable upon attainment of certain revenue milestones (see Note 6 for detailed discussion). (4) Includes 3,725,962 warrants ( 27.3 %) held by officers and directors that have had the anti-dilution feature removed. Roll-Forward of Warrant Liability from Intitial Valuation The following table is a roll-forward summary of the warrant liability: Fair value at December 31, 2012 $ 4,173,140 Fair value of warrant liability upon conversion of remaining December 14, 2011 Notes  Q1 2013 1,445,091 Fair value of warrant liability upon issuance - Q1 2013 6,022,319 Fair value of warrant liability upon issuance - Q2 2013 711,675 Fair value of warrant liability upon issuance - Q3 2013 1,622,069 Fair value of warrant liability upon conversion of August 9, 2012 Notes - Q3 2013 731,662 Fair value of warrant liability upon reduction of exercise price of Series A and Series C warrants  Q3 2013 626,328 Reclassification of warrant liability to equity upon exercise of warrants - Q2 2013 (204,513) Reclassification of warrant liability to equity upon exercise of warrants - Q3 2013 (6,542,904) Reclassification of warrant liability to equity upon exercise of warrants - Q4 2013 (7,712,170) Cost of inducement from Warrant Exchange Program - Q4 2013 3,274,313 Reclassification of warrant liability to equity resulting from Warrant Exchange Program - Q4 2013 (19,639,465) Loss as a result of change in fair value 19,271,977 Fair value at December 31, 2013 $ 3,779,522 Reclassification of warrant liability to equity resulting from Warrant Amendments - Q1 2014 (7,367,915) Cost of inducement from Warrant Amendments - Q1 2014 144,548 Fair value of warrant liability resulting from issuance of Crede Tranche 1A Warrants  Q3 2014 2,810,000 Loss as a result of change in fair value 3,676,691 Fair value at December 31, 2014 $ 3,042,846 Warrant Activity The following table summarizes the Company’s warrant activity since December 31, 2012: Number of Warrants Warrants outstanding at December 31, 2012 12,972,664 Warrants issued 11,570,274 Warrants issued as part of Warrant Exchange Program 138,666 Additional warrants due to anti-dilution provisions 1,665,400 Warrants exercised during 2013 (9,831,414) Warrants exercised as part of Warrant Exchange Program (5,862,121) Warrants outstanding at December 31, 2013 10,653,469 Warrants issued in conjunction with consulting agreement (see Note 6) 4,250,000 Warrants exercised during 2014 (1,247,443) Additional warrants due to anti-dilution provisions 18,383 Warrants outstanding at December 31, 2014 13,674,409 Composition of outstanding warrants: Warrants containing anti-dilution feature 129,809 Warrants without anti-dilution feature 13,544,600 (1) 13,674,409 (1) Include 1,250,000 warrants containing Exchange Rights (see Note 6 for detailed discussion). X - Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 28 -Article 5 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of warrant activity. + References No definition available. + Details Name: xxii_DerivativeLiabilitiesWarrantActivityTableTextBlock Namespace Prefix: xxii_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 42 R40.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT(Narrative) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Class of Stock [Line Items] Stock Issued During Period, Value, New Issues $ 9,324,088 us-gaap_StockIssuedDuringPeriodValueNewIssues Common Stock [Member] Class of Stock [Line Items] Stock Issued During Period, Value, New Issues 39 us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Stock Issued During Period, Shares, New Issues 3,871,767 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Common Stock [Member] | Private Placement [Member] Class of Stock [Line Items] Stock Issued During Period, Value, New Issues 9,324,088 us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember / us-gaap_SubsidiarySaleOfStockAxis = us-gaap_PrivatePlacementMember Proceeds from Issuance or Sale of Equity $ 10,000,000 us-gaap_ProceedsFromIssuanceOrSaleOfEquity / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember / us-gaap_SubsidiarySaleOfStockAxis = us-gaap_PrivatePlacementMember Stock Issued During Period, Shares, New Issues 3,871,767 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember / us-gaap_SubsidiarySaleOfStockAxis = us-gaap_PrivatePlacementMember X - Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R53.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Dec. 31, 2012 Class of Warrant or Right [Line Items] Number of warrants 13,674,409 us-gaap_ClassOfWarrantOrRightOutstanding [1] 10,653,469 us-gaap_ClassOfWarrantOrRightOutstanding 12,972,664 us-gaap_ClassOfWarrantOrRightOutstanding January 2011 Private Placement Offering Warrants One [Member] Class of Warrant or Right [Line Items] Number of warrants 2,817,952 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsOneMember Exercise Price $ 2.2029 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsOneMember Expiration Jan. 25, 2016 January 2011 Private Placement Offering Warrants Two [Member] Class of Warrant or Right [Line Items] Number of warrants 653,869 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsTwoMember Exercise Price $ 2.0000 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsTwoMember Expiration Jan. 25, 2016 January 2011 Private Placement Offering Warrants Three [Member] Class of Warrant or Right [Line Items] Number of warrants 3,062,665 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsThreeMember Exercise Price $ 1.9600 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsThreeMember Expiration Jan. 25, 2016 January 2011 Private Placement Offering Warrants Four [Member] Class of Warrant or Right [Line Items] Number of warrants 292,965 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFourMember Exercise Price $ 1.2672 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFourMember Expiration Jan. 25, 2016 January 2011 Private Placement Offering Warrants Five [Member] Class of Warrant or Right [Line Items] Number of warrants 37,177 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFiveMember [2] Exercise Price $ 1.2018 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsFiveMember [2] Expiration Jan. 25, 2016 [2] January 2011 Private Placement Offering Warrants Six [Member] Class of Warrant or Right [Line Items] Number of warrants 62,329 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSixMember Exercise Price $ 1.2018 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSixMember Expiration Jan. 25, 2016 January 2011 Private Placement Offering Warrants Seven [Member] Class of Warrant or Right [Line Items] Number of warrants 10,831 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSevenMember Exercise Price $ 1.1718 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_January2011PrivatePlacementOfferingWarrantsSevenMember Expiration Jan. 25, 2016 December 2011 Convertible Notes Payable Warrants One [Member] Class of Warrant or Right [Line Items] Number of warrants 172,730 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_December2011ConvertibleNotesPayableWarrantsOneMember Exercise Price $ 1.1984 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_December2011ConvertibleNotesPayableWarrantsOneMember Expiration Feb. 08, 2017 December 2011 Convertible Notes Payable Warrants Two [Member] Class of Warrant or Right [Line Items] Number of warrants 802,215 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_December2011ConvertibleNotesPayableWarrantsTwoMember Exercise Price $ 1.3816 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_December2011ConvertibleNotesPayableWarrantsTwoMember Expiration Feb. 06, 2018 May 2012 Private Placement Offering Warrants [Member] Class of Warrant or Right [Line Items] Number of warrants 401,700 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_May2012PrivatePlacementOfferingWarrantsMember Exercise Price $ 0.6000 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_May2012PrivatePlacementOfferingWarrantsMember Expiration May 15, 2017 November 2012 Private Placement Offering Warrants [Member] Class of Warrant or Right [Line Items] Number of warrants 925,100 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_November2012PrivatePlacementOfferingWarrantsMember Exercise Price $ 0.6000 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_November2012PrivatePlacementOfferingWarrantsMember Expiration Nov. 09, 2017 August 2012 Convertible Notes Payable Warrants One [Member] Class of Warrant or Right [Line Items] Number of warrants 92,632 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_August2012ConvertibleNotesPayableWarrantsOneMember [2] Exercise Price $ 0.9520 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_August2012ConvertibleNotesPayableWarrantsOneMember [2] Expiration Aug. 08, 2018 [2] August 2012 Convertible Notes Payable Warrants Two [Member] Class of Warrant or Right [Line Items] Number of warrants 92,244 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_August2012ConvertibleNotesPayableWarrantsTwoMember Exercise Price $ 0.9060 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_August2012ConvertibleNotesPayableWarrantsTwoMember Expiration Aug. 08, 2018 Crede Tranche 1A Warrants [Member] Class of Warrant or Right [Line Items] Number of warrants 1,250,000 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche1AWarrantsMember [3] Exercise Price $ 3.3600 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche1AWarrantsMember [3] Expiration Sep. 29, 2016 [3] Crede Tranche 1B Warrants [Member] Class of Warrant or Right [Line Items] Number of warrants 1,000,000 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche1BWarrantsMember Exercise Price $ 2.5951 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche1BWarrantsMember Expiration Sep. 29, 2016 Crede Tranche 2 Warrants [Member] Class of Warrant or Right [Line Items] Number of warrants 1,000,000 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche2WarrantsMember [4] Exercise Price $ 3.3736 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche2WarrantsMember [4] Expiration Sep. 29, 2019 [4] Crede Tranche 3 Warrants [Member] Class of Warrant or Right [Line Items] Number of warrants 1,000,000 us-gaap_ClassOfWarrantOrRightOutstanding / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche3WarrantsMember [4] Exercise Price $ 3.3736 us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 / us-gaap_DerivativeByNatureAxis = xxii_CredeTranche3WarrantsMember [4] Expiration Sep. 29, 2019 [4] [1] Includes 3,725,962 warrants (27.3%) held by officers and directors that have had the anti-dilution feature removed. [2] Includes anti-dilution features. [3] Include Exchange Rights (see Note 6 for detailed discussion). [4] Exercisable upon attainment of certain revenue milestones (see Note 6 for detailed discussion). X - Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Number of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Expiration date of warrants outstanding. + References No definition available. + Details Name: xxii_WarrantsExpirationDate Namespace Prefix: xxii_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_August2012ConvertibleNotesPayableWarrantsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_August2012ConvertibleNotesPayableWarrantsTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_CredeTranche1AWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_CredeTranche1BWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_CredeTranche2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_CredeTranche3WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_December2011ConvertibleNotesPayableWarrantsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_December2011ConvertibleNotesPayableWarrantsTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_January2011PrivatePlacementOfferingWarrantsTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_May2012PrivatePlacementOfferingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeByNatureAxis=xxii_November2012PrivatePlacementOfferingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R2.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSOLIDATED BALANCE SHEETS (USD $) Dec. 31, 2014 Dec. 31, 2013 Current assets: Cash $ 6,402,687 us-gaap_Cash $ 5,830,599 us-gaap_Cash Due from related party 46,069 us-gaap_DueFromRelatedPartiesCurrent 42,069 us-gaap_DueFromRelatedPartiesCurrent Due from officers 0 us-gaap_DueFromOfficersOrStockholdersCurrent 7,471 us-gaap_DueFromOfficersOrStockholdersCurrent Inventory, net 2,064,796 us-gaap_InventoryNet 1,406,280 us-gaap_InventoryNet Prepaid consulting fees 1,978,785 us-gaap_OtherPrepaidExpenseCurrent 0 us-gaap_OtherPrepaidExpenseCurrent Prepaid expenses and other assets 214,469 us-gaap_PrepaidExpenseCurrent 0 us-gaap_PrepaidExpenseCurrent Machinery and equipment held for resale 0 us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent 457,696 us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Total current assets 10,706,806 us-gaap_AssetsCurrent 7,744,115 us-gaap_AssetsCurrent Machinery and equipment, net 2,850,615 us-gaap_PropertyPlantAndEquipmentNet 2,997,760 us-gaap_PropertyPlantAndEquipmentNet Other assets: Intangible assets, net 7,077,759 us-gaap_IntangibleAssetsNetExcludingGoodwill 1,544,869 us-gaap_IntangibleAssetsNetExcludingGoodwill Equity investment 1,318,335 us-gaap_AdvancesToAffiliate 0 us-gaap_AdvancesToAffiliate Total other assets 8,396,094 xxii_AssestsNoncurrentExcludingPropertyPlantAndEquipmentNet 1,544,869 xxii_AssestsNoncurrentExcludingPropertyPlantAndEquipmentNet Total assets 21,953,515 us-gaap_Assets 12,286,744 us-gaap_Assets Current liabilities: Demand bank loan 174,925 us-gaap_ShortTermBankLoansAndNotesPayable 174,925 us-gaap_ShortTermBankLoansAndNotesPayable Current portion of note payable 320,513 us-gaap_NotesPayableCurrent 0 us-gaap_NotesPayableCurrent Accounts payable 884,412 us-gaap_AccountsPayableCurrent 54,665 us-gaap_AccountsPayableCurrent Accrued expenses 1,081,545 us-gaap_AccruedLiabilitiesCurrent 575,730 us-gaap_AccruedLiabilitiesCurrent Accrued severance 212,012 xxii_AccruedSeveranceLiabilitiesCurrent 0 xxii_AccruedSeveranceLiabilitiesCurrent Deferred revenue 0 us-gaap_DeferredRevenueCurrent 179,014 us-gaap_DeferredRevenueCurrent Total current liabilities 2,673,407 us-gaap_LiabilitiesCurrent 984,334 us-gaap_LiabilitiesCurrent Long-term portion of note payable 605,217 us-gaap_LongTermNotesPayable 0 us-gaap_LongTermNotesPayable Long-term portion of accrued severance 412,308 us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent 0 us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent Warrant liability 3,042,846 us-gaap_DerivativeLiabilitiesNoncurrent 3,779,522 us-gaap_DerivativeLiabilitiesNoncurrent Total liabilities 6,733,778 us-gaap_Liabilities 4,763,856 us-gaap_Liabilities Commitments and contingencies (Note 17) Shareholders' equity Common shares value 641 us-gaap_CommonStockValue 569 us-gaap_CommonStockValue Capital in excess of par value 70,744,190 us-gaap_AdditionalPaidInCapital 47,452,055 us-gaap_AdditionalPaidInCapital Accumulated deficit (55,525,094) us-gaap_RetainedEarningsAccumulatedDeficit (39,929,736) us-gaap_RetainedEarningsAccumulatedDeficit Total shareholders' equity 15,219,737 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 7,522,888 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total liabilities and shareholders' equity $ 21,953,515 us-gaap_LiabilitiesAndStockholdersEquity $ 12,286,744 us-gaap_LiabilitiesAndStockholdersEquity X - Definition Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 24 -Article 5 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04.2) -URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 2 -Article 6 + Details Name: us-gaap_AdvancesToAffiliate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amounts due from owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are usually due within 1 year (or 1 business cycle). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864 + Details Name: us-gaap_DueFromOfficersOrStockholdersCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 2 -Article 4 + Details Name: us-gaap_DueFromRelatedPartiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20 -Article 5 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Assets -URI http://asc.fasb.org/extlink&oid=6509628 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Carrying amount at the balance sheet date of borrowings from a bank, not elsewhere enumerated in the taxonomy, with a maturity within one year (or within one operating cycle if longer) from the date of borrowing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details Name: us-gaap_ShortTermBankLoansAndNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. + References No definition available. + Details Name: xxii_AccruedSeveranceLiabilitiesCurrent Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of all assets excluding property plant and equipment that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + References No definition available. + Details Name: xxii_AssestsNoncurrentExcludingPropertyPlantAndEquipmentNet Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R45.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 MACHINARY AND EQUPMENT (Narrative) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Jan. 13, 2014 Dec. 11, 2013 Property, Plant and Equipment [Line Items] Machinery and Equipment, Gross $ 3,031,375 us-gaap_MachineryAndEquipmentGross $ 3,220,000 us-gaap_MachineryAndEquipmentGross $ 3,220,000 us-gaap_MachineryAndEquipmentGross Property, Plant and Equipment, Other, Gross 0 us-gaap_PropertyPlantAndEquipmentOther 210,000 us-gaap_PropertyPlantAndEquipmentOther 210,000 us-gaap_PropertyPlantAndEquipmentOther Proceeds from Sale of Machinery and Equipment 631,484 us-gaap_ProceedsFromSaleOfMachineryAndEquipment 0 us-gaap_ProceedsFromSaleOfMachineryAndEquipment Gain (Loss) on Disposition of Assets, Total 71,121 us-gaap_GainLossOnDispositionOfAssets1 0 us-gaap_GainLossOnDispositionOfAssets1 Payments to Acquire Property, Plant, and Equipment 0 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment 457,696 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Depreciation 230,012 us-gaap_Depreciation 3,027 us-gaap_Depreciation Machinery and Equipment [Member] Property, Plant and Equipment [Line Items] Gain (Loss) on Disposition of Assets, Total 85,621 us-gaap_GainLossOnDispositionOfAssets1 / us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_MachineryAndEquipmentMember Payments to Acquire Property, Plant, and Equipment $ 88,167 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment / us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_MachineryAndEquipmentMember X - Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765 + Details Name: us-gaap_MachineryAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash inflow from sale of machinery and equipment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 + Details Name: us-gaap_ProceedsFromSaleOfMachineryAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 + Details Name: us-gaap_PropertyPlantAndEquipmentOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R6.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (USD $) Total Preferred Stock [Member] Common Stock [Member] Contributed Capital [Member] Accumulated Deficit [Member] Beginning balance at Dec. 31, 2012 $ (6,131,217) us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 0 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember $ 344 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember $ 7,645,017 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember $ (13,776,578) us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Beginning balance, shares at Dec. 31, 2012 0 us-gaap_SharesOutstanding / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 34,286,979 us-gaap_SharesOutstanding / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Common stock issued upon exercise of Convertible Notes 0 us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities 0 us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 24 us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember (24) us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Common stock issued upon exercise of Convertible Notes, shares 0 us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 2,406,720 us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Preferred stock issued in January 2013 private placement 0 xxii_StockIssuesDuringPeriodValuePrivatePlacement 0 xxii_StockIssuesDuringPeriodValuePrivatePlacement / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 4 xxii_StockIssuesDuringPeriodValuePrivatePlacement / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember (4) xxii_StockIssuesDuringPeriodValuePrivatePlacement / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 xxii_StockIssuesDuringPeriodValuePrivatePlacement / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Preferred stock issued in January 2013 private placement (in shares) 2,500 xxii_StockIssuesDuringPeriodSharesPrivatePlacement / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 416,666 xxii_StockIssuesDuringPeriodSharesPrivatePlacement / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Conversion of preferred stock to common stock 0 us-gaap_ConversionOfStockAmountIssued1 0 us-gaap_ConversionOfStockAmountIssued1 / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 42 us-gaap_ConversionOfStockAmountIssued1 / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember (42) us-gaap_ConversionOfStockAmountIssued1 / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_ConversionOfStockAmountIssued1 / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Conversion of preferred stock to common stock, shares (2,500) us-gaap_ConversionOfStockSharesIssued1 / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 4,166,666 us-gaap_ConversionOfStockSharesIssued1 / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Warrant exchange program 23,340,847 xxii_StockIssuedDuringPeriodValueWarrantExchangeProgram 0 xxii_StockIssuedDuringPeriodValueWarrantExchangeProgram / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 58 xxii_StockIssuedDuringPeriodValueWarrantExchangeProgram / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 23,340,789 xxii_StockIssuedDuringPeriodValueWarrantExchangeProgram / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 xxii_StockIssuedDuringPeriodValueWarrantExchangeProgram / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Warrant exchange program, shares 0 xxii_StockIssuedDuringPeriodSharesWarrantExchangeProgram / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 5,804,368 xxii_StockIssuedDuringPeriodSharesWarrantExchangeProgram / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Common stock issued in payment of accrued dividends 0 us-gaap_DividendsCommonStockStock 0 us-gaap_DividendsCommonStockStock / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 1 us-gaap_DividendsCommonStockStock / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember (1) us-gaap_DividendsCommonStockStock / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_DividendsCommonStockStock / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Common stock issued in payment of accrued dividends, shares 0 us-gaap_CommonStockDividendsShares / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 161,153 us-gaap_CommonStockDividendsShares / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Stock based compensation 2,361,962 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation 0 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 28 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 2,361,934 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Stock based compensation, shares 0 us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 2,820,000 us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Exercise of warrants 14,097,594 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue 0 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 68 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 14,097,526 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Exercise of warrants, shares 0 xxii_StockIssuedDuringPeriodWarrantsExcercised / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 6,820,218 xxii_StockIssuedDuringPeriodWarrantsExcercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Exercise of options 5,200 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised 0 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 0 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 5,200 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Exercise of options, shares 0 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 20,000 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Stock issued in connection with acquisition of NASCO Products, LLC 0 us-gaap_StockIssuedDuringPeriodValueAcquisitions Other capital contribution 1,660 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 1,660 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Net loss (26,153,158) us-gaap_ProfitLoss 0 us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 0 us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 0 us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember (26,153,158) us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Ending balance at Dec. 31, 2013 7,522,888 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 0 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 569 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 47,452,055 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember (39,929,736) us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Ending balance, shares at Dec. 31, 2013 0 us-gaap_SharesOutstanding / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 56,902,770 us-gaap_SharesOutstanding / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Stock based compensation 2,433,253 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation 0 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 13 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 2,433,240 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Stock based compensation, shares 0 us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 1,282,768 us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Warrants issued as compensation for services 1,260,000 us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 1,260,000 us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Exercise of warrants 486,951 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue 0 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 12 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 486,939 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 xxii_StockIssuedDuringPeriodWarrantsExcercisedValue / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Exercise of warrants, shares 0 xxii_StockIssuedDuringPeriodWarrantsExcercised / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 1,167,737 xxii_StockIssuedDuringPeriodWarrantsExcercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Exercise of options 48,300 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised 0 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 1 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 48,299 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Exercise of options, shares 0 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised 0 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 70,000 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Common stock issued in September 2014 private placement 9,324,088 us-gaap_StockIssuedDuringPeriodValueNewIssues 0 us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 39 us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 9,324,049 us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Common stock issued in September 2014 private placement, shares 0 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 3,871,767 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Stock issued in connection with acquisition of NASCO Products, LLC 1,952,000 us-gaap_StockIssuedDuringPeriodValueAcquisitions 0 us-gaap_StockIssuedDuringPeriodValueAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 6 us-gaap_StockIssuedDuringPeriodValueAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 1,951,994 us-gaap_StockIssuedDuringPeriodValueAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Stock issued in connection with acquisition of NASCO Products, LLC, shares 0 us-gaap_StockIssuedDuringPeriodSharesAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 640,000 us-gaap_StockIssuedDuringPeriodSharesAcquisitions / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Stock issued in connection with equity investment 394,500 us-gaap_StockIssuedDuringPeriodValueOther 0 us-gaap_StockIssuedDuringPeriodValueOther / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 1 us-gaap_StockIssuedDuringPeriodValueOther / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 394,499 us-gaap_StockIssuedDuringPeriodValueOther / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_StockIssuedDuringPeriodValueOther / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Stock issued in connection with equity investment, shares 0 us-gaap_StockIssuedDuringPeriodSharesOther / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 150,000 us-gaap_StockIssuedDuringPeriodSharesOther / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Other capital contribution 25,200 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 25,200 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalOther / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Warrant amendments 7,367,915 us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 7,367,915 us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember 0 us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Net loss (15,595,358) us-gaap_ProfitLoss 0 us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 0 us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 0 us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember (15,595,358) us-gaap_ProfitLoss / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Ending balance at Dec. 31, 2014 $ 15,219,737 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 0 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember $ 641 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember $ 70,744,190 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_AdditionalPaidInCapitalMember $ (55,525,094) us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest / us-gaap_StatementEquityComponentsAxis = us-gaap_RetainedEarningsMember Ending balance, shares at Dec. 31, 2014 0 us-gaap_SharesOutstanding / us-gaap_StatementEquityComponentsAxis = us-gaap_PreferredStockMember 64,085,042 us-gaap_SharesOutstanding / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember X - Definition Amount of other increase (decrease) in additional paid in capital (APIC). + References No definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation". + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Warrant -URI http://asc.fasb.org/extlink&oid=6528364 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Number of shares of common stock issued as dividends during the period. Excludes stock splits. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 + Details Name: us-gaap_CommonStockDividendsShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 + Details Name: us-gaap_ConversionOfStockAmountIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Amount of paid and unpaid common stock dividends declared with the form of settlement in stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details Name: us-gaap_DividendsCommonStockStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686 + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Number of shares issued which are neither cancelled nor held in the treasury. + References No definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Number of shares of stock issued during the period pursuant to acquisitions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of shares issued during the period as a result of the conversion of convertible securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. + References No definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Value of stock issued pursuant to acquisitions during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The gross value of stock issued during the period upon the conversion of convertible securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. + References No definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Value of stock issued as a result of the exercise of stock options. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Number of shares issued under warrant exchange program. + References No definition available. + Details Name: xxii_StockIssuedDuringPeriodSharesWarrantExchangeProgram Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Value of stock issued under warrant exchange program. + References No definition available. + Details Name: xxii_StockIssuedDuringPeriodValueWarrantExchangeProgram Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Number of warrants exercised during the current period. + References No definition available. + Details Name: xxii_StockIssuedDuringPeriodWarrantsExcercised Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Value of stock issued as a result of exercise of warrants. + References No definition available. + Details Name: xxii_StockIssuedDuringPeriodWarrantsExcercisedValue Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Shares of preferred stock issues during the period for private placement. + References No definition available. + Details Name: xxii_StockIssuesDuringPeriodSharesPrivatePlacement Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of preferred stock issues during the period value of private placement. + References No definition available. + Details Name: xxii_StockIssuesDuringPeriodValuePrivatePlacement Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 47 R59.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 EARNINGS PER COMMON SHARE (Anti-Dilutive Securities Outstanding Excluded from Computation) (Details) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities outstanding but excluded from computation of earnings per share 14,814,409 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 11,813,469 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities outstanding but excluded from computation of earnings per share 13,674,409 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_WarrantMember 10,653,469 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_WarrantMember Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities outstanding but excluded from computation of earnings per share 250,000 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_RestrictedStockMember 500,000 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_RestrictedStockMember Options [ Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities outstanding but excluded from computation of earnings per share 890,000 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_OptionMember 660,000 us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_OptionMember X - Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R35.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 INCOME TAXES (Tables) 12 Months Ended Dec. 31, 2014 Income Tax Disclosure [Abstract] Schedule of Components of Income Tax Expense (Benefit) The provision (benefit) for income taxes consists of the following: 2014 2013 Current: Federal $ - $ - State - - Total current - - Deferred: Federal (3,494,787) 829,306 State 160,319 186,414 Total deferred (3,334,468) 1,015,720 Change in valuation allowance 3,334,468 (1,015,720) $ - $ - Schedule of Effective Income Tax Rate Reconciliation The provision (benefit) for income tax varies from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss as follows: 2014 2013 Statutory federal rate (34.0) % (34.0) % Permanent items 0.6 1.8 Derivative liability 8.4 35.5 Stock based compensation 2.5 - State tax provision, net of federal benefit 1.1 0.5 Valuation allowance 21.4 (3.9) Effective tax rate (benefit) provision 0.0 % 0.0 % Schedule of Deferred Tax Assets and Liabilities Individual components of deferred taxes consist of the following: 2014 2013 Deferred tax assets: Net operating loss carry-forward $ 4,775,536 $ 2,616,624 Derivative liability - 21,725 Inventory reserve 17,713 19,584 Stock-based compensation 809,319 131,450 Start-up expenditures 388,130 - Loss on equity investment 35,398 - Severance liability 218,450 - Other 6,561 1,292 6,251,107 2,790,675 Deferred tax liabilities: Inventory - (52,445) Fixed assets (80,251) (2,956) Patents and trademarks (624,010) (523,157) Other intangible assets (21,986) - (726,247) (578,558) Valuation allowance (5,524,860) (2,212,117) Net deferred taxes $ - $ - X - Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 + Details Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 + Details Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 + Details Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 49 R65.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 INCOME TAXES (Schedule of statutory federal rate to pre-tax accounting loss) (Details) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Statutory federal rate (34.00%) us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate (34.00%) us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Permanent items 0.60% us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome 1.80% us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome Derivative liability 8.40% us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments 35.50% us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Stock based compensation 2.50% us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost 0.00% us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost State tax provision, net of federal benefit 1.10% us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes 0.50% us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Valuation allowance 21.40% us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance (3.90%) us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective tax rate (benefit) provision 0.00% us-gaap_EffectiveIncomeTaxRateContinuingOperations 0.00% us-gaap_EffectiveIncomeTaxRateContinuingOperations X - Definition Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Subparagraph 2 -Article 4 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Percentage of domestic federal statutory tax rate applicable to pretax income (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration XML 50 R22.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Warrant Exchange Program [Member], Warrant [Member]) 12 Months Ended Dec. 31, 2014 Warrant Exchange Program [Member] | Warrant [Member] Class of Stock [Line Items] WARRANTS FOR COMMON STOCK NOTE 15. - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK During the fourth quarter of 2013, the Company initiated a warrant exchange program (the “Warrant Exchange Program”) with existing warrant holders. As a result of the Warrant Exchange Program, the Company had 10,653,469 outstanding warrants remaining at December 31, 2013, a reduction from 19,616,308 , as of September 30, 2013. Of the remaining outstanding warrants at December 31, 2013, 3,921,381 warrants contained anti-dilution features that provide for adjustments to the exercise price and number of warrants outstanding if the Company issues shares of common stock of 22nd Century Group at a price that is less than the respective warrant exercise prices. These provisions require that such warrants be classified as derivatives for accounting purposes, which means they are reported as a liability and adjusted to fair value at each balance sheet date. In March 2014, the Company entered into warrant amendments with existing warrant holders (the “Warrant Amendments”) with the goal of further reducing the Company’s warrant liability. To that end, the Company offered financial inducements to certain non-management warrant holders to (i) exercise their warrants on a cash basis, (ii) exercise their warrants on a cashless basis, or (iii) agree to have the anti-dilution feature removed from their warrants in exchange for a reduction in the exercise price contained in their respective warrants. The warrant holders also had the option to maintain the terms and conditions of their original warrant. Management elected to have the anti-dilution feature removed from their warrants without inducement. As a result of the Warrant Amendments, subsequent warrant exercises during the year ended December 31, 2014, and additional warrants issued during the third quarter of 2014, there are 13,544,600 warrants outstanding at December 31, 2014 that do not contain the anti-dilution features. A total of 129,809 warrants containing anti-dilution features remain outstanding at December 31, 2014. The Company calculated the cost of inducement as the difference between the fair value of the warrants immediately after the Warrant Amendments closed, less the fair value of the warrants immediately prior to the completion of the Warrant Amendments. The Company estimated the total cost of inducement to be $ 144,548 . This expense has been recorded as an Other expense on the Company’s Consolidated Statements of Operations, and as an increase to the derivative warrant liability that was subsequently reversed into capital. As discussed in Note 6, the Company issued warrants to Crede on September 29, 2014, in connection with a joint venture and Consulting Agreement, whereby Crede will provide consulting services to 22nd Century Asia with respect to the Company’s efforts to sell its proprietary tobacco products into the Asian market. The terms and conditions relating to the issued warrants are discussed in detail in Note 6. Outstanding warrants at December 31, 2014 consist of the following: Number of Exercise Warrant Description Warrants Price Expiration January 2011 PPO $3.00 warrants 2,817,952 $ 2.2029 January 25, 2016 January 2011 PPO $3.00 warrants 653,869 $ 2.0000 January 25, 2016 January 2011 PPO $3.00 warrants 3,062,665 $ 1.9600 January 25, 2016 January 2011 PPO $1.50 warrants 292,965 $ 1.2672 January 25, 2016 January 2011 PPO $1.50 warrants (1) 37,177 $ 1.2018 January 25, 2016 January 2011 PPO $1.50 warrants 62,329 $ 1.2018 January 25, 2016 January 2011 PPO $1.50 warrants 10,831 $ 1.1718 January 25, 2016 December 2011 convertible NP warrants 172,730 $ 1.1984 February 8, 2017 December 2011 convertible NP warrants 802,215 $ 1.3816 February 6, 2018 May 2012 PPO warrants 401,700 $ 0.6000 May 15, 2017 November 2012 PPO warrants 925,100 $ 0.6000 November 9, 2017 August 2012 convertible NP warrants (1) 92,632 $ 0.9520 August 8, 2018 August 2012 convertible NP warrants 92,244 $ 0.9060 August 8, 2018 Crede Tranche 1A Warrants (2) 1,250,000 $ 3.3600 September 29, 2016 Crede Tranche 1B Warrants 1,000,000 $ 2.5951 September 29, 2016 Crede Tranche 2 Warrants (3) 1,000,000 $ 3.3736 September 29, 2019 Crede Tranche 3 Warrants (3) 1,000,000 $ 3.3736 September 29, 2019 Total warrants outstanding (4) 13,674,409 (1) Includes anti-dilution features. (2) Include Exchange Rights (see Note 6 for detailed discussion). (3) Exercisable upon attainment of certain revenue milestones (see Note 6 for detailed discussion). (4) Includes 3,725,962 warrants ( 27.3 %) held by officers and directors that have had the anti-dilution feature removed. The Company estimates the value of warrant liability upon issuance of the warrants and at each balance sheet date using the binomial lattice model to allocate total enterprise value to the warrants and other securities in the Company’s capital structure. Volatility was estimated based on historical observed equity volatilities and implied (forward) or expected volatilities for a sample group of guideline companies and consideration of recent market trends. As a result of the Exchange Rights contained in the Tranche 1A Warrants, the financial instrument is considered a liability in accordance with FASB Accounting Standards Codification Topic 480  “Distinguishing Liabilities from Equity” (“ASC 480”). More specifically, ASC 480 requires a financial instrument to be classified as a liability if such financial instrument contains a conditional obligation that the issuer must or may settle by issuing a variable number of its equity securities if, at inception, the monetary value of the obligation is based on a known fixed monetary amount. The following table is a roll-forward summary of the warrant liability: Fair value at December 31, 2012 $ 4,173,140 Fair value of warrant liability upon conversion of remaining December 14, 2011 Notes  Q1 2013 1,445,091 Fair value of warrant liability upon issuance - Q1 2013 6,022,319 Fair value of warrant liability upon issuance - Q2 2013 711,675 Fair value of warrant liability upon issuance - Q3 2013 1,622,069 Fair value of warrant liability upon conversion of August 9, 2012 Notes - Q3 2013 731,662 Fair value of warrant liability upon reduction of exercise price of Series A and Series C warrants  Q3 2013 626,328 Reclassification of warrant liability to equity upon exercise of warrants - Q2 2013 (204,513) Reclassification of warrant liability to equity upon exercise of warrants - Q3 2013 (6,542,904) Reclassification of warrant liability to equity upon exercise of warrants - Q4 2013 (7,712,170) Cost of inducement from Warrant Exchange Program - Q4 2013 3,274,313 Reclassification of warrant liability to equity resulting from Warrant Exchange Program - Q4 2013 (19,639,465) Loss as a result of change in fair value 19,271,977 Fair value at December 31, 2013 $ 3,779,522 Reclassification of warrant liability to equity resulting from Warrant Amendments - Q1 2014 (7,367,915) Cost of inducement from Warrant Amendments - Q1 2014 144,548 Fair value of warrant liability resulting from issuance of Crede Tranche 1A Warrants  Q3 2014 2,810,000 Loss as a result of change in fair value 3,676,691 Fair value at December 31, 2014 $ 3,042,846 The aggregate net loss as a result of the Company’s warrant liability for the years ended December 31, 2014 and 2013 amounted to $ 3,676,691 and $ 19,271,977 , respectively, which is included in Other income (expense) as part of Warrant liability loss  net in the accompanying Consolidated Statements of Operations. The loss for the year ended December 31, 2013, also includes a charge to Other income (expense) in the amount of $ 4,330,734 as a result of (i) warrant liabilities issued in connection with the Series A-1 Preferred Stock in excess of net proceeds raised in the amount of $ 3,987,655 in January 2013, and (ii) warrant liabilities issued in connection with the July 2013 issuance of 1,101,034 Series C Warrants in excess of the sum of the net process received upon exercise and the reclassification of the warrant liability to capital, in the amount of $ 343,079 . Warrant liabilities issued during the year ended December 31, 2013, in connection with the December 14, 2011 convertible notes and the August 9, 2012 convertible notes converted to common stock in excess of the conversion amount by $ 17,386 and $ 509,062 , respectively, were recorded as additional interest expense. FASB ASC 820 - “Fair Value Measurements and Disclosures” establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: · Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; · Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and · Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. A financial asset’s or a financial liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The warrant liability is measured at fair value using certain estimated factors such as volatility and probability which are classified within Level 3 of the valuation hierarchy. Significant unobservable inputs that are used in the fair value measurement of the Company’s derivative warrant liabilities include volatility. Significant increases (decreases) in the volatility input would result in a significantly higher (lower) fair value measurement. The following table summarizes the Company’s warrant activity since December 31, 2012: Number of Warrants Warrants outstanding at December 31, 2012 12,972,664 Warrants issued 11,570,274 Warrants issued as part of Warrant Exchange Program 138,666 Additional warrants due to anti-dilution provisions 1,665,400 Warrants exercised during 2013 (9,831,414) Warrants exercised as part of Warrant Exchange Program (5,862,121) Warrants outstanding at December 31, 2013 10,653,469 Warrants issued in conjunction with consulting agreement (see Note 6) 4,250,000 Warrants exercised during 2014 (1,247,443) Additional warrants due to anti-dilution provisions 18,383 Warrants outstanding at December 31, 2014 13,674,409 Composition of outstanding warrants: Warrants containing anti-dilution feature 129,809 Warrants without anti-dilution feature 13,544,600 (1) 13,674,409 (1) Include 1,250,000 warrants containing Exchange Rights (see Note 6 for detailed discussion). X - Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 51 R36.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $) 0 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended Oct. 07, 2013 Dec. 31, 2014 Dec. 31, 2013 Aug. 27, 2014 Sep. 30, 2014 Apr. 14, 2014 Jun. 07, 2013 Jan. 11, 2013 Condensed Financial Statements, Captions [Line Items] Licenses Revenue $ 0 us-gaap_LicensesRevenue $ 7,000,000 us-gaap_LicensesRevenue License Costs 246,434 us-gaap_LicenseCosts 413,566 us-gaap_LicenseCosts Deferred Revenue 0 us-gaap_DeferredRevenue Deferred Revenue, Revenue Recognized 7,000,000 us-gaap_DeferredRevenueRevenueRecognized Equity Method Investment, Ownership Percentage 20.00% us-gaap_EquityMethodInvestmentOwnershipPercentage 10.00% us-gaap_EquityMethodInvestmentOwnershipPercentage Amortization of Intangible Assets 265,284 us-gaap_AmortizationOfIntangibleAssets 141,261 us-gaap_AmortizationOfIntangibleAssets Income Tax Refund 0 xxii_IncomeTaxRefund 122,024 xxii_IncomeTaxRefund Payments for Royalties 7,000,000 us-gaap_PaymentsForRoyalties Patent and Trademarks [Member] Condensed Financial Statements, Captions [Line Items] Finite-Lived Intangible Assets, Amortization Expense, after Year Five 310,000 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_IntellectualPropertyMember Licensing Agreements [Member] Condensed Financial Statements, Captions [Line Items] Finite-Lived Intangible Assets, Amortization Expense, after Year Five 98,000 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember License Costs 75,000 us-gaap_LicenseCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember 125,000 us-gaap_LicenseCosts / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Property, Plant and Equipment, Additions 413,566 us-gaap_PropertyPlantAndEquipmentAdditions / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember 660,000 us-gaap_PropertyPlantAndEquipmentAdditions / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember 22nd Century Asia Ltd [Member] Condensed Financial Statements, Captions [Line Items] Equity Method Investment, Ownership Percentage 51.00% us-gaap_EquityMethodInvestmentOwnershipPercentage / dei_LegalEntityAxis = us-gaap_SubsidiariesMember Maximum [Member] Condensed Financial Statements, Captions [Line Items] Property, Plant and Equipment, Estimated Useful Lives 10 Years Minimum [Member] Condensed Financial Statements, Captions [Line Items] Property, Plant and Equipment, Estimated Useful Lives 3 Years SPECTRUM Order [Member] Condensed Financial Statements, Captions [Line Items] Revenue Other Manufactured Products $ 448,000 us-gaap_RevenueOtherManufacturedProducts / us-gaap_ProductOrServiceAxis = xxii_SpectrumOrderMember $ 5,500,000 us-gaap_RevenueOtherManufacturedProducts / us-gaap_ProductOrServiceAxis = xxii_SpectrumOrderMember Common Stock [Member] Condensed Financial Statements, Captions [Line Items] Convertible Preferred Stock, Shares Issued Upon Conversion 4,166,666 us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Series A One Preferred Stock [Member] Condensed Financial Statements, Captions [Line Items] Preferred stock, shares issued 2,500 us-gaap_PreferredStockSharesIssued / us-gaap_StatementClassOfStockAxis = xxii_SeriesOnePreferredStockMember Preferred Stock, Shares Outstanding 2,500 us-gaap_PreferredStockSharesOutstanding / us-gaap_StatementClassOfStockAxis = xxii_SeriesOnePreferredStockMember X - Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_CondensedFinancialStatementsCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Number of shares issued for each share of convertible preferred stock that is converted. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 + Details Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details Name: us-gaap_DeferredRevenueRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: instant X - Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_LicenseCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_LicensesRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details Name: us-gaap_PaymentsForRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAdditions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 35 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6539997&loc=d3e1205-110223 + Details Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Revenue not otherwise defined in the taxonomy from the sale of manufactured products. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_RevenueOtherManufacturedProducts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Income Tax Refund. + References No definition available. + Details Name: xxii_IncomeTaxRefund Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: dei_LegalEntityAxis=us-gaap_SubsidiariesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ProductOrServiceAxis=xxii_SpectrumOrderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RangeAxis=us-gaap_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RangeAxis=us-gaap_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=xxii_SeriesOnePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R24.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 COMMITMENTS AND CONTINGENCIES 12 Months Ended Dec. 31, 2014 Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES NOTE 17.  COMMITMENTS AND CONTINGENCIES License Agreements - Under its exclusive worldwide license agreement with North Carolina State University (“NCSU”), the Company is required to pay minimum annual royalty payments, which are credited against running royalties on sales of licensed products. The minimum annual royalty for each of 2014 and 2015 is $ 75,000 , and in 2016 the minimum annual royalty increases to $ 225,000 . The license agreement continues through the life of the last-to-expire patent, which is expected to be 2022. The license agreement also requires a milestone payment of $ 150,000 upon FDA approval or clearance of a product that uses the NCSU licensed technology. The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. These costs vary from year to year and the Company has certain rights to direct the activities that result in these costs. During the years ended December 31, 2014 and 2013, the costs incurred related to capitalized patent costs and patent maintenance expense amounted to $ 123,968 and $ 101,902 respectively. In addition, on February 10, 2014, the Company entered into a sponsored research and development agreement (the “Agreement”) with NCSU. Under the terms of the Agreement, the Company is required to pay NCSU $ 162,408 over the two-year term of the Agreement, which grants certain licensing rights to the Company. A payment of $ 81,204 was made in February 2014 and a final payment of $ 81,204 is due and payable on February 1, 2015. The Company has two other exclusive license agreements which require aggregate annual license fees of approximately $ 75,000 , which are credited against running royalties on sales of licensed products. Each license agreement continues through the life of the last-to-expire patents. On December 22, 2014, the Company entered into a Purchase Agreement (see Note 12 for details) with one of these licensors to acquire certain patent rights the Company had previously licensed from such licensor. The Company has no future commitment to that licensor. All payments made under the above referenced license agreements and the sponsored research and development agreement are initially recorded as a Prepaid expense on the Company’s Consolidated Balance Sheets and subsequently expensed on a straight-line basis over the applicable period and included in Research and development costs on the Company’s Consolidated Statements of Operations. On August 22, 2014, the Company entered into a Commercial License Agreement with Precision PlantSciences, Inc. (the “Precision License”). The Precision License grants the Company a non-exclusive, but fully paid up right and license to use technology and materials owned by Precision PlantSciences for a license fee of $ 1,250,000 . An initial cash payment of $ 725,000 was made upon execution of the Precision License with an unconditional obligation to pay the remaining $ 525,000 in $ 25,000 increments as materials are provided to the Company. The remaining $ 525,000 was paid during December 2014. The Precision License continues through the life of the last-to-expire patent, which is expected to be in 2028. On August 27, 2014, the Company entered into an additional exclusive License Agreement (the “License Agreement”) with NCSU. Under the License Agreement, the Company paid NCSU a non-refundable, non-creditable lump sum license fee of $ 125,000 . Additionally, the License Agreement calls for the Company to pay NCSU three non-refundable, non-creditable license maintenance fees in the amount of $ 15,000 per annum in each of December 2015, 2016 and 2017. Beginning in calendar year 2018, the Company is obligated to pay to NCSU an annual minimum royalty fee of $ 20,000 in 2018, $ 30,000 in 2019, and $ 50,000 per year thereafter for the remaining term of the License Agreement. The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. There were no costs reimbursed under the License Agreement through December 31, 2014. The License Agreement continues through the life of the last-to-expire patent, which is expected to be in 2034. On September 15, 2014, the Company entered into a Sublicense Agreement with Anandia Laboratories, Inc. (the “Anandia Sublicense”). Under the terms of the Anandia Sublicense, the Company was granted an exclusive sublicense in the United States and a co-exclusive sublicense in the remainder of the world, excluding Canada, to the licensed Intellectual Property (more fully discussed in Note 10). The Anandia Sublicense calls for an up-front fee of $ 75,000 , an annual license fee of $ 10,000 , and a running royalties on future net sales. The Anandia Sublicense continues through the life of the last-to-expire patent, which is expected to be in 2035. The Precision License, the License Agreement with NCSU and the Anandia Sublicense are included in Intangible assets, net in the Company’s Consolidated Balance Sheets and the applicable license fees will be amortized over the term of the agreements based on their last-to-expire patent date. Amortization during the year ended December 31, 2014 and 2013 amounted to $ 32,524 and $0, respectively, and was included in Research and development costs on the Company’s Consolidated Statements of Operations. Lease Agreements - On October 9, 2013, the Company executed a guaranty that guarantees performance by NASCO of its obligations to a landlord under a certain triple net lease of the same date between NASCO and a landlord for a manufacturing facility and warehouse located in North Carolina. Upon the NASCO transaction closing on August 29, 2014, the lease became a direct obligation of the Company. The lease commenced on January 14, 2014, and has an initial term of twelve (12) months. The lease contains four (4) additional extensions; one for an additional one (1) year and three for an additional two (2) years in duration, exercisable at the option of NASCO. The lease expense for the year ended December 31, 2014 amounted to $ 97,593 . The future minimum lease payments under the lease are $ 123,000 , $ 298,275 , $ 338,250 and $ 338,250 during the one (1) year optional extension, and each of the three (3), two (2) year optional extensions, respectively. The Company has extended the lease for its office space in Clarence, New York for a one-year renewal option expiring August 31, 2015, with the Company having the option to extend this lease for either or both of two (2) additional renewal periods, each consisting of one (1) year. Future minimum lease payments for the years ended December 31, 2015, 2016 and 2017 are approximately $ 44,000 , $ 45,000 and $ 31,000 , respectively, if the Company exercises each of the optional renewal periods. On January 25, 2013, the Company entered into a two and one-half year lease for manufacturing space in Depew, New York, which commenced February 1, 2013. This lease was cancelled during the third quarter of 2014. There are no remaining rent commitments under this lease. X - Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a)(19)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details Name: us-gaap_CommitmentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 53 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {};
Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none';
}; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; }
}; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } }
}; XML 54 R7.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Cash flows from operating activities: Net loss $ (15,595,358) us-gaap_ProfitLoss $ (26,153,158) us-gaap_ProfitLoss Adjustments to reconcile net loss to cash (used in) provided by operating activities: Amortization and depreciation 462,772 us-gaap_DepreciationDepletionAndAmortization 144,289 us-gaap_DepreciationDepletionAndAmortization Amortization of license fees 32,524 us-gaap_OtherAmortizationOfDeferredCharges 0 us-gaap_OtherAmortizationOfDeferredCharges Amortization of debt issuance costs 0 us-gaap_AmortizationOfFinancingCosts 4,232 us-gaap_AmortizationOfFinancingCosts Amortization of debt discount 0 us-gaap_AmortizationOfDebtDiscountPremium 134,296 us-gaap_AmortizationOfDebtDiscountPremium Loss on equity investment 101,165 us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal 0 us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Gain on the sale of machinery and equipment (71,121) us-gaap_GainLossOnSaleOfPropertyPlantEquipment 0 us-gaap_GainLossOnSaleOfPropertyPlantEquipment Interest due to debt conversion 0 xxii_NonCashInterestOnConvertibleDebt 526,448 xxii_NonCashInterestOnConvertibleDebt Warrant liability loss 3,676,691 xxii_GainLossFromWarrantLiability 23,602,711 xxii_GainLossFromWarrantLiability Warrant amendment inducement expense 144,548 xxii_WarrantExchangeInducementExpense 3,736,313 xxii_WarrantExchangeInducementExpense Equity based employee compensation expense 2,293,083 us-gaap_ShareBasedCompensation 980,162 us-gaap_ShareBasedCompensation Equity based payments for outside services 2,231,385 us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims 1,381,800 us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Severance expense 624,320 us-gaap_SeveranceCosts1 (Increase) decrease in current assets: Inventory (620,660) us-gaap_IncreaseDecreaseInInventories (175,754) us-gaap_IncreaseDecreaseInInventories Prepaid expenses and other assets (214,469) us-gaap_IncreaseDecreaseInPrepaidExpense 10,044 us-gaap_IncreaseDecreaseInPrepaidExpense Increase (decrease) in current liabilities: Accounts payable 625,389 us-gaap_IncreaseDecreaseInAccountsPayable (629,101) us-gaap_IncreaseDecreaseInAccountsPayable Accrued interest payable to related parties 0 us-gaap_IncreaseDecreaseInDueToRelatedParties (3,567) us-gaap_IncreaseDecreaseInDueToRelatedParties Accrued expenses (93,985) us-gaap_IncreaseDecreaseInAccruedLiabilities 118,105 us-gaap_IncreaseDecreaseInAccruedLiabilities Deferred revenue (179,014) us-gaap_IncreaseDecreaseInDeferredRevenue 179,014 us-gaap_IncreaseDecreaseInDeferredRevenue Net cash (used in) provided by operating activities (6,582,730) us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 3,855,834 us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Cash flows from investing activities: Acquisition of patents and trademarks (726,989) us-gaap_PaymentsToAcquireIntangibleAssets (290,336) us-gaap_PaymentsToAcquireIntangibleAssets Acquisition machinery and equipment (212,487) us-gaap_PaymentsToAcquireMachineryAndEquipment (2,994,757) us-gaap_PaymentsToAcquireMachineryAndEquipment Purchase of machinery and equipment held for resale 0 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (457,696) us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Payment of license fees (1,450,000) us-gaap_PaymentsForFees 0 us-gaap_PaymentsForFees Acquisition of NASCO Products, LLC (250,000) us-gaap_PaymentsToAcquireBusinessesGross 0 us-gaap_PaymentsToAcquireBusinessesGross Proceeds from the sale of machinery and equipment 631,484 us-gaap_ProceedsFromSaleOfMachineryAndEquipment 0 us-gaap_ProceedsFromSaleOfMachineryAndEquipment Equity investment and advance (700,000) us-gaap_PaymentsToAcquireInvestments 0 us-gaap_PaymentsToAcquireInvestments Net cash used in investing activities (2,707,992) us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (3,742,789) us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Cash flows from financing activities: Net proceeds from exercise of warrants 486,951 us-gaap_ProceedsFromWarrantExercises 2,254,999 us-gaap_ProceedsFromWarrantExercises Net proceeds from exercise of options 48,300 us-gaap_ProceedsFromStockOptionsExercised 5,200 us-gaap_ProceedsFromStockOptionsExercised Net proceeds from warrant exchange program 0 xxii_NetProceedsFromWarrantExchangeProgram 3,239,385 xxii_NetProceedsFromWarrantExchangeProgram Proceeds from issuance of notes 0 us-gaap_ProceedsFromNotesPayable 150,000 us-gaap_ProceedsFromNotesPayable Payments on borrowings - notes payable 0 us-gaap_RepaymentsOfNotesPayable (1,620,299) us-gaap_RepaymentsOfNotesPayable Payments on borrowings - convertible notes 0 us-gaap_RepaymentsOfConvertibleDebt (339,250) us-gaap_RepaymentsOfConvertibleDebt Other capital contribution 0 us-gaap_ProceedsFromContributedCapital 1,660 us-gaap_ProceedsFromContributedCapital Net payments to related party (4,000) us-gaap_RepaymentsOfRelatedPartyDebt (5,100) us-gaap_RepaymentsOfRelatedPartyDebt Net advances from (to) officers 7,471 us-gaap_ProceedsFromPaymentsForOtherFinancingActivities (3,893) us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Net cash provided by financing activities 9,862,810 us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 5,717,366 us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net increase in cash 572,088 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 5,830,411 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Cash - beginning of period 5,830,599 us-gaap_Cash 188 us-gaap_Cash Cash - end of period 6,402,687 us-gaap_Cash 5,830,599 us-gaap_Cash Cash paid during the period for interest 7,094 us-gaap_InterestPaidNet 135,247 us-gaap_InterestPaidNet Cash paid during the period for income taxes 0 us-gaap_IncomeTaxesPaid 0 us-gaap_IncomeTaxesPaid Supplemental disclosure of investing and financing activities Reclassification of derivative liability to equity due to warrant amendments 7,367,915 xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantAmendments 14,433,178 xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantAmendments Patent and trademark additions included in accounts payable 193,454 xxii_PatentAndTrademarkAdditionsIncludedInAccountsPayable 42,490 xxii_PatentAndTrademarkAdditionsIncludedInAccountsPayable Machinery and equipment additions included in accounts payable 10,904 us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1 0 us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1 License fee included in accrued expenses 300,000 xxii_LicenseFeeIncludedInAccruedExpenses 0 xxii_LicenseFeeIncludedInAccruedExpenses Equity investment included in accrued expenses 325,000 xxii_EquityInvestmentIncludedInAccruedExpenses 0 xxii_EquityInvestmentIncludedInAccruedExpenses Issuance of common stock for equity investment 394,500 us-gaap_StockRepurchasedDuringPeriodValue 0 us-gaap_StockRepurchasedDuringPeriodValue Issuance of common stock for acquisition of NASCO Products, LLC 1,952,000 us-gaap_StockIssuedDuringPeriodValueAcquisitions 0 us-gaap_StockIssuedDuringPeriodValueAcquisitions Issuance of warrants as a derivative liability issued under a consulting agreement and included in prepaid consulting fees 2,810,000 xxii_IssuanceOfDerivativeLiabilityWarrantsIssuedUnderConsultingAgreement 0 xxii_IssuanceOfDerivativeLiabilityWarrantsIssuedUnderConsultingAgreement Warrants issued under a consulting agreement resulting in an increase in capital and included in prepaid consulting fees 1,260,000 xxii_WarrantsIssuedUnderConsultingAgreementResultingInCapital 0 xxii_WarrantsIssuedUnderConsultingAgreementResultingInCapital Reclassification of machinery and equipment purchases to inventory 37,856 xxii_ReclassificationOfMachineryAndEquipmentPurchasesToInventory 0 xxii_ReclassificationOfMachineryAndEquipmentPurchasesToInventory Other capital contribution 25,200 xxii_OtherContributedCapital 0 xxii_OtherContributedCapital Patent additions acquired with note payable 925,730 xxii_FiniteLivedIntangibleAssetsAcquiredWithNotesPayable 0 xxii_FiniteLivedIntangibleAssetsAcquiredWithNotesPayable Accounts payable converted to promissory notes 0 xxii_ConversionOfAccountsPayableToNotePayable 769,377 xxii_ConversionOfAccountsPayableToNotePayable Accrued interest converted to promissory notes 0 xxii_ConversionOfAccruedInterestToNotePayable 26,422 xxii_ConversionOfAccruedInterestToNotePayable Notes payable and accrued interest converted to common shares 0 xxii_ConversionOfNotesPayableAndAccruedInterestToCommonStock 1,650,305 xxii_ConversionOfNotesPayableAndAccruedInterestToCommonStock Common stock issued in payment of preferred stock dividend payable 0 xxii_DividendPayableOnPreferredStock 93,361 xxii_DividendPayableOnPreferredStock Common stock issued for fees relating to January 2013 preferred stock private placement 0 xxii_IssuanceOfCommonStockValueInPaymentOfFinancingCost 416,666 xxii_IssuanceOfCommonStockValueInPaymentOfFinancingCost Refinance of convertible note to note payable 0 xxii_RefinanceOfNotePayableToAccountsPayable 57,500 xxii_RefinanceOfNotePayableToAccountsPayable Issuance of warrants as derivative liability instruments and reduction of capital 0 xxii_IssuanceOfWarrantsAsDerivativeLiabilityInstrument 5,675,634 xxii_IssuanceOfWarrantsAsDerivativeLiabilityInstrument Increase in warrant liability and reduction in capital as a result of lowering the exercise price on certain warrants 0 xxii_IncreaseWarrantLiabilityAdjustments 626,328 xxii_IncreaseWarrantLiabilityAdjustments Reclassification of derivative liability to equity due to warrant exchange program 0 xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantExchangeProgram 19,639,465 xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantExchangeProgram Common stock issued for fees relating to December 2013 warrant exchange program 0 xxii_IssuanceOfCommonStockValueForFees 462,000 xxii_IssuanceOfCommonStockValueForFees Common Stock 2014 [Member] Cash flows from financing activities: Net proceeds from private placement 9,324,088 us-gaap_ProceedsFromIssuanceOfPrivatePlacement / us-gaap_StatementEquityComponentsAxis = xxii_CommonStock2014Member 0 us-gaap_ProceedsFromIssuanceOfPrivatePlacement / us-gaap_StatementEquityComponentsAxis = xxii_CommonStock2014Member Preferred Stock 2013 [Member] Cash flows from financing activities: Net proceeds from private placement $ 0 us-gaap_ProceedsFromIssuanceOfPrivatePlacement / us-gaap_StatementEquityComponentsAxis = xxii_PreferredStock2013Member $ 2,034,664 us-gaap_ProceedsFromIssuanceOfPrivatePlacement / us-gaap_StatementEquityComponentsAxis = xxii_PreferredStock2013Member X - Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 8 -Article 9 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 + Details Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of gain (loss) on sale or disposal of an equity method investment. + References No definition available. + Details Name: us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInDueToRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The amount of cash paid for interest during the period net of cash paid for interest that is capitalized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of amortization of other deferred costs recognized in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_OtherAmortizationOfDeferredCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The amount of cash paid during the current period for fees which are not defined elsewhere in the taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details Name: us-gaap_PaymentsForFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow for acquisition of machinery and equipment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireMachineryAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash inflow associated with the amount received by a corporation from a shareholder during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromContributedCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow from a borrowing supported by a written promise to pay an obligation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3098-108585 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow from sale of machinery and equipment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 + Details Name: us-gaap_ProceedsFromSaleOfMachineryAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (j) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow associated with the amount received from holders exercising their stock warrants. + References No definition available. + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686 + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow for a borrowing supported by a written promise to pay an obligation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 + Details Name: us-gaap_RepaymentsOfRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a)(10) -URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Value of stock issued pursuant to acquisitions during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Conversion of accounts payable to note payable. + References No definition available. + Details Name: xxii_ConversionOfAccountsPayableToNotePayable Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition It represents that the accrued interest is converted to note payable during the reporting period. + References No definition available. + Details Name: xxii_ConversionOfAccruedInterestToNotePayable Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition It represent that the notes payable and accrued interests are converted to common shares. + References No definition available. + Details Name: xxii_ConversionOfNotesPayableAndAccruedInterestToCommonStock Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition It represent the dividend payable on preferred stock. + References No definition available. + Details Name: xxii_DividendPayableOnPreferredStock Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Total amount of equity investment included in accrued expenses. + References No definition available. + Details Name: xxii_EquityInvestmentIncludedInAccruedExpenses Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from acquisition of notes payable. + References No definition available. + Details Name: xxii_FiniteLivedIntangibleAssetsAcquiredWithNotesPayable Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Represents the value of gain or loss from warrant liability. + References No definition available. + Details Name: xxii_GainLossFromWarrantLiability Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of Increase in warrant liability and reduction in capital as a result of lowering the exercise price on certain warrants. + References No definition available. + Details Name: xxii_IncreaseWarrantLiabilityAdjustments Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Common stock issued for fees relating to warrant exchange program. + References No definition available. + Details Name: xxii_IssuanceOfCommonStockValueForFees Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Common stock issued for fees relating to preferred stock private placement. + References No definition available. + Details Name: xxii_IssuanceOfCommonStockValueInPaymentOfFinancingCost Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Represents Issuance Of Derivative Liability Warrants Issued Under Consulting Agreement during this period. + References No definition available. + Details Name: xxii_IssuanceOfDerivativeLiabilityWarrantsIssuedUnderConsultingAgreement Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Issuance of warrants as derivative liability instrument. + References No definition available. + Details Name: xxii_IssuanceOfWarrantsAsDerivativeLiabilityInstrument Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of license fee included in accrued expenses. + References No definition available. + Details Name: xxii_LicenseFeeIncludedInAccruedExpenses Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow associated with the amount received due from warrant exchange program. + References No definition available. + Details Name: xxii_NetProceedsFromWarrantExchangeProgram Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition It may represents non cash interest on convertible debt during the period. + References No definition available. + Details Name: xxii_NonCashInterestOnConvertibleDebt Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The value represents other contributed capital. + References No definition available. + Details Name: xxii_OtherContributedCapital Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Patent and trademark additions included in accounts payable during the reporting period. + References No definition available. + Details Name: xxii_PatentAndTrademarkAdditionsIncludedInAccountsPayable Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Reclassification of derivative liability to equity due to warrant amendments + References No definition available. + Details Name: xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantAmendments Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Reclassification of derivative liability to equity due to warrant exchange program. + References No definition available. + Details Name: xxii_ReclassificationOfDerivativeLiabilityToEquityDueToWarrantExchangeProgram Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Reclassification of machinery and equipment purchases to inventory during the reporting period. + References No definition available. + Details Name: xxii_ReclassificationOfMachineryAndEquipmentPurchasesToInventory Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition It represent the refinance of convertible note to note payable during the period. + References No definition available. + Details Name: xxii_RefinanceOfNotePayableToAccountsPayable Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of inducement expenses on warrant exchange. + References No definition available. + Details Name: xxii_WarrantExchangeInducementExpense Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Represents Warrants issued under a consulting agreement resulting in an increase in capital and included in prepaid consulting fees. + References No definition available. + Details Name: xxii_WarrantsIssuedUnderConsultingAgreementResultingInCapital Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=xxii_CommonStock2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=xxii_PreferredStock2013Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R3.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) Dec. 31, 2014 Dec. 31, 2013 Preferred stock, shares authorized 10,000,000 us-gaap_PreferredStockSharesAuthorized 10,000,000 us-gaap_PreferredStockSharesAuthorized Preferred stock, par value $ 0.00001 us-gaap_PreferredStockParOrStatedValuePerShare $ 0.00001 us-gaap_PreferredStockParOrStatedValuePerShare Common stock, shares authorized 300,000,000 us-gaap_CommonStockSharesAuthorized 300,000,000 us-gaap_CommonStockSharesAuthorized Common stock, par value $ 0.00001 us-gaap_CommonStockParOrStatedValuePerShare $ 0.00001 us-gaap_CommonStockParOrStatedValuePerShare Common stock, shares issued 64,085,042 us-gaap_CommonStockSharesIssued 56,902,770 us-gaap_CommonStockSharesIssued Common stock, shares outstanding 64,085,042 us-gaap_CommonStockSharesOutstanding 56,902,770 us-gaap_CommonStockSharesOutstanding X - Definition Face amount or stated value per share of common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 56 R17.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 EQUITY INVESTMENT AND ADVANCE 12 Months Ended Dec. 31, 2014 Equity Method Investments and Joint Ventures [Abstract] EQUITY INVESTMENT AND ADVANCE NOTE 10.  EQUITY INVESTMENT AND ADVANCE On April 11, 2014, the Company, through a newly formed wholly-owned subsidiary, Botanical Genetics, LLC, entered into an investment agreement (the “Agreement”) with Anandia Laboratories, Inc., a Canadian plant biotechnology company (“Anandia”). The Agreement provided for the Company to make an initial investment of $250,000 in Anandia in return for (i) a ten percent ( 10 %) equity interest in Anandia, and (ii) certain rights granted to the Company for four patent families (the “Intellectual Property”). The $ 250,000 investment was made on April 14, 2014. On September 15, 2014, certain milestones were achieved triggering an additional cash investment in Anandia in the amount of $ 450,000 in return for (i) an additional fifteen percent ( 15 %) equity interest in Anandia, and (ii) a worldwide sublicense agreement to the Intellectual Property, including an exclusive sublicense agreement within the U.S. In addition, the Company issued 150,000 unregistered shares of the Company’s common stock to Anandia with a value on the day of issuance in the amount of $ 394,500 , and on March 31, 2015, the Company will issue to Anandia unregistered shares of the Company’s common stock with an aggregate market value of $ 325,000 at the time of the issuance. The additional $ 325,000 payable in shares of common stock is included in the Equity investment and in Accrued expenses on the Company’s Consolidated Balance Sheets at December 31, 2014. In January 2014, the Company made a non-interest bearing advance to Anandia in the amount of $ 92,894 . $ 50,000 of this amount was applied to a sublicense fee paid to Anandia, under a certain sublicense more fully described in Note 17. The balance of $ 42,894 has been written off and is included in General and administrative expense on the Company’s Consolidated Statements of Operations. The Company uses the equity method of accounting to record its 25 % ownership interest in Anandia. As of December 31, 2014, the Company’s equity investment balance in Anandia was $ 1,318,335 and is classified within Other assets on the accompanying Consolidated Balance Sheets. As of December 31, 2014, the carrying value of our investment in Anandia was approximately $ 1,199,000 in excess of our share of the book value of the net assets of Anandia, with such difference attributable to intangible assets. This intangible asset is being amortized over the expected benefit period and this amortization expense of $ 16,815 has been included in the Loss on equity investment in the accompanying Consolidated Statements of Operations. In addition, the Company has recorded an equity loss of $ 84,350 , representing 25 % of Anandia’s net loss covering the period beginning with the Company’s initial investment through December 31, 2014, resulting in a total loss on equity investment of $ 101,165 . X - Details Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 35 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=35687916&loc=d3e32787-111569 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 35 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=35687916&loc=d3e32847-111569 + Details Name: us-gaap_EquityMethodInvestmentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration ZIP 57 0001144204-15-006466-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-006466-xbrl.zip
M4$L#!!0````(`$8Q1D8BZ,"9ID4!`"L.%``1`!P`>'AI:2TR,#$T,3(S,2YX
M;6Q55`D``Q.AU%03H=14=7@+``$$)0X```0Y`0``[)W]S":1">F_VKJXH80O0MK$9V4Y@K^Y_OT>R#;:Q:6`P
MV*"JZ2D'6[+TU4>/'LEZ^?27Z5A'[X19U#0^GRG%TADBAFIJU!A^/OOV]EBX
M/D-_^?*O__+I3X4"^DH,PK!---2?H0=LXS>&U>^6'QXI1:5XC>"B5"L\DGZA
M7%)JZ+]+E[?EZFWMZG_0_[X\_Q]J=M]0`7U\?!0UB,$6,115 !/#W%Q@IC)3)Q75&DX8`:H?%AX$;,XV2J
MCN*?YW=B`E#CG5AV?!#W7DQN#$Q5*SZ,N,6#*.$@%E7C`\"-N,?M"4MX'N[$
M!'"LPA#CR3S,`%M]4;+>C9BL3_45_/SV%(#:L=D*;.#N&=1@A#[QBG!K"<1?
MR0")BG%KSR;D\YE%QQ.=\RM^&S$R^'S&*W3!K\7%J:6=H0N(R#44#=.PR=1&
M7:+:8'^$D8!7N&9"]6Y2P/FEI/3@/UY*;R9<5-QK-TGS$&`WJ#WS?IO_2C7^
M^X`2AD2R22B;ON2-UE_/OI2@!E>J5]>UZT\7T
M,QO,+?GB8U92_'@6]_RH`MG10H$JRN+EFA ,)6\RAL=1MA(5!E#\+ZIN"D
MA$W;%%0#IN"4A$W+%-2MC@'**I4\">IVH.RYG$IE'KUW9U?*E'NE*E>FEC]E
M:H52N5"JIJ5,)6?M<4"92MC^[UJ9:D^IYK LKD
MJ]L0KDW!CE5:RN25F524*5U[[E`9_$RXOA'7.5$HY`Y!$W6]L3OD!KI)RQW*
M6Q\^7!EOTD%.*04ZXW!]E2>%(IUQI;1-9QP"7:6`''1G7&$5T;5Q?0 RJ;`BT,+E2$-8M\]8+N>I&8GT&;<05@0JEU,RDIS4_/K_'+FT_/_ $?3Q_HF!ABVL8&GT]#
M`Z6]ACD>FT;7-M7OSV3HLA:LJ`7_B1F#%J@Y54?8&)(79@X9'KL*
M\>D[;[,)%'I]R(A0WZT"7J"UZTS^Z.=9OXW+^]D7<6N5;`]T)]*N9,^XPC;`@#=#4:XYJ=QA4E'>JDGQ#
M$)\;UQ`L*W`@OR+#4R4#GK0D)CO$9,P332#F&4_IV!D'67GEO8E\`Q+(@O]3
M**,2B55(4.-$D`AF5"*Q_&VCUX);N@X6U/CY)F>C3/J!DI4[B.^ZBV\^:Q'SQ%?/6M08+H:L
M)##K`),HW)'QDM#H2&[RRTV6&[325=S2)XG;$>%VE:$%89'6[ADA)/)HW0
M)S+$>E-D.)\`01YNES*Q]*UVGN4C:\#"$Z.DBWPL+O*>)HQ59-N3X[;G$+Q\
M,U2N!2\%$$LC`Z&='J==D*/%HT?.TL89]0-N+.QQ1-3^RP5SH F]@?D'&!3LM036$=NL%)A+P62ZJ8POEGS!O^=I1]O#WY?P9Q'^
MOH1_;?@]S ,P$)!7SLE"P/D2)S&%Y$6'.EDWM/E#]S->*OF$
M*K#BZ<>9 +7V`LF>\?ZWA<6.D];]+'@GWXAMDD=ATE;)
M=J#)/VEM\QZ9'R:!.19@TIQ0F)*%.;$I0GNB+(71V@S,7MJ+<2Q5/(>M%C@W
ML;9;YOFR/O*[P[5^)\L;S@9NY=_72\Q0P@-IH)U3VQYR.FO\0+--GAGUK4Q-:AE0YSTG32G$[X6(+QZ0C7'
M9-YD/IDJYK%*;%-R3E;J[3^T5OG)ZK1B6$J:[Q,WWWO9"JW2J_-/8H:HG-Y0
MLBU)6XNTE%]:=&RT\9@D'811AQQJ5'>X
M?%VB.HS:8-\A0MW1B/;(S#$?*G%LX9!T!DW,#&H,K1?"NB/0^GX6'T&^&0R*
MMO<3-%(MD0.?O[&7 3&BJSANU^4%!+?!QWJGF
M@(>=:W83LB,@3I;BR,QDTB[Y8JES(\8,GNRZ[T863N+)QSP::4@R94BRW"%,
M(.A7;#B8S>!:B1Y"!XH2/LW(7RC0,4(C)L))=G;#7N/IL,D>IOH),G;$7E0)I*\
M3722Y.V&O"Z=2O`VD$ERMR/NR#LQ)'D;"2796\'>`U&%&ES3AFF\$V;S[4_;
MIDVL%SS#/3MUN&93.'JY)W=);SXHTH),NP/V["*S4J
M>UG-%,EY60*P),.A`$AQJ4X``'=)0MW0PFL3K!,%81TYCAD(V4W.9#?Y$+OX
M=55B8(CFT61$Q59X4RE_WPS_H7P3D)"=^>U8)0Y4^GM9&U^3I9_%TJ_MI_0O
M9>EGL?0O][UV]P64B;3]CZ=PP/=&F9QO8!`4ZT"##?E8U"NQRAE661S#*ON;
MJO:>J,J5#AS $XN]F&LYN"4DNSXQ'NS[X2
MBV"FCO@6.N2=Z*8X^>=4-F->:\?C-222?=L5B)WZCM^YWU8['YB%CLE[Q"K5
M(;=!N.1I;XO3WA*EDHBM&*63C66.&\N,C=@E("8;RYPWEOG`3#:6.6XLLXI8
MV!^3N[S+C=9SX>,M#8C8C*HVT9:.RY3X'@K?V$*1&*_`N#/A>DMZLT!OL"PD
MM"N\4NDR9(C:++@,6?5TEX:%I,N0-7RSY#+D`V/I,F2'W@RX#!F#5LS&+_7*
M`M92CP_9V#-JJ#Q_[V3"1W(^X'IF$V.\M$ZO_H&9EO]QJT@VQ*2'=84XR%S`
M4@'^*^]Q>OX?P*+7&1NT[_`S&]W`?'0P-"0:.HXOKPS%'"J8G/%D:(X7WUST
MF\+4OXTH L^>K5P(*AZF*/(G,\
M-HVE#Q!SB^RZAGQHTC3@3TLZZ?MPTE?*OV@8EPKO:
MXXENS@@1-GSY2ZK[2\O0R)1H;V;+LAS"+%=Q]__YYFG=_/G/)\IUD,Y@>=^[
M2$E:\D9+IGL$":/W$K(\0Y:Q88I0>R ]I7M]RK
M:QKE><7Z"Z9:RVC@";6QOO8P5GX!67-X:*5`1^8Q1]AX)3:F!M'\:902BL7'
MVCAECIN&%T8&A+&8B?:GS4*@P-^1CCD:(JT"EFT"KD8,0F#
M)(U*MHQ*#A&2?9E\]&5RB);L"F6U*Y0+F"('3DB?*>L^4\8^`"2`)!N\'#9X
M^4!+-GBY:/`R!E/D0Z5LZ++8T.W_8Z3LW6>M=W\(!J2WD@]OY1!L2' RZN@QR(;?L#*5@?BH2J[QAM61^*ND/['C+,7G*ZT-&Q$40%G'$A..=#-@P
M+7Z4(#__E+WG?'>8'V;,W2\F49YC'>&)W5]!XI%=/++L"X J[38Y
MV_-YO]#4CYUQ""1H\.56[7O9!7(N=>!4X6"!2(.X\JCJJ40W4^@&"T2B&]-Q
M^!4;#F8SN%9>&'V'ET#QJ**MZ@P&A#=PWNF*$(X$>7T@XGDHT/M9&T-;F'-R
MD_(C&-Y&IB/K6FP/SMN'*38=)=C;12:+C
M2P*B2G0VT4FBXTG2I5-)S@8R27!\13_%P(9&\1/NFPS;)J.$3WD,\Z3#J[472/:,5SH+
MJWP?&NM^%KR3=[36SZ/; 9@=V-B=Q\:H0^D2'6FR(C8A)QU^E;Y'E=A!H:QQ:Y2;-AK/V9G)XJRZ\F\QFE]3NB=H=3\)/M3&O
M;=.8NYA74VC,HYA+&[U_^YB%ZI95YF]VP[QC4!=X:X09B8(W)MB"#N(7+WGB
M$3\Z_U[P%3RVA/B_=1\2(J>662TK5[?PQ/9Q]R##O2Y/8.0M&GT'UJ.EP(.V
MG3$1'F84]+63%A0\&F/,"Q^(88ZIL?J5/Y(Z^L[E2/V[@9ROH>'$69(NG"3^
MP%KE\^E/A4)3%]\T49+W73?4[\N!])8/$OON9R, 7LR\^Z?0 Z6`;G^NO7UOM6U2:
MV/!O>H<>.^VW6Z3PO]_`CEBH33[0JSG&QKG[PSDDG]$!.OMY:-^A2'2-IV;]
M];9OVB,WIL)C_;GU]/?;2%1WXEZW]5]-]U5W%OTGN477Q1HUD*(42]38:?3S
M7$+TXM_$7L3?YU?\8@!J^F^*Q"">;G?>FJA21#_C\>3NWY1:"1+1:M?;C5;]
M"34Z[8?66ZO3YC%=\*C\:"_F+[B`K.PR6V_-W]X*K?9#DQ=9B8MWAU9F]4 +F-)$(IG5^5+L^O2Y OUBGN4QUJ
M.MG]^\OGEU>5\VKI*OQZL)J.;E-CB$#5B6E1[MNB#Y-]Y[^I[LZ^.T_,]7FI
M4CFOW-R$$E-$#6R-D&E`>8`J.*;8T`>V=IN42]`$M+D.ZU)]=AABMX"
M8/:)3LD[!(96YX/J.B@#Q8,U$-*Q\W
M$H"-"0&P(;A/FMG7Z=!_P.)U809-QI@@S2$(&A:$D>L1\:+'DPDSIQ0:&Z+/
MD%)&8\CIR"JNL@FQ?ZPMY2)X^!59MS2!HG-3?@W>T)V%'J&I1MU"!4&C_TZ8
M!57*&A%]`&4WI);M%A5$[.TY*"@?4)UH4.CV2)BJ;\5ND;L'#G/M`R_6YE0=
M\37;_)UC:G'''OW9?W&Y=-=M-N9_*7?_P6M6?
MT`I(;R-;I(>+!XC@L>D8MJA_?:A!!'IL8[X5-NK/@EDNKFXY8__@US:??H+Z
M)G25V>>STIFO$*3/'MTJI=)/=T@\4]#QS'3LVP&=$NWN#*E$UZT)5L&2BW#\
M[PD&5]+]>QX_FU]I\Y0%+]GBDK^&__7I8FO7U/>G%SMMPH\C4X?<6>YFFWS:
MS98^[58'./2B4PNC(PY4HYC-NE@GG8&(6O20@^YS6;K/OK6\0_?UQE^_OG:^
MM1]ND 7[NM%'WK=/X*WIY;?VM
M#B%>GNJ-YC-8]3UZW"DKL:JMS4\OHF,`XQ/;]>F4JSA7')HQ!TSG+IL#5#F_
MOE+.KRXCOJ\[:,"-.P7KK0K+`>_CIH:[0+MV_TLE\2_B\K;!,Q-N'/A8*B$:
M-/S,'`M)N!3\FS'Z((SL-CDWYY5R];QT?1WIC`QL/DI(-$<5?0(RG1##XBV=
M99E@VNV@1Q(2S$_K#QJY@U6TH^[?0OGPQM%MB#G/O'@F;J.&)GZKYM8S$$8X
M,60*#@TO3XQ>@YX :VCB,%ZZ-O=P/D94'85J+.;/:?P>(,R'
MT,#18*(7$G(1F1NKP`>JW01\31[&?]9+M5?]`]Z68X!G(.X%O-\Z!(80RDVE
M4H0_5'".@%=]=LY]UXYJF\+`E.(,C.M7XX5/'LI^-^#(>IR#%UU$G46TY4HP
M6K@+%4;5@3=-_)`0W=R[/DXWM2T7:PE:>N,NKI,;]6^IE::#6RZ6*O&C
M0$7T(*9M>J3Q4=%D&<5(G.J6"./7R,=4Z(G3#I(VR13>,4>H$'QU1J$2U>W\4#/-J=O777I713BB\EZ24%O:2&J>ON!$_P
M(.N\*(?"3]G%I]^J]%Q2\UPN0V-7C4Z[^^WIK=7^BNI?7YO"44'U]@/ZM=."
MJ[_!G]]>FW+0*EO=ZY;!JY3ASLQPNX48_ !\QP]\%0@97.!T%/G[..ZG&CAV?FA(JB)^0^#H8I>"/'I:3X&L7@5_SQ*5?&S0)((6\-N7#*G_C<6'I,*=EK9I1M"PQ)T1-8L$Z 6\&O-8ZT*QF9C_;C!6#]6
MCE7NE59-6N[ .A@?.PJBDA;(!
MKB;>NI$S:LWBX1/<>A5X]MXCN*LKWZ096A;PD(9$;$'#R(4\TG@/ 7X'8)Z%Y,%F1`S=+`9>G8M[.R`= `HKZ84_&[@9$S;(E,RLVR
MJ>/=9^EJPN/EPN3>P:Q$WS#&I=FLU"_&*N52_&$S;A5Y5K"62":*"#I)D!!#
M![('>:8"M!(\[N]N.]-5U 6'BNH\'!&PP2^!O+3JH[G%.4\BP"AGY'.8$(#$!.0
M9B8[$Q`89;,0`GQB[">JS`!0/_\M;12F&YTH[J+E$E&E
ME+N1:`HSM^1,1;`1M6%^-[/B=1Q?,8=+'`S`F;RE[^*M50'Q$^)E756ME 5Z
M'>!J5"/'IG7PEG5P/K/YCCH1LU=JN#S"R8-]J8?PK6J)F'LV ]:4F&V5_NQTCB(0"N,*X+`S6>8;B$URI7/%A0T22[:,F5H5MR5.@5C%)[#;:G6J",V@*YGC(69
MLS9AT%(NW#'W_)#_A7;N+M898$%D&GKF\JV(?Z3[/?B`R/1E+HZ^XDA(S4O8
M&@%YVR7G(A[I*L*)/99LO@E!N&LYD2WB;N07YC(?((OXS08K%:>;W&'0*P@W
M)WZ:$B&DY3(],B!E9`G12+`CQ[`2$0G4@[].DVQ@@F?I_6@>NQ`3&9H#C..+
M-)SDS,N#R*06F3QR2Q`#8Y_'UQ]%>@](&9((1NS:U+=Q(C:? K@C(B
M1N&@E,3/@7Q` ?-A!.@5B# M* -/AX=C'>\4'>1GH,X#!LY:A`9^U>I,S9!!._(.+6#%!-Y"I)= _5&]3Q&1,
M&"8)1R%L\J(@%XXR8B"2^!HQ#I08/T'9,H\=Z!+#V3"+P0$Q1(S=E:PHR)$P
M3G%;^+O$LS#]& ?6#>>\O?
MH1\D3D_1AT1@ZO7BJW(:D-_> $JKYDU)TN]6=!VY\E"-T'A/B^%+E;9T
M:JM2+L2-.6 61U[RJZDH*`.\+QVD26VBZ18J>M5
M/AI@#MQL$?D%>(5(XHU>PK_\Y%:1($[[6;-D:QQ2.9ZENR$$%Y9[GR6>HXC_
M"%/1.W=)3OA:CYN&2O6NRHV$^.
M(P9B$);E(P\G1Q6/ZQS&LM;=S(.M01_+]PB^^&:'G>SROHUNX@.N2(E#ML7P
ME^1)L94HQ28/-?)@(I-(W/62:?PA_9[#RU7G6-EW"[=-X[8GGO *(9F(.\U/B\@*0
MW"9D&M,3HQ-P.!V2/`L`G3HI3G;Q/&;2\@I*8`\@_P[`;1@KT!YH0/T'$82C
ML0XVUB_#*AH+%9/2^=;S;)&9*4*MB9U)[O+!4)*/9Q@:'`7:+)13#@`)NQ`'
MW=W;,Q>S=L:N?2KUV/,C0'T=`7II!&A8B`!]&5_\^GE\ .#/YF&Y*N/"V:^'JTY5
M(QWCDQE=H`4:))I:!%,^9CV=>#8#39]>W1,?G$_3[SI5KOK6"&M6;77GR9K&
M6AXE*P8I0'MYTZGP-2,?;%>2(`\V`?^&G^_8C%M.'%A"2D=(KUCF)MQ[O??DJ9VX;D!LZ,,L')4`@RKGHTC7TBUR
M2R%3<3(7DZDCB=SL/-#QP *C)S'*T69WM/DQ?2IC8 =I&>]`W^H.JBS_3:%9&;I"5
M=-8B49,ZU$]N_)LP%]SY.(63Q<5E`I$G>81`T8?E(6)+$N,HN-L1A4FJ@]BI
M$,&(.:!3`,+493*"'>12;X#(GCCK++-[CE:P2%V9)CG?*-:P)9U19!!QF4W-
M.5"F,1H-C':W9(#0G#]J;W"?7YXN@ZDPX-!DPR&DWYB;T"=[?N_,:)I=H]<>
M+;,B#PIY%.-\7`A_M_.SJR?#*%E4F]OYG2;0-G]B?JY(W)CB?3TRVBE6(]B8
MA(4P8I*Q4/M%MFVCVRL*MO"@;9"P*`@2)``HK"L4R]"Z%12!"+W*"Q#E$0A
M'1.\G">)X@0L&TB0F^ [`Q*X+UZM'T:\Z_CDNTRMYC8^/SLEXOW(BOT`RE.%2?Z^]FG
MFW_C\ZT?L@E*(U'6=KG'1V@F/EY^_73Z]>CD\OQ\?'4-G5J8I+@(V`=R^=OI
MU\_GE[^_)WBR#1I[U'Z`$004\?,;<7EC;B1^,HQ_GY[]\F_4LN;B>^YW._D]
M-UEBB82MA%EO_G,.@W/QIFBG2,#X=FT7*.@+"A*8S.77]^3_M<3_EMC]`X&)
MW9R=C,^3KF!50F\>/_A[/,9N"R8D+.K/;_J]'PIJN8(E"K9:VLJ&3*Y=P]SN
M9SQD1\@:[#V@29\N8CY]\7QKF!],$-D:1@>\:2Y--E%HV:1!L^DUU6MZ,&L:
M`W:MC-6?W+8$-[;S'R]O;BZ_I",F[<5W(@(PS1%MA)QZD0]_D3NO=I%?KJX=
M-@V?0X7\97[_S[(8FTYWI/X,=]DN&.;=MAVU9#:@SW6358R5T 0HU_/(,(OG22JZAP-?[TZ>SBEZ.O<>=)U$]YRK262=,Q6H!H.X->X_A$
MBX46BRV*13[KJDE\LD6Q4`1/3,7_=H4G+DM)74::T54,:>^+49Y-C6;JS^TM
M?MW3W9ZFW"(-*E1AKV=T>GN#!YJ]-7MOE;W;`Z/5&S5NO0_?S.\V;'".%]U@
MC0S"YW@;ILP?T^A/[>D>D-;;(@TJM-Y1XY9:3 [Y;
MM_T3$_>TRY,:N4-= ,(.6
M#BT=RDM'_CBQEA&5@,=N`PD-]CE>J8M5XX[JH7I@-6<-WO[V)%24#T6@Q&YC&. .)TM'M#8S^J*]E1#GDH8,8^VKG30=Q-#RH>5#/?EH=8QA_SF'
M+P]6/A2!$OL(8E#+BK!F-%[/E[_33R--[8UI;VS5EG*G;[3;^NB%EA$M(ZMD
M!"2DM3>0H:*$*`(R=ANO6''-H`'#T_S[X_D4ZO
MQ+TSC6&O9?3WATVTV4H-QF2\%7?P
M5MP-7*)U^1)PT6NQTT*UE8G_4_74J@=0Z&Q/!6`NW5IIOU1J2Z"Z]66BTL*(
M\Q4W3L=U4=,2GL4%WD7)KCJ[P,EM<095M;'J;%^4VUU@Y [8G@0Q:=*%6WC4EU;7+O\'GZAUDJ])4B&1KL_*'82KU&I]'9:&T.23M8Q
M30O1E=>NR!E%ZOF,.OPO6$[PZK`L")@I.]=4LB28`U=[R95^IVUTA]W"A)>*
M1M^*0B-2T22CB"=<>PF8GM$WVX7A2&+Y;`ZCP"$]GC@H*F[)VD992:$\2U<7
M1RH5'8KK1HG6ZM5"'=!";7/+G-PQ6F:)D1-U@95^@M75DN)R!266S0&:#4M"
M-+0^RU,*K92+M."SX4(9QC3?&9YS@/1]X]%NU&M,)M#DC9(!^]
MD+K >+)>5B""AMSX3E]^0M]AW`I7,UH=Q
M\DOZ7?O#.UG0?.R",N24G&,-P+CZET'.7.L8L!TYH2Z%7UVT-=#NA`.ZLV:N
MYWBW#VD-T[?YGF1S^7ZD<4N'@.;_CMO+T$Y6S/K&Y*QD"?'6OX-1A\S%:I&6($6=!J==Q-4_O!,6.<0ZE+@J09@;F2&L
MS%L.(TJJ_(HH2$!N`33%I?KRT\?Q8R4SL@"8B3"9SKF#M=C*JWD&;SL.6"TL
MX9ZH\F6*UVO0>Q5N46YU$$',J NS6ZRBBGHTF%$_+0-8Z65B-4#T
M34*$-$"7A-6$^J3DCCH12UP'FXH2E#@5Z@(@WRX[=D;9C3F99R-N1G')%PJ^
M7`)Y>T528[G"S.`*PN=G]A("2:K`&M\"!]Q2X:3BD*AJ?*>@!LK
MU*Q])Q8O)Z3;52TCTQB.BC&3XWI[J-+,0EA!&N))(:B@BP6`(`&6:-[`3!G>
M!,7M'$F,N&HM3:%%[OFYY^-5T("V*^*5[8'4"Y-81FK'# 63% 7;6_$JLXW_O.Y]`3:*>:J=(>C2I=%D#M+`B2
MP0E@DF"EB>=]R\:.WV#4/HN&I^I68+T@`IAI\^D46`=)1$/PVR:1#(`"'P-3
M4?<6BX?&3:"J%3JN^#TNTX0)8R=+R6-E\[NX"#EJ.@L78@+:MU-.KG2< QT^[BL$3*JO+2NLE`4+>@>95,S70K9)]D%B1IF`0^.*
MO17!M*MT5T7+WL-?1/B9'Y-/I%]S3^#B^^%]R?CF^
MV.&NQJ9EQ9/*U_^-@I!/'XJSV&3*9!W.G>QD>O4B7IO-T3X['@;TA8F.=7*5
MY@U0:@G@SSEQ.)UP!Q1Q7*@'WDUB*,(+Q-@)\RW4TQ/J?DN]/I_=> (`WQ"X,;HYCH2!?/&5%OH]OV!S,:>CYI]3%8![.HU7BWC@=E\TTG8)^E;?8Q0H?]&@0H76O'W>,2Z/WAB<1+&`%W
M*`#T2SPA I8#J/N4;3([>/(
MG;)`8+W[&0>8'2]H4-XV`_!%18H2DM2U^`+C!2*&`@.)PB!$M`03P`T*FD"B
MFI>Z4_(QP-X&S(I$H,*F#^`7WF%J'R9F%&D]BU.^$`T[B8 Y!":P+9L7]RD"D?U:BHC)V^,G'0
M]XKZXKCNR.=DLCJA ?B%?3\_'-Z>?R-7XZ\U_
M]@4:UF"B5QKB0Z6#V7>1"%D4\UOEIJ$OY4S4,G@PR-@!H^'*H&Y:!3E.PRBF
M5YP4]_G')VBJT.OV,78D\T@`VJ0!W\/*[N*L48HR/3DXO*['1
M,?F4)1QNFG&W3`Z8!!H+W'#$)'#N.F(3-=[SD!A06#CA`4KE+B)2 \;K?YH.;98]S;! 7R"X2O;S!/,1BD8PW%PZ:9&L%,T
M@NTWX*]P^>"OUY_>`'BQ^)PZ`-/[+!D= M0,#!VB&UNZV^. 3V:H
MT:9+M+JS6H95I)+96K],H\%P,.P]9W`O(Y>Y7G^W\CGV6QA,B4CK=;O9[G;S
M2FNC$8V%#WPY! (L08IH#CW Y+/9F&CUB"WJ"?%X#G
MCV@G M)Z\"H]8DD&WVV[WRN-]X1!*Q%IO'MJM0:L_;"VQPDI9
M6G&HY2GFP5QO'LS1:##HMS8X25.AK9\YP!+-'C$?PUZKGU^VIPSP+-V2EX2&
M1TZ_QPSYB^?9F#:Z.277&Y9VK]L=YK73)IW7/.`B93OK3 B\,9;O3*5%_O849=D;]UJA;RW2*:G=S@J^W+&W3'/;!
MNI35^I-[+=%EO3$QVZ->I[=LT%9F#WRD[K=SC[H!$`>31(.K>`]R8S(\XFD,
MNB.S5Q&@7]5QG2,MD6Z]37GQ2, DO2Z_7Y^62L[>_&0BA3K
MKK<5PR&`)_,98\(HW7FV_?U42G4?B2X->H-.JS"LZ@[K&%F)8(_8C-80]'#O
M&4/[Q*8,?K"_,G"3HR?S5O<1XS`8P4QR88K*WEX\IA*M-O8A-AO.2QAJO2H?
M#;N=3HX\CR_72UCH$07?'W2ZK946J_I.X/!J&>:
M^65;VV]]PRP1&O7[EFCZO^R)%>NO5
M.'`4K-UPH^Y/O/F _9:[U%&KTEM3W]X"_=[GS\YL0M.$;\E,]
MO9:(L*2:-^G5 1)K[Q!-=KVU[>'RQW\H)!E.:[7KWVN^W-!S%.#Q)>
M46Z?N2=TP3$)>&."K->OW4&W9[9Z!5^JLL.7CZM$H_6Z%GQA`#BCUI/']97A
MMC2S3ZF/R=C!.+MW7ND>=48C MKV?VA./V_.'F]TQD_G0:3[R2EW&- .0LV3;>>`76*^\!
MV+SA,*SB==7,?^(QL3/7`T!YW!MF>=LT2@^)?[V'@1^^M=AF5G_;&>
M:QQIB?*/[7:4'?RGCG3Y"71JGYGZ]L?OU,= [)^N(_#[^^G5\<4-._[^3?X\O?CDE5U\O?_DZ_B+N((I_O(9NOY*3RR]?
M+B_(] &F66K&E+2>MK 9D
MQ_<>B@RL>H )I>,R5SWFT\E2-/5,8WV[#O
M>(0DO>H2L][<2,P*R)-VE2GB9XQE7?./#T=.0G*?>SY`*@Y7M&"C?()5Q&03AL
M*2!KU?%*#3].&UC6[?C*K4?%V8LI6AKF2^6W+O Q/N[4I/H"9,VV`IWS%
MY6,3&G`0%'&7UJ-/"Q&/WQ`WA(D;N!#X88 )`T#;$S85V_46HA=Q91\7; \R^%P@[LXHQ
M"V:T8O[0_J3F2R?;P+"];A'!Q@=PDRL^TB,.V>47J'_BZUWJNB`I
M%NM`7DUJ^0SO2(\)FB&J99,E96;I)GH?SS$&B0FV9*A40Z(M0R(P`S8/K"@(
M 8A[$+EJB=-B92_$=[N+L11 &U4M`9J`86XG5TH3=!5P"_0P012-;$UK`;-[[$,7_`N63DQ8FV
M^.JJY,+%/"71H!7(;V-XV\D68OO\OR6^:KYDU&J>"T2XW#"$T$U.`"9&:>HY
MCG')Y?CZ^NH916L`T=!&P
M#^3RM].OG\\O?W]/,$@BRI$5ZGRM'$5 H$/98%/XQB&7E9UY]8_Y,GMN!YVE>QNI>+\#F2[RA+'X9J,
MAI_$==8B'OMJ6:7.Y=\W19ZBW&-F"/3"O[*%O\+M'+WJA[;J%4#@]/N"RS#T
MJUWNYP&!/=/AN77%M?>M]MR>72_^$8W>-#KH-=9KW.2Y/7N-M;.^'1O]7+?[
MX_CD?W_Y>OGKQ2*^;5)E=7E^0?G6-@H_OG>V7[)Q,[A5?\[JG*PK`5L_W:OSIT]G%+\D&5# S-SFK]?"WC;+5N;Q]AZXY:YJ>!MBXNK
M,'A3<9D5`6\Z]J8HN%=QN@#;OF-O[>/>_N&;BO!>Q>D>$'S;<9!B9!JC_8$WS=^O
M!;SMEJW;QV9_L+=T@.9PM8Z]'=@R*P+>]AU[*X`W\6@0+9+9XMT'1^+O]W)J
MHL&W[7>"@/"@H+?V")2>[@$AOAT'[`9&>S!HW'IK]FX8X-MUM`Z4_[!QR]Q4
MP*>C=:HLLR*`3T?K%'4(5)SN`6&W'6?*F49G?_G@FKU?"W;;>;!NC]BM.5RM
M@W4'MLR*8#>E@G4:VZL]W0/";CN.4+2,8:?=N/76[-TP[+;KN%M[H.-N.N[V
MZI99$>RVV[A;>D^^`&^6Y]XQ/\3[S,G%U=X1G(H(7\7I'A""VW&<8F`:@XX^
MT:?X=)L/X78=?FN/AMW&+7-3(=QNPV^?V<07&&XH(-S>\CY47&9%(-QNPV]*
M0S@5@;Z*TST@"+?;[IOB&;BL!>Q>D>$&3;;7BBVVH;`WV/ENK3;3YDVRU;
MMX[[+ D>$.C;;41C9!K]CKYS2_'I-A_S[3I.-^J9.DYWF'&ZV,0/
M][NQJN(B*X+X=ANIVQ#Q::]`W>D>$'K;= E-QD15!;[N-UYWXS&;D!F":-6.D/2:_/^G^7_+6U'&Z!DWW@)#>
MCL_[&6:O9>QQ(TMS^&L!>[ME[,YQ9X\5NYK#U8T,U5VS11BG48WT37**`K[=
MANM*@.]C"OBT*Z#V=`\(NNWXG!_"MGU"-\WAKP6Z[9:QS>/>J* KD-U>\9[FL-?"][;>:ANT-$1G%<2
MJM,5:]3#>_L,U74:BO=4=!^RZ7Z\_/KI].O1Q\N;F\LOZ>A(>_&=!)[#[0]$
M'8+L!!$^C2"'$DK9.V946TK4F6[S,>.."Q?O%3,VAZL/(T:X-\RHXD(K@AEW
M&R/ ;1O^Z.OKWW&!7!_"&[443[%\=
MBNPS_+>*(H<2)FEWC/Z@:W1;VH-6?+H-18J[9>)N(W]Z@1]#BC^%
M%*Q5OJ&$%"?GI^.O[X'LL^*$R_,MS>1--8Q:^>'E/7[X,O[ZRQF0K,5=^4\\
M"M$^XKZD@\JA%FF&CU?.0-`I:>C\[.+T*(76[=X/'\CO9Y]N_HWMMGXH,`H8#Z?%I>_#2,!]O9MYO_\!M;78HX3+*@%(#;]O*"VG7Q.%5I>
MH^7!?\K-";9(8`H0)P, ?;^*OXK&;G>-6#WFQA$D*KXF($WSSAMS!O&[=
MG]^$WB(=5*>=K7^E@#UQ2.W> 36QI7,
M]C+:/9U8NZ(0B?O\;Q2$?/J0\LIC!#MS+2>RH0?P\OB1S9THY)Y+IHR&D0K.D$!>1LP1BZ\D)$^F7H^L5E(N8+ZCX0,.5\3D,6"&8!`0Z_XQL3[GIS3AWB`,H`#B9SSV8.
M"3V8C.-9^'`H=O#%YL+"YT$R*GADJ4N@+O-)P*S(YR&'20!UPFQV 3`*.;U[&J2T``&C`?P;)CSC`'5\;L%[W@1X%V2&
ML#\C?.,N>9DS.1@^7S@ !S!$B4!#`\`PJWO
M10NDZ&W$@1;<9<02XT\:MCPW@%]\*D08'@1I1W`VI_XWH'#H,]=^+.*U[:`Z
M4-5S;Y.N^::L2-9)5MK*3\76MRIR[8&$#U5"UW^*SAC#XL%*!9$3)N)2C@K`
MPB*T!NZ(^;;B.E%#_##E+OR" JUDD8:FV?KP
M"00"7H]X,,-6SN,N!5/[WIR,$4XX]("PJ*RN$U'_(U#!^FQL/+'BJF2CYYGKW
M8-'Y=_@B?97.<8'WK`P4,J>5MK.#(OZ$X=:)()=FO!7TA"9^ZH%%O1>&5S`E
M%PH)OCR*#13(QGR.3%.TYIG\O&_&\NR.FTC!5!2\SJ)KG??\"VY^G"9V _OR=W/,!*((_Z]3E7?HO9G:$@B@M$\7>:
MOC$UITEW?;=;M]HS6:(NW?C9OR171I'N#
MD!L$.H_VK1E5M,!ZN@>$,?M&RS2-SC:OP&C>DBNB&17$F'G-:&K,J*=[N)AQ
MT&X;_4%/+[AR>E%QQ-C1B%%/]W`1(VA%0(RMOD:,ZFE&!1%C,2H9E]&5U^Z9
M<2!R[SI315NKIWM(6+(#6K._MPU*%1=
M7C,?DXC&(CDP_G"2)4;F=W4T$M73/6`DVC?[1L< KHOO,Y*)=3YUFQUC5X[/A&KEU JN,"*Z,@&H\BN1I%ZN@>"(@?&H&T:
M[4%+XTCU=.1N<>2)%XCCK-RU(XN) []?%:IH7O5T
M#R@(V3',0=?H:`Y74#FJ#2#E[0!X0D=Q':JB^=73;2JNZ#P T:O>[>,M!57'!%E*):YWI*@#%_D?J)S^S*JY^73_)H,*FG>YB;
MZ*8Q;+[?:UN?%,N?'/>P`,J+QHYU:NCMK?./-&7F+A>KKDPE*X8G'M,BPX)I8(@UPGGBLTIZBF=QW"?^2&`#1ZN8@KV07'
M!)=?-)E?MQ7+UC$(=0(OF8(HVS6C_JVH#+AB+LG0Q#)CY[42OVMT.BUCT.F6
M%KG(O&_YNR5&%37`L*:86`C+ %7K,G(
ML3QD\50H4@$?]2L2#"IK;B$WQZ4JC6VO9!>0RF!4H,#QDM#GELN._*2.YWI!
M7;&NRW5(Y-V`(1=%\\15@`G!2O&)UA?\O*OM $E3O3\C0;)&C?!E-X97_)KSR+XP&D1_;1^293SRPP"C"=T&^
MCB8L'*!F'LR$Z4./7BJ2&0=[ZELS"7[L].6$^;F[B*!E$)+LG2B08C.7?>>B
MJFB3`2=DC2Y\[F'5RK]8D&\.>`GK\?J,D8GO41LN
M0BF_\[.+TZ,T8-3N_5"H_U?RT4ZHPR`,?P2OLL!G2 \F5@C(`0K^#Y+B@3U2`RJL$`XMNI-8*AW0NZ34(9H+J]?
M`)TS+N(4-@>$'H*/*UI*/P&"V^[X&P4UDA7`PUF@`*!`V&9=)E
M8?C(<0C`^M0GK2IU+GP1K=JT:M.J[OVB(WIX;B[R<473W/71E#]^Y=
M5%71?"%BLDNNX0JM"'HOYS36HEN:XA&J&V\8Y[2_6+?B2H.)RSV0FJ7"0Z4H
M)8;NXB!D%A+@`;$9VASN`J\4.`P T5G);8#DP"FW$3]E%]@.>Q;"DQ?R08NPO"/ECEF%SG9E Y-C)3@;"
MH/P:`OZ8\5M$,V]QT?UWJU;S,,)`*FZ>UKHALC3]K6R8HV3+^*#82)!H,IH#
MXDT#C.LV>@401P8%@;?8TLZ#>2`QQQK&28K W/$`=V0>1>LY@+[+M+OZ\U\&IB+'
M%>J9VF"OR;86PPTI168/TT<6!R8&Q&\ND>(B0D63$<2;9G\G>\4J+_^ 7,*PUEYIGJK8TM6=GGSZBM9JQP)6Z2<4S@BJQ[C9U4S%B!E/;
MY\G!P2-*+,W4\L#/#L&O1\^BXJC#WB[Y43$;6T]7[>,(JVE0=0>!:8P&IM'O
M-^\T3V-4O_(LKK`]V-Y9P+7V0":M[HM'5#P`J:=[0$=\VVVC-VAA[8'&K7DS
MM;Z*+*ZPUM^>D=Q`ZU>=8BJ75=#H04_W,/V!SA":=/FZF65"1OQ4V"[MU
M!L;9Z:>T.*,=B2.CF$9Y9',G$JD4NCO+P0D_WD!P&,`H]H[N_
M*]:TO[!W#E?8,.S)7TA.:J>GFW6M2CW=P[BS?60,.VVCVVY@:?-F:GP5^5EA
MC;^G?8%,XRL44[FVE-5.1XA:V)FEE'
M!^)*J)@IO+\+0+=)#84W(9Y-HJI@5,OH]SI&MS]J', >7V@L#79:\Y2
M?'_>?R,W=X$>?)&4D*&W/I-'1=\&C)$++V2DWSQ8ULR@57.F>R@;%UW#[.VU
M-HQV//;.X0J;"H4V+IJ7`-Y,&]" UV],:%XM-]G1I?YS`U
M"#GH78OM[UHTRIUH#XW.U+[%T`%+8L:FYB'(A;L:/;;@ZG2MR>"?9:
MMD*P6%37Z+;T5HCBTVWH5LC>S/5C]F?_K+"]^2K)^2^>;I7>RZMO%;;)FT&/
M"D/08/YHIB%04?H5,02[=43PSE 86_.=)NXM='@
M]6UF_$E%=MY=_,E4>V S%Z$
M.3*&^PO\Z,V(O?.WPL9@3XE-F.T*'H!:ED!%'+'7G>U#(LCFUJ2GC`BMV$GH
M=;M&?^-,V7T<6]PMX\"?0;1(YHL55X[$W^_ER,4+;^,CC?!@\HY6,4I%HW;K
MEAP:4#F$?>^M1.H;O^_]5'.T/RHJN>_]8O='E4.C:HC8EG=#:B\7^J;2VF^K
MW9U6H@M"WW-ODW&\I"Y=L:7")%Y!,>C.\+@G:K,^O_9RKYWQ@ZX&O8H%$PRN
M"SZOHM!97-NU\MGG5OUL%XY6)L3/SAGD`O/IS4A?$9X$^:/'HC:]S>!)!X^C
M\TOZ(#?*XB#_^5,4'-U2NGA_'7K6MYGGP.""TS\C'CX@Y3\!
MI1T/*^W>L._A1P>>^=??__;WOQ'RS^3%$V\^YR&>%0\JGA;K"Q^^LBG(4JO]
M!_P?\WUOO+;Y1T?^_89P&Q8.2Z_:?_2[;_Y5$HI4$A8A22., KW,YI-*AJ]AAD\N3\SK@!=\)]/I=%?5
M5S DIDM?##$-(`K829]L10KII_5%3EI2O=V@0'H7>$?N^`"X"-@GAO81)
M.++U@EFA9*\)@VF;YJK.J!-X"3L&A`)E@'%"SV4)\V&?M9*B786*H@4P[>=/
M8T(7>-02U@0XT7(8!:QDB7G3A(.!`C0DD5@EF!+*6L;E(;-FKN=XMP]RPCF9
MBV P'%AVTFKU\OB@1X8Y40L490.,.C1G%
MH@L>`DK_"Y5%?KK80/S%'$8-?X@U0283O#3W(C=NHUY&,3O&J#\L,@H.IMY>
M6FUCU#*+O2";,%P'YCP [*G+P$C^F4MH?#;;0'OVF4W\"`6LW9)L
M732IHMJYN-P)3VX3(>.>Y.\`A`--)_"-S6`]O874>]D]3]A0SGBG>"-OP6,,
M`!KBF$CX@&]!I_,@4 X]:>Z%HZF7BOFET6R51\>Z28=Y[1U(GP7@KABOM
MQFWLEL:Z2:I4`2Q2+96;US$9;\U"#,%U;G7+;G,`V@?@&56`U(X/PL4M,*K@TY[6'GL8_DW)WH(`$!@8B$,&^)>@4!#+02RM\`/\
M <1[JY;;]NUS8JVWFXEY!K'T1E,I1!,GR>;[02]222Y;HKABM)(JKP`U(!7;'
MO2B`14LI(W!;$*5$\?PB?D0N `O,!;+6K!#_!Z$_"#2B(X$:&G#K`20#?,;XI+KX'YO;9
M@G([Q F^?"!%BT!Q\"^,X56YH"AG^DCL#6US/&XG$%T20`C00]0B]Q>S8V
M"#`G]"FR^)'#030F-`"3E!I]T$XP4V&6%J!I/#MV@D6D6WC#7U?-4-4=6+>ESIN+H^AI49=>B0!GOEA4E"V[E%JK`TRB4)0
MOBAH0JZBA53N@G43@8891?B?-`0@?D7S[,,$@3OO79CYY&'5G*3OGS?S]<$`$N[B2H!-SR8;0W'#BK"4!FT%D$8]IU947):,*Q'I]98;,0"&L$L/:PXXBX&H.M1W8KQT8/&X'LF`+R''F(BV;
MA+*^7WKB\9C)TBO%@0FV%0$2:0,`N`&60QACB,_2]1&PQHGF"X!'\^UJ[,K`
M?79OH/-@5$\+%+GC2)N2GU\^!`1R!B-^;)9QP_G0J_!`94`X#K_6/F]5VVH_
MLM=35(0`1H7W/D=J)1M;>6W8,^2F4!PD'QR3C^R62V A?'A@
MN!3 %MV#_TC^=9/`0;+;E.ZR;8%/S8I-%;GC!4.NM:?.RIY&1OWA^:K-
M(EQ5&F)GAI
M.T N_'>E^S12A7/M91ZQVYZVCB5#MP8Q=O^Z#DG$X\\,P]
MGZ_TWI)'L\:*[MNJC8^EUXI#130J?#R,CK@Y?!%D@XZ-V:\N3T,*01S9M[RC
M=:](@<>!QZML-04
M)!1SI)#'^/,#K:6@:6&WYYX[#O(4@&T_%!D2V>9J#F;D0LH3&H=IX7ON5_,N
MP;&`,R$;E:$3NYC6\6A6Q_;2+SJFT3-+>YX"WK6,0GZ$%']4\@<57%Z;G]EP
M\7U&,B8K;-4%FR5B;IR\6Y'8N7DZ)Z"E2ROT4#Q&1B[5*85*(J*)X(/<1IA0
M%C[(/;OX$PHX,-84CW6A3IB`>SZ^/KE$CL,DT2RP*3/>Z@T"W2GBO.>.8#L
MWK;-=V0.2ST+BNV*4Q*(JR*?O.V^*X:J0LQ1@87Y(':'8^R5>P*_?=M^ET_%
MPYC+\H.8(O#6?!?GTG&AB*E,/XJK`0FK0&6.GK=(R"&(G!]PLN67.*3KM?BV
ME/=H8/1&G8ITTQB/)2$).>9T[S1S2>4/:'5KS^E;QH_U1D)&0\,`5@D>E1)^SXE#1;*#(8;\'\__%ML68!F9"0@_LWO4
MCU*1"5B*?!6;A5A!]0P)SHL9-' HE">D%!#Z7ZIK3V#54SA4&O/GNOZ/`O,[AF
M]BKA X=G+R_(];_'7T^7)6/-]17[.#.[DWLY]C&Q30Q0;;<6
M+%%C*U=D)D^@MQIN@IA=1F(8=,+O5DL%$O+:2H6 DUU6MZ,&OZ\JM,5:*#5L;/$-RG77>LLF@_LRBK7N2&+?)SRE0?
MQB)K==V8R=5]F^T>YO:4BWR?(L)-HX->8[W&>U'6BE=0J-+?%YA!Y04!H6'H
M\TF47%&5B_+%-W8^@R]>0:V_?901V&F-C7]LAQ#UEF&I8>85=_N_;?>,WJAG
M='K#=YK[-?>KROV[J :L<
MA[QZVADYZM%]>Z2'DA6QM3AH<=#BH+0X*`(4=AM?^,1D>4`'UW;I6O9$Q&G6,
M[K-VRC2+:Q97G\6[':/?Z1GMH=FX-3]\2*!C!_MG!16GJY*V4V.^VMEI\'0U
M.VMV;K:AWJWO?CJ=BEM)IO(DD+@5CEF1+TIFO= `%;CEI1(+> HYD]*TYB
M*,XHNR?(]N*7NW6+CK1T:.G0TJ&EHS%P8[>Q`HT\FS+=%Y\D.DP_Z]GDT&Y8
M@Z>KA4$+PVL&";N-2923`1^]8&QE5B"U_QL%^'W:3'%W0N-158YK-=)=>\:Y
MK4;Y:_M/.-2"H@6E`8*R_[1%%05%$?"B(QS[9P45IWN@9[SV2`_MUC5XNEH<
MM#B\;J"PVRC'.5ZGM'15^M'RQ>H:4KY*WTOI.V5VZUZ];1V;_;W=)J/E0,N!
M,G+0;VDY6($ R5\^K"ZALW.ZMQ<
MISLT^ ]Q9>LI9KEJR.>5H5&%-W%PK[PQ@.Y]R('Z^7>
M83%>YL)3(3]*]Y-$LST8NLR]DH$,[?[;Y_ QVCV]Z&4?MV.57NAMGMG73#
MT5YUI981+2/*RTB_KV5$33RQVP!!@WT)G1.M8KSU.;(H0]>%+Z?\N_,_K!1OK6$<>E?=CJ8_)]^]F="EW_^%`5'MY0N
MWI_&B?]7S+_&M/\;]CW\Z'C6MW_]_6]__QLA_TP>_,0#R_&"R&>7TQ-OOF!N
M($X/?&4.#9E]X@5A(%KX2`-F7]&'.7/#(&V.6$`K^/"537]^Z=UW.VA
MDJL8/3&?,H-+EUQ:H8?G:DQYKJ9EB),W*&;4?2`L0,'EP8S9XGM\@IS^&?'P
M@9RYF`2'QVJN'.J2MY(<0]-L?3@]NTH_M3^\$P=ZO.F46\P'P6#SA>,],)01
MF_L,!H#?@I0&D1-B9I8XVT/M.Q[`+R3T"D/"WS@^`^TY'!1`_"X/0CQYY$UK
M5;:D:^3WOI(U3HO93M-#X;C_>TQN8*0P>S*C,`,2,G^.SX3,%8>9Y,PX7G ^IK3
M!QS"+:;8(=-X!";#%QQ5,HE F)G,6M6"]"'4 %& O1)[B
M6HKVB27&P!(.:9M&3FS$>LX\!U1=D#!%:LH7"]^[2Z#%DLHT$&( K;X=/4X:'S@QLPHGL1*GD.1T-@5>O3NBA1EB'4'(D3XC3
M'GP(BD9K$?DX2B&?\;PS^W2)AC4AY8P&3X$V2>^)UX8?8K0"KZ\`/DU$'Y K[\)$*E2G3-ZAQ-&""*@!'3EP9A!;&_QLQC[7\SW)%KP&8MU3#HI*7R(
M-+8`5[;.1J\\[/`Y=[]'\.@%'T6N!WV.\4Q;7".2VA3V'?]F\*L("4J565$E
M+]:/(LLKX9G$6!3=!6O04BSF!EQ$WQD03#*@6*3U]TMKA;2L+&9"-@3]([0*\
M*[PP!IN"*=R!7"*X1_)#8UQ**)U[$;Q4*TW:W9;1'K2V3/FVT>EWC$%WN([V
M317=YBN?L)0,ZB=JN>YLJ>-7??]9MU/,
MPZA81ODG-C6K8HJ#N<=C&U,_W+M:JZ5W=S/-!C1JWI4UAP1YM+1H:3DP:5$$L2@5Y4D1
M2YPJ*S+)[CR'AMSAX4/C8/!!(I>=78/37%V\NSMP-J#12$=K&AVMT>*BQ44Q
M<5$$NZ@9;4D.*7G[O>)2AUM>N0/9:[(#V6[)1+K#XY<=9)8TB!I:>K3T*"$]
M>[U BSGA5&9O3QX()0O&
M?'(KSO`"?EM$$X=;XH`*=3D+9!IX=K0#SV7?TWRF>994CC=A^=0*"R?6)2"4
MS?C5^4RYW'+1=GHV.VE+AL3OJX)FO7X^OH6%?G+:$"7JNG3LV7QAS
M\30:GC%W&3ZXH-PF^)4XFY]L& E
M\<8$5GR.MZ'`PN)-/\4#HWB`!R4UP-L'EHY1F.+Z`P7+RZO($[6=KQB-]/F*
MS8%*[^FH39^O:&XE\T%]J?&:#30;:#;0;"!I\3O#D`5[3M:>9H)#80*M"[9_
M9DHE,FGPJ#6%UA2:#30;:#9X"1N,[YA/;Y]S2E;SP*'P@%8%&CMJ%M&:0K.!
M9@,=<=),L!DMOB8E(#07-&GJVAIHW*AQHSHL\BILQ84HZY%1Q)MJ=GC%[*"#
M3IH'3N+\UX@ZF@]>,1^,;V]]=ON\BQI?!1=H#*DQY`'?&%RC*KE\]G%:S26O
MATM.OS/?X@'+J':%E\AHKM% G2J[QKKZ)C-UJ)$P1_,OTFX$M;2D:4G3DJ8E34N:RKRC)4U+FI8T
M+6FJ44M+VFMR^+=W]=@S'/[+*`Q"ZMKBHJ1P^1Z;?;&7OAOTE=]NV.CB$MU^
M+ZT)WR1VT'YAY:95:1I'??W5D5."XRJ`J.`7Z"4E#28.[2L:%G1LJ*Z
MK"CB)"NU*_Z+3UV\\)>[Z!-W=,A%!=G258N:5;7(;._5)];"HZKPJ.43*R4S
MK>.A%A@M,.KA?*6DI,' 5'\J_U7K,2PJ8/TNQ]6VV'AVOZ_9;>J3X8T3M8
M%UNI?876\:#;.!;1`G/X;H-24M)@[M"RHF5%RXKJLJ*(BZW43G4Q>WMO**6!
M`1L5J=$@S7M(6VB=UEY]8BT\J@J/6CZQ4C)C'O?;C6,1+3`-M39JD*.).%_+
MBI85+2L'*RN*^,1*;3N7L[=U[/XYTK6'[.U&1RSWD;VM5$SS[6"_V=N-EC9U
MJ''P;K120K//B\&TP*@J,`JX!DI)28.Y0\N*EA4M*ZK+BB)NM%);RX]D;^N]
MYH9XU2]F*H7SNVMSNO>]-;?##/#A2.]V*V,K5=J04,M-5VIOHGWNU*;W_M5-`\,^
M*E*C`5ZW@A%479Y02YH",.<01$G+BI85+2M:5K2L:%G1LG)`LJ*(VZS4)G><
M*TXG#M.;W%O>E>V`/V9[T02'IP[!5-#63R38*PF,]KMZHUH9>Z>2?.G-A#7Y
MY$-=:%H+C'KN@U)2,C@>Z(UJ+2K:MCR)-'JCND)FQ$M3SPV3MPHS^O%&3.D"
MIO05I_2C\6/`?#[]<6G8V0A^PM9$)YLZ\S^%Z+]F'_/O5,^G0/?2^4"?IE
M_/67,Z!CB[ORG_QHEZ9>FE))NZR<6PWC%!QW=O'I]`+6MW7 /:+.5P]QL9)UWQP2H";1$50D/T#OFTULFFR$V#1F94NZ3.^I$
MC'C3M!\>!-'&W73)/0W(/VHEPG%K4*3`VUK;;QWWA\7VIYZ_*3E#+Z3."L*%
M,QJ2.Q9LODA=0N=>)%8U].JE8KO5, :YN$-+NF`6KF6;3\M!E]C'K5P&"-
M%A!*AZ476>`\+!K,R,+W+,;L`%>Z5O)UAT:G-)A-Z=*IF2ZF2G3I&6:9+(\8
MZ:H/`AJ)(//$\VWF__P&T$7_]+,_$[SPSY^BX.B6TL7[3SRP'"^(
M?'8Y/?'F"^8&%$G^E3F@G.T3+PB#ZQGUV4__XV0?R;-74>3@/T9P3.G=X4'B06$@P]?V?3G-U>M]A_P?Y2M&Z]M_M&1
M?[\AW(95HU;([3_Z@S?_*@&$U*@O0O@G1M1RS4AI=0WYA4&N<8W)8SCO27@C
MX'^Q]V2(0(.TV\M?/UZ?_M^O`(_(
MZ6_P[^LZY619*`H?)H_+2@TD*\/T'76RVH'>-JI]J@"@173#(^3")A`$M&@G.\05*QX)Z]N\,. &$R7N@!RTAZA^UQ?L`"H=\3+`5X)A;^!X9CC CU1LMF42)`(OCO^>.0R8L
M!>=`ML]LXLNUZR=K=\_#&4XC,:-@/(&@9(**'5]!`B3X'&T"0@#Y2)&P!>K@
M6L&[ 35#JZ[9J_M+^\(Y$@,]CR6/^7,Q4J"N00H1K0/OPGC&WL!ZH.DMM+@M> XW*@6#SW-EEEOBG4
MW1J I;7;8
M'7-P3BZWO!!F)30!+"XH@O@K;L%+WZCC<0!.;]GQ[;&!NCYYP8`W*(A@\BY\
M`@P!G]Z)[KT)M2Q/#CE`10?`Q&:6SR3.\.&AY`/@!"^ZG9%;YK(0>F7N+33#
M1/`!6XZG#6H,E85$/HG^\NX!^$!K[+OEP.K>R,<1UH%>D"I"]INT`_U"JY.' `,8@I<4/W./Y%C[:,'Y?VE3\0;2*?5^'%"F?V6=HSI`")RP0"U8#ZV3A )Z[]!B\L)""E,+J_B(E*I!$O)]Y0,$CR;H!6$H.4!S&"S0I
M*)Q?0!P7 ]OR%YR=P#0;!'1X*!PCPF"SH-O8E
M[1[#^Z#-7`0UT#!\,9<6-+:H8?QJY$HS4J7!SESKN*#&EQ_*:W5#J`89M:C6
ME1R9K0C.^)S#6)<=M3*$*W8D3=M5K'&6WQ:_%U]!=;RLV9=?77YFN1U:K[?=
M*WJX/Y"RB3$J=#[09,WBX"/+XP[OO=4KL\0%`C@O(:O81"P3KOQDP>!7X#&+
M12'2N6(-2D\66GIKP?@3O&20W%L5!@S?."9CM%J(F:P46,6,+XCB4S>@EHP!
MSN@=&!J$)LP!UG11D!IOJ#8Q/4M;4!C8`5:!B02G`J.@U?X*.)+-L>4KGTV9
M#^!4/'B&N%RV^&0;-FAI&[9W&Q8O)A&K":Y$./-\_A>S=V+"$G\'47;: H?=]:X`C!%PM
M1_FM*Z$_
M?!TW*B*+=C*L>K?_C5YY]S\+W**,P%_CHS8I+3DH2?'$_T0N(X-D)N`Q;GUT
M7NZBU$U&*I,80,GZZ"[1KO?-_K]_BJR%G9O2MMGN,ZN
MEWNXQ*O@_L\IB'&.#`=C;YYM0\K&Z,S%:+3G/[S47QJTM:W9LZU)UW*%:5EA
M2YZ2^+R4TUS(72YL)R8CSYND9(2H@#!F*#:V;#S@*B*_WKV,HUA>$&+X 1X&,P68;POC,G(&-D]E72>S$870J8D"",FD$;,K]
M(#SBP'CR+Y!@\O;SV>?+=UG4-6X-]`]J:VF[>#:#XRVF6)\+CKA2)-`6DCU%BRA1X`C % 7O[\G=SS@XAARX9ZME1W'IUV6'MC(:K_@?@*Y0AN"*":4FKEFA+E;HO%I6>/G5-"K10:M^M>?V[,M"'Q'LIM%!
MK[%>X[THZPW/@R]184<7TE7I[S3H0XX*,8]G@.&K?26V1L14SY]JZYJ3+E
MYRP(WNR^B;
MSPE9:1'1(J)%Y'6*R#8!1\(: C+W*4,O^XZLJ@F`5
MIZN",GW.K?.JDD,+0X.GJX5!"\-K!@G["X5,N ?96RS/T3S\J.)T
M=YY(5H\BW.W& K=8^:CJ;G>+V[VNT>OO;6-"RXB6$?5EI&.8K;X6D5<>,M`@M"G3/ RLV?F`UK>A=KM1QR72;86*7051` YAAE1UJK86!BT,>R>'%H9F@02=
MA+!_5GC4@^B`Y-E>),H)J$.1;5ZG]T1"'(HO91JM?M<8C/:6KJ7%0XN'(M2I
MOHFDU3?,H8XVK``264$VLOQ.U0=!+Z7KR:TJ`U RX?]QD9CM`@8/%^5=W%26-1Z[7R->GRO8K"8UBW#(0D
MJ0K'?4(MX+)`EB<39=YPJ\UF"WB2BYIH6+8,AN!3U,#$P ID$;V?E%CN8.I.;ROMR6 U80E 1ZWJ%$DI53E+` 5Q#4U\\`@??!!5WD5U
M^(@Z.'"A%N#ESKNLSPE0; =NM&FMNNA2K`-O _`A6-%1?E"2JLB,,&18JK_2JJ >1\@!8A_F)A6&4*NRY5TJX_EM/K[:LZV@XFMZUJ
MGO7,MX;Y/: '.4G[5>G)M[PQ/%8BXDL'\P@:?#,OOBUU4S-Q6T1MN,=%6,[9F[-TSMFGT>B.CVS8;M]('8>#-_A.Y8[=1@I5UW*EE
M1?-(I@#E=[\U3-S9S0?[XI-FW7RP-RI5'D ETM) T#"'>]/+6L:4
M80\M8]LJZ][K=HUA?Z1E[)7G9^P_!*LB#%9QNBHH4[T-K2IW:&'0PJ"%H=D@
MH5$Y&?ECGB(D0MX&C)$++V2D/7BG@:7:TU6IDL6^/:LGND[=7LN`#AJWY)K#
M-8=OPN%'C5OJ@[#W.D7C<=]0BHD7D=8C(WF"(
MBM*A,`S9)5;!TZMWE[C;'AC=@3Z,HF5,R]AV9$P'6W0&QKY#
MK"H"7A6GJX(2U9O.JG*'%@8M#%H8F@T2&I6!@;=,9U=/RUNJLQP,G8)Q.%Z;
M0@11V"U[DFXU#;-EZC0.+25:2G1T8O_`0T O
M.. X\*^+\0>
MCL\3ANWOHWF7 A.]8`"I87&03!6P:
M.<3A4T:\*?%"XR71O\MAO"LM.73>"=8'E\RFL)ZU2AHF2
M^G_#NS
M/[PA%G.PJ+P%\BW>P\\+:MOQY[1]/_W+3@>3_]//_DS0RC]_BH*C6TH7[[-:
MY6-ASSYSEX?L');8OO)@Q@__^OO?_OXW0OZ9O@!RS7T4X$O_$P\67D"=R^FY
MY]Z*EV0K\M4;X):/CF=A$1&P>=_#KVSZ\YNK5OL/^#^:Q1NO;?[1D7^_(=R&
M=0.=P>T_!MTW_RI)3\KQBQ#^B5&S7#526E]#?F&0:UQE\F:OPKAW;1"$/BQ.
MP@,\^>-1!5>C1)&"M&0 =(L`Z1O+,L6>F8?RK.Y0DZNJ"MLU:.2JT*
MPY9829_=<78?",5G4=]_0$-[1YU(V$6.JD?J2OS>P6DX8AHQ,+R?,9>!4B7P
M+[!V!#2(-)F@-EUB<=^*YF`,74M\$>\_-:BP8Q,'0]HA(;"BF$MH,'(`3,!#EW6K`%SM)P(E9 ULO(!'7O!:
M"_[NPI)PW[PUA,I-`9[A&@W4'BZ7>AD\+8$[\6NW5@B::JZ3A`T1)FCU]S*5A4/#WWX?
MC2[AW3.T5]Z=+C[#L?T96(%(&K!0#F-CT6HDU=HA//-@!0ZX?'5V>.H\]S,/
M"'LWB5)3EC!2P01)L"#L>-*7%ETTM)5%^C))81PF!B8*(HM[F?D' RZ..X8`06R* +&/=K&&F,0.0@`$!SY'!&D&O@`%K>*O#G==L%B7T:POZ&3'#_XX\!X8!>H"^
MN'0M+T%9FX.F/H&F5TX`%"B_\SX M/@N\@6K"P?\08P(@\&[9W$`
M_G@H7CV%E\K'46>8)@QV@CXJV-3?`S^>M32YGW+^A;FF(=*\(XF^M=!E`;B4
M'!Q /$L\&]3GUP8:N`MX>K;$\[N4;=-.;B[
MD>\E*[['KWMW+>TS[I@MO&1\#-8&7A0N7FA4N;('#EMZB^OU0@Y["1/@81B+
M$##,)8XP&B$T:#R#F:5C-T5?;J$'%U7I%48N8G8E,3Q^\=7>YJ#NBG.=WFJ(
M'MV?+YHPDY;CIM3)ZJW"DUOKZ37N9Y"\7\3I0/,XL0W#6"ZJ%AF#G/G@'LB?
MDC^#D@LG?#:3@3X+T!PHHRD+$FT5@?BCCQ"!D@TEV&]I5_GW"'4$[WC*FTE>
MEL7FQ'QEZ`\='(S^I1%!8'TYXQ2>XCPR3P2\UI/LW&4*:]EWFXP8]FQ4/E"L"7@H*.%R3[7\572Z(4Q_$?.V_%%SM6:S JT6]T>E@:MF+UF;NDHB1BN/0'3*ER76\QXA_$M:OT`%#H880%=M-ZA2,;?
M(1#PIC)7*1_)(C-7-V?:&1B+P!-V"#CS72H%9OL]_#7[S7C_ZU>,?\+N,L5"GK]_%?ND 51H.A#N\IS@QW(V,#
MGI26^'$`?/Q?V%*0)H'?1;`!)"9Y7()R*Q=Q37&$@5$`
M*B[%,[*\#I/QAZ=X(\<2#L,T8;"M,T-PS>^+Y
MKG_W*-.#/'#@CT$DBJ%2@%.$*T*0Y6@B*)5W9=&()/8@MC!2"HP)3K!@Z=Q7
M[@*65$H5L[@I+$$YS3F$S$V&Q[&MI\;#SW&4P!$L+NS`Z/I$Z[=[+>W"TR[`
ME"$'9L5C!8_X/`*D@I9+O$#@P` /F:\>>N;8NU?B=#!W`4+AY(NOL+^U,$ =^7$H-T4@
M:O!XD,()J,ZV4!>3G5G2@
M)4F60MP&K,443$J*OK!P(BTZ`+?.QY=D4`*EQT$F\6>IE5UGL!+-M:BL8-=:
MVA @AU8Y+.2@H<4V;2M1D3(\7#=*_<96(AWQ>FL^YI/Z%XB%/)',-]6#_I*M;6F?
MD4SIIP+*PIE1NB[I85-
M+`>[?]USL-/N8ZZH3>J/C'EO=\R"74!KO7Y_A>G-U;,E%FI.]]T>1.GV]6YG
MP7'#J.`MACWR[MA5PF[SXFID)9[Z9*&8VYWO`Q0*?=?10CQC,A?E54;P!%@;
MC\R+O;[.CAK@5RYD*82_D,1>:\2:DO=X-FFQF.7X!,2]%R4DKZ_C/JI[>J.<
MO'#'7._+OKJ<3LL1=(=IA<4I%5,7:\K?'!\V!>.43C8G$'AX.)9R"BIQPIP[
M)D+A88QI2PRUIQ6_N@@C8B)`!/T8^#U)18G]J`4\_+;@*C-9GX2H&[!A4K4]
M/XNT\.9Y-IHG,"K_@`AWSG=2U'-+1UL;,RN2 ],W'TF"_:L,%_G)P.D*_<2PQ%XEH,+$SI7N]&\.CG9RWG=
M,@SFR3"&^$P\S2Q[,J\ #,#S]-:N%2! ?]W-;\VV`Q6)X"OD4^?"!N?=(LM^')%@_3(1Y[S:1YF.)4U+=L6@PW)Z%=N]*_R$:0 P$
M4%1$*J'Y.LE Y#(W!GKJQ!<5HN`P\=>[]T=&W95/)=6+>]5% 4WH_::%X@
MO$O=M-KA%LZ$79C,+XG+G,YG119:YCBR:0I-@.?/]+0&+LI.24O1!V^635'L
M18+"Y=\PTR).`Z,+(2*LXLB?!5HH0`V1^BV/NG1W\^%XD4&2/E02_$X]0/Y$
M&Q,\N0POTY>'PG@[J$\FCO!EG5'FFY(%$3*)E$O#$]U6P,/F>"0O5T*+ZNO/
MD%V,3S._>V,59=9=134`'^VT-J\@$G^&HI1XSA^[5FRS@,VL((O2K%(`HIV#
M[XW]8"J"1:C'\F CS+6(2%RI4_6] 5^Y=F`5=-A\L3VTEUM"S-RI4A+$>K
M1J*F*FE"$28Q(9G\2B$D:N1LDQJC8HN* HXZI%TK;I:`A-7^2IN=9+35 IU$W$62
M1\\=M0"^R"H=9]8C?B0^"3`QD>H"77/8%)7#K>5]`U<5F4I6_HKDP!S!K3P^
M?"'"S0(M+GU!SR "CU:'+N95Z/O=#])4LMAVO2.KHKHM*IT>A7L;3D!_
MR2(I/'\B\DCZ_,^YDR>B[]FC_-%+EJWCIUAK(+2I*,=DH/DB+;"RZO/\;`5@
M+CYCW5O1JTJR9E IEMCS;_%\I)@%
M]\"YES:!B]Y+`[\0-2A84V\=HX1-ZVC39F%)DG6.\)?QE@.#F1-
MBEVDC97E3+W&*/L7J?.EV*-(`?TA #&N2.<9 0TN#CFG(%FOK[$9_[.%#S?^TFP
M`&-8H#3N`H:^ME3L,O4I^WKMU`\QBS5B/TKXFS4CPU:H_X"^0DN2`MQ\'Q41
MZ4@T(58]8/VKJ./&I+!8VQC$&VU%=II\WLQ%M._)[,L,!3C9;:GA<8=8 4Q4X[@2M9G@I9-.ES(M&_N!'CAK+2(
M^7IIZ:G`IX#O7&9'858MA+TIK/000') 62G#29/8"[LC\#;6$4MCFB$OBYCSO_$SET6
M;I_'7C"&NZH49Z+DG09F1=HF$;(15V/B.R(DC+1-DX>>Q!Q
M$:R^O>.>."5DC=$X9@6O1D\4O/:EF1+>`9]F7Q,`G(/6DIE%QF6%3H+R?3QJ
M+V(Q2&^Y$FG/PV/M'?\9MSD6,760J[1'_+SD*B%]&LS!X^RYBJBHL#Q/9A2`
M'+"VQ;#//'F0.SZ"0VX\SMCW(P_=EGG8+?RY6-[(PUP_
MK23UDFYFVG]=[&.N;#YMDI7.8$'J?=E6L%"UMS9H)T`+YED>17NWI'I28IT$
MUMVF)]YX)',BXL5+M(77#UJ[-"O+2KX!.&A3:+/4"LR>,"=VP6EO,9+2O,B%N<>/4)Z3RYU.+L[/1Y?7\`X;J-
M0O9>N_CK].KS^<7?Q]H]#Y'$+Q)T^>ZM[ABTQ:'';>Y-JL&%@BHM;A?7HX%A
MB]@A,@,[]OR'P)H5KP';?KT[6!\L$!D99N=].#"7%INJHOFB02<138FFC:'I
MZR]\56D?2!EO(;AKKFW,7:QTJ+C N&:[$=*VX>KC%WD#"0,)`P
ME'L/]ZX!0WI+^_GI9QRKH\PM[:M`Q*6\#544F006%@8&W^0)W*K81<5KVU5<
M[C9P^M^[U8DIIU\E+U>&TU ;??TWE&_=I0FQB;&?H*Q3;W7&^I=PZP=
MI1MAX,W^AMQ1;I3@G(7A\:KS"Y:=E*7(,U/9O>T$$U E4(;LC]=
MN\==6J%K#=WL#O1.>YM0*TD)2 YU24KJ@4A4"3E4FL!0$<56JEE?
MS1551G554;S5;>(*O=S1C=Z1;AY5II=)QI1A#Y*Q_ 0,)`PD##4&R34JB8CO:-NS)@,B>1O51O\3,!2
M[>66$EBNB6>UH>O4[ >.J??,; J!
M!T4G:H5!55PN.63DD)$PD#"0,#05)-0J.I$KU!"7] E90$2\^ZSQT0/([[%]ZNS(_N\?F'#C6B*&S70VX.!/NA13T`2
M#Q(/:IFY*9#X);*`^/-?"]])A\4MPL>`!H'#@@\',(OTYEN S9^D/WDI#_]DO\QF/^8
MSOC77^+P\,ZR9L?7]H0YL .E:7@3?.OUOS&=3YD79-S3;]R+XY8J-/QQ<
MMHVO\'^\__C&-\RO'?GS@ ?+3OBSM>CPRQX
M%(W>64HHS8JT]*IYK6/H&A)$/((7&"/U0H[5MOY8BR:8WG)=_P'8\%@L&E^:
ML5C5.Q!&@>_=I=-Y;C\6Q+ZPDN)(>UF85%A7TF(4EXH+_?OLT\U_\/F\>I;J
M9%$H :@/-K%D(:O$"].7G\XN_C[5['J*X/ZMI-,OE
M=]Z'`V': MR]WJJT.:+!LU&-"6:-H:FKP]K
MJ;0/I(RW$-S-,N`JBS9"3B)R\XF\S34WS2"R(EF(_94JK-+@)UGQ(\PD'H-[
M'P?@5LQ]3\I3J;W21MU;H76JG\;4=O`Z+M#'JUXQ,2"Q*+/8J%:59:&*RB
M6"B")_:7EEJ%)R[&8VXS;1P''@ $#L3>R]W[*#@=ZFDAP%S7RY88-S9H5LXKN.QJ>SP+]G:--#0G]J+[=!
M6H]Z_Q-G$V?OP)YW]1ZY[0K:\W+=]D]LYH@'G' CR8LT"Q1@D@PD(Z!TS%PU3`#20=)A_+281K42$1-X%%N(*'&/LP.]/Z3K:-5#'A3$J)X5
M5%PN.6D4Q"#Y(/E03S[:'?VHO\WAR\;*AR)0HHH@AF7;\31VK8@YFL-F`;.Y
M%7'?(Z1)WAAY8^M2RIV^;AAT]()DA&1DG8R`A+0K`QDJ2H@B(*/<>,6:-H,Z
M3(_Z/2C3;5 !*+#;_B*=MA'JK;#
M+C0M[K1;W1XRXHH.S5J_M$;9+Y_&,5R.^A[IYDK:9EQ[^=LNI6#;873>*0W?9MAA*7VI+D"7E'\8J_
M[Z1%]X)%6SN+Q-XN/?`B'?H*'_7%#1H7B;0'A[1[5%4?V1(6IU0#Z#VM=[!!
M0]$O*P*??66#SUNTNJ4QKE5W^'\N+K>`1,UB&=GEYH?V[TP(V>MC>*ZMV$U0]2U,5S54Z
M+%/9'JPNES(&^K!GUH[DQ.'*W:*C%&.WS+:YQT8U3>'J[3%+6<1=@=(R:]T3
M-2=[[`I0/S(K`M_V=]:B1O!-Q5,8*BZW0?"MY#-&/3S*7)F9(_Y^*^"MY..E
M+1R]=F2N*WC;(W$5!F\JDED1\$:Q-T7!O8K+;1!X*S=$T=';?5/O]_=X5)$X
MG&)O%5QTU1KVJX-O]>%JBKTUC,R*P+>J8V]&JUMC9;9'U16#E`?KJ;86\/(K`AXJSKV5@!OXM$PGJ6KQ=X'
MA^+G8[DT,>`[XV>Q@?"@V&_R")1>;H,07\D!NX%N#`:UHS>Q=\T`7]G1.E#^
M1[4C ')D5P6[EQMVR/OD"O-F^=\^""/N9:U\N*T=P*B)\%9?;(`17 *:A4;@,PO4%A*-@JWH0
MKMPHW!^6R)Z:(GM:-613$=BKN-P&0;9RPQ/=MJ$/J(^6ZLNM/V0KEZW;K7Z;
MN+JA43>TT$:/(FZ*PK5R(VY?_/LLXJ8&9E,1R:NXW`9AMG+C$4.SIQO4/$OU
MY=8?LY7+UM5BMOIP=2W#;)F9'E:+VU0DLR*XK=PPVRB^B\-(HK8G\J1U:2RB
MHC^@XG(;!/K*C6@,3;W?H9Y;BB^W_IBO[#C=L&=2G*Z9-U)P!RFW0!,LR=,,T;:WQOU_]7>F12GJ]%R&X3T2C[OIYN]MEYA
M(HLX_*V`O7(9N]/J5'AC5WVXNI:ANFLVBY(RJB%UDE,4\)4;KEL`?!\SP$>N
M@-K+;1!T*_F_%;Q7>JANT*$(SAL)U=&-->KAO2I#=9V:
MXCT5W8?Y 7'TZO3K\>'%S ,/QXUM\OSH[4F7X;]V.-"5,8G3T
M_J"K=]OD02N^W)HBQ7+9N?T;W_\QNOK]#+:LS3WY+YF%&!]Q7_J"E5,M[AD^
MOG(%8I_2@9M#:Z/WX7OO[[-/-?W#>%AR`(^
M+I+?@)D`>P H^7!?\;-*;9(80IL
MSAQPG)]^ODD^2N9N=EKM'O+B`B8I?$U$G."3`^T>UG7G?3B(_%DVJ8XQI_]*
M`=MP2D:O9;QN1F;[X!E>6\$^3XNXOH*(YB8\EW9M7,MLK]N[S3>KK!W2DG?^
M$X<1'S]FO/+ 7YZ/^C:?'8DE68RQ*I)5)+^U=+)JFE;=22=OK=GEC>'=.NT`D*M7 :PR.(N \\R(^Y\/1H>_+8@99EHS2+X
MER0')=LL"97\0->ND *ZNU0$!CR&L:U@2#6+`0X=_'7Z=7G\XN_
MC[5['F+?]1>IH/W7TD1B4SS8E*#49-G18,5=\*#$T.@#Z@>S\HG9LF:^8XB:
M^3U>OE+5)E24\5=HN64?^:ELZ:ON_M:-04 -+I"3QHB1`*.B-SP'LSZ_QGXATY5
M?%:?:O,WMMS]:=*R.\ETNSV]/=QCC[7ZD5P135H9A%RO27D8QI9G,^VP:LVH
MH@6FY38(8_;UMFGJG7T>.*X?R171C`IBS+QF-`DSTG*;BQD'AJ'W!STBN')Z
M47'$V"'$2,MM+F($K0B(L=TGQ*B>9E00,1:CDLFEA;+)D9D$(BO7F2K:6EIN
MD[!D![1FO[($I8H$5T1C*H@E`^;$=I0H3":+89DV"[@MOH6E,["@D:BT2GXY
MF5=\Y;,ZA$1IN0U&HGVSKW?,/5Y]7#^"*Z)5R\6A5\QVK3#D8VY;J=Y 8A*J/.=V>[J/2,Y?T3D54E#EHL[=ZHA"572
M F( J]KZL-VMS(=J2*!%=&1-4:174*1M-R&H,B!/C!,W1BT"4>J
MIR/+Q9$G?BC.X'//B6TF3N2/85;IA5;S-B.7@7\76-/J5:&*YI66VZ`@9$ 5$]EEHLG
MS_TPU"S1F4`H0]'?26H_[FGC+%M.MK6T*T_?SH8T!8&"0C4'ACXVE0[/;[& =@
M4#3,#HYWR233 PJ$E@175DNQ'PN!:22$E31P-)RU4:8
MF[G>W:[>ZU96@:XBP151BFJ=ZUD`C-EI<7CX)&`.TV[@"_:$:<8H5:0K3O(0
MF*3E-C.);NI'1EN'%Q#)E=.DYIW:6"
MZE2ECND$*#=1&AU0&HX?W^*=Q^KM2`4YHPWW26&PNMNT4KL+>+;;)^%2[T)O
ML?4UN1)HLYM\TAN!OG_G_'CE5Y/`PLB&SWGT^,J+@(9MN@@(7E:\$J;5PTMA
M7G?;^ZIG]G8KD+P#B/\O"\4=0"?^=&9YCU*HCTQC\#[,HEE6PC=:R#%TM73[
M2B77!37NGJ"C?D.N"=J]]1F8B@0+=[.T0:6NKLU`W0>*K!Z6CRP.3.Q].#"7
MMN)+C(IFOB'^>/YS&BU7F?Q3[C@NVS/YF\;8U;GKI+G4S&CL:6E;^W[/:*UZ
M$'BE;E(Q0Z<2Z^Y3-Q4O0S;:E>;M!L\HL2Q7#6YR&%D>8DZZFI$RUV\G F_0QLX?M:-Y
M/;6^BBRNL-;?GY%\@=;'\JV9%8C2K75-30@]T'*;Z0]TCL`9J%_NOYYF047^
M5M@LE.L,C!R'XVE:RYVW1G5BAN=HX6=^Z'`W%J=M9X&/R4S?*S.+HSR\H.4V
MR6$`H]#3N]4=4%YAI?X2"1BN"!SOCM:$-JV3.WIQ_U3=TPC?JUS*VG
M-5&1XQ6V)FI6'37$E5"Q4KBZXW?[W`V%DQ!;;]&J8%1;[_ K #3!#](&3M9=P&3;NW XCJ:5E4%`"%+8N:
M28R&N!4E=;MI3H_&BC?LK:1"L%5N5^^V*16B^')KF@JIS%P_9W^J9X7]K5=)
MSG_U [[Z(4_OO MVNWG]QI6P5QQ;+91SX,8QGZ7KQQI5#\?.QG+GXPKOD2",\
MF'Z'5(Q2T:ARW9*F`94FY+WW$JFO?=Y[4W-4W2XJF?=^M?NCRJ%1-41LS]F0
MDNYLW->XI=Y$%T:![]VE\WC-O73%D0J+*-P==W[VY?0P`P9&[\?"A7,+C'AB
MN?PVX'IH>>&AN#VPR&8&3"Q_.^8SU\O-M4SA:KM@A=2D"C35Q>)FO**?G+\L
MKW/4ZO60YQ<4;^%K0OSADP.\Y9C?>1\.(G^63:IGS/EAI2!O.*5VR^SEG]A\
M1F;WX!E&7,%;"Q1 !+FCQYK8S_0'`9/NG@ _8MSM[SP-KTO-[UW]S)@8Q8$S+F.X*_7$RM@X2B.)C[>CNH4K\<=A1=>
M=BUNIW@MKG&@Q1Z7#X9BE`,@C\T!$80?#LZ^?#[XS9#6O3V_]/?IE^]LJ@LW
M^)IE3_72"BZ"Z\B*F"-N,+YD@1C@Y;O;R4WYS^M/7V ]U$=C[]A1WOECO]$W\Z];U7,G3O>2[IM)?8Y(E7[V:6"SO;+W&6KV?C
MP;9\\()9[';B"]M\5,W$)7'.9(..%^_R\'F>Z/6';7,P>(HEY%M?/[GB3AKH
MHCTWNWZW?=1K=\W7S^XB5]7UTOTSVB^P92_8P-R[=S3/Q:U\@2%[P58^,\* 02SI4?Z-HUXD[M.1R]D =`6X'K!Y-M&B"&G %43O"T`/P[Q"(]HS'/@X:5#8V(HE.CCI[T`)>GR1$1DQW/7BI//>?H+
MX8Q\M"6WN(4X2Q*2/+DX/Q]=7L-+;&`":Q:R]]K%7Z=7G\\O_C[6\)@XC/8B
MK^@5N9^J+W@O)'IZ.XZYJK2X7<23'R8\8H?(#)@(MC!RE 5]'[W=Z
MNG%DUH[FS8'[#@0)]KKUXB]GMJN$:Z*&NM54ML1.Q,[$SN_!>-=KI>=]E'6M8"%
M4,15XGPNHIXCVX+WM&&-*5#_R%)!TD'20=)1VW@1KFQ
M`D*>=5GNJT\2-=//VGH[R`VK\7))&$@8WC)(*# P$X5%5CFO5TEU[_94 +DD#B0.;QLHE!OE.,=V2DNMT@^7&ZL3I'R3OI?2/67*
M=:_>M5MFO[)N,B0')`?*R$&_37*PV3V`A5_$%BEY*>`K+^Y9?__/R(MXFOJX
MSC(?I]_%_9#.9Z#TR?QFE^6WON9JH*ZJ5P,I>0V0EMPGBBDK/GY^//PNTS
M _!CU]$F
MUCT(&6,>/!7QPRSYAH-;87+94*C.93_;[C[=_4-W_]1H<71/#-T30S1M,DWI
M,HG:+(ZNA:&[?XC(=/>/`KF/ [DUJGNONLW=+FOAC8[>'W3U
M;GM8.XXA`2$!*4%`VGJ_U]&[?1(0]:!$N6445PMM*R@[IO9R56K04ZL:RY10!.T4:Z:C=BD^51CKE-O`[&E:J
M*TE&2$:4EY%^GV1$33Q1;H"@QKX$%9"K&&]MSAGWG89DN_J146G.@L1,'08A
M,=N7F!D@9I5F/E04LR8?`]G5^8WU)T32TR7,N;0>I\R+1@]6X%QC-B4)QOQE
MN;$8?Q2&\51^5CQ_LL7ID)ZJIT,*9?:==JO;0W9><6A`,TL[-_+R:3QW8.%F
MPK2QQ0/M'HC*Y/$/>Y)T>M?NL"Y'XZ'&0E`#%J;5X%,\">+`+_BT?"(.Y1D3
MIGUT+?O;(7"3[^()%#',X2S@*!_:U'>8V]+$.\6)#_S0FC.1/*`2ATF+MO3$
M2?CLD9/]'QQY\HQ0$T^%#)XY%++TXC=]2J3;^?$YI2-_Q*$FJYBB,=6.^UAZ
M 7[!;#:AZ-HE%]LTB=:^9WAN+*!+FW%^X>PO;[,43BWM*D;S@BTT6D?URTKM09O_6-M-('&KE[C5
MKTJ\='%3!#/M+S6\!68Z_3YCHK`G1U(HRT+Z9K'+R54EM1H-TAZ2'J4D)XFE^#OHD#^)>7W6,C/O%`.A!T2
M[QB^[>/CZ@FD[V9XQ?7( /C1Q?SNP!>7:K?KT6I_A/=_5?S8A43>*YR
M?*0!`TVMX!$AL.6Z22@O*SI?IX$ROW5;Q=X<7+KV/A_'!(
MA?,OMT"]S %&PHWJL,B;L!5?XN*U]/Z8V.$-LP,%G8@'
M3GPO"BP[BBV7^.`-\\'H[BY@=]MUX'L37$`8DC!D@UO![E"5;']A(G')V^&2
MT^\LL'G(YKMVB=U!B&N(:Y[8K1L63(E%B$6>V*TS'?7T^I+1S^7',BS8J6^]A4Q5[4]/&-MZVK]:T!W7Y/A[?7CEU(>/8L
M//\FF5FW->U6O[+KP4A@5!48!?P"I:2DQMQ!LD*R0K*BNJPHXB0KE17_/;`\
MO!"!>]J6U[V_U9"+BKM1(\W;I.MH3*-2GYB$1U7A4 X5US#&,M^-S0ZG*,Y%RNU7`V.:
M[\PV>M$_D[2I8,M4DB6UW&BEA*;=,ONU8Q$2&-6,3\--2XVY@V2%9(5D1759
M4<2-5BJU_$S]->6:E1`V.DA3>5JMQ,,U_7Z;,M6-$;W&NMA*Y17:K4&W=BQ"
M`M-\MT$I*:DQ=Y"LD*R0K*@N*XJXV$IEJHO5VY6AE!H&;%3 F15L NE))[^K530W#/BKN1@V\;@4CJ'0](4F:`C"G
M":)$LD*R0K)"LD*R0K)"LM(@65'$;58JR9W4BENW+J,D]YZSLAWPQQP_OL7I
MJ;-A*FCK#3?LC01&^UU*5"MC[U22+THF/%%/?D0739/`J.FW"BOZZ48LZ0LLZ0J7])/^4\@"/OYI:=KS&?R"
MHXF7O-29_R5"_W7^:^$[R2^".,+-O?4#AP4?#F#]R93%-AP;[?:/[S7QS*%K
M/?IQ=#SFWYGS_D"SF>N&,\OFWIWX'OX^LQPG^3T;/\A^ EZ\)Q?L/-(?9'&0F_'!P]N7SP6]FK]V>;][Z*;]D ?C\DKM&'_\W7_46RUC ?$8YA/#
M,)>![\1V%!:7#?S O(^J\8O1?WTZ807T1)
M=X$";M)T>]$F09)SBO/)4&PFT5E;\DIR6^^O7U*2;8J22.K-=L[]T@:)+3[/
MFM88:?/*PLOHHM$!V!3A":TD'O/J!!
MV5RSL5/*_[3X$C)3],+?U&F24&8!5A%[^=^2[NB,*$3I]3&O/AK]D7JN9&
MX,0>QGPL4\F-O]P!%`DJQOVX_>;_&<69_:T1`58J*P+E=[$'OV.)ZBM[* P9(/)0*X*!U@KF))6R`)QE1@$44A#&!NO*0N&L]C3R&*-IK*>
MVA,!9(O!A9Y-;_[.@;_ES9`U+G^H"#48?T+*>M^>OZ0>^__FT4L8_%M>'YB\
M'E`=/%3>51T"&7$>EWZCZ6O$A,D\6,H)WOX,6;#X&JSO:,RF(O5?U#;V8?.4
M!(O`Y^%_/E,+&GRE+_[R4YBRY]=,!11XK5E\(Q)C487UW@8'5L8H1Z$G(4;9'70`;!MO*1H2WHZGV]6FR5?HXDVXC1O.%(''X#-@8V1V8JAGM?(DAE+
M09`ZQ#%<1)U`)"-:"@35R@*Q@ZSS59;QK`E"ZOP$M"$^DEAN:'HB2Z*)Y6R,
M7>(928%Q&)#Q:).NC@?-+,205,=\\]6!(`*V"UVS-W]8QJ--KCH(9"L3!SMF
M05$-X2R-_B5 X"(I
M =^:P2J;T'[R.@T7_#^>*/KA+[.MX?32
MC^,M^]KO_E*9QI:1J6,C@BU(7$?8/#89OIKM9Q]=!.GV*DCFRRC9Q/1A\_P<
MS`.^J9\_\;L?\,WFFRAMVIU0R1>_^_#X2B=\K]P/MY,G]IY1OM<7I).?P7(Y
M>?5_T(F_H/_:^/SY;,A)3!,:\\^DT239)*D?A!/ND_T\Y^R'B\F*,O_FLZ_/
M-W',H$ZBIV7PLOL`^^8KW3*P*SI9,)D_1_'$G[`G!-%B$CU/_/4ZCGYEVWW+
M[03`R8K1>DW>BQL3K>12585,0^X9JR#F%2D?Z7<68!2_KN:.=^4'=IT$%>'2
M!7GW(5]QBR^1?O1JICN9Q\$Z3[G=TQ<>24?QMGA"%AT4WYYF,S7?WFWB=928
M[=E*?$BN$8P3%Q][:9-7NGQFL_X2)&D^R9-D5VF1*PF;Z>CGWR9/FW021CRP
M6:WI\F]\EO>*Q70E]H.$/7?-?_YO;$]6[*O\86S&YX5]B-B03!725Q;T7/"B
MT)U6L-]$FY=7]K>?P8(I9!S[6_[%A#(-"]*`,?73HF:-*R!327\5;9A@^&A/
M3,]H2N-5$+*I?=J*R-Z+Z?RN8I8G+*L*R>M!KAB^\.4NHY&]XS?T9_87L]VI
M+J4NL[N8V9>4WBW]>?:ATC=WNP?;!S^K[ZJO"X O[EZKINY,M`KX(?
MS%"&BWL^>PT;;^-3![K=.R"^''K\M1.>^?H,2-)@@,J/%CYO(@^)DB(@Y05T
M4"Z@ZPO1R&8^-Y8FM@\`;$5@>X$80PO9>JO6C$A%J""]NS1J/,,F45;D^'+*
M7K,AES%7=/1@'`^*?/N\WY;^2%G\2Q_9,Q(.1T[UBJ2%J@TFWF2S3,4,44Z>
MKX0>MVLVPB%U5,/8;E,1T)K"D=Y360]:BF3&$3=)2#K/>I'@+84;
ML71$RI/.V/I\E@6FD@-![Q$ITG(-3,]`&GT-$P$FTL`L@'AO>]RA'D4>`[T=
M!!J28U/MM)KL\ONS/Q=&X]4Q+25A@=V=_< W8[IS3=\K7X'0Q9:LN%IW?;/CHQ?'-A-'A7-B(RVVV1.-G3ULH
M;/\Y-#A$64F4MZ8DR^2P&I5=\76T.T*6W/*]L6!U]IY7'=A!5SHLU(K[.0NN
M]PNEB?(@&5!PV09IN41Z=TC@DJGMBW%*H]?JWE'O9LL;NDJ\E71-?L0[>8RF
M\VQ?Y.,F"4*:)+2N[-4DX>2H]Z#EQ;,.0*ND _@6=#$PH5)+7;]OE$+WBZ3?AL!]":8CZKG-E4C%W[XO.#
M N'R,OY30(X>$7O#")C.EAU/([)O[0U#2(>CZDU(?M]PTU&B<
MYH2'YSD`RT:A@ C7@)CJITZ8D$0:@Q[
M+:M!92'9]A%EH0Y"(!A"%*TT7'%\S=44PSDN$HMBS72V^^LG@5-'"S9T/0^T
M!6=PJEHE+W61FGS25W6JFO_R]CD#^A`MFXZPJK"HW3)FRP1;[&A2&JX;&M5D
MJ?TMY#$"-(:331U[]9X#(]LF05$[0>*R-:IXYD\8K#T.E4@T)>>6;=M&*.YI
M0OUXSDO=KIA^+Z.\3T;N!3O(1^VG'(PA*C5.48P^!%25"#5['!![EN5TQ/J9
M,C/K+]EGIXM5$!8U;S]H=\'J^@!8A'C",1H-@&'P*J3KJ:V_ZW@(B)O#+?%V
M"!@5PO6,C[.U"A7I -"Q7$V(SGJSM1CYOG%6L[&L?O#5,E2[68P@8X#.\',
MXH6#\G:(4SRUZV%K7PR)%!V((W9$I)*69F>?%P7:B)A#VK_27T)>7OZU4_SK
M:?R+RSP,%OQ+S:#= %V6S%-DOU"@1<9A#;@UR7P8V?^7]SKZ$BTU>
M,MO5 1'!UZI$'P:F2J=J5L!@*J>J?P]1)8#2".^;-`>P!0RT_0Z=2QQ66D"ZR8*
MHW+$T-EY`;7SNH".1VPBYJ(:!^^+4B5!M=NZ0*[M(L?I`I*F/4)0J.D,>@$)
ML'EW`@&9.&`7-"HQJ3W1!;!MST;&:#[Y< - 1PUD&-PJN3KFN"'IC%M91R.T[ TT'Z!NW#,8M5;>`*
M*]]6H,9@I)H7@R-KMN=Y"`,T$*/:#9[F/F*@;B(T'3 ^$3E8 O@%_])
MWUI2`J>IM7`L6VQKU33@$,ADL:F76S8+->P.R+Y2/Z&OT7+Q9;6.HQ]Y\5Q;
MH6D64[ATD+=YQ$&PR6(S7D*9XVIK^)ODING'V-OP=P,I"="\-Z(9OBS;U?A1
M%A\O-SP>R,WC/^ARP0M,?;DR6RE638H0$QZ:%WFW#DA&9"++7M-JT'*)PW>A
M^C+1SF!+@Z!I#X@L"[D$&6A.N]>OI6G0]/3;2[TIJ-K "6C+TZBYO@$1`.SQB=>G-VO4T-QU'3-`\#SAB-I=(]`D\;A-IU(3G$!PD@ZV?^\`L3:RR.`=NOC6)='
MC*GKJILH,C'`(<0@M-HH)Y#RHQ-?0J-&(4,>6($8Z[-A0.YPT8*&F28\;%8K
M/^;[9]0]G5/>*O16H;VHT%[[,6(_Y[SL86TA;UA&_[7A2O^#5GN9
M"7^J3X9I>N(AK[SZ;R6-%KVC>0T4$P+OK+EXC.YI2'_>QI]^I314;$%8X!@V
M4AW7F=\]H:#X1@4UTY3)ECOZ\IVSO87^&LWS^L"JO#4Q)G0]L_[\+>0]1K7%
MB"II:ZJ9,;('*$7)LQ)":ZP;FIINM8Y)7A7U[F.6)O#5.MDGIB0)OYB5[QCX
M29`\L%6ESPS9[\Q3\`/XO%M?AXHL6Q5B8H[3LL0\N2F2@1DHMHAL570X&H-=
M30?_Z*?G9SKG!L4H4I8G`.L4QRK.1*;#V21U$(6A)=ZFHJ(P$%T\+EW-+62D,]W:'JSJR^-W.08TDVIP
M[^+H)?9+MS;S+."-O\K"X-W'Q;]/0\:/UYLPJ3WLNW"S!RXWB_RT/%]3;M*B
MJT2E9&5;_X`:"1H48P"/`((LH0!))YW^TFRRI<2@WR^PB(VP./-M\=8W7:VT
MGLM_P:P%576#;>YW"^469Y4UC^L0<3>V&ZY*?4_1<85],A-$8C83>';++P&@
M<9(50\7,CD?E\_J/0 WSBRRN:!*\A-DM
M:LD_Z.(E*T+=?V!_+F6:7OM!K+O/1)X)3=+(@P"YM:3Z8FQ\289[0PRZCP'H
MN997\WX8OASUAD_?:%P(N_+&ZY S__/#C1]OVP)"CS^CUH3061/B]P.UIH3/
MF=)UM(E;,[+/FA'#WIH1.6=\&OUH2 G=(5G66.ZY$>I@O%TK(^1FA,A1"'WSNGF99.DG,SP+XZ+=GKF'NO%,:;3
MY;7!1Z=S&=,%W34ZGG96JWT M'V"$VVV-NYKNV:5PV*KX)@KG3?LK^R(>*P*.0WE>
M3;>WRJ4,8Q/ N4_68Y375?VV
MCL)=WM(D-=YHO33'8"QL[_MB]45W+*I-%E"=T2 12G6UJ'8;".G:\3F(.!YH)M\:8HGRH?E H,`&2DA-SJ,P)P$)P>T+;#*"M1_.=^2,=]11J7]?
MX\:?[5A,'0K!*L95X$N*#Q:':WX+%S0>S#81D^(2EQ!22\$<6IG?X=!2^0:T
MZ6*1-17QE_FQH@Z$3&H!"'.L^V(98S"#4FC>.4>60Y+`0%NQ>A!>$$M7:) H@=C-$P$`=]2TN=`)L:5KD$
M9AU#.^.JS67M#O1=1N&?FS`KBN55,Y?5&\S:*SHPN"H+[TZ+=T0UH)^2T1O5
MY1&F4E:'0M`2W6[X3/SH'E_3>)6['J*MOTRWGS%_ZZR#UEUD/K^1ZPQ.3WQC J]:6B*89
M%G*AW78R1"0=J?`:M;9,-.VQNC'9`ZDXL+X738UF\36M(`&!6#R^U.K*JLIM
M@3*TTS)7!RTN@.+94BV7RLTJV0W&\WG,XGW3;2"XZS4Q(.F^T8^FZ:4D)BUK
M*;%;ITU3'LN_%&F\,(T9$'ZQ?/M2?@3==Q_2G]'%EHTR2=DS_L=?K?_^7X!8
M?]_G;=L@J'3'U%_/>"1=UFQ1E"-4U46/"DJND*UP9Q`640KOW\:/H13?'(2/
MIBTGD#NQ#(&7>2-&T\`1QDEKQ23HF9$BCT 9,R)3LX"V;E9 2!8F=D+PZ5+(+
M\J9$ZOVDT.Z1;YWEAW(O7_WXI 9*0.J+LUWD*8'*0#`%AN_FG$940(C-"!"NH:D3&>1YYV1
M$$I7>Y=7W]TZY"--+U/KI.3+4=$([X`Z'F*N&!/GC"0PQCN@:8**`;$MQSTC
M(0S_#F#-M1Z.!WM;PMK;58H+;RI7K$P7?V[RWEWM]]*PP::3\%9WQ#4N/87/
MQ@:[4D>B5_0$E:_&Z7$3%#+I5=KN+J)F=*-R5,V@05U)N]N)S#E.^W7]J=M$
M,II6DRH4X()R3YU!P)Y,`J=LNH2P295,I8G1&Q H+8G
M2\I8?QFQWZ[Y(TXC;8/")$+>N+05KL0VJ7K"+BB7J+QM"9S4KMH&A5K5FJ`W
M+O!SL*NV050O9[O?N-A/:%=M@T6&ZQU!VO5+3&'?Z>/V\)%B[W'ZTX\7Y5L+
MIIOT- 2X$6"?``:7P
M^!K$>:/8`5K+(EN3@&;+7`>[H](K&YP33;(N!^TA2USLCRZ&@6=9=^.DE1V*
M:\?NTVJ]C+:4V=GX1S"G]5^ZB;(.^'21S53R&*7^4OP[WV6ZB=(_*,,VCU["
M!O/8%'IJ^@`XL'Q)R5B(ST$TO0N#B28'[:#_/\+L78>L:7D,I/7@7UJ83F]A
M:HY">J>19>=8*0^JD\_Y*9,P[\PIY5:S/_(F*@UM>$TRGJ6FSDQNLS6-9QFD
MRM4,1.OC1^-UGF*5ED&=(PNY.77C',#WEG-> V\!"I>KH8PE([+><96R*[_ ;>#A?U0JQL\3P4!8/DMJA=K2&-:_UKKKANVD#H;.%->G-#
M8`^39FEF>3I!#N4J'8.\-K(&RE>=DR"Q4""*#]VE.ERZVD?Z!LGM?-/P!.+O
MXK`.O0CSIY^ET-&[#W?`^F,`_RS3/9(0[94]:Y=;L/DC^
M>1U3*MX$V#[,=<0PM_X60N`*&[NF2`9FH`@:'=>`@34.`U[YR:?OBE\L0L-%
MQSGP%`S*%=FF(`8&KQ"_:YT4_._1DAE97@_<3?:NZN(7P+5'H_SU0`:GH)H!
MU5VTQZ'`ST!VD'TE'M&-,1`FE3`K$4!;3'VC5*&TM:[=5KG/W&R??SXL=T5G
MEO_F2[B@O_@]V9DCBI,\0,C_K;HYU\#K8S+L$K-">MQUD5D%P`BB-8@@QEV]
MGT2NTJ;["'(U*/X==S$_6KIL?)TTJ-^%+6+\$V831Q&/04[2&5P\1_0AHRB5
M9Y"FE,N4S]Z'M)'J*+KH&>0LY2+%LY=J\1+P:PE.)%6#7"3!PTJU0GI$797V
M8W=&YRX.YJK;=D>)+>4K)%1%`MXH2JR21NM)2/ILC"LFXGC>7[[O0C$A;AO]
M'TXRYS 'P3G[G
M3-B-0CB"3%!/=8GEF`=B0BF>;A$3C/JZRR;^>Z^M`$"H`W0GY0>1O[3_[GU7M7!X/
M&A!@A\[@"G;RP\0?K2C\WH/E83 HA91$&3LHR40PM.M
M#(5=-']BJ3J9@U?+CV\-X/[1_M_%]*%;UR>S6K+FW\*U>S6Z<69C6(:I?!-D
MN\,I6%_L%2_`-Z47NR+_1-5MVS++C>N.EF*W<=YF=+/:T!J]A/L\'BV=FA30
MUHC$Z0=ILG$[UQ$)PK*`%CD;EANJ'U+<>N'TE84Y0V0T.*@(O,$*M[8"8*
MJ^]MJ9=='2!M7/-DJ)R)'[JE.N4AVIO#M!^L)'&0':7R[]0/3P1&1IR9:%1)]+IA;B-9)$4^G"EJ[523]466!F]NFJ'KFJFW'RM)1G"S
M.*V-=)!@!#GCUXY!&N0:0 [6]4OKIGBNS`H6@"O?B.@QP2!$1DI#U(B&WQP^Q-*+)H
M+$\&PZUV#*M3PG<8D$K\M&@IE.V=-P8B#P@WDJE1@M.Z0ZMW#=XQ!FVDF"3]
M8X>WWSN-)2BU^`2;[Y'`DN-03F3>V0UY,2YGNN$!J$R'MZWQAWE; %F(NP7QQ&EUK
MK<1;LOEB1X=$\G6GE7209+PXPQ3W*?O[BU&HL+W1,]G9-;7U))!K]$QVULWH:X[3>I)(LGHF._NV!^W(
M+Y4/&QF9`K?D[>S_)3M`,D4Z]!U)-S0YHB'06N\8B"%!-`0:Y ZA@L[VG-(:6%?L/!\#L;.8) Y"7%,34)Z_M1[`S(W8(/998WK@/I"6HLT!XIO=MU;;JKPO+
MPCMK@#W**D>(P]HCNZ5D[ [-KL*$HP2[A#%.4:6IN=^0+A-433@#O$69)EM;D59K+QS)L-
M[%E+!9)7HK9TE\A*4%:!K)2ZR62RE>B*%%FSL&9 R-BSVWCT"DF14
M.,AI"=;;"VM?:E7_'E"6ZVGZG.K^-HJZ)+_3%PZ;#H8W([[MLR,BK5H>T0X,
MY!BIOO"U8$NPEF"DA$.DEJ`LV4BQLTSME'595DKJ^ZJ-\ V9(S7H.@`)Y-HWAQV$'8MV2+)XCM2X
MC$F'VS@:^^GU^NG4C$-B?5I2O>.I9JFFKIJE>_K%;MO!(<S-+@E
M&`[A0$@:T))57?C"3!H"LM22T^%7JKPS0HGZ`).E3L.FZ9CZ+N"0I'?"[E\:
MW%OKG5F?E;$'H*7JG:D(5UI+0T".WID*VQUN).]4!';9]5F.;S(Y`Q*.OSNV
M!%]H\F8<6/4;HF,DDV0KP`X?#-LP-<4TOP&ZR3(^['#E1'< F:6I`
MU58-D)`4/$F?O+`1"MN;!U6@FP,$-XIFV[M"0Y(WJ$Q0V#,G9!AJ5:"8VS*4
M/H2BV@9HG.-I#(O0AG?P[P!3Y0J]P83HV=_-AG>8G+D$JF%HY3&.(D!(!'Q]
M0L/D#!`P+!!T;3O`Z;5/^8'A^#R7[S/@UM/:8GD6O85#'?[N2_GIRL.7?NB&
M(Y\,"$S2)I"RXPU#TTOD96TM`4R6'(C?"S6&\1P_IN=^,HIF80HF;N+/)IO3
MD]/\7M4-S;'60;L"`ED@,V@KWI]^8V@_0;A" )VYR7,1<0W#LRA\@=_X
M$)81?C4@-2>3HEF&472.XNTN`U06=<7:,8I"6?'9VT_0,CE]S)V^HEKU4('?
MP%[.9!N3T_I;TQQ=Z>N;0D=N%L'^@NS24`L\<=%8ZC**\S:^R3`^"UQ_TL!Y
M<=IIJWI?[9>K7S8"9Q>XL!C`]G":I@,ZIBQ ]
M\HFJ*`:3L%4`)`',(B^G\A).&N74^_8`#T8T_DANW3>2>FA`8K9_.[$T1U54
M%L@U$&3!S*(RV]%9FJGWF53>&.3S&7Z([G``QV/OU@5?V 4X2U,"@>(:]:]]]]`._(;DYWE'MJXK)D9(:$!(!9U&;[0I/'-WI
M2P>\.'7?8;#O#68!F)Q^NJKM`*),0:E"(`MD!J$-MC,\V1KF&YR24!L.+B^^
MA[V/;U\@8+P*AW",@7@Q?!H`'"^401"#PQ]F\+?\R_7O\K)XP/:7$$"9_?+\
MS>W@VPNV+/9QJNPLLZ_9NK(K=,%Y%.6%Y/7E&,0A=LYC@&A.T,
MP%?"(15Z%M4YQU55,_K2@(
M.3T_SA(@)PAP\BEN4C%L K@!MW=XK*M-&&'O)91Q-LCR:)`T2;U`J"(*`
MM7K!>4UW`W"% Z;6AVV3-L
M!^!>T&5QCNT&3S1;L1U'VQ6Z90W+\V!%9\(FO./X1@WL:;G'!&MW"9"RR,[V
M@\7\GFT!O8E2W#S%8G(.HG7?LV;C+0%D47&3LG,AV.[P-+=-P_%VQ.,T?U0M
M3:FT/5ZW\Y80,JC'Z=FH;`?;UA=8G-:*NNYHYAH8.1=#FX/)HJ)P6?ZL=^H].-KR&"Z9Q( 6H^G&6;6LK5OS5S.3;;9YNJLL: 6`":#F)PV@(;2%,PR[4N9
M!%KK-J_(6@3X#0C,N1?5^XZ^6A0$P-D--BP^Z5M:7^4GY!MB2Y8:A![Y/^*D7MR`"$?6
M+*Y^==.`DVQ_;O9UQ5!+@KH)-#O`A,4EMG\&ZU()3+9%A%&(KM4`XSCB.E3+
M5X1921MYJP9$JP&/.6EBW=2,RA5]9;]FX#`8Q>D_9U?>4>$",XHF^,']2DZ=
M_N;3"$U.-[AJ#4!YJV:0L,@BG,E=`PDM@[S#H\!-$G_LC^8%O33P]%]P<7/^
M]A!EX2XM8L@S1@/P.5[#)#2G,YMJ&+JNVD4]J000]X0RBUML#SAO8+,3C&\A
M3H,O0^\A=CT\<>._BG?ODNP-+N)NMJZAXK1@,S3#*8IOFP"T*XQ83&,[.]71
M#5+1*`>E:W]$BMTN,:X\3TI8\CJX)IHF-MI<8&])L+*HS?9[>G[MTPC@XG7%
MXF)()HFYA]'-()`*-X/ 9)P6TYYEQ9G7*;6Z;D(2K>@7AKP#1N
M2=2V,.T8-Q;KV/&`;O=-2S)^-.TGX0[`XC W[1Q242AD@LZB,=?72X.:1(M%DF9;@G/J
MA"U#TU9#OA8(F9"SZ"WVCNK64)?+*T@#A/H:I3O>!N3GG(XM4]$5 W:##X(+*/4S+P`16I]_A
M3$_F+F/;E*.ELEVN:9O*(I84@D$BW"RRB_G;)C`O6%4YEFU:NK$D.H+P[`0;%B_$?/&6>.0WA/EOYX^7^K,WX`/;`5N:I6O%
M)8H``)(`9I%:S*]N`&N1@AK&3VZ8]Z0A9]\H\#TW;_L$'B.!WU1[`;G!O)0K
M(>UK@BB9Q<1SW_M/(3V0A6FN9K2]7>"/?#B``;H?@T;^3NV_^^ _>,I_8!JRYU=7PSNWC]&Z7.VTLGEX//5]9_O:TM]H-_=7_W/1;;5
MA\3_&[]'_5/3#Y&JGBI^*'7Y.9:P//UOFB[6!V6)PB?RD7P:`U&+[6K+O"N>
M^94\-/^P^+TL?Y._W5Y]NKBZOS@8W#VAP=C;\ +A=##,T8NA%.3J1N^Y6U9\^VQA\9%3`8+
M%T$9\K,[9I3F/R4''@*XIH4>.H-'9O$;^A1'LVD/0<1XBG[.^-_7-.7#\D/S
M+]4/O_20#VNESS'&Z/4Y"H*WD^@U!$"2V6/B>[Y+^CKUJCM=^Q,?8.VAZ^NS
M]5M=IUYUHYO!_=D0W \2FC"80QY9ACM]C=9S9DD*8(<>^A1%
M7NR/GM%#]$CD!9UETK9,N/J3Y>WI[K_C>#0C>G+[[,83=X1G*:'S"A[4GJRL
M]/,(X,>D=AS;A>!3HL!I*"''"7*?_^R^
M8/2(<8AP`*(9$D4Z7=;CLA' H.U5.E B)WNYF6)5/2+CKP_R:>"7A5>B1]
M=E/D!D'TFJ!Q%%-O%:((36-\H!:RH=D9T[FG^)W\$/_K+#2+?2]#/^/3I
MM(?"*"Y^0(R GM%3Y@(0#I]@&4RJ "&A8Z9&IKBK.-Z]CARI],@O]=.LGV+
M=3*+_OA6WSO(BOH\@O%L$0`4/\NA`0(Y%J)FD3B#TV7#O\*$(Q>D\#$709J#
M6K"S9HE5^P.PS/\%38M6ROX3_#I-<6:%IQ$!AP0KD\CSQSZ`%/O)7PNNY;Z>
M/ORS#PLED^@O&O/`WEECUOR9'HHQD;W,1529XV:]+#P*XH2^@I@\^]/,/>`D
MBX6RZ`(6',R>9DF*-`< %I7X.OJ"KDKUIFHZP#)"@W\!R68P0T5=@$HGD8Q#7-!K`$(DLJ$CT21
M,"VKA(>*NDH0*9#3\8PPR\/)*/8?,XDGZ7\P?* :Q";>L+"?F>>N!]P=QG^98>\O*ZAE+H&/M/SV!!D]F4
ME$_'!)QH%I,@=0)FFNYSBH8A^A [U7MM[$V/I/8>9OX,_YHF#Z
MR48Y6%)S`EK/5)2J2F>#JQ0)Y9&-`Q^@G#GB;AR^+E4H(V>:ED]R[+6D;4L$T58
M-@\=Y$@O0&5>V]=-9?CX:T20G=?:
MKT%ZC35Y^/,:5@F)B`55Q%!*,8/#&HHI9G4KF?_ACXNK3[\_%&LP0IGR#`R2
MX'@A%7D04F3J&D2OV:%O1$H#(:`@+Z7B]!314D$(?3P,I\()&26)R(GXB3HU
M7P
MEX4LY*L1G0`OG\4\_@*#4[D^M,*T.J$PH51Q)I^3`8(X3*&B;G22)]YC3(U(
MC$<1H0VI]WO,\G#@@('&J(&>$ZK+$W1.1YEN1$<>&8ZG5#*A*(T*A/Z[.'WXG7RL_+K:B@U.+
MS3X.[\XO[DX^#A\>AI_?HQ\ N+RX?5GZ?[^&8/\Z?
M/1M>7P]N[P$P 8%P7[>V[T5&WZM?2]5WQ/*3BXOOH$4I5Q
MJ%!\AL&M\P4!^D/@]P_T77)EA0$&4CQ I[Z?-O
M[^PR_W+I9/B_7U/OB)!3)>`&)^,4GQ!AP._#Z#5VIW/YF8MV!C%2%Q+66HH`
M28CJ`#Y@*K0E\A0&>T&FPG)WHM")0IZQ^6Y%X= 320@L-B/_$]CYSD]J;\+6?V"G3_HP&6]#YM-9JW@_/SJYM/Q:G8*-[H.CSJ
M*^1@XW0EV)]A,P=:=?L\V[*/C]`X%NR6N?$S_MR]7?HV3Y'V)
M0/-_+:XO\C3\H42E,3WV8@,WR\RT7$#V3Y#=&=0=4FF%&IE*S]*:I*PZ%>E4
MI%.1[U-%=AEP%**177NJ2FO"T4WR"3T4XK0+45MB5+>6B<9IR&_(YAZ.B"N/
M@4;?ZO6=?J=CG8YU.K8C'=.-?D_5FI0V?+,Z]EVF6@Z?7VUC$-Q&=-M@3`5-
MY5&0HU.&(T:W4X9.&;[G(.%PJ9"Q'_K),_;04Q1Y21 2R3&$^[UX
M/F+^=N+ ]ML6H:/=,ZV,5$IR.=CK1?1_2>IEB=BGSG*8,N"#T6=+_-5&JKKEN/6#HZ
M9>B4H5.&[R9(V&\JHGRO$+NO:.*F./;=H,M"M!S=(\W#[O /ZG6)^;7"BEL%.JXE"DF?VB[F:TGNM-UWL&W)G>[WYM;0])ZN*YV.
M=#K2Z>.NBBT6-!]]M,J7:EVITR=,IP">('30/"^:T7$"[:'(+MOI;4B(;^4LI?44R^C9SL'*M3KUZ-2C)=19W8E$
ML7I:O\LVK`DD?J53;\H+;3EN9S'&K[S]SD;_5I' D4/#)$+_;F(PK]&+FC
M?\_\))N51V 6+X"3U)__/
MWK $'#7*63,$G'H^I:\(K+R/JLG9Z#&ALDCAQ#)-WKL>K@FV3
MRF:Y&TBWE,%M*O]+-T16Q]Z!@ZHE?(Z4"WV$,W,O$?14K)..E1,?I-6W'=8U
M]UC]1.CKA&+#S`@[5MNN&;%NU:QY>CBR?8M,##_$CI@^=9*NG2BD$]\#H66M
M2['/M8%MBXGI&/:8GTH%K6%1['H:\,&>4&>XK)]OW/8=1U6P">18^P0*QZ1N@`V*` &_B
MP9-/^5_'F-6$:P9=`UL%V[9)C9+-M-BG$=0I5:#/*!B
MC/NBFL;$#@W'_B\L!U\6'*802]Y5.MM!VGO!YLBLQ?W+R#9'Q`[)R&"MGITH
M`.4=TYM/&;^58*-VOP1+)LH"Q:F*S`@@PU+]-VUSBY`D%N6$692D-6UL4N(6
MZ:Q!?&B$$5L)QQ[2I-DJY^!IPAR@>:@!6.0[L>?@#5^\^;>&QMAV&`=Q&H`4
MX`K`8%I3[<>-7K4>.4[M49`9,F/TF+53\#+["1`$/CC33PURF[2=1E1@0M;P
MFK6>=>D+$(TM/VN&B](7\%ZTB?`UBN[-'[@N4GL,E!E'XSP?X4#FR/"?N'3&
M8S;(U6:",;=N.2?@I,`)(`Y(13SQ3&I3TL849S]RDV\98>PA4"[4C-3AR&=-
MR+6FWL[Q'H@F+!4Z%3%;!8$7.RA,LS#)92V4,[(;:RD01-X&F(E8PH!+Q0P$
MX1G+WX`P%L5[ M_L@D.NS4?O@#'+IX[WFFIV`A>GDN]`ZO?KD7;N]KW9X.T!N
M6^U;J\&W`OPV:<8JUU2NZ]L-T^4BB['(6VV%
M+O0B[ZR4:H$*.]H++]+@"\G"+;?!V1+NHI:;;GFIZU9N*BHY]E1C*(5!B-67
MPB"%032'8>Z,N+Y04%=.KNT=VBIR(FYY,C^WP3\OMB%Q%+]45$MPZ]S/>&
M>M$I5:75;"OMWA8KJR5C2\;>/6-K2KO=5UJJ5KN5/@@#KW76Y([=9@FN:!!\
M+BI`,$PS&D>\!"B[^RW=Q)U==;$O/JG751=[HU+A^1.MU57TYA;[DTLI$67]
MI91L+"5-M:6T6U)*ZN&1B))RV.L&AHA>[%XU:ZUOU!!%\0IU#X>NJ.V>HO7V
MII>EC`G#'E+&MB-C*O@]+:77Z4L9^^#U&?M/P8KH!HN(K@C*5&Y#B\H=4ABD
M,$AAJ+>34*N:C.PQ3Y82(<3:"RE1NY^D8RDVNB*U+MEW9+5FZ-1J-Q68
MH'9++CE< *542'5T1T15"B !!!\FSO.@1YQ>'(MML
MO[`F(0XEC.HJS6Y7Z;;EG8!2/*1XR"LSUW4D?@H-6/S9Q^P[0\\-$\+D4/[Q
M@>%\#3C?( '/R[@Q4!D`^-@67B3@4^OS@=WGV%Q1WFZSDWQ99Y@
M;*4NK\_.KX$NS4;;!LI_&]S]>@FT:]HN_R2CSQ$O@7:"*B+`/,C=X
M$/HZ87LX/G7@"_>)A!X)1Y08C]XS)?9\:U>VSX._3ZGA!X2Z%K5(TK*=Z*I"
ML,DSNU,=&P'C;2&1B]>&P+#_J))-M$Y;T7JM/+?@M)7.HK941>NHN5D4H%4P
MH69H/U-GVJC?^M>9=\\BGS%IS(%+&%!7V!.GWGABN%-BCH")D0?A.QJ`"F87
MV40!'48.<>PA)=Z0>"[[#SXSX8T!AL;8=FP:-,@#?,D'(99M@68/R"=8'E\PU8
M3Z-(&29*SJ6OP`8@Y[&ZLP-B3":^]\K& %8G 2&LL=V[A9Z. <2
MT_;-:`S&RS79%W%=3S@R0C;AR`Y"SX `/L;3A.SS(=[G";*/'$$AE$8^91$`&1@QNXF7E9K
M&L&(#!T/:(2*W8S=4/#>(@?4.@1@LV$5P-%T(@O'9`1!&P'C3;S`1M/0()?#
M.?]AA6D-^-T!E)!N[I*%RH``S]@SYG.\@%D6/1Q2G\+R
M`$G#%TK=V4B ]ECO_
MP$GH@TF;(6W&A[$9KNF-*7DP7NF*!F*EQ25KF0/3>W+M_P(*%@75X*.V,UX3
M=8]R[]A !2_ERH;'!I^^W4PN(6Y)VAIW">%
M?8=C>Q/0WR$W/0$?QL3RT)`KI!-XYL7P+0BN1.;@.DO?6[!?NK"P3Z,P,4(Q
M(^6,!S?SS`+'-\!B,(16+K^^E*\P#A,!$_FA8;NIX09#D]C*$-B(QUKY"'T$
MM@ WG
M;3XL8STL8:8AM8!G'+8$+"W"ULNGP!IN<6+QGD[">/V:;/U4Y(&%;`_SL\P(
M6,`-D3LFJ)\\8D2H;L`_HWQDG#,**6,,QQ[;(>.O7%XF_8N[1#@NN$0P'G,,
MV8!+64OZ.Q]4XX*&LI_ $8GAA\FZ0;P(&.K!\!?L"PRCZ91#\4I:*[77NQPE.Q$
MH+9#&N2(AFJ5#&V'6JENC1&.U=FB=N7A>!`]_AL'C8 GL6F]H)2CUALP-)-)SP#] (N^CUJ/;:'%SAS7ULD,=#QQO"F-S9F'8A\DVIE&K"IQS`I?QR%7]-@L%-,!$+X\ZOO19,&X?3D
M\.=@3?:-LMDZ3&`R4??I?R([`)-$8.6>T13$:I@/A*_'.44V\<3W'I/$)[//
MP`#,`I@CFSZC_AB#3H>PS(TQ?L;7W::S`PYA,=E'=4TOG2&\V6FVL0RR`GF@;
MYHJ8!V^.P&2Q[,TCEM=`*(+AAP\>-!@WYA*0]@ESGI_0P+IC7AC!'TF3TW
ME^32!;?"9?89./,XD0*M^05^33^I7SZEF //$/PIS0\F^=%%B7`6!GP"SG6QRT^4$;V8\2*E=(L5I%4
MCPW_NS(3BT6I:`!.F7BO)%HU9CX1^C& "&LIY_7DG80HX8,M\5ZGE9K267-FP$@&8`6
M>G')Q)@FP6BU876WK\`\> \IC[T7!88B,843`*L(IO!M-EO)%A"8MBC8._N%N]-&B7"GYW"CZN*`M8
MKHH7M:&YI^;(]1SO: 8(//16%X^&R*B$8GM063@
M9A$P)LM>V6[VE2>?QF69RW.0F4"+.O'PLVS8DO'P>QS%MQB+,SLPN#\EG6:[
M06Y<=)*%7<7# 9 TGVFYVAX`1G.?$9#=,Y,[`F!C36::LFA[.[$66TXOS)F('5JC,2(7@,F"G,$CV]P6%^HAB.3,L
MR=/LQC+/]M/U,GFB#J&!5Q:&`0A9F%@$(A,B]FLZ-L8.R>II>EQ^,+N\7=52
M7W#LH;=/@9E17#'^CH(`H/C4(+>1'T2&FS(QKGB0T,I97"SD^QP8!?8%:>:C^M?6"SDB1C>1`]Z"[:V02YPF9)O
MF2L++^7BHE8!P9(`L9"%F(N*!
M+ZF+6!OJ<11[1XQW6!;:F#F;VXH[.IV")>1AG!'PM;2S4L/TW0)B(\/"JP:?
M;;#3SC13D #BX#-X\ID5..Z[$,;R``E,.%HI2""Y\'#$!0YTVXA:3Y3EM(,(]_4P9YZ<
M.U!8/A`S^BQ[1R&`B:OCS"GQ[>#[7,Q+>:TENL_@Y,5G1V8G&.=FGFW7VK$_
ME'V`Y2UGA&2G2GC$3(;4"#FLJ/#Q+(,]Q#,?!'6#Q4X8S%[DNYD9_)?`@T/A
MG''Z&$&V9IEG.@MIB7D%&_>'F"V 11V>)44<>300;^L$N '[F-83:-Q#05PYT]
MO/,RHJSP9X$S@Y$7@9V+SQ\E9C);V@XDQ*WZG4N%!DD=*T*#_G3R,2T62!!DOX>XJW;")#^@8>C0
M;"!;S/'FC`R`+.:9D$^1#U^H\XP+[H:C-,3(@X?\^1%J`988J?<8W/Q(TOX6
M5:=F\C)GF;S,287F^&Y9\B*[$J9>JO1F";_)P5F*-Z+!R)E>I1
MD#6;IP5ODP>6@Q/+:EQ?DA;`\.FYPV`GQX\HA.>\P@9\(?LDF7+ULV!U
MJW"KJ;RCF-N\H)_OS[%R3!9\#6;5F57*?W$PQQQ5,P?,3W$XEL!3L%7)$^$I
MF$S:\)RFDA1*A>D]`%R\V&$+%"V6Q7;L[YB.9^?=T3UE:3A6@F^`I/LHA8E/
M/%5X*)7-V;)M!NZ?QQG2)+JP2R[6P;/Y,)FR.!0F94%%47;4-;VK9T:4-$#E
M%+&3Z!3O+#`@5/Y8WJY4!/6H;OTM8#6>YVF<7:4R89'WQ,=326G8721U[)80
MSQUZ_IA%_Z@\LM7G/OC.]@0K-D&RL#K48=45N'.1ICU^L0S&(P]RA6%N'2=_@L&"LG470A_9+]F2)PXF-+<=TJ+YK);!`OIA\&
MK-HEOMLDB(-\OBV1^$:H!E,BR0S\(2O,6E[.<8'IT=^3:W$N4I&YG"7Q*L[+
M\X-+\]3(K]E (Q[R8E#8+@2B7,W;[)8NG^)N#,&+M)X\GQ7]8`$R
MNCVCU+-704PFQFHQ?=H,NDBMH'$)(65/-HTR!R7B)^.CYNR '!#C&5`0Z">?8CS)E2[?.N*WLU6Z$EJ^6.8'[FVF5\KA
M!;3_!EV"6C[Q)[-WZK!H/M92N&N,A8"LH!4WU1AN0]!L[(Z!Y+CJ[&(?=I53
MJOLGGF.;,;6Y]D4*41DA2X=O"_'QW#WY"ONLL+$KARH'5"9%=POT\O`ZJT7?
ML]*(^](EWXQI7,:'HG4QN/^:',L>W/_&?CEI]A62"89S)S]/XP,/<=GZ:7)Z
M,O-\FK^+0+[!EV#4-7P,RAT\N&FS@][IX1T_ ?CS ,C\GPG+G/4-7 1@XK
M?J2$W6O`=BY".D% GY6DQ$N?Y$;PW&ZF8B3,H>?RK#@L!^`V
MGT69)J/
M#`LG!GBRO)8Y(C"76>*/`YS' GQ=L'
M"3&36^T9'3/UP PI ^;$,:9>%'X>VJ_4^G($>M]Q`M"`H.O8
M>_AY@MJ5?T[']]._K%0BLG_ZLS^3!DK__"D*3IX,8_+YQG\RW/A6U%F)/7P8
MN-8M'AQS>3G#S3!-.\Z*[\]2M0Y/W\\BNYD;>QO';0_T-?SJ0/#ZR]__]O>_
M$?+/UU?;_@S$Q[OHV,U&YZ^\6/4;JWB%D1V3C9R^R38_X,,='?Y\=-M4_X+_
MH\I_\%3M+YW_?41L"S0-VDGKKX[:/_IECAG2&`44>#-I!\87G,PQA,*_4,@]
M*B9R5"5O!6!1/Y,>QDU$51L0+54Z?&DD]KAJ['5]\W!.M$8FWT*N_[P_)]_^
MYX& M#8"L`WF`,5%P&GBTIC$ 0__W?R\N5XX:(!.!\\_>^.W^[`B\7Q,"/R=`O'[I:MV>WM-GAB*9
M:4T(2M2SII9"T-9Z_;[Z-@!XG.QFF&0DUJ>#5@I%JZ-VNADH -Z:X,%XY;?_;K`\[5(P3E1-:VJM
M6)3F9ML`DC*"=-XB2!D,%K4_GWDFV[Y\F$XV69#NT2]J\^1__OG3_%C9.0;P
MI84_7#C&TP:3](Y^&0)*E,^2&ZT(E5N6NSAWK3.VB[OV=."AL;!=U4YT-8]9
M;NBBN2_`^S2[G`Q[XVQAL07-T^-P'.I=8FY `_&5X4\O;`=3TNO/W9F?>V[(
M@B7G%+I+\I88!F[$^:#'_J1!;LD+AUX$@8%VRBL8-N$Y4&[WH+!A$)+.E;BR
M67AR\RR"< ^A/\YER@Q4L._/JF7?*SHX$-YE3$(O8:W\U6SAE>V[*
MK*_'CU-D"7!Y?7'T2Z>EZ^UF2\MQ1LGL\R[//3:4PZTB=(P"=0.ZE+N"X!+I
M6L;OF9MO`1P$F@FPQ:_2X(J=U9B=IH=2;H;\[Q#;'-_/J@K6=I1:Y .[_=A4W]B.3Q3@Y&DBBA>)H""#TG3#8/!J!W/46=F;K1EU,@*R
M*6G*/6QTKFM*FT&Z$W5KV-:E>VI,[-!P-J53N?]_4F-"W5%^J^"YX>/V:K`I
MA;HB"1FW%R+IH-[;-O!M&JV(UAZ(5($JZK]-(:W5['2UK=$I^P(;>S&J9NER?Q]HG?^_FQ_49N4-LC=M4:MW:Y]WBR
M5U0K,D_ME7W`=V+(5 .,\OH0[0"ABEBVMU).74P*
M5,#+)3DAW`'K"8U_M1:H4^XH,9GH]OI"4Z0B0]5YTZ?:(@VX9MRW8NAH*\5*
MFR*R$T*\7S]T]+>IT.XU6WKG#4VQ"BT26WEFXS7;KA5D T;O-MS-2.JK;U==!CJO^.YF\LO1G.;@6]2DZ+
M/W@ 8ZHN26L$^9(RXUF
MM=COJ)CNZK)B^MWWL"Y4J,Z=R'P_N$=;*E26X\IQ=W_01AS17E_0MW,VG9^\
M:#;(";F\/KWY=DX>!O][?E^F642\3*3.]Q6L 0/-FL=;K/VA-[\046[(ZUT'CEC:W8!;7'C]2E0SO\E.MC$BQK9,(.L&H[
MZ2,IUWXG@L]O/RQFAQG'\&@EL(,P6#C&_KF&Y-P=*Y`\\`CZ'Y=G#__"GYL_
MS$#FQX7F/>`$.?R'XQV_W,?C0U]O[L[.[TY.;ZZN!K?W,*,):V),`OJ%W/Q^
M?G=Q=?/'9X(K"T.O=*Z(0^(G8/SK_/+7?Z'GK4U>,[];R>\,M3JX2J:"
M10B] ;KZE$!-U\DK8$=V8D]]-D0HH`"1`5@?XW9^/M`5R:$FK
M9[G(![W(^H==Y/APIU37XB-7A23O&;=8:3S NPV\666H].N*T%UO\^,#!#+K$61[CL!NPY^]Z4TI'5(Z
M-O`JI'0 "'VC.8)?.ECBHWNN_?O=IV8&,2B:0EI5P<
MNESL/.D@Y>*PO8?=YA_VKS-$="1%1%?NE RO1$]%E$Q'=FBJVW6Z&UGA])3M+=CZ@]:VIG:[5)O^>2_1$].%$1+>FJFZW
M( [-1NP3^F+=]M'+[7@CT1O;R]
MEB2)'=:(4K"WVV`("*3H:E_*B)21&I7M[5A&>AVEM=&U-P ;&>#%
M>U: V2YX-)V)-`XB!M[QBRW'I6LKP2Z8HENC0U,F04B*E
M9)=2(@9%BOSNU*W8F]\MHDP(XE?(,P'[9X4WM8$.VL#RHD><7QR*;"%*6_46
MES7IM/T+"_82K\D3VE*(1!2B6B=!I%`M<5)^8HU)L@.]LR-*VL^F)AW)BL?-
M?:BJ,P\;.&E&4Q'XM6Z> 1K8Y(B]>Y%CDD1+Z
M.J%F2.%O(X!_8P)N,G&FV,L+FRX%H1%&H>=/R9"7`!/?"%F'KXE/3W`"PS2]
MR`WQ!<F0/9IDGV:Q+I37S;^J#1-)!3V!>C+ODRR+]-A+[+LRU0;
MY#YXSYZZXR[75:*^S3.TA\'2'W*WZ;XP1I;YO9H4?ZYEMH[U5F-_&\P[/4CY
MPX?`\K`YN+`^67*P2+9JMQ67MQ0`=,'7('9(Q\&^V$#$2IG:W2^\EN%J-O9V
M&ESLRK@/C.[!G$5LU*\,5@9AU1JV,^K;ST9H/U/BV,:C[=CAM'9.S@%9M]V&
M9;W&WDXBUR=:^6#H"EQ(MI9UT]N-MEQMX TZH`/Y$*G45<1D%LUQXZQ+)BU+1>
M50'00N(-TQVSN'RU=GZ.2")?JXA-;:BU6VP9L8G"VV)';$T9L`EH]':[T?:[
MO-!D-70_P/T=1=& 6F'2(92
MP,(S80X$",[NAXFN*,R;3;0%,*QKP9K?EM
M2_)6)'DK4@[]2Q?PM:W(*Q(SC#GZ)Y0U&4ED+C]Q'ONY%D!3M
MQNJY]LEI,0U37=GY#8M4-SH(:96Z.K_`L71A=KF*K/@U'JV:4-^8
M7 D\&97+2GK=6N$Y.3:EJ]3L?_C$M^FX#]TOWF;JLD8!/`^H_RQ/C@J,KL!(4.V17NTIWHZ(7
MR=Z2O<4/W-6^TN[)J+T>-G[7EZ%YYO<3<2[R%-$A%!%=@77ASBYZV\C4]YI]
M15?[M5MPR=^B\+?8\;RJJTJKO;=SA2+RM\#&?GN^T9*;3_WP))H0^@J&WK+#
M"`)[Z19*=`\RJ-=[/475ZW?"6O*WY&^A]Z1$7&J!;?SV7*(B&W^%]76>2^A_
M(CNY@1O=Y6]/[>.N[59[T_&+J'PMZR]*0>9G['H3Q]
MIC[>XK[_8CL1W4&)[@$%.IK:VV=*LSX+_L'0/13^EH%\/2S\;G?F;\(1]:7O
M)TA/#K$W,D5I6K/;R*BCM#OUZ]HF)>20)$3P8@!%ZVM20H2[1F>W=?PRIA!.
M6;Z;`?9Y -QI(!U)L=`4^_K5IED+N'4M.KH]5W^T%!<=M36FUVI]JM[H?TVCO-M:_
ML%\AT.?7_TNO3FQT:ZKM=ENWMW:[@6"7W#HF/#_RXO'!` 0UQB(5[,GCR'LGQ5$1/ +^1=!ME4"6S#$Q+*FVMI?0Z
M^]MSD#(A94*HI,*QIFBJIJCJ_OQH$65"$-]!IA?VSPHBHBM:2%4I-?:231`'
M? +]`TPGU)@[#M\GV&T^X9J&Q,I?
M@=JC/,(/#-]KP/>.X3N'"0-J8?IMC5OQ)%_8^E]>GYU?`[6;C;8-Z_EM?K
M):Q(TW;Y/S$P;,ZAYX;)I(40YY[7'1DB=*?E'X1R)V/PXA\Z/RH\!]>WA
MCPNRP6!1=:7;;"H@.SDZDG#D>]'3B)Q1DXX?J4]T52%:4VWQHRDC.R#&V(L`
M"/CKD2*TIN'[-F`Q]/P7PX>'/#*,L&$FF5+#YV=:Z.O$]BFB#(/I*OL._M`:
MY"RB^$8(M(E GY%EN6Y\5=-IP6UBPR
MV2ALX;)^,Z_XQ8?^2WVO01Z08M HG#G46YFVF@3D\]FV8.ZGR+88>W@QO]DN?+0-!T8!
M!L6V \B3TR\@+T17C<2?L[)3690GX(TN`TR6P(RKYQSF?56D'%Y=XZ7I7O?C\/?2_1T?;FF2WWJ, 'G(5Y'\N6(F-1Q@HEA@FBS]_#SQ+"L
M^',ZOI_^9:5@9O_T9W\F0=8_?XJ"DR?#F'R^9-;MP7@]LP,3'&@PK`_T-?SJ
M>.;W7_[^M[__C9!_)L_>FR/PX!QZ,T1=Z;EX]/IFF(YPCCW?`_H5G,NA'3[@
M7.E08%G=$#[ '/1[=-]2_X/RJE!T_5_M+YWT?$MD`K&69H6W]UNJVC7^86
M+U7QDQ#^B>-\OD!D;@$5_H4"^AB4FJ4@&M;7UJ8?Z82Q:@CW7\R%?P$S-P
M,_*J8I[;
M$^3P'XYW_'(?54><23N]N;H:W-[#C":LB3$)Z!=R\_OYW<75S1^?":XL#+V2
M3GG'!HX)&H'ZFR2K:E#!(1)R5>2B7T9V2$^0&>AGUWOQC4G*3"L6=&U.D0HH
M`"1`5@?XW9^/M,6;W,&@R$4^_$76/^PBOW^_720Z2'4M-FX;U\^\(%KGI>:0#UYM2.J1TR&-*=9(.05+WNXW_'[S0ECBHUNC:Y\
MV'>VH,IK(&3L)3BZ]96+G2<=I%P PV_S#_G6&B(ZDB.C*O5*Y5WI`Z$IV
MENQB*Z;"*B6U/%MMO-T!JOKV1GR B#Z K-3NP7_F+9\
MMW'X7@OV1/3R]EJ2)'98(TK!WFZ#(2"0HJM]*2-21FI4MK=C&>EUE-9&U]X<
MK(P(DM7?;6:`%^\E5R1+AU-L=&M4I50+ )]7\H:)_.[190)0?P*>29@_ZQ0\]:0%49I>^\ Z,D-Y1TW--V[%9
M'NG=+:':LB646"VAR+/AVP#8$+0:;[3Y,K+-$7GQ(L?"WIIIJ\U'(X!_8RYQ
M,G&FV*UPUM_0\Z=IIT76EC;T8&YZPGJ[FB:VS4W;^QI!W'0JD"VG9,LIL=H#
MR!XFE6:\A,*^`'W98DJVF#KL198MIFJ#W`=O/U1WW.6Z2M2W>1SX,%CZ0VZ<
MW1?&R#)569,ZUK7,UK'>:NQOKWRG9T)_^!!8'C8'%Y9:2PX6R5;MMGCTE@*`
MN*%`[)".@WVQ@8A%/[6[*GDMP]5L[.U@N]A%?A\8W8,Y5MFH7T6O#,*J-6QG
MU+>?#=S?)HYM/-J.'4YKY^0 ]W6C+
MU1;.O&TOA"G.,6)!%J_1,;TQ%H"QBJW:^3T'9.*V2(.B8H;]:8'Z+/8'0[?:
M(V<5X"=2S;:(RRB([=I#LUM6C)K6JRH`6DB\8;IC%I>OUL[/$4GD:Q6QJ0VU
M=HLM(S91>%OLB*TI`S8!C=YN-]I^EW>SK(;N![B*I"B:4_>7L11QST+>0K)]
M`1(H4E*8U^_>X?.7R+*>\?$ 780-V%0 !9'IO`\N@LM/WL\/^:4*U=MZ3B+E
M4R*&%0)>+[7;0%,*QKP9K?G%4;6_X&G]6YF6W_"4]`J'009!0,-@X%I7<2VL
M38-W7^[4D9H>HDL7H+*MR'!8M1>_`@SWRY.>,>@,`DBPB($=L)UTO*V)
M7[P$K"JO7I)7+XEUIES>[?$&;@=_2\\N][O$#$?HGE14Q260N/W$>^M4:0
M3//&ZKGV.78Q#5-=V?D-BU0W.@AIEP3?32H^"SP+DHG!4B&?:[>/5L^S,R)N
M&XJ([D9':0X:WX-"5Z32>3'PE>PL@,5.-NNNSB]P+%V8S;HB*WZ-)\0FU#=F
MO05,P_>G)T//?S'\O;5-%[OD01QT-]&!J[9'$KQJ8R/KWE*ZW;;2UNMW3Y=D
M[#TSMMA5%YK243M*1ZO?@9>/:>;EQ5TB,8J(Z(H4WNRJ26B]+K^0G%Q[3A;[
MC+NF*EVM?L??!=1!-"7\'06W88
M06`OW4*)[D$&]7JOIZAZ_0Z*2_Z6_"WTGI2(2RVPC=^>2U1DXZ^POLYS"?U/
M9(=38KO/-`C'U)57LDMT#S.BU]N*WM];X\#ZK/B.RC1/:!`1U-[^TQIUF?!/QBZA\+?,I"OAX7?[>DA!R2A`A>#*!H?4U*B'#7Z.RVCE_&%,(I
MRW #.@,^N-(*\'%!Q=$73KUJBQ%\=#'/0E[]>+]P6Y:U`*0YU=
MA'K>:"`=2+'1%?CXUZ99"KEW+#FY/E9]MQ<4'+ S)X\A[)\51$3W,`N5A#HNE`7Q7(3=9AI^-YR(M1\@AN-X+WB_D70;95`ELPQ,2RIMK:7T.OO;
M 50I;]TY_]
MF5#XGS]%P M^?V7O__M[W\CY)_),*<1O.J&%Q20-!P8XAR[/P;T*W7IT`Z)Z;DAO'M'AS\?
MW3;5O^#_6E/5'SQ5^TOG?Q\1V_KYZ,(P0]OZJ]/M'I'(M?D;O]V?'8&/9=K`
M\P'B_DMSAL$;4UN">Z2F2N!LXRLVG;@3)1)S.O5T54OA;>G]?5F9P;T:F!4
M"GP9L5NEP)_HK7ZKV^M6!7Y.`JI;@78I$FJOTU);BRBL`LP6$"E;C4XY(IVF
MKO:K1:2Z12BWCFI3;7>UYB+P6X6WC-;E-O)$U_56J]/;&.#TL3L*L)G@LK`*
MC].1X3[12W?!M4EK0`9)"ETV?*^\]% **B["&\QR#V]`WZRQ
MGD0^S:*A`QH-O95!I0(8=X=VV>*UZH`V8QDZGL0>W0:KVWX+S:;:6P_-.9BV
MAU;9ZG7>1"OK8>X(+78\ VV^OA-0_4%A$K6[#>FPO6
M:^T>L6(_D6ZR '>;95Z2RE;^
M+3R+`*D 'B1]VG*R\(3@W?GPX]_\7PK3D
MQ=#4KM8N`;QP]LIAGB?WRMG^BN!-KY->@Z[EF0FUW^Z5,70Z8R6PS=%/+4\?
MJ-VNJE'QJ?>&/_+-;UKQ9%R#4"\+5*:Z69Q)4
M76VURUBC`F#W3)#Y92Y/8/2:_5*VOE6E9G.S=(,U3
MN7Q#H=/NJ*N"]/IJVY_O0\_\?AD$$;7.(A],PBVH+,]B-`[8CS<39IDAG/5-
M&XBNKN_OJ%F#&["ALW!?7E\P-;HI0&_2^%[-P:RUYN7[5NO]GIEIDI-M^[
MH9I?^7+3V=':JMHLV$E:&:K,SO^\(!H3.S0N'GA]-8QW!#4Y_E_(GN"#LCJBZ:56VZMWR[V
M,E>!8GM(S*V*5FZH>TT0G"UC\:OG62^VX\";E^EU9XEWD_^\QN*4V]NVIJOM
M8G6P&62[1'5^" L`N'+&J)20;]AG3=54M 1^\\W0MM]QM,'Z]3EFL
ML`&\F;7`TPJKTW;S8# P5PJLA9Z>762M6[K#9Y!M?J.:HKSWUZH/XXB\D:
M"U=N6S(0% U&_D4%5-;_:J0@+>8IF_!V]@@N?HTQ7=VE5B:[W $'D
MS^K>-\"F?_3+W+F#;X.[7R^O/Y/F)(1_XL,J_&P!F3M[H/`O%')/?7M(CBH\
MQO`E@R,^DUVK9+5+71M-U*AT^QA.'9/_')"3;^8W(F80CT3&8J.F=Q??-P
M3M1.@YR0N_.'R[OS;^?7#^3V:G#-3C3@Z^GQAL ,R-9%@
M7T@I>F]A-7%Z+`_C"C!7*OA3DDP\=S`\P-BX!%8VZ46$Q#??HS8#5L3
MD$.098OZY/+N%)C89%]#A';\_5-C1@6"@[*'3>^9XGB.0^AXXGA3"MB]C#PR
MIN`7@JR2L>W:XVA,J&-#E(;J=DI\RL2?*8/LL+^QJ?$M/B6?@[\)MG@V@^%3
M?AT8GN&%R8SOE#Q[#FAYPY_.CORQG8 1!@_3*D!#$-AI2UR1DTZ?H37
M=%4AJ(M96QBTDS$%.(W_42766E=I]=HYU-FLE4ZBMY1>-T]?!;@^F'"^$I+N&AH^T%(_A,9?@ACP.KB$(U5
ME5E-3\AMZBKD=E8@P@3?Q*34"BY\;_P'A##@H9R_FJPF!7YZ\HWQ^OY>ZXUB
M;$WOZ[UVO)FR$@R505WB$K7>K+M>']Y9!.N:1C"Z\6^!2>,/S#D,;.3KV&4/
M!D$0C3?:OFJM7)J])BC;P:1L&=[8T&SVFZW*L#GC[D$L+^B?7Z!?8-UR0V0\
MK1$9M\K*C31>*Y=+_+PQ\]NPYLSNU^EYUCJMQSWED;+>`BU?!OH20*K&H(QK
MWMH/;?7:[\"`27X<3M]3\`4QP9F)J]?.Q;7>/$B\XI3503A/T?)X5U/1!&\&
MY@7XRB$\]$P7MCGBB-GZPPY'RQ-4*_'TFSG836'9$BXEW-TN-ZA]K=W5JT((
MZQIP#6^&$`J,L589O`;,[M,+S[^@&Y2*=]OEEK75T5A:=;7I*P&VC-9O6M+U
MX$QTSNQ*@]E..9>-_!T&&T"L;R67LQAQKW/)Q\+]';E[.O@8?*Z$''8`\^A_.249?.;MB$>PB%>?#L,J0NAPQ"?A`"&^L^L\38Q)A/?F_@V
MP-/(0QJ6A74P1V`'81)J#CT,X@&0S_F`3-1DR@X30?P]O+1F=$0,QWYR?SY"
M!XCZE:;]2)Y&2*$_+L\>_H4_9Z_#X4'?DKN`^O2Q8U(4J.1VOO@)WLNNX/=X
MCG[[A_39TYNKJ\'M/0!F`E<8DX!^(3>_G]]=7-W\\9D\@^/ZN'!'YM*)X[N%
M%AY8*0A]QX5X?(56N/QG?EVV4:F1#U+5I"L$"<8/RPKO/\N5)'H(%6_
MV+AM?+?Q&X)=-SK(-99K+/+%U0M4V-%-I$7Z>W9Z[X2$WJ-AFAZ@80RW=T'I
MEK`7]7K_?2WV.R[EK>K&W;VA7L#GJM+6NTI;4VNWTI*Q)6.7,K;>[RG=5K=V
M*WT(/2C*2;.]OE1%IOR*!L'G#('2O^S4QL>Y]GVQBHCM2K; =7172"1417!&6Z21MD4 4=F=O&Q-21J2,B"\C
MNJ(U.U)$/GC*0#JA=4'W,%.I0FVWUI@[I#!(89#"\&& PLV?F`UK>F=KM6QR72;86"705V.[[G8CL#
MZ?,)DCL5>P]6E-SI;G=N6YJNZ'I3RHB4$2DCRV2DI?3;4D0^>NI`>J-U0? YR^W6DU
M]X&M@]!M5U?MXI7O4I8\^L#OG[JBQO!7WPN"U?L%MEOE73'U?J_;ZB:]R9;-
M]VZHYCN/E?>-5-MZMZVIJT*5T#A]\'?6",SVW#M^2^@Z]"KO!]EN=K1,1\OE
M,U8"VSS5RGL_K@U;GKKAC+K7=(V.E.WR?H^JWNJI6FM^+?.SO1.B>3J5=W!4
M6[U.K]];#:(%:E[$YY]_Q>//`]?ZP_._7[JLL^\Z 5.>4/&5JO?;A9`NV3>
M"N&>8YM3_N]W=)'L
MM+;21?+]SL3Z[0VK[E&X*@!)_\)_1T%H#Z>IRQ&$ON>L"Z 1CTT_\>4H-GU!L
MK+W0KE-7V!,)-LGKV%#4-F%@WQNS!Y`O_@151^Y#$%,89F+XX1A[*7M#`F)H
MI+U$04%B2UC\WH!A"&\)3XP($`://1SA=><3:H;8V11ID"-:&/DN%MP`"$C0
M#,(`/^)S3R=AC$&38:`VV'H$T>._<=!X")1\`]M;`Q`9VG.Z)Z2,"0N0_J.0
M/9+`YL (_^#=&M,[.@86
M!."N0)3S/S!']K&OO[KUM@#SN`(>-!OC&R1P&:
MSY(NUU^GWXQ_>_ZI8P3!X-4.YLQ<> 0MLZH:L
M_W;`>@^_QU!W1#74`>CMSZ2'!I*`GWS+LOU8*.7[\',$:N- PW
M[DS1@E%ABC9OL%F+-XKN`%A3@]Q&/MC;@)+!DT^Y33C&QQ/CH36_I+^DWZE?
M/G'#S`P]DW7#(1A@&S`:3!6YINV@<3DU7,,RR'%FN.N[T]Q`"`9*.)@3D_IH
M@\F$R3W/I`8PB1'F4!@9%IGX]-GVHL"9$H V1
MAB^4QGX1."00,7!OH(`.$]][MJVL7V%,^2#3'#B``$X:-RT/O1!HL2U'0>EU
M=05T;8XS%9R'^W;']J=J9^QTF@OSQ4X(6S/6;OX1:6-;)%XGT_$"]`#X,H3%
MU)TGJA4Q_X7U@4^=R#D28V=Y=`8C)^T1/_9XTII*NI8NH[5T/JB"2K\@$N3KC(L
M!2QRFRUUAZTT_-%5DC`*Y,29*GSUP8&WF4$(0F049(;,JB;"&8`H.Y@LRXJ6
M18$*=@=^]/1-7W5RQ5 MSX+_`NKGF90OGND%J;J//04KUK?!M@-S1=5["XM&CIF>K7JR0NT^<2).2LSZ
MQ(R)!`M2?EVD0,QHGUA^!T3#B2SF\)%9S`40,`O!Q@Z%-K163%G7*8*P<
M&PLHHHPNX1Z3?V-]D4B1S:WP"J<32^
M\Z:&$T[AZ=O8`V(OX?,77N3O!>]N^9ZIUISAO1H6ZR(.(.\'\?*-5WT]Q&'^
ME1%GF6YC",9E/XB7;^&V5T1\AL7\+B[;/`!C.+;YSDP1DFE:F3M<6<0N(;X?
M;HQG0JW,KJECM-
MW8S_,(,WAT;)U(,XTO@#HOJL8YW'%]8NNU\5K^, V5.PFJJO>ZV0*J51"91_[4F-BAX5Q1",6#BRB,?!H[
M'!DW8_62KUZYZ>]WV_T,MZPT^8(RY44-[E/Y:RL$JW.@EUOU5BMOU->"8D,<
M5HM!Y]`HM]>M]B9H+$:2ZP^P4F@YA\L;1EG=$)>%`+',WMU3S%TMM]3ZEH2_
MW%)K:JD//0=YSL;=TVMKQBPC UA59"+W*=0^
M=0S&RBM![RNH.2:NA
MD>.'##!SR7[T@+TH)*=&%-!/.-DWOY&!,P?:^7CB>+PP(4WJ*,1*MBH03\.-
M#'^:T"$N*BUZ#Q;4GD0Q$;&6)3\O"4:&XR05#)D%2#=?8UYY8J>,MK73U5.Z
M[?F])UBE+18%NAM1D$(`P+JR$(CS\&]""QY>&8U-VR'#Z#3._Q=W" );/1B]40A;N/3FS0L&RD^BT\36FJVI:W
M7ELPB][LS=4`Y3=.+T'8+;Z9IE1;F(';RPO;E)'[3`- `$9#DC\
M933!+ "#98S?>C2PC`LK`R#:3S5*KA*DZDWL153`T?),FTEZ6B"#
M>+!:FF&\OYA'6.([SCO0`
M+0RUKF8"N Q3`&D*C;K4-_!6OF1&3+:8[7QP+7BLW\%#G1YE@7D&<1Y
MYD`OA;@`-:;S9ONJBZ]>>ZZY:WS[Y9F:9@[5-3"8Q_]^9/B4B?-I1IH'OH]'
M.Q"#K]/9(W'V'<43&ULGFD@`&1)=CE
M]05+;N5BK&U@OL!=#H@3:BCV\]?YR ,:7WOKV,XQVZQ@F7=S-2ME%SZ`_=V2R7YZ72K*MZP"Q
M5>CQJ,>0@OQ9;.3LLJ4G?,Z9H3I-;R`N6+3RE)9X6&,"PW/?A?(;Z2_A4!ZD
MKM*M85N7;IP3W13]\HS9B7CXWU%^-N_\_Y=WM;UMVT#XKW@9!K1`8XND7HNN
M0(.V0X$V*9)TPSX%BDTW0AW+D^PDWJ\?CY1EO44ZR98L=_U0Q+8DWG/'EX>G
MXYT;0)ARV!1XN;NLK:ZN)O$#CG"[>AF#$USE\(M1M(Q_#V/=J0:O$U/\VP5^
M^NU*H2 HB\]2F6`FT!Y)N+^[EWNPH_
MB0W('/;"PE+SY)7P^=R]SY,76R-"/]K?&2:W)V"'5YK[U(K2J%`:ZTAI\B7(
MQ?0O%YZVO`@N(;KW8K4,EZXZZEVVC8K\=>"JRP[BBZF88\7]T8/%?:E(@_=<
M7B_T &&**M8E@'HG=9!6>0^&_?O1KX]>K\9L&LTWG".##F[_:
M"C`06T7-I*9I]%\#$*146P$F8@0XU#D*_`)I;?P6H@-8Q++Z#__*>ZJ-'D$Q
M3 `3C
M K[*EP"]!8&/(+N.=1DAR*[:.Q-1CN"Z3F4ZOJ!L$/R(7X-K^#N
M.'G7N'LCZ!RA1MJC?SB<9XUQ(F@;49F'>X"3-H:)X&?]@ ZV)X-J5;)T*N`]DI;#:9W
M2M#:0G2CX])6$\&)?)'HJLV/50,2^.UH6/0GTA7#:8JAJ7P0E>:
MV7]=[<&8U2][NJ75AI[UQB6=XNN8K'^K_5[
M\<4Q++G>JU)4-B0X>#9;QT=1(&Z]SND!'M_9-!3>9A6IZ&S+B',W%4A;?!8;
M3C?6/GUM,QMBM"#R+_^T?%T?E4DQ"KY7U26*JPY0675`7)N?[:&$-!\1]3+ 1!PK>$^/0\!JX
MM764*ZT7\!JXH764ZZL?Z)JXC764SPJ+[]R?;_)7GW$7A'LW>9`)('(478"-
M_0$J-]YG]]8/W*4?>!S"]]-T%5).3+ZZ8O4&+K^ISW6V3OZ21V>4 MIXY^1O3G6-)'/U`I2G,E(N/CJ7#^1_QMYE&IEF"ETLG('#0+'S*1B9]F
MZVUREW3%G7&VU:@68A!UD=!3=1E4T9E-54L/JC$FF_66*]G9H5X`9.#YKE)J
MI._B3V,>U0*9\HG8GX) MEM[8@[3_XN-<3,B07$C.HE$:H.>$^K)]&)0RX(]AYO*'31Z+;?:/Y!.@>H(;
ME9STQI#"Q`N'1YB\`S$OY*>0^'"FF,`N`GDJ,]H2\4`NB(5K&)$^`^/FZM[_
MP8./8L*<3V9KN=N>1\7$U.PYX=YG_MV=?1#&5?/CS=7J-N3_K.#HYT-F:YSY
MJ7@[G*T(7[QV&^#KAL4DZ-VV6Y`YJ^KRK,;,8([=@MSBC\UWD9 QS/CGC [$:0("_A@&D`L2(5(=4-DCB<426`%/C-+Z>G'WU_"8%"
M #T5ET#AN\_BP^!)?A7XL"6]6RX7KT>CQ\?'X=-M,!OZ
MP?<1U30V@I]' OGG\S!]'5]T%`.[7"#*%>BK)
MVV4^.#_8?#ES;_E,?GLCR,(H$CDK=`V!-[>(!NYGXO&P;^;STV]7:3'$;.FO
M@C'/R/'Q7(CQ]I.JIQA*C\/IQ)M)-\!@RJ6S.!R^&:6D>T;H=\$XU:0;C$\&
MD4>`Q-+X4:/19RA7&*M#?27NJP`>73&:"IV?;A60U>:S-H)B#3@;L>=MM"-<
MUB%7U.,N.?CP-+Z#-#L#%1,S>!%R/I!#WY2YQR>016TC4O'*_"
M4/3;ERWT5SUO0+U#`UI8`YK],*!Y\C8*;E*%CB%7LKN$?'?2*0D.5A[`1_!/
M\OF*#^Z%$ /=K93$GE%
M#55._C$9YQ-5F^_)A.7DS>MT9EY&T.8E?6%!21K$7EG4>.68=&OA%]0:LM]>
M#N[X3)9$"3@$GJU*^#NV(A,HX$$;.P'$_TJV@,=\>_Y%$R).`2`K8KX.X8B3SY
MA`,,J45:FK3@T9T!1F_Z:0D%VW$,TPZ)!T,O2Y#>HRW`="^`A51I8OA9?!#?
MOQG!([S7\+\$\!]02P,$%`````@`1C%&1K);ZT&!#P``*?0``!4`'`!X>&EI
M+3(P,30Q,C,Q7V-A;"YX;6Q55`D``Q.AU%03H=14=7@+``$$)0X```0Y`0``
M[5UM;]LX$OY^P/T'7_:SZZ0ON]NBO45>ZEZ`-#;B]/:`PV'!2+1-5":]I.0D
M>[C_?J0D*[(EOLB6HY&RGS;K /?^OW>U\PQ1R%V._=/?8N4(AN.?*^B[5\
M[^35R:N?>_*/XW?](;[KOSX^>=?[]_&/'UZ__?#NI__T_CO^^K_>Y\EMK]^[
MO[]_Y 5(R*3T?S,%Q^&`Q4^8)24_/`@R$;I^S?KLB>#?WV]FGASO$!]0D6(J/ "F-36?7J:4NH_^NOB_753_V3U_TW)Z\>A'\D;=#K?>0L
MP#=XVHL5^!`^+O&G(T$6RT`I'O\VYWCZZ>CA@1!EYK T26"TS#HYZJ\-O-Y:;>4MB3_QKQ1T7`0)49:.0'4J\]-3MG5+"`^,J!
MSE"@6)C,,0Y%!>T,==2@X3627\.CZ5DDI`F$D":81(L%XH^CZ83,*)D2#]'P
MU/-81$/91,92%X]@<8%#1`)Q4@%)#=^JF9.);(U8L2U&T]%2-73IZ+N2HZNL
M!IU+/32URKZ.GE5S0-N>(S$?!NR^#M/FZFK2_Y_#[VM!>"G'M@6^10^5=-Z0
MJEB9'V2D)AXSGRE7W[WT^ ^_/E4"-EM
M2_:O"+HC`0E);2!=OP)@Q'C&`2.'UT.!%P5QEWPET6W@Q@\AIC[VU\C5M_<9
ME^-X1GXS8-[&=P(523&^:>#T,W&X-$7B+HZ9(M&?(;0$]'7-`;K#0?R]W[8+K`W2A'KGD711%5E9M,S*Y93-\7?*-_5&
MW%M7*?\LDK<1B*8E!D+YD:JM3^3(LI:? ]SD+I(KN[%G$6\:B!4TY
MFV\@L'E)5U)%QA^OL8FUS6)M86=3ZW(6WD)@813.,1]SO$3$__RPQ%1@>TLR
M";6%(1.& 0>"K*E4M9ZD203]"("B!)6=\1"R90,$7SJ*EG!,&D5K`EK]Z
M3$V%(NQG:U"N=NE;:%ZGTPEOO#3Q#\8 V8Q,)SJ
MVZU)_8/$F,65$/5+K*U9_Z*[7*)V[9J9P5!41.;TUC
M:EGI;C%:"M&Y\Y4V&&PMRQYNM7;_O<]?:;Z)O=4B":*#SE+9/MDJOS%W+5KF&ELD24]&9D\JEI0&TA%*3%Q;&
MRI0'W,7%G;",CJ;$-.)NE`)`A=,A*/I#5YA&ID"[ZUR`,@H
M ;ATVMP;B-185QH
MC(D)"C)%XS9KF]/K!%K`BTYUP`TE'M'4NEZRU6DBIE@4`"45`MJB_NX3YR9&
M#H&E,>92X0OI40&+5UU3W8W#B5$.`&4ZERL.-$8D@/N\Y'18(!4_]1>$$A$J
M'UUA.WM6R1;Q9\4"N%N,TW04T"><64]CRU#2BK6(.S,0P!NP$QS(.F=2[:^(
M?\=*7WNK,PFUB#03#,"Y@!=XR;%'$KM2UUT!HU2+2#/B`)P1>,THVXR][.W,
M(`.`,:=E:@.$YTPO^H((56JJ7.Q?$>>(ANMS78^Z)"*S#`0";"ZUD3UDAG.0
MZ%!#1OKUSP_>'-$9OJ1^Y&%SM.XHUSI2[)`@S[G6+C6B238H45J.ILGVZXDI
M;+8!20/["_#0R9,O*J5]5&KJNC
M/$@\J>E?LZ/--W@:T;(]C?)B;6*B'($]_FNNL[RD(>;24U)`N7-]91&(DU2;
M"',"9#\P`H:_>,;O3EQ:O`.,I4CL9SD:2:(RWLU2*7U*T[EJ$WRS,S#)B/\/
M'/A#QM46AZX#WJFJ9IR_U*RVG2F34-,9W'O0N-T^3#`!+[H/(TZ)RN:6:@_)
M@_K+GC^LE^D0H0:4@)?@KS`26!TLOUPL.5LEV:,V0DU"'6+4!!/PO$QK`5OP
M81/L$+4VJ,X3KY:&*>TX_@H!BJTOM`D"B-UW.5UF@P4X1,F=X,AO^\B_`URR
M_Z-%:B"]OD^TU#WJ,T#+CM4\78#90'^K/BZMI_ZC++B2`YQ4:HPY40N*'E?Q
MR@5._FM*,:M434,;GSA4^L7W1TKRSAZ_"756*TN/./5"LHJO5SQ/;HZ0O^7O
M?=7OCNY9,8`&NXL;%'98]S0#X/X_2:RVG.+*%P)`:3WN7C*(9R`!$^8R@CCF
MJ.C%.TNR&WS`2Q#QE"NO[=.-NN=SQ&?&=&D7X \$+%IN9#0A'U)&[;
MV3:S6&?)-L,&G'FX[:!W87S?5T3#,<PV;W=>,*JCK#(`1E8A6
M4BMUR8KJQG0[VW:YSO'HB+N C>%GU!C&]#
MUY`.Y93&MOKI7<9BC![176DR=P79%T1[`;N&=Q#/@135OXCP+=M\?*L2]:7R
M+XC^4OP:%P#Q`DBI!_,(YQ\`K=KX"^(OR`'*X&OXWW/YZV!=0+H#:[\4ST'V
M!3%?P*ZA_3T$VC5&2;9D#I">YEPQ`( ?%##L 6XSI/;LMN8)S!QQ_ ?D50SC =[F=)V'5/]YTK!N`K!YSN.YL!\"&'?#>7Y1UA[A'S,P!F,0"TU],D3(-"
M$3;@,VP;HYE*.!G%:HJU]J8W@AQD7P3A&NS/>>.O!%GJ@DFBH/RG&4=EYU6J
M"'>.RRK@6])37[,0.^S=ZT4Z1[(=,N`C:#=XF HZDCM7J1SE*KAPQY+I[7
MVG[0Q$GJ13#L>,@$QDFQ?*_SE-D[YG*Z$>)Q@)+T?<>>VE1!9ZEW-8!]&@["
M"11T3NZB$,N9YY*$Q@.D-L$707H9\(.+$VT&F)?O2^X`QZ])("&
MYT96X7%3&S+`*Y2I[O%EAJ?4OY)?VH55FWS;N;7A \ILX-(>`>=`UAHXO8G6NW:MK/N!O.%O6K
M:V#RYR3S6(%[.K`"H&/--,NI9;Z3W2K9;)/+U/HG"J*D!00!NU>+6%5`E4D#
M:F`6VG0-S`@/ /AM&4/PXQ?LRCKTJA6TAMZJP`#?N5P`7'Y=^RT.-[?XER=!2E_IG4Q+;NRC[5@S(&4Q.;FC+
M.\%NQ^I+#MHN5T94KJE3SK#7\Y/`V/_"F']/@D#"V+X`I\)%0C74W2D/J83\
M("M#E:;LX8"-868S+%2N(%=Y)P197N(3V7.
M62#ME,Z8#?V*7;29OM0M6(86&[L2L=W'N=R>"6&$NV)T=HNYZVG+\N*P>-)2
M4JH[8&ZV+F)6#XH6KF:]9M1+LB8-K%6MJ!U\5D4%.LYQR/&+>,9SH2["G6?=Q0C.LYQGW#1=7V2OAC%E4OXXFD[(C!*IO4H_2*9NL;4"B:?1\Z)9+HSY /0*G^0L 8('YRO* U7A`([J,@@WZ/ZKC$0X04$RO"^7@>U]5YMHVVC4`MDS*OLX
M4-^]0P+'!OD_4$L#!!0````(`$8Q1D9F^1K),G(``)]@!P`5`!P`>'AI:2TR
M,#$T,3(S,5]D968N>&UL550)``,3H=14$Z'45'5X"P`!!"4.```$.0$``.V]
M:W/C.-(F^OU$G/]0V_NYNRQ?JNR)Z7?#UU[/NBR%[>X^$R=.*&@2DCE-D6Y>
M7/9L['\_">I&24A<2$!(J>?+3'45`.63#XC+@T3B[__C?9)\>F-Y$6?ISS_T
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M^G%>[$?^5S_V#G\\ZOWT7D0+NZ!,5"Y^IMG`R>?I/_X`[OKTZ>]YEK`'-OI4
MV_JW\N.5_?Q#$4]>$XZQ_KN7G(U^_N']/8XY(\>]P^E/_?=']EJRR3/+^=]>
M9I-)ECZ66?C'((_?@.5!$H1LPM+RAT_\-WY]N%U%#>V%\*]5_L'I^\S+?-9O
M\C-8W]'^?P1I%>0?\'='`RC"\IQ%70$8M&D!P3?XM5$0@@GPO=T$89S$Y8>!
MM4A]"Y9=9FF1)7'$O_:+(.&?S.,+8V5A8)VD#0L6_A[D>9"6U^_A2Y".V2#/
MQGDP.4^CV3\4-UG>Z($&=ANW[-+?@R`'^UY8&8=!8L/Y:PU:L/T^@)]F_=%%
M5<0I*PKPU&,UF5Y&&956D)/'8!A8 ^[/,GYC5ZP,
MXL2D;UG\39\>F!G1VP;RY6]90'P3I]"EXB"!?A;%?$KL0*9.8Q9LUIV ,6,,V_8^@M
MS_`==/R4M%ISM7+I8+=F>Y9GVD?8@-1$%_U1_Y7O;:/EQVWZQHIR]MV?1V]\S=3!
MRR:-6L!P!=O3%)9ZZ1]W6=!E"%$U9,/6BMWDV>2!)?S#@15II[%#J[7M[S@Z
M(.K\2]M'ZQRD1VP/69*,LOQ[D$?]T:S(71P\UY,4[WJW*:Q:@^2W(*GJ4=^Y
M,]I;M'WOS?[V/(0>"M8Y]PWV>U;6#I-)7`_F?-L%DS]?+;*TXU[6J-6MK(!L
MB`Y:+=N8NX,\!7\5`S;O!"_P&_#'UZJL?Q.VRD$1A^#:JSBIP#)QC183O.U?
M=N:-M(C"V&174+GZE 5%4D]?Z2[,%2/-7W*&<
MBUOG25*7Z->_W'XZZ?8S-G!6SP7[LP*[KM_X^-BE#RJ; I^M,(6[3X8QW&10O-TGVW ,U#)Y\'PGKO4G=54VV
M1M)F+-AYF\)OL:?@G17+@0)6:&\Q/Q&^8"D;Q26LSQKES'MYEQ]QA9%37Y59
M_G'#H+,&R0/TA*=LD,/OOB^U][NLL(6WQ0^ZPGXU$W[AKV$J8/6R=;[[B*T1
MK/LK=E%V&(REK5BP\@%6S7D]W`R23@J/JB$")V);/!"S@S 5;F =6OZ5Y@PO#H,?&:3UTW4%S*S_$WF%PBU@T_REND<6HLSIB#BQ(LG#E
M9Q,>UI?E0H`UN%%0/-
M)D%1\-4;V`-PV2U86LQ_*`F>65+__%!:?GATL/3?=NUO+D#YOOFC-O")3T82
M%)):P\.C%2S+WG">KZ*"'CG_B5GG-)H&1GDVT?7M[& GCBD#5M?"#A3>E_,&@Y*S-;1KK,UW%C\N61M=1'KGK8E.C%]Q[[H:RPQ
MOJTL0$7S^7K9X>$7EW2)UL6;5.%?BI@B,0HQ+2?>IK+JN8BC^C\%BP%=-
M8UB=X>'7'9_"I,C$U'WQ1MW2Q/M@`G]\RH.T",+Z$%`U.JHK#P]/:4QL4DX0
M'O70B0G]NK^$$IO[7#&KF@1/?3&\OKE6SH3B"L/#,__3H>8W)J91@DM,V9F_
MO1X`7#E=Y=KR55SPC6B5LR?8K%XD]94FR;Y/LXWA4-PS_PZT+,+$*:SH\,BE6B%4
MI)2.6>V>4LOW0H6RNG0_ /4`'#F]SD>GEWY'2/;&&]?H1N
ME371$5.DW!.Z*^OUCLR2%:ULK=>/7.HB]M;K_!LS6J\?H:J(/T'+R=G,D4LM
MQ-GLJ(1$3-&R(_$?.=T<6SJ0.4*WQC@H8G*5+;:(37*6:2.L137'$HV9;;/X
M\/C`_[R&?R_85(8`^4L+3\>'_I@TW-BW`T=&=Q+GG[*A,?7+%Y;/K@VFXVED
M-;_$\,XO[#"EYJ19?7C28FW7RF*I)J51=7CB4DW%-2H31PHT*UUD^Z!A#?(,
M@)8?/*:^;&:JN/AX@M]6K-DU:@]/7`YL^BMW75*Q.4L/*#'%"S6;&ZU0E5 9_C5^[Y!0I>"
M5R$88GN#IHW*Q>)FX>%7&BM_N %7`M<73/E1`B)V?#RSMS\:Q2'+BW[>/"[5
MYD]:?7A*X/B_)8]J8/(#X^T3RI.BISR7V3V3$= &5AJ<>0R_:DJ2`@U#F\2#2C"T$F5/)P0U1.!*$(V]Z
MPQ19?W05%Z]9$22_Y%GU>IOR',=Q.N9A/762[XI%B\S8:B+;-SH\);#G-66[
M(URD2W@3-%;@Z^Z_AJ=.$[*X)*Z)`.'"FSR!'I3*ER.R:L-3`M*%]@Y9B01A
MS+.*<9^EH:&0L5EE>+I[6@:"`F')FYYQFY9!.N9"Y M15I7J,B!LC>!9`I=.;L-
MS\CLM[7GLMIFQ-_>=)!&7GF>/GSC-H;&>D.WB>$9@:VWT2&7$3*$66]R2EJCL\([#+
M5A`B9E$/&D*F-RFD::!:$!&4'O8.#FA]AOJ4X7`0FOP%<4P?S-!G2EQA>$9`
M&6E%E00/PI4_?20,\XI%FS#E=(GK#,\(*"1M&9-`0DAK(9=@.[?ISV\\=R*E
M0[,F#!)NDY@ZH,4,&D*/OVB16:S=`UB>5AKCG[C"\&S7:-/`@W#E+4+$:.`3
M#0\$-*I6'"%8D/AK;WK&79:.^3I584N]3;]->&BH:X-PBH)!:X;H4;Z07>-)0K5J=,B]^8*>V*FGSGLQ 13%
M4V,&01S=II?!:UP&LN`9I`;`(R"_;H]>J1L0EKTI3`_\\>.41==!G@+.`K8&
MU:2J+^5%##8 U1HE%U:P((:#;%\
M16X>VNGU7$HO+B VT%3
M8@\"'F7RPLHX!`MW,#]V;_<29/>^N)0Y33-D][139-=V_R=']GKBW-Y7ER-9
MER39-6$*:L5P]BQ-=L]I3GH;>;)KKXNIPO#L6:9LP$1T(=Z=K+]@LNR>TZUN<5Z5+UD>
M_WNYB5:^]+Q>$3"3"(XTV 3BQ"5V-:@"4
M0);&CIQMX)$G[M[B: T^2;\M!= BSB*X4-^
M#!8A42K%#:L#;J&CNIFRB70*.59BITH-&^^#"?SQ*0_2(@BY?6JI1UD9,!,1
MZN2L(%1JXB-V"K4%3HGI>.[()7MJ-:A3IK!!$H3UP*0\K!)7`(P4+K!K?FB8
M#(0C(W94-5\5SUYA4DR;@M*`BF!8=*-T&F4$S&%^MB('7!MB5-:TZ4C ?_$'==6Q'(M"@(6`
MD*[_22%2T1H>:Z=:R+VM^RSE/]F('[EBS^7LD=Q93Y/?XM)O`1`1$,G;,M0*
M++7C*[OAHX=.$QEZ40'D6,F=:W4,7(1F2:Q;%&Y'ADH$#[GCJNXDT5J(6&1+
MM?CP=W3U"/,#*\X-0TLEM0`NS;#2^J-!AD,5''L/SB+KDZD%_50WQE=="0PG
MD!14CP==--3>FN6+HMNT*/.*#Q.*]<5F80#E4G[VL;#`0%)[ < (!&)Z
MY5\.LBS$X=A[ ZA'W-$+%!#6&A[V]DXAE2*F].BLP5AU*A-4!B$3D8AD%VJPU05%[AM8Z
M;\2F. G5\U6"\BB\@"1@'2L^(2T:&OBL? L+5.
M&JV)SBI[JEFNS4NWV+';*PNYCM?G+2L.VS:+@K$$HI,57X+HI`V#0NV%V@>>
M85HQ/RW*`(1]BSU>PT;MZ=C:/.52KU$*8-`((%YSK,3[3 _&MZQ<9! TL\6PM*#0^=YI?>
MYGR-HG/S]*@N+5-KT'W&>A$PV:_NB;IQT]N;=KMY_].AJVE,Q!U\KIR'[5W?
M>'J)\V@0Y.7'' I^.%6?+%C$Y=@$,@,E;[$Q.L>?11(F1Y$QQNN*/97?S&
MHMNTA"T\C_(]+PI6%A POAX+D9DH3!)! 85!FWL8K`4@"08W6DLJJ@")L>M3"-NW5R\ZMJ`EP*=RO=\GK
M!EJ$7(]7:Y#GP)K]\M?7+)T6;.YD3-Y+PUL#MS@-G]QR)VCM`:1C^(N,86\L
MK5B_?&'Y4E!@T3Q63A8NHZ@*@`D$_5FC7`\NPJ_']+*(T'1=E/&$)RG[M6"C
M*N'KEU9G':)VP!4$-#:+([XQ=J0;4%3>SB<9#&3_#KBM\TR2HY+E_V1!?@,5
MVFVY5:V"FP@\4V6MBW3V!-)AO*ETTZT(*V:CGG)[MB@)H/:JWD\/"8@,IAC2DA.H0L
MGY>0Q#/^>135GF^U5%I4!M`$GJQROSY:`XSD@?>F7ZUUQ<7_A=DX5;S?J*H*
M@/=)R]*#B_#K.27,-U:^9+`J@[5YR9'WOZ>P(7^)7P ^A4-.B*B@U[!R?[L"R28$,\[T]*"CYJ7#=9_I!]!$D9RQ4C0?%AKW>R3]M^
M"4:$O9D"]&D''O" [#PYT>
MHBB/74IZSJ(H:\:-]5HQ>F+/?7H,FSMVJANZ":(\1D-N6L$G]DZHU\ZPPS&4
M5GL%V0=&K8=04MAWM?ILQ5RKH!)[>=1R!.4)`2':(ID*I.1>(IWYN_-JSK`E
M\(9+>=K'BJZ5!\B]8BK%8#B9MV@-O.)4Q-9>W;5BLU7'P-U`[/53$IV#UFK/
M?R]1K?J\G6#_FH; (;`,4GK#U_<0UIZP=Z#K\CY
MR2STY88IGN5=+S?L'5`(R;;$D@PBM4=:)>O=>U:>/Q=E'H2EY(/4:P# !D]JCL+*XWS"L)E7]#GCS
MG+UE.+6X,7`*@6!;I^1+D=M[;78;(WOK$1W`$@C6=4KS`B6UEVOK^SZ*18J$
M6)WJP\,OM"5537KUL5)[Y%8`^/H]3"I^H?.7+(N^Q\OC;+%:KJP.P&E+K9HD
MZV.5OXR[Q0B8Q +!3P&*6)!(
MTTBE(+Q9`YU0_,GZ\5>UU,%8:'6.R&!8YH:?(6R2(;4C%=^5Q6>3X=J3&^
M5LH!(@)[] !:!,E*#4\_$I@0VQG<2A"1BSLX#(H7L[3B/\?O_;U%B0 Q_K7U.!IB)Q1' ZQ&(W[E`R;M
M*:S?@YAG+;K/2GGF!Z.6P!N[=R=6-J"V0$\L2F`V*CTP@)*SZ"F[8+^S))G]
MM>(.M+HR8-Z].[&R;UX/L+TC?UOWW(LPCU^GMSP?V)B?IF3YQPS'W`\ $'X,J?\T*Z?6^]HV"DPC$'5CK%5T=(8].V*),^LA>R]IIO!M=9I-)EM8;
MLD$.TUO)!DD0UG!2"N)I8\.H)9**R@\/3[UM(9=1K[5-%Q^UA?KW^S9J06?R
M=Y\/]RZBHZEP[)5J.LVE`%_4:Y;6JT1-Y514#]Q#\"X>PJ)"1,7Q$1-2UPQ5
MZG3"\H",QLTY#?^+B9/`(J:J6B.,J+9JC3FR$FMC_:&,3]XH"U,/`?U(\KD@
M^PLQ#F*RZN)MOX_'8#'VJZ8TK`X@=*D*;64ZDV,C=N6L82,/J.Z/GO(@+8*0
MVZ<4*,^(*>0:-]8
M!-#'1DU1'>19R%A4W(`7N)U!&K)^/NW5TV6?],-450;0%&[NF!*J"XS:?2RD
M(TZ?\NCPE:XU`.`)W-2Q]9D*P V`?I?3;(_ RD=,ZMU2%@I"C92"+]I[7H!&- .92'2&YRE8X@YJ6[?J8
MZ $;@2ISNIV9V>'B&
MYY[Q]XI56D)732JN3S^RL,KKZWO3=!LLXL 1JGXV+`\EJ=
MO_@0-Z"8HAW^ZO#HP*7&2G*2=^Y.:CG1Q/9J9:55507`3B\1:J\1G)-JTI?6
M_4,M*YKC#D%K?4&X9RC7)]YB2E6[?&$Y@$3@/JG>)RDF30"'6F8T-Y=8C@Y<
MJK\DEP$:#I$G3-O56Q1'!T[E9DO77FH"Q,Q)8"&,>5/DK#%&:TZU3YUR*O1W
M);_3Q9>C`P('#9(/!CGH%.-`H@R\:64/K$Y#/`CR\J.A.107'\U_44R,^HV`
M$UR>8)"5"SV02(L.9-9[/`&JT)
MTR5]JJGST-[3\)>P(XZ"=)8^XUN0_\'*XBX)Y:?!\EH`@4`:/NS+$!P'Z\!!
MF/"F^#P$Z9BI)L)Y&8#@\E2!YCRW"A[ASYL>4YNG7'XV2@V/>DYO7.M/7*N.
ME7B_:3CB?V^J2RO_$YN"6A"AG%J\22'?P(F3:J*D9*4<0"*0\G"CLXNI$%B.
MD.!-W?@6O.N1T"P'4`BHQ+HD;%J.D$#M1JOURW)'/0)1JAWNY1B@1,+Q/=YN
M;48V7\5O<<32Z(%'3FP6$$0G8[?O.=\2,=QILX(KS5S=_J?F-YR=\!6L4C'1B,
M6@)W$+@OW66,:`$78=];,$\3Q*R?7K_#$!?+L\/*J@%0`@J,'5[%V!`2C[=^
M#1XZ6P'[*1A_SL S\S//(X@R_RE%E`I)]QUM:/#8\.7>Z*%>]]V>X"R$K`
MD=?\WLU'5/HGJ-$?+088+#((+0O07.[06^8`M$N<0-?'76'M=KTF8>B1EZ0T
M6.KT`J]2\%7X4,/A32#6;L0[=CD-C=>F[[=WBUVP&%(50J*68=1-T>NC]W W\KH0B;UKZ'*G'QDY_6C=U".RCS4H
MG"Y$0NT2>4/>7IY-]D?][RG+BY?X]8*-LIPU%I2R!;9I6^`2`M$76Y/]VKF'
MV@5NTD?$1Q3RQFVK/UGQEKWKX-@3SROF7;^_LK!DT1/+)]A,@-V^XCZ$X:X.:;K,4JXN@1.2C_JP6WZL9-P6N(3`
M/F1;'WY+]U"[/+Z,>E@?F6ZR_)'E;W'(BGY^F02Q].36J!UP!8&MT[9Z2@O7
M4+MF?L/987?@B.@65DSIF,?&G!M)EI?QO^ND&=.9KR?I+RU;
M'/9Z%.X&;:OK=/,2M:OO_?*%Y4US^Z.KV;*(WZ`:2\.5U)7!D02D@6UU#5U_
MV+L\CRPMYX%5@SSF8YQDAR$K#L82"";?RJ)2Z@'YA?HMQJ5=5`4@*6`I,WF.
MT[J'40A$$YCUR%X#L(LE'P\LS,9I_&]8HAL&GG5I=GAT[.VJ1PN[5>%D;9L$
M-[C4D:1!8]WI$P^RW7RQ#\^TW*8S&L6KD(N/;\&_LKS.H:TX^3=L"5Q()@%5
MMVZ`[`K:N(/8HRX*#$L$6HD$6[0&7J&1N:H5FZTZ!NX&8D_&D.@ N&O$6=X3"9MEXNU
MA0;X_8PF/*:1FDO#_V+B)+#V,YKPF%A6+OO,D7VMOF,6RV,",KSD G[#P$A#F;SQ&L^"7/"NFE7D75X=$)@4@N5W*-'GIR[_O(\I#4
M0(J:H-896YIM@`L()#QRU0$,W4#M#2#$_#J"J%M'V&@"'$`@ZF_+_0#Q`K5P
MT/IH3[$;5)V4*JH#J[HU_G(6JP-N\9YX6( $8FS4J`WH76[J'8^2V@")'4VA=G.KE1^G1FU`
M[72/KCVB:C-D2/`Z5&*'4ELAF-9PO!VF52.UOQSRHF6]1C)SM!:@):"S:'^`
M8E:5^%SGR;B,QT'.2K9BR`*$(D.41EU`04`D: \0>Y=\=('*PH(O.>',E_GR-&X.8W2)61N#SJ;
M;18"L_WF;)+[`
M+H.0W._%$$343DIFEO*;6?,[M#I+ (_G:'J;I(Z.62H$GH"H>V!M+*_9+ED7*
MD#YQ!0#G\;)[5]IDF$AF+;ABKSD+X^EB-XV:]^Y5WYVD*OCHU'>6ZJX?GQJ>
MO0P$CL)KOP7A"P#./YJBBTF0K;"!X=%7CY&67;DUP4@F9P%/H9XE<<3?;5X<
M+!;]T6Q*X)&3'E(6+"RYDP3AX(7!Q_XFJ[DURC=H5@J"R2Z'-6DJ`,R!R$0D
ML'NO@G`>X2,)\CC3#)=;940I*-V$0BS@9F[@KVGQ"E,HOZBIW`NC
M=0`AL53ZF_Y'")-#(A:!8YTT6OJ%7?;(AN0T-R#WK#Q_+LH]9%V1_5O>0Q2R*-J0:I,3PZ)7!WUVRJ
MD4(A=NUZ-O!RDV5?2[,8X"`PR4B=+)UD&B"HW8I>`Z7_N0`-8J,6@/+""@3M>P.`K^+23K#[+F-DN72=+
MZ@%4I_J;_AB'$X&MGI6PJ+US\@M+61XD_+PQFH"7.4A^CUK-H:(FP"7QAHDY
MBUK`_A+Q+*O"&`)2!ZMR#0!B+#I3?R89CW^QLJ7++I-WUA1\@[XP(*$Y]!;
M1Q0D$GY-FP*'$)!'.C'>#C+2!UH()\B`.\7Q%+P_L%&5BHZ[1,6&9ST"Z\7V
MPZD0#N)K;RK'; 6
M\-L"@R`7KC4U:@%,`JJ5#A5R$E%H"(/>!)`U@VO95)^ZNOCP^("`7&6-LP8F
M)%K:FR2"CB]M-ML`D8!^U6G(5&!#Z/.GF;!22\M:*0=0"*Q*#+6030`(%]XB
M/:Z#G+_W70Q87C]HCZ>7N-*ZEJBL/CSV^FQ*^L*A*6'^$Y]!376#5;`(ZFTL%
M1'JU59(NH@V9V$5:]XEZC]W>C+&:
MB;EFR)#@=:C$+MUNA6!:%W&WPS39"[K"=",:F9C16CS;"8&C1^TO4$RK&B"Q
M^[M"@U6W1?%*L,`A("UT6XBIT!&[ZXN"50FO\HJ`E8#HT(U)'83$K@.#R2%C
M41U;PF_:]D?&V:_T6@#T!&2'SOSJ0R5V[=A5S,=QCT#,1S=:=1`2NYN\D8X-
M]8#LR]5NA*\E=O_K-85+[0IT,S1=0FNS&$^YN/,+)`$@^37HK:N[:Q/`/JNZ
M;>)\=U#5[;G4=SJKNHNINH>]'51U.S.]6ZIN%S7P5#DXN,H9
MF'L3O_,_*9/_H74`X8[L,G'^%."(B;EW+"C82Y9$MY/7/'N;)DA7\8=7`HR4
MSU2T"%2AHR?@NI'C#W=$U\.9U$'H^JE2U(;;-$PJ'K,VE1G_)TNBFRSGJK*`
ML[9-`48"][/:L=@-,S&]=FIE?S2_10;C2?6ZP`!_RW?:<5JQ:/$VQ665YW+]
MMGVCX","=XVZ?=U=T5-3=U%OJ*9C>44`2^`ZDJ.!O(&06F+,\S"L)E5]=ZJI
M7\.?$R;(+=/F_,;63PR/CPC XB"45NJ?
M( P#.A9)1@%
MYN2\1Y>0J3&HRK]>!"SV^[P5ZL5-9V_:[>3@Q:&G:1R:='`YV1.0S8^7,658
M.UX)L'H4?,2=73R]J#`0.^=XK)X+]FRL0V"K^J4^K`X@I'$#3,J`-FE-4,0..*S31F,R:\_P)]V#L)$L?
MRRS\0SGA;90%:`3"V20?C)@F!`>U)[J:B0V?\B`M@I#;5EQ\-/]%,>7I-P).
MF/0V:\J!FLPF0VC-?%EBC-16ZI$\Y
M*=I+5GV>\O1KP5WPG.6\4LR*VS1$)SQE'3"?0/`A]E6LDJ`)AMI373? 6725"H=GP&K8`;7"K36Y[_C(%3>_%+`F!I
M_GTP46MMABV!.YR&'FI/G<84&O\3,UJ@W S%-`]G ^]: O:=!BQV`1'[V4X1SQ2FVO=$*J:
M0?V](O)/4EN@DXG;^SQJ_0S=Y.4\ZF6O7!!022)VA\=F)Z#3!2>V4.
MF6B4H4\;-0`>`:71SGT\*41R;],)C>U_ARY9O,2O`UA^P'\'8]E%2^TVAL=?
M""B3+EE&05-[T6Z:%;V._5I]I.VV*"J^+VA$.>R:1WCD4"G47`2@?37+HU8B3XIC1):3"*,!K3#L]=R>3VZ-#15$)'^$
M-REL9AU_U68TBI,X*&5[:D%ICHM`,D@[(QV.#^'-7W[`1C:Z_FA]II91**W(
MT>Z-Y*4%%2'V WFD:J3P\W2P,F(@E#1![74P5AH?8XSD6.*)UJFV1+++9
MWQY?8('SQ/+)?-50G*?1?5:R8A!\J/*0JNH"6/6S7^=B82JM5`22SRWBN`FKY-WA1_]$=@=9U$ \/C4V\J@"8[R&JH/=I]4`RVGJ;IU.4Y1LO(>V/FQ5W)U`W$9(BNZ7_@
M*W,ZRSK)VG2*SKTH0F+*A`W::$D33OES(%9@:9L26)2G]:KG,AX'.2M+G<1-
MTEH?T>O@3IF`WR;)P'D_,TFOU#<9/EC3R:%'8G,VEU9F`_?XC'+UIGBO**
M0.BQMPMB0M-4VP^\$O0QEPL,Z1Y#R\M2T1P%M`_;""%&Q:X!K0-N(?.&AXH\
M`\J7T(@M_(76ZAYRB6H!2AJO=RAX,""O"8S8!L`)?;1V!"YXW-Y&8&Y!JLA*
MM5YN>'Q&X.*=\G,0K/G%2*PM\N5^?OJ>:?EY40ZL(W#%K8.?UY!8.]A3^!D*
MZ?7H1DFPD,"-L2Z^7L=B[5A-[NV;K,JUG+TL"/81"!KOX.MU*-:>7)*[^D3+
MSR06'M:>2Y![^HN7A+PO+"(1C=/#P"@Y[[Q9A.3`9SX\^^VE%
M&LS-HF`D@8"(-LY&P=A[=TCJ\0L#EU^LFTD@/*&]ST5H[+T4)'7ZI8'3+]?-
M)""DMW>Z"(V]-X"D3C_O#:`0X]= N`V01NT[0G08:*VIL\_('$.(J#
M_*-QL5WCD5UAG>')@ J[(R@':Z!39Z
M;U=""\*E)CY[+_7L#*FT=#R'["K?8[*W(Q_D\5M0LD$2A/61#(_2O*K8M^#C
MZ3O\)__?Y$VAC)BT`?`(:":Z'YE@LC0':^\]'_1N?LD*L&%FP$N \_4:(YCYVGTC>5C
MIG*_O!H83T"NL3A:"?&1>W-FS6CUXS/""@".@/S3CCP=9,Y?H/E'D%:PO(%_
MZ*W;T1_!3C%.Q\IS0),V`!8![:C#UV8.UMY#-NTY5)XQFK0!L`A(46XY7`-+
M[0&:U8M6"E5DLS"` PMFU4ZM!U^P*L.3GM/P"FW-`_.]#E/K
M.R6H>/-6_YS:SYLEP40"0HUY9T:`
M4'LZA"N\]2WU\OJ-9VJ"W],X8Q+4`'@N19TMG3"AP*B]"2(P5GT"@=4!B$XE
M(*/3))0";=::H*B]!&*=-UHK+-L$*M]TQZK92OU.6!X@4I#OY)^0%FU-
M//8>X4#6$[.G'=(Q?\V)C_%C)I$!5%7`:)>2G,.92P^9O8 EO[7URSE3QCQW-S]T713=L9W
M"O6AKGR'I%,7X'@,T]/]#@0DZ8.S]QJ#I?SE:1E'<5+Q6^F/+*SRF%^VOWX/
MDRIB$;^&?YE-7JMREKS[.LA3Q`SU!>7?8F(ZFN8PC+
M`20"XK?>)RDF30!'_FZ&QZN[FPIYRQO^LWLCK+F96V-6@"70*`R]M$@
MPZ$*#I*5RIO(,DCXZX835=A,LQ@`V?'PXTTT""W^+MC,+%0.?ZL%AR='-(*,
M-STL9Z)I/L*%-RVC`Q>TIJ'VI*AFG1-[UV'$R92U,C@)ZX#Y!,*)1?U<"J\/Y
M`@6#L-!1+]!E86H-.ARM%P&3G<8@*RV#!!;"F+=-^8:IO\?E2_VD!EA8
MO,2O3YEBB&O9$KC#:6RP]DY$0I8FNSI`D23(WK;U7GFG,0-NLP.HILPO]M)_
M]D>C.&0Y?T7Y*LY9"/44,9=X#3"=0#J'5A^<8$95X42H\:8K7+$Z>T'\QBX^
M[H.RRE4BG+@"@-OQ]TMDN!#2O(5#+&W5O%V^67S8ZQ$)1Y0Y7D75!AZ$*8])
M-NPP16LVLTB9 `D$_4F^'L%\U@$H0JB]2SH&
MMME(7K31%L=)XF*](T+7@2*$VE-B3&Q3O\32KC6.E4!J17>D;D!%:+67(<3`
M.G4FS%:- 2H
M!L8]QN_6*%VTQ7$2D`*M_E8;RU9Z& 1I-_X+!/]9_(PL7;=7@\.28ZC/->NQW@8WT">MO
MLLX#,&_3J)JN/:_?7V%F89H1J!OUP'P"4:@M6#-`AY#C+?9EODV`SE0#+?2&
M7UDU`$K@&*'#QZ(^*Z]8$8_3H&31>?$_632&0:11X"X.GN.$!Q^7-T& ;O'-->8YAUL U
M:>YB`F>V'?J!)0\@?<9>&,W\]P9Y'*ITO6DA?M2PPT.K"(O8RV>SB1X0?EY"
MA)_X8P;][ZM_NX* Y@(F_;NAQF8IMROM&D+
M8%*]F&N!S368")OVPIJ^!7S0.%0-&G(:C1H!8`1"G8SX:X$/( !G2?O HZ-9JW!!!W3?II"Q+AT9[RHVV8 +>9KSEG$GN"GPQ?6.]M>$$B4:Y"#=GA[2M.#(G(*C#:-W
M3=E0HD$H\'8]S.6U^%ZO1T#)L!R`M`D0H=1;?(K0['DH?1UKV(CDGOYKT3/E
M6=4>]PT!X`);(O-"5)"0KQ_
M3#V$]B%+DE&6?P_R:.&0Q17"^FX3MRY(>+3V%/(>QMR>>;M=9SWF]M3E3JI3
MS.T9_N:S`H_?F%MD-+R)4UAP\4Q$:73.#1_7ORY+!2>I`D!=;KZLQ=*>BM/U
M*9%9BZ8U8T.>I4Q:">SV^UZ:GF/UR6C"LA8UNU4Z:$3%NN/%072LG5F*WU*/
MZEOJ;^R1A54._F:P#`J3"M8G?)4`*XK7JJP7"/W1=9"G`+,8L+R^67OQ(6Y`
M<>O`X:^"MUUN\AT.MUMSCK687I==4"O(7E45\#I5#+3O13CGU*0KK?O'6ECP
M3O0'&E/-#G0,9>I3?S=QGLME6ASE!;?UPH!M)RZWX3,$ALE:\+`+GC1O38FK
M`#XJ%]S$KM F+O627HM
MOI7>JMEG)***NGTK`DCV@FJ)I2PX Q>%,'UL/ ;"--,6ME78!_@[$*FVR:Q&\\^A3,?V.QA(:ZFBF-HNG6F)8WZ`*D%);M]AN3+`0'MQ\;J3`I0
M'E9,-[!UWD5#0,.'E_T+6_UR0.M=PPYAJU\.7&Y3NX2MUDX6?T`J//N0*O:Q
M#,KIT#\%.TW3+9=>T3K@EEV(NJK)$U.N@$8L9VS32*6JMUD8,-&(BU)X7?IU
M;N`AEC#6`D>T=%>+9)&-AW5Y?_'+`?W]O^FDN('/=.(Z^J*+W69J"=IT`=G,?/;/L/(KBZ:_>
M5])#2=T&H,O25U%0$LU0ND[S.OVM9:=2OOR'5@!["63D: 9CG%D_.^#(U+NMSVO,T@GTCWS2R-*PO
M\^5Y?=[G\7RL?B.V8:/.T1A:9_CEV%L@X+I1J@,Q8?GAET-O*5P47A4K?A(4
M)!.W3%^??8)ZLEPMJZ4`#IGT+!)_"T8G$0[7R5B6ORE/^+%>#JPCD')%Y#&I
M8YO&NTZLTL6U-,Z)NOIX>T\(WL1%&"3_9$'^]!T^M`_XWT3UV)&L#ECO,;.H
MI-,*/*_&X?H(9\."ES@OF>HU&WDML-SCSKHC`P(DKH]NUFW@[Y"9O3E@T;XE$+"IJ5P&[?>^#V#&P"<7T6LF["8_QN3L!*);#;]ZZW
M-0$"(,0R5#QP95@1HK8H`PA XC&_@1,GU41)R4HY@$3@*':CLXNI$%A.
M+9/$M^!=CX1F.8!"X$A5EX1-RZEEAGBLG@OV9P6SW/4;_(]$C%/4`'@N)2.W
M\[<4$[4D$0)CE?'*:!V`Z%0*T0\MEU&@S5H3E+T-AN";,V?[GOO"A865Q\
M?`O^E>5U=(UBRC-H!=Q`)ENI\31HC-->V@CG="_-UTJM9-@2N(-&PE-C"HU[
M`@[?7H:(/>@-M"9G?]U"-8W[>_ONCL?G%,U;&WA^+V4=@$K@9E*KSU9,M0(I
MM003@Z#4(G"E'$`AP0F!VZ^V&)&C1#CQ)_#,+VX_@JU!'F>Z
M:1Z:Y:&[D4FP:Z['X8@0LORI.C,+?TV+5_CL1S&+U*H.5@`JIX[8).J<3)E
MI7UP'9G42.9Q*/8\@,1/^XMA:0]-ZZ3%2OO@.AJ)FBQV!.L];=U=2$_S%ZVS
M*SV-UIIC=[J $"4;Z4+D"X
M]A;^])!]!$GY\4L5\$NKC!7-RZ&3K)*^5Z"N#*`)"-*M[C'J@D,8M:>E?8L3
M5I19R@;!ARP=UGHY,(^`KFSD>PD.Q,W>Y+&;(*SSE4\_[N(E?H51I0_+ZCJU
M>5&GQI:=Y6E4'WXY(:!'M_IX].$AO/I+91R\QF60W#$8QHN;BC\4-(MBG77'
MXJIBE\JG7$R:`4<0B"9MQ;,Y3(1O;QJ[OULA?PTK0K\W&5`3!K_B:8G]15/@$`)!
MER[)7X.*W,PGIN)=O[_R0UECS616#Z`2.*MNM]51XT(H]":/S;O;4W8>_EG%
M.5L_F9=&WRCJ`N1=W;5J8D/H]"8YU5C/PS"O6&3Z:J*R+D#>M8VP(3:$3GOA
M5?K*&1>\,(7"K)7AER^[MOUMC1(AT-N%O%G,F$K%:!8#(`0NIK;ZRC9A('SX
M4YOJ$+1$%((V&^>CGH0GG>H`?%=5"'UX"*_V4N3TGY-X7(M<3QG,Q0^,HX[3
M QO]>O%DY8C#U1I E=E`%UP"*/V\O%H]*W;]#8-\^GU@0Y?7[,9'K2[KY^B`"?"HKVW"N9!ZF!,
MR=(@#=D-8W*I7:L>V+^;JTA-8$C:/7NO%Z!V2#5QW:H X=`
M9HI,O-:OS)'LY&!G@@[AR5X:W)E0.HLK`$-6)%-N"I=-\=-]G=H 0I7-Z!C `QH)1B5\\TZO-L>R:(&P.
M#Z'*7@K?7U\!4UJ"&1@=RQ)@T]>=_#HV("!NI1W@TO6T$["?[MJZK@U`A%Q_
M>L4TQ`JV TR)(X"DH6+>[=%OW1,N9V$/#QZX65
M<0BF>GC7:6'6G /[=&]833:L'A%Z?;!NG;39@#Q5^`R&Z_
MKS79(>XVA2^$+7W!?XE[7WZ%5U(+7$,F0;R(-#&]2D#6GH!R2IOR4J.T'O1_
M&NGDE6P8D=@$9^VY*>(TTKISZHI/!T];;2%^5OW"@+HVH"<02Z3QP8F9U49H
M[=$L.[S^PE)8+29@]GDT`7_SET[Y8Z"ZS&K5!^0$E*'6W!I@M/8 81D,9@JRUE:&\_MKLI9Z"L@B4.^W(^3"M"):URQ,HB3
MPH?V>IZ6<<1M@Y7J(POA4^+7B*[?PZ0"=]P`JRMP&O;7ENLHMK9^8OCEU)M@
M\1B^L*A*6'_4$8U2)[;Z0^`RE\J65&>V2SNB3COPUCZHVXNQM\Y`W1\]EEGX
MAVZ:YO4ZX!8RJ9I=$*XX^!"[@Y@NWC12N0/8+`R8B"5V%GM=3!6&AYCH;8$C
M6ILRBV215;3O63E5!.^R0C9ZKI0#1`3"7K8Q`0M@$Y.N?V?Q^`56WN=O+`_&
M[+[B3H/^QR$6_:HL2O[V0CJN%^H2@HW:`4\0V%YOHP.T21MRQ;!.P34G5:4&@PANGX@)LW+AL/UT7"I"K6<=O`&P3_"M30"4-RT.F0DU77#B4F
MA8O-U7I'6U45\-((?'+.J4E76O,=G=<7^@) 33@J8CKZ99:^L;SD
M&3:OV+/Z 8!!8QMKQUH\TZR7TQNV=>RXUSRC%]XH:CZ]"R+S'([
MG7\/\DCG=+)[X\.O_I[U7IY%*'$4&!#](\F.OP$=WE_J)$LTJ\XAK;AH+XX@
M:TSJ'`0KY0`^G4Q,=CE%)I)-],3.Y-J#7V)+(WY-6.O A>QDT3?W8SL>:$=W?QKCX">Y&Z(,-'::U=8.WM$A`J>6Z+\
MB%.^98&=R"M/.?$=_OP!VYRIF^3:A6Y]0$-`6-H6L2U<0^S8\H$E/.W$(,C+
MCR=P3Q&$W#3P3_-?%.M/_4;`!P1CT!PN3DU=0^Z0=&FD HGSZ:_+I]KU ,]AHOA_57F=@R%
M_-#-8]*G1]B(!7F Z9 [)!?Y+&SU5Q.S]3XJKY)@PG0,R+]I..)_?P$+;?Q/:QIJ0X1RHO'XX-8[
M?^-=XXFM1KGAUR,"U[DW.KN8"H'E2%BW-\GA&SA/BX1F.8!"0)6'3 P6]]Y6DT%?UZ5+UD>_UN:Q];Z;X%+"=PM=GQMS(W3D'Y([`J1<6$:TNTZW*J8=P;RQX==C`DJ.
MXX&DI5>0KN)-.[4[B?^2R]]Y=/!KX%8"BM4NK;0:;D-ZHS?AN/7T?/W^&N=U
MX2E&%\NG]=\`%^["774_ZR6QLY!
MSVE"-QJ#BWV'(5WOB$A2T&7 `I6_E0``7NLS2?_R=_,_*U; 01=?W3,!EY
M6QD[PJ9*/.KR9\&=+L][I+E(M]-5Q(.5>Y_N0_+216#N91(417\T71AJ7@M8
MKP-N<7D<8Q0QZ9Y^;`$N=0ZQG*=-(Y6QYIN%`9/3LPSSJP%BKXNIPO`0RQQJ
M@2-:49@6R2*;?U.T7'R(BS]N (FH"\!,0\:GU%-Q3Q+*`RHS_+4O`'^##
MCPY]9;41\`$!O8QJ;Q'YBEA:4)GY3RR?M.PEO"K@)2"E4^T;2P]) J
MR23(/_JC\R1IZ,/G80E#8?GQGX=P"D TZ>BZ(VO1GXAIA');.?/H"B_;KT&.'BG
M`I'VL&Q$ECG?&Y")*3W;Y)O6$+]=XE6S@#?I9G&!7PB ]1)QHCV@P>5S> Z-
M:X@C[;V#1:-O-AR[EE=D_E$.\CADW.FC;>Y=-(T!4O8D$])6]C5&7B7W[MAV
M_."_?X/[=SDE4L=NY_4CF+J>W(-LK8]4=!)(6>O]]JP`&G8YP9*?+\"V^\D]
MO!VK0%:=EG\UN]YDB[OP^/4
MWO7LZ@A\QL( CZ_0'T-\'%NWQ6I-^+G"OH(K]2>S?7XGRS
M"G=+RXJU'P4G[\&94+?.Z]"Q\C>$MWG+NWHNV)\5_/7U&] Q2N0B-TY%MBJO`B%U@&$3B53_1O(,@:T26N"
M(G8-V3IMM&ZLV>:/[,WD-:N5]]&$Y0$A!457_@%IL=;$0^RZ\%-HNC*D@4\YJP/"!S*3DZG=4D@(C=]-VP]/>X?'E@2;U%*5[BUZ?L.BUY,B;5
MD&G8$BS\W-Y9T9X`)61ILJN%E-@-7[_$TYI"M](#5/.JMYWE59RS$-I63JBK
M!3DH`E-INX]13*L0(+';L_W1*`Z9FJR5 %\"C]J]R4$2I/?!1*6I-(MQ)#NKI`B`4+N+.#=1N:18+!C.1DK`*A=O^M"!ZT%7!=>5.NR-G?&D.FC/TGCYZJX3?G)2?S&
MN#7RF02OP6TGL7&0
M3& K-$.2?@CMQTN,!R-S W*L;[%)AQ[:W22_Y/+U%I ;(YKVNWY`)VE/$Q3
M]XD,43UP#QW%5$",R4%P$(LK6UZ6&01Q=)M>!J]Q*9&^M.H!4@*[9F/&-#`1"PY[X/=U4A9=
M!SF_FXR'.\@K`#8"%VN-^9*!(1:[=9^E?.L![DBF5QOKMZ:5=,FJ`4X"YXK&
MI*DA$0ODJD?P%2'B-@V3BE]1'61Y[>ZRS./GJN2[F:=,#%`E3'7^`?`=A0QN
MACMX>\A)OE#0O,\LZP'K98>G!Q1>4C$C4PR"6K@9(I+6!R.76?H&71%,[8^F
M?RYCZ'B/_"'H^JUH 'AYW]+XPL-KKP((_?`/`@"4(VDXC7V35N8]CK'1#0&?28;(O.>70>
M8M.T:W6D3=P(1T9@K=V=-RD\:@G)FZ/$]`7?25:EY710D25(D5>$L65GN#1!
M1"V3]H;-T\[7@KZ5B@"60DA.-_H$B.S%&2J'S 6A=_S0X?.>$Y>WX
M1)Z,T]U*?;;H+.7N/%NLC+5H!:#NC%+>&AS#70J?JREQGT@`0@L?-$-]X6N&1GQ/^.(!'>_3UCYOEM]M/=.3[HBA*AWN,U&+P'
M=[@VMEH?H.^VRE)P>NES@FV8IJ1V(
M+1XV[=ZK+"6/\(T$L![2S4[2+`_NDF%&+92.8&_IH6KRR,
M1S&L8)5/*F%U`*'3I;MY5I)-_R.$R2$1RTABG32BF4FLL.(9NZM(UL\FEM'"18?#TT.49N.NU/`Z)6F8).QGK3@_]IN4W($#,G`06M9P3
MUABC,6N[HTZ9][_%3AJ9A1JW4_@_RN 'AZ1&!&`+)9R"8G21`G&=;6,U6
M"/]^I%@`(.7!7`*'^V9^EV.QES+!4K8R5G(]>Y!G_-I6=/'Q:\&BV[0/,W!0
MQNGX/"SCMSI1QV66PE]4\'>S?\S2XORY*/,@E*6\LO,#X#R:9\D2.=@F V.X#:(]12:ZSWUN?R*BY"G@\+
M=EF3N!(EO-&N"Y`)W/GPVPE0MU#+V#'=@W]CY4L&V-_8U&4/+$CB?[/H%_`T
M]U0_!3"O61$DDHYAVM3PE$(FI&WWDW9>HI;M8VGG8Y"P_@B3QO99ODHATF/JGI@/H'[
M*-NBUL`ESK-JS+O7#7AC%JI]%P?/<_W.D[F@V5!4]L@\&2
M@F.HY0=9DNBUDL.SH[_0@DSJ!&K).@![SF"PNF+3_V^B+0I6ZIP9:;FR8. _`45US8^HI929!/#>5@?+A2#
MX$-Q[5=9%R`34%G;T*1+N!`PM5PCFV9?58Q_(0F_*3\( S6&]P%@&%UWUDIPTO(5W*WZ/G8DS3P`&'UP@,
M?P"<1T`MMG*-H!5RI-MX$PQAG3M/T<6S7N8P@I9!.N8'S=.MM>QV@:HN0"8@
M$-JD3]Q!-!V!),WP)@5NF/TM"%_@@\@_SM-()S1'KP$`3T`:FXI=<<850475X^H6`4NSA2Q;Z`2'>FU((#@D9
MB^KPLVF(J/$ @#&^A&YBX`^D-_NX,;ZY3YV'EANO\134`2D`E]K+$
M7_,!0K8W';&;3YP)`>`L`D*S^PYCPTM(EZ(F6R[NL;G2F`Q_`)Q'8'-A16-J
MA1SI-MZDR>: @58#H'25ZE:DJ9Z6"GL@=/K#_!/XSP0W0#6K\QE#[KJH`5*C5V!
MD.I/&FP8?I^53".."*L"_J%['N#H\]W$CQ#L3>)[8*^SS4U_I$DP5@4`[O7'
MK((=B;^M>T5GTG5Z,6P*2K[3JB6>@"A&D2 /J5KN;K:!Q7>0/I"C[S`RYLY_CS^+DJ631[>$NS"VQ6!+!T=5Y'U&->
M0"CWIO@UAZM&6.N'P4"_7@V`TI5W'8WT8A\@9'O3XIH=M'$&6:<8$SA&\X/7
M:`G<05?`=30":+L%Z274H@(UW>1,J05G$5!HW? \T$?7-\R,M%WL(#N>D*`L%P`GJL.3%3
MNQ&'>[S'.TWWQ)_(A9%#>L]CI23`(2"[F-$@A(`PXO/V;39A3\$[5WABV='%
M6DF`0T`A,65$``%AQ)N6-7_Z]SY+PSI#VOPX/8T$LRI/K)ED194SC([H&%25`4\2@.%VE3:Q4F?F.+=&I/V31C9GVM B+#X)EM-#T]/"1!OATK!X94U#R'=Q.(SE]#UZZCJISR(V"3(_YB_.U_`
MX)94$5]\JZ_#MVX+8!(0QYQUA/8N09CW%QLW=4T_YR+/[#_JN+ZBAC.SO3@O
MBFK"(EEJ+,.6AKT#IX_5>NPBW3R"]!![;XO>Q2'/\G+#V$I?Y5?"9PE@T"E"
MHRIT \JG+PQ%1>^2U(I%D2E'4!\IX/TIHN0!Y\]B9)U6;SDUB!Q8TY
M1OZLKEX3X``"FJ/S/J#M":0KM!#+D)%]>.K4'V]-;&H2PFMX@]G\5CQE\RR>Z,,%'9H$T`3T]RT*0(:>0;J#/7VP
M/I37BG*2%0=C"8CVSFB4HD8HLJ?-W7!/PISRQK<8J]E19C \2A/@6TASZ]CL/G"WJ<6--''S*N$$*MG7K@V_V>;]NY@:$
M57MRVIHY7#"8G^BV816M#W#V="O>P@T(J_;4M:8YS;&"/UF[;MUE-IED:;V)
MU"'9H#D`NZ=;[^Y>0;I`"QT.Z0)7,0]52Z.947V>)7V:45-*M:(:&+_/VV GFCUP-T\M
M:TP7/$N)UBFW9G4`L]\;7`,O()3:4[B6?6TNPIP7`E7N-@54E9[LJ=D0`-SG
M#7!+?R"$VQ.SYN'`Z^]#-IZ_0"E65QV>'>SSSE?;`PB-!(+4-/,IV&I_>$;A
M%59ZX6I"-R&]QIXNAJ\L\)2;>A6YP+//X6BZ#D`HM*=P/;"H"DN1,@.KB8=\
M>IWP*9,\2H1_\EU;!N\1"$S2"TJV"AEA?;9)`4=\7GH"K/ICYJ&_K_[MBH/8
M>PE[O&4&HQ47??_^_2 C'!CTK2LEY?C+)\,GV#
M][_:QE`4+/QIG+T!B'@:/@%_6(^:@+\:SG^]\:,+#@2]3E5E>-;K&+39P?`G
M9" 9@]N\PK++HYQ]@; _,QH%+/D7/W\Y]C^4!.TB=8:]WX%(;?H&:>5@]
MLQ_A;UG*!3MMKAN\K?*LBPIY6-;;M9N&E5?UF"]A;+,P!^54TIT3]&.T8IQD
M)D+\+F8+180\Y['+-$&7'@554FZ'KOEO;86O)30D:^)VIK;I,N"!C6.^8$G+
M^V""36NBHL.S0X]+NK:3&XX$N>"^32XN`4P>)+>PNGO_7TP4(H26!0P>=]/=
MV!!"02*]MT/'997G8-0-[`*#Y)\LR*_3Z`I&`(01K#@@\7AJW)84.1KDY&^;
MG\E-G+#\$BP:B^/HD))@O\?3@VZ?B``(LK/A\_)L^9*+YMH\SP
MS&?@4UOG"R"(W=[Q`HKA-+'4F1Y?@IP5_:HLRB#EILKG#$E%0.=1I>LX@2AQ
M(;O6CC=(3$6$)VA6(1SP(@#6XR%V5]E@B0!Q>L?$)KI.7US[ODD"[+-8*0-&
M[^#\(("`^+WCKMVTLT^O\8'
M$Q Z*E4&Y4#Q89/([O\ ']& *&@1E!LH%'33M6$]!2N(+3D2UI'Y!#=Q)^T)GHNK.?I]$=_%(;
MNN7UAV=?*%S1<4FZC@.<1#BX&O5;C^R`EV>X3H([NG>*V51E/@3H-0#8"=S$ZTR>O$_HN,!-E$AW_E=F
MK?:]0*<9.^X*^(]R$L#B;)MI/!0"70+(;Q[Q+L;N)FK'PZ,\#"[,T
MC).X!GQ97PZ^3>>8H,`TP1J_ SY 3Q&=OE1N?(K(':AWBHB_*?Z7/D5T^OIXIU/$KY)$^U(X
M^W:*Z/;%SD40?(?<9WKCQ5%JP^9_OE
M^@[F!7_/ZS*;\+^9BB?B1+_N?FS8ZU%X.L]^YVGE!F+GG3HXQ3*],!6AC6:!
M%@*:EOWN(L=+[,A3!Y`="=SR+X$WB4;#=>L]QBZ@=H@J!BG2AHT[BZ@1`LV_"M]M'HVT(WZ?H3(3AV3?A^_1X9X1O4[+("M]\
M8YRE7&T1K1$T;LKHU`$!6L\*G/`!@Q>7K#VD4^=A[B22;
M[@Q:`2\0T`@,"!,S;HR8F#*]8?_R;8WELSE&E`L;`.P$]O3VV9:`)29!;Y@N
M>S];70DP$MB T')@G9.7O[[6ID=Q6>7X.T7:#0Q[/:?!>JZY;H66
MFFB[@7CZ3M8W5KYDT?3M)N,I'FF">X#"34CKW[86^MB6V,QTEYQ$S0"3B`:,VHLNZ'HW"3%M?)Q
MKAROKDX=P6MV5Y^3%(@ND;E;!X?9T=IIKU$[0EY3B7N5;_V[AO&+0-+J.K]%OI+XV$CDJ=>G&M2;-L%W*W27
MA9H4MP0MSW],(*]%`X?&5RZJ-NP='-#5\5I^P1*@2!@+'0G/*#I7)]P4@:7?">&1W(K-;D>`D(:1UY%&)".#ST&2A['^1Y??:[PX&P
MO0-_1Q-M(V&A1[A<4)J&PDY=*.[<0LO_$PR[\?3SP8'+\)`NT;!3RA3L(H#V
M+!X60#F-^;#QYGOM=T0EQ!#M64@L![4K,;$M^"(;%=LJ8E(2+@CS"LU%N6S"
M4^*1QKUN<1WWP,HXKX%QC8_"4NZ*0V3S,V%NU55-&F'(W;Y'4F7BR:K8VBO3:$/'ZN
MZC0(%Q_7D] JUP5U`X*S9!=MRQ-);95O<5=T'/!:^/[JH"K"_X`DC
M'JO)),@_8",?C]-X%($.E3\8?WX@-9>PBI?#C8*2(S:8D!XRIX#6!# #
MZHLIEYU&'#`D*\Z-)7#%H]77(D1"+-/"PM@;'LQW0K]G^1^WZ2#/
M0KXS4E_:,6N(.X/`=8VVWY0)1F)9&?0P="::@R!\E4[GA]3?0NY>DVP1U`0-5J^V7KH:.6-T%E?@=>.6("V9`,"6K'
M\@PKM1P)"[/E\=;-8AP)@91';;_")0)Y4H%MBL59R8I!\,&%(.@R`^@^7!K^
MLXJ+^F>Z!>4@:VC5C\I$8+,&P-U?6W3PEG9CRJ]^9;#7Z4/V0AFXE4L%.P03
MA/N@$]^F,W+8'7P@&] 7TR^SR20N%5D^UDKRQ93'4Q,+
M*S\Y,&*9EM>,O*K8;7H/R\RG[RQY8]]@S?DBO2BB49T#]WBLXHY1&5IBZK_(
M\D?^#E3T3Q;(AE-Y10#K,X.V8VHW1M.%_6XESR>PSFF=!TF
M,?E>9/)-5N7E2PM*EQ4Y6(^'Q>CQW*CU16G"_T/"85LTB;!!VU7,+382.1#1L]"8\Z
MU3ERCVD++/)J@%:>4'B+1ZJ+1/+S)%H?3@Y1-W]&>6PJJ0)./+.7^G+SAZ1'
MHTAQ;I/+S1E^&*IVE&`]($>Q#P>>#XR_KQ5"=X_3,4_*#!_V+/Q6<C\`U#S,:]#`1.]E;])7ZK0C9!FJM)'>!;^G"=+DIAV+M,`[Y
M0.J3O^1CY<>Q3T-4EGEP'BLV14KMJ4K_W^[S^WN]Y#@X9UTN;BX]ED=G[C^(GIF>/G,E&%JT&
M.'K?46:M1Q03A/)3-Z&J__?/_&=Y7ZJ]\_\#4$L#!!0````(`$8Q1D9,_OZ&
M-98``/-'"``5`!P`>'AI:2TR,#$T,3(S,5]L86(N>&UL550)``,3H=14$Z'4
M5'5X"P`!!"4.```$.0$``.V]>V\L-Y(G^O\%[G?@[5D,;*".W KG5(ZDT4AU[#6,Q2&6RI!QG998SLW14?7&_^^4KGTR^\D%2W@4:;1V)$ O#QJX]?_3-`/_SQSQ^N
MX-.';_[X\ O
MPFP//GS`WTGB]->GH(``=2PM_NT/+V5Y^/[KKW'[MZBN@/:`P`^-_+TP'^VQ^*>'](VW_/'
M,LC+"7UOT]OL_38K@V14O]N4-GM\!\>- /2[ZWQH/*
MC6:"_WV#^M#I'7PK81K!J.H?II;850FO75`\
M$8;'XL-S$!P0XX]_^AHF95']!B]9?_KPQX_,&O\#^_5__L<1*2',D]-5G*+E
M(PZ2ZW27Y7NR&%S$19ADQ3&'ZZGV\/@:7P/T4J*^.`-`TP_?'K\PW^O.8":!6CQ``T3\$O%YG_]*^U8
M3]IUWIWC(`^KKJ,?%>*R%E^'&5KQ#^6'CN2[/-M/G!K6L6SB^+5GV!ZDUU$4
MXQX%B;R?6Z2G9Z@?OTI`/8*7=5B/D;[(:'!K(Q(T`X";`]662T[W[*ZJ5@
M4 ;^[MI'U&T@5B8P,WNL42`/#N=)T%1;(.G9L,W``LI
ME76,R&7H`Z9J#;(=(.VQ%X)0(%N+:3Q`D,:L].&D/246L56B8\8>IB6%^GFV
M/V0I^F>Q?HL+&;KD=/;QI9!#8)*:=L@ZH98^X$IG1CADZ4^'[16L[LM%M@_B
M5+F0<>T=K6=\OU48`K_0IAZ`2#KTPZN<=-SM@09U8Y^EQ#[>POT3S"6`&6AK
M'2Q#_>T#A;9A*]DOM)D'(!$.=1\@BG&VN%H=GXHXBH/\]!C4RZAJI1+3V%^E
M)/WG]D!!>__CS>JDF@%N9=(;?HL8:KIQ%^S1C]L\2`NTO'/]42I4-L'U4Z
M$DGAM0*8$/^S1>K1 _RTIHYOXWX.'`!Z`O'[<<
MMF@!.]AA:LMN_JC^V@_'.&+1*XO(>WF_O;P]NWP`&"S@?'-[N[D#C]O-^;^#
M^X?K']?;2W!_LSZ_O+V\VRXD;-FZW%Y$R+^M[SZM'W[&(GZ+I+J\NGQXN+RP
M+*7FS +1;ET\[/Q>737FLQD'V>9;WMRED9!MO3D(>+'WUAEZB<5P
MOO/>Y,]!&O^=A!B<9VF1)6ASA_^Q3B/4U0*=*,D_-[LZ**&^T2DT0@!FXF_=
M+LTU+GT4M_FN0( 5^4(%FR'/7P
M%:[S',&`=,SL6&O$QQ-%W=P]?KK97M_]`-8_
M/%R28QU8WUV`OVVNT4\_HG]^>KATK\XC0,O?R8U$K#W5/#L6:.$MBO-L_X0,
M!S8A.HN9G,RZ\BFDZ$.P:@[:[;U:2W2FI8\V_3EQ"B\SHZ_+P`?(Z=F_(?#Y
M:.7'"_CI\?KN\O$1>[G.KN_6?@0GFR%10[M(,PZ@FJP"U;@#EB3O68+(ZSA;CF;+IKLU0O\K3/9J1$O?I
MMV-\P-ODL],6?5L1.J9%[[04G_,D +8U!L-A/7U11M>
MBVU)E3=ZVN0^;4UE-WXZVU-_+@$-9\]@G^K^DE"^C=9P:&ESKN\^7:W/MY\>\.4%^NGZYGK[LWLC;@C*03>#*2(]V))K^+ >+NW9TMZ&N[["$';,["+#C(T_J-3S^ 5+%EVGK[`H::Q+&OTM
MB]/R1_0/U$V=6Q!C3HY>NYO(*G@'3UF`%@^BJH0+J-AXM:",G.;A]_,CY]@Y
MJ,V6&A,FOD!9S^@:H=C+56>:^&B5V?X,KN]^O'S _#R>=L;?XM/,ER\LMS/>X
M6UKO.`4$]A]MBGK.O5C$#3^4J"4@*/(EEDE;@(O+6VQ2S]9W_PYN-FL/XI;D
MJ.%>XFE`QA[B'V!"$F
M@/OU@P_N^Q%HU55$CS;.]6NDU@NE^ZP@>7XUU@,] 52\GL-W0%,F(:W:N`^0%4^ND)\^)%;
MMYT%2#>O+D_C#A\#_5>E;/(DDE0Y!4+DR,??3:XO99#H4&.G6;Z$(:!]O'@3
M[2D>;UEN+] (?^9K,$$.
MEK8;C?2#0XW=+68WDEC(UH;GQH>01_5P"] 4F_H?UR0?V>
M /[I$Z/.MT=XY?O-+8RT
M!?`%OOH]#DC[[WV!LP`BPZB6XL/BGC`H7F0;/_)G^[L[VBMNWM&OW3J![7?L
MP)5\'=,Y\`$\P> ;4Q&(X
MR!%>H = KWLXZ7^
M\PJ@!BM`2M6[/`3I]S>%2ZEHB0=AOH[>B3IJ4PN'T-K7-C%4+;_OO [K'7U5M>3) Q#&ST$.RQ*"?2=%DJ'\]J\9IMB`X;N(Z0;`T6VZSRGZC'I(`@[=V^^Z(06S)WO8049#>3N$SF9/UDZAKT`BAR.
M0L^`G67%4!C!0NG$-HPU=D]9$148(O:EI0$7_I]@PY7;Z`R>?%NF$"0M[O;XI`B^M(](K?
MYA7;;+W;Q4D @WWFCD"L%2@S4+=S[%?1ZCC+`137Z6' VFJU F)OH&\7+"A19$H$LI_>5>_278(>VV2!+(3C!(,=_>H*G
M#'''_4NS?(]GITZP')["!*Y`O`-)EC[#_"O'&;^G69Y.`O`YS([M Q4P?H%/FNUV 7#X],OLNKZ_-K#_(1FV*TKV'C`.I$!_6?J SZOEXH`P@XMT9SMT$B\A.,@4V:8:2$#3![X2
M,1;/S&%('##::!<1V#]3BWK.G;%90\]@;]Y_;Z`N!PUW*M=`C%7`YT<8\;LV
M.>9%-"Y@+^S_`')PV_;QP!_P&TM1!=-[@7\YA@940`=`%L_)6?J,=UZ:IX+A
MYO;/QL.]5FQR&N^U6\QK]AXWHUG[O=WJR-##'8^5T'&VV4&G#5XQ&[3H;X*4
MC%QOCM22JC9-Y.@\N)[XHEZ311Y4O(")7$#4#7POZ5[[QJ%8L2LS@K#-"C]Y
M_!J4\2LT55$EI8.:/RI9>%]/15&KW,D?A3.7YZ0V,6.L]J\^U=!
MG(/7(#F2B(3/?6'`\8!LQG51'$G\PM V_O*\T!*!U3^,>S@,`D-S+N$LSO=]G*;DE_1&;#0E6^:8.
M$DESO>4S1^,F-$?2"I!6*V+QX%(9]+1,N7[/"QQZ4%`C[A[%(GSP.:UEX+`9
M@!V1BB%! J,TK`MC21+$[-INKH@X^O3F:&
M/)LE$OK19'7ZA7OJD%F791X_'4OLL-AF^!B2I24:-M25Y^L4;15@(5.ZN3[@
MH!3#3"/#EV]H&`/*N9T`AC$';>XXBK[+'U0?\.`@L]A(T3-0P46N0O(1]QFO
M%Q/\K$Z6S1YFN$Z5O9BDZ-M*,>W6,)G3'O)U3^8WAG9/UC&M1[].HW.2FN<9
MIJ'%LLP=(!EK ]XU(`DP0)V^W!%_B>$'S\)\&+)X+JA`%=9#MJN*\_*NNI,D-I\BV=GPBOF
M+:+8[-;/.804U%."5M[;Y`%O27V\VA9M@9TC1T7H!3.=R=AYGJL9YQTH55
M-*6MW4Z\L([FT-0[KZ6I,>S2Z1];35,``&8X+]_"%S1T\#[/GO-@+ZR-J4%C
M%PR*_HNNI:OV@!%X4`Q3>SHZ\-"?"WO[$-8G98'57COKNXQ^/T5@<8\-Z \R17
M5Z&H;>UXP#1>&6S5=/1!I3<7[N"D8X$E-,X!);-2'40Q*'EC TGBSPLT_-(_;S?F_@[/U
MXR4^ 7]X]KK?7F[MW9![D*C':/NCH@\7KT^-3`7\[XM27KYJ+I9C$_I6I
MN/=\ 2=X8 4QF9`[^I5`K>:]IJ
MO@*4`/S"_NN- VU5Z@1'&.J1ZTC-!QA!N, 7H2WZDG_T`!;MJ6!7RNC^5+EN.R#R[?*2\C84$D#!02N@]I
M-4"R7K2K,8RM;G-#9*BI@7F(BU_/4>?B$O\DW^6*J5QL P-['SU@&>SDB(^L&;Y2?^0*"9Q4#%1V'N^
MBB!KZJ^*C)'&O1ZH$,27/M2!CP=5LO4U0I^%/]6S=1P/TDK:OFK1!(FOXC=<
MELR3(DRFP-2N4>V)XO5KH%[%:5S"F_@51LH#EP:M\_*]0_)HU.ZE9!\(G;]:
M-HNP[G5,&X.J`KX*`%K4JOTAB'.LYIO\(BX.61$DFQU.NDHZ1WMKL-D;Q 3()B)QL$H*>\^O%[@I0&T]5K8QXOB0VE.%(G[!TX'0A!N[![@[IA')
M@H)'"&U8T7^I@X1IGN8-W@A&=F_TQDC*YX.K>%!`D?K 7C\E)P#OET+@ESQ1B01KB*=@Y)DGU,31(_N;Y+'*WDG;O%B1IN
MLT1D%6G9CL7IS2Z)NY@M,'`1_1"? G@=80"3V"UKT+I#6)AFYNKFDQ1F56T4M:@ :),'A7I,_$IAYC.@R-)`C%_E6TFF7LBG\"Z
M]E6ZUT-SY!KD2/-$.S\5IG'Q3U)\;;.[BM,`J5N07*=%F9/+%[6/7)/>N@;H
MRC58#)408OVH24&+UE]=F21T70%V5PL=-[3NM L]`2,'OVSI?;POZK>8I.Z5
MSQ2BW#73*'QZ\"AATG,$+Q\BC'Z"X)V^C1+Q=GW^U^N[RX>?25K )X.USYS^65+1)L;+=A'
M>0+,=`7J"D%9#BAC[W1WD9%!._9:],VQ+,J`U+YSK]N3]4"\GDY2`A>6H+GZ
M:Y6R7Y?U#GW$GM>4I4,[8"R]#.P-,]#B!M8E:!UC_=7\R6/QD"7)AZLL_QSD
M$3:+51&3BMT)8%7$A5P1:W2>Q5Q]">&:J`]B@S!%&2:$DP]^EDW(.D2_1].A
M5.W1G.P&E(^251S!T5'>"L,5'WOZJ\XB-8O0%=QH_/(A!J/SNAX%.5TV;>J:`D9>0>0Y@&>9P)BCPJVCO(%S7D='IHXUV&^E!SI3GW0;[)R3H1D8-+%:NEK4%B!HXU22*94J,0+7;K46IV
MQ*\##OW1KE$B,BT[!.PVVC?M4B%2KF5Z=.X'-V3"+P$J!A?X*0S,.'JIL^V:VY-5=LTI916R?1T_T*PFL<
M\D;V:3155U&'MJW1R69/?S=B0S3/AUS&6J)%*:5F*(AHK9(2]B*(UG
M4@Q_PVFTA]>JXC%+?:1]!R@&W6OD,YO'^
MGJ3D/\^*LKC+2K0:HB\B_"I#O?7(7=0_TY%JH"H8)@.4;@4()7XX#&I:C\+!
M3:9NH&:8X;Q9O`(.BI=;N'^"N01X[4;VKW?;/>160O1'\`O]LP 3N]D4
M#.6$%X]W68JYHO41G0M*7)KN`CZ5#S#!D3;,Z@FGV)B#W1>.1K)QRQ ,0;.L21&T;$3,+')^F$-.:V\`S1';>?LW%JX6CS#(U,-BW8V[5II9
M*97](XI4!NYX3UJ#WC,!IXHU29"U![IB@";NV*0+I0GK#OW&)H6:,- *!Y?A4P-^.
MN(`+3HNZ1=]3I2D14=@_J`C[SM]!5BT!:0IP6^FJ9>F$LJ`$5@\J 0%PZK93KO$/D*9Y4:-%8SL$?'L-SDCS!_C4/5-FBXN8LLZT.]'LBKCIO1
MJE6L:>'-]D$V]`.YQA7C;ATRN%Q4-:;*C8.$QA5X!ONOB2!OEESE7`B`I)J(
M*7YR'&V7'_>;/(*YPCL^U-2R3WRPM]S2 UO]X])>X[]YLWIP(\D5K!T>1LMSK=Q"=UJYF6^AVK,9
M]\;:#XSHX*R[U?';X"W>'_?*F>^ULS[W_7YR)6OHWSVP]M*1[2-`,JP6,1"G
M>ACHMK./@5X_.0S0O_N$@:&1Y3`@'E93#!0P_.HY>_TZ@C&=?O1#?];1K_[S
M!CX'R24N^7`2K.^#K:S-^'`?N7+;N`6@39PO]9)AK29 Q
M.M&]WG$EX]G\.E_812/9GE[Q,$XXI&U?XCRZ#_+R=(..@&F1*4YJXO9VCVN2
M?G/U(7!30-J"JK$'=EQK^#O'-[VQM^LDCZ,XP(%'6A[R?F,G[G&NQT/NY:J1
MX_@VHWY_\PVN3P_3\IB?P+J(`W!31AX`70V7(<>X#"L3[-UY_!SDL(2W07K<
M!2$:JSA]K@LVRFV?'JU=.Z@I#Q=,PLA`AZY=:]0Y;(RGJV,KS>?*8LUWM"DO
MX4W\"J/KM$33@F-AUD4!R^+L=!O\5Y:?)T%1*+QC1ESLUW\WDI$KB$ZH/Q!R
MT-`#R@`\G0!A`0@/Y]OS"?/*U4D?.ZE>H+?IH%8 4*J&A,:Z
M9LCZSSG^JK:@:>P1G)13T4>3YCQ8C=,7YC,Y#VC*GILXA=?H=[+]KR$?%W']
M1G*:);M9@8H'^`5S`82-!P`=-;T#;P3&SJW;.H/*4AHR(B_J"PKK48AJ"[JO
MJ3%2##\K:ZA1I5-+T&U]C:$>Z9784%)ZH2/RTA0B15&6VG`-,XT"%4;SX^3M
MGU@;/AVRE#8L!DJ2#S]GT^?F\MV@@ 90X;LHM
M1M/!5Y@>X:9\@7GCW891%=`K`;::U'[ +"
M]HRFR&JL/W%$W*.I*'$NU>HJY;(HXSU.0/2I@+MC@OU\BG G%]L=YG:`GX.TDO7&7-
MW*$3R,\PR*\0P;BK##57GZXU-,;`](JCS;+*R+8"`>8*,%MPY46%E!F`87#U
M888*VZY>6+!U2.G@;;5TY-9M]W78F8NVL*R)VWL-=7\?LE.0D')-I-904OEN
MW6N'`!?#WF8!**RCF.2<54.8-7.%WZJ7`O#2!,$N_6N*?K9`F^4>8K:#`@%@
M!R!@,P46/7"J;2[7TD'"JWY?^3Q7S(D@M;EV,UL-CB^?T$HRN!Z JMD2&!ZF:U#V\]"=,^\`DF"UG)JG^3Y@]I_'?I3= @5J>M`P-2*4D?C!V?3K;CW3[N\: #43C_N8$G+Z*)S
MU@]9%GV.DV3]5)1Y$)82W)FQ<1'`:B+E0$AKW_6(.(`O:AZ@8O(E^*7BXT'$
MU)C)'8@9'3FS-D$ $.H^O8OYE(:X(_$NQOVLNIT,=EOU)F`$
M+^M0'R-O'^AM'D#'D'OQ[&8.R6\?U^`Q?DXQ&D^LM*$_CR=&8[FOOQ.![$6T
M`]HB:AP9=!GX%,/0E MZ-H/>5:,?,O/2'W2KTH:4\TB=-XJE$BJU@/3LGI@"D+QG;PGZM2!G($B#>#-
M"Q5:A^%Q?R2E+ML^NI$Q>2)F/JF96&+C"+R&4R Z*JOIEVY2249L+9=2N:P,DFF[2:.E[UUL)\=M
M(UWI#7GRH7`,2;1'C]RZ#FE*U4<>?=NC=IVXW4V.%*X*[-Q!2$(F#SF,8H0K
M"$*:M0S]])0CK7.O8":@[*N9.2(M.O%QXH#K%-^0X4Z=9VF1)7&$U]`ZT\!F
M5V ^DM-0:
M=IMO+(*G.(EQX/_Y,ZT0JP9BNPQ?MKEWMWK;Z3
M7H*0_ATD#8E[&RI&"_\B0PZ5"7;NIRS_-4Z?SX-#C`9*9-[ZK>Q:-:Z/_4EF
M#0!KL1`HHRPD=;T'G6S:?3T/\OR$.QOLLR-=[#^S[H>4"`0%_NU3@.A""(H7
M"$N`E\"O'%OF8:QT#+(,*!9SGP3%RSJ-\']PQ.QKD.`L6>NR&OL?@T3ZIDB3
MWGY^$TVY>,P5+\1E07YHD:Y`4((:D81 8GY#-K+H_YH>LD&;GFKF>']:,,.M/FM*ER#
MBB6H>+I'^71$\,\$YXQ9)$.&7XVPRI5(,@>JU10&(811<85DQCW!1_M-_HC.
M)9L=?=4I44$=8A L!1P#7Q8#7C*3U8!2>[\ T\'^+X:7\G-^5A&=AWS8R3M8Y/QP!#\MI]N&3`^H&;DQ27X
MM%GN^,LG3KPJ:G3 4A&583WC'
M-)3]!&+7*-M)415Z.H%!LJJ]^UO_)2$F+*,Z.[XLNEKQ.[O-[J(*U"S3\AK0P\VM;M!'>XMMZR25F!=
MP\'MX_/E>FYM &4"UW]8%5KG^"J;\S,\I'Q[N@3F7C?7D
M23\WF/1^6Q>3SO57,.GG?D[Z\'`/3+ILK"WF*$Q+M*M/CF7\"A]A>,Q)8"7-
M#08C[+4]S_:'8\D2WET&>1JGS\4]S(G'Z.PTS$"Q`U_TJ_:S(RXZAEQJQ59C
MT+3VY@Q@`5%<4D9;OH34SGU&,R*RZN\EJW'3?]^O/2R[EA
M0H?7;0))Q!=H_6NR7S`9('0>6"*]*1)?;JGGQU7E\XOX-8Y@&CW@RVV=VA5Z
MY(YKH`NE4A9"KR@!)EUY5:W"9.+D1=%U9LUR%!QY-4.<484@9+0K0JN]*CYN
M$FLWD7/31F,XIHZ^R**-Y.'6_:B?-J5[-9@++H-1:;-AQ7$D\TY8+5YJV@TY
M^1'C+)55&/!\U0EXWNQ`BTM?`]R&F G"D)OB&44 'U8U"=B>1X$#:WBP9QK[GD9;0E^+AN3M*>0$$Q]!T@:(W[
M##!X,H,!U]P-#/A>"V%PYBT,!$,_"`/IN$^'P3=&*.!:.P$!WV<1!K[Q%0*"
M81]"@'3,IP/@6R,`W/X"[+8:O+,G^)
M.2_[[I`1\G+>CG;H0OO2&/^RY@2>"*NVDKA7B]'3S3DJILWUE)3)G0N[R[[=WE;-`6[O-,FRB10/\(`Z0A:4$NV?8"5$
MB9H7;2=YE1DEHI?4!W('ZSSGLA)LW?S+FDBS9]]_@O@5*HS6KS!'&GIWQ#L^
MI+CD"O`\2[%_"$U. UNW[&'DYQ6,\`&,"*!=B\EE.HC8G4+%R
M;]Y'SW;?O$^ (":+E[Q,=M(,14D5FFE:>@0*I\"$[T5(,ES8YE$4<0%(R)
M>\4=!6.N>L]X#'M1C/$!XE!^?&'1*AI)8[$^2E1W-$>?RC MZUBSZU17
M99%_[N$^$00&Y1/U$6!/! G1(SP$>5#"Y/0`P^PYQ7F\
M34(5QK.TK@03I.]K0<4*M'BM0,,--.P\C2R8"H6^)LR#`Z]50U`)
MF4]WO%IXY^H."E\QD]-56>5$5*1AD5 X6S^>;\!]GD7'
MD#V]=*^"NM#C0D>- [IY\8U)QMUEXG(Q;2](F$3=2
MAA028P\^Q^4+")2:^4Y2 &H1N$> 5*5GY#3V(U;4/2_CY).F$,4QT$).FCJA"7H0VEFC(O<
MUBH"]^@6N9P%T';M3]:;`24H9O`%%S#\ZCE[_3J",5U(T0_]]1/]ZC\OTS(N
M3V>G&\P0Z:L@OY^XJ36,2'K+73F39KCH1]70>>$3;LRT;3GM[Z$WY`O/SK"C7*0F82PNX.4`G^A*U_X10Q^L=@/_BP?X"M,C_"'+(N5=DHC`20C_8,^'
MXO0+P%JN`&F[T&V1H5O(1`*:NX?Z==S#7PZ;H5-EITQ`KVZ9RCS#=61HTLMI39#%".44K''PL@U)5=51)
M83_J6-CWH;P968+V%"7)HL8("IQIC2UU),#$@_*AFO/"!=?J3(J;Y?L.ZJ!*
M2.%T`>_VG7\\Q-9NG&=K [`BZR=5N(%9LOQ8MRLR,;B, A*+C(-KLD;8`-_8&\N9"/!,AT)(0>8!^!7[X=]T:X'&&
M?GW4NT>[%LI78)N50>(R/D'=[7MO3F`"."A`[`J\Y,"'!F\7R\QUIY5UT';[
MV)]Y\E=`_[P41C'^51C5Z>5!TDN;&!V8]3X^A5-NU[`6C4NNT-Q7#),X,;6"
MW@_9W*+M:5:?Q&SN+#2EJ%VF)(D`;NS)UD*&H2&SK`:0S1I7!40BOZ`N7:#]
M?I(=\.F6]4ZB"`HZ!Y6OY'+P1S/:GFA%BZ*YBUER4Z*I').$BEI"Z5Z]?/OM
MQ]6?_O)/].[EX\>/JS__Y5OO;F"T(,N7#-/&J\7-$4R124NPHS+:QVF,30$>
M9K7Z*2GM;Z*4LG!;%DI!7=`=&J^45TTPV=.)<1>F?MV5FEV3
MMENO\'5I`@?O2E 0<6X$]T`7043E/7`625.-(;T5OY%'C@VVMA\O
M,]AGL9.)-@-?X(9?>@!PT_Y_D>".@YBT=@]Q"62X2!X57NP!'2WP6; >X:BQ2AU8>\'1T]8V9[P+B;#Q&CJKC
M2=4&X$4!?``IG/TNLYLP9VM'%) B+XR[?P!9=6N$[1.1S*;Z\TZ9PDA9?)(5*&B@8T1$NY
M[_3R84T5*$#-(B)&W$@$W3DDWZ$\)BG\341:[[-C2D*W>%$*@-.2,)DA8^K:
M:NG:AZ$,_IK&P>)5(;.HF_0B+@X9S4^QV=$DM[+LR"I"^Q>%*DD&-V/T&(YA
MUJ+"8*PR'GO@>QTG&1(#[P>J,NW[('R)4YB?B(,-_G:,R4VU^U.*'@*YBSX#
M^-G3)IH:_A:6+UETG;["HL1C_`"#!&?_[/ 'N#NF`X%[0\WLWOTX'O)I=^C[C+4!-`V#L\5VKTM46_#'$9Q"7(+G5;[
M.CP89Y/3P8CNNM[L"_2ML[>7*IO-!\'HR(DL$3M1/,`$@^@^R`==J5I4#AX&
MRV3@T4);-W%]C``0"KP8OWL@PHGMNA$&H%U6>;QT['$J3AQQ1.T+B_@;#")
M/-*18,F2"'W*O9X.8IN+_1`#VZ(?- S-AE-#17$+B(3P@Z=IZ`C[@5TM,RHC2XH=-(,J2),@I`6GI.$AL07G=&PE-
MU>, XMO2\`5&QP1N=O G^M(-I%8B!"M`2.C#HHK(?6F%L?/'O>P<
M-7D6RXR*>G6C47!7A]A^J5$=B0S1>.-3A5S]*>,*=!K.EST8WE;Q3^U>J7*3
MRXBLPTXJ`5]/IAWN53?W(DVYD2#G\3-:; @J(="4JNFNESZXR\
M8`M([*1[==*#HO;*X_2>#O4JA#`B#U9P/I'-;E#UY?JEQ\&%HFG*-J!QA)(^
M2ZJ*40B6++=KU?L64M>PS"+BNX@V-U3(`2MCKHWVS,W5,4]CM$&"J#-7\1O^
M25E_1T)CW:3(^M\'7]V60*QJ[<4&UT2,S6X7AQ#L*I(5V#$*WU1'":Z^LF@B
MRYYZW$"T!+V`#XQ[.R^]!@G+2B$R`[`*X[
MKKF:$WL2"#`O@)B1/9V+^)G?M>1:#PGF$?X:/^/H)$\(ZK?(A]HI@\>)ALSP
M:ZF6?16A/WXMT;*I\&L1,@]JI-B7RPMGEG2?8`(^>[JT#I%I/I)''>UTF'4B
MTUY>3*$0$JV;[Q/6]7/&T>%29#2L@7X2V9Z>K/SQ."TX5#>P*+X'06O`_$H]
M.[ #W7BAN')F."!6: ._NGU%X_N'RZB4/\[%%N'?AV
M=BW"0#^Y3 8 4_ROATS6/$/
MWBD7_`Z\Q<-SO@QSGV+V*TR`-XR"Y3G=9OB=;8$IC
M;"7UF'IB2#5'0-?6@H8?J!F"%L<5VQBX1_YT1.B9;7,X.+'LYUE:Q!&ITI6E
M#S"$:,\=; _P`!43G*/<5]NN/[L2XVXZM18?JN#\QQ&V^P!G2X_;_++MQ(.9CN?RM#^$Y>QDG/O
M7PBC#X03:%C5A4LP-U"QPSGI"$-DCQ4TMQ\T/]I:[K*M;85N*4QW>.*Z--Z;?:96B,:*9`W"@=PX/.`@*
M_>L`\SASGF9>@IYNY+4*.O9,.$[:>IT697[423$TV-JZ\1WNL\PK=I.ESQ]*
MF.]IJN&&V*.(*\E,\&7L%=/@"C\Z?E@AA6, ,AAP':XOZ(#G`8W`]!"655[/19.,:85#H%Z&B^Q@)0 !^'UTD($$=VC)Y^>]@_3X*BV.Q89?!-_H"33:L`+B.RCF*I!%PB3]P8
MX[2J89_E@!#X@T7UC/0!ISL=$QS+%>]4\4B`;V?7I3S03Z[*`)MYU,:#Z$?I
MZ':\KO*AG3ZWV\^9UMRVVCF9VW8_17.+VG@VM]SH#LVM8&AGF%O42$]S.RW=
MS&^GK\(9QJU\FV-^E`=G633$T^?Y"LV(UC2W&SJ9Y4Y/19.,&WDVQ_P(#TVQ
M:'BGS_"?M:;WST[G]L_*B?VS8E:7]BV9]?8*N\/\@N&?U1@ `5#=V\?XS3/\_46-OT$(3'FG#/$;^/7'>]0(XB`:$EVF>+,L
MI;'\?EG>?\ZI0IJ#]8>/H*:@D82^0$%G0KK/G+5G8U+JT?@U*.%]$H3D92)V
M/EX UDPQT)U@H[=924LT%?8)U[BO(0PE>N4G,:N#BGZ
MSY57QLT):BKU8!3N%62T)&A2O_5E(=&!4P?T^EB:%DL;9Y'Z1,VWLQY%V^_G
M0"@J:J)SG)[<5=T`VOFZ;#,\=A`0_=A8"1IFW->LT^@6YL]0A4X5F=O="R^%
M>@W'^'\-V)W\#/>/BH.*]U&ED\GO1YRFWCX&>`&/K@P?>FKUK9SIL[:.Q'E]F532ZW>ROTJ&=
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MYGG>QB5^7G.=1O%K'!V#1&$2!.VM`T/4[SX^2#N\QC0MO3$7TK'OPT5CX!VB
MYJ>X?"$/L?";K)?XL,TNTS(N3TH+8\S)/=*4LO8QV&Z,$W?1YAX9K)'3J82H
MR5Q.V%9O=KLXA'F!]NX7<0Y#1*?83,LH[&ZAI7WO`ZEJ3.YMZ^:^[)35T]#9
M'^O.@ [H#SFJOVQB,#!"WI!S_GW\E5#\H:8MO5F091/`/\6
M7CWZCE__;HYE4>+B8^FS!$9J4C]>`G>ET7X/O`(M0K2E-6W)VOJ#\ 25N,J=_9K(O)0H)
M\'HL@[Q[C"[2/H;^`Z(_D-S+'RDB&]ATP8R7G@P\I(X#1TO'^
M]M_DX$N%AA_]I7M(3X,`Y_R98?[MP;]:`U&/B$86>OL:.9EU*"ND$"[\&(^4
M0+V1L8E(G5GIXTY_2J8_;RWP\1^M4@CKKS'>)FUV:W3\OXB3HZ":@1&UD^>P
M:IF$,&*4H"8%FQW`Q*"B=O;T9;IPGYEPZ!_QAX@1@!TDQS*7@6JC1>-WP2"F
M%80J67'>\4,]F:AA1WC7& =6@YLX>(J3N#RMRRLT/3_BV='2Q>D? ]#PQ[K!OM!N
MM0+U1U8@*`'^#OC1-T69"U9BC9H74S-MAB?LA#W`,\U^[W'6U]Q^Y[/=OT#ON+J@X;.QH;0D\ O2<
M@,-S,R7;$W8=TDJP%Z1B%GU83RO$LJ]=OL$\C`LX5))O#!/+^:`,)>021!&_
M,RL03#FPW/%5\>#JTJ7FXM*D3Q67;'"P`A5$;F;8>V !UP;]U%H
M[N;.&@_EF>H)5BHN=Z/KD;FK,S@LA;QV7[UE6CXDP+C^H)X\#Y#=P!=T%]01
MK]XLM2]G`Q(5P>YF0?$"80DB=!9QK4F:B!36*U3"T87#0BNL?;BY0R>"-,2]
MX]'S*])=-N[BL_F4J/?Q*3%JN,Z0HF6`EW QW/P%;T?FZ?#%[-XC@/FI'PUAT;Q/`/$%#*N,:1_/
MF\=K)#O-?7#"-2^U76;C>-D%\$AY>6]L6"?)^PA:C%C:(L;*2Y?9E"GO0'?Z
M?-L!KM)E-HZ7M\"5N N1RVS*E(\%[OPNL]L`&_MO5,9>CEA#)G:A:BIA
M'Z-5*2&M?8$GV!PUJQU03IC2F=+73H/D&$[NTM^.!F X[0NCXF1:FV+6,
MU2:'\]2=ZAA.KE)Q3]BEMI-UOZ\]ZOBI%F3]MKX_U?ZT @Y,QOE`CF0XP2Z63,A))OS$'"D;C#"-][
M.42^\1HA@KD0`D0Z$3/AXUMS?'`D[O#!]UZ.CV^]QH=@+H3XD$Z$XXR+-W$*
MKTNXE[V)4Q'ZD6VQ+8EVKD7P"R8#A,Z#^'"]*=+*`B>8GZFEM]D&^YNZ;)#*
MU26C<5!Z6]S_X8+5U6F*'+9H6U],DLY\\+6KM29CRNM)F,>P6*<1_>&\:_OD
M:-&CM?Q64D\>[HDD:0W6)!L:^\=YLZKYA223.>L^#32>L/GLS\<1]N>C1_:G
MWW^E_?GH&6ITYD-F?R23,0$E#S#$RV&\BT/RDK%>%^NL)=OL\K \"X[)%![E@GQU3\CX^'QBE
MS]PH'=,(&3@?W]'/95 HV+%:CZ0C`=Q^HRSA>F=J81&[0HC=W-ZQ';#8W8^["^
MXX:J98I-[+`(5._'%AM8JY&&V=A4S6JEFR0!7, S=99"T/S@B3NUYZA-09#/^W! A]C([#%6BT)5:L.Q/-\(35YCJ-CC1:\3PKRJ*UOJF7$SU:N^N%ICQ]U#9D
M@-!U]]N+FS(=8S]2,MP8ZV#<2"@PTQ_`?WS$+L@_N31*(Z7L)2!K/!*A0'S>
MV+C>[YIH8L> -9%6H!BZC$39\:&+OL.8$@HJ5#]G+
M)PDN3F9>U?'D9$8;=?*4!Z^P.3QD.?DS+>OH6AG'`W\PV_E8U,^VLA;,/K">
M?,*N.C-'_'A^+M=D([E5"W91K]A%E ,@]-4Y*,`AR,OVA:4E
ML4=L""9)?HT=WYUS0%H;N;`*#JR')\M!3J'1SO5=#55U/H#54!W\\(I/M1*2
M' +%9YPR`"P$2$NN/0AY(ATWKN6DF5H.^&9>HA
M?@DE''%V&+$]4UV[3*M-KR:64.I3<3GM 20U;$]&ZV5 @%CQ;LW(PL*N/W[G?F1LCL;\Q'P'*&VPB-DEZ#3=WF7:-7J @3IKUE!+A]N-^0R#5Q?\.7%FDL*'TJ+2;1A\`["
M@Q)B&[0SR?%Y/BY)&,$68V5`A17MK;\=%_6[CR+2#K0:@E](4P]>B4N'OO\X
M7&/ +P^45->`P`8]7
M<1$&R?T0"?T/\GJD(R *-N8?\[01*2
MZ\.31_8Z@.I`6Q]-PMU$&C3!WWH+^$%H
MR2$OP=6,H,)'(.^)X$.YBF)EY`WD`;-[I^]1?P0KN2`%X-J1KP_QF_F>.\1N<5[
M7P(-O#,2__8U)K*@N?V+KV@?1)44[1)(37&@Y#`DD64W<0C30G%4%;6V[$P1
M]9GS3U0-`6OI"QKDH]YU56@,N3VO_R/J0Y#'V56&NA44I1`N*@+K?G]AS[G,
MC:SA"E1-/4"-WOCW??\Z@V\/.P^P0,8L?%FGT05\A4EVP#[(-;[1>F9O5%-R
MR;S-[F&^R_(]ZC>YOBC.3I(KAIGY6T?F7./"/WRF?,F%;HLS:+%>@8HY#CIF
M[`'Z/T`_L%+?BMB$_ZP0ZFO+`OAY%\HEO3V9F?][4B[IU<> 7(M!C\RZ,BBDX+;/K#FHVP-"X-@+,E(:
M^H?B)3Z`6K#ZJ:Y'6SP=J/5U2Q]G[@*$;C0J34AHG`JJ"'!1%C ],="3BMAV4"#14
MJS;L5H!2NG#739)KG:;'(`'[.(WWQSW(F9B'X.0XVYLY_KA]CR'XIA3,CA-8
ME%D*[^FXB=QX?#O+9:_Y?G*K==4$L#;./-!&G66`I8E2@@-^MXM@G>WP^YP\
MBXZAT^PP,XOB.M1+!/=NL7`IUNTM8%=!2)(W-MM0=!#:'&!.9JP@^=DD2Y@>
MN?5%3%,J[I:&D8'6IAP?I!M*FFO1O=TWF;:^Y3>?,XO%X()#7`;)#42GAN+J
M6!YS>$L77Z8GQ<41GA_S?'@9&&?J$X,RFY5U^4'%#Z%:`H'?,+'/5Y49/L6=HODZWGS-\GRJM=6C*R4],=V2=`&N<
M]`[7#R>LW@F>^7D>!6G1)/N':O1-.!>N6[R\179;WJG8QKS>&[JY^1Z+;\%D
M>X=P'-DX$\!;K'S%=UO:B?#&K-X9NKFY'@ENP41;O#)BO=EFZ_"W8YRC/I5H
M*N.G!*Z+`DI/>QJT]B^/-.3AW'JX)4N;L-DA>)8$G?BHM\V#".Z#_%='U0#G
M$BO;@4-+K%(AEM6;)%T$ T#L/\B":6E 5BR;+V\F]E;?C?**6^$%+_+`.\\%,7;O%Q\&Z5X9H/*8M
MNM31MJ^$2?R*T[%W%RBV;D4?92YU+7+[+G4]J?B'#YCL`Z$##2&@E*`B=;\P
MF,P:YU$WGK()R\/F*8F?B;'99FA']`!Q`%JH#!U3$#O:WRLD
M&D!FW1[CDV[X*SK`"-W&7LXB6*5N.R@2Q_Z!10=]PR<6?>BY?A5P^7:0/O4S
MHO8DHK\ODW:\/B/T*`#88-+T8NPE,V8/BNN$,(?1(R[:=A842#G0ZHHZ1E2&
M]5&"1ET&U@&I+1EG#RM"0"@_/&%2T*:MT.D>E&;3U\?EF+FS^:CU!4;'!&YV
MZ[2,:=&-5_@(PV-.7$^7;V%RC&"$RV?B;A]+9N4O@QQOG8I[F!/!5#DPY_Z0
M@T>T,X\4__B6?@!O#]J?`,TW0/416JVU]1E,5'T(/[>B:N5/WLYEA&%[2OL3Q#498;1&\Q\\0YKWGO65]+N=)WX=_=>Q
M*`6O@B9SM*[$XV7G2B`P3H"Q8K43*X6F^MVIZ0`:?BNPS ;L:18-4%
M5OC6L\SC$(M?D%*3V&N2'>C+C$Q5WMW5YRH0QL^_)7F$1.\YH:]O<7X`V"AW#`788*03"IZF**K&N)HWTN
MX%-):T9?P)!\Y>.?$,%'>>)2`P:VZR[J2\87):QI`2:NZL!7Y.#CGW`.W(\>
MV,!QL]@K43AJ"N=#7>/7VW[.C.`V2.D49\.R*`'6\@?C5Z'.LT//(Q53F_7Q
M&6U ;H?MCEP LJ(M$]-K97WE[_>3"KPCPO"JZ
M,#BTG,D6CZM%TSL:NTWWT^@>3 AO(-0S9
MZXH4#SRK,.M'* U,IF0XYYA)X=YNN)FCV13NI=KSZ7PG)1O9X3F=>>=2\]VD
MZT,>)Q]Q/7NY&9:2.)KMP=Y+9GZ3`D(`/N)U^UM?;+7&;`RC0C454U*Y[-/X
MZ5AT=G)R@,@H+"=ND?6="QJBC?O[.D^@H9Z&;JH2S3GPR,$@.K_=:+Q'G(.Y
M?\X#G1'AW+@:KEN%Y_9&]?K0SE72NQT>KUPPVEIE['`Q5*EW8&DZ\>?%^EB^
M9'G\=^FCCP6^]7[LD&2\AO7N3*YW9Y7>G?%ZM^(?ES0??,=ZJ,+-"T@
MATF5/S3-T@]L2-M/K=D#RK1Z=4U?7+NW28OK-9>`P8Y2N]XH:.QXV"LPXB0K
MKM-[F,=9U'MR6GO0KH(X_S%(CM+0,=L]\61KL^18+W!08'U9`=H;`=,OMNW1?YF""DX2?@WB>.7"_FUS4JJ=`\U
MG5O;,4:L.W3^/W1$@ZPU?H_!TH>YUV!M!')E\ 2F2C:&F?V]PAB)EURTJN^T3@ENZUK.,D*>&*-996G9HA5SN;FW2>,UF-LO
M3%3?]^H3^R'/BD6B:V1?>^>^K6K,[/I.R%L^V,`>^_`Q7'Y=HAS
MTIA*L81/@__&^W%B#(S/`FK9?$6Z27D7!VH1HF8[0 =A2YBL2UUQ8PYN2),U8TQI&$.K0_L0(U?]!\P)\\'#9PR-4\M@;"
M=Z_/-QJO+);_].]%KV\D3Q!FU.T;GYXBV`*F)247H-*-HA_W]#3[$!>_7N40
M7J 0`TX.*`IIBU.%$ESBF&B0?^'E-@ZBB>&I5^*-Z/68)6:+2JGR:H7I^)5\K'26BL
M?@T'SQ50*6HM$HWF/^3XF<5K3>6W*@Y#U40993CU0QVW,-^/5$)*ZI7J,6F,
M%0[3^:ME`JGJWB?QSJ_P(EW`F:@2CS;;Q9^NTPB^H8YDQ&>L]&JQXO2_:JROVR`F?P.4Y34A M4T+FO0AP_1^K'DWS--:+/,[M./<2-F-8,8/G9"FHLW##L;ED42/.4]V
MLOB8D@;O.D^95,^6#=I^KS:)O1+!P4*+[S`'OO7N+-/0>"V9'J3UO6J'^=XW
M4#I#V!'[=[9Q$JK _P[FQX^[ D-[:&CA;U498%U,G/^!L
M*\Z 7%N,W2<5I9?^9QRRXZ[N_'9SN_BL]7?7>B?K\C0UJG
ML7)M2PT[\O[,J>E(+VI1![*7N3*JZ.'"/:/?#/ILXVMM9NY%PZ1NQ>U8TSG[_W"SP7A_U1"OX.+.@ZBF+66B`>(JZ-CY_!YEA*J(QHH\2N]=V$:391W-H-HKKGO()&FTJ5;XZ
M;U3&T79OWD]RSDEC[NX6SM226#V\.Y^'=W/OY,9*S%V(9+*)>#^V6;P#%XFZ
M9(FG4;UY=[9YW)B[ -!90KZ
M+D_<78$L':RYC[[G\S,_@A8J)]*CGH^&SM:@MAJ#H`07,(0DV=.W'U;L0MT,D';^5&Z1
M#3L'.N68VZS]A TAM3L_W01Q=I^?!
M(2Z#Y!8JLH8HZ*PC4R4'YX5IG%*8X$.)
M3072@EE?<0PP9D]A'F`9Q"F,+H, /('4CK3T@>6_IQ8=BBU_5PJ/U"WK1OW3:^_@UZ7OFO8UVRR"EF:
M;C_1;J]`0 V)BX:M`]%RWF!MFV;
M'?VYC-%)_!$7/21U$:7'WDE\?2ETK3T.)O6N"=,5:-CBJY068]!P=GR?/O.@
MG&?[/9*65F.*Z=@+Q;DS%^6,;9#(^V!+-HC*;Q&*4N.M;C[2V.B4WX^`VS"/@W
MK6X4G`V[S^-7=&R_3X*0N$P'E'\$#VMZ/D8^B4H7795F]>`8#U`S JUCCG24VMYQ
MJKU3(QU>[[-C6M*-G2QR3D5H_3BDE&3@DK-UE"$D*T")V"'([4%FHD!]]2LS
M$+9.,N[/)7K0ZY\[3'#G4(VHEH]0HQZA>S7J2Z*E1FP5\%*-S`12J)$_QWP]
M""K528*_67;)O*OQIP#' ,`7
MQP[NC!.H6`'&RXNM\P3!*[E@)==A4;D,]\03!/NQ.GAW'8EIA`[PGP5"^[,)
M-E5;P4YXG,[.;WBHE9O%\LA9>6%Z%-(:V!ZVKK\?XV,HNLCZ+!R:,,4*&4K8
MN`RI1._:$.FHL8XETM=A>T>*B_@UCF`:%?3^B6[.\/])3A,2&NL'"5G_^Z"L
MV^(+1K*YKLX1XJ.JK?.#B1Q#5X5Q"@[LW1M2NB`, MINZU
M=3S23:+F=N7+NIR9E+O>7-%OA Z,@-[^4
M?1W]U[$H\;ZIV&:"QX[#J10>X&_'N(A+^`CSUSB$5,8'&&;/*>&BRA6U_*<=
MO`!>?#3Y1\3U)_$E4^]-,6C>%,M,3_UUP#Y?.>Y:'7"96=_!N#*O3NWH"HJ.
MW2+1)P7EZ8'QLJ7&_/-HFSH\OT._FN7+MY`5Y1)9K5% 7][(5B.C
MU])-&X9ELDWQUIQ,MB3OP89HF@^/;_RT9&KN^2J):GL1M6-PPV.>8V :E\75H[(?U>
MNM[!\'/=V:*()GHRNBXR7*U%CJ^JC0N$U?T3S1YMX`'*='OJ!]*Z\SZ`M:%)
MGXRV30J%>=J&F[G`7+N7@LE$399.2"AUC&OVMO-VU'VJ.!D2!B`H@,%D%&X_
M9SHH;#5S@`W?B&00\$``@40F(#`5C`7_J, F72-\9YB?*HG@=4'OE58(6%[R^9(W&]Q%H,:!OZL
M.XKA[ZJ_UMA;S'D+2WS.O,\S'``:G9T^%3"Z3C'N%3&"RB0/?N"
MNKV+RYNLD#U]:#>RKN>='@[IZG4:9GL(OL!-OL3UH,+D2)+MWF -#TE4*$&$?QC3BZ*`WC!*(QI'#!7=MF
MFHJKL8PN\SFW<8SSC9HL=G&;@?I#@--G_.?N8GQ6+\
M'LR4&0R2@P2/X1?':A-S:&UM/%VUEU1@:33C(MIK\1TP/"`(Q&1[@7Y.("E_
MET;K/5X._ZYZMJ%';O]UL)Y4W$/A%MD*U(0@2"/0)G7\9'B< XL6GW8[*[B-$#6(GT^SXI2MHF6D]E?Z>522+&VV8&:`!`*
MQPOM!%FR'5*;IY*$S.+2'"`4RV-U^=-`&;>,:4/,E;9 :(T&<7'V4L
MB"M$5FP`X0-J1G/KVG=4RA0^XZ@WE:Y-$Q9)AN.O"T2*1=P'X4N H3V`"(KNC4=':OZC3D&"@L2#TK
M=4G!3=HI2X+I'#[0&"%2+4ET)(Y>LC"%=<92EZ%B8Z0ID9*?0(Z/0@7Q[J1H
MRH@C)ZX$Q;]H31E=B?L)TUT'GNDJ6> ^J"B^Q!D26D0+W?Z9[1#-Q:)_/;G7`RUD
M];7"`%8N=00=_PY!'%U2FV.D)GU2#S2%DT9'6:Y3P.C`I DM.U:"`OC^9FL"($C-*+)'QCY*L%.=`F/NJ5`'5J?9)"SJ4>71PACAU)
M\.[E/L@5U:,UZ3W0IV&Y-'7J@CKBE@])YJEIZD:Y9BNO;!,2VCL5=4S@.E
M]E'Q)#!5*Y\2HXX7,CPQ-W'P%">JZNUZY!ZHWZ!4^BL:@6J+V%/5TY*R$J -%4J&M??R;$^B75,9O[-G>D/WUK,]SUOJI0]>8%6*N\BP&`;Y
MNU?\>=1DWA=YGID,?"%2+/G2U_@#OI@0\Y$Q-"7U!][[2]_I(]5_Z1O70^/5
MFZ%Y=4C3KDQ2((LO?6F5+)RN/?SM&.?PMHH@7*>13A"I+@/[+X1U)>-N!!DA
MJ9]`2F0N5].NE+H+"`M"B^B.@U%PN:P/+$C%E$,O$0$T2L.'_9'*60P
M4RX!0HPY][?4KV:7\K<8?\`7?XOYR!CZ6YHWY>_ ;R#>WITV>\J7W.@Z'7[";$EE\-:DHT
MI,
M?[S`U`VW!:1Q%:?J.&&AL03T`J%*MX(.?2DF=+^8J;`TD.-0`TCV=.$!'M@V
M>[/3U`4QB75=D/1>>.;;I.`LR_/L,UKX'7LYQG0_2\%3W7WP@>J!/T';*CSU
M]4$/3&[T09W608O*J5:H,P8TK4G5K85S.8Q7$+4D0AUI9SOP9-W0P)E,53S)
M:]!>S:[9XHS3K\2O:';ODR"$JDLJ309.=UE2R>0[ENO6CH41@YK:;13H:`GY
M@]R!27:02^9J7Z9&IFR7I@M+-UJ'G1@D3SF,SH-#7`; $6V[S^D$J3]YYCJCQ "Q33GHWO]'(/8OG*.
MAZO-QZ_T8?]]$$=H)B3*Q[5T\+"UWU=A3E3<9(4+[+A^L:KJ,=%UDJF+RV1*
M0AJKQ`ON-4*`%/Z5J@0F5A]U9WNX#=ZP9SZ.I+CNM73Q8+O7UX'GV;A*%&E"
ML.T:UJH.JV%-!"HQ"Q^@/0B6@0?88J1,*9F+CE$D-GR;!Q'?EKD[**%ZT9@9H3J%CA/'/];%?NRHC/+GI9BQ[4
MHL>5Z&@[%6CEQYHLNE:0DGOIV^8HAP=L\V0;8#$P&0T,
M6BLV.78CL7^TWO&QWA7KHD#PBF09R(TYV0\U-I9UH(P!"=9#*RCF`:I_M[BL
M*AM7`,;([5YANM"W@M=C4^R=U;CA<1#G`H2GX'O"[N2&OE*Z@K!C/'#R)I9P
M=\BEJD]J=^^A)TT?@HP*/S#K[RM(DJY+:9*NI55M!L%V$/:U2"/[F)U=PSC)
MUC1HN?O,3BJCZ_7?0-$ZR[VQEDTP!O2Y5O.@R=@D"P:QA,)!,\8FN(?342
M,PC9>JGGJ\&8(B7QIE 66B"Z
M(( [>FTL &Z32GZMA"-#_0-2,5%*/5$P'Z$@&*,!AA=40!=5'B`>@O0`?6)F;
M5F-Q-@T[NX]EQO*A*8PX(^0:=VA<>.(%G=%H=38WLUNL"899[W,/D/WF.A6'
M2$_D9] U,.;H&Q>3P>#@E1"&0MHD9D
MM%>..V,TE`W'_?%W+MT9BIF<3W$F[-$>8'0,\4*TV?6NRN^R\H$]Y=AF`WG6
M)>9A-LYV]VVSC`6_^C*F^!S3#]#!23]`Q1F_`AJJ=.#-@8'&0/N""6-"OK
MQT1E-ECN0)`OR\X>S5>\5-Q=[[KFLRV=_=? #B:JK
M),'%-JNK>XO-Y@26MNWE%.EYX'>Y8?PW,3'K=KYH4+/$.J`HF&[).BXZ%)+D
MTH=Z*)")C!<>"DVSZ-=8^!P,.8,!Z=G&F:S'!*-(7N5I)3Z0-[=KS,2]'DX+
M8"^Y@8[],>V]?E(#.S9#O_\XD^,KOC_$NESYM3(J5&M*F("N]5NA"QW=U5*$
M"7J)#I9Q"6]P;LMK-!WI,TY/Q"J8TPS.T4]Q^:)(,S>>E5U]'B=M'VV4"R!L
M0,,'4$95=O((8%96,CCJ&(-Y1*^>']3AQT$E+,F8BA-U^?#88AYAFS#*MI:9QR'N&!&W;:->VQ%0/.P9DG!+.9S5P5&CUXGN,U9#0.[4:,KF45H.$!->I
M".Q8#9WMSP09*ZFJ=`3OQFZ8"'E=MH].Y4M0TO3W?=GCHBM^VYKX[%,QU5V9
MI=%4W)DL37L#M$XC[OOG)&"81-;J&!XC=N[LD)G4 Z/$9LV!&V;UIBT5#DPZ%2;0\GH^&3+1E@'
MH6D;;1HF6+J+&)?\22/VV4UZCUK#'!W^I!9-26;7 ;8& ?DZC6.@:RRQS?MK0M]
M`X?#O1DKW*")-<3 `W0P0W#[EK,_
MF@GP[1@@N^.B'`K7EFJ\-1"\>QEG"NR%8V_RYR"-_TXP@N/&LR2.R#_0/NR>
MKC+LZOZJNFQX1+\AD]6.!$VCQ_@Y)3?]: (7QK#8PK?R+!G>5[GK
MBO5P;P>CS1W/@A)'/"/;?'8LXA06!3F*/![W>VRQT.];K$'#&U3,7>:H]F'\
MUMM/#Y=@ WUT^/H+UW05X_'1[NW[X&?_^\?J'N^NKZ_/UW1:LS\\W
MG^ZVUW 6C^S!R5SK?#SMWJ_`3]HS$G%?U*561YX+&=G=^HAX/
M)SJH&BICO:VMR](1[RR]&L,]J4+OYY^S_-?.1VZ#_%=8(CPF(X[,LK
M3*6I=GKM[+]D[/63/R,6Q!O'6CBMG3!'5ZV^^QO"`/>(3PP`F\6SR.=E]7Z:
M)@Z*8M6]XP/[Z9] 8VKI_FT=SQ+(&:!)(2&A?Y
MBH7]'\A,W#Q#9.4*OF#-?2A28R(+S0%(0^=9H8(O6(:_+]VC7HFJ@<3!.I":
M $O7T :EB:=@`W
M=`L)V4"WX:`>Y66A
M!*/-`T(ZU$LAXOR8Y^B[5W$1!LG/,,@OT^@B*$4&0MS9\![0IH&T!
M;HQV)1'`S=W"0S7T;83HC?NR9N,J3F!^CC[Z/)R?0MC2@ 9;^'=`&;N=Z%?=&OE&0$KK8-,F/XA+S>P:?2["
MG[Q*`I&9Z+6Q.K?]_O'O^]G?`6[@=G8'Q[(]O9*!7%IS:7T&^1%!T-:)+O?[
M*U1J5EK>CX.!=+2'%%TRU$LC@IY(:`>NT.^&+AH5[9T@8ZC?0G2PLR,#"6GN
M!T*$HS^$$L70VT$*/KOJXZ35VB%*VGU6883X%[Q#"#?J8GP(AGS94\=/,$G^
M/ B[`B(+&P5E#W'_!,0,3?/@54X"*A-9PR'TX8"BF@S];
M:,W%LA#Z,4N.:1GDU#4B,B^"M@X@P_=7`)6Z(?56.;8KTL'F@2$=Z84]&=1E
M^E"EG\"1ZL)E1T[BPGLAZKW(;\' "HUI6!8[]\>G)`ZO
MDBP8BM@0M'.`DFX_!="@C0!IY0,*X
M*T!(/:B1.TJR)K,(4H`4TIH8)*6JKV5R=0`Y6"97'XW.58S=+(W3L0ZQ+TK6
ME 4;
M"4^_=)#5_Z0V9*(N]GAYJ9-]>2?H)F/%UE/_E50E>B5/4-W8>[`TCH;P&&65
MX'=2635:9P'21)5UIN]>ZN\!W3,CMUTN35 I26W9OJN9DP)>I-R%.D:63J$].Y@.V9"EN
M!.!RGHQHK#AWYYO;2[!=_T\?4LOI($I#,9QGW7D,7V!T3&@"ST.6XFWG9E?W
ME+WE/X,I6CI*\KA61W$FWP-
MO-%.'P;%O9K/H!Z(81E@(0XX.C8.I[#(=J'@1[+/BMSB)=2?LQUN38'DD?#($HQ1`;`,FH-]B
M`D\:GR78R>`*VW%ZC--G%MF4I3HQ?E.8VD\-.F4$1`DV9!OD%6B8@H:K-Z&`
M2PR(!S%_TY'.Y32=">;6M?T*1JA'"==EM4J+*5WIK4068?8;2F)R?+6L>P9"
ML:;>Z)Z2%/H$TFL/-EKSEZ/^G=GG'DOM!ITGE3@6A"9/:ZPQNE44#+;`/G2DVJ
M)G@$C1N>/(HW4
M' ,2C9J#N;M0VBDCPN6%T8Q8
M0<=#6BHT3@?OM>N/@?IK*[#>XQ!]3R)VYQRU9BQ>:[F#JKU[2S"?[@C#@6=2
M'`?V1'O9]6>YU5^3_-VLFJZKK,Q ;!+J.8V:LZ6+Z;[:8SS,.2)1]@-^2@+B$>P]B82=`>HQB2_'LER*33"NM
M+`\3-9EGYZ4J#T@]7I=IMIX6MW>DRQH#<0'S^#4@(U$ENW181&T.;(]1:3FP
M_=+INRR-8'0,228)=BPAN %[*"\Q,>\M`?&(S;>6G0^
M59WE61[!#T_X ;OP^2,4[TQ!FF*WED,C6R]
M*N;?#6F\N-&CMQ\HJ2D7YU_N/#\K?[$I8U5L):)NS@"TAK#V*QC'#(A5.:
M@]#^[7/=H297=U84YT&>GW99_CG((]G>WHB+LUMI/1F%B&RT;-7.6H]8@`X/
M/X(_Q@E[!TN0U;(E6+80DWQ@-.Y5<01@13?;QFAUJ);-,>HZ11;CJ#IMZS)P
MKXPBR;3TL'6Z;%%[IH'Z$OIX5#:#HE+7-'#H4,VNTU?4G^':]3I$[M6I+8&6
M"M4$GFF-3)#Z;P`GP\Q?/;@,4D-)J1H"'#E4!_1#]3MV1FR?#-=IQ*ZKBU'^
MH64^YUX%YQDU+>7%/]=_J+U!'0\0CEBN/JAP%'EF`9891^(A^N"CAVA)]5,:
MG]EU;T+R[E;G6IEA'LL@+S\=2.^BN#PB*`X8%U,&=A-XFT@F-0#MK$F$'!P/
M`+88.,SA/45(TNJ#'5FTLG5/$8;&N6)7714-3MQ:]>8>!"4MS4&R7I49_BO]
M$>X/68[KN4;Q#E%"9#\*@"W&\&2[3N1MK+"=5-XCM76"@9%6\"%_W!S(\\?+
M-YB',;)U'T6F9A0KNT9GG+3Z9:Q8%2M`6S!>H&'F4GWGD?WNN'^".59D4KT*
M9$S&+[* :8HJ7Q2Z24C$L[V7Y5[-&/I/L3L-_1VLG`=WBNN21ER6YA^9)%
MUW5M,B-_FI"%^_.'6#JM,P4E!Y0>M!AX=CS0%Y/XZ-$9Q\.JCZ;05.[CM7#I
M_`;7K#BR"1-?[G+UR@-++G1]+( OX?8ZO],O3/9K" (MPP+L"8Z66)$BV6RZJMMQ07]E)#BC&D$:DX^
MJK*)V%?Q&Y*9QE;YJKY*R.KIJR9>72OH#UD6?8Z3!/7P.BW17.&@S.I.L/MO
M8Y4UXNV)$IN-A\EJ7!&SPZZ/JCQ-^'OTX935$T#;S0CN@_Q7;]5\!/#U%'\T
MZF>_M2(O/S2TV)R%#S=7(NFT[Z[HZR=/%',&0:D\<2./;)UU>8.E*]`2=UB"
M27?M&1^AP!KW6!K:Z]`3;I0>R R%7FS13"0[4 JJ*A[^"X"YQ_#V^^\<85QV`\!0F9I>(%8FW'3ZO17[*G)'YF
M">WCE,1I1.3H?`A.>!.[PC$;91"G))0C`R%V[H(=COHXP#`.$H!^1!I-+G:.
MZ)\ES/=Q2M=>EI.LH'G*(FQ;LCH6!&V.D^P$(?[N:Y:@+7:0Q\FI9H!:'],(
M[9*#B@]`HN%L>GC@\*DB0]_'S>`;^AOJ1A07AZQ`?0CPVU^*P\,Q+X[8@8F^
M'*#=P+%\R7+LK@8'-!RN]]OZ1J2SS3:U(/8W`P^H:^D1BBVABL#9TL_U7+CB
MLY8KM[9N?/]SVM*?E7X8-*(%7H88>X`?]5C8J[?!1J]C_7WU.\LC7R"7Q:92
MF#_J]>\-+XF!?,D2M(JSJ*SK-$R.$0Z5S'*:P:]QG6VS.S0T>"N1):@KS] N80\VW#]I H?[1V)7KC/4'?J;E:)`)KN;N%;>8:Z\ZL$Q^-96@?U!.GY
M5.:$%0$WC7KI,4=`6#H^6\XX$@^7V^N'R]O+NRVXOUG?N=?DJ1CO
MJ_4\`'>^A[V*TR`-%]C#:C/V90^K/Q*&>]B:\;O CTOZ=K`7]=OL>+!
MS1A^+B[W1\D]!V9H0]XGS_>"8J\WN)Q*.5A;K5D;?REU_
M:E+[BL)`1S"R&Q4Z1E+NE3SC`38[4'$!ZZ*=M;IFU,I?[3!L=%:IT3[H .UO5.M.9$17>Y/#9+
M^0WZRS6N16BT5`[2>[!L#LNEM82VO928&!!J+]=*R>RIUTWEU+G$Y16.#(]8
M3:_@6?%B3TGL`2(')-*!XPI00M!0^HA$T7RI82B?+)<8Q`XJ$O.$/5-GITOZ
MG"$W@J*0AP>(%,NG!\P./?9S5AQ\!*AB,M4XU9K)*<>.-,QA4$"VA:AW#?+*
ML_JDEH\66M+P*; J(8-4Q-&@8G`^;\+*)O`+JG
M#U/MGV"D'F"8!$41[^*0UOS=#9QSMAF-7+PXPFW&>G7Y%K[@EWWW>?:^)?UI6*2%$22F-:?
MP$_P=_CU?`X3^HP1J>`%#"&ITX!P\:V7EFM1\7VU0-HZ*?`;:RFDBW"8?E*O
M=1I5>0=)G(-.6.PH;@Y#8TQDE@7(6%H6W[V/
M:`+(Q:%!(Q$^83MP@XZS:0&1N;@E*X-H]>?;V5WL!_K)/U\D3?`"#GZAK1Q>
MNTA'MV/'Y4-KSVS7"=KOH,Z;^N'FU@VOH-?"=/PD^YI7#V9DX]XW%>I!=X`7
MEF)%%=TJ:.\.,;U^2R##6OH3DBH=>R%HQ`/O`#4Z$0-#C=WA118+T-3;]NO6
M7SS<0I1,N,\77DXQUMOL*0C#[`8&NQ_RK)!<20D);%]$B7LNA@!K#'!K0)H[
MO70:(\('=%ZF0B2HO=O;(/W^LSN@)XB._Y!D.&Q>SMY<7VWP]0[,7R%)>AC7
MPK9%!P*+YO:1G3/8_61"& Y.[W:5>(_8R8>+<1&(!8NSB,0[)O"3E94;Q5T)L5\#]HX
M=$4=/P M!3F2.!]1>Z1_FEB5*B!1@#U1P /!JSL>MN-9>2*]!2
MJE@5Q >F#/P"
MG"S*6@]QC@/+ITNYV5X^@OOUS^NSFTNPOKM`/V]Q;N7U^7]\NGZ\WEYO!"F6
M[2QK4V3;XA?)*4[.AFM:5NEF\),7G;EUO8`9:Z61$9D_1'Z=HE-M'#P>G]BF
M01XI+VQNN6:OL-?&*@N163/#KP9+,BD`]M5)!JT4*1N.(?@A9.ZHC^FY!,_VC+LJ?.B-_-
MYF7H(<98X"ZQ7%VGV\_9S\A&"7U@6J2>+%H=:8S6K>L4(%)`:+U A70,$_
M'V7C@*RM;@(43U"XVSB-]\?]0W8*DO*$OH264^*@)A_$W[I"P!%IG"ZU7973
MEJD/2D8(&"5Y]E[15GJ'R0&F=ZEUHR5LU&[/9,V9K$CE\,4,E;6E>CO$J'QY
M5[IGANF.\HT!]++:%[\*SVVZU-YI'Y5IO/;%HB=/WFC?L(0CM"_>_?Z4KP5I
M4^7C\+R0\J%3=@[)RYXQRM>F]D?Y.C(9*U]#[:OJ2>4S4#WZH.OWIWT\IK6U
M3P3H!3V6-Y)T*P@[N0L2OK@NP%X9*":3@%8UP*ZGD)6UH/M.7[R@4(DO)O31/W4:>"\>W'F4H'UQD:
MR&[P#KZ5V\\P>86W65J^R%X[Z)&[QHU(*A685F1WANP5I@64&%!J[W`FG3D%
M^#2FS2TB'\F-`#ZE&&*Q3>@%"CN2:../4I$3NI_`XR=(!W*BV7$+MBUVB(_`
M6HO."ZBUY=!&&B'R&&C ZW?9?6E=6^D`\SB+7!]2>4QT3J$B0#@V>=CG-\;B-71^&+R6'/KVCC@\
M/39W_ T&MH-K@E67!W+8PZ9L[7E8I7`39/>.NQTY>+>MK/J
M$X8N8L6K\JB9R\>^)@_+&,[-M'4TDY@UGG
MV]/`[,I/5\RHV>;LZX2I]@[9TKC=";Q\Q; A GUV?7.]_=FE+\VL\^*7_P/SX]JEIJ$>"HV=_S'_P#=DKTV%
MS9VKJN#%Y;":.G]`JB_`FCT7+5^"LGDSVHZ*RN%SD$=X3U34PB8>8U[X(E0+
M7/9VZ0\0+8_'L"2>>9P":IU&K,S%^BV6[ ^8C6;%'LSPT&YVG L_MUQC&&4[T`77+[2]
M!\A2SD4?4YH383$#ZOZ09"CBLZ7DKC>Z=U(`M,'=WLW?@3 `LBTL#AMI:?HPWWEWM\1INU3#%NZ/2=F5['6Z_*F`BXFE=:
M("AC!T)Q@$@1$E;-BSC*CNB?) %6J&.86N!9(_3(R)@= 522QLY6EQ9#\7+*6[@Q>(IZ&DOR`[C&2LVU4&J3\\YA&X?
M\(A1,;P6\9`P/4<4,/SJ.7O].H(Q/4*@'_HG!_2K_[Q@ Y<5'@QFPA[I]#'%[3G/`O0GO,\V^-UAW1KW2QO9Z>F
M";NM7'\.\HC\WX_H.(TVN? LGW=G'B7.>F/:#T^8&+0_`%I?
M`$]HX]9JQ[X"R!=6]#^`?0G03[D_8"^!KOZI?#EHV0PSP7V^1IO,-QAML^NB
M.*(S'*T_@AU72C>C+@,'P22:DO'Q(T0#&"7>`U/:?_R';[_[EP)0#BOF[O;&
M+6DVD7RDB/DL.G!8EEGX*^VJOLN2IW'GM!SHO]AMB1L#!D8//9>BN1#Z+N43
M,>$0Q;Y`S&NU@Y?GFY=1V#U>2?LNP`9=?:O6'F!# YW$(ZS\6[*^%;. 9>?6`^^$3-
M&F,7$&F]`A4W0-BUVA1UHZ62G$HKILP]!%TYW1OK29#FWKI,Q_,$(U]QOGP[
MQ-3%>!&4PA@D46N[QEW8YSYN:FUH6@+ V>-PU 64=UD&[9J?.D/A(_]8_$=&-8X$,QC.Z.>!^PV9&F
MLB"J93[GQLDS_Z@MX.QA'UP!^LD5H!_%>D0_ZW[-6Q*"@QZ@1?$WY5@TO#0+
MST2BYI8/1,)>RS=;8--L*ETN1?K][]U'P4J<0[5'KE UB7!D!
MQU;\GS`F12"#E@YT0QH,%&""=E[%"3IIH+4Q?@[R0NZ1&VYK5Q,%_>WCM6H&
M:#M?_&^RT>[,OGJH[9T7;H/P!>$N/ZW3"-\V'*2^6RTJZ[MWN0R\]6:M`3IJ
M@KJ]!R@RF)/^/EA[0FR^S"$A;/=!7IZV:-=1X(`X> 1)'(OI1/%/=4QF:4HM8VPN<>#C*R0F$Y8E+*[34%'26$%EN;*Q2@8N
M\+4A``W%"B":KSRP5083TZUX;#`K,SBKR;E'Y:-FC=RXIJL>"CW2DIL,N[Y=
M94_K Y\$`F##MP!&$RJOI'B\G)H5LHS&.!]_CIZQ0&C(C1*
M"&Q7UQ#WG*^FD7ZX9HT!:PU8%,_1EZ+F!7H/D2%"0`PWM[X]%/2Z
M#[4ZB1U^NU(W=+\%E`UZ?]NG'G%[8+F( 4"WED##_9V
M\M'MXT$VM!;#:'^*A[6Z7&%4.&Z
MY)HYB2"$8H=EWO O#&N/N76
M6"P[9HVT=88V]Z9C`57B=O)+Z9%#@T/*59C8#D;@W@Q4/=?2:-+8,YT4"2#I
MJU.%ZD!%J1L#.'$(\Q_RK#!:(AF!>YA7/=>".6F\5$Q^ANN(S-7]+>:&0YBH
M$"42@J1B\6`3*@>/$O@#R+$/_.LTS/80]:E*!27W$LO)G"F!0`JI*K2:+J0/
MWU$A4OB,K_>W)FJA*="` ,.J99:?9 WTDM^6-G]V;U6&AI3?HXG&TV(J
MG=T.XLR@L-XH/J!M]@/$8J+M(NG;8XE^M4ZC&]2-I&XG/>%,8VL_(`N
M6"MV@+8C)R7,$719HET:9DJ\VX1MJSW>PZ$=3"C,/FG+D3;SV%")\1F+),`M
MR#"DD.34WYQ\XW*,!-/3(E`PO%6PN-MAK&L>&.1
M8R&_8)N(+YM]AJ\*+H.LGNZ*\8JDI%+?(&[HW^A?Z`?L%B3#\/\#4$L#!!0`
M```(`$8Q1D9C?MIL27P``%9>"``5`!P`>'AI:2TR,#$T,3(S,5]P &UL
M550)``,3H=14$Z'45'5X"P`!!"4.```$.0$``.V]:W/C1M(N^'TC]C]X?3[;
M;NK6TL3,>T)7'\U1BUQ)MG=B8X,!$44)8Q"0<5$W9^/\]Y,%D!0(5M8%*+`2
ML+_,M+M1Q7J>3!2JGLS*^OM__[8(OWMG21K$T3^^'_WXZ?OO6#2+_2!Z^?G=E9=Y3XDW^SU=M_]N
M]./HQ]/OX`^?CG^X8O/_K00U;T\.,L7GSWPP_\=\(@^OW92]EW,+`H_ ??N+/
M?WM.PA_CY.6G@T^?#G]:/_A]^>3?OJ7!UM-?#]?/CG[Z?[[ V:L/D_
MOO_V+0@XS4>C@[+]?[N*9_F"1=EYY%]'69`M;Z-YG"R*47__'>_WEX?;[>%#
M'S-HD2=+;H>?^#,_R;OY"4;9 &8)
M_]O+>+&(H\ ##T2
M:6]A9+PW/M.]LS1;> ]/M=[!G-Z+6&%L9R
M'V F,KN[*TNP2AX'/ES`77LAM\OC*6)8:3BI(
M'U:^0+"6XGW>!=ZSZ2LK:FS#XW)VD\2+!Q9RS!,O,1J4L+6%4?WF)8`UN_XV
M>_6B%S9)XI?$6X#KK/XAO8F3RO?68,3&/5M`\\"R("F^4/`]-7EOZ@VMO"6+
M15!,72F`!G_G7U#8%`3,[#V1]&)CKO:2"'I,)VQMC%?/:'6`=6#C+>9^<0&+
M>\"]>&-1:KHHP#JP,+9;V-TMV)/WS K,7#9QWRQ@(7O>/X8O$3!/)AY_(,TB_/"DR?P#>"^O/Y_DT]=
M^]_J\EL(4S2,^!7FE9D7VO@PUCIT::TGOKS8BZW6O]35>MD8B;27_7^/C?
ML/_.OC3&`.3==/;5,1ZGO!N[7R#CP0G:NIQ/[KGO9K)M.E?H6+)MT:EW);S%N54=[4/K;+(2-N][+RL**+5 J1S0O"
M7>\V@MG*"W_UPKQXS3LGH_F(]L_>ZF_/9^"A,+K.N
MJRV,0:^=Z:] F"\KY:G2HJ3
M+_"[83S;^JF0G[F)$Q4%_&^FLA\X?T[Y::-LW5'H/;.PZ'ZJW79Z-CKZH$AW
ML"M:BE-`*9O]^!*__^2SX""CGSA]EK$&Z\80ZK_$;,KD83
MZP++4QAB7"R#N)8:)_!U^L?WH^^_>UO'#>]*GE`8!8:"S'9VG7OI?77T\V\=QEZ: A7<4++X@D)MY]F#/A]&76M978PB@@L6D/'9BVQ>0,7TAV
M"ZR(WEI5$W@O3OKTSNKA$9OUB+!9RX_3`WL)^#>)A]@7V/=6].CT[."`H!EK
M9MDU)8Y%;,)C\B:\!`9@EWH+*]1O_Y,MI3:L/0O`#_MK1"$8L15/"%OQ,D\X
M1S=!.O/"?S$ON8[\*_CF((;$'@?X%-="2EO*\8C-^9FP.4O?O`E"EEP"C) C^$\+A?/<8A8;NN9Z=GAIS[:3`!";*TS
MPM9:?0D^HN%%M*H:C)-_#R4-@9)1'^VJBPR1$SX1MO::CB?H5K'UX(\`0Y_[
M:,%=#(BM7&@_NK8Z!P0^1W$3>MA+N/4,(.WEMT\``C&7"P'']-6:L"2(??D2
M5/@L(#_KH_DD8!`S]D&L*9?3):8;^#N54K/S/"S?>OGU4P!"3$I9J-E&Q'=(
M^@;=/`WH>[E(E'_C.*OT2/STCAB_FV:YBR1+E61-L"$4YF\
MW2I5"@HQ+V4MIT3U:QSF8(&DW!!C;ZKP64!.41W7-*<0#&)&^AK.2IEZ8&]Q
MPI,8BKP@N37%38"'7NY#U)@0VU+6=TI0D_PY#&8W8>R)4B2$SP'B7BYP$2"(
MZ=J(/\1\[I=\>Z%\J$]@V(NPJ!N'HC;N:^IV)=O&6N)F?)
M /5W7YP6@N-[S._JI+%S-/JET4B"I9,I]%JZC9"
M+"%8_#*IH`PJB:YDA1^;@+T3/Z*FF4@G:C=U&S[6M1]B=26R(:34UR5:'A^:O&W(V=9L43'_"'IT>DM`B!/1L
MOPG2\0]":;*Z@SET?SH7,Y;IMN40%1SZ)2EUO6TY)"%)R.W8>-MRB.H4_5*=
M;&U;#FDH%'J&,]JV'*(J1B;WE3U>HUI>_?QZ1$)#0*W$S9/(U# 5
M*/Z2B$PEE".GU1:4!FVK$!VA!1B,%:(,?LQA/I/&1=P.)*%Q\N)%P7\*H!]U
MZ+CS1/ZD0L)XOLE!^RA1IZ$D6>E_>M2RWEB;P'L(J.*R@.`Y+ZC]4HS-['4V
MZ&5Z1"(-PY[=L."^&2.61#/' ->$U5TZ^L-DK6]5%YJ4?O_%*UDSKTREM.#W^9&T;
M4OS2ZFZ>Z*7^D](@C4;3Z3&)**8&G8+-BBZ^(01U)DD,0+,EOXHCJUY:=K'D
M%2<44J!&Z^FQ^\V*KD$Q>4$/Y!!"0"A6CE0I&FJTGAZ3.$*@:U-#CZCA'$(\
M2/A-5:J+DE;38Q+Q?%T;BCU`AE;#L]/B6WZC+3
M-$RZF1Z3".7J6<5P%8;!' 5_U.IB=.]]!M["/+Q-"&/I07=_N^ <>
M7^,D>V+)@H],*ZPN;#`](1%RD]"+1-%Q-,/0\'E20#KQEGR/QN..7L:_G ^B^TPB@"6WD]BV")@A1*G@
MDP>[NRP`YS;,@U>TG'XF$:U"3(?860/2H`XPR4)7^,/3SR2V@.93\S:"(02A
M5C>-JY>#VP]./],X42HVC-B*`@26XD3U78 [OR2^EEGU#XY^EG$IFRN#&03^5ZZ)8.(>U*S`XTWIS=`#$/+.0"
MP,2#E0!;4R)3>B7-II])1`M-K:N$9.F4$2&KC^?S8`83QCBIGK?2MKZT^?24
MQ/'0AEZ@AF;K$CP*[L"C:A'TO;QG,K-7'YN>DA"E3,V[`\'6_7CNO[M%LA%L
MX=Z\8)UAI'Z3\4;34Q):E*F!%8!LW:]'X:TUM37""@F%RM3,.!9;5^]1L'#)
MRGA^%:1O<>J%/R=Q_G8;S:?34Q+REJFO
MM`1LZ^(_.@ZEZR,;%DA(7\W,7L5@Z]:_+,Z\T/'4CV0SRA=PLF;34Q+RF+:2
MHL1BZQ)`]RN[DI/[.)H9BF6[3::G?=3+$!RV[@=T;^%;,$'TPF,P*\`LN_ZV
M^D#]',?^UR`,I1LS=?/I*2'-#3$HMF?31&?K3D$27^HR1SM]BL_G\R`,Q'=J
M2YZ>GA)2X8SLC8&Q=>]@._,BZ78<9UH%NG%1PV]UB]ZF9X0T&2V3MP6+I)@8
MBW#N5W0E: 82S(N5_#56#K![7Q1M,S$F*+D3&5_B#"B'B`L6#GW@,V
MQRW6AW8X9=6L CCY]HC8!
MZ!LTC*G9$B8W&M K`3\`ZBC7F+G%#:9G_3.Z!B+$TKW,=#.:LD73&@D5M9&%$33("9X>
M:F9W3"=Q6:6RS1XS"WC4@H:C;VV3@^Q.86BF(X7W7S>C8[BY(/+5E_-:[H
MB#-)0HNSX"F-D",^U,O4N2M6W-85O#-3IU&TY+O!J;=&
MX`OC@1A[!Q5B6&,QSOTJX3)>+()-\:G+(M?OA44SN9DEK8"@H7P(E"@1-^BE
M7+?+T"8)=!(GA?&R+`F>\XQ_%)]B/MF3&PLTY0Q^X/@2&H"ZI@/+/."B/G77A(!1REL
MX_)%7AQ@O6+S8!;(/E/JQD`8B5#%_CQ'EQ/$B7HID=IAM_/U$!!/0FW?GS/:
MY`TIX=-'U5>Q#FV1=0=449/[+6SH)5`1KVB=D[GG&I8[P4O#>]R0B/%NMZI2
MKW@+SK>]^]AV?T=9SE72A(_-_0712NX$P6LUJ,%4`]^I3N+DKL+J[S\!\RF8
M)]"['%35='KB[()0;&AF)?H->IF>D%C*:)D$6RB;@1W*>_B;QZ\BYD=47OF-
MQ),D?DF\!7QB5_^0WL1)19EP4T19='=Z(]VRVG`Z&CF[0N-Q]LK\/&2KHI87
MRZ+$I;*,,MX*P)`(W>A0CFP.5.#<5E=&%B[\OKSQ?'._?8I42D:?!6@D8B]*
M]@6+%1R/VTK)FJ9"RQ]+G@9X3F,7"MXUC%3%X;;V,6(F\0:"#A`[=
M]:$'E@5)\77C14M >'[XB:N7<0*#+(=85GZ-
M84R;L5ZPB,T#TZM6FW;)>2"QP#*WG?@5;DG$4"1?60*QF_:?XRD&(/.
MU>5($S!1@_M?NX&A=2 H')#YZ7,KZX6G-PROIFK
MQO/J6%81YDM8=:2%)9[Y:"?>LIPJ-6XC;]4QF/O4U [Y8>,ER/'\,7J)@'LQX
M<>BRHD5Q,B(,^-YY_?\NWK5Q\N)%P7_*JV3B*(6A^&LU;E+A:#R_"2(/MOI>
MN`F*ZKR85OH'/SER)^E4!EU82IK`KM,,X)`07RW:!I-Y5"1T]NY;2%=:O\^;
MJY92M?GU&@)V$JNASAS`A`9+&87N3T&+PX@/S&=LX>W<67^;ICDK"3$.OFKT
M"=R2V/YV/L>T9,A2HJ1[[P-R^8JD?-,>@O3W2QA[D/$_R3]36"N>WO2G^4PI
M2+"4DTGA"/7F6EG]M0S69#HZ(I'PT;F#R`FPE+5)P3G06VSTG46W"^".Q!5`
MG3N/&2&6LD,I.%/],C3@+\C87?#.?.6Z1]D6V"*AA^QA[M%BPE)"*@F_6;QY
M0+00"('_+U?\*T_7E'F,.^)EWX:]
MYFG%"Z(%&M?]H3"E?,3=JY'Y\=N*Y-MBPPDS+%\4IFH5R+PW>`^'+3&VY@9Q
MMUX6FE_=C/'`9O%+%)A%*I1M@:X_APZDR03B.#VO+F^PHL8;`4$DCOAU[BHJ
M"A`?Z66Q^0?@"^A_!>ZNX`T)XT*]N/[&)UMU!$.C-5#VYXA5:'.!N(]Y27OG
M88EZCK+^+*-H.1T=_SG$9RT>$(?II0@M.65BDG^AVPD0..Q-65-*$)_JI1;]
M2\K&\^LT"Q;`F.R0^_:#0,2?0V46P4;LWTM-^<8+DJ+T?H6AVPAXR0N*E*L8
MK?9`&XEC>IU[BP$;B!/U4B KOV==*IF\21_#'&:M`UE_+F'8%9/XY@A#-B$$2#BWHS'L_[;_FE/D77LB+
M2S^^,AZP*\SSRK)@!@B=U'5=F;%BVDF
MA"&3T#GTZ44D=P$JMR5[_:4I0E7I>9Z]
MQDGPGX^=K?#$@*PA$$0BD0DSG=C0.I@L9="ZC_%N@YUXR3@IV/(+C7@=M]3V
M`*P#8(U$'E(;3Y!CLY0VZ]XC*M^;#$=G=)2T)J]\U4PME)'"5IYG&=I
MYD7\QE\34U>:`46TU+5F]MY!U%TN:%\*'!7[HK_*&^$ASF-G]XE^W)NQ.>1^
MF2?)>C.K5;-,LXOIZ!.-&F86C89)-T:,D"B"9-^=ML\M`[ BDP7WL
M'0-K50NDXI(G)-9\FC;`)!X]F$,I=&EXL;2[M[*SZZ5/#MU_8,5C7)M@G#P$
M+Z^:16>;]@E$$(FMJ 1*+OL_!O8@L6YHYX)V
MV>AL+4'B$C!WGP^R5X&=$@@E[-PZ=?[52\H$F+(P4\K7ON5KF:;YHOR[!E\H
M&S\$E)%0C&T87KG)M)+P4,[@FCZ5@*:X`?GMC,[Y>
MB/E?52+"K7Q\/X,"^Y)(M-GO^[!/;H?R3:[ ?N0]S%S7ON#I9N/)/[8QQQ
MC^8!OM5@5Y6B5O>9-YA+C'L%,DA,!DI[J=[TAL@'^9F[GL\9UYO8AH@'+RO*
M'D:S(`P^5M:& T_A10%0ZF/CRL9`%(FXEL*2B/DUX0VA!LBD
MB*[S.O]E"3!EZ0]Q`R"$1!!)UW182B*.;0B%/]8+Q-4.7C';"YX&*FCDDMB9
MYU&$0Z@' '-H1R
M(9=>^JHNZ+1Y"("3".SI&TELY#HBM\5"L,O284#77Q#.L&N.?LX^X&Q7=X]V$@A(8\9NH5$+F:$WJ'W\\#WR0$,?D]D+66#@@6Y>DT:B96IX\
M^\AKTMU"B=H!/R3D+]O;*!RKK ^SLM#/0K"%I,
M#T:#DK]D*&U=#D9``=V%J4Y4P-H`.30$,9GMM,U=Q63KGBYR!E>+8J+G@102
M 3)/;S639.'EGR'LQ4D9YDF^&//A*/3MW4
M`NPD=*R:,206JXX;L5F_-*DOWK=@D2^45MMZ#O"3T*!V3"*VGLB.WZI31]
M"2(]VU6?`_PD%"9=V^V.';&="TTI9;,?7^+WGWP6E&:#/]2M!7\UO6,O7G@=
M94&V1+YW@J>F!P=#4(M09(@=7>1'Z=JQA(!N&NJ/`$ZG8@]*_:Z%=H>-'#+9
M5Y83LA-X>@T2?^(EV?*.GT--8\5V`'L>,#J59\2_6&J$3C1:`V4DI!=[JIL>8L1)^I75A%??
MUXFK:+0&KJBH/7IF-?2*.E+$*_8E!2'?Z +,N3('K98)!_
MLW7:`G82 '&B6?X4NOK!5[M[Y-5IZ-K]\/\$ \AU!HV"+J!_@CX3D:O&S9(P>\9[!"+'GBQCFVK+D[;JHV1R66O]B
M7G(##9K):ZI>@5L20JTUSVK-!>)G_9)N2RF!I:N)62FP;)X$#DA(K];\08@/
ML7&_Q-45LJ* @2Z-SW@X*@)JO'36-@BH3FV?V2L089J>/;+ZFSYO:;_YO%+U'P
M'ZG@J6H*+`U+]M0#C+A%O](UR]H07UCV&L/J%K9&&:=K_#5B2?H:O$U8PB^(
M\5YD7PSM/H"W86FAAL@1C^F7*EK=\_#[W+9W1!(WD3K`11S"\0'=
MCXO4V#R/1%\&T6/3T2 MXJ47\MO-9*M$P>/3T>AX6(J/!"7B`&TTP[[`,XA8TJV7U@1<2DIK,:F([
MJS`-X +6R-YM7&>%W-*-9:1 &X*?0B1$P=E9&A\
MSXVM+78:8^1#",$XK")#8V%@;'5CY\'1#R/08[F(#(W$IT;VQ-:2 @$HB@ ^)B(4$J'Z6!GW!302";4V
M]`"Q0S7D@43D#8FMKPZKWC#\IA[A MGT>AT`8R2B[0W,;*R.[,`>4L1,@AM+LM1M"F21D.Q-3&OL
M'!6DML)OQ-WB?#;+%WG(#[15#STV M(L2/.9*R\NJ^U*>>P
M\9
MXC;BG',KPMC2.`Q\_EW?;$;&\]VQZZ0#M>P:#']H37[:_1DLOT?V.`R)AA9E
MA5J!,"7%/80L'KOGGP].G,I.:I,A^5MR0$-(O&E[]OG@A(1$I+`4(A\B`]!V'`ZQRI+;S[,!!!0GFQ9F8,HMM^GH>^?S_>*7)=R_DO)QGE[#'70)@7@Y`=II"JSW014+X
ML/;R&J"VE-OA>.X&D#Z_L#Y(9V& 1/[(%4MG2?!6EK%]8"\\/LF/$)?@U^1QX.>NFWN!/QA4IK.IZ/WUA2_(ZCFJ.\`/!F/%I'=84MIH>?&TCN
MEI59Y,BFC"AFV`F10&OLCO#]>$L2Z^GKU>:"#1DJGP$@*'%K&(:@A3]ZX>;Z-[T ,A9A6!F9`U4>;7WEX-B(AJ4D-A6D@
M`B0DRHO:?W6+XGFJG'9Q`Z"01,2C@85E@"R)YA0,O4*H [3PGFMV^.YX5W/L:AK_&!15I,#T])Q+G,/K!2,`,JZ]GDOMG#4Q*?5JF)
MI)_6"@Q;^K#[(QTU.O1?5"""2!#)V)Y")+;46"HF5:]]MYZ#]2*)^;:Q.;=P
M=%4^ ![*/:.4I8(J$`FSVX=P!8.W0G',+%I\-?DGQM[=B@Z:Y
M)A(U`6IHJ$9F3V9J=B4LQ.Z]E,/J!!DL[8$,,K*8J8W%6)#L#G-MS/G.;?.9*K.9
M[N3Q)L'30`@)C "%L*+*IL`Y!):&F:MMDVK"8ZQ*![
MK4Z%G8\K!WS];?;J12_L-O+S&9,K*EKM`#@)&:VY6?40(J;5E];.2M-&[(5G
M>+N55E:./(ZN@O0M3H,R[;X\UCN23-?RAD`4"7&MD2N80$1\H9 8*GSH;P9&W3KH!,$D)
M1Z(PMNBQZ=F(Q/J\^8=`"`BQE+Z>1FC>Y_?9@%&R(H+PG.DOT^4-@5`2@FJK
M]U@'(N(+/937UFA7,!]846YUXB7"M;U&*R"(A*JJ8T:Y`Z#@$.OKBVP$9X)U
M#(&'%?0-7SP^/?I$0E"U9O$**N2LC;[L1LC4Z*S81)8!>D@HK*VF>@4ZQ/A]
M5.98IJ6V;CT'))!8QQDJ;KL0$#OV,&_MVDLB\-5TPI+'5R#OPDN#&9_O@C#/
MI&4I%"V!J!ZJJUJ@$.L;2W%TXN"_L>#EE1?%ATV?]\+N 4)".\RS-
MO(A7-R[HD/B$43]`)@G5ULQ#&D!$_,4X=6Y5DQRZV?:7/5>3>&1O67'_$W>F
MRWBQB*.B:. /'>XJ@HO*99IT+4#N@A
MH:\H+8@87HUM"$4L:NB4!2R$SP,=)&04#9O)Y'`AJB$4L*A\294WCNX\.SV@
M<0Q38B.Q41$D@RABD3^G@1]XR9*?.]8LVH^U`5I(J"--)VHYKB&4>*X`XW>I
MCN=/B1>EL'(!4.J20\K&0!0-[41N2<3\FO"&9V":8AE'\NWN[B1"2A3OO7)9IWLX[`?F?NM];C9#=+DK'*HO5BN?OP
M^C&E:&[Q9Z8';@\)MC&R:D]OBYTAR/2KV7*5^3].'GBX4*'ZH&V`%AJJCW53
M2[<2&!%#T/*%$'7O>A2U`FI("$,*VQD8O(K+K;*/?'0?83W#TG'$MB=15.E1
M-P*P)-0>I3VVS:@+S)* 2P4/Q'6-[G<4BR4Q@DP7=.9Q4+Q`V`]T\7/HPS>AC#G
M&N OXAD4-T^]H:J 9_0?
M?B*A4TJ,A(1TQ$AL50YW:M%JY8[*WB^]6%;_13'CZWC2>PLR+RSKIJ=WX4P>
MZI"W`KPDM$W,$H)8APX@6V7$W;ZJO(BG:G9?/P.X:8B6^YJ\MX';*B_NWN#*
MM5OEJ>DAC>O9:L:06*PZ;EN%PYW:[$L0!8M\H;3:UG.`GX3PMF,2L>4$8[=5
M\-NM[;QO>K:K/@?X2:ABNK;;';NMVM[T"^R4QLZ
MS8$M$NI: (\\E?AHQ0Y )!U?AG#YSO)`OAV;Y,@G8:,>@(.2>AX;6:D!H!MU3VG $E0 IW=9'`>T!":
M]C+]&E`RA)*?EM(X#VC(1VJ;B8TM047R6#+W9'@;1MY:OI)/X\CC`)"$7B-A
M7_35E8%Q>S)98:UG,VL][P`DH:,TLY80C-MSPG)K'1@9ZV`''HG$J4:V$F)Q
M>Y17;JI#(U,=UN$=DDAW:F0J(99!',2UL,332=RP^3/`/@GQ:K_K9/L,#N*$
M;27&\!','L_'7R.6I*_!VP6;QPFKL"#;G9GV!3R2$,SL^P:R5VM&T"!.X9+.
M*C@DD?>V-S>TPI?CH\3(4FL;$[\1=I8Q_XDE"VRYA;1E'7'0%YL)ED50ACRH:]P4\DI`Q]C7--"1H$.>1/Y)RZI/G39P\LN0]
MF+%TG%R&7B!=]QOU`_R14%[VY6`-R!G$T>@;?C4MNP/V_%NP;O3",[[.TY1E
MZ0/CVW$>.EK$2;;*#"B_Z2.)FS7L<3H:T3A!N2^/:\?3(,Y0C[-7EE0QCN=7
MJ\'SPZDOTOP[=6-@GX0BN2^/TF6$YJGL=7KA)`GX-"S9J\D>!X0DSHWL99TM
MY:"#H]M[SL^\R%.@((7UW>(YB(J>*21D"H:EDV MQL+E`YO%+U'P']B]&21)-NT2:""AX:E-)9Z`V^$>PC4JM_"6S_&%S<7RB_?O
M."DJ @DL1JHI$'-'(F
MG(4A7-;^2S3CT()YP)&OB0B%1*B*&1CW!322D(`;>X#8H1KR\%?J*9JS=T0B
ML;"++YD&\+\23#=Y,$ G4:Z59MN@5P2"F87WX+VO`SARIV)MRQDP:?X?`;O8L+6M+#TYR1.I0?0
M%4VGA\ 5(E-.GT`;212.KMR&T,B!I%9
MC&`N4K/:^!A$7F\15U2H!JI`K:(YL-57^5;+:_0Y&$2"
M[J67OJX^RL6U0Y470[9+PEL!-R2$V*[\0PF]@PS9/4=SOWA1/@=.BDGSQIL%
M(>P\V\5SD4R"W5_*EI(`K;(-6."SM30'T0]A\51Y`QB64PU!DS=!WH("TA`"
MH1O5;'4+L=95NU@;H,6I#*!C-(7@*X8TA"!E%9E2Z=U]>'IX0F*7KK`4\ME"
MX`PA5CA)XC>69,M)Z!5UX;A4^L8)NECR(BR*=UFC-5#E=*/=_*W6!C>$(!\*
MED-5OO`:K8$J$CMF;:L:.D4=Z1`B?,+%K,;]!V@KH(;$!EC;BF(G4"(D65KF
M,G@! (?/_.R/D*I
MLV`6MYF.1C0J?.!&DQH91>0X1H2LB6[`@1D_. V-1RL:POO=X
M,015/!9I!O,8Q9B"P(*2.*L4VR!JC_#B3^D#>V=1SGZ.8U^9*R9N`(Q0C"MH
M6UN&:A"E/PIWOF(PXEFPOHNA>L!;]99+F@*QI^[+F;=]U=4`!U&E8R?5\8L'
MK$8L6595')-<46$'T\//%+_XVBYA@K*#`AI[3ZC@X+PUN`(;A?/QJ,JH<4A>
MV79Z].G$V5=W4V04%U*UKP^2=P$P21S^T;0'\GDV`CN$K(_N8\9'-(HDF9FV
M>13Y"*]UU*\LD>ZCR$>?2!P5TK9J\RAR@70(*2;"Y8E&%!EMQ5='),Z8:YL1
M"R.K(`XZLT2FW.DWGAZ-2!SDZ?1;44,[C-P2@?.K!!Z\$1!#)6RB94*#&:&"
M;P@GRE&&"JFCR5Q0-`2"J`1B6CB`#D8ZF2=V;J,N:_P;:SUZ/0!EM).2=-U"
M'ZREQ!8*EY;_#"NH.YC]QM%5D+[%Y5&A\;P\228KSRMO"#R1*#[3SBET,`XB
M=Z:N=Z*TF4C#:"=\Z3V$*^
M G?PK1?T1;PMNV1UO1?X1'Z7LUL^Y!]#^@<430R+0M1/\#]`CA7Z)_
M34,]("'Q:5NUA>A_@,I[_1+].U=]#TBLV3J=+&IHAQ`,L*[Z'O1&]#N0'">4
MX[,D]U,0=&[R)`I@CK-1QZVO@&=)\J=@_#OFI>PU
M#OW;Q5L2OY VG8/_.(C\'O5%S<3_0P6A)V":I!5\`.[3Q"J0>T0VU)X ')$31EK.0539L'4YV[X@HT'O6*)($S8`BVEIIN_EH
M@]#6T>;ZNF?/`.TO(_*Z!=H4_9$#8]?OJRBXJG2XN`50
M0D*J:3[):@$ 9!W(U8A:: "^@/SO;=02S2&/0&')`0[8[,;>P^.?A"5>P$N"T,VRW(O7,?L
ME1L$O!$P0T+0:V10L6^HP-HJW$LBOQL^R##;*AU@Z[GIT3$)A-7*"1-^$L(/DV_9(=RVF6GV9Y25AYUDVY
M7$#;`"\D1,7&)A5[B`(OX@?]$A1OHUF\8)MPRYW\2DJ-5L`-"8G1QN=&`1)Q
M@'X5#4%0:GQ$).V`'Q+:I-*$1I:O8D-LWR^A\F<6L<0+BUSW! (5_5(CE3/GG4;E&/U.@#D2&J2%1!-#S(BW
M]$MY1*":'T$!3DAHCJ96E.6A("`1P_ 9"=T
MM/N8'IV0$">[=`X4-N(N/4M2+*IE%SD\]SG_8L)_O`+GZ6V:YGRO5LD#D'U7
M#+H!]DBHHW: =$L\,+;:!XGB\*V91OC
M>4>G4V"V'VIJBXE(GP?$P_HEKE9>K,LX2@-_57_C@ Q20D1#AVME5C@ZQV[XD6<1N]W$41!D#NK,+YO%+IE=U13#K
MH0VFHQ&-(*P%(ZI`(K;LEY"Z@L1O?IG/@S#P,ID6(GB:D]$/;51K.L81(N;N
MEQ):K9PUGM>7+C++2QMRB@8DC&J!1?RAC4"ZYWI25VSA1?Z%%_U^%WL1A1I2
M5^PYXW4FPSCE-:[5I:+$#>!;>^;J#>,CNHU@'+G./3B"IZ='GTG(R#)JQ:\-
M"H9._28+!]B+Y)R5D*![>+W>!F@AH?JB%D,D%#D>.D6>6AQ>KB!3YI?L/@Q$
MT)!>Y982FQ>#,X3R4-N>KI,=@+0`2DALH4UVQ-+%NOU#*]*
M>!]G+)UX2U411E5;H(F$$BZU(C)GZV$;T+4QVR1=>&F0/@(*SQ]'O\(VGF-^
M@-E1=B.P;A?`'0E1NX%?F$$ J]Y.2D%%>OF/2M02H_;3T:?C!NI)PU%C`HE^8QBO
MVQ2J)NP*PPWZ8(0*79JM2 0W:5L]OH'O9U3U]9^,Z^Q%'V
M*EL\ZC3G;#D5_;MS!!G>(=0=%\%]9+,X\O_%/-EW7MX0IUFO74L4?L(!U"
M]7$1T*?7(&GB"IMVG%KZN\GFGE`'.H0*Y2*9*\-/.&C(6?(:3BH8U?8
M03J(XN9"I,&\F2^LVW&"G`H$7;M"#:CCPN7(YE!R2J=@`4;U6Y"]*K($FG;%
MJ>G[&J$E=L=5SNU,$%5 (,JBW\71"T^6T4PWHI8O$>N55V5L/
MPI!)'#N3,BI^C41`AA'1MUVG\X1&=$UD,"R&J@`SC/![%^4X3V@<>U):T,CP
M56Q#B)(_@$V`SU=80URQ=Q;&;\4%B)JU.#5:`U4D3D9IV%/L"-H8AW#H8C_%
M64]HG*EJ[!(&*(<0;U_?7#,)/5@/13X_B5V\!!?+]6W7LOP:=6N@BL01+/UE
M@3:H(03D4;`?%V$WL7_E&NT3&J>QM*UJZ!1UI$.(PW_QHGP.^Z* ;=WY$>:T(>YV-RGTFD
MY$P0()8#&H*T";OZ+,E7GVE>X1.^]'RGG[RK]C.*EIPC]SE#O$6QDO&-N^& "M." *K=RH_9J2K9?5#7A
M[+C/PC/YP&HB&H)4N$')OS^I+-6F]B3GP'U*G=I(B"X@!.-6YD->QN)`4+C<
M&C'V%HJ>Y1.-TX]?(T.IX+@]#:.:-WG&GG*FY`]Q-!3G1@WCB'`,0E:;S9(<
M!KJB(F"I.N48;0.\?'*?BMITEE3!&L3I$P`9YU%6R )J)S`H"-.
MH?NLU!:>88[5\1$56U4N@=7GNIY\G@"++ZP,/7X\LBJZ=?[52_QQ`3S]%;8/
MS-^^FTVVZNK@Y[@YW)^J;[QTZXZ101R6V5=8""AS?R*_\?QE@K :)E[0-$-G2]#_&4[GZ+=5(HU >F`5D:_=#L!XF@D]36W.A8G,Z-@"!&S*C)E
MJ&SW8?CR'9*(F)C:3NT!6P#=ALD0&>D\S%@2%1_GR^`%:,HREMY&,WD`1=Z*
MXR5Q6@LUA4!BTH(TA"Q^Q,ME41?=IIPE$M'N?4WK=>1#2.C?7;]KR9*R9L`L
MB:"JIA7%+J`&V-FU"7O>P?W&MVO\%-/LE>L >2O_B&]B8L*,7%4
M7!Y$87=7#.0U#H'QM+P+D)^!U]C;R1N"74] K^YE6G(^3A^#E57EJ&F\$
M4$@LLG0(%[^`*FQ#V(8),2IV76@;H(7$,DQE.`-S?\`:PL9)"%'W'CI1*Z"&
MQ!%ZA>T,#%[%17(#M1YNA&+( 61*P=#5JN9$$CP(^$JIG$TNAQ2>C-BIQD?CWS5 ,NG
MK_"?R]5=3]*YW*0/X(*$[J)K-QKK.!W8L[Q%7:VVU9\#8"0$G3;OI1`28BO'!S#K
M#!"34'TL3JY"A(A-^W5\LXY4?9VPL`$P0D(_:F9S'6Q(
ML-ZQF/1/+\IAH0C_,*H/?CR'4071BS*L:]('Q++]
M$L"VP?'70:F#8$VFQR,2\A=F+QWKUM$@-G: ':L\!-!)ZDK&!Q$`0&SG.X;F/WXLQ
MJLVS^R3@(B$(F;]!"!3$1/VJLP%"=F7MSBZ3=.<5V GQ`0EIJMCKOG!C$:?N5FR4&J:5(
MJIH"2R34K\X=P<3_ZO0@3M2ONAVJ/&OA QC06`$(/VK%S^^A*R
MLDP"?S_B"/Y3]3&2M@-^2&AY#<4>-33$]/W2]FKPE%\!X?/`!PE=3\-H8FM+
M4"%6[I>P5ZFAHYRU=YX%'D@(>1(CB:V*($$LVC/Y;NWJJ^E-ZTP%U@9X(2'C
MM9RJQ;"08A']*N=?A:9;MJ7R,#!!0NM3F`IYC1$XB&'[589I=01,\S2<1BO@
MAD3^%V8UY!U6`4*,W:\,+WZ7-]]I*.;IZF.`OL=97;M($#OV2_I;PU+.Q-L/
M3H\/20ALNU:16Z\Z>L1^-&HOU>I(:M7`$+8!K"2T+)$%!,J[&@IB-A>Z4\IF
M/[[$[S_Y+"C?./A#_46#OYK>L1 ]%E]Y;D'GA%R_YG67I7:@H
MM"YO!7B=*CQB_@53H0X,Q&S]DG2>@HP?L+B-_.`]\',O5"PJA5_XU>'N*%;-MPYZ`0Q)ZD,3`FAZA@Q,I5^DX
MV6L\GP _L
M8GGO97FBD@W$#8`12GJ0\;$P'!-BY7Y)0A\`-8^%[3X^'8UH9%[(C*4R[PX<
MQ+J.:W!K'$U=7UUAXT#W3E^;]<8)(I%^T9TO[(!%O,'QT4I8$5=P7+[+`-%C\,V:)VSZ
MXN20V/YWY@AUJ(@?[$O]L^`'[%U55[%9;YP@$G)`=[ZP`Q:YZ<2QOL?/J([G
MYR^PLEE(4JW19SDX$MD$# 99F7N2#ZYMZ0*7I]/B0K@O4C6G@!SL0$4?8
M RQ,U&'4Z/C^@NR?1\IPUP
MQ*-HW"FX3HZ\C?R\W#E [KXJSW3&Z
M.=-K#?A)A-=:OMQ:*!$K]RM7[D-/^AFV1W `]!R'/`>)^TYL!X9[EN"`SU77W0`8BX@./DOF(KRX?,_*N '
M&+1?) <>WU_"]"@QBG
MC28(Q/Q4909&]ON*L[_7_WZ+,O8M8Y'_L1;;)0U0\"]8GBQ_G,6+\I?%U1(J
M;G@3)Y7285 2OG\&7;0WDRF:,D;PG?[B%3D
MMHALF\9LRW#X\3$)[42'*5*/HC0]T
M 'Q"0@/MS`_J4)%X>V\\H:NCB\ 69,%SR(I[W2;>DBL?VMO%)GT!
M-R14/B,W:`X4<0+'V4\&>)3[Q29]`3 V2L;
MG>M-\[(V@+5_"I\:$&(\U["3A]!.I*;O-D813$BJ'#N$& A-$\-WG92\C_YP/_*70
MW&5E=25-`"@)M4-E"L'\JD3E]K"!F?GDA7:EC0"L4]5#SQCZ!JRB '(+KT6:WS3JJF0!*)77_G?F#B?G5ZW!ZB
ML'5.[CG[*(*E/`A9?QB(H+NU5\XR&!ZW9R*Z,*SF(4AQ$R"%2-*3V%PZQJVC
M(7G>H1J;YV'[,DRARF3"VP!4$MJ,W!2"1: 2A&1H3WUP)`\?U-QQU."]'&U#/2.23=3NO12` $LI#.Q%JXFB6)YQ=K1E:V!(X(J%IZ5A2-6E+`-I*WN\@W^"!
MS3CV8![,5H)=/;[\%)?!P5_>XFB=7R$M9&VE7R".KHHE]0R+\%MG_9^5?A.Q
M%UYBWY7G/+#5A8-4"L.)S:V`-80JT%5D2H%_]V$@@H1BI+"4]&W>@3.$;,VN%.*33W1U
M(.7[K(-M"&F/79YV//G4!]&F,*6!$^P@M)2Y^%;>KY9Y269W*RU$4=[?@P;[
M\":`N0_JBL@LI2MV(HJL]S7E>&^CRSCZ=Q[-^%CYU9SPGROU\/PE8<4W
M#C.P>4_3DQ&)%7E#NS*TSGOA^4X[W/I;D>NAW`.]('S0QU`#. M98LV`*1TT^S4%E7@:IU0V674#!U[@QF]25]`$8G\.]NF5T)NG8!IQ2MZL)\;
MT17H+.WG1GCBEWGMFF)#=QU9GB;X&;TX# Q;6X65)KT&
MZ(>0X2!'*_A7Y=G&!OUQ/DGLS)MX@=B?VO`PA%P*$7[UF4FD#>>%1&RFC57U
M_:2*>0CY%[L8/TB[TTC#T&K/^2*QG>]R#L%Q#R%58Q?O3^#T8GF]>`OCI3#:9]P'YXU$
M4D\73B+';+^.U9YWHCS:&63%T1#8"G"PL-=FT:PHQD9B6XH-SW1CJM_/],3=
MSG2 /LI@$-B/R?A
M6J#4B3"0+#C\,5!YC>'Z ^"_F)4]?`?T2
M_C=\5]PI*6L#4)W&H27\"PRE1F)I;])!?&)G[*]!DC'5??#R5H#9Z3ZTI?4$
M6"QM(O9@OYLX;V"_[5:`V7VXN+']1%@H9WSOC#^8-S!@M1%@=A\`;FZ_72B6
M,K3W8K['X)NY^;8:`6;W0=_&YA-`(9!&;6:+20&JXY[$$5EOP11L,@72JMM/0?X26@E.R81
M6TXP]D&4BOWB?=.S7?4YP$]",M&UW>[8'9>"M91-DS^G[(\ .>GGC/X>@4PP9VG* J0C'BI^>GAR1T,$LV$^)TE;15+M6/(_XB2D/UK"A
MCAF1QZ>C3\?4/\5&AI3C1$S9+Q%M4\7P$0!Z21#KEMVL/@^N34(0-1=A,*2>9PL@(IB4H0MJ(;&;J5_X)N$4FL>DK:''O&V?BE^+?C0TOJM]`]\
MD]",+3J/=>^LLX5X9[_TQDD.9'@IV]3L>&+)0D,XD#0#=D@HSA9-C:@+2A(0
M%]ES-EPWYV/N-,["HFV`'A);7..OFP(18O!^J8\=(+L^7/N<=+P3"65D\3
M+>)<>E&ENC$P14)35I@2^7YHPD,?`V`D]&$C
MNTF0(*=SC#5$][FN-]ZLN&:N_/2DK\$;?//&;RPI3),6=Y+)(H4:S: >F]!YH5W#-8FZ4W.KTQ?)2^N_#^]RMFE\LIADVZ`/1*B
M5B/W,`>*N$F_5$TMV+?1T]>8GQB0WCQCUA-P2$(=Z\Y9ZE@1?^F7-JJ+''Z3
MV?*835_`(TDYS*K/U-`B7M,OL543.S\):,EI-ET!BR1$K2Y]I@86<9DA**;7
MWWCI1%E%#FD[X(>DXJ"WZU0C0RS?,S5RY=I/\?GLCSQ(6#WO0)K+I&@+//57
M=]!$AWA!OS(8"X+.9[,DA]&NKE#G59'B:*; L"\5$M&=
M]/5X+J-CJI19+].3D_[)%HUQ(G;OU_G?5;:?2K2J/@;H229.:;W3NT"0"C3]
M.A)E
MC8&I_JH^NO`01W!/O2^-#C+\^
M<0$(,A9YT8S=,":/&FFU`]!]78]K0D/LN2\!SM2>TO".;E,.O7\+,4-TB&'W
MI:\U,*PL#J/?F,/OZ8QL@@\QK^.;Q5>*_RKI"$:_I?WS\7/]'T_@T6G-">A?
MF,0@
M?[$- 0,BH@S&CEGQXPD`\KFG[^(.",0:`TR6:YN4`(2=]F^%
MW`0BXA,]4[7*U%#8N[=,H33KB%/8OZ5V*ZR(N_0K,4X3N58JI7%?G,@>:Z0-
MX2)^TZ_4.'WP.BF5#7KC9/9OZ]<>,.(];42Z/5\>=NTE7%M.)R5M+P!G"G=4M7XT[C:/\MGX"2">QQ]W?O&*7N2% *V\20OE08A)GH[]B$H8BRAD)>5%NTOW$),[P
M*RI[)?6T9.-B*>Y`$=7H\%?!-(/4+\_0>O"=DSF$R(H8H]9%;:JF0-(0A$^U
M'YBX7YV>(41Q?O-X=0?UG1-;SP%\PLIFW4S(SFL7T!#"')/U4(N8H[JFNN!Q
M((.PJ*AG71R7I9B&VY!Z','^*^/5&Z[8L_KE%3X/=)"0\=J860+,4GC!=5&Z
M+`EFF>[;+'P>Z"`LI^G960+,DL+O."F7#U]IWNIC`)ZPL*5GU5T\!*1TY+Q5
M;::Y3=.G2J]X2B"(A/UI CW
M )GKJ!";#4$DHYFF^OD3"=&M-S)OC3G$7_LER+6D1'E7
MEI7^@6_"`F!3_^G$1ZN$(0YJK##6%T1[#KW#)R.-P\#WBOWXZEC$*FGE-0X!
M5'K]1QYD2Q?A].J`N%:P-2"-V+I6^^GG4W>'_]8#5`;*MQZ )
M>@M@#2%JO^'Y0`)E[@WT:K^E-*XTK;`3TD-O3&AM9`-:#C6P\\^3?Z*%>B
M$6<5-0!>2&R*C:TM@S.@`U3\QB)^?TT<0M ,XSSM)3+'9QJ0/8^`$@G$1B!N8*F./8PVXK[/O&DB#F`F.2.?UN[!P`E?E0
M_=GI*8UL#D-W$,.P%<0E8UGN]:O\E#SAOEX,[% P.&TP@[2#;"C=36&LB=)3O50>NI=DQ$$UB0VK%MXPPVXH-MW,N
M)`WE`V"Z\_),DN`=R)J$WHPA]1R,^YB.1I](J(IZ?M`4GZUPZSYM7CIU2Z.+
M.^&LD-BMMK>Z%"!B=F,]DL)WI#J[E14'BW2" MZI([>$NW;V#\K89`%"U9HYGQ!9@0X^]9K51.^+LKY-5AQ.MOLU=^U?8DB5\2
M;Z&>]75[`GIZ)$JT`HGX@+%PN4\?*%W9BA/(NIJ>'?5(BVB'$GE9'N@K>
M`Y]%?EJ)OQ;_(_D$H&V`'EH905JSOP(.DA%DH:J1T]2"#>K2W_5R#&J-@"!:
M.4*:7WLY'L3@QDHD!8/+OG3K0E[,Y\$]%J6%V1I*C^+.IJ AA`V0\KB`NW/H'2W=YHM X?S3N"^CL48"L)4S$:WJ9Y"E?W-EQ&TEG0&@/`RM-<2*.LV>MM?OI
MYIY]+6.0#:>837N@K8>A%P-HB$?T4G:5OA4M7*+6`1#7H]A,$VS(4;Y>JK.R
M=^%\5F[$^$S9(:0])QRU>BG6_L]@'T#4>UQ>`AWC$D
ML;9X+XHKBQK.&$5;H&LX0FP=%N(%O91=I2]`0S>H-`;">BA]ZN)"'&'/^9S[
MT]]5_J#=!]#7(YFS(3S$.WJ9]JD#?:4!EN]-2R_9Z@OH[)%,VA(FXC6]5$PG
M23P/,L7]QA\/`0$]U#CKXTNB\RVYCODJ Y;'(*\C
MO\_'6T=]%#3%,!"[&HN7(KONN41CX>X[:2SW_/O'ZU@ZO.[PXV9>?EZOFL40
M\GJ2EW&:I1]Y#A-O67S2-0HWMNMX^KD6N-GG&[BIMRO./CKGJY:7PKW3B^7'
M,RL,YU^]Q->_-;'E;P!1)-YX&^9&9@>[5`VA-F6)"7Y%=0=B]3F`3R.P8=>>
MR/9C%_D0RE0V9^R#D,B?A%ZD=2UA%S\W_4PCC"+P$,GJI!,2AE!3T\Z=6)^)
M1$\Z,[78M21DN*W*B>0&ECNU(.+K6UBVO@'0["O\>0EKXD4Q>/F5';KM@0(:
M\9,]^4,# =+Q85O]%L=31[P3XHQ&4V< TXA\7YY>@Z0 N4["P"!N/5S#^B5*W]@LF`?,5XMO6)OIYP,2
M"IK$:)B2+T4TB/L"UQAOXH3-/(UZ]N(&P`@-14QN,KF=19!L%8%T:N2UHJ.8
MUZN/`7H:DM8^IO-=X+:*0)(PNW+JKBM^!R0$IUVKR*U7';VM.HYV5]+C110\
MY^GM6C/E(Y ^AG`32+7;3^1NVW4MBHLNK>V.D7DXRG`3D($JQE#8K'JN&T5-W1JLR_>
MMV"1+Y16VWIN^OF0A$2U8Q*QY01CMU5 O<9)\!]Y
MV2_;OP7&("'(V7(KRTXKI\U634."DZNQ#P(C)#1#%XY48K=5J]#]C':]>`OC
M)5M7[16#ON>WWJ09*_-[TZ K]RF>VSGX3C$-#R>K4
M,3NFSU8Y1?>^W=@,JSJ31=I.>ANMJMVRX.65$_K.$N^%;7)Z;KP@414;W_-(
MP)`D-#^B7_HVI`ZJM*2PD/LN@
M#7FQ57^3X-:[Z6+EYT1>7JN#7P-;D-#'^[2FK!!GJWRH>R=NLOZX_O86),7#
M)3%=K!#KOP&\TY#J:2X)Q739*FY*]VM>*SY02J.'XD7^P49'.X85>E._M7X4==RO]'1V[FG"J%F(PI`C>
M!N\Y"(,L8.D7YG%,_AB`S/*$S\;PP'TO_!-L'*6]?P'UBL] T.H"+DY,G`9>FDZGI>K3,U3,O4V0`N)J%GWIL=6
M\E)BAE!(LHI,>5AF]V$@@D:426XIL7DQ.$,HQ]C1*W.GD5/:]4^#D4@LO5W-
M2OOAUVW=2?LOP7HE_A"DO]\DC*VO#GB`B4/3F65=3#\?DPA8[< ?:(BF
M^6+A) AUPQDCH-T8&-O>1'<26
MU#ZWM>76QTP_=BK*BBIH&\X+"77%R(QB3U"!',)E,N3+L!R3"(KM9[5JB2ZW
M=]_0.$93N6WY(0[#FSCA_]CA21KQ#TX_G]!875ER+ [=52HMW:-4WOX.V^ 5J_]Q:
MQ*.M"ZD(E)1Q?5#\A$0DT8%;-N2J] R%1S!Z/9>Z7BCTNV@ @H3D8,"F)Y(3>B!U&O-JZ66Y@2HB,0_=O!YB.1K:%(Z=U
M^@J5Y-NZFJ\W0@L:@-`IAVGM_;$W"C`CC125?KU#M@U@ZXI$`MI.6^K6[#A_
MB8P&`F:D$4L=UGO4P`:V+J_\:RFWU]7$YWZ' AEI0D50<
MO3F:(P#C#2UT3.#-,2+?UO6H/7]SSGT_*#GXF47`5?AQCD7GD%.GOPN&ZG C:>L!X8SWZ%O[^,HX*ZW`OYZ C-)@-?H?D7;]&C3FW=44RF=>H
MQ8+UPXA[6G7I_"Z8J=\1_;W$+#4HM'6A]!`\O?+5O859(8C28-;US7'H;X)Y
M^AV5U_?!SB4J$;.V;N,FM+6V\Z7-Y;>>PF_,N6=.2S5LQG.A\4U%DN25M/1IT\G[O+I5_4=E*5R
MMA[D8R;Q`JMYQ=+9!7#^*DI3+_(!O-#(\1"92V%9!,Q?Q64BS@2-E`.%K<06
M1@$-H;[,AI([G8/\.P\#$T3JQC1X8^LHAE'IA?$E2_1R%Z?I):Q?EJL8I+Q&
M$-:(,T,C:(L936QC):+.ZC.[6ZU^%*>8)/%[D,*/7+"(S8/L)DXJSPUJ,7M6
M*[7:@[7LV3$)%5[)JM9*M@#SUT*VOIXX.Z8A)PN,9;J,+:#\M8J-@`@:`JK<
M4MIKV#.\+NJ?:PE[1J02JOF[6L,PA/7K99YPLC8?)UXS/$K9:B'#HZM!E,.Z
M;K7`XYJH>@'1O%,@EI8@43,Y\K:WQ#N@RTM65-PPG^XC7C]R3`+S5Q%GG[Z1F-*G"=NHP.!0.Z1D3.9>-O$O!$
M0G;IU%6DV"T5_,OBS`N=>LC5:KAVES0M>@5^:628&ZUI6@.V5&B/PJ2SYF+U
M>3:??/0Z`-Y(I%VW-KW B=9DZ
M@O[4W(5PJDBHJ!U[C12]K:IO[M=!&Y@/;!9'LR`,"JHN7WD*VFVT9@,>**^K
MV]P\=QZ&\5 JU$3!^BZC3* @%$2JI%]5Q("'5`07H>#;*DG/_
MWWF:%5496_I.O3O@E(0*9-]YQ$@'%(G7(>$^YKI`#H_!8F"E9HC/Y/*KZUOZ
MEMF/34>C4UHK)FNNUXB(`5WXI\.1.'3$VLYO6+=@4A**I7UGDR,>4!*`#AEV
M@BN6?PDL03:GMIWO&9/0.JV`_,)?%',P=C51)T`@B?Q;&UZ$X^LN3X!"=&7G
M/>'S=N`]P_N4!4,[J'@Z *(*VFB
M=8S&F42=]D`763GR%#]LK`]M0"FFC2)<7?SS1@Z)
M``57\`HW'!VLG)#_315U1:4KKL+]Y:V`[0<9KT@LT@CO
M$$\9;MBZ_B,/LN47EKW&/I^EU0D J6&[E4\U_A-B"AC[O\FB&DV#JU2-(QBTPJHRT\;P"?]X'.415X0SH=N(/S
MYR1.C>:6H@$00R+"8M_N%7BV#@&Z/Z6,T%19OC77=@6=`'VT8C5M!%X4'^(>
M?9=YMU(5MC^7WEL`GAS\A_D;08+O\32GCP8=`]$D@D.FKJ& QG:$U!)(@#5I5LIP"-^I"\CD_>C
MG^/8_QJ$(6"_!=-&+SQ/>RVG;O^WL6<9]`UT4XYG6?$U8SH0[]-7L*UXGY$@
M6.P'-!S'M`N^MZ2\E-9TD(:P$4?05X8)3D.;S+X*!QHSC*@9O_&%LF+< SXM\)@_I^R/'/[ZFF_L2%S$61^3SI7E2)/IY\_N
MZBMMCTEY)$#P^/3S*8E/K9Q>\6N$XQG$V8`:.O@]U QOV-!V-:%SO(#&PID=H`;5T%L"ILUP%"9M!W\HI
M?OM!S@")R;V9Y9!]K@BBI4Q^IT8>S^>PT57;>.LYCI_$]&[3Q"*$EA+U&UH8
MB6],E8BAI-]!A'1")H:L-F$H"64M6=OI0\YGOO+52[Y.IC''TO]\8"
M$+82SDG84+F2VGZ0Q]5(O*8"N\@-N#5^6SG@=F?.\2(*GO/T-N+2;O#.^-#E
MDRC>@@,ED1@@Y%\P72JAV$J/MO#:I6SVXTO\_I//@O*-@S_47S3XJ^D=>_'"
M\FN!S)6"ISA3:;87]8?X4"='@K%R=\UDF#@MG*0[4Z$
MCXOX=Y;D&:,DZ*IFG._*L\":(7`!G$?H$3.?2M.D_4
MM$MN%A*:42._:8FZ=;XL>6>Z9U^+?VKL.IL.^%>7HI)AP5'J&%MGS^ZZQ9Y3
MHB[C*(W#P.>SZ"9S+!W/+[WT]2:,O[K)B5H/I#(.G;PH2;/IZT)@$%C#:M\
M[80#=YN>).4??5EVG@$H3M5;(;,H^=4QN\T@DM(_CIA.)V@%'-`0W\[4>#L=M9HT=:]?0*==[PN>!#A)%3S5L)C:V!)7;7!QDAJU(
MP/P?Y?.L\.'IZ2&)DT82Y@4SKP2*XX0;[%.X_NWUF`\5WT3D>/\&LM?2ZUHY.ZYU-/#OFH@-0R$,F^:6_.>95S?FR3Q>^`S_V+Y2\HK!6RJ
MYI_S&\:*@\&BB\4T]%D[/P",T])6:KX@]AR;V&TE#;E?;@,=\R"[DP =T\7-@$A+I
MA]V[87?L#:MV(XQY5M[5"G\.V:JVDK\H.%11L*L*\:/FT^6KE[Q(DS34C8$P$HGO^W8F769L98Y1UHPGRX4?G3K=!\9'CY]5WJK%K%//6J\#((Z$,+UO!S-AAT;Q2"1"<1]'
MG);BZ!"\)N,(-LHP:6:\3"Z?G;%(A:H=0">A;._+,0Q(L55*LI.KZ-:.?0-,
M_L:+0W)UMZR'*;H14]D&()/0JO?J!VI"$!_0%[!K-8;M9_&LQGW];?;J12_L
M-O+S61EJ0@3M%#B5M\G$@6&A4V`%I(R,S[7EW(
MV$" >1OWI-TILX>63)>S!CZ3BY#+U`&E8WZ@=(
M_%/*R`U(0CRMEWKRYC[%0JL:R6:B[2>G9S0R-/8^!8EH0#RBE[(P\)8PF&*O
M6/G_5::VKNZ3S3RZ?,-Q@2A/A7+]7C7>CKN]3D=[%(VP%-)`(/AG;5
M=8X=I(A#]/)NGEVXDX2]>8&/;ZATFP)9)(()';F%""QR#J^76JV$-K/K4 _RF#`TU80MRMEQ?"[^(_GQ41N'3B+17G\Y5M@2X2`8$F1M9U%R%DQ$-Z
M>3/[+N2KG/%W,^1SY<1+%/?):;4'VDCLK+KT%!0VXBV]O,]=^((D.2#0NGQ0
MISF01B**T/&L(D2-N(JQ*DS35=;I9P\,EOZYV:>GUA;H(A%9Z'1"$4%&/*27
MF<3M,KH[.WH#1).(1'2?\&Z#)\0AS8L3.+\Z%6&CS"GJ\$28X0\`[22B&E9.
MA#7"CKAV1;((B%$VS2]V+DTJ4#\9L_7P'?D
M.5\\,$/$DN5YY.OD_.EU`,21$*$=^)"$#\21>BE5[^#>2F]LZDQH)]/1IQ&)
ME;L#CU*1@M0[ZZ7.O09_$R WS.R_`19["
MC`I?Y%15MEO5='IZ0B*>X6`6$3*!N(V^(DW);9)XQIA?9-26&??&:QN]'H`Z
M$O&+/3B1"2&(+_6QX,;NOF!]/LAP9[5I!A21B&0XV5356$`<15^M)C3IM..S
M,]$'B"81#.G>W6SPA#BD>;XT52UR `=A*;.2M:9"/LB,OMM3:O
M_677Y@P+2V9!*M^^29H!190C*8T,KEY@B5E`'*6/HG5U, U!;)(1#?VZS(2*A"_V7.>-':BF&5"SR^/OL$_O22>J'2&?F,NC5%6H"TX
MA#$9B$OT[-+P"MK[.&,:"8E8$R"5 "LM5I.H:%AJM@"+*08>.G$1(`N(GO5>2/P[%3I+@
M'88V";WR7+[F%P?O8'KZF7(PHJ/OCXH/Q)%ZF?9 Z;CN".PLA`,TD0@?=^Y\-
MGA!W-%>/G4>V.!7GD _;J9V`DSF?2#5!((@QA%J4R1X@X
MB;%43,-)%,8'R"0"!>9&+4>.&,M8Q'TK'`)&D60],!D)G;:1R5!]]<187RU-
M=AVYKD115BZ=>($/GRB)[6I/`ADD%%4S,PI!(!;M:ZF'>,&>O&]UF8@&>;JL1/<5DR
MORA8L0HTGP.+/I87:ZOKZ>DI";>QXPB"(+XUCA`GVZL4BEUS"Z]<<7KI*?%\
MMO"2W\]]/RBVJC`EA[G/][;J(D.-^P*"2&CFG3E1 `5J>.$*[^K
M_RBRT-."B!7J]#Q-\P7S925>#7N:CCX=D)"ENG"O=IP@WK7G$L'(K'07S'B]
MP!O&MMX17F1G54H0_;!I-(77BT3PI;,Y1YL#Q`GV7!48<8+RN_IQ3,78%;0[
M`#)(!$\Z 6U;P5DGA`C0%OYLLJB:;I=`'DD@AF=>Y`V%V)'^KS7M%?DB_21
M(R78"*XO92B!_A+!L"\!5!X6-+XD#,M.L]4UT$ MI`#RP%9_ &'&;\KQ)
M6LQW-0'[*>9@%+ZBVQYX';8Z8T8$XA-[3675\P@N+*WS-)IX!-H>B!BL[-*`
M",0C:*BX52C5&0XXVD%V&2\6<53(!3HN8M`=$#58F:4]+X@#F6>:VI]2K@*>
M91WY*SAC?J-4.2*IFRB:`>QA2R5:^!&S[UFR56IM%7 C)B5,^!F!:69O:+9'(@8NIAAP`/B
M$#24U`\O7TM]YZE`.;Z-@)%<3YS7[`C(&;;8T9`1Q%UHB*;K4S@K1!L0E4L.
M40=1-YV>?1JVRJ'-`>($-,3.QCF?FE6R;/4_/3L:MBABERC$YVCHK_AJ#"^W
MK]>0RXC#3J_5I0!Q`!I*Z@/S\UDFTO]@!?:0E%43GF+)I;GX=-.V9V">1+*D
MWN$0JZ`1G[&0(@LT_E3E$3#]OF+X[_6_WR*8? M"0S?J22J(E:P#&B`S](+H/W!__M/?-C/L&LNB/W?4$L#!!0````(`$8Q1D9'
M!IQS,1D``"XS`0`1`!P`>'AI:2TR,#$T,3(S,2YX )V,>C\]?_M+I
M&!^I1QD)J6TL=\8U" M+D.8WNB^Z+_YJP!\OWW0&=-EY];+[QOC/EV_?
MO_KA_9L?_\OX[^G-_QC]^_$UAKNB%&2-@=
M#<=D0X,ML>B'BW48;M]?7F*^AP?'L:@71FR'&2_A,S]T7[WN`G27;N#%P&>;
M:[HBD1M^N/@C(JZS LRN6QS, C.4>;
MENPZWI?CDI?,3=._OL372Q+0/1!X:X?[#-G$;R[CE_NDKJ3 -8!1`%T(F+WW;MWE_QMFC0*.G>$;/>)5R18\J3)"UYQG9?=SK[JWEM^
MY(5L=RQC0*T7=_[]9?(2L[W.98L8`S44Y4O>EGS/IDYY'GA1DIP^6.OR]/BF
M)(/CW=,@+,\2ORN1QB..%93GX:\P2_ ([WG1
MIKP0.V27B/@2$G4@%66.M0'8#_[B=#:6]`Y?NVK ):D2O\:)+M\HB.3)%->>KY7N"[CHU*>T5I/Q?#(:7IN+_K5Q98[, J8$>OAP34,'D%5P=9Q63MQK=>*,[XX*_KXE4I'(??T&D]5DBP8C@"EIXDZBH:HTHF.:EOFI#:ML]329ZL
MYFNHPK7OVC"!Z_\1@64AH; /1(`#+?AYM-H3MH)$Y=YZS@BX-Y@X6GR([WMT4^+, Y':\&(X_&E/0C]ZPWVJ!5`MV`;WY$O8?K#7Q[FC";>ZAG+%W!<9^G_>-
MFU\61O^WWB=S_+'?,B!A8.!X,(]PB`M=I.T1@,QS"7&)HC
M["VOAVBQM$Q(F)C3+8PO2\K03]7S-QO?FX>^]67*G'L8>:8NL?CP$_.CG%K.
M6C?/VKP_A4,;0]A(2J)Y YA,'M,-25O9#3\T.>GKUM"/WE%8Q[[6!70<8-]':X
M/A(Q:"0#8CGN?N9=_DI.R)L\(3?0Z0W,'C0*;#+PUW#43J6K*+'6T`[8#M=K
M_HB)V@D,!)AOX6^C6D[X%1P$KN8AGQ9-1E%3/L^7KQ&
M8B3OY>S\F& ?Q,
MSD7!YW#=O\'*OS+'OQBCB=F.)%(7@A_28$IV9.E24/\IF,KH]X&&$62FLY6I
MY!05G0R317]N3,W?S:M1GS>5*9C1W`,$#6G>SG:K9[OWE&%'-7+(,C/ZESR7
M4O.JX'>8]S_W9WP5 F*JZF>0T
M%EP(OYJS&;JW4X^J,9U-/L[,&][Q)2_GQF`R._(7M31+:)[1T&'K0U6S'\(\J/9@2M/."U??DYE/^3LY-P4W0=^ ^X+DY
M@]FZA_"]\5V"HM6=1]&=\ZB,FJ847$QGT)16.YY`.[KG48]NA7Z^?-7C^,
M;JLA]?:`E`\J"NGD'!7ZAY*XG!H[2UHE>+3M
M)N5MNWEVN1H4GUMJ.TO34%UQD:IM86LK/L;6EG&.5A')2
M"]ZRLJTO+87GV1!33J):4CF-!3]:^8:9ELB&"THD72_:BH= $2
MDWE88IJVH^@)-.:6_4KH$Z20TZ:Z-ZKEZL1=4N4-KT9Z.8_U=E&UK?#$O57E
M;%:DD3-8N?>J)>WL.[($*Q9U*E6N5X7.4X12?45*'@0FJJ"BW]
MYZ=_YKONRF=?";,GJR3)?LC&`6"(TA/W,W$C+LLI^M+X8W(%*SBWFBH8XNL,
M8H"&OS(2B,8>H[$"D$:"TMC#;+NF1]'-Y*EI0?0LUEPSTFW8K?<
MGBDN'X.ZH[@&)JLK$C@6\'CMN!',&\MS''MGSURH7$H4A3*A"["QBJ%ISJD5,1")!I,HQ'N\\)XV&/7=
MR*8VFHP9DA34ZM2BY ?LY")%Q+:D4LGJP%Q&,[)J!D$T6:++P,%AM4*D-->
M/%=;2'OZ.1Q2\(-\&DF-S"=;?3A)'](H==-U>8H)K]726>1))G*I#%SQE_KV#5^M>
M40\$PHMM,^E$3-;-+R>ZX$\\)CK;@>\_9WR7?/![8^4S(_ZFP3_:ZL,)^H"W
M,$7\-E5J4T;Y82GWX^6V0IQ0@5X^" @7#QLW38)?D-SNSDG/UU/R
MX;2(Y(9N^9WO4(B_I0S;VF4*_L*X/*-@P$A=P8Y)U%,LERSKB@59J*NO1-``
MZDJ4:S/GE2MN;]F;W.%7]J9W_@C$\EEH>&1#@RVQ9)`=#UV,>*M$`*/0AHQ\
MBQ XE*UGG9!=#"#_./EF:\I&X8I$\ZAZ)JR1]0Z\6=
M?P]*@`'Q6.YK%4`EV9*_.X 2K-N/]U
M*D?TP5K7AK+/Q/\Z%8)''"O`XKIU,!QRQ7]V#@4T0A$X5FT,:1[\X^3OAUM6
M'T":B?_5`$*^"WH7#S8>O RV7L*!=V7^^PV^R^/1F&8N>9@1">Y?/)
M>'J)VR([]&'K$H_PB3W\5H>4+:5_**0!PB/6;>K4;K)I'ORC08,]$LT.V25:
M.I=>M*',L=0J))_K5)X.Y?E>IR$2WQLW!I,=/[&TX$PC+R]+3!%UXSO#$="'
MB^.C%?BY:!=&;(7BIYSW08B;>H `DZL(@2W@"ZOCA(F01VJ@\%5B%CF\O
M>#X[8ASSA>$YKHLEIFD#F-.&3ACAVX_,C[;Q1^SP_1IR,BM:4OQ0/`%&@_>?
MI?"41`$;EQ<6/+DXSGM')D0&F$"02;BF;`(8"#K;8O;NE\P/4?JAU'2G`;
MB:H1A\I`!8*BRRP(@['OQ897&`=.X*E4\9QJA\&!87;G[A@'KZS415`]BG:SVQWP$YH/S]*2#
MCML.?!Y72W(Z7HY/49AK?T,39^$V^
M9``M$/[OP>CCA$D9>DK@!JXI/R'*N:>9U8E#T?EG2K@B;`17KN>ST2
MK'N^=X\..\AS39=ALE FQL:2-B!3Z15%MJP7 W!&NA`6^/F*(H0EDZ3EWA-&0'AUWM#=OM)%+#:9`
MQN*)FMK--X0016:,S[X`W![9.B%QSV!2BX7)V=06'[UJ6#0YI`*!E$]&-!-9
MOOWTJ0%D:4>?#(K:M+E25%()KO04(0]+*D-/3QGRL$3=^9HPFWA):[LA[`L-
M@Y%K:2--%4"17,5C,_4128Q-9$#@&2UKVB7IMEEM9!$BJY!DJ:TD!61R25[I
M*D@!F%R.U[K*40`F=]0$PR"(X@F3!1.G!66;XY$_!?;$TUH9/(%$Q1-%PYT^
MUHP<70V1M+.M)2`%8GV$QH$!R;@=,7]@ALZVMARWFD=TZ-E1;+8F3HJG%+BF
MP[X:ND#F??AQ[*#36,0"4N%"H6"%`@J(US#B`.=/U+4'/IN3?!O5:2&FD3"B
M12H/=_62$5GZ#`,-P):&4K09%>7P1#.5:!F[=_1Q=Q8AB105^F@,&KZCD]68
MAMA=[>$#]FW\^HE'\U)0\OYRXNE3^45( 4V=5ZZ4G[9=#ZYPS3*D`>1*LJP=%E+J:2.C')YX"`:+F*R@D8+5K)/-4@]N ;:'W 9K!K%QR4\R#/8N9\HL)Z"V!K+6Q*O@ETMK+W,HHEX^NE*`S6W$?7'/
MRSXN@7UZ'3PS>[D$]AGJ0"L?8U/@I]>#5E/\AKC/4`N.1DZIAKA/KX6Y\_`<
M*R$#^PQU0.\U\MTU!2[<86*E$\IN9M="]L8X'/;Q=I1`
M,]G48*KQUM5,-CD\X 55B`_&$
M@>II2'O/#\)L8/^WJ9O:T>LJ\$6&`=;J7B,G;.; /D51=AX+JR72`#
MI[2E:>B!T?ZOR+/P4[A.5;*/4(/5I2:@E0@-DDI+2K[U;,I4>M!O4@O-H0LW
MM.9O24T*,^UX_S]QQU'6\/B6PJMC%5E6_/6A_G1:/I5@JRN-WCKE00B3T2G9%: O$<=A8%&L[M)U[CB4A0]U-*.H?7AI6ZP).+?7
MF%XE].)SA[+'-R91ELER>_>'@QM6@P9:`ZN:M(?KL75:]%0!62V?5EMH!+@$
M4L2.1,?#:%CGGN(-"B$?8$+J;?1:LE"'6GG4IC8R%2&)3I'!"=HU";6;=>6`
M5#)(W)#P8!1M!)*!J]QB
M$62W+/`[V?.!3#HO_=23HUYEQ/LWY+7QC?>;*.&MM\N&5]WS6TAM(LU)VX]T
M ^\4;S;3!+\"E=#695B:V&)K\9I&A%U+H, =*:&7^M:&_()E?/P PY7N#262;B.9D=6
M')"3ZY+&?CAC\1U9"W]_-:49WQ.&D?W:A!6=0P;E>.D;8JT=C[)=]C#D:<1@
MK(-VO/"QL7MXB[+&W=))4HG\HGB#*5_#=)81U/ 8S#S6X.T5@)&DDC7 :R5(9%"HA*SJX*%K^?(RDUR-VTECB40'&\#88U//3HJ9>,=39)VUHQ)Z
MI1&;J2#N9QUZ2:#/9+4_G^^I8UB:VZSJTLB\R>D\61^#2@!+?`KJ[S[[ *[?]T(^TUOY;,.QZ +OE\W?H/4!=SN&'>*1+7&J(
MT&0EE+^P2O(X7H?);8ZLK/`P
MANQEXKT("C^+Q^FQ*D`%?*45L]^O%)1XK8:`G$6:QUDWD$5\?Q>C)$A#*_99
M3?M?4>STU'K'N!+\ 3L?;<8."S`7U:]_[YI@)[\)7K.MHLU18A
M"9M\X@QC
M+6I+HG#HD(E>#KZ.B[[0>,^R/E,Z=:0-1=5NOJZ.5W[YY#P"9=%K-Y\0F7SH
MN`&@4`O88G"D@;%7?^N[&GI3?2TZ(9XF1E%TT[$BX+H4#[W%5Q_WL>H\R51"
MWT!R/%']. P2_ LYFV@S\W?$#7>0,_$GQP5@7MQFKK'XJ@(TEQ_F'FV+)`-5>+74BOE>")6D
ML6V=!2D\CS3G2]OI8RC+L"F+HYLQ+$6H+I5N)I,0HK)(&G4/4G"BWA\:VMK=
M[;-J?IA#.=PJLO!XBV.A4GS?JA7%B$11R)NMZ^_XDWUXI38S1QFXBJ#8_L/6
MB3^/^Y]SA,"3)R9#!$O$2K)>-V6.57)" V)!A,B$5WQXT0I`\>7)
M`;%TZ\>J\`E#)5V,B;)[SAW1Z#+) [>YX1*3'/TU'AI:2TR,#$T,3(S,2YX
M;6Q55`4``Q.AU%1U>`L``00E#@``!#D!``!02P$"'@,4````"`!&,49&LEOK
M08$/```I]```%0`8```````!````I('Q10$`>'AI:2TR,#$T,3(S,5]C86PN
M>&UL550%``,3H=14=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`1C%&1F;Y
M&LDR`Q0````(`$8Q1D9,
M_OZ&-98``/-'"``5`!@```````$```"D@4+(`0!X>&EI+3(P,30Q,C,Q7VQA
M8BYX;6Q55`4``Q.AU%1U>`L``00E#@``!#D!``!02P$"'@,4````"`!&,49&
M8W[:;$E\``!67@@`%0`8```````!````I('&7@(`>'AI:2TR,#$T,3(S,5]P
M &UL550%``,3H=14=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`1C%&
M1D'-D550%``,3H=14=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``-KT
$`@``````
`
end XML 58 R1.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 Document And Entity Information (USD $) In Millions, except Share data, unless otherwise specified 12 Months Ended Dec. 31, 2014 Feb. 04, 2015 Jun. 30, 2014 Document Information [Line Items] Entity Registrant Name 22nd Century Group, Inc. Entity Central Index Key 0001347858 Current Fiscal Year End Date --12-31 Entity Filer Category Smaller Reporting Company Trading Symbol XXII Entity Common Stock, Shares Outstanding 64,335,042 dei_EntityCommonStockSharesOutstanding Document Type 10-K Amendment Flag false Document Period End Date Dec. 31, 2014 Document Fiscal Period Focus FY Document Fiscal Year Focus 2014 Entity Well-known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Public Float $ 133.4 dei_EntityPublicFloat X - Definition If the value is true, then the document is an amendment to previously-filed/accepted document. + References No definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. + References No definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. + References No definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". + References No definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - Definition State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K. + References No definition available. + Details Name: dei_EntityPublicFloat Namespace Prefix: dei_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. + References No definition available. + Details Name: dei_EntityVoluntaryFilers Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. + References No definition available. + Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration XML 59 R18.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 DEMAND BANK LOAN 12 Months Ended Dec. 31, 2014 Debt Disclosure [Abstract] DEMAND BANK LOAN NOTE 11. - DEMAND BANK LOAN The demand loan is among the Company’s short term liabilities and is payable to a commercial bank under a revolving credit agreement and is guaranteed by a former officer and current director of the Company. This loan had a balance of $ 174,925 at December 31, 2014 and 2013. The Company is required to pay interest monthly at an annual rate of 0.75 % above the prime rate, or 4.00 % at December 31, 2014 and 2013. The Company is current in meeting this interest payment obligation. The terms of the demand loan include an annual “clean-up” provision, which requires the Company to repay all principal amounts outstanding for a period of 30 consecutive days every year. The Company has not complied with this requirement; however, the bank has not demanded payment. The bank has a lien on all of the Company’s assets. X - Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for short-term debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.13) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 13 -Article 9 + Details Name: us-gaap_ShortTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 60 R4.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Revenue: Royalties from licensing $ 0 us-gaap_LicensesRevenue $ 7,000,000 us-gaap_LicensesRevenue Sale of products 528,991 us-gaap_SalesRevenueGoodsGross 278,383 us-gaap_SalesRevenueGoodsGross Revenues 528,991 us-gaap_Revenues 7,278,383 us-gaap_Revenues Cost of goods sold: Royalties for licensing 246,434 us-gaap_LicenseCosts 413,566 us-gaap_LicenseCosts Products 252,002 us-gaap_CostOfGoodsSold 48,105 us-gaap_CostOfGoodsSold Cost of Revenue 498,436 us-gaap_CostOfRevenue 461,671 us-gaap_CostOfRevenue Gross profit 30,555 us-gaap_GrossProfit 6,816,712 us-gaap_GrossProfit Operating expenses: Research and development (including stock based compensation of $331,467 and $111,563, respectively) 1,249,007 us-gaap_ResearchAndDevelopmentExpense 744,230 us-gaap_ResearchAndDevelopmentExpense General and administrative (including stock based compensation of $4,165,078 and $2,250,399, respectively) 8,793,151 us-gaap_GeneralAndAdministrativeExpense 4,106,694 us-gaap_GeneralAndAdministrativeExpense Pre-manufacturing facility costs (including stock based compensation of $27,923 and $0, respectively) 1,176,676 us-gaap_OtherCostAndExpenseOperating 0 us-gaap_OtherCostAndExpenseOperating Sales and marketing costs 85,930 us-gaap_SellingAndMarketingExpense 9,052 us-gaap_SellingAndMarketingExpense Amortization and depreciation 462,772 us-gaap_DepreciationAndAmortization 144,289 us-gaap_DepreciationAndAmortization Total operating expenses 11,767,536 us-gaap_CostsAndExpenses 5,004,265 us-gaap_CostsAndExpenses Operating (loss) income (11,736,981) us-gaap_OperatingIncomeLoss 1,812,447 us-gaap_OperatingIncomeLoss Other income (expense): Warrant liability loss - net (3,676,691) xxii_GainLossFromWarrantLiability (23,602,711) xxii_GainLossFromWarrantLiability Warrant amendment inducement expense (144,548) xxii_WarrantExchangeInducementExpense (3,736,313) xxii_WarrantExchangeInducementExpense Gain on the sale of machinery and equipment 71,121 us-gaap_GainLossOnDispositionOfAssets1 0 us-gaap_GainLossOnDispositionOfAssets1 Loss on equity investment (101,165) us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal 0 us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Income tax credit refund 0 xxii_IncomeTaxRefund 122,024 xxii_IncomeTaxRefund Interest expense and amortization of debt discount and expense: Related parties 0 us-gaap_InterestExpenseRelatedParty (17,889) us-gaap_InterestExpenseRelatedParty Other (7,094) us-gaap_InterestExpenseOther (730,716) us-gaap_InterestExpenseOther Total other income (expense) (3,858,377) us-gaap_NonoperatingIncomeExpense (27,965,605) us-gaap_NonoperatingIncomeExpense Net loss $ (15,595,358) us-gaap_NetIncomeLoss $ (26,153,158) us-gaap_NetIncomeLoss Loss per common share - basic and diluted (in dollars per share) $ (0.26) us-gaap_EarningsPerShareBasicAndDiluted $ (0.60) us-gaap_EarningsPerShareBasicAndDiluted Common shares used in basic earnings per share calculation (in shares) 59,993,413 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 43,635,182 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic X - Definition Total costs related to goods produced and sold during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_CostOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_CostOfGoodsSoldAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Total costs of sales and operating expenses for the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References No definition available. + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Amount of gain (loss) on sale or disposal of an equity method investment. + References No definition available. + Details Name: us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_InterestAndDebtExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Interest expense on all other items not previously classified. For example, includes dividends associated with redeemable preferred stock of a subsidiary that is treated as a liability in the parent's consolidated balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4D -URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph -4 -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 + Details Name: us-gaap_InterestExpenseOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of interest expense incurred on a debt or other obligation to related party. + References No definition available. + Details Name: us-gaap_InterestExpenseRelatedParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_LicenseCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_LicensesRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 3 -Article 5 + Details Name: us-gaap_OtherCostAndExpenseOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_SalesRevenueGoodsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_SalesRevenueNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. + References No definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Weighted-Average Number of Common Shares Outstanding -URI http://asc.fasb.org/extlink&oid=6528421 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Represents the value of gain or loss from warrant liability. + References No definition available. + Details Name: xxii_GainLossFromWarrantLiability Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Income Tax Refund. + References No definition available. + Details Name: xxii_IncomeTaxRefund Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of inducement expenses on warrant exchange. + References No definition available. + Details Name: xxii_WarrantExchangeInducementExpense Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 61 R12.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT (Private Placement [Member], Preferred Stock [Member]) 12 Months Ended Dec. 31, 2014 Private Placement [Member] | Preferred Stock [Member] Preferred Stock [Line Items] JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT NOTE 5. - JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT On January 11, 2013, the Company sold 2,500 shares of newly created Series A-1 10 % Convertible Preferred Stock (the “Series A-1 Preferred Stock”) and warrants for $ 2.5 million. Net proceeds from this issuance were $ 2.035 million. During 2013, all Series A-1 Preferred Stock was converted into shares of the Company’s common stock and all related warrants to purchase shares of the Company’s common stock were exercised. Net proceeds from the exercise of warrants to purchase shares of the Company’s common stock were $ 2.090 million. X - Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: xxii_PreferredStockLineItems Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 62 R11.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT (Common Stock [Member], Private Placement [Member]) 12 Months Ended Dec. 31, 2014 Common Stock [Member] | Private Placement [Member] Class of Stock [Line Items] SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT NOTE 4.  SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT On September 17, 2014, the Company issued 3,871,767 shares of its common stock for $ 10,000,000 . Net cash proceeds from the issuance were $ 9,324,088 after deducting expenses associated with the common stock issuance. As a condition of the private placement, the parties executed a Registration of Rights Agreement pursuant to which the Company agreed to provide certain registration rights with respect to certain of the issued securities under the Securities Act of 1933. Accordingly, on October 10, 2014, the Company filed a Form S-3 Registration Statement with the SEC. On October 23, 2014, the SEC declared the Registration Statement effective. X - Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 63 R23.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 RETIREMENT PLAN 12 Months Ended Dec. 31, 2014 Compensation and Retirement Disclosure [Abstract] RETIREMENT PLAN NOTE 16. - RETIREMENT PLAN The Company sponsors a defined contribution plan under IRC Section 401(k). The plan covers all employees who meet the minimum eligibility requirements. Under the 401(k) plan eligible employees are allowed to make voluntary deferred salary contribution to the plan, subject to statutory limits. The Company has elected to make Safe Harbor Non-elective Contributions to the plan for eligible employees in the amount of three percent ( 3 %) of the employee’s compensation. Total employer contributions to the plan for the years ended December 31, 2014 and 2013 amounted to $ 27,485 and $ 34,873 , respectively. The contribution for the year ended December 31, 2013 includes a contribution made for 2012 in the first quarter of 2013. X - Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for pension and other postretirement benefits. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 70 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6414718&loc=d3e28014-114942 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e2410-114920 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 80 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=35742057&loc=SL14450702-114947 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 60 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6414199&loc=d3e39622-114963 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 60 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39675-114964 + Details Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 64 R19.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NOTES PAYABLE AND PATENT ACQUISITION 12 Months Ended Dec. 31, 2014 Notes Payable And Patent Acquisition [Abstract] NOTES PAYABLE AND PATENT ACQUISITION NOTE 12. - NOTES PAYABLE AND PATENT ACQUISITION On December 22, 2014, the Company entered into a Purchase Agreement (the “Agreement”) with the National Research Council of Canada (“NRC”) to acquire certain patent rights that the Company had previously licensed from NRC under a license agreement between the parties. The Purchase Agreement provided for the payment by the Company to NRC of the total amount of $ 1,873,000 , of which (i) $ 660,000 was required to be paid at the closing under the Purchase Agreement for the payment due in 2013 from the Company to NRC as a result of the monies received by the Company from BAT in October 2013, and (ii) the remaining balance of $1,213,000 being for the purchase of the NRC patent rights, of which $ 213,000 was paid in cash at the closing on December 23, 2014, and with the remaining $1,000,000 balance to be paid in three equal installments of approximately $ 333,333 in December of 2015, 2016 and 2017, respectively, with no interest on the installment payments unless the Company defaults in any such installment payment. As such, the Company computed the present value of the note payable using the Company’s incremental borrowing rate. The resulting present value of the note payable amounted to $ 925,730 ; with $ 320,513 and $ 605,217 recorded as the current and long-term portion of the note payable, respectively. The cost of the acquired patents in the amount of $ 1,138,730 (cash of $ 213,000 plus the discounted notes payable in the amount of $925,730) are included in Intangible assets, net on the Company’s Consolidated Balance Sheets. All previous license agreements between NRC and the Company were terminated as a condition of the Purchase Agreement. NRC has a security interest in these patent rights acquired by the Company from NRC until the note payable has been satisfied. X - Details Name: xxii_NotesPayableAndPatentAcquisitionAbstract Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for Notes Payable And Patent Acquisition. + References No definition available. + Details Name: xxii_NotesPayableAndPatentAcquisitionTextBlock Namespace Prefix: xxii_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 65 R15.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 MANUFACTURING FACILITY 12 Months Ended Dec. 31, 2014 Other Operating Income And Expense [Line Items] MANUFACTURING FACILITY NOTE 8.  MANUFACTURING FACILITY On December 11, 2013, the Company closed on a $ 3,220,000 purchase of certain cigarette manufacturing equipment from the bankruptcy estate of a company located in North Carolina that was liquidating under Chapter 7 of the U.S. Bankruptcy Code. Additionally, on January 13, 2014, the Company closed on a $ 210,000 purchase of various cigarette manufacturing equipment parts, office furniture and fixtures, vehicles and computer software and equipment from a second bankruptcy estate of a company located in North Carolina that was liquidating under Chapter 7 of the U.S. Bankruptcy Code. A portion of the equipment from these two transactions was not required for the Company’s manufacturing operations and was subsequently sold at auction during the first quarter of 2014. The Company’s warehouse and cigarette manufacturing facility was primarily in a pre-manufacturing stage during the year ended December 31, 2014. During this time period, the Company incurred various expenses to prepare the facility for production. Expenses incurred during the year ended December 31, 2014 amounted to $ 1,176,676 and consisted primarily of expenses for salaries and benefits for employees, sub-contract labor, rent, utilities and other miscellaneous costs and are reported as Pre-manufacturing facility costs on the Company’s Consolidated Statements of Operations. During the second quarter of 2014, the Company placed $ 2,997,140 of cigarette manufacturing equipment in service. Depreciation taken on the equipment during the year ended December 31, 2014 amounted to $ 224,519 and is included in Amortization and depreciation on the Company’s Consolidated Statements of Operations. The Company did manufacture a quantity of filtered cigars during the year ended December 31, 2014 resulting in revenue of $ 81,456 . As discussed in Note 7, on August 29, 2014, the Company closed on the acquisition of NASCO. Accordingly, the Company and NASCO are now signatories under the MSA. NASCO commenced manufacturing the Company’s proprietary cigarette brands and an MSA brand for an independent chain of retail smoke shops during the fourth quarter of 2014 at its manufacturing facility. Sales of these MSA brands commenced during the first quarter of 2015. NASCO will also continue to manufacture non-MSA filtered cigars. X - Definition The entire disclosure for other operating income and other operating expense items. + References No definition available. + Details Name: us-gaap_OtherOperatingIncomeAndExpenseTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: xxii_OtherOperatingIncomeAndExpenseLineItems Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 66 R60.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 STOCK BASED COMPENSATION (Narrative) (Details) (USD $) 12 Months Ended 1 Months Ended 3 Months Ended Dec. 31, 2014 Dec. 31, 2013 Apr. 30, 2014 Oct. 21, 2014 Mar. 31, 2014 Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015 Oct. 21, 2010 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity based employee compensation expense $ 2,293,083 us-gaap_ShareBasedCompensation $ 980,162 us-gaap_ShareBasedCompensation Unrecognized compensation expense related to non-vested restricted shares and stock option 672,000 us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 0.68 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 103,250 us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 242,160 us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Proceeds from Stock Options Exercised 48,300 us-gaap_ProceedsFromStockOptionsExercised 5,200 us-gaap_ProceedsFromStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 0 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Stock Issued During Period Shares Stock Options Exercised1 0 xxii_StockIssuedDuringPeriodSharesStockOptionsExercised1 Common Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 70,000 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember 20,000 us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Omnibus Incentive Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 2.07 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 300,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember 215,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember Stock Issued During Period, Shares, Restricted Stock Award, Gross 147,556 us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember Omnibus Incentive Plan [Member] | Maximum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 3 years Omnibus Incentive Plan [Member] | Minimum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 0 years Omnibus Incentive Plan [Member] | Common Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 5,000,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years Scenario, Forecast [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Unrecognized compensation expense related to non-vested restricted shares and stock option 39,000 us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized / us-gaap_StatementScenarioAxis = us-gaap_ScenarioForecastMember 160,000 us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized / us-gaap_StatementScenarioAxis = us-gaap_ScenarioForecastMember 473,000 us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized / us-gaap_StatementScenarioAxis = us-gaap_ScenarioForecastMember Third Party [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity based employee compensation expense 140,170 us-gaap_ShareBasedCompensation / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_ThirdPartyMember 1,363,748 us-gaap_ShareBasedCompensation / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_ThirdPartyMember Equity Incentive Plan 2010 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized 4,250,000 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized / us-gaap_AwardTypeAxis = xxii_EquityincentiveplantwentytenmemberMember Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years Stock Issued During Period, Shares, Restricted Stock Award, Gross 850,000 us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross / us-gaap_AwardTypeAxis = xxii_EquityincentiveplantwentytenmemberMember Equity Incentive Plan 2010 [Member] | Omnibus Incentive Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity based employee compensation expense $ 2,293,082 us-gaap_ShareBasedCompensation / us-gaap_AwardTypeAxis = xxii_EquityincentiveplantwentytenmemberMember / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember $ 998,214 us-gaap_ShareBasedCompensation / us-gaap_AwardTypeAxis = xxii_EquityincentiveplantwentytenmemberMember / us-gaap_PlanNameAxis = xxii_OmnibusIncentivePlanMember X - Definition Unrecognized cost of unvested share-based compensation awards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (j) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Gross number of share options (or share units) granted during the period. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of share options (or share units) exercised during the current period. + References No definition available. + Details Name: xxii_StockIssuedDuringPeriodSharesStockOptionsExercised1 Namespace Prefix: xxii_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=xxii_EquityincentiveplantwentytenmemberMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xxii_OmnibusIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xxii_ThirdPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R13.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSULTING AGREEMENT AND JOINT VENTURE 12 Months Ended Dec. 31, 2014 Organization, Consolidation and Presentation of Financial Statements [Abstract] CONSULTING AGREEMENT AND JOINT VENTURE NOTE 6.  CONSULTING AGREEMENT AND JOINT VENTURE In connection with a joint venture arrangement entered into on September 29, 2014 by the Company’s newly-formed and 51 % owned subsidiary, 22nd Century Asia, the Company entered into a six-month Consulting Agreement (the “Consulting Agreement”) with Crede CG III, Ltd. (“Crede”). Crede will provide consulting services to 22nd Century Asia with respect to the Company’s efforts to sell its proprietary tobacco products into the Asian market. In connection with the Company’s entry into such a joint venture and the Consulting Agreement, the Company issued Crede 1,250,000 Tranche 1A Warrants (the “Tranche 1A Warrants”) and 1,000,000 Tranche 1B Warrants (the “Tranche 1B Warrants”). The Tranche 1A Warrants have an exercise price of $ 3.36 per share and the Tranche 1B Warrants have an exercise price of $ 2.5951 per share. The Tranche 1A Warrants and the Tranche 1B Warrants each have a term of two years and are exercisable at any time. In addition, the Company issued 1,000,000 Tranche 2 Warrants (the “Tranche 2 Warrants”) and 1,000,000 Tranche 3 Warrants (the “Tranche 3 Warrants”). The Tranche 2 Warrants and the Tranche 3 Warrants each have a term of 5 years and an exercise price of $ 3.3736 per share. The Tranche 2 Warrants and Tranche 3 Warrants only become exercisable if certain revenue milestones are met by 22nd Century Asia subsequent to a certain commencement date, such commencement date likely to occur between January 1, 2016 and January 1, 2017, and the Company is cash flow positive from its investment in 22nd Century Asia. The Tranche 1A Warrants, the Tranche 1B Warrants, the Tranche 2 Warrants and the Tranche 3 Warrants all contain a traditional cashless exercise provision. In addition to the traditional cashless exercise provision, the Tranche 1A Warrants contain an Exchange Rights clause (the “Exchange Rights”) that provides that the Tranche 1A Warrants may be exercised on cashless basis by exchanging such warrants for shares of the Company’s common stock using a negotiated Black-Scholes pricing formula beginning on the day that is sixty one days after September 17, 2014, subject to certain conditions in the Exchange Rights. The number of shares issuable pursuant to the Exchange Rights is determined by dividing (a) the product of the number of Tranche 1A Warrants to be exchanged and the per share price resulting from the negotiated Black-Scholes pricing formula, by (b) the Exchange Price, defined as the closing bid price of the Company’s common stock two days prior to the date of the exchange. The maximum number shares issuable under the Exchange Rights is limited to 5,000,000 shares. The Company valued the Tranche 1A Warrants and Tranche 1B Warrants using the Black-Scholes pricing model as of the date of issuance. The resulting fair value of the Tranche 1A Warrants and Tranche 1B Warrants amounted to $ 2,810,000 and $ 1,260,000 , respectively, and have been recorded as Prepaid consulting fees on the Company’s Consolidated Balance Sheets and are being amortized over the six month term of the Consulting Agreement. During the year ended December 31, 2014, $ 2,091,215 of the Prepaid consulting fees were amortized and are included in General and administrative costs on the Company’s Consolidated Statements of Operations. The Exchange Rights contained in the Tranche 1A Warrants cause the financial instrument to be considered a liability in accordance with FASB Accounting Standards Codification Topic 480  “Distinguishing Liabilities from Equity” (“ASC 480”). More specifically, ASC 480 requires a financial instrument to be classified as a liability if such financial instrument contains a conditional obligation that the issuer must or may settle by issuing a variable number of its equity securities if, at inception, the monetary value of the obligation is based on a known fixed monetary amount. As such, the fair value of the Tranche 1A Warrants are included in the Warrant liability on the Company’s Consolidated Balance Sheets at December 31, 2014. The Tranche 1B Warrants do not contain such Exchange Rights and accordingly the fair value has been recorded as an increase in capital. No value has been assigned to the Tranche 2 Warrants and the Tranche 3 Warrants as they are not exercisable until certain revenue milestones are attained, as described above. X - Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 68 R14.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 BUSINESS COMBINATION 12 Months Ended Dec. 31, 2014 Business Combinations [Abstract] BUSINESS COMBINATION NOTE 7.  BUSINESS COMBINATION On September 17, 2013, the Company entered into a Membership Interest Purchase Agreement, which was subsequently amended on May 13, 2014, to purchase all of the issued and outstanding membership interests of NASCO Products, LLC (“NASCO”), a North Carolina limited liability company (the “Transaction”). NASCO is a federally licensed tobacco product manufacturer and a participating member of the tobacco Master Settlement Agreement known as the MSA, an agreement among 46 U.S. states and the tobacco industry administered by the National Association of Attorneys General (“NAAG”). The Transaction was subject to various conditions, including the required consents of the Settling States of the MSA to an amendment of NASCO’s existing adherence agreement to the MSA, with the Company becoming a signatory to such amended adherence agreement as part of the Company’s acquisition of NASCO. On August 29, 2014, the Company became a signatory to the amended adherence agreement under the MSA, and accordingly, the Transaction closed on August 29, 2014. The purchase price for the Transaction (the “Purchase Price”) consisted of (i) a cash payment of $ 250,000 and (ii) the issuance of 640,000 unregistered shares of the Company’s common stock. The common stock issued on August 29, 2014 had a market value of $ 1,952,000 , resulting in a total Purchase Price of $ 2,202,000 . The Purchase Price has been recorded as an Intangible asset in the Other assets section of the Company’s Consolidated Balance Sheets. The Company believes the intangible asset has an indefinite life and as such, no amortization is recorded. The Company also acquired cash of approximately $ 105,000 and a like amount of accrued expenses. In connection with the initial recording of the acquisition the Company recorded a deferred tax liability associated with the excess of the book value over the tax basis of assets acquired during the third quarter of 2014. During the final accounting for the acquisition it was determined that the book and tax basis were equal and the need for the deferred tax liability was no longer necessary. As a result, the initial recording of the deferred tax liability and associated goodwill from August 2014 was reversed. X - Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463 + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 69 R16.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 MACHINERY AND EQUIPMENT 12 Months Ended Dec. 31, 2014 Property, Plant and Equipment [Abstract] MACHINERY AND EQUIPMENT NOTE 9.  MACHINERY AND EQUIPMENT Machinery and equipment at December 31, 2014 and 2013 consists of the following: December 31, December 31, 2014 2013 Cigarette manufacturing equipment $ 3,031,375 $ 3,220,000 Office furniture, fixtures and equipment 55,355 17,059 Leasehold improvements - 14,500 Deposit for purchase of machine parts and other assets - 210,000 3,086,730 3,461,559 Less: cigarette manufacturing equipment held for resale - 457,696 3,086,730 3,003,863 Less: accumulated depreciation 236,115 6,103 Machinery and equipment, net $ 2,850,615 $ 2,997,760 On December 11, 2013 and January 13, 2014, the Company acquired machinery and equipment in the amount of $ 3,220,000 and $ 210,000 , respectively, as described in Note 8. A portion of the equipment from these two transactions was not required for the Company’s manufacturing operations and was subsequently sold at auction during the first quarter of 2014. The Company allocated $ 457,696 and $ 88,167 of the purchase price of these sold assets from the two transactions, respectively. The Company realized net proceeds from the auction sale of $ 631,484 , resulting in a gain on the sale of assets of $ 85,621 . The remaining cigarette manufacturing equipment was placed in service during the second quarter of 2014. Depreciation expense was $ 230,012 and $ 3,027 for the years ended December 31, 2014 and 2013, respectively. X - Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13-14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 70 R64.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 INCOME TAXES (Schedule of Provision (Benefit) for Income Taxes) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Current: Federal $ 0 us-gaap_CurrentFederalTaxExpenseBenefit $ 0 us-gaap_CurrentFederalTaxExpenseBenefit State 0 us-gaap_CurrentStateAndLocalTaxExpenseBenefit 0 us-gaap_CurrentStateAndLocalTaxExpenseBenefit Total current 0 us-gaap_CurrentIncomeTaxExpenseBenefit 0 us-gaap_CurrentIncomeTaxExpenseBenefit Deferred: Federal (3,494,787) us-gaap_DeferredFederalIncomeTaxExpenseBenefit 829,306 us-gaap_DeferredFederalIncomeTaxExpenseBenefit State 160,319 us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit 186,414 us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Total deferred (3,334,468) us-gaap_DeferredIncomeTaxExpenseBenefit 1,015,720 us-gaap_DeferredIncomeTaxExpenseBenefit Change in valuation allowance 3,334,468 us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance (1,015,720) us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Total income tax provision (benefit) $ 0 us-gaap_IncomeTaxExpenseBenefit $ 0 us-gaap_IncomeTaxExpenseBenefit X - Definition Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6509736 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Paragraph Question 1-7 + Details Name: us-gaap_CurrentFederalTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6509736 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 + Details Name: us-gaap_CurrentIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6509736 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 + Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Deferred Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6510177 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 + Details Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Deferred Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6510177 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Deferred Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6510177 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 + Details Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Income Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6515339 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32123-109318 + Details Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 71 R66.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) (USD $) Dec. 31, 2014 Dec. 31, 2013 Deferred tax assets: Net operating loss carry-forward $ 4,775,536 us-gaap_DeferredTaxAssetsOperatingLossCarryforwards $ 2,616,624 us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Derivative liability 0 us-gaap_DeferredTaxAssetsDerivativeInstruments 21,725 us-gaap_DeferredTaxAssetsDerivativeInstruments Inventory reserve 17,713 us-gaap_DeferredTaxAssetsInventory 19,584 us-gaap_DeferredTaxAssetsInventory Stock-based compensation 809,319 us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost 131,450 us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Start-up expenditures 388,130 xxii_DeferredTaxLiabilitiesStartUpExpenditures 0 xxii_DeferredTaxLiabilitiesStartUpExpenditures Loss on equity investment 35,398 us-gaap_DeferredTaxAssetsEquityMethodInvestments 0 us-gaap_DeferredTaxAssetsEquityMethodInvestments Severance liability 218,450 us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments 0 us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments Other 6,561 us-gaap_DeferredTaxAssetsOther 1,292 us-gaap_DeferredTaxAssetsOther Total deferred tax assets 6,251,107 us-gaap_DeferredTaxAssetsGross 2,790,675 us-gaap_DeferredTaxAssetsGross Deferred tax liabilities: Inventory 0 us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts (52,445) us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts Fixed assets (80,251) us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment (2,956) us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Patents and trademarks (624,010) us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets (523,157) us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Other intangible assets (21,986) xxii_DeferredTaxLiabilitiesOtherIntangibleAssets 0 xxii_DeferredTaxLiabilitiesOtherIntangibleAssets Total deferred tax liabilities (726,247) us-gaap_DeferredIncomeTaxLiabilities (578,558) us-gaap_DeferredIncomeTaxLiabilities Valuation allowance (5,524,860) us-gaap_DeferredTaxAssetsValuationAllowance (2,212,117) us-gaap_DeferredTaxAssetsValuationAllowance Net deferred taxes $ 0 us-gaap_DeferredTaxAssetsLiabilitiesNet $ 0 us-gaap_DeferredTaxAssetsLiabilitiesNet X - Details Name: us-gaap_ComponentsOfDeferredTaxAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of deferred tax liability attributable to taxable temporary differences. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Deferred Tax Liability -URI http://asc.fasb.org/extlink&oid=6510232 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph b(2) -Article 7 + Details Name: us-gaap_DeferredIncomeTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxAssetsDerivativeInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxAssetsEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Deferred Tax Asset -URI http://asc.fasb.org/extlink&oid=6510090 + Details Name: us-gaap_DeferredTaxAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxAssetsInventory Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 + Details Name: us-gaap_DeferredTaxAssetsLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 + Details Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxAssetsOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from severance costs. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 + Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 + Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 + Details Name: us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of deferred tax liability attributable to taxable temporary differences from Other Intangible Assets. + References No definition available. + Details Name: xxii_DeferredTaxLiabilitiesOtherIntangibleAssets Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of deferred tax liability attributable to taxable temporary differences from Start up expenditures. + References No definition available. + Details Name: xxii_DeferredTaxLiabilitiesStartUpExpenditures Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 72 R63.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 INCOME TAXES (Narrative) (Details) (USD $) Dec. 31, 2014 Net operating loss carry forwards $ 13,700,000 us-gaap_OperatingLossCarryforwards X - Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 73 R34.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 STOCK BASED COMPENSATION (Tables) 12 Months Ended Dec. 31, 2014 Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Fair Value Assumptions The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2014 and 2013: 2014 2013 Risk-free interest rate 1.80 % 1.89 % Expected dividend yield 0 % 0 % Expected stock price volatility 90 % 90 % Expected life of options 10 years 10 years Summary of All Stock Option Activity A summary of all stock option activity since December 31, 2012 is as follows: Weighted Average Weighted Remaining Number of Average Contractual Aggregate Options Exercise Price Term Intrinsic Value Outstanding at December 31, 2012 465,000 $ 0.69 Granted in 2013 215,000 $ 0.80 Exercised in 2013 (20,000) $ 0.26 Outstanding at December 31, 2013 660,000 $ 0.74 Granted in 2014 300,000 $ 2.61 Exercised in 2014 (70,000) $ 0.69 Outstanding at December 31, 2014 890,000 $ 1.38 8.0 years $ 532,900 Exercisable at December 31, 2014 640,000 $ 0.89 7.7 years $ 532,900 X - Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the following for fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position: the number, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or share units) outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 74 R51.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 DUE FROM RELATED PARTY (Narrative) (Details) (USD $) Dec. 31, 2014 Dec. 31, 2013 Related Party Transaction [Line Items] Due from related party $ 46,069 us-gaap_DueFromRelatedPartiesCurrent $ 42,069 us-gaap_DueFromRelatedPartiesCurrent Alternative Cigarettes, Inc. [Member] Related Party Transaction [Line Items] Due from related party $ 46,069 us-gaap_DueFromRelatedPartiesCurrent / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AlternativeCigarettesIncMember $ 42,069 us-gaap_DueFromRelatedPartiesCurrent / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xxii_AlternativeCigarettesIncMember X - Definition The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 2 -Article 4 + Details Name: us-gaap_DueFromRelatedPartiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xxii_AlternativeCigarettesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R21.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 DUE FROM RELATED PARTY 12 Months Ended Dec. 31, 2014 Related Party Transactions [Abstract] DUE FROM OR TO RELATED PARTY NOTE 14. - DUE FROM RELATED PARTY The Company has conducted transactions with a related party, Alternative Cigarettes, Inc. (“AC”). AC is entirely owned by certain shareholders of the Company, including the Company’s former CEO and current director. During the years ended December 31, 2014 and 2013, transactions with AC consisted mainly of advances and repayments. The net amount due from AC amounted to $ 46,069 and $ 42,069 as of December 31, 2014 and 2013, respectively. No interest has been accrued or paid on amount due from or to AC and there are no repayment terms. X - Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 76 R26.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 STOCK BASED COMPENSATION 12 Months Ended Dec. 31, 2014 Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK BASED COMPENSATION NOTE 19. - STOCK BASED COMPENSATION On October 21, 2010, the Company established the 2010 Equity Incentive Plan (“EIP”) for officers, employees, directors, consultants and advisors to the Company and its affiliates, consisting of 4,250,000 shares of common stock. The EIP had a term of ten years and is administered by our Board of Directors (the “Board”) or a committee to be established by our Board (the “Administrator”), to determine the various types of incentive awards that may be granted to recipients under this plan and the number of shares of common stock to underlie each such award under the EIP. On March 30, 2011, the Company filed a Form S-8 registration statement with the SEC to register all of the shares of common stock of 22nd Century Group that it may issue under the EIP. During the first quarter of 2014, the Company issued restricted stock awards from the EIP for 850,000 restricted shares to employees and directors that will vest on January 27, 2015. All awards were valued at the closing price on the measurement date of the award. Subsequent to this issuance of restricted stock, there are no shares remaining to be issued from the EIP. On April 12, 2014, the stockholders of the Company approved the 22nd Century Group, Inc. 2014 Omnibus Incentive Plan (the “OIP”). The OIP allows for the granting of equity and cash incentive awards to eligible individuals over the life of the OIP, including the issuance of up to 5,000,000 shares of the Company’s common stock pursuant to awards under the OIP. The OIP has a term of ten years and is administered by the Compensation Committee of our Board of Directors to determine the various types of incentive awards that may be granted to recipients under this plan and the number of shares of common stock to underlie each such award under the OIP. On April 18, 2014, the Company filed a Form S-8 registration statement with the SEC to register the 5,000,000 shares of common stock of 22nd Century Group that may be issued under the OIP. During the year ended December 31, 2014, the Company issued restricted stock awards from the OIP for 147,556 restricted shares to eligible individuals having vesting periods ranging from zero to three years from the award date. All awards were valued at the closing price on the measurement date of the award. For the years ended December 31, 2014 and 2013, the Company recorded compensation expense related to restricted stock and stock option awards granted under the EIP and OIP of $ 2,293,082 and $ 998,214 , respectively. The Company also recorded equity based compensation for the years ended December 31, 2014 and 2013 as payment to third parties for services rendered in the amount $ 140,170 and $ 1,363,748 , respectively. As of December 31, 2014, unrecognized compensation expense related to non-vested restricted shares and stock options amounted to approximately $ 672,000 , which is expected to be recognized approximately as follows: $ 473,000 , $ 160,000 , and $ 39,000 during 2015, 2016 and 2017, respectively. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2014 and 2013: 2014 2013 Risk-free interest rate 1.80 % 1.89 % Expected dividend yield 0 % 0 % Expected stock price volatility 90 % 90 % Expected life of options 10 years 10 years The Company estimated the expected volatility based on data used by a peer group of public companies. The expected term was estimated using the contract life of the option. The risk-free interest rate assumption was determined using yield of the equivalent U.S. Treasury bonds over the expected term. The Company has never paid any cash dividends and does not anticipate paying any cash dividends in the foreseeable future. Therefore, the Company assumed an expected dividend yield of zero. A summary of all stock option activity since December 31, 2012 is as follows: Weighted Average Weighted Remaining Number of Average Contractual Aggregate Options Exercise Price Term Intrinsic Value Outstanding at December 31, 2012 465,000 $ 0.69 Granted in 2013 215,000 $ 0.80 Exercised in 2013 (20,000) $ 0.26 Outstanding at December 31, 2013 660,000 $ 0.74 Granted in 2014 300,000 $ 2.61 Exercised in 2014 (70,000) $ 0.69 Outstanding at December 31, 2014 890,000 $ 1.38 8.0 years $ 532,900 Exercisable at December 31, 2014 640,000 $ 0.89 7.7 years $ 532,900 There were 300,000 options granted from the OIP during the year ended December 31, 2014 ( 215,000 options granted during the year ended December 31, 2013). The weighted average grant date fair value of options issued during the year ended December 31, 2014 was $ 2.07 ($ 0.68 for the year ended December 31, 2013). The total fair value of options that vested during the year ended December 31, 2014 amounted to $ 103,250 ($ 242,160 for the year ended December 31, 2013). During the year ended December 31, 2014, 70,000 options were exercised for cash proceeds of $ 48,300 . During the year ended December 31, 2013, 20,000 options were exercised for cash proceeds of $ 5,200 . X - Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 77 R49.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NOTES PAYABLE AND PATENT ACQUISITION (Narrative) (Details) (USD $) 1 Months Ended 12 Months Ended Dec. 22, 2014 Dec. 31, 2014 Dec. 31, 2013 Dec. 23, 2014 Notes Payable And Patent Acquisition [Line Items] Finite Lived Intangible Assets Acquired With Notes Payable $ 925,730 xxii_FiniteLivedIntangibleAssetsAcquiredWithNotesPayable $ 925,730 xxii_FiniteLivedIntangibleAssetsAcquiredWithNotesPayable $ 0 xxii_FiniteLivedIntangibleAssetsAcquiredWithNotesPayable Notes Payable, Current 320,513 us-gaap_NotesPayableCurrent 320,513 us-gaap_NotesPayableCurrent 0 us-gaap_NotesPayableCurrent Notes Payable, Noncurrent 605,217 us-gaap_LongTermNotesPayable 605,217 us-gaap_LongTermNotesPayable 0 us-gaap_LongTermNotesPayable Patents [Member] Notes Payable And Patent Acquisition [Line Items] Other Commitment 1,873,000 us-gaap_OtherCommitment / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember Other Commitment, Due in Next Twelve Months 660,000 us-gaap_OtherCommitmentDueInNextTwelveMonths / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember Other Commitment, Due in Second Year 213,000 us-gaap_OtherCommitmentDueInSecondYear / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember Other Commitment, Due in Third Year 333,333 us-gaap_OtherCommitmentDueInThirdYear / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember Other Commitment, Due in Fourth Year 333,333 us-gaap_OtherCommitmentDueInFourthYear / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember Other Commitment, Due in Fifth Year 333,333 us-gaap_OtherCommitmentDueInFifthYear / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember Finite-lived Intangible Assets Acquired $ 1,138,730 us-gaap_FinitelivedIntangibleAssetsAcquired1 / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember X - Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from a business combination. + References No definition available. + Details Name: us-gaap_FinitelivedIntangibleAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20 -Article 5 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details Name: us-gaap_OtherCommitment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Minimum amount of other commitment maturing in the fifth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details Name: us-gaap_OtherCommitmentDueInFifthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Minimum amount of other commitment maturing in the fourth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details Name: us-gaap_OtherCommitmentDueInFourthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Minimum amount of other commitment maturing in the next fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details Name: us-gaap_OtherCommitmentDueInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Minimum amount of other commitment maturing in the second fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details Name: us-gaap_OtherCommitmentDueInSecondYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Minimum amount of other commitment maturing in the third fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details Name: us-gaap_OtherCommitmentDueInThirdYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from acquisition of notes payable. + References No definition available. + Details Name: xxii_FiniteLivedIntangibleAssetsAcquiredWithNotesPayable Namespace Prefix: xxii_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: xxii_NotesPayableAndPatentAcquisitionLineItems Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R41.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT (Narrative) (Details) (USD $) 1 Months Ended 12 Months Ended Jan. 31, 2013 Dec. 31, 2014 Dec. 31, 2013 Subsidiary, Sale of Stock [Line Items] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 2,500,000 us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Proceeds from sale of preferred shares and convertible notes 2,035,000 us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Warrant Exercises 486,951 us-gaap_ProceedsFromWarrantExercises 2,254,999 us-gaap_ProceedsFromWarrantExercises Common Stock [Member] Subsidiary, Sale of Stock [Line Items] Stock Issued During Period, Shares, New Issues 3,871,767 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Proceeds from Warrant Exercises $ 2,090,000 us-gaap_ProceedsFromWarrantExercises / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Private Placement [Member] | Common Stock [Member] Subsidiary, Sale of Stock [Line Items] Stock Issued During Period, Shares, New Issues 3,871,767 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember / us-gaap_SubsidiarySaleOfStockAxis = us-gaap_PrivatePlacementMember Series A One Preferred Stock [Member] Subsidiary, Sale of Stock [Line Items] Stock Issued During Period, Shares, New Issues 2,500 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_ClassOfWarrantOrRightAxis = xxii_SeriesOnePreferredStockMember Preferred Stock, Dividend Rate, Percentage 10.00% us-gaap_PreferredStockDividendRatePercentage / us-gaap_ClassOfWarrantOrRightAxis = xxii_SeriesOnePreferredStockMember X - Definition The percentage rate used to calculate dividend payments on preferred stock. + References No definition available. + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow associated with the amount received from holders exercising their stock warrants. + References No definition available. + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Value of preferred stock and warrants for common stock issued. + References No definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xxii_SeriesOnePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R5.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Pre-Manufacturing Facility [Member] Allocated Share-based Compensation Expense $ 27,923 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_ManufacturingFacilityMember $ 0 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_ManufacturingFacilityMember Research and Development Expense [Member] Allocated Share-based Compensation Expense 331,467 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember 111,563 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember General and Administrative Expense [Member] Allocated Share-based Compensation Expense $ 4,165,078 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember $ 2,250,399 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember X - Definition Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R10.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 FINANCIAL CONDITION 12 Months Ended Dec. 31, 2014 Quarterly Financial Information Disclosure [Abstract] FINANCIAL CONDITION NOTE 3.  FINANCIAL CONDITION At December 31, 2014, the Company had current assets of $ 10,706,806 and current liabilities of $ 2,673,407 resulting in positive working capital of $ 8,033,399 . Cash on hand at December 31, 2014 was $ 6,402,687 . The Company believes it will have adequate cash reserves to sustain operations and meet all current obligations as they come due for a period of approximately 12 months. The Company’s Form S-3 universal shelf registration statement was filed with the U.S. Securities and Exchange Commission (“SEC”) on April 18, 2014, and became effective on June 5, 2014. The universal shelf registration statement will allow, but not compel, the Company to raise up to $ 45 million of capital over a three-year period through a wide array of securities at times and in amounts to be determined by the Company. X - Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 81 R58.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 EARNINGS PER COMMON SHARE (Computation of Basic and Diluted Earnings Per Common Share) (Details) (USD $) 12 Months Ended Dec. 31, 2014 Dec. 31, 2013 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net loss attributed to common shareholders $ (15,595,358) us-gaap_NetIncomeLoss $ (26,153,158) us-gaap_NetIncomeLoss Denominator for basic earnings per share-weighted average shares outstanding 59,993,413 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 43,635,182 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Effect of dilutive securities: Warrants, restricted stock and options outstanding 0 us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment 0 us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Denominator for diluted earnings per common share-weighted average shares adjusted for dilutive securities 59,993,413 us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 43,635,182 us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Loss per common share - basic and diluted $ (0.26) us-gaap_EarningsPerShareBasicAndDiluted $ (0.60) us-gaap_EarningsPerShareBasicAndDiluted X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References No definition available. + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). + References No definition available. + Details Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Weighted-Average Number of Common Shares Outstanding -URI http://asc.fasb.org/extlink&oid=6528421 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 82 R27.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 INCOME TAXES 12 Months Ended Dec. 31, 2014 Income Tax Disclosure [Abstract] INCOME TAXES NOTE 20. - INCOME TAXES The following is a summary of the components giving rise to the income tax provision (benefit) for the years ended December 31, 2014 and 2013. The provision (benefit) for income taxes consists of the following: 2014 2013 Current: Federal $ - $ - State - - Total current - - Deferred: Federal (3,494,787) 829,306 State 160,319 186,414 Total deferred (3,334,468) 1,015,720 Change in valuation allowance 3,334,468 (1,015,720) $ - $ - The provision (benefit) for income tax varies from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss as follows: 2014 2013 Statutory federal rate (34.0) % (34.0) % Permanent items 0.6 1.8 Derivative liability 8.4 35.5 Stock based compensation 2.5 - State tax provision, net of federal benefit 1.1 0.5 Valuation allowance 21.4 (3.9) Effective tax rate (benefit) provision 0.0 % 0.0 % Individual components of deferred taxes consist of the following: 2014 2013 Deferred tax assets: Net operating loss carry-forward $ 4,775,536 $ 2,616,624 Derivative liability - 21,725 Inventory reserve 17,713 19,584 Stock-based compensation 809,319 131,450 Start-up expenditures 388,130 - Loss on equity investment 35,398 - Severance liability 218,450 - Other 6,561 1,292 6,251,107 2,790,675 Deferred tax liabilities: Inventory - (52,445) Fixed assets (80,251) (2,956) Patents and trademarks (624,010) (523,157) Other intangible assets (21,986) - (726,247) (578,558) Valuation allowance (5,524,860) (2,212,117) Net deferred taxes $ - $ - The Company has incurred a net operating loss of approximately $ 13,700,000 through December 31, 2014 and this amount is being carried forward to future years and expires in 2031 and 2032. Due to the uncertainty of the Company’s ability to generate sufficient taxable income in the future before they expire, the company has recorded a valuation allowance to reduce the net deferred tax asset to zero. This NOL is included in the net deferred tax asset that has been fully offset by the valuation allowance. ASC 740 provides guidance on the financial statement recognition and measurement for uncertain income tax positions that are taken or expected to be taken in a company’s income tax return. The Company has no uncertain tax positions as of December 31, 2014. The Company’s federal and state tax returns for the years ended September 30, 2011 to December 31, 2013 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2014. X - Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 183 387 1 true 71 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.xxiicentury.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.xxiicentury.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.xxiicentury.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.xxiicentury.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.xxiicentury.com/role/ConsolidatedStatementsOfOperationsParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) false false R6.htm 106 - Statement - CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Sheet http://www.xxiicentury.com/role/ConsolidatedStatementOfShareholdersEquity CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY false false R7.htm 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.xxiicentury.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 108 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.xxiicentury.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R9.htm 109 - Disclosure - NYSE MKT EXCHANGE Sheet http://www.xxiicentury.com/role/NyseMktExchange NYSE MKT EXCHANGE false false R10.htm 110 - Disclosure - FINANCIAL CONDITION Sheet http://www.xxiicentury.com/role/FinancialCondition FINANCIAL CONDITION false false R11.htm 111 - Disclosure - SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT Sheet http://www.xxiicentury.com/role/September2014CommonStockPrivatePlacement SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT false false R12.htm 112 - Disclosure - JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT Sheet http://www.xxiicentury.com/role/January2013PreferredStockPrivatePlacement JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT false false R13.htm 113 - Disclosure - CONSULTING AGREEMENT AND JOINT VENTURE Sheet http://www.xxiicentury.com/role/ConsultingAgreementAndJointVenture CONSULTING AGREEMENT AND JOINT VENTURE false false R14.htm 114 - Disclosure - BUSINESS COMBINATION Sheet http://www.xxiicentury.com/role/BusinessCombination BUSINESS COMBINATION false false R15.htm 115 - Disclosure - MANUFACTURING FACILITY Sheet http://www.xxiicentury.com/role/ManufacturingFacility MANUFACTURING FACILITY false false R16.htm 116 - Disclosure - MACHINERY AND EQUIPMENT Sheet http://www.xxiicentury.com/role/MachineryAndEquipment MACHINERY AND EQUIPMENT false false R17.htm 117 - Disclosure - EQUITY INVESTMENT AND ADVANCE Sheet http://www.xxiicentury.com/role/EquityInvestmentAndAdvance EQUITY INVESTMENT AND ADVANCE false false R18.htm 118 - Disclosure - DEMAND BANK LOAN Sheet http://www.xxiicentury.com/role/DemandBankLoan DEMAND BANK LOAN false false R19.htm 119 - Disclosure - NOTES PAYABLE AND PATENT ACQUISITION Notes http://www.xxiicentury.com/role/NotesPayableAndPatentAcquisition NOTES PAYABLE AND PATENT ACQUISITION false false R20.htm 120 - Disclosure - SEVERANCE LIABILITY Sheet http://www.xxiicentury.com/role/SeveranceLiability SEVERANCE LIABILITY false false R21.htm 121 - Disclosure - DUE FROM RELATED PARTY Sheet http://www.xxiicentury.com/role/DueFromRelatedParty DUE FROM RELATED PARTY false false R22.htm 122 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK Sheet http://www.xxiicentury.com/role/WarrantExchangeProgramAndWarrantsForCommonStock WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK false false R23.htm 123 - Disclosure - RETIREMENT PLAN Sheet http://www.xxiicentury.com/role/RetirementPlan RETIREMENT PLAN false false R24.htm 124 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.xxiicentury.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R25.htm 125 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.xxiicentury.com/role/EarningsPerCommonShare EARNINGS PER COMMON SHARE false false R26.htm 126 - Disclosure - STOCK BASED COMPENSATION Sheet http://www.xxiicentury.com/role/StockBasedCompensation STOCK BASED COMPENSATION false false R27.htm 127 - Disclosure - INCOME TAXES Sheet http://www.xxiicentury.com/role/IncomeTaxes INCOME TAXES false false R28.htm 128 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.xxiicentury.com/role/SubsequentEvents SUBSEQUENT EVENTS false false R29.htm 129 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.xxiicentury.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R30.htm 130 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.xxiicentury.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R31.htm 131 - Disclosure - MACHINERY AND EQUIPMENT (Tables) Sheet http://www.xxiicentury.com/role/MachineryAndEquipmentTables MACHINERY AND EQUIPMENT (Tables) false false R32.htm 132 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Tables) Sheet http://www.xxiicentury.com/role/WarrantExchangeProgramAndWarrantsForCommonStockTables WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Tables) false false R33.htm 133 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet http://www.xxiicentury.com/role/EarningsPerCommonShareTables EARNINGS PER COMMON SHARE (Tables) false false R34.htm 134 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://www.xxiicentury.com/role/StockBasedCompensationTables STOCK BASED COMPENSATION (Tables) false false R35.htm 135 - Disclosure - INCOME TAXES (Tables) Sheet http://www.xxiicentury.com/role/IncomeTaxesTables INCOME TAXES (Tables) false false R36.htm 136 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Sheet http://www.xxiicentury.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesNarrativeDetails NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) false false R37.htm 137 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.xxiicentury.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) false false R38.htm 138 - Disclosure - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://www.xxiicentury.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) false false R39.htm 139 - Disclosure - FINANCIAL CONDITION (Narrative) (Details) Sheet http://www.xxiicentury.com/role/FinancialConditionNarrativeDetails FINANCIAL CONDITION (Narrative) (Details) false false R40.htm 140 - Disclosure - SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT(Narrative) (Details) Sheet http://www.xxiicentury.com/role/September2014CommonStockPrivatePlacementnarrativeDetails SEPTEMBER 2014 COMMON STOCK PRIVATE PLACEMENT(Narrative) (Details) false false R41.htm 141 - Disclosure - JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT (Narrative) (Details) Sheet http://www.xxiicentury.com/role/January2013PreferredStockPrivatePlacementNarrativeDetails JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT (Narrative) (Details) false false R42.htm 142 - Disclosure - CONSULTING AGREEMENT AND JOINT VENTURE (Narrative) (Details) Sheet http://www.xxiicentury.com/role/ConsultingAgreementAndJointVentureNarrativeDetails CONSULTING AGREEMENT AND JOINT VENTURE (Narrative) (Details) false false R43.htm 143 - Disclosure - BUSINESS COMBINATION (Narrative) (Details) Sheet http://www.xxiicentury.com/role/BusinessCombinationNarrativeDetails BUSINESS COMBINATION (Narrative) (Details) false false R44.htm 144 - Disclosure - MANUFACTURING FACILITY (Narrative) (Details) Sheet http://www.xxiicentury.com/role/ManufacturingFacilityNarrativeDetails MANUFACTURING FACILITY (Narrative) (Details) false false R45.htm 145 - Disclosure - MACHINARY AND EQUPMENT (Narrative) (Details) Sheet http://www.xxiicentury.com/role/MachinaryAndEqupmentNarrativeDetails MACHINARY AND EQUPMENT (Narrative) (Details) false false R46.htm 146 - Disclosure - MACHINERY AND EQUIPMENT (Details) Sheet http://www.xxiicentury.com/role/MachineryAndEquipmentDetails MACHINERY AND EQUIPMENT (Details) false false R47.htm 147 - Disclosure - EQUITY INVESTMENT AND ADVANCE (Narrative) (Details) Sheet http://www.xxiicentury.com/role/EquityInvestmentAndAdvanceNarrativeDetails EQUITY INVESTMENT AND ADVANCE (Narrative) (Details) false false R48.htm 148 - Disclosure - DEMAND BANK LOAN (Narrative) (Details) Sheet http://www.xxiicentury.com/role/DemandBankLoanNarrativeDetails DEMAND BANK LOAN (Narrative) (Details) false false R49.htm 149 - Disclosure - NOTES PAYABLE AND PATENT ACQUISITION (Narrative) (Details) Notes http://www.xxiicentury.com/role/NotesPayableAndPatentAcquisitionNarrativeDetails NOTES PAYABLE AND PATENT ACQUISITION (Narrative) (Details) false false R50.htm 150 - Disclosure - SEVERANCE LIABILITY (Narrative) (Details) Sheet http://www.xxiicentury.com/role/SeveranceLiabilityNarrativeDetails SEVERANCE LIABILITY (Narrative) (Details) false false R51.htm 151 - Disclosure - DUE FROM RELATED PARTY (Narrative) (Details) Sheet http://www.xxiicentury.com/role/DueFromRelatedPartyNarrativeDetails DUE FROM RELATED PARTY (Narrative) (Details) false false R52.htm 152 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Narrative) (Details) Sheet http://www.xxiicentury.com/role/WarrantExchangeProgramAndWarrantsForCommonStockNarrativeDetails WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Narrative) (Details) false false R53.htm 153 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Details) Sheet http://www.xxiicentury.com/role/WarrantExchangeProgramAndWarrantsForCommonStockDetails WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Details) false false R54.htm 154 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Roll-Forward of Warrant Liability from Initial Valuation) (Details) Sheet http://www.xxiicentury.com/role/WarrantExchangeProgramAndWarrantsForCommonStockRollforwardOfWarrantLiabilityFromInitialValuationDetails WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Roll-Forward of Warrant Liability from Initial Valuation) (Details) false false R55.htm 155 - Disclosure - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Warrant Activity) (Details) Sheet http://www.xxiicentury.com/role/WarrantExchangeProgramAndWarrantsForCommonStockWarrantActivityDetails WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Warrant Activity) (Details) false false R56.htm 156 - Disclosure - RETIREMENT PLAN (Narrative) (Details) Sheet http://www.xxiicentury.com/role/RetirementPlanNarrativeDetails RETIREMENT PLAN (Narrative) (Details) false false R57.htm 157 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details) Sheet http://www.xxiicentury.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES (Narrative) (Details) false false R58.htm 158 - Disclosure - EARNINGS PER COMMON SHARE (Computation of Basic and Diluted Earnings Per Common Share) (Details) Sheet http://www.xxiicentury.com/role/EarningsPerCommonShareComputationOfBasicAndDilutedEarningsPerCommonShareDetails EARNINGS PER COMMON SHARE (Computation of Basic and Diluted Earnings Per Common Share) (Details) false false R59.htm 159 - Disclosure - EARNINGS PER COMMON SHARE (Anti-Dilutive Securities Outstanding Excluded from Computation) (Details) Sheet http://www.xxiicentury.com/role/EarningsPerCommonShareAntidilutiveSecuritiesOutstandingExcludedFromComputationDetails EARNINGS PER COMMON SHARE (Anti-Dilutive Securities Outstanding Excluded from Computation) (Details) false false R60.htm 160 - Disclosure - STOCK BASED COMPENSATION (Narrative) (Details) Sheet http://www.xxiicentury.com/role/StockBasedCompensationNarrativeDetails STOCK BASED COMPENSATION (Narrative) (Details) false false R61.htm 161 - Disclosure - STOCK BASED COMPENSATION (Schedule of Fair Value Assumptions) (Details) Sheet http://www.xxiicentury.com/role/StockBasedCompensationScheduleOfFairValueAssumptionsDetails STOCK BASED COMPENSATION (Schedule of Fair Value Assumptions) (Details) false false R62.htm 162 - Disclosure - STOCK BASED COMPENSATION (Summary of All Stock Option Activity) (Details) Sheet http://www.xxiicentury.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails STOCK BASED COMPENSATION (Summary of All Stock Option Activity) (Details) false false R63.htm 163 - Disclosure - INCOME TAXES (Narrative) (Details) Sheet http://www.xxiicentury.com/role/IncomeTaxesNarrativeDetails INCOME TAXES (Narrative) (Details) false false R64.htm 164 - Disclosure - INCOME TAXES (Schedule of Provision (Benefit) for Income Taxes) (Details) Sheet http://www.xxiicentury.com/role/IncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails INCOME TAXES (Schedule of Provision (Benefit) for Income Taxes) (Details) false false R65.htm 165 - Disclosure - INCOME TAXES (Schedule of statutory federal rate to pre-tax accounting loss) (Details) Sheet http://www.xxiicentury.com/role/IncomeTaxesScheduleOfStatutoryFederalRateToPretaxAccountingLossDetails INCOME TAXES (Schedule of statutory federal rate to pre-tax accounting loss) (Details) false false R66.htm 166 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) Sheet http://www.xxiicentury.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) false false R67.htm 167 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details) Sheet http://www.xxiicentury.com/role/SubsequentEventsNarrativeDetails SUBSEQUENT EVENTS (Narrative) (Details) false false All Reports Book All Reports Element us-gaap_DebtInstrumentInterestRateEffectivePercentage had a mix of decimals attribute values: 2 4. Element us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost had a mix of decimals attribute values: 0 3. Element us-gaap_EquityMethodInvestmentOwnershipPercentage had a mix of decimals attribute values: 1 2. Element us-gaap_ProceedsFromWarrantExercises had a mix of decimals attribute values: -3 0. Element us-gaap_RevenueOtherManufacturedProducts had a mix of decimals attribute values: -5 0. Element us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants had a mix of decimals attribute values: -5 0. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 364 days and at least 69 values. Shorter duration columns must have at least one fourth (17) as many values. Column '1/1/2014 - 3/31/2014' is shorter (89 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 364 days and at least 69 values. Shorter duration columns must have at least one fourth (17) as many values. Column '12/1/2014 - 12/22/2014' is shorter (21 days) and has only 1 values, so it is being removed. Process Flow-Through: 102 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Dec. 22, 2014' Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: Removing column '0 Months Ended
Aug. 09, 2012' Process Flow-Through: Removing column '0 Months Ended
Dec. 14, 2011' Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Process Flow-Through: 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS xxii-20141231.xml xxii-20141231.xsd xxii-20141231_cal.xml xxii-20141231_def.xml xxii-20141231_lab.xml xxii-20141231_pre.xml true true XML 84 R38.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $) Dec. 31, 2014 Dec. 31, 2013 Intangible assets, net Intangible Assets, Net (Excluding Goodwill) $ 7,077,759 us-gaap_IntangibleAssetsNetExcludingGoodwill $ 1,544,869 us-gaap_IntangibleAssetsNetExcludingGoodwill MSA Signatory Costs [Member] Intangible assets, net License fee for predicate cigarette brand 2,202,000 us-gaap_OtherIndefiniteLivedIntangibleAssets / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember 0 us-gaap_OtherIndefiniteLivedIntangibleAssets / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember License Fee [Member] Intangible assets, net License fee for predicate cigarette brand 300,000 us-gaap_OtherIndefiniteLivedIntangibleAssets / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = xxii_LicenseFeeMember 0 us-gaap_OtherIndefiniteLivedIntangibleAssets / us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis = xxii_LicenseFeeMember Patent and Trademarks [Member] Intangible assets, net Patent and trademark costs 4,405,586 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_IntellectualPropertyMember 2,559,412 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_IntellectualPropertyMember Less: accumulated amortization 1,247,303 us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_IntellectualPropertyMember 1,014,543 us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_IntellectualPropertyMember Patent and trademark costs, net 3,158,283 us-gaap_FiniteLivedIntangibleAssetsNet / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_IntellectualPropertyMember 1,544,869 us-gaap_FiniteLivedIntangibleAssetsNet / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_IntellectualPropertyMember Licensing Agreements [Member] Intangible assets, net Patent and trademark costs 1,450,000 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember 0 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Less: accumulated amortization 32,524 us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember 0 us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember Patent and trademark costs, net $ 1,417,476 us-gaap_FiniteLivedIntangibleAssetsNet / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember $ 0 us-gaap_FiniteLivedIntangibleAssetsNet / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_LicensingAgreementsMember X - Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights not otherwise specified in the taxonomy having a projected indefinite period of benefit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_OtherIndefiniteLivedIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=xxii_LicenseFeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R20.htm IDEA: XBRL DOCUMENT /* Do Not Remove This Comment */ function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } } v2.4.1.9 SEVERANCE LIABILITY 12 Months Ended Dec. 31, 2014 Severance Liability [Abstract] SEVERANCE LIABILITY NOTE 13.  SEVERANCE LIABILITY As of December 31, 2014, the Company has recorded an accrual for service in the amount of $ 624,320 in accordance with FASB ASC 712. The severance accrual relates to the October 25, 2014 termination of Joseph Pandolfino, the Company’s former Chairman of the Board and Chief Executive Officer, pursuant to Section 4.2 (Termination by the Company Without Cause) of Mr. Pandolfino’s Employment Agreement, dated as of January 25, 2011. The Employment Agreement stipulates that Mr. Pandolfino shall receive severance payments in the gross amount of $ 18,750 per month, subject to customary withholdings, over a term of 36 months. Amounts owed Mr. Pandolfino have been discounted using the Company’s incremental borrowing rate, resulting in current and long-term liabilities of $ 212,012 and $ 412,308 , respectively. In addition, 320,000 unvested equity awards vested upon termination. The additional equity based compensation of approximately $ 60,000 associated with the vesting of these equity awards was recorded as expense during the fourth quarter of 2014. X - Details Name: xxii_SeveranceLiabilityAbstract Namespace Prefix: xxii_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for Severance Liability. + References No definition available. + Details Name: xxii_SeveranceLiabilityTextBlock Namespace Prefix: xxii_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration 